Generated by All in One SEO Pro v4.9.7.2, this is an llms-full.txt file, used by LLMs to index the site. # GenInvo GenInvo ## Posts ### [Meet GenInvo at DPHARM 2026, Booth 116, Boston](https://geninvo.com/dpharm-2026/) **Published:** June 4, 2026 **Author:** admin **Content:** ## Advancing Clinical Research Innovation | DPHARM 2026 | September 15–16, 2026 | Sheraton Boston Hotel **Geninvo is exhibiting at [DPHARM 2026](https://www.dpharmconference.com/)** the industry’s premier conference for disruptive innovations in clinical research taking place **September 15–16, 2026** at the **Sheraton Boston Hotel, Boston, MA**. Find our team at **Booth 116** and discover how GenInvo is transforming the fields like Data Analytics, Biometrics, Regulatory Writing and Data Transparency with cutting-edge technologies. 📅 **September 15–16, 2026** 📍 Sheraton Boston Hotel, Boston, MA 🏷️ **Booth 116** 👥 Contacts: Craig | James | Daragh **[Book a Meeting at DPHARM 2026](https://geninvo.com/contact-us/)** ## ABOUT THE EVENT About DPHARM 2026: Disruptive Innovations to Advance Clinical Research [DPHARM 2026 ](https://www.dpharmconference.com/)is the leading conference bringing together **senior clinical operations executives, R&D innovators, technology leaders, and patient advocates** to explore the future of clinical trials. Hosted at the **Sheraton Boston Hotel, September 15–16, 2026**, the event features TED-style talks, fireside chats, quick-fire demos, and the renowned **DPHARM Idol Disrupt** startup pitch competition all focused on driving efficiencies in clinical trial operations and improving outcomes for patients. Key themes at DPHARM 2026 include: - Decentralized and hybrid clinical trials - AI and data-driven trial design - Patient-centric research models - Disruptive technologies accelerating drug development - Operational excellence in clinical research ## WHY VISIT GENINVO AT BOOTH 116? At DPHARM 2026, the Geninvo team will be showcasing our full suite of AI-powered clinical research and data science solutions purpose-built for pharma sponsors, biotech firms, CROs, and clinical operations teams. Stop by **Booth 116** for live demonstrations of five transformative products: - ✅ **Live product demonstrations** — see all five GenInvo solutions in action - ✅ **One-on-one consultations** with clinical research and data science experts - ✅ **Real-world use cases** — how GenInvo is helping teams cut timelines, reduce errors, and stay compliant - ✅ **Exclusive conference offers** for DPHARM 2026 attendees - ✅ **Meet Craig, James, and Daragh** — our senior team on-site at Booth 116 Whether you are a pharma sponsor, CRO, statistical programmer, medical writer, or data manager — Geninvo has a solution built for your challenge. ## GENINVO PRODUCTS AT DPHARM 2026 Discover Geninvo’s AI-Powered Clinical Research Solutions Geninvo is the go-to partner for the life sciences industry, delivering innovative software solutions and data science services. Our unique combination of deep expertise in life sciences, cutting-edge AI, software development, data engineering, and cloud technologies helps bring life-changing treatments to patients faster. At DPHARM 2026, we are showcasing five products solving the toughest challenges in clinical research today. --- #### [CodeMagic™](https://geninvo.com/codemagic/) — AI-Assisted Code Generation for Statistical Programming *Stop writing SDTM, ADaM, and TFL code from scratch. CodeMagic generates it for you.* **CodeMagic™** is Geninvo’s AI-assisted code generation platform that automates statistical programming using structured specifications and mock shells. Designed for pharma statisticians and programmers, it generates **SDTM, ADaM, and TFL code** in open-source languages like R — delivering predictable, controlled, GxP-compliant, audit-ready programs with full documentation. **Key Capabilities:** - Automated ADaM generation with variable-level metadata mapping and derivation logic - TFL code generation from mock shells and ADaM specifications - Raw to SDTM conversion using detailed study specifications - Reusable global standard programs for common derivations - Seamless integration with client Statistical Computing Environments (SCEs) - Human-in-the-Loop framework ensuring accuracy, quality, and compliance throughout **Strategic Benefits for Your Team:** - Accelerate time-to-insight and shorten development timelines - Reduce manual coding errors through intelligent, structured prompts - Ensure CDISC standards and Good Programming Practices in every output - Free up programmer capacity for strategic analysis and innovation - Help SAS programmers transition to R with built-in learning support - Code is production-ready for validation or QC purposes **On the Roadmap:** SAS to R migration, Python/SAS/multi-language support, model-agnostic LLM compatibility. --- #### [Datalution™](https://geninvo.com/our-products/datalution/) — Intelligent Synthetic Data Platform for Clinical Trials *Start analytics before the first patient walks in the door.* **Datalution™** is Geninvo’s intelligent synthetic data platform that enables clinical trial teams to activate downstream analytics, testing, and validation workflows — all **before First-Patient-In**. With privacy guaranteed by design (zero patient re-identification risk), Datalution accelerates study configuration and early programming activation without compromising data security. **What Synthetic Data Enables:** - De-risking system validation and programming before trial start - Validating reconciliation, coding, and data cleaning processes - Eliminating patient exposure risk entirely - Testing QTL programs and pre-building TLF shells and analysis programs - Conducting realistic UAT for EDC, IRT, ePRO, and vendor systems - Achieving time and cost efficiency across the study lifecycle **Key Highlights:** - Privacy-guaranteed synthetic data infrastructure with zero re-identification risk by design - Accelerated study configuration and early programming activation - Unlocks early testing, validation, and system readiness across all trial systems --- #### [Shadow™](https://geninvo.com/our-products/data-anonymization-tool/) — Achieve Anonymization with Ease *Anonymize documents, datasets, and DICOM files — fast, accurately, and compliantly.* **Shadow™** is Geninvo’s AI-powered anonymization platform covering DICOM, clinical data, and regulatory documents. Using custom **NLP and Computer Vision (CV) models** to identify Personally Identifiable Information (PII) with precision, Shadow significantly reduces the time and manual effort required for anonymization — while eliminating human error. **Core Capabilities:** - DICOM + Data + Document De-identification in one platform - PII identification using custom NLP and CV models - Risk Analysis to assess re-identification risk before and after anonymization - Anonymization Reports with real-time results - Data Utility measurement to ensure anonymized data remains analytically useful **Compliance Coverage:** - GDPR, 21 CFR, and HIPAA compliant - Health Canada and EMA Policy 0070 aligned - Scalable, customizable Anonymization as a Service model --- #### [DocWrightAI™](https://geninvo.com/our-products/docwrightai-document-generation-software/) — AI-Driven Authoring of Clinical & Regulatory Documents *Create your most complex regulatory documents in minutes — without compromising accuracy or compliance.* **DocWrightAI™** is Geninvo’s advanced AI writing assistant for collaborative and efficient authoring of clinical and regulatory documents. Trained on official regulatory rules and medical knowledge, it accelerates document timelines from weeks to minutes while keeping human experts in control at every step. **Why It Stands Out:** - Accelerates document authoring timelines from weeks to minutes - Ensures compliance by design with built-in regulatory intelligence - AI-assisted, human-approved workflows keep your team in control - Built-in inconsistency checker catches errors before submission - Generates documents weeks ahead of schedule - Collaborative authoring allows multiple team members to work simultaneously - Customized user prompts generate content tailored to specific study needs - Human-in-Loop control ensures oversight and validation at every stage **Ideal For:** CSRs, protocols, INDs, NDAs, regulatory briefing documents, and all clinical/regulatory writing workflows. --- #### [DocQC™](https://geninvo.com/our-products/docqc-medical-writing-automation/) — Automated Medical Writing Review & QC *Cut review cycles. Cut costs. Never compromise on quality.* **DocQC™** is Geninvo’s automation tool that streamlines medical writing reviews, dramatically reducing manual effort and time-consuming review cycles. It solves the five biggest pain points in document QC: manual review burden, repetitive tasks causing fatigue, scalability challenges across multiple studies, delayed turnaround slowing regulatory submissions, and high cost per document. **Key Functionalities:** - Document Editing & Review Comments — real-time feedback and document revisions - Dashboard and Repository — central hub for managing and accessing all documents - Quality Review — document accuracy and compliance through predefined checklists - Collaborative Workspace — shared reviewing and editing for enhanced team productivity - Audit Trails — full change and access tracking to maintain document integrity - Queue Management System — organizes and prioritizes document review tasks efficiently **Two Flexible Business Models:** - **Service Model:** Geninvo FSP delivers Clinical & Regulatory Documents directly to clients - **Licensing Model:** Clients onboard and operate the DocQC platform independently within their own environment ## BOOK A MEETING Book a Meeting with Geninvo at DPHARM 2026 Don’t leave your DPHARM 2026 schedule to chance. Pre-book a dedicated **15 or 30-minute meeting** with our team at Booth 116 and make the most of your time in Boston. Email us directly: [**info@geninvo.com**](mailto:events@geninvo.com) ## FAQ SECTION **Where is DPHARM 2026 being held?** DPHARM 2026 takes place at the Sheraton Boston Hotel, Boston, Massachusetts, on September 15–16, 2026. **What booth number is Geninvo at DPHARM 2026?** Geninvo is exhibiting at **Booth 116** at DPHARM 2026. **How can I meet the Geninvo team at DPHARM 2026?** You can visit us directly at Booth 116, or email at [info@geninvo.com](mailto:events@geninvo.com). **What does Geninvo do?** Geninvo is a life sciences technology company delivering AI-powered software solutions and data science services for clinical research. Their product portfolio includes CodeMagic™ (AI-assisted statistical programming), Datalution™ (intelligent synthetic data for clinical trials), Shadow™ (data and document anonymization), DocWrightAI™ (AI-driven regulatory document authoring), and DocQC™ (automated medical writing QC). Geninvo helps pharma sponsors, biotech firms, and CROs accelerate drug development and bring life-changing treatments to patients faster. **What products will Geninvo demonstrate at DPHARM 2026?** At Booth 116, the Geninvo team will demonstrate five solutions: CodeMagic™ for AI-assisted SDTM/ADaM/TFL code generation; Datalution™ for synthetic clinical trial data; Shadow™ for DICOM, data, and document anonymization; DocWrightAI™ for AI-powered clinical and regulatory document authoring; and DocQC™ for automated medical writing review and quality control. **What is DPHARM?** DPHARM (Disruptive Innovations to Advance Clinical Research) is an annual conference organized by The Conference Forum (TCF), focused on transformative technologies and innovations modernizing clinical trials. **Is Geninvo exhibiting or sponsoring at DPHARM 2026?** Geninvo is exhibiting at DPHARM 2026 at Booth 116, September 15–16, 2026, in Boston. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [Meet GENINVO at the EMWA 61st Spring Conference 2026](https://geninvo.com/emwa-2026-barcelona/) **Published:** April 21, 2026 **Author:** admin **Content:** **Barcelona is calling!** As the medical writing landscape shifts toward an AI-integrated future, Geninvo is proud to be at the forefront as a sponsor and exhibitor at the [**European Medical Writers Association (EMWA) 61st Spring Conference**.](https://emwa.org/conference-barcelona-may-2026/) From **May 5–8, 2026**, the global medical writing community will gather in beautiful Barcelona to discuss the future of the industry. Whether you are navigating the complexities of the new AI Masterclasses or looking for ways to streamline your QC process, the Geninvo team is ready to help you bridge the gap between technology and science. ### **Visit us at Booth #10** Stop by our booth to chat with our experts, see live demos, and discover how our “Innovation First” mindset can solve your most pressing documentation challenges. - **📅 Dates:** May 5 – 8, 2026 - **📍 Location:** Barceló Sants, Barcelona, Spain - **🆔 Booth:** #10 ## **Why Connect with GENINVO in EMWA 2026 Barcelona?** **GENINVO: Transforming Regulatory Writing Workflows** GENINVO is the go-to partner for life science organizations, providing intelligent document management solutions purpose-built for pharmaceutical and biotech companies. Our innovative suite of tools addresses the critical challenges medical writers face in creating compliant, accurate, and secure regulatory and scientific documentation. **[DocWrightAI™](https://geninvo.com/our-products/docwrightai-document-generation-software/)** revolutionizes document creation by automating the generation of clinical study reports, investigator brochures, regulatory submissions, and other technical documents. It integrates with multiple data sources and features AI-powered validation and verification to ensure all generated documents meet internal and regulatory standards and guidelines. **[DocQC™](https://geninvo.com/our-products/docqc-medical-writing-automation/)** automates quality control checks that historically required multiple time-consuming manual review cycles. Using adaptive AI and ML algorithms, it validates citations, abbreviations, in-text data against source tables, and compares Clinical Study Reports with Protocols and Statistical Analysis Plans enabling medical writers to focus on science. **[Shadow™](https://geninvo.com/our-products/data-anonymization-tool/)** is a sophisticated data anonymization and de-identification tool compliant with EMA Policy 0070, Health Canada, and other data transparency requirements. It performs rigorous quantitative and qualitative risk assessments, maintains data utility while executing precise redaction/anonymization activities, and supports secure data sharing. **[CIS (Confidential Information Scanner)™](https://geninvo.com/cis-confidential-information-scanner/)** is an AI-powered solution that automatically detects and protects commercially confidential information across 50+ specific categories. > **Expert Insight:** The EMWA 2026 theme highlights “Moving from Content Creator to Process Owner.” At Booth #10, we’ll show you exactly how our tools empower you to make that transition seamlessly. > > ## **Schedule a Private Demo** > > Will you be in Barcelona? Don’t leave your technology strategy to chance. We invite you to schedule a one-on-one session with our leadership team during the conference to discuss your specific organizational needs. > > **[ Book a Meeting at EMWA 2026](https://geninvo.com/contact-us/)** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [GenInvo at PharmaSUG 2026 SDE Conference](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) **Published:** April 10, 2026 **Author:** admin **Content:** **Proud Bronze Sponsor** GenInvo is proud to announce its participation as a **Bronze Sponsor** at the **PharmaSUG 2026 SDE Conference** a premier event bringing together industry leaders, data experts, and innovators in clinical research and statistical programming. ### **Event Details** - **📅 Date:** April 11, 2026 - **📍 Location:** Bengaluru, India ### **Meet Our Experts** Join us at the conference and connect with our experienced professionals who are driving innovation in clinical data and statistical programming: **Amal Anandan** *Principal – Data Scientist* **Krunal Patel** *Senior Principal Statistical Programmer* Our team will be available to discuss how GenInvo is transforming clinical trials through advanced analytics, AI-driven solutions, and efficient data processes. --- ### **Why Meet GenInvo?** At GenInvo, we are redefining the clinical research landscape with cutting-edge solutions that enhance data accuracy, compliance, and efficiency. Whether you’re looking to optimize your clinical workflows or explore next-generation technologies, our experts are here to help. --- ### **Let’s Connect** We look forward to meeting you at PharmaSUG 2026. To learn more about our solutions. Contact Us👉 [Now](https://geninvo.com/contact-us/) --- ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [GenInvo @ PHUSE US Connect 2026](https://geninvo.com/geninvo-phuse-us-connect-2026/) **Published:** March 16, 2026 **Author:** admin **Content:** **Join us in Austin!** GenInvo is headed to Texas for **[PHUSE US Connect 2026](https://www.phuse-events.org/attend/frontend/reg/thome.csp?pageID=56977&eventID=88)**. As industry innovators, we’re excited to share our expertise and present our latest advancements in clinical data science. --- #### **Event Details** - **Dates:** March 22–26, 2026 - **Location:** Austin, Texas - **Team Onsite:** Daragh Ryan, Hitesh Raval, Inderjeet Arora, Pinku Hooda, Shweta Shukla, & Parveen Kumar --- #### **Don’t Miss Our Session** GenInvo is officially **presenting** at this year’s conference. Join our experts as we dive into tech-driven solutions designed to accelerate clinical development and streamline data standards. #### **Connect With Us** Looking for smarter ways to handle your clinical data? Meet our leadership team to discuss: - Advanced automation and AI integration. - SDTM/ADaM clinical data standards. - Transformative life science technology. [Let’s meet there!](https://geninvo.com/contact-us/) ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [Product Adoption Specialist ](https://geninvo.com/product-adoption-specialist/) **Published:** January 27, 2026 **Author:** admin **Content:** **Title: Product Adoption Specialist** **Experience: 8+ years** **Location: Remote (Anywhere in US)** **Job Type: Full time** The **role covers value realization management, change management**, and may cover some **project management activities.** **Responsibilities.** - Responsibilities include developing and leading the launch management strategy containing value/impact realization management, change readiness, stakeholder engagement and communication plans, training plans, that is well integrated with the overall project plan to enable effective organizational change and optimized realization of projected benefits. - Embed and oversee standard approaches to persona mapping, value story creation, internal/external partner engagement, adoption and activation plans and value realization measurements. - Ensure the readiness of the employees and the organization for the new implementation - Create and distribute project-related communications, including but not limited to, newsletters, updates, FAQs, and presentations - Measure the effectiveness of communications and change management efforts and make data-driven decisions to improve future efforts, measure and report risks linked to value and change activation. - Design and lead training programs for the new implementation and roll out to stakeholders - Measure and report on launch success capabilities, and overarching value realization, within Innovative Health. - Partner with internal and external team members and collaborators, to promote a collaborative and successful team dynamic with a high level of sustainable performance. **Experience/skills required** - Value management, plans and measurement, data driven - Change management - Stakeholder mapping and engagement - Presentation skills, communication skills - Project management - Analytical skills, conceptual thinking - Interpersonal skills, influence skills and ability to influence through ambiguity - Cross functional work and collaboration - Can Work Well Independently ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** job --- ### [Senior Analyst / Lead – Google Cloud Development](https://geninvo.com/senior-analyst-lead-google-cloud-development/) **Published:** January 13, 2026 **Author:** admin **Content:** **An immediate joiner will be preferred** We are seeking a highly experienced **Google Cloud Developer** with strong expertise in **GEN AI** technologies. The ideal candidate will have 10+ years of experience in designing, developing, and maintaining applications and infrastructure leveraging **Google Cloud Platform (GCP)**. This role requires a blend of advanced software engineering skills, deep knowledge of cloud computing principles, and hands-on experience with **RAG**, **MCP**, **Vertex AI** **and** **vector DB**. **Key Responsibilities:** - Design and develop cloud-native applications on **Google Cloud Platform**, ensuring scalability, security, and performance. - Strong experience with **LLM** ‘s, **RAG**, **MCP**, **Google Cloud services** for enterprise-grade solutions. - Proficiency in programming languages: **Python (must)**, Java, Go. - Expertise in **AI/ML model development**, including **GEN AI** and **Agentic AI** solutions - Build and integrate APIs, containers, Kubernetes, and service mesh (Istio) for microservices architecture. - Develop, deploy, and manage machine learning models using frameworks like TensorFlow, PyTorch, or XGBoost, and integrate them into applications or standalone AI systems. - Ensure adherence to cloud security principles, network design, and best practices in software architecture. - Troubleshoot and resolve complex product or system issues by analyzing source code and system operations. - Work with SQL and NoSQL databases (Cloud SQL, Firestore, Bigtable, BigQuery). - Maintain active **Google Cloud Certification** (Developer or Engineer). ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** job --- ### [Senior/Lead Analyst - DevOps](https://geninvo.com/senior-lead-analyst-devops/) **Published:** January 13, 2026 **Author:** admin **Content:** **Job Summary** We are looking for an experienced **Senior / Lead DevOps Engineer** to design, implement, and manage robust CI/CD pipelines and cloud-native infrastructure. The ideal candidate will have strong hands-on experience with modern DevOps toolchains, AWS cloud, containerization, and Kubernetes, along with a proactive mindset, leadership capability, and excellent communication skills. **Key Responsibilities** - Design, build, and maintain **end-to-end CI/CD pipelines** across Dev / QA / UAT / Prod environments. - Lead **DevOps architecture and automation initiatives** for scalable and secure platforms. - Implement and manage **containerized workloads** using Docker and Kubernetes. - Configure and manage **Git-based CI/CD tools** including Git, Bitbucket, Jenkins, ArgoCD, and JFrog Artifactory. - Manage and optimize **AWS cloud infrastructure** (EC2, VPC, IAM, EKS, S3, CloudWatch, etc.). - Perform **Linux administration**, scripting, automation, and troubleshooting. - Implement **Infrastructure as Code (IaC)** and GitOps best practices. - Ensure reliability, security, compliance, and operational excellence of pipelines. - Collaborate with development, QA, security, and architecture teams. - Mentor junior DevOps engineers and provide technical leadership. - Participate in design reviews, incident management, and continuous improvement. **Mandatory Skills & Experience** - **7+ years** of overall IT experience with strong focus on **DevOps engineering**. - Proven experience in **minimum 5 end-to-end CI/CD implementations**. - Strong hands-on expertise in: - Git / Bitbucket - Jenkins - JFrog Artifactory - Docker - Kubernetes - ArgoCD - **AWS Cloud (Must Have)** – hands-on experience in production environments. - **Linux (Must Have)** – strong command over Linux OS, shell scripting, and system troubleshooting. - Strong understanding of CI/CD concepts, branching strategies, and release management. **Certifications (Preferred – Additional Weightage)** Candidates holding one or more of the following certifications will be given **strong preference**: **Cloud Certifications (Good to have)** - AWS Certified Solutions Architect – Associate / Professional - AWS Certified DevOps Engineer – Professional **Good to Have** - Hands-on experience with **Microsoft Azure**. - Exposure to **multi-cloud or hybrid cloud** environments. - Knowledge of **DevSecOps**, security scanning, SAST/DAST tools, and compliance pipelines. - Experience working in **regulated or enterprise environments** (Pharma, BFSI, Healthcare). **Soft Skills** - Strong **communication and stakeholder management** skills. - Positive attitude with a strong **ownership mindset**. - Ability to work independently and lead DevOps initiatives. - Mentoring and team leadership capabilities. **What We Offer** - Opportunity to work on **complex, large-scale DevOps and cloud platforms**. - High ownership role with visibility across leadership and customers. - Learning and certification-friendly environment. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** job --- ### [Head / Associate / Senior Director - Product Adoption](https://geninvo.com/head-associate-senior-director-product-adoption/) **Published:** December 8, 2025 **Author:** admin **Content:** **Position Overview:** Accelerate time-to-value and maximize ROI by driving seamless adoption of our solutions for clients, upskilling internal teams delivering services, and leading a specialist function that can be deployed to support adoption of clients’ own or third‑party solutions. The Product Adoption team is responsible for driving successful onboarding, utilization, and long-term engagement of customers with our products. This role sits at the intersection of Product, Customer Success, Marketing, and Sales, ensuring that users not only understand product value but fully adopt features that lead to measurable business outcomes. **Primary KPIs:** - Time-to-value (TTV) reduction for client deployments - Product adoption rate (feature activation, usage depth/width, DAU/MAU) - ROI realized vs. planned (client & internal services programs) - Net Revenue Retention (NRR) / expansions linked to adoption - Onboarding cycle time, customer health score improvements - Training completion & proficiency metrics (internal & client) - CSAT/NPS for adoption programs; decrease in support tickets post‑go‑live **Key Responsibilities** **Drive Client Adoption & Time-to-Value** - Own adoption strategy across the post-sale lifecycle: Operational Discovery (validate success criteria, assess readiness), Onboarding, Change Management, Enablement, Value Realization, and Expansion. - Create outcome-based adoption plans and scalable playbooks. - Use product telemetry to identify friction and improve activation. - Partner with Customer Success and Services to streamline handoffs and accelerate time-to-first-value. **Enable Internal Teams** - Upskill delivery teams under services contracts to maximize ROI. - Build certification frameworks and enablement content. - Standardize methodologies for success planning and value realization. - Coach teams on adoption-first approaches and executive storytelling. **Lead Adoption Specialists** - Build and manage a team deployable to clients for multi-vendor solution adoption. - Define operating model, quality standards, and resource allocation. - Ensure interoperability strategies and mentor talent for growth. **Strategic and Operational Enablers** Cross‑Functional & Strategic - Partner with Product to influence roadmap via adoption data. - Collaborate with Marketing on adoption campaigns and customer stories. - Work with Sales to position adoption programs in pre‑sales and shape SOWs. - Create commercial offerings (packaged adoption services, success accelerators). - Risk management: early‑warning systems for stalled adoption and recovery plans. Operational & Reporting - Instrumentation & analytics: define metrics taxonomy, dashboards (usage, activation, proficiency, value realization). - ROI tracking: baselines, benefit hypotheses, measurement methods, and executive value reports. - Budget & vendor management: tools for enablement (LMS, digital adoption platforms). - Global delivery readiness: localization, multi‑region support, and time zone coverage. **Qualifications:** - Bachelor’s/Master’s in Business, Engineering, or related field. - Min 8 to 10+ years in Customer Success, Professional Services, Product Operations, or Digital/Change Transformation. - Proven leadership of cross‑functional teams delivering adoption outcomes at scale. - Track record reducing TTV and increasing product usage using data‑driven strategies. - Experience orchestrating multi‑vendor solution adoption. **What We Offer:** - Opportunity to contribute to a growing technology company and make a meaningful impact. - Collaborative and innovative work environment. - Competitive renumeration package and flexible working arrangements ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** job --- ### [Quantitative Risk Assessment: A Smarter Approach to Clinical Data Anonymization ](https://geninvo.com/quantitative-risk-assessment-a-smarter-approach-to-clinical-data-anonymization/) **Published:** October 27, 2025 **Author:** admin **Content:** In today’s clinical research landscape, openness and transparency in data sharing are essential for ethical integrity and scientific progress. Traditional data anonymization methods like redaction often rely on generalized rules or expert opinion, which can limit both privacy protection and data utility. Modern clinical trials are generating more data than before leading to rich, complex datasets that hold the key to groundbreaking discoveries and life-saving treatments. This poses a question: **how do we share clinical data responsibly without compromising patient privacy?** This is where Quantitative Risk Assessment (QRA) steps in as a game-changer. It helps in sharing the clinical data by keeping data safe, making it more meaningful.It allows researchers and data custodians to measure the likelihood of re-identification, apply statistical thresholds, and make informed decisions about how data can be safely shared. With regulatory bodies like the European Medicines Agency (EMA) and Health Canada push for greater transparency and the adoption of quantitative risk assessment is gaining momentum. It offers a scalable, intelligent solution that balances privacy protection with data utility empowering organizations to unlock the full potential of clinical data while maintaining patient trust and compliance. ## **Foundation of Data Privacy** ![](https://geninvo.com/wp-content/uploads/2025/10/image-3.png "image - GenInvo")## **What is Data Privacy?** **Data Privacy** refers to the protection of personal or sensitive information from unauthorized access, use, disclosure, or misuse. It ensures that individuals have control over how their data is collected, stored, shared, and used—especially in context of **healthcare**. ## **Key Aspects of Data Privacy** Data privacy involves obtaining informed consent before collecting data, ensuring only necessary information is gathered (data minimization), and implementing strong security measures like encryption and access controls. Transparency is key, patients should know how their data is used and shared. Compliance with legal frameworks such as GDPR, HIPAA, etc… ensures ethical and lawful data practices. Together, these aspects help maintain patient trust while enabling safe and meaningful use of health data for care and research. ## **What is Clinical Data Sharing?** Clinical Data Sharing refers to the practice of making data from clinical trials available to other researchers, healthcare professionals, or the public. This data can include information about how a study was conducted, the results, and sometimes even anonymized patient data. ## **What is Quantitative Risk Assessment (QRA)?** Quantitative Risk Assessment (QRA) is a method that uses data and numbers to find and manage risks in clinical trials. Unlike methods that depend on personal opinions, QRA uses statistics and privacy tools to measure how likely it is that someone could be identified from anonymized patient data. This helps researchers protect privacy while still using the data effectively. ## **Why QRA Matters in Data Transparency** Transparency in clinical trials is essential for: ![](https://geninvo.com/wp-content/uploads/2025/10/image-1.png "image - GenInvo")Even when patient data is anonymized, sharing it with others—like researchers or the public—can still carry the risk that someone might figure out who the patient is. Quantitative Risk Assessment (QRA) helps measure how likely that is to happen. It gives researchers a clear idea of the risk and helps them decide whether the data can be shared safely. ## **Key Components of QRA in Clinical Trials** ### **1. Personal Data Classification:** - Direct identifiers like names or addresses - Indirect identifiers like age, gender, or zip code. - Data that poses minimal privacy risk. ### **2. Risk Metrics:** - The first step involves calculating the probability of re-identification for each subject in the shared dataset, assuming an attempted attack scenario. Suppose we have two quasi-identifiers: age and gender. To begin, we group all subjects who share the same values for these quasi-identifiers into what are called equivalence classes. The re-identification risk for an individual is then calculated as the reciprocal of the size of their equivalence class. Equivalence Class means grouping records with identical quasi-identifier values to assess the likelihood of singling out an individual. **For example:** - If **Subject 1** has the attributes *gender = M* and *age = 26*, and no other subject shares these exact values, then Subject 1 forms a unique equivalence class of size 1. The re-identification risk is therefore **1/1 = 1**, indicating a high risk. - Conversely, if there are **12 male subjects aged 36**, then each subject in that group—including Subject 1 if he shares those attributes—belongs to an equivalence class of size 12. The re-identification risk for each would be **1/12 ≈ 0.083**, indicating a lower risk. Once individual risks for each record are known, the overall risk of re-identification of the dataset an attempt can be calculated. The two metrics typically calculated are the average risk and the maximum risk. - **Maximum Risk**: Assumes an intruder targets the most vulnerable record (used for public data sharing). The maximum risk will take the highest value of all individual risks for all records across the dataset. For example: *Prmax(re-id | attempt) = max (1, 0.5, 0.5, 0.33, 0.5, 1, 0.33, 1, 0.33, 0.5) = 1* - **Average Risk**: Considers the average probability across all records (used for controlled access). The average risk will be the mean of all individual risks across the dataset. *Pravg(re-id | attempt) = (1+0.5+0.5+0.33+0.5+1+0.33+1+0.33+0.5) / 10 = 0.* - Common metrics include: - *k-anonymity:* Ensures each data point is indistinguishable from at least k-1 records. - *l-diversity:* Ensures that sensitive data in anonymized groups is diverse enough to prevent attackers from confidently guessing individual values. - *t-closeness*: Ensures that the distribution of sensitive data in each group is statistically similar to the overall dataset, reducing information leakage. ### **3. Thresholds:** Industry standards often set acceptable re-identification risk thresholds at **0.09 or lower.** ### **4. Statistical Techniques for Anonymization:** - If risk exceeds the threshold, data is anonymized, e.g., through **generalization, suppression, date offset or redaction**—to reduce risk while preserving utility. ## **Benefits of QRA in Clinical Data Transparency** The primary benefit of Quantitative Risk Assessment (QRA) is its ability to provide a clear, data-driven understanding of privacy and security risks while preserving data utility. By focusing on generalization rather than redaction, QRA ensures that sensitive information is protected without compromising the analytical value of the data. This approach not only maintains data utility but also significantly enhances regulatory compliance by aligning with legal standards such as GDPR, HIPAA, and other data protection frameworks. Furthermore, QRA contributes to improved data security by identifying and mitigating specific risk factors, ensuring that anonymization efforts are both effective and measurable. It also facilitates safe data sharing across internal teams and external partners by providing confidence that shared datasets have been assessed and treated to minimize re-identification risks. Ultimately, QRA supports informed decision-making by translating complex privacy concerns into actionable insights, enabling organizations to make strategic choices about data usage, anonymization techniques, and privacy controls with clarity and confidence. ![](https://geninvo.com/wp-content/uploads/2025/10/image-2.png "image - GenInvo")## **Challenges** - Incomplete or inaccurate source data in datasets can lead to misleading risk estimates. - Historical data may not reflect future risks, especially in dynamic environments. - Rare events are difficult to model due to lack of frequency. - Risk depends on the data-sharing context (public vs. controlled access). Public datasets require stricter anonymization (maximum risk focus), while controlled access allows more flexibility (average risk). - Over-anonymization (e.g., excessive suppression) reduces data utility, hindering research. Under-anonymization risks privacy breaches. - Regulatory bodies (e.g. EMA, PRCI) may have strict guidelines on risk management. QRA must align with frameworks like ICH E6(R2) and ICH E8(R1). ## **Solutions** - Identify direct and quasi-identifiers using exploratory data analysis. - Align with EMA, Health Canada, and GDPR guidelines and use iterative testing to ensure risk falls below thresholds (e.g., 0.09). - Prioritize transformations that minimize risk while retaining data utility (e.g., generalization over suppression). - Use statistical software (e.g., R, SAS, or Python) to compute uniqueness and equivalence class sizes. - Leverage tools like GenInvo’s Shadow-Data Anonymization tool for QRA, Dataset, DICOM and Document anonymization. ## **Conclusion** Quantitative Risk Assessment (QRA) is more than just a technical tool—it helps make clinical trials more open and trustworthy. By systematically evaluating and mitigating re-identification risks, Quantitative Risk Assessment ensures patient privacy is preserved while allowing researchers access to valuable anonymized data. This balance fosters transparency, accelerates scientific discovery, and strengthens public trust in clinical trials—making QRA not just a technical safeguard, but a cornerstone of ethical and high-quality research. **Author:** *Raina Agarwal (Associate Director, Data Transparency)* *Diwakar Angra (Anonymization Analyst, Data Transparency)* ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs --- ### [Secure Scanning with Confidential Information Scanner: Safeguarding Your CCIs During Clinical Research](https://geninvo.com/secure-scanning-with-confidential-information-scanner-safeguarding-your-ccis-during-clinical-research/) **Published:** September 16, 2025 **Author:** admin **Content:** In today’s highly regulated life sciences industry, **managing confidential details is not just a best practice—it’s a mandate**. Pharmaceutical companies, biotech firms, CROs, and medical writers are under increasing pressure to ensure that **commercially confidential information (CCI) in clinical trials** is handled with utmost care. As regulatory agencies demand greater transparency in submissions and disclosures, the challenge is clear: **how do organizations balance openness with protection of proprietary and patient data?** This is where **CIS (Confidential Information Scanner)** provides a breakthrough. Designed specifically for the life sciences industry, **CIS** is a **[CCI Redaction Tool](https://geninvo.com/cis-confidential-information-scanner/)** that enables sponsors and regulatory teams to securely prepare submission-ready documents—without sacrificing efficiency, accuracy, or compliance. ## Why Confidential Information Protection Matters? The pharmaceutical and biotech sectors face growing scrutiny from health authorities, stakeholders, and the public. Agencies such as the [EMA, FDA](https://www.mabion.eu/science-hub/articles/similar-but-not-the-same-an-in-depth-look-at-the-differences-between-ema-and-fda/#:~:text=The%20FDA%20is%20responsible%20for,5), and Health Canada have reinforced **clinical trial transparency regulations**, requiring companies to disclose trial results and supporting documentation. While transparency builds trust, it also creates significant risks: - **Commercial Risks:** Proprietary methods, strategies, or formulations may be exposed. - **Patient Privacy Risks:** Sensitive details about individuals participating in trials may be inadvertently disclosed. - **Regulatory Risks:** Mishandling of data can lead to **compliance breaches**, rejected submissions, or reputational damage. It is important to manage these risks, which is a manual effort and prone to error. Traditional methods often fail to keep pace with the complexity of handling **CCI** in **eCTD** and **CTA submissions**, especially **CCI redaction** in early-phase clinical trial protocols, Module 2 eCTD and other disclosure-heavy sections. ## The CIS Solution: Automating Compliance and Protection **CIS** is more than just **regulatory redaction software**—it’s a comprehensive platform tailored to the evolving compliance landscape. Leveraging advanced AI technology, CIS automates the redaction and anonymization process, ensuring consistency and precision across large volumes of documents. With **AI-enabled CCI redaction** for clinical trial documents, sponsors can safeguard sensitive data while still meeting disclosure requirements. This approach dramatically reduces manual workload, accelerates timelines, and minimizes the risk of human oversight. ## Key Features and Benefits of CIS CIS empowers organizations with a suite of features designed to make **document anonymization for regulatory submissions** both simple and secure. **1. AI-Powered Redaction** Automatically identifies and redacts sensitive terms, phrases, and data points across documents. **2. Secure CCI Management Software** Ensures safe handling and tracking of confidential information, allowing sponsors to demonstrate compliance and audit readiness. **3. Customizable Rules and Workflows** Adaptable settings enable teams to define rules based on regulatory requirements or company-specific policies. **4. End-to-End Integration** Seamlessly integrates with existing document management and publishing systems to streamline workflows. **5. Built for Clinical Trial Disclosure Compliance** Acts as a cornerstone for **clinical trial disclosure compliance tools**, enabling organizations to meet global transparency obligations without exposing sensitive data. ## Who Benefits from CIS? CIS is built to serve multiple stakeholders in the life sciences ecosystem: - **Pharma/ Biotech Sponsors:** Protect proprietary assets while ensuring regulatory compliance. - **CROs:** Deliver added value to clients by safeguarding confidential data during submissions. - **Medical Writers, Regulatory and Legal Teams:** Improve efficiency by automating repetitive tasks and reducing the risk of manual errors. - **Compliance Officers:** Gain confidence with robust, auditable processes that align with patient privacy and **CCI in submissions**. ***Written By: Abhijeet Arora Designation: Lead-Data Science (Research & Development)*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs --- ### [GenInvo is Powering the Future of Medical Writing at AMWA 2025!](https://geninvo.com/geninvo-is-powering-the-future-of-medical-writing-at-amwa-2025/) **Published:** August 7, 2025 **Author:** admin **Content:** **Date:** November 5–8, 2025 **Location:** Sheraton Phoenix Downtown, 340 N 3rd Street, Phoenix, AZ 85004 GenInvo is proud to sponsor the **[American Medical Writers Association (AMWA) 2025 Conference](https://www.amwa.org/events/event_list.asp)**. Join us as we showcase our latest innovations in clinical data and document automation. #### Featured Technologies: - **[Generative AI](https://geninvo.com/our-products/docwrightai/) & [Document QC Automation](https://geninvo.com/our-products/docqc-medical-writers-automation-tool/)** Improve content quality and streamline medical writing processes. - [**Data & Document Anonymization**](https://geninvo.com/our-products/data-anonymization-tool/)Ensure compliance and patient privacy with automated anonymization tools. - [**Data Collaboration Platform**](https://geninvo.com/our-products/data-collaboration/)Enable seamless team collaboration and centralized data access. - [**CCI Automation**](https://geninvo.com/cis-confidential-information-scanner/)Automate the redaction of confidential clinical information with precision. **Don’t Miss Out!** Discover how our solutions are transforming clinical trial operations. Learn, network, and explore the future of medical writing and technology with GenInvo. [**Register soon and secure your spot.**](https://www.amwa.org/events/EventDetails.aspx?id=1959780&group=)Visit: [www.geninvo.com](https://www.geninvo.com) ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [Live Webinar: Accelerating Authoring and QC of Clinical Documents with AI-Powered Automation](https://geninvo.com/live-webinar-accelerating-authoring-and-qc-of-clinical-documents-with-ai-powered-automation/) **Published:** August 19, 2025 **Author:** admin **Content:** Join **GenInvo’s AWMA Webinar** and explore how AI-powered automation is transforming the future of clinical document authoring and quality control. Clinical trials generate vast amounts of critical documentation, and ensuring accuracy, compliance, and efficiency is a growing challenge for research teams. With GenInvo’s innovative AI-driven solutions, you can significantly reduce manual effort, improve consistency, and accelerate timelines—without compromising on quality. ## Webinar Details - **Topic:** Accelerating Authoring and QC of Clinical Documents with AI-Powered Automation - **Date:** Thursday, 25 September 2025 - **Time:** 1:00 PM – 2:00 PM EDT - **Duration:** 1 Hour - **Mode:** Online (Live Webinar) ### Why Attend? - Learn how AI simplifies authoring & QC processes. - Explore real-world use cases and best practices. - Gain insights to improve efficiency and compliance. [🔗 **Registration opens soon – secure your spot!**](https://www.amwa.org/events/EventDetails.aspx?id=1982137&group=) 👉 www.geninvo.com ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [Python’s Future in Clinical Trials: Innovations and Collaborative Advancements](https://geninvo.com/pythons-future-in-clinical-trials-innovations-and-collaborative-advancements/) **Published:** August 13, 2025 **Author:** admin **Content:** Clinical trials are at the heart of life-saving medical discoveries. But behind these innovations lies a vast amount of complex data—and working with that data is no small task. From reviewing lengthy clinical protocols to extracting meaningful insights from regulatory documents, clinical research teams face growing pressure to automate, streamline, and scale. This is where Python steps in. Known for its simplicity, flexibility, and powerful ecosystem, Python is quietly transforming the way clinical trials are conducted. Whether it’s extracting key insights from unstructured documents or generating synthetic data for model training, Python is proving to be a game-changer for modern pharma. This blog explores how Python is shaping the future of clinical trials—from natural language processing to document automation and synthetic data generation and how its helping researchers work smarter, faster, and more collaboratively than ever before. ## **The Push for Open-Source and Automation in Pharma** Open-source is not just a trend—it is a movement. In clinical trials, it offers transparency, reproducibility, and collaboration. Organizations are embracing open-source ecosystems to keep pace with evolving data demands, tapping into faster development cycles and a vibrant community. Over the last decade, there’s been a noticeable shift in programming preferences within life sciences. While **SAS** remains dominant due to its regulatory legacy, the rise of **Python** and **R** has opened new possibilities for advanced analytics and machine learning. Python, as a community-driven language, brings flexibility, scalability, and collaboration—all of which are critical in today’s fast-moving clinical environment. Python’s open ecosystem provides thousands of libraries tailor-made for: - Data cleaning (pandas, numpy) - Machine learning (scikit-learn, xgboost) - Natural language processing (spaCy, transformers) - Document automation (PyMuPDF, python-docx) Python helps overcome some of the most pressing challenges in clinical trials using above mentioned libraries: - Manual data extraction and formatting from PDFs and Word files - Lack of reproducibility in legacy programming - Time-consuming synthetic dataset creation for testing and development By tapping into Python’s growing open-source ecosystem, pharma teams can now do in days what once took weeks—while improving quality, compliance, and traceability. ## **Turning Clinical Documents into Actionable Data with Python and NLP** Clinical trial documents—like protocols, investigator brochures, and medical narratives—are often hundreds of pages long, rich in content but poor in structure. Extracting meaningful insights from these unstructured files is time-consuming and prone to human error. Python is changing this landscape through a powerful combination of **document automation** and **natural language processing (NLP)**. Using libraries like **PyMuPDF** and **pdfplumber**, clinical teams can parse PDFs to extract structured tables (e.g., visit schedules, dosing regimens), while **python-docx** enables parsing of Word-based documents such as statistical analysis plans (SAPs) or clinical study reports (CSRs). These tools convert static documents into analysable formats like data frames, enabling automation across the regulatory workflow. But the real power comes when combining this with NLP. Libraries like **spaCy**, **transformers** (Hugging Face), and **nltk** allow you to extract and classify key clinical concepts, such as: - Inclusion/exclusion criteria - Adverse events and causality assessments - Endpoint definitions - Protocol deviations For example, a 150-page protocol can be automatically scanned to identify eligibility criteria and extract them into a structured format in minutes—making manual review faster and traceable. Together, Python’s document-handling and NLP capabilities empower clinical research teams to: - Automate repetitive reviews - Minimize human error - Improve traceability and reproducibility - Accelerate the clinical trial pipeline ## **Generating Synthetic Clinical Data: Smarter Testing with Python** One of the biggest bottlenecks in clinical programming and biostatistics is the lack of meaningful test data. Generating realistic datasets manually is both time-consuming and error-prone. Python enables the creation of synthetic datasets that mirror real-world conditions—without exposing patient data. ## **Why Synthetic Data Matters:** - **Privacy:** No need to access sensitive patient information - **Scalability:** Create data for hundreds of test scenarios instantly - **Consistency:** Reduce testing errors and improve automation outcomes Using libraries like Faker, Python allows teams to simulate realistic patient populations, adverse events, and treatment arms. This data can be used to test statistical programs, validate dashboards, and even train machine learning models. ## **Faker and Beyond: Python’s Flexibility** Libraries like [**Faker**](https://faker.readthedocs.io/en/master/) allow teams to quickly simulate patient names, addresses, dates, and even ICD codes or drug names using custom providers. However, Faker is only a starting point. Python enables building **custom tools** that go much further: - **Clinical Logic Simulation**: Inject domain rules (e.g., diabetes patients should not be assigned metformin *and* insulin glargine if trial criteria exclude that combo). - **Time-Series Event Simulation**: Simulate a patient timeline with enrollment, multiple visits, labs, dosing events, and adverse events—all in realistic sequences. - **Synthetic Biomarkers or Genomic Data**: Use statistical distributions or machine learning models to simulate patient biomarkers, gene expression levels, or even omics profiles. - **Interconnected Tables**: Automatically generate SDTM-like or ADaM-like datasets with relational consistency (e.g., matching subject IDs across domains, derived variables aligned with study designs). - **Reusability & Automation**: Create synthetic data generators as reusable components that integrate with test pipelines (e.g., pytest, CI/CD). **Purpose****Library****Description**Statistical simulationsnumpy, scipy, pandasGenerate distributions and structured dataBiological data generationscikit-bio, Biopython, pysynbioSimulate sequence and omics dataML-based generationscikit-learn, XGBoost, pytorch, spaCy, scispaCy, MedSpaC, tensorflow, BioGPT , Bert and ClinicalBERTGenerate data using trained generative modelsSynthetic tabular dataSDV (Synthetic Data Vault)Advanced library for learning real data structure and synthesizing new samples## **Conclusion: A Python-Powered Future for Clinical Trials** Python is more than a programming language—it’s a platform for transformation. From unlocking insights buried in PDFs to generating high-quality synthetic datasets, Python is helping us reimagine how clinical trials are planned, executed, and analysed. As the industry embraces open-source, automation, and ethical AI, Python will continue to lead the way—empowering teams to solve today’s challenges and build a better future for clinical research. As document volume grows and regulatory expectations tighten, these tools are not just convenient—they are essential. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs --- ### [Medical Writer's True AI Enabled Assistant](https://geninvo.com/medical-writers-true-ai-enabled-assistant/) **Published:** December 15, 2023 **Author:** admin **Content:** At GenInvo, our motive is to support pharmaceutical companies to bring life changing therapies into the market sooner so that patients can be benefitted as early as possible. As we know, there are several areas in clinical trials that requires tremendous manual efforts, and we are focussing on eradicating these manual efforts by developing the tools that automate these tasks. Clinical & Regulatory Medical writing team spends a lot of time on drafting the documents manually. Authoring Clinical & Regulatory documents requires significant manual efforts, resulting in a time-consuming authoring process. **How about automating the document authoring life cycle for Clinical & Regulatory Medical writing so that medical writers can spend more time on result discussions?** **And to add more to this we have introduced AI capabilities!!** **We call it your AI enabled Assistant:** A system becomes smarter when artificial intelligence (AI) gets integrated to it. Imagine a system that uses intelligence and work as per your requirement. At GenInvo, to eradicate these manual efforts we developed an intelligent tool – [DocWrightAI](https://geninvo.com/our-products/docwrightai/). It is enabled with AI algorithms and models to support Clinical & Regulatory Documents (typically produced by Regulatory Medical Writing) that will work just like your assistance and that too digitally. [DocWrightAI](https://geninvo.com/our-products/docwrightai/) is your AI enabled assistant (already trained on 400+ study documents) that will work under your supervision and will learn from your actions. This AI enabled true assistant helps you to develop the first draft of the document just by uploading the document template(s) and click of the buttons. **[DocWrightAI’](https://geninvo.com/our-products/docgen/)s Modules:** - Clinical Study Protocol - Clinical Study Report (CSR) - Development Safety Update Report (DSUR) - Statistical Analysis Plan - AE Narrative ***Note: Technology is not restricted to these documents and any specific template*** This AI enable assistant creates contents based on the prompts, that means you just enter keywords or parameters and the content based on the fine-tuned model for the study closest to the inserted prompts will be generated. This will help users to author the draft protocol for conditions or therapeutic areas where there are no reference(s) available. For authoring the document(s) say target document (such as CSR, SAP, etc.) where you need to utilize the information from source documents, DocWrightAI allows you to upload the source documents and corresponding sections from the source documents can be utilized to author the target document(s), here come another advantage of your AI enable assistant that will apply different methods such as copy, copy (past tense) and summarize on source document before utilizing it into target. It has more to offer; your AI assistant not only insert the table into the document but also interpret the tables for you as well. You can use either standard text or AI generated/suggested text to interpret the table for you. ## **CSR Authoring Flow:** ![](https://geninvo.com/wp-content/uploads/2023/12/DocWright-AI-info-V1-1024x572-1.jpg "DocWright-AI-info-V1-1024x572 - GenInvo") ## **Protocol Authoring Flow:** ![](https://geninvo.com/wp-content/uploads/2023/12/DocWright-AI-info-V2-1024x464-1.jpg "DocWright-AI-info-V2-1024x464 - GenInvo") ***By Inderjeet Arora, Principal Data Scientist*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, DocGen **Tags:** Content Generation, Data Merge, Document Assembly, Document Automation, Document Collaboration, Document Formatting, Document Management, Dynamic Document Creation, Efficiency Tools, Productivity Tools, Template-Based Documents, Text Generation, Text Processing, Workflow Automation --- ### [GENINVO™ Sponsors PHUSE Data Transparency Autumn Event 2025](https://geninvo.com/geninvo-sponsors-phuse-data-transparency-autumn-event-2025/) **Published:** July 30, 2025 **Author:** admin **Content:** We are excited to announce that **GENINVO™** is a proud sponsor of the **PHUSE Data Transparency Autumn Event 2025**, taking place **16–18 September 2025**. This virtual event brings together global experts to discuss the evolving landscape of data transparency in clinical research. Join us for insightful sessions covering the latest regulatory updates, data sharing innovations, and transparency best practices. This is an excellent opportunity to connect with thought leaders, explore new solutions, and stay ahead in the life sciences industry. **Event Timings:** - 10:00–12:30 (EDT) - 15:00–17:30 (BST) - 16:00–18:30 (CEST) ✅ **Secure your spot today** and be part of the future of data transparency! 🔗 [Register Now](https://www.phuse-events.org/attend/frontend/reg/tRegisterEmailNew.csp?pageID=65117&ef_sel_menu=5200&eventID=101&tempPersonID=132268) ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [The Changing Role of the Clinical Programmer in an Open-Source World](https://geninvo.com/the-changing-role-of-the-clinical-programmer-in-an-open-source-world/) **Published:** July 29, 2025 **Author:** admin **Content:** Clinical programming is undergoing a transformation. Once dominated by SAS, the field now embraces open-source tools like **R for clinical trials**, **Python in pharma analytics**, and **PySpark for big data in healthcare**. Today’s clinical programmers are not just coders—they’re data explorers, automation architects, and open-source collaborators. --- ## **Key Shifts in the Role of Clinical Programmers** ### **1. From Static Reporting to Agile Data Exploration** Modern clinical programmers now: - Explore trends using **pandas**, **ggplot2**, or **seaborn** - Detect anomalies in real-time - Visualize missing data instantly ### **2. From Manual Scripts to Automated Data Pipelines** Open-source technologies like **PySpark**, **Apache Airflow**, and **Docker** empower programmers to: - Handle massive clinical trial datasets - Automate data transformations and validations - Orchestrate end-to-end clinical data pipelines ### **3. From Closed Systems to Collaborative Development** Today’s programmers: - Share code openly via GitHub - Build reusable R packages and Python modules - Join open-science communities like the **R Consortium** and **CDISC Open-Source Alliance** --- ## **[Essential Skill Set for the Modern Clinical Programmer](https://clinilaunchresearch.in/clinical-sas-programmer/)** **Area****Tools & Platforms**ProgrammingSAS, R (dplyr, tidyverse), Python (pandas)Visualizationggplot2, matplotlib, plotly, seabornBig DataPySpark, SQLAutomationJupyter, RMarkdown, Shiny, DataBricksVersion ControlGit, GitHub, GitLab, BitbucketCloud IntegrationAWS / Azure APIs--- ### **Conclusion** The clinical programmer of today is part **data scientist**, part **engineer**, and part **regulatory analyst**. By embracing open-source tools like **R**, **Python**, and **PySpark**, we’re not just improving efficiency—we’re fostering creativity, collaboration, and innovation. Open-source isn’t replacing SAS—it’s **enhancing clinical programming**. The future belongs to programmers who speak multiple languages, write reproducible code, and bring insights across every stage of the clinical trial journey. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, Uncategorized --- ### [Beyond the Buzzwords: How GenInvo’s AI/ML Tools Are Transforming Life Sciences](https://geninvo.com/ai-ml-tools-life-sciences-geninvo/) **Published:** July 24, 2025 **Author:** admin **Content:** In today’s digital landscape, terms like **Artificial Intelligence (AI)** and **Machine Learning (ML)** are more than just buzzwords—they’re driving innovation across industries. At **GenInvo**, we’re not just discussing the future of **life sciences technology**—we’re actively shaping it. We understand the critical demands of the **pharmaceutical** and **healthcare** sectors: speed, precision, and data security. That’s why we’ve developed **AI/ML-powered solutions for clinical research**, designed to accelerate innovation and bring life-changing treatments to market faster. ## **Why GenInvo’s AI/ML Solutions Stand Out in Life Sciences** Our philosophy is simple: **technology should empower, not complicate**. Through **intelligent automation**, we streamline complex processes, uncover hidden insights, and protect your most sensitive data. Let’s explore how our flagship tools—**DoCQC**, **CIS**, and **Shadow**—are setting new benchmarks in **clinical documentation**, **data privacy**, and **regulatory compliance**. ![Geninvo’s Ai/ml Solutions for Life Sciences](https://geninvo.com/wp-content/uploads/2025/07/GI-NEW-LOGO-All-Service-products-logos-2025-V1.webp "GI-NEW-LOGO-All-Service-products-logos-2025-V1 - GenInvo") --- ## **DoCQC: AI-Powered Quality Control for Clinical Documents** Imagine if **medical writers** could spend less time on manual checks and more time on scientific storytelling. That’s the promise of **DoCQC (Document Quality Control)**—your AI co-pilot for flawless **clinical trial documentation**. ### **Key Features of [DoCQC](https://geninvo.com/our-products/docqc-medical-writers-automation-tool/):** - **Smart Automation for Clinical QC:** Built with adaptive AI/ML algorithms that evolve with use, making your **quality control process** smarter over time. - **Comprehensive Document Checks:** Validates citations (AMA, Harvard), abbreviations, and in-text data against source tables. It even compares **Clinical Study Reports (CSR)** with Protocol and **Statistical Analysis Plans (SAP)**. - **Time Efficiency for Medical Writers:** Reduces review time by over **60%**, allowing writers to focus on strategic content. - **Robust & Flexible Document Review:** Supports multiple document formats, offers offline reports, and enables on-screen editing with track changes. **DoCQC** empowers medical writers to deliver high-quality, compliant documents—faster and more accurately. --- ## **CIS: Confidential Information Scanner – Your Digital Data Sentinel** In an era of increasing **data breaches** and **[cybersecurity threats](https://www.spiceworks.com/it-security/vulnerability-management/articles/what-is-cyber-threat/)**, protecting **Confidential Business Information (CBI)** is essential. Enter **CIS**, GenInvo’s AI-driven solution for identifying and securing sensitive data across the web and public documents. ### **What Makes [CIS](https://geninvo.com/cis-confidential-information-scanner/) Powerful:** - **AI-Driven Data Discovery:** Scans web pages and PDFs for over 100 CBI categories, including **dosage information**, **drug regimen**, and **storage details**. - **Dual Scanning Modes for Data Protection:** - **Web Scan:** Input a drug name (and sponsor, if needed) to initiate a comprehensive scan. - **Document Scan:** Upload PDFs and view highlighted sensitive data directly. - **Self-Learning Algorithms for Accuracy:** Continuously improves detection precision. - **Ongoing Monitoring for Compliance:** Enables re-scans to stay ahead of evolving **data exposure risks**. **CIS** is your proactive defense against **data leaks**, helping ensure **regulatory compliance** and **IP protection**. --- ## **Shadow: Secure Data Sharing Through AI-Powered De-identification** Collaboration is key in science, but so is privacy. **Shadow** is GenInvo’s advanced solution for automated **data de-identification** and **anonymization**, built to meet global mandates like **EMA Policy 0070**, **GDPR**, and **HIPAA**. ### **[Shadow](https://geninvo.com/our-products/data-anonymization-tool/)’s Privacy-First Capabilities:** - **Smart De-identification for Clinical Data:** Uses AI/ML to detect and anonymize **Personally Identifiable Information (PII)** while preserving data utility. - **Automated Redaction Tools:** Supports full redaction, partial masking, and tokenization for secure data sharing. - **Analytics-Ready Privacy Solutions:** Enables research without compromising privacy—ideal for **open science** and **clinical data transparency**. - **Regulatory Compliance Made Easy:** Aligns with global standards for **data protection** and **ethical data sharing**. - **Seamless Integration with Collaboration Platforms:** Works with GenInvo’s **Data Collaboration** platform for secure, scalable data exchange. With **Shadow**, you can collaborate confidently—without risking privacy or compliance. --- ## **The GenInvo Advantage: Innovation Backed by Expertise** At GenInvo, our **Data Science & Analytics Centre of Excellence** drives continuous innovation. Our team blends deep **life sciences domain expertise** with cutting-edge **technology development** to deliver scalable, tailored solutions. ### **Partnering with GenInvo Means You Can:** - **Boost Operational Efficiency:** Automate repetitive tasks and reduce timelines. - **Enhance Data Accuracy:** Ensure **data integrity** and document quality. - **Strengthen Information Security:** Proactively protect sensitive information. - **Accelerate Scientific Discovery:** Focus on **clinical innovation** and **drug development**. --- ## **Ready to Transform Your Life Sciences Operations with AI/ML?** Discover how GenInvo’s intelligent solutions can revolutionize your workflows and drive innovation in **clinical research**, **pharma operations**, and **healthcare analytics**. 👉 **Visit www.geninvo.com** to learn more and take the next step toward a smarter, more secure future. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs --- ### [Empowering the Future of Life Sciences: A GenInvo Perspective from the Inside](https://geninvo.com/empowering-the-future-of-life-sciences-a-geninvo-perspective-from-the-inside/) **Published:** June 30, 2025 **Author:** admin **Content:** At GenInvo, we often say we’re not just a technology company—we’re a transformation partner for life sciences. As someone who is part of the GenInvo family, I’ve had a front-row seat to how our teams blend innovation, technology, and regulatory expertise to solve some of the industry’s most complex challenges. This blog is more than just a recap of our latest work—it’s a window into the ideas, tools, and passion driving GenInvo’s journey toward reshaping how clinical research and healthcare data are handled. From artificial intelligence in medical writing to data anonymization and digital automation, I’m proud to share how we are actively leading the next era of life sciences transformation. ## **Synthetic Data: Training Smarter, Safer Models** One of the most exciting areas we’ve been working on is **synthetic data generation**. In clinical research, data privacy is non-negotiable—but it can also be a bottleneck when training models. That’s where our focus on **meaningful synthetic data** comes in. By generating data that mirrors real-world clinical datasets while ensuring no actual patient information is exposed, we enable safer model development. This has far-reaching implications—not just for product development, but also for driving regulatory-compliant innovation in AI and machine learning. Synthetic data isn’t just a workaround—it’s a critical enabler. It ensures that our solutions like **DocWrightAI** and others can be trained to understand real-world patterns without risking patient privacy. ## **[DocWrightAI](https://geninvo.com/our-products/docwrightai/): Redefining Medical Writing** If there’s one product I’ve seen generate both excitement and measurable impact across teams, its **DocWrightAI**. This isn’t just a writing assistant—it’s a full-fledged AI-driven tool that understands the nuances of **clinical documentation**. Whether drafting clinical study reports, summarizing findings, or performing real-time quality checks, DocWrightAI significantly reduces manual effort and turnaround time. More importantly, it empowers our teams (and our clients) to focus on the content that matters while automating repetitive tasks. We’ve seen it in action: what used to take days can now be done in hours—with greater accuracy and regulatory alignment. ## **Embracing the Digital Medical Writing Era** Transitioning from traditional to **digital medical writing** is more than a technical change—it’s a cultural one. Within GenInvo, we’ve embraced this shift wholeheartedly, and we’re helping clients do the same. Digitizing medical writing enables centralized collaboration, version control, real-time editing, and seamless integration with data repositories. These capabilities don’t just make the writing process faster—they make it smarter. It’s all about **bridging the gap between unstructured data and intelligent documentation**. Whether its writing narratives, generating submission-ready reports, or conducting automated reviews, digital tools are elevating the role of medical writers to strategic communicators and data interpreters. ## **Data Anonymization: Privacy by Design** Working in life sciences means constantly walking a tightrope between data accessibility and patient privacy. That’s why **data anonymization** has become a cornerstone of everything we do—especially when it comes to data sharing, research, and compliance with regulations like GDPR and HIPAA. At GenInvo, we use robust techniques like **de-identification, masking, and tokenization** to anonymize sensitive datasets. But what makes our approach unique is how we balance utility with protection. We don’t just anonymize—we ensure the data remains meaningful for analysis. This principle of **“privacy by design”** is not just a checkbox—it’s embedded into the core architecture of our platforms and practices. ## **Unstructured Clinical Data: From Complexity to Clarity** One of the biggest challenges I see across the industry is dealing with **unstructured clinical data**—think handwritten notes, PDFs, audio transcripts, and so on. These are often rich in insights but difficult to analyze. Through our work with **automation tools and NLP ([Natural Language Processing](https://www.geeksforgeeks.org/nlp/natural-language-processing-overview/))**, we’ve been transforming this chaos into clarity. We’ve built intelligent pipelines that read, structure, and classify this data, enabling better decision-making in clinical trials and regulatory reporting. What used to be locked in text is now actionable, reportable, and even predictive—thanks to automation and AI. ## **Automation and Quality Control: Precision at Scale** In clinical research, even the smallest error can derail timelines and impact patient safety. That’s why we’ve put so much emphasis on **automated quality control (QC)**. Our AI-powered QC systems identify inconsistencies, validate formats, and flag missing data across clinical documents. Whether it’s SDTM datasets, ADaM listings, or submission documents, we’ve built tools that reduce manual QC time dramatically. Internally, we’ve seen these tools boost our own delivery speed and accuracy. Externally, our clients now experience faster turnaround and improved audit readiness. ## **CDISC Standards: Data That Speaks the Same Language** Standardization might not sound exciting—but it’s vital. Aligning data with **CDISC (Clinical Data Interchange Standards Consortium)** standards ensures that clinical trial information is interoperable, consistent, and submission-ready. At GenInvo, we’ve developed solutions that **automate the transformation** of raw clinical data into CDISC-compliant formats. Our teams also assist clients with **SDTM and ADaM conversions**, making regulatory submissions smoother and faster. By speaking the same “data language,” we empower organizations to conduct more efficient meta-analyses and regulatory reviews. ## **Clinical Document Review Gets Smarter with AI** We all know how tedious and time-consuming **clinical document review** can be. It’s essential—but historically, it’s also been manual and error-prone. That’s changing at GenInvo. Our AI-powered tools now **review thousands of pages** in minutes—spotting inconsistencies, verifying references, checking compliance with templates, and even assessing readability. The best part? These tools work alongside our medical reviewers, not in place of them. This human-AI collaboration ensures both speed and accuracy. It’s not just about automating review—it’s about **enhancing insight**. ## **The Bigger Picture: Our Vision at GenInvo** When I look at all the initiatives we’re part of—from AI in medical writing to advanced data privacy frameworks—I see a bigger mission at work. At GenInvo, we’re not just building tools; we’re building **confidence in clinical research**. We believe in making regulatory and clinical processes smarter, faster, and safer. We believe in democratizing data without compromising privacy. And above all, we believe in enabling our clients—pharmaceutical companies, CROs, and health systems—to bring therapies to patients more efficiently. **Looking Ahead** The future is exciting, and we’re just getting started. As new challenges emerge—from global data privacy laws to increasingly complex clinical trial designs—our commitment remains the same: to deliver transformative digital solutions that **empower people and protect patients**. Whether you’re a regulatory writer looking to streamline submissions, a data scientist working on patient analytics, or a compliance officer ensuring GxP standards, we’re here to support you with tools that are **built by experts, for experts**. ## **Final Thoughts** Being part of GenInvo has been more than a job—it’s been a journey of innovation, collaboration, and real-world impact. Our blogs are just one way we share what we’re building and learning along the way. If you’re a life sciences professional ready to embrace the next wave of AI, automation, and digitalization—let’s talk. We’re not just future-ready. We’re **future-defining**. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs --- ### [GenInvo’s CIS Tool: Safeguarding Confidential Company Information in Life Sciences.](https://geninvo.com/geninvos-cis-tool-safeguarding-confidential-company-information-in-life-sciences/) **Published:** June 20, 2025 **Author:** admin **Content:** In the life sciences industry, protecting Confidential Company Information (CCI) is paramount. As regulatory agencies such as the **FDA (Food and Drug Administration), EMA (European Medicines Agency), PMDA (Pharmaceuticals and Medical Devices Agency), Health Canada**, etc. emphasize transparency, organizations must ensure that proprietary information remains secure. GenInvo’s Confidential Information Scanner (CIS) Tool offers an AI-driven solution to identify and manage CCI effectively. ## **Defining Confidential Company Information (CCI)** Different regulatory bodies provide specific definitions for CCI:​ - **European Medicines Agency (EMA)**: Under EMA Policy 0070, CCI is defined as: ​ “Any information contained in the clinical reports submitted to the Agency by the applicant/MAH that is not in the public domain or publicly available and where disclosure may undermine the legitimate economic interest of the applicant/MAH.” - **Health Canada**: According to the Food and Drugs Act, Confidential Business Information (CBI) is:​ “Information that is not publicly available, where its disclosure could result in material financial loss or gain to a person, or could prejudice the competitive position of a person.” - **​U.S. Food and Drug Administration (FDA):** The FDA defines Confidential Commercial Information as: “Valuable data or information which is used in a business and is of such type that it is customarily held in strict confidence or regarded as privileged and not disclosed to any member of the public by the entity to whom it belongs.” ## **Regulatory Guidelines on CCI** Regulatory agencies have established guidelines to protect CCI:​ - **EMA Policy 0070:** Mandates the publication of clinical data while allowing redaction of CCI to protect economic interests.​ - **Health Canada’s Public Release of Clinical Information (PRCI)**: Requires the removal of CBI before public disclosure of clinical information.​ - **FDA Transparency Initiatives**: Encourage data sharing but emphasize the protection of trade secrets and confidential commercial information.​U.S. Food and Drug Administration. ## **GenInvo’s CIS Tool: An Overview** The CIS Tool is designed to help organizations identify and manage CCI effectively.​ **Key Features**: - **AI and Rule-Based Detection**: Combines artificial intelligence with predefined rules to identify CCI across various documents.​ - **Comprehensive Category Coverage:** Scans and extracts information across more than 50 categories, including dosage regimens and exploratory endpoints.​ - **Web and Document Scanning:** Supports scanning of both web sources and documents (e.g., PDFs).​ - **User-Friendly Interface**: Offers an intuitive interface for reviewing and managing identified CCI. - ​**Integration Capabilities:** Can be combined with **GenInvo’s Shadow™** for data anonymization and integrated with their Data Collaboration Platform for secure data sharing. - **​Implementation Workflow** - **Input Submission**: Users upload documents or provide drugs/assets information for scanning. - **Automated Scanning**: The tool analyzes content using AI and rule-based algorithms. Scanning on web can be performed within specific URLs or in google as well.​ - **CCI Identification:** Potentially confidential information is flagged for review.​ - **Review and Validation:** Users assess flagged content and confirm or adjust as necessary.​ - **Reporting:** Generates reports and redacted documents for compliance and record-keeping.​ ## **Benefits for Life Sciences Organizations** - **Regulatory Compliance:** Ensures alignment with EMA, FDA, and Health Canada guidelines.​ - **Risk Mitigation:** Reduces the likelihood of unintentional disclosure of sensitive information.​ - **Operational Efficiency:** Automates the identification process, saving time and resources.​ - **Enhanced Collaboration:** Facilitates secure data sharing with stakeholders while protecting CCI.​ **Conclusion** Protecting Confidential Company Information is crucial in the life sciences sector. GenInvo’s CIS Tool provides a robust solution to identify and manage CCI, ensuring organizations remain compliant with regulatory requirements while safeguarding their proprietary information. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs --- ### [Why Clinical Data Transparency Matters: Benefits for Patients, Researchers, and Industry](https://geninvo.com/why-clinical-data-transparency-matters-benefits-for-patients-researchers-and-industry/) **Published:** June 13, 2025 **Author:** admin **Content:** In an era where data drives innovation, **clinical data transparency** has emerged as a cornerstone of ethical, effective, and efficient healthcare. It refers to the open sharing of clinical trial data, including protocols, results, and anonymized patient-level data. While once shrouded in confidentiality, clinical data is increasingly being recognized as a public good. **Clinical data transparency –** the open sharing and disclosure of clinical trial information and results – is crucial for building a trustworthy, effective and ethical healthcare ecosystem. It’s no longer just a regulatory obligation; it’s a vital part of medical innovation and public trust. But why does this transparency matter so much—and who really benefits? ## **1. Empowering Patients Through Trust and Safety** Patients are at the heart of clinical research. Transparency ensures that: - **Informed decisions** can be made about treatments, especially when patients and doctors have access to comprehensive trial results. - **Trust in the healthcare system** is strengthened when patients know that data—positive or negative—is not being hidden. - **Patient safety** is enhanced by reducing the risk of repeating harmful or ineffective trials. For example, when adverse effects are openly reported, future patients are protected from unnecessary harm. ## **2. Accelerating Scientific Discovery for Researchers** For researchers, access to clinical data is a goldmine: - **Avoiding duplication**: Transparency prevents redundant studies, saving time and resources. - **Higher study Quality:** Knowing that data will be publicly scrutinized encourages better study design thorough reporting, and more ethical research conduct. - **Enhancing Reproducibility and Validation:** Open access to protocols and datasets allows others to replicate studies, verify results, and improve scientific rigor. Strengthens the credibility and reliability of published research. ## **3. Driving Efficiency and Credibility in the Industry** Pharmaceutical and biotech companies also stand to gain: - **Improved credibility**: Transparency combats the perception of selective reporting or data manipulation. - **Regulatory alignment**: Agencies like the FDA and EMA increasingly require data sharing, making transparency a compliance necessity. - **Market Differentiation**: Organizations that champion data transparency can use it is a differentiator, showing they are ethical and patient-focused, appealing to both investors and consumers. Moreover, transparent practices can lead to **faster drug development**, as shared data helps identify promising compounds and avoid dead ends. However, initiatives like **[ClinicalTrials.gov](https://clinicaltrials.gov/)**, **EU Clinical Trials Register**, and **[data-sharing platforms](https://geninvo.com/our-products/data-collaboration/)** (e.g., Vivli, YODA Project) are paving the way for a more open future. **Conclusion:** Clinical data transparency is not just a regulatory checkbox—it’s a moral imperative. It empowers patients, fuels research, and strengthens the healthcare industry. As we move toward a more data-driven world, embracing transparency will be key to unlocking better health outcomes for all. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs --- ### [How Meaningful Synthetic Data Generation Tools Are Transforming AI Development ](https://geninvo.com/how-meaningful-synthetic-data-generation-tools-are-transforming-ai-development/) **Published:** January 2, 2025 **Author:** admin **Content:** Artificial Intelligence (AI) has become the backbone of modern innovation. From recommending your favorite music playlist to helping doctors detect diseases, AI touches every part of our lives. But behind every AI model lies one key ingredient — data. Without high-quality data, AI is like an artist without paint. Yet, as businesses aim to develop AI faster, safer, and smarter, a big question arises: Where do we get enough reliable and meaningful data? Talking about clinical trials, manually generating the test data required to support processes such as Clinical Programming (CP), Biostatistics, and other statistical analyses is often time-consuming and inefficient. The lack of automation in such areas leads to significant challenges, including delays in quality checks, due to limited data coverage for specific scenarios. These inefficiencies highlight the importance of leveraging AI algorithms for automated data generation, which can surpass manual methods by ensuring efficiency, consistency, and broader data coverage. This is where “synthetic data generation tools” come into the picture. These tools are quietly revolutionizing the way we build AI, solving challenges like privacy, data scarcity, and bias. In the following sections, let’s dive into how these tools are transforming AI development, making it more efficient, ethical, and accessible. ## The Struggle for Data in AI Development AI models are increasingly used to predict patient outcomes, optimize treatment plans, and identify adverse effects. These AI models have also begun to be adopted in clinical trials, However, accessing diverse patient datasets to train these models is a significant challenge. Privacy concerns, coupled with strict regulations like HIPAA and GDPR, limit the availability of comprehensive datasets. Sharing sensitive patient information could expose organizations to legal risks and compromise individual privacy. On the other hand, creating new data manually is time-consuming, expensive, and often impractical. Businesses and research teams struggle to balance: Privacy: How do you ensure sensitive information isn’t misused? Quantity: How do you get enough diverse data to train models? Bias: How do you prevent data from reflecting real-world stereotypes or unfairness? This struggle creates a bottleneck in AI development, slowing innovation in clinical research. For years, it seemed unsolvable. But synthetic data tools have changed the game. ## What Is Synthetic Data and Why Is It “Meaningful? Synthetic data is artificially generated data that mimics real-world data but doesn’t include real personal or sensitive information. Think of it like a movie scene—actors look and behave like real people, but they’re not real. Similarly, synthetic data “acts” like real data but poses no privacy risks. However, for synthetic data to serve its purpose effectively, it must be more than just realistic—it needs to be meaningful. This means it must: - “Look real”: Synthetic data must resemble the patterns and behaviors of real-world data, including maintaining a logical chronological order of dates and preserving relationships between datasets. For example, in clinical trials, data points like concomitant medications (CM) given for adverse events (AE) must align accurately. - “Be useful”: It should retain statistical relationships and insights required for AI model training and support processes such as Clinical Programming (CP) and Biostatistics. - “Be diverse and relevant”: It must reflect a variety of scenarios while avoiding mismatches, such as ensuring pregnancy test data applies only to females and not males. Synthetic data tools must handle these requirements carefully. Without meaningful attributes—like maintaining the interlinking of data and ensuring consistency—synthetic data fails to meet the demands of real-world applications, particularly in fields like clinical trials. By addressing these needs, synthetic data can provide ethical and impactful solutions, unlocking the full potential of AI. This combination allows synthetic data tools to create datasets that are both ethical and impactful, ready to unlock the full potential of AI. ## How Synthetic Data Tools Are Transforming AI Development 1\. Breaking Privacy Barriers Privacy concerns are one of the biggest challenges in AI. Businesses often hesitate to share data because of legal risks and public trust. Synthetic data eliminates this fear. This data is generated by algorithms and no real data is used to generate this meaningful synthetic data,hence there is no risk of de-identifying patients. Take healthcare as an example. Hospitals can use synthetic patient records to train AI models for disease detection without revealing sensitive details about real patients. It feels like a win-win: AI advances, and people’s privacy is respected. “We were always afraid of data privacy risks before. With synthetic data, we’re innovating faster and sleeping better at night.” — A Healthcare Data Scientist 2. Solving the Data Scarcity Problem What if you’re trying to develop an AI model for a rare problem, like detecting a rare disease or identifying faults in a complex machine? Real-world data for such scenarios is often scarce. Synthetic data tools can create new, high-quality samples to fill these gaps. For instance, automotive companies use synthetic data to simulate thousands of car crash scenarios that are difficult to capture in real life. This allows AI systems in self-driving cars to learn faster and safer. 3. Reducing Bias and Making AI Fairer AI models are only as good as the data they’re trained on. If the real-world data is biased—say, underrepresenting a particular gender or ethnicity—the AI will inherit and amplify that bias. Synthetic data tools allow developers to create \*balanced datasets\* that include all perspectives. For example, in facial recognition software, synthetic data can ensure the AI recognizes faces of all ethnicities and ages equally well. By removing bias, these tools don’t just improve accuracy; they also make AI fairer and more inclusive. 4\. Accelerating AI Development with Faster Training In traditional AI development, collecting, cleaning, and labeling data can take months—sometimes years. Synthetic data tools automate this process, generating massive datasets in days or even hours, which can save businesses both time and money. However, it’s important to ensure that the data is meaningful and representative of real-world conditions. If the synthetic data lacks quality or doesn’t reflect the necessary complexities, the training process might not produce reliable or accurate models. By balancing speed with meaningful data, developers can iterate faster, test different models, and achieve results that are both rapid and effective. It’s like putting AI development into overdrive—without sacrificing quality. 5\. Enabling Creativity and Innovation Finally, synthetic data opens doors to creativity, it doesn’t just accelerate AI development—it unlocks new possibilities. For example, in healthcare, synthetic data can simulate clinical trials by generating diverse patient profiles, helping researchers explore outcomes and optimize trial designs while safeguarding privacy. To enhance usability, developers can also set up dashboards to visualize datasets. For instance, a dashboard for fraud detection could highlight transaction trends and anomalies, while a clinical trial dashboard might show synthetic patient response patterns or subgroup analysis. This flexibility empowers businesses and researchers to test innovative ideas, refine them, and push boundaries like never before. **Case Studies/real life examples: Synthetic Data in Action** - Healthcare: A team training an AI to detect cancer from medical scans used synthetic images of tumors to boost accuracy without accessing real patient records. - Retail: An e-commerce company generated synthetic transaction data to test fraud detection models without compromising customer trust. - Autonomous Vehicles: Companies simulated millions of virtual driving miles, teaching self-driving cars to handle accidents, pedestrians, and more. In each case, synthetic data made the impossible possible—faster, safer, and more efficiently. ## The Future of AI and Synthetic Data Tools As AI continues to grow, the demand for clean, reliable data will only increase. Synthetic data tools are not just a nice-to-have—they’re becoming a necessity. They are bridging the gap between innovation and ethics, ensuring businesses can build powerful AI solutions without compromising trust, privacy, or fairness. The future is bright. A future where AI understands the world better because the data it learns from is richer, more diverse, and truly meaningful. ## Final Thoughts The power of synthetic data generation tools lies in their ability to unlock human potential. By automating the data creation process, these tools save time and resources compared to manual methods, which are often slow, costly, and error prone. Automation ensures scalability, consistency, and the ability to generate diverse datasets tailored to specific use cases. However, automation must go hand in hand with ensuring data is meaningful and representative. Without quality and relevance, even the largest datasets won’t produce reliable results. Synthetic data allows developers, data scientists, and businesses to innovate without limits while respecting privacy, maintaining fairness, and addressing the complexities of real-world scenarios. Interactive dashboards can further enhance the process by enabling visualization and analysis of datasets, helping teams refine their models and strategies effectively. Synthetic data is not just changing AI—it’s changing lives. As these tools continue to evolve, they will empower us to tackle challenges more efficiently and ethically, building a world where technology serves everyone equally. “When we have the right data, we can solve the right problems. Synthetic data isn’t just a tool—it’s hope for a better future.” ***By Inderjeet Arora Principal -Data Scientist Research & Development*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, Uncategorized --- ### [Launch Your Career with GenInvo – Internship Opportunity](https://geninvo.com/launch-your-career-with-geninvo-internship-opportunity/) **Published:** April 23, 2025 **Author:** admin **Content:** At GenInvo, we sit at the intersection of Life Sciences expertise, cutting-edge technology, and innovative software development. Are you ready to take the first step toward a thriving career? We’re offering **unpaid internships** designed to provide hands-on, real-world experience in the **Life Sciences industry**, **Project Management**, **Marketing**, **Business Development** and **Product Development**. ### Why Join GenInvo? 🌟 **Mentorship & Learning** Work alongside experienced professionals who will support and mentor you throughout your journey. Gain valuable insights that will help you stand out in any role you pursue. 📈 **Professional Development** Strengthen your skills in your chosen area and gain exposure to strategic workplace approaches. This internship is designed to boost your confidence and capabilities across industries. 🏅 **Recognition & Rewards** Your contributions matter. At the end of the internship, you’ll receive a certificate of achievement and may qualify for a **performance-based stipend**. At GenInvo, we believe in empowering the next generation of professionals. Join our passionate and forward-thinking team this summer, and take a bold step toward a career you love. 📨 **Apply Now** Don’t miss out on this exciting opportunity! Send your resume and a brief statement of interest to **info@geninvo.com** or click on **Apply Button** above and start building your future with GenInvo today. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** job --- ### [GENINVO™ at PHUSE US Connect 2025](https://geninvo.com/geninvo-at-phuse-us-connect-2025/) **Published:** February 18, 2025 **Author:** admin **Content:** 📢 **We’re excited to announce that GENINVO™ will be presenting at [PHUSE US Connect 2025](https://www.cdisc.org/events/education/external-events/2025/03/phuse-us-connect-2025)!** 📌 **Topic:** *ML01: Intelligent Automation in Anonymisation for CTIS Submission* 🗓 **Date:** March 17, 2025 📍 **Location:** Orlando, Florida 🎤 **Speakers:** 🔹 **Pinku Hooda** – Speaker 🔹 **Hitesh Raval** – Speaker Join us as our experts, Pinku Hooda and Hitesh Raval, delve into the advancements in **Intelligent Automation for Anonymisation in CTIS Submissions.** Learn how cutting-edge technology is revolutionizing data privacy and compliance in clinical trials. This is a great opportunity to engage with industry leaders, gain insights into regulatory requirements, and explore innovative solutions in data anonymisation. 💡 Don’t miss out! Visit our website to learn more about our expertise and solutions. ***👉 Mail Us on: info@geninvo.com*** We look forward to connecting with you in Orlando! --- ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [Join GENINVO™ at the DIA Medical Affairs and Scientific Communications Forum](https://geninvo.com/join-geninvo-at-the-dia-medical-affairs-and-scientific-communications-forum/) **Published:** February 18, 2025 **Author:** admin **Content:** 📅 **Date:** March 10-12, 2025 📍 **Location:** 39 Dalton Street, Boston, MA 02119 🎯 **Visit Booth #202** We’re excited to announce that GENINVO™ will be participating in the **[DIA Medical Affairs and Scientific Communications Forum](https://www.diaglobal.org/Conference-Listing/Meetings/2025/03/Medical-Affairs-and-Scientific-Communications-Forum)**! This premier event brings together industry leaders and experts to discuss the latest advancements in medical affairs, scientific communications, and innovative technologies. Come visit us at **Booth #202** to explore how GENINVO™ is driving transformative solutions and discover how we can support your medical and scientific communication needs. The countdown has begun—don’t miss this opportunity to connect with us! If you have any questions or would like to schedule a meeting, feel free to reach out. ***Mail us on: info@geninvo.com*** We look forward to seeing you in Boston! --- ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [Thank You for Attending the GENINVO's AMWA Webinar](https://geninvo.com/thank-you-for-attending-the-geninvos-amwa-webinar/) **Published:** November 8, 2024 **Author:** admin **Content:** ***Topic: Empowering Clinical and Regulatory Writing: Harnessing AI as Your Assistant*** We would like to sincerely thank you for joining us at the recent AMWA webinar. We greatly appreciate your time and participation, and we hope you found the session both informative and valuable. Here are the survey results from our successful webinar. ![](https://geninvo.com/wp-content/uploads/2024/11/Screenshot-2024-11-08-190038-1024x653.webp "Screenshot 2024-11-08 190038 - GenInvo") ![](https://geninvo.com/wp-content/uploads/2024/11/poll4-1.webp "poll4 1 - GenInvo") ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events, Uncategorized --- ### [CDISC Standards and Data Transformation in Clinical Trial.](https://geninvo.com/cdisc-standards-and-data-transformation-in-clinical-trial/) **Published:** July 23, 2024 **Author:** admin **Content:** Clinical trials are research studies conducted in humans to evaluate the safety and effectiveness of medical treatments, interventions, or devices. These trials are essential steps in the process of developing new treatments or improving existing ones. In clinical trials, data transformation refers to the process of preparing and organizing clinical trial data according to specific CDISC standards. CDISC standards are used to streamline the collection, management, and submission of clinical trial data to regulatory authorities such as the FDA (Food and Drug Administration), EMA (European Medicines Agency), etc. Here’s how data transformation is applied within CDISC standards: ## **CDISC Standards and Data Transformation:** ### **SDTM (Study Data Tabulation Model):** **Data Mapping:** SDTM defines a standardized structure for organizing data collected during a clinical trial. Data transformation involves mapping raw data elements (from various sources (such as EDC, Third Party data etc.) and formats) to SDTM domains, variables, and controlled terminology. **Variable Transformation:** Raw data may need to be transformed to fit the specific format and definitions required by SDTM domains (e.g., converting dates to SDTM date format, coding categorical data using CDISC terminology). ### **ADaM (Analysis Data Model):** **Dataset Creation:** ADaM provides a standard structure for analysis datasets used in statistical analyses. Data transformation involves creating ADaM datasets from SDTM data, which may include aggregating data, deriving new variables, and applying statistical methods to prepare data for analysis. **Variable Derivation:** Variables needed for statistical analysis are derived from SDTM data in accordance with ADaM specifications. ### **CDASH (Clinical Data Acquisition Standards Harmonization):** **Data Collection:** CDASH provides standards for the collection of clinical trial data in electronic case report forms (eCRFs). While CDASH primarily focuses on data collection rather than transformation, adherence to CDASH standards ensures that data collected during the trial are structured and formatted in a way that facilitates subsequent data transformation into SDTM. ## **Processes Involved in Data Transformation in CDISC:** **Data Standardization:** Transforming diverse and heterogeneous raw data from clinical trials into a standardized format (SDTM) ensures consistency and interoperability. **Controlled Terminology:** Applying CDISC-controlled terminology ensures that variables are coded uniformly across trials, facilitating data analysis and regulatory submissions. **Metadata Creation:** Metadata describing the transformation processes and decisions made (e.g., mappings, derivations) are documented to ensure traceability and transparency. ## **Benefits of CDISC Data Transformation:** **Interoperability:** CDISC standards enable interoperability between different clinical trial datasets and systems, facilitating data exchange and integration. **Standardization**: Ensures consistency in data structure and format across clinical trials, facilitating data integration and comparison. **Efficiency:** By standardizing data transformation processes, CDISC reduces the time and effort required for data management and regulatory submissions. **Regulatory Compliance:** Submission of clinical trial data in CDISC-compliant formats supports regulatory requirements and speeds up the regulatory review process. In conclusion, data transformation in CDISC involves converting raw clinical trial data into standardized formats (SDTM, ADaM) using defined processes and controlled terminology. This transformation ensures data consistency, interoperability, and compliance with regulatory standards, thereby facilitating efficient data management and analysis in clinical research. ***By Amal Anandan Principal Data Scientist Innovative Solutions & Strategist*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs --- ### [Business Analyst/Senior Business Analyst](https://geninvo.com/business-analyst-senior-business-analyst/) **Published:** December 4, 2024 **Author:** admin **Content:** **Job Description:** This role is ideal for someone who enjoys both the strategic aspects of project management, and the detailed analysis required to improve business processes. This is requiring a blend of analytical and project management skills **Role and responsibilities** 1. **Business Analysis:** - Gather and document business requirements from stakeholders. - Analyse business processes and identify areas for improvement. - Develop functional specifications and system design documents. - Facilitate communication between business units and technical teams. - Conduct feasibility studies and cost-benefit analyses. 2. **Project Management:** - Develop and manage project plans, timelines, and budgets. - Coordinate with stakeholders to ensure project requirements are met. - Monitor project progress and make adjustments as needed. - Conduct risk assessments and implement mitigation strategies. - Ensure project deliverables meet quality standards and client expectations. **Skills and Qualifications** - **Education:** Bachelor’s degree in business, Computer Science or a related field. - **Certifications:** PMP, PMI, CBAP, or similar certifications are often preferred. - **Experience:** Proven a minimum of 5 years’ experience in both business analysis and project management roles. - **Technical Skills:** Proficiency in project management software (e.g., Microsoft Project, JIRA) and business analysis tools (e.g., SQL, Excel). - **Soft Skills:** Strong communication, problem-solving, and leadership abilities. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** job --- ### [SME: Data Transparency and Medical Writing](https://geninvo.com/sme-medical-writing/) **Published:** November 30, 2024 **Author:** admin **Content:** **Job Summary:** - We are hiring for a highly motivated and experienced SME in Medical Writing with a passion for digitalization and its impact on medical writing, we invite you to join our team. Together, we can revolutionize medical communication, improve information accessibility, and shape the future of healthcare through digital innovation. - Leadership Strategy: A strong leader who can articulate a clear vision and strategy for automating medical writing tools and can help us demonstrate our digital medical writing tools to other companies. - Digital Transformation: Lead the digital transformation of medical writing processes by identifying and implementing innovative digital tools, platforms, and technologies that enhance efficiency, collaboration, and content delivery. - Digital Strategy: Develop and execute a comprehensive digital strategy for medical writing, incorporating best practices, emerging trends, and audience engagement techniques to optimize the reach and impact of medical content. - Industry Knowledge: Familiarity with Healthcare/Pharmaceutical/CRO industry trends, emerging technologies, and market dynamics related to automated technology in healthcare. - Technical Expertise: Develop a comprehensive understanding of our automated technology solutions and their clinical implications, staying updated with the latest advancements and industry trends. - Technical Knowledge: Strong understanding of automated technology solutions, such as artificial intelligence, machine learning, robotics, or data analytics, and their impact on healthcare delivery, patient outcomes, and clinical decision-making. - Communication Strategy: Collaborate with cross-functional teams, including product managers, engineers, and healthcare professionals, to develop effective communication strategies that highlight the value proposition of our automated technology solutions. - Project Management: Proven ability to manage multiple projects simultaneously, prioritize effectively, and meet deadlines in a fast-paced environment. Strong organizational skills and attention to detail. - Regulatory Compliance: Ensure adherence to regulatory guidelines, such as FDA regulations, medical writing best practices, and industry standards, while creating accurate and compliant medical content. - Scientific Collaboration: Partner with internal and external stakeholders, including key opinion leaders, researchers, and clinicians, to gather insights, validate content, and foster scientific collaborations. **Requirements:** - Education and Experience: A minimum of a bachelors/master’s degree in a scientific discipline, preferably with a focus on healthcare or medical writing. Proven experience as a medical writer, with specific expertise in automated technology and its applications in healthcare settings. - Regulatory Understanding: Familiarity with regulatory guidelines, including FDA regulations, ICH guidelines, and Good Clinical Practice (GCP), ensuring compliance in all medical writing activities. - Collaboration and Communication: Excellent collaboration and communication skills, with the ability to work effectively with cross-functional teams, key stakeholders, and subject matter experts. - Attention to Detail: Strong attention to detail and accuracy in medical writing, ensuring scientific integrity and precision in the interpretation of clinical data and research findings. - Time Management: Proven ability to manage multiple projects simultaneously, meet deadlines, and prioritize effectively in a fast-paced and dynamic environment. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** job --- ### [Empowering Clinical and Regulatory Writing: Harnessing AI as Your Assistant  ](https://geninvo.com/empowering-clinical-and-regulatory-writing-harnessing-ai-as-your-assistant/) **Published:** October 11, 2024 **Author:** admin **Content:** **Date: Thursday, 07 November 2024** **Time: 11:00 AM EDT** At GenInvo, we’re constantly pushing the boundaries of innovation in clinical and regulatory writing. We are thrilled to present our latest advancements at the AMWA Webinar, showcasing how our AI-driven solutions are transforming the landscape of medical writing and communication. **What to Expect:** Our session, “Empowering Clinical and Regulatory Writing: Harnessing AI as Your Assistant”, will dive into how cutting-edge technology is streamlining complex processes, making it easier for professionals to focus on the quality and accuracy of their content. **We will be featuring live demos of our key tools designed to enhance your workflow:** - **DocWrightAI:** See how our AI tool supports regulatory and clinical writing with features like method drafting, automatic table insertion, and interpretation suggestions. - **DocQC:** Discover how our platform simplifies document quality control, with an in-depth demonstration on in-text post text checks and statement of findings (SOF) reversals. - **Shadow:** Experience the seamless analysis of clinical study reports (CSRs) and datasets with Shadow, enabling quick data extraction and cross-checking. By incorporating AI into everyday tasks, GenInvo’s solutions empower medical writers and regulatory professionals to reduce manual effort and increase efficiency. From automating document quality checks to interpreting clinical data, our AI tools act as powerful assistants that help you focus on creating high-impact, quality documents. Join us to learn how these solutions can redefine the way you work, giving you the tools to navigate complex documents with ease and precision. Don’t miss the chance to be part of the conversation that’s shaping the future of medical writing. **How to Register** To register for this webinar and learn more about our groundbreaking tools, visit \[[American Medical Writers Association (amwa.org)](https://www.amwa.org/events/EventDetails.aspx?id=1896561&group=)\]. Stay tuned for more updates! ***Marketing Team, GenInvo*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs --- ### [Join Our Free Webinar!](https://geninvo.com/join-our-free-webinar/) **Published:** October 4, 2024 **Author:** admin **Content:** ## Topic: Empowering Clinical & Regulatory Writing: Harnessing Al as Your Assistant **Date: Thursday, November 7 Time: 11:00 AM – 12:00 PM EDT** *Online registration is available until: 11/7/2024. [Click here!](https://www.amwa.org/events/EventDetails.aspx?id=1896561)* ## **Learning Objectives and Key take-aways:** **After participating in this webinar, attendees will be able to:** 1. **Identify the Optimal Balance** between AI/automation and human input in Clinical and Regulatory Writing. 2. **Review Real-Time Statistics** on AI accuracy and time savings, assessing their impact on efficiency. 3. **Understand the Impact of AI** on Clinical and Regulatory Writing within clinical trials. 4. **Recognize Areas for Effective AI Application**, including specific tasks and processes in Clinical and Regulatory Writing. 5. **Analyze the Successes and Challenges** of AI in various authoring and content review scenarios, gaining insights into both its potential and limitations. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [The Impact of AI on Medical Writing: How Artificial Intelligence is Revolutionizing Medical Content Creation ](https://geninvo.com/the-impact-of-ai-on-medical-writing-how-artificial-intelligence-is-revolutionizing-medical-content-creation/) **Published:** September 13, 2024 **Author:** admin **Content:** Artificial Intelligence (AI) has been making waves across various industries, and the field of medical writing is no exception. As the demand for precise, up-to-date, and comprehensive medical content continues to grow, AI is emerging as a powerful tool that is transforming the way medical writers approach their craft. From educational materials for patients to detailed clinical reports for healthcare professionals, the sheer volume and complexity of medical information can be overwhelming. However, the advent of Artificial Intelligence (AI) is transforming the way medical content is created, delivering unprecedented efficiencies and improving the overall quality of the final product. ## **Streamlining the Content Creation Process** One of the most significant impacts of AI in medical content creation is the ability to streamline the entire process. AI-powered tools can automate tedious tasks, such as data extraction, citation management, and formatting, freeing up medical writers to focus on the more complex and creative aspects of their work. This boost in efficiency not only reduces the time required to produce content but also minimizes the risk of human error, ensuring a higher level of accuracy and consistency. ## **Enhancing Content Quality** AI algorithms can analyse vast troves of medical literature, clinical trial data, and regulatory guidelines, providing medical writers with deep insights and up-to-date information. This enables them to produce content that is more comprehensive, evidence-based, and aligned with the latest industry standards. AI-powered tools can also assist in identifying and addressing potential gaps or inconsistencies in the content, leading to a more robust and reliable final product. ## **Personalizing Content for Target Audiences** AI-powered natural language processing (NLP) and machine learning (ML) techniques can help medical writers tailor their content to the specific needs and preferences of their target audience. By analysing user behaviour, preferences, and feedback, AI can suggest personalized content structures, tone, and language that resonate better with the intended readers, whether they are healthcare professionals, patients, or regulatory bodies. ## **Ensuring Regulatory Compliance** The medical and pharmaceutical industries are subject to strict regulatory requirements, and AI can play a crucial role in ensuring compliance. AI algorithms can scrutinize content for adherence to regulatory guidelines, identify potential issues, and suggest revisions to meet the necessary standards. This not only streamlines the regulatory review process but also reduces the risk of costly delays or non-compliance. ## **Accelerating Knowledge Dissemination** The rapid pace of medical advancements and the sheer volume of new research can make it challenging for healthcare professionals to stay up-to-date. AI-powered tools can help medical writers synthesize and disseminate this information more efficiently, ensuring that the latest medical knowledge reaches the appropriate audiences in a timely manner. This accelerated knowledge dissemination can have a direct impact on patient care and outcomes. ## **GENINVO’s contribution to automated clinical content generation** GENINVO offers [DocWrightAI](https://geninvo.com/our-products/docwrightai/), AI enabled document generation software designed specifically for medical content creation and drafting. DocWrightAI is trained by our document SMEs to learn from the drafted documents and user behaviour, to give more formatted and accurate documents. With automated technologies like DocWightAI, time taken to draft clinical documents, the overall quality of the clinical documents and the accuracy of the information is increased, thus saving time for Medical Writers to focus more on other aspects that require their critical thinking. **Conclusion** As AI continues to evolve and become more sophisticated, its impact on medical content creation will only become more profound. By enhancing efficiency, content quality, personalization, regulatory compliance, and knowledge dissemination, AI is revolutionizing the way medical writers approach their craft. This transformation will ultimately lead to better-informed healthcare decisions, improved patient outcomes, and a more efficient and effective medical ecosystem. ***By Hargun Sethi*** ***Software Development and Business Growth*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs --- ### [Shake hands with GENINVO at DIA’s Global Clinical Trial Disclosure and Data Transparency Conference](https://geninvo.com/shake-hands-with-geninvo-at-dias-global-clinical-trial-disclosure-and-data-transparency-conference/) **Published:** April 18, 2024 **Author:** admin **Content:** We are exhibiting at Global Clinical Trial Disclosure and Data Transparency Conference. Link: [Exhibits (diaglobal.org)](https://www.diaglobal.org/en/conference-listing/meetings/2024/09/global-clinical-trial-disclosure-and-data-transparency-conference/exhibits#showcontent) **Date:** 23rd-24th September , 2024 **Place:** 801 North Glebe Road, Arlington, VA 22203, USA *Looking forward to seeing you there!* ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [Associate Python Developer](https://geninvo.com/role-description/) **Published:** August 22, 2024 **Author:** admin **Content:** Role Description: - You will be working with other software developers and data scientists to develop new tools and processes for developing today’s most complicated machine learning models. - You will use both Java, Python to analyse and create sophisticated machine learning models from small to large sizes. - You will receive regular code reviews from senior engineers and data scientists and participate in all aspects of software development cycle. - You will be writing effective scalable codes - Test and debug programs - Improve functionality of existing systems - Implement security and data protection solutions - Assess and prioritize Feature requests - Coordinate with internal teams to understand user requirements and provide technical solutions - Develop back-end components to improve responsiveness and overall performance - Integrate user-facing elements into applications ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** job --- ### [Transforming Document Creation in Life Sciences with DocWrightAI™ – GenInvo's Advanced AI Assistant!](https://geninvo.com/transforming-document-creation-in-life-sciences-with-docwrightai-geninvos-advanced-ai-assistant/) **Published:** June 5, 2024 **Author:** admin **Content:** Transforming Clinical & Regulatory Medical Writing through the Power of AI! GenInvo is leading the way by accelerating the availability of life-changing therapies, ensuring patients benefit sooner. Leave behind the hassles of manual tasks in clinical trials with DocWrightAI™ – your premier AI-enabled assistant. **Introduction** In the fast-paced realm of medical writing, where accuracy and efficiency are crucial, GenInvo proudly introduces [DocWrightAI™](https://geninvo.com/our-products/docwrightai/) , an advanced AI-enabled medical writing assistant designed to transform the document creation process. **Regulatory Compliance** DocWrightAI™ prioritizes regulatory compliance, adhering to the highest industry standards and ensuring the security of your sensitive medical data. **Automated Document Authoring** Enhance your workflow with automated document authoring. DocWrightAI™ streamlines the regulatory document creation process, saving time and ensuring consistency across all your documents. With its cutting-edge feature for prompt-based content generation, DocWrightAI™ takes document authoring to the next level. **Cognizance** Trained on an extensive database of over 400 clinical studies, DocWrightAI™ is finely tuned to comprehend the complexities of medical language, delivering exceptional accuracy and precision by utilizing insights from these studies. **Specialized Modules for Clinical Documents** DocWrightAI™ offers tailored solutions to meet your specific needs. With specialized modules for AE Narratives, CSRs, Protocols, SAPs, DSURs, and more, it caters to the unique requirements of each document type. **Content Creation and Source Document Utilization** Empower your content creation with intelligent source document utilization. DocWrightAI™ leverages source materials to generate precise content, whether it’s a Plain Language Summary or detailed language adjustments, ensuring your documents are both accurate and enriched with relevant information. **Table Interpretation** Enjoy seamless table interpretation. DocWrightAI™ effortlessly processes and integrates tables, transforming complex data into clear, structured, and meaningful content. **Information Extraction** Harness the power of information extraction for standards such as ICH-M11, FHIR, SNOMED, and LOINC. DocWrightAI™ leverages these standards, ensuring your documents are aligned with the latest in healthcare interoperability. From automated document authoring to specialized modules and compliance assurance, DocWrightAI™ is your partner in precision and efficiency. GenInvo presents DocWrightAI™ — where innovation elevates medical writing. ***By Pragya Anand –* *Marketing Analyst/ Lead Generation**, GENINVO*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, DocGen --- ### [Embracing the Digital Era: The Transformative Power of Digitalization in Medical Writing](https://geninvo.com/embracing-the-digital-era-the-transformative-power-of-digitalization-in-medical-writing/) **Published:** March 18, 2024 **Author:** admin **Content:** In recent years, the widespread adoption of digitalization has revolutionized various aspects of society, and the field of medical writing is no exception. The digital era has significantly impacted medical writing, revolutionizing the way scientific information is generated, communicated, and accessed. Technologies such as electronic databases, online publishing platforms, and collaborative tools have streamlined the process, enabled faster dissemination of research findings and enhanced collaboration among researchers and healthcare professionals. Furthermore, digitalization made a profound impact on medical writing and has enhanced efficiency, collaboration, and accessibility. ## **Enhanced Efficiency:** One of the key advantages of digitalization in medical writing is the significant improvement in efficiency. Gone are the days of laborious manual processes, such as handwritten notes and typewritten manuscripts. Digital tools and software have streamlined the writing process, allowing medical writers to create, edit, and format documents with ease, ensuring accuracy and consistency in medical documents. With digital tools like [DocQC](https://geninvo.com/our-products/docqc-medical-writers-automation-tool/), it enables medical writers to also review the clinical documents for consistency of the content/data. The different sections of the clinical documents can be analysed, and visually represented, to display the discrepancies and help medical writers make profound decisions with proper facts and evidence. ## **Collaboration Made Easy:** Digitalization has transformed collaboration in medical writing. It has facilitated seamless communication and collaboration among researchers, medical writers, and healthcare professionals across geographic boundaries. With the advent of cloud-based platforms and collaborative tools, multiple authors can simultaneously work on a document, making revisions, leaving comments, and tracking changes. This collaborative environment fosters interdisciplinary collaboration, allowing experts from diverse fields to contribute their knowledge and insights. The synergy created through digital collaboration enhances the quality and comprehensiveness of medical documents. With the feature to update clinical documents on the user interface, DocQC provides an easy access and collaboration platform for medical writers to view the latest updates made on the clinical documents. DocQC has built in feature to add comments and update clinical documents, making collaboration among the medical writers seamless and effective. ## **Expanding Accessibility:** The digital era has democratized access to medical information. In the past, accessing medical literature often entailed visiting physical libraries or subscribing to expensive journals. However, digitalization has made medical literature more accessible than ever before. Online databases and digital libraries provide instant access to a vast array of scientific articles, research papers, and clinical guidelines. Researchers and medical writers can now retrieve relevant information with a few clicks, saving time and effort. Furthermore, the rise of open-access publishing has facilitated the dissemination of medical knowledge to a broader audience, including healthcare professionals, patients, and the public. ## **Data-driven Insights:** Digitalization has unleashed the power of data in medical writing. With the advent of electronic health records (EHRs) and data analytics tools, medical writers have access to a wealth of patient data and real-world evidence. This data can be harnessed to provide insights and support evidence-based medical writing. By analysing large datasets, medical writers can identify trends, patterns, and correlations, enriching their understanding of diseases, treatment outcomes, and patient populations. The integration of data-driven insights strengthens the credibility and relevance of medical writing, enabling more informed decision-making in healthcare. ## **Dynamic Visualizations:** In the digital era, static text-based documents are no longer the sole means of conveying medical information. Digital platforms have enabled the creation of dynamic visualizations, such as interactive graphs, charts, and multimedia presentations. These visual aids enhance the clarity and impact of medical writing by presenting complex data in a more accessible and engaging manner. Visualizations can effectively communicate scientific concepts, treatment pathways, and research findings, catering to diverse learning styles and facilitating knowledge retention. ## **Ethical Considerations:** While the digital era has brought numerous benefits to medical writing, it also raises ethical considerations. The ease of online publishing and the proliferation of predatory journals require medical writers to exercise caution and critical appraisal when selecting publishing outlets. Additionally, with the increasing influence of social media, medical writers must be mindful of disseminating accurate and evidence-based information, combating misinformation, and maintaining patient confidentiality and privacy in the digital realm. GENINVO brings[ Shadow](https://geninvo.com/our-products/data-anonymization-tool/), helping the medical writers to anonymize confidential information in relatively less time, thus maintaining patient confidentiality and privacy while publishing to the wider audience. **Conclusion:** The digital era has transformed medical writing, offering unprecedented opportunities for efficiency, collaboration, accessibility, and data-driven insights. It has revolutionized the writing process, enabled seamless collaboration among researchers and professionals, expanded access to medical literature, harnessed the power of data, and enhanced the visual presentation of information. However, it is important to navigate the digital landscape ethically and responsibly. Embracing the digital era in medical writing empowers researchers, medical writers, and healthcare professionals to advance knowledge, improve patient care, and shape the future of healthcare. GENINVO has been working towards various innovations, to help medical writers manage different aspects of medical writing like document creation, review, and anonymization. Few innovations also help the medical writers to perform risk assessments or manage various workflows. The different technologies help in different areas of medical writing, all helping to reduce the manual efforts and overall time of the medical writers, to help them focus on more critical aspects and also work together with digital tools and platforms to continue revolutionizing the drug discovery and development process. ***By Hargun Kaur Sethi Software Development and Business Growth, GENINVO*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs --- ### [Data Masking and Data Anonymization: The need for healthcare companies](https://geninvo.com/data-masking-and-data-anonymization-the-need-for-healthcare-companies/) **Published:** March 7, 2024 **Author:** admin **Content:** In the healthcare industry, the protection of sensitive patient data is of utmost importance. As healthcare companies handle vast amounts of personal and medical information, it becomes crucial to implement robust measures to safeguard patient privacy, comply with regulations, and mitigate risks associated with data breaches. Two key practices that address these concerns are data masking and data anonymization. [Data masking](https://geninvo.com/our-products/data-anonymization-tool/) involves the modification of sensitive data by replacing it with fictitious, yet realistic, values. It ensures that sensitive information is concealed while allowing organizations to use representative datasets for testing, development, and analysis. On the other hand, data anonymization focuses on transforming data in such a way that it can no longer be linked to specific individuals. This technique enables the secondary use of data for research, analytics, and sharing while protecting patient privacy. For healthcare companies, data masking and anonymization play a pivotal role in maintaining patient confidentiality, meeting regulatory requirements, and minimizing the risk of unauthorized access or data breaches. By implementing these practices, healthcare organizations can achieve a delicate balance between data utility and privacy protection. Data masking and data anonymization are essential practices for healthcare companies due to the sensitive and highly regulated nature of healthcare data. Here’s why they are important: 1. **Protecting Patient Privacy:** Healthcare data contains personally identifiable information (PII), such as patient names, addresses, social security numbers, medical records, and clinical information. Data masking and anonymization techniques help ensure that this sensitive information is protected, reducing the risk of unauthorized access or data breaches. 2. **Compliance with Data Privacy Regulations:** Healthcare companies are subject to strict data privacy regulations, such as the [Health Insurance Portability and Accountability Act](https://www.cdc.gov/phlp/publications/topic/hipaa.html#:~:text=The%20Health%20Insurance%20Portability%20and,the%20patient's%20consent%20or%20knowledge.) (HIPAA) in the United States and the General Data Protection Regulation (GDPR) in the European Union. These regulations require organizations to safeguard patient privacy by implementing appropriate data protection measures, including data masking and anonymization. 3. **Enabling Data Sharing for Research and Analysis**: Healthcare data is valuable for medical research, clinical studies, and population health analysis. By anonymizing or masking data, healthcare companies can share de-identified datasets with researchers, analysts, and collaborators, facilitating valuable insights while protecting patient privacy. 4. **Minimizing Insider Threats:** Data masking and anonymization can help mitigate insider threats within healthcare organizations. By obfuscating sensitive information, even authorized personnel with access to the data may not be able to identify specific individuals or misuse personal information. 5. **Supporting Testing and Development:** Data masking is particularly useful for creating realistic test environments that simulate real-world scenarios while protecting patient privacy. It allows developers, testers, and analysts to work with representative datasets without exposing sensitive patient information. 6. **Reducing Legal and Reputational Risks:** Inadequate data protection measures can lead to legal consequences and damage a healthcare company’s reputation. Data masking and anonymization help reduce the risk of data breaches, identity theft, and unauthorized use of patient information, thereby protecting both the organization and its patients. Additional details on data masking and data anonymization in the context of healthcare companies: 1. **Data Masking in Healthcare:** Data masking is a technique that involves replacing sensitive data with realistic but fictitious values. In the healthcare industry, data masking can be applied to various types of data, including patient demographics, medical records, diagnostic information, and financial data. It helps ensure that data used for testing, development, and other non-production purposes does not expose real patient information. - **Types of Data Masking**: Common data masking techniques include randomization, substitution, shuffling, and encryption. These techniques help maintain the structural integrity and statistical characteristics of the data while protecting sensitive information. - **Test Data Management:** Data masking plays a crucial role in creating safe and compliant test environments for healthcare applications. By masking patient data, healthcare organizations can generate representative datasets for testing, quality assurance, and software development without risking exposure of real patient information. - **Data Anonymization in Healthcare**: Data anonymization involves the modification of data in a way that it can no longer be linked to an individual. Anonymized data is useful for research, analysis, and sharing while protecting patient privacy. Anonymization techniques focus on removing or transforming identifiers and other sensitive details to prevent re-identification. - **Techniques for Anonymization**: Common techniques include generalization, suppression, aggregation, and noise addition. These approaches help protect privacy while retaining the usefulness and integrity of the data. - **Secondary Use of Data**: Anonymized healthcare data supports secondary use cases, such as research studies, population health analysis, and public health initiatives. By anonymizing data, healthcare organizations can contribute to advancements in medical knowledge without compromising patient privacy. - **Balancing Privacy and Data Utility:** A key challenge in data masking and anonymization is striking a balance between privacy protection and data utility. While ensuring patient privacy is crucial, it’s also important to retain the usefulness of the data for analysis and research purposes. Techniques like k-anonymity and differential privacy aim to achieve this balance by preserving statistical patterns and enabling meaningful analysis without revealing individual identities. - **Compliance with Data Privacy Regulations**: Healthcare organizations must comply with various data privacy regulations, such as HIPAA in the United States and GDPR in the European Union. These regulations define requirements for protecting patient privacy, including the use of data masking and anonymization techniques. Compliance helps organizations avoid legal consequences and maintain trust with patients. - **Advancements in Privacy-Preserving Technologies:** Emerging technologies, such as secure multi-party computation, federated learning, and differential privacy, are advancing the field of privacy-preserving analytics. These techniques enable collaborative analysis on distributed data sources while preserving privacy and ensuring data security. **Conclusion** Overall, data masking and anonymization are critical for healthcare companies to safeguard patient privacy, comply with regulations, enable data sharing, and mitigate risks associated with handling sensitive healthcare data. By implementing robust data masking and anonymization practices, healthcare companies can protect patient privacy, comply with regulations, support research initiatives, and mitigate risks associated with sensitive healthcare data. These practices are crucial for maintaining patient trust and upholding ethical responsibilities in the healthcare industry. ***By Ramandeep Dhami, Business manager, GenInvo*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, Shadow **Tags:** Data Anonymization, De-identification, GDPR Compliance, Privacy Protection, Pseudonymization, shadow --- ### [Artificial Intelligence in the Healthcare Domain: How AI Reviews Clinical Documents](https://geninvo.com/artificial-intelligence-in-the-healthcare-domain-how-ai-reviews-clinical-documents/) **Published:** March 4, 2024 **Author:** admin **Content:** ## **Let’s know what Clinical Documents are.** Clinical Documents are written records or reports documenting various aspects of patient care and medical encounters. With a crucial role in the healthcare domain, including communication, legal or regulatory purposes, research, etc, these clinical documents can take various forms. The clinical documents can be study templates, protocols, discharge summaries, or reports, along with other documents. However, it is highly crucial to maintain accuracy and comprehensive information. These documents should be legible, timely, and adhere to privacy and confidentiality regulations. ## **Where does Artificial Intelligence fit in all this?** Since years now, these documents have been created and reviewed manually. With a lot of efforts and expertise from Medical Writers, these documents go with multiple cycles of reviews, to ensure that the information shared is highly accurate and proven. But in the recent years, Artificial Intelligence (AI) has grown tremendously. Not in a specific field, but AI has made its jump into a variety of sectors, Healthcare being another sector highly benefited. From spending days on reviewing the clinical documents, now AI has come with its algorithms to reduce the time, to just mere few hours. ## **Now we know the basics, so let’s get into how AI is able to achieve such complexities.** Artificial intelligence is the development of computer systems that can perform tasks that typically require human intelligence. In the context of clinical document review, AI algorithms are employed to analyse and extract meaningful data from vast amounts of information. These algorithms are trained on large datasets of interpreted clinical documents, enabling them to recognize patterns, identify key information, and make predictions. Since being trained on variety of clinical documents, AI is able to understand new patterns and analyse them into meaningful reports. ## **Finally collaborating AI and Clinical Review** - AI can process and review clinical documents at a much faster rate that humans. They can analyse large volumes of data in a short period, allowing healthcare professionals to access critical information promptly. This efficiency leads to improved decision-making and better patient care. - AI algorithms can accurately extract relevant information from clinical documents. This automated extraction reduces the risk of manual errors and ensures the completeness and accuracy of the information captured. - AI algorithms can be trained to follow predefined rules and guidelines consistently. This helps in maintaining standardized documentation practices across different healthcare providers and reduces variations in the way information is recorded, ensuring uniformity and clarity in clinical documents. - By analysing large datasets and recognizing patterns, AI tools can identify trends, highlight potential risks, and suggest appropriate treatment options based on evidence-based guidelines. - With AI handling the initial review and extraction of information from clinical documents, healthcare professionals can focus more on direct patient care and spend less time on administrative tasks. This improves workflow efficiency and allows clinicians to allocate their time and expertise where it is most needed. - AI-enabled clinical document review facilitates research and population health studies by providing access to large amounts of data. Researchers can leverage this data to identify cohorts, study disease patterns, monitor treatment outcomes, and contribute to evidence-based medicine. Now, GENINVO offers a variety of innovative solutions, keeping in minds the medical writers hard-work. With expert subject matter experts and technological leaders, we offer tools to leverage the burden for medical writers and help them shift their focus more towards leveraging their critical thinking and factual interpretations. To help with the review of clinical documents, [DocQC](https://geninvo.com/our-products/docqc-medical-writers-automation-tool/) does it, merely within few working hours. You can just create your project, upload the documents waiting to be reviewed, and be ready to review. With different quality control checks in DocQC, you can select which section of study report you want to QC, and also select whether to review in the moment, or later with downloaded offline report. With just few minutes to generate reports, DocQC save medical writer’s time, and also reduces potential errors that might be overseen by human eye. **In Conclusion,** Artificial Intelligence has transformed the field of medical writing, particularly in the automation of clinical reviews. By leveraging AI algorithms and NLP techniques, medical writers can streamline the quality control review process, from data extraction and literature screening to data synthesis and language processing. AI-powered automation enhances efficiency, accuracy, and collaboration, saving time and effort while producing high-quality clinical documents. As AI continues to evolve, it holds great promise for further revolutionizing medical writing and advancing evidence-based medicine. With continued advancements and proper oversight, AI will play an increasingly vital role in improving patient care and healthcare outcomes. ***By Hargun Kaur Sethi Software Development and Business Growth, GENINVO*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, DocQC --- ### [Importance and examples of usage of Data Anonymization in Healthcare & Other sectors](https://geninvo.com/importance-and-examples-of-usage-of-data-anonymization-in-healthcare-other-sectors/) **Published:** February 19, 2024 **Author:** admin **Content:** Data anonymization plays a critical role in healthcare to protect patient privacy while allowing for the analysis and sharing of data for research, public health, and other purposes. Here are some practical examples of data anonymization in healthcare: 1. **De-identification of Electronic Health Records (EHR):** Healthcare organizations often de-identify electronic health records by removing or encrypting personally identifiable information (PII) such as names, social security numbers, addresses, and other direct identifiers. This allows researchers and analysts to work with anonymized data while preserving privacy. 2. **Anonymization of Clinical Trial Data:** Clinical trial data contains sensitive information about participants’ health conditions and treatment outcomes. By anonymizing this data, researchers can protect participants’ identities while still sharing and analysing the data to gain insights into the efficacy and safety of treatments. 3. **Public Health Reporting:** Health agencies collect and analyse data for public health surveillance, including tracking disease outbreaks, monitoring population health trends, and identifying risk factors. Anonymization techniques are applied to ensure that individual identities are protected when sharing data with public health authorities. 4. **Health Research Datasets:** Data anonymization is crucial for creating research datasets that can be shared among researchers while complying with privacy regulations. By removing or obfuscating personal identifiers, researchers can access and analyse aggregated and anonymized data to gain insights and improve healthcare outcomes. 5. **Healthcare Data Sharing for Collaborative Research:** Data anonymization enables secure data sharing and collaboration among multiple healthcare organizations. By anonymizing and aggregating patient data from different sources, researchers and institutions can perform collective analysis without compromising individual privacy. 6. **Population Health Studies:** Data anonymization is essential for population health studies that involve analysing large datasets to understand health trends, risk factors, and outcomes. Anonymized data allows researchers to identify patterns, develop interventions, and make informed decisions without violating privacy regulations. 7. **Genomic Data Anonymization:** Genomic data, which contains highly sensitive and identifiable information, requires special attention when it comes to anonymization. Techniques such as removing direct identifiers, aggregating data at a larger scale, and applying cryptographic methods can help protect individuals’ genetic privacy while allowing for research and analysis of genomic datasets. 8. **Preserving Data Utility:** One of the challenges in data anonymization is striking a balance between privacy protection and preserving the utility of the data. Advanced anonymization techniques, such as k-anonymity and differential privacy, aim to minimize the risk of re-identification while maintaining the statistical and analytical value of the data. These techniques ensure that useful information can still be derived from the anonymized datasets. 9. **Wearable Devices and IoT Data:** With the rise of wearable devices and Internet of Things (IoT) technologies in healthcare, anonymization becomes crucial for protecting the privacy of individuals’ health data. Anonymizing data collected from wearables, such as fitness trackers or health monitoring devices, allows for population-level analysis without compromising the identities and personal information of users. 10. **Telemedicine and Telehealth Data:** Telemedicine and telehealth services involve the remote delivery of healthcare services, which generates significant amounts of patient data. Anonymizing this data ensures patient privacy while enabling analysis and research on the effectiveness of virtual care, remote monitoring, and telehealth interventions. 11. **Health Insurance Claims Data:** Health insurance claims data contains comprehensive information on medical procedures, diagnoses, and prescriptions. Anonymizing this data enables researchers, policymakers, and insurance providers to analyse trends, evaluate healthcare costs, and identify patterns without revealing personal identities or violating privacy regulations. 12. **Open Data Initiatives:** Many healthcare organizations and research institutions participate in open data initiatives, where anonymized datasets are made available to the public for research purposes. Anonymization techniques are employed to ensure that the shared data cannot be linked back to individuals, fostering collaboration and innovation while protecting privacy. ## **Data Anonymization in other sectors:** 1. **Financial Services:** Anonymization is employed in the financial sector to protect sensitive customer information, such as bank account details, credit card numbers, and transaction histories. It allows for data analysis, fraud detection, and regulatory compliance without compromising customer privacy. - **Marketing and Advertising:** Marketers use anonymized consumer data to gain insights into customer behaviour, preferences, and trends. By removing personally identifiable information, marketers can perform targeted advertising and campaign analysis while respecting consumer privacy. - **Education and Research:** Anonymization techniques are applied to educational and research datasets to protect student or participant privacy. This enables educational institutions and researchers to analyse data, conduct studies, and derive insights without revealing personal identities. - **Government and Public Sector:** Anonymization is employed in government agencies and public sector organizations to protect citizen privacy while allowing for data analysis and policymaking. It ensures that sensitive information, such as social security numbers or addresses, is properly anonymized when sharing data for research or public use. - **Transportation and Mobility:** In transportation sectors, anonymization is used to protect personal information in mobility data, such as GPS traces or travel patterns. It allows for analysis of traffic patterns, urban planning, and transportation optimization while preserving individual privacy. **Conclusion** Data anonymization is a versatile technique that can be applied across various sectors to balance the need for data analysis and privacy protection. The specific anonymization methods and considerations may vary depending on the sector and the type of data being anonymized. Overall, data anonymization in healthcare plays a crucial role in enabling research, analysis, and collaboration while safeguarding patient privacy. It allows for the utilization of large-scale datasets without compromising the confidentiality of individuals’ personal information. Adhering to best practices and staying updated with evolving privacy regulations are essential for effective and responsible data anonymization in healthcare. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, Shadow --- ### [Data Anonymization and HIPAA Compliance: Protecting Health Information Privacy](https://geninvo.com/data-anonymization-and-hipaa-compliance-protecting-health-information-privacy/) **Published:** February 12, 2024 **Author:** admin **Content:** Data anonymization plays a crucial role in protecting the privacy of sensitive health information and ensuring compliance with regulations such as the Health Insurance Portability and Accountability Act (HIPAA). In this article, we will explore the relationship between data anonymization and HIPAA, highlighting the importance of anonymization techniques in safeguarding healthcare data. ## **Understanding HIPAA:** The Health Insurance Portability and Accountability Act (HIPAA) was enacted in 1996 in the United States to establish national standards for the protection of certain health information. HIPAA consists of several rules, including the Privacy Rule, Security Rule, and Breach Notification Rule. Key aspects of HIPAA include: **a) Privacy Rule:** The Privacy Rule governs the use and disclosure of protected health information (PHI) by covered entities (e.g., healthcare providers, health plans) and their business associates. It sets standards to protect the privacy of individuals’ identifiable health information. **b) Security Rule:** The Security Rule outlines security standards for the electronic protected health information (ePHI) that covered entities create, receive, maintain, or transmit. It requires the implementation of administrative, physical, and technical safeguards to protect ePHI. **c) Breach Notification Rule:** The Breach Notification Rule requires covered entities to provide notification to affected individuals, the Secretary of Health, and Human Services, and sometimes the media, in the event of a breach of unsecured PHI. ## **The Role of Anonymization in HIPAA Compliance:** Data anonymization techniques can help organizations comply with HIPAA regulations while still allowing the use of healthcare data for research, analysis, and other purposes. Here are some key considerations: **a) De-identification:** HIPAA recognizes two methods of de-identification: the expert determination method and the safe harbor method. By removing or altering specific identifiers, such as names, addresses, and social security numbers, data can be de-identified and no longer subject to HIPAA regulations. **b) Limited Data Sets:** HIPAA allows the use and disclosure of limited data sets, which are de-identified data sets that may include some identifiers for research, public health, or healthcare operations purposes. However, specific privacy safeguards must be in place to ensure the continued protection of individuals’ privacy. **c) Data Use Agreements:** When sharing or disclosing de-identified or limited data sets, covered entities should establish data use agreements with recipients. These agreements outline the purpose of the data use, restrictions on re-identification, and obligations to protect privacy and security. **d) Re-identification Risks:** Organizations must assess the risk of re-identification when anonymizing health data. Techniques such as statistical disclosure control, generalization, and suppression can be used to minimize the risk of re-identification while preserving data utility. ## **Benefits of Data Anonymization in Healthcare:** Data anonymization offers several benefits in the context of healthcare and HIPAA compliance: **a) Privacy Protection:** By anonymizing health data, individuals’ privacy is safeguarded, reducing the risk of unauthorized access or disclosure of sensitive information. **b) Facilitating Research and Analysis:** Anonymized data can be shared and used for research purposes, enabling advancements in healthcare, population health analysis, clinical studies, and public health research. **c) Compliance and Risk Mitigation:** Adhering to HIPAA regulations through effective data anonymization practices helps organizations mitigate the risk of non-compliance, reputational damage, and potential penalties. ## **Some additional details on data anonymization and its role in HIPAA compliance:** 1. **De-identification Methods:** HIPAA recognizes two methods for de-identifying protected health information (PHI): **a) Safe Harbor Method**: This method involves removing 18 specific identifiers listed in the HIPAA regulations, such as names, addresses, dates, and social security numbers. Once these identifiers are removed, the data is considered de-identified and is no longer subject to HIPAA regulations. **b) Expert Determination Method**: This method involves engaging a qualified expert to assess the risk of re-identification by considering various factors, such as the nature of the data and the intended recipient. If the expert determines that the risk of re-identification is very low, the data can be considered de-identified. 2. **Statistical Disclosure Control:** Statistical disclosure control (SDC) is a technique used in data anonymization to minimize the risk of re-identification while preserving the utility of the data. SDC involves applying statistical methods to modify or suppress data points that could potentially lead to re-identification. This technique ensures that the anonymized data remains useful for research and analysis purposes while protecting individuals’ privacy. 3. **Limited Data Sets:** HIPAA allows the use and disclosure of limited data sets, which are de-identified data sets that may include some identifiers for specific purposes, such as research, public health, or healthcare operations. However, covered entities must enter into a data use agreement with the recipient of the limited data set. The agreement must include provisions to protect the data, restrict re-identification, and ensure compliance with HIPAA regulations. 4. **Data Use Agreements:** When sharing or disclosing de-identified or limited data sets, covered entities should establish data use agreements with recipients. These agreements outline the purpose for which the data will be used, the responsibilities of the recipient in protecting the data, and any restrictions on re-identification or further disclosures. Data use agreements are essential for maintaining privacy and ensuring compliance with HIPAA regulations. 5. **Re-identification Risks and Mitigation:** Organizations must assess the risk of re-identification when anonymizing health data. Re-identification occurs when an individual can be identified from the anonymized data by combining it with other available information. Techniques such as generalization, suppression, and adding noise to data can be used to minimize the risk of re-identification while preserving the usefulness of the data. Regular risk assessments and ongoing monitoring are necessary to identify and mitigate potential re-identification risks. 6. **Data Utility and Preservation:** While the primary goal of data anonymization is privacy protection, it is essential to balance privacy with data utility. Anonymized data should still be useful for research, analysis, and other purposes. Organizations must ensure that the anonymization techniques applied do not overly compromise the value or quality of the data, allowing for meaningful insights and accurate analysis. **Conclusion:** Data anonymization is a vital component of HIPAA compliance in the healthcare industry. By implementing robust anonymization techniques, healthcare organizations can protect individuals’ privacy while still utilizing health data for research, analysis, and other purposes. Ensuring compliance with HIPAA regulations strengthens trust, promotes responsible data handling, and contributes to the advancement of healthcare knowledge and innovation. By effectively implementing data anonymization techniques and adhering to HIPAA regulations, healthcare organizations can protect individuals’ privacy, facilitate research, and ensure compliance with data protection requirements. It is important to consult with legal professionals and privacy experts to establish appropriate anonymization practices and maintain compliance with HIPAA and other relevant regulations. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, Shadow --- ### [Automation of Unstructured Clinical Data: A collaboration of automation and Medical Writers](https://geninvo.com/automation-of-unstructured-clinical-data-a-collaboration-of-automation-and-medical-writers/) **Published:** January 30, 2024 **Author:** admin **Content:** In the field of healthcare, clinical data plays a crucial role in patient care, research, and decision-making. However, a significant portion of clinical data is unstructured, consisting of free-text narratives, physician notes, and other non-standardized formats. Extracting meaningful insights from this unstructured data has traditionally been a time-consuming and labour-intensive task. However, with the advancement of automation technologies and the collaboration of medical writers, we are now witnessing a transformative shift in the way unstructured clinical data is processed and utilized. ## **The Challenge of Unstructured Clinical Data** Unstructured clinical data poses unique challenges due to its diverse formats and lack of standardization. It often includes handwritten notes, scanned documents, and narrative descriptions, making it difficult to extract relevant information efficiently. Traditional manual methods of extracting data from these sources are not only time-consuming but also prone to errors and inconsistencies. ## **Automation in Clinical Data Processing** The emergence of automation technologies, such as natural language processing (NLP) and machine learning, has revolutionized the way unstructured clinical data is processed. NLP algorithms can analyse vast amounts of text data, identify patterns, and extract relevant information with remarkable accuracy and speed. Automation tools can now parse through extensive medical records, identifying key information like diagnoses, treatments, and patient demographics, transforming unstructured data into structured, actionable insights. ## **The Role of Medical Writers** While automation technologies offer significant advancements, the collaboration between automation tools and medical writers is crucial for achieving optimal results. Medical writers bring their domain expertise, context, and critical thinking skills to the table, ensuring accuracy and contextual understanding in the interpretation of the data. They can refine and validate the results obtained from automated processes, acting as a quality control mechanism. ## **Collaborative Workflow** The collaborative workflow between DocQC TM and medical writers: ![](https://geninvo.com/wp-content/uploads/2024/01/Screenshot-2024-01-30-171847-1024x139.png "Screenshot-2024-01-30-171847 - GenInvo")## **Benefits of Automation and Collaboration** The automation of unstructured clinical data, combined with the expertise of medical writers, brings several benefits to the healthcare industry: 1. Time and Cost Savings: Automation significantly reduces the time and effort required to process large volumes of unstructured data, enabling medical writers to focus on more complex tasks. This efficiency translates into cost savings for healthcare organizations. 2. Improved Accuracy: Automation tools provide consistent and accurate data extraction, minimizing errors and inconsistencies commonly associated with manual processes. 3. Enhanced Decision-Making: Structured and processed clinical data enables healthcare professionals to make evidence-based decisions, leading to improved patient care and outcomes. 4. Research and Population Health: Automation facilitates large-scale data analysis, supporting research studies, clinical trials, and population health management initiatives. It enables the identification of trends, patterns, and correlations within extensive datasets that were previously challenging to analyse. [DocQC](https://geninvo.com/our-products/docqc-medical-writers-automation-tool/) saves about 70% of medical writers time in reviewing the study reports, while at the same time maintaining consistency in the results. With reduced potential human errors, there is a great impact on the quality of the document as well. **Conclusion** The collaboration between automation tools and medical writers is transforming the way unstructured clinical data is processed and utilized. Automation technologies streamline the extraction of meaningful insights from unstructured data, while medical writers provide context, validation, and quality assurance. This collaborative approach enhances the accuracy, efficiency, and value of clinical data analysis, leading to improved patient care, research outcomes, and informed decision-making in healthcare. As automation continues to advance, the role of medical writers in this collaboration becomes increasingly essential, ensuring that the human touch and expertise are integrated into the data processing journey. ***By Hargun Kaur Sethi Software Development and Business Growth, GENINVO*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, DocQC --- ### [Quality Control of the Methods and Procedures of Clinical Study](https://geninvo.com/quality-control-of-the-methods-and-procedures-of-clinical-study/) **Published:** January 24, 2024 **Author:** admin **Content:** Methodology section of the Clinical Study Report (CSR) provides a detailed description of the methods and procedures used to conduct the study, including the study design, participant selection criteria, interventions or treatments, data collection and analysis methods, and statistical considerations. Quality control of the methodology section of a CSR is essential to ensure the accuracy, completeness, and transparency of the study methods. Here are some key points to consider during the quality control process: 1. **Consistency:** Verify that the methodology section is consistent with the study protocol, Statistical Analysis Plan (SAP) and any applicable regulatory guidelines. Cross-reference the study protocol with the CSR to ensure that all relevant details are accurately represented. 2. **Clarity and completeness:** Review the methodology section for clarity and completeness. Ensure that all essential components of the study design, including objectives, study population, inclusion and exclusion criteria, interventions, outcome measures, and statistical methods, are clearly described. 3. **Accuracy of information:** Confirm the accuracy of the information presented in the methodology section. Check that the details provided match the actual conduct of the study. Review any relevant source documents, such as case report forms, to validate the accuracy of data collection procedures. 4. **Adherence to ethical standards:** Verify that the methodology section adequately addresses ethical considerations. This includes ensuring that appropriate informed consent procedures were followed, the study was approved by an ethics committee or institutional review board, and any potential conflicts of interest or bias are appropriately disclosed. 5. **Clarity of procedures:** Assess the clarity of the description of procedures, such as study visits, data collection, and data analysis. Ensure that the methodology section provides sufficient details to allow for study replication or independent verification. 6. **Consistency with regulatory requirements:** Verify that the methodology section adheres to relevant regulatory requirements, such as those outlined in International Council for Harmonisation (ICH) guidelines or local regulatory guidelines. Confirm that any specific requirements for the study type or therapeutic area have been addressed. 7. **Internal consistency:** Check for internal consistency within the methodology section. Ensure that there are no contradictory statements or gaps in the description of the study methods. 8. **Cross-referencing and referencing:** Cross-reference the methodology section with other sections of the CSR, such as the results or adverse events sections, to confirm consistency and accuracy. Verify that all references cited in the methodology section are complete and appropriately cited. 9. **Peer review:** Consider involving an independent reviewer or subject matter expert to perform a peer review of the methodology section. This additional layer of review can help identify any potential issues or areas for improvement. By following these quality control measures, you can help ensure that the methodology section of a clinical study report is accurate, robust, and compliant with relevant guidelines and regulations. CSR Match Protocol SAP check, under [DocQC](https://geninvo.com/our-products/docqc-medical-writers-automation-tool/), helps the medical writers to accelerate their QC process for the methodology section. This complex quality control check helps validate the data present in the methodology section of CSR with relevant data from CSR Protocols, CSR Templates and SAP. This QC check generates the results within a few minutes, indicating whether the data is accurately present, and also helps reviewers visualize the discrepancies, and make better decisions. ***By Hargun Kaur Sethi Software Development and Business Growth, GENINVO*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, DocQC --- ### [Importance of "Table, Listing and Figures" Automation in Clinical Trials](https://geninvo.com/importance-of-table-listing-and-figures-automation-in-clinical-trials/) **Published:** December 18, 2023 **Author:** admin **Content:** Tables, Listings, and Figures (TLFs) help to analyse and summarize datasets of a clinical study into an easily readable format. Statistical programmers along with inputs from biostatisticians create these TLFs. Once Lead statistician review/validate them, medical writers use the TLFs to create documents like clinical study reports (CSRs). Some TLFs are straight forward and easy to interpret, while others may require writing an extensive discussion to explain them. In addition to their value in CSRs, TLFs are used to answer regulatory questions and support publications based on the clinical data contained in them. Creating TLFs is a tiresome process that involves frequent quality checks to verify the validity of the included information. In addition to that, medical writers could request changes in the outputs, which requires additional time to rewrite the code that produced the TLF documents. This means new rounds of validation and quality checks to confirm the correctness of the new outcome. All these processes lead to delays in delivering the final CSR to health authorities. The outcome is a considerable lag phase in providing life-saving medications and treatments to those needing them the most. There is a need to speed up this process and here automation can play a crucial role in creating and managing “Table, Listings and Figures” in clinical trials. Here are several reasons highlighting the importance of TLFs automation: - **Efficiency and Time savings:** Automation significantly reduces the time and effort required to create and update the TFLs. This is especially important in research and technical writing, where large datasets and numerous visuals are common. - **Consistency** Automated process contributes to the standardization of data preparation. Table and Figures generated through automation adhere to predefines templates and formatting standards. The consistency is crucial for ensuring that data is presented uniformly across different stages of TLF generation such mock shells, outputs and supporting documents. - **Accuracy** Automation reduces the risk of human error in data entry, calculation, and analysis. This is a critical in clinical trials where data accuracy and integrity are paramount. Automation can minimize the chances of transcription error or miscalculation, ensuring the reliability of TLFs generation - **Data Integrity** It encompasses the maintenance and assurance of the accuracy and consistency of data over its entire TLFs generation process. In the realm of automation testing, ensuring data integrity translates to guaranteeing the quality and credibility of testing processes. - **Reduced Workload and Resource optimization** By automating repetitive and time-consuming tasks in TLF generation such as generating mock shells, aligning the layouts, writing code for displaying the analysed results, data extraction and other similar tasks, researchers can optimize their workload. This not only enhances overall productivity but also allows researchers to allocate their time and resources more strategically to focus on critical aspects of the interpreting the results. - **Regulatory Compliance** Clinical trials are subject to strict regulatory requirements. Automation helps in maintaining compliance by ensuring that data is handled consistently and transparently. Automated tools can generate audit trails and documentation necessary for regulatory submissions. - **Facilitation and Collaboration** Automation enables seamless collaboration among members of the research team. With standardized and readily accessible TLF’s, researchers can collaborate more effectively, share insights, and make informed decisions collectively. Let see, At GenInvo how we are using automation to generate Table, Listing and Figures. GenInvo has leveraged use of Machine Learning to develop tool ([ApoGI™](https://geninvo.com/our-products/apogi/)) which offer a robust TLF Module to generate mock shell and associated TLFs. This tool is one of the best automation tools out there in market these days. This tool utilizes artificial intelligence with the technologies to go through thousands of layers of inputs and data to create TLFs. ## **ApoGI™ – Table, Listing and Figures (TLF) Module The ApoGI™ – TLF module comprises of two sub modules. **Mock Shell Generator** – This sub-module supports generation of mock shells with automation directly by scraping Protocol and SAP documents automatically. Below mentioned are few steps to explain How mock shells generation works in the tool. 1. One can choose the type of TLFs from different available options such as, Summary Table, Vital Sign Table, Demographics Table, AE Laboratory listings, Laboratory Listings, Box Plot Figures and many more. 2. Then select the required Protocol and SAP documents. 3. TLF Module then runs a smart [AI/ML algorithm](https://www.quinyx.com/blog/difference-between-ai-ml-algorithms) over the documents to capture the necessary matching details based on TLF type selected in first step to generate the shells. This reduces most of the manual effort of designing the shells. 4. Tool support mock shell repository to maintains the generated shell with versioning feature. ![](https://geninvo.com/wp-content/uploads/2024/01/TLF-info-V1-1024x673.png "TLF-info-V1 - GenInvo")*The flow diagram shows how ApoGIs TLF module uses automation to generate TLFs***TLF Report Generator –** This sub-module plays a vital role in TLFs output generation. Below mentioned are few steps to explain how TLF generation works. 1. Choose the generated ADaM dataset (GenInvo has an innovative solution to generate ADaM dataset. See [ApoGI-DT™](https://geninvo.com/our-products/apogi/) as input data to use in TLF output generation. 2. Tools allows to choose the requested TLF from wide variety of repository. 3. Tools allows to set up general and standard settings for proper display of layout with their relevant mock shells. 4. Finally, tool will run the automation algorithm to generate the requested TLFs. 5. The generated TLFs can be exported individually or as single combined file in multiple format (i.e. PDF, RTF, MS-Word) along with their source programming codes, log files etc. ## **Benefits of using [ApoGI™](https://geninvo.com/our-products/apogi/)** – **Table, Listing and Figures (TLF) Module** - Generate TLFs in click of button that are compliant with regulations - No programming experience needed - Update titles and footnotes and other general display text with ease - Reduce/eliminate bottle-neck processes like frequent changes and quality checks when coding, creating, updating, and validating TLFs - Accelerate regulatory submission to health authorities ***By Amit Gupta, Technical Lead- Software Development*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** Apogi, blogs **Tags:** Automated Data Discovery, Data Automation, Data Catalog, Data Classification, Data Governance, Data Quality, Information Governance, Machine Learning, Metadata Integration, Metadata Management --- ### [Automated Quality Control: Get the best out of your Clinical Study Report Review ](https://geninvo.com/automated-quality-control-get-the-best-out-of-your-clinical-study-report-review-2/) **Published:** January 18, 2024 **Author:** admin **Content:** ## **What are Clinical Study Reports?** Clinical study reports (CSRs) are critical documents that summarize the results and findings of clinical trials. The different sections of CSR provide a comprehensive overview of the clinical trials and its results and serves as a record for further documentation and communication of the trial findings to the regulatory authorities, sponsors and other stakeholders. ## **Reason for Quality Control in CSR** The structure and content of a CSR may vary depending on the specific guidelines provided by regulatory authorities, but researchers and sponsors should adhere to the applicable guidelines when preparing a CSR to ensure regulatory compliance and transparency. To attain these guidelines, thorough review of CSR is mandatory before submission to regulatory authorities. Historically, performing quality control on CSR requires approximately 40 working hours. But introduction of automation has reduced the manual time, and human efforts to review CSR. ## **Conducting a Clinical Study Report Review** Conducting a thorough review of CSRs is essential to ensure the accuracy, integrity, and compliance of clinical trial data. However, manual review processes can be time-consuming, resource-intensive, and prone to human error. To address these challenges, automated quality control systems are emerging as valuable tools to streamline CSR review processes and optimize the efficiency and effectiveness of clinical research. ## **How can you enhance the efficiency of your CSR within minimal time?** CSR review, involving the careful assessment of numerous documents, data tables, and statistical analyses, through automation can save a lot of time for the reviewers. The 40 hours required to review different artifacts of CSR, can now be done within 4 hours through reports generated by Automation Tools. Automated quality control tools automate key aspects of the review process, significantly reducing the time and effort required. ## **Can you tell how consistent and accurate CSR can be through automated quality control?** Maintaining consistency and accuracy in CSR is crucial for ensuring accurate and reliable evaluations. Different reviewers might interpret evaluation criteria differently, leading to subjective assessments. But automated quality control systems can enforce predefined standards and criteria consistently, ensuring a fair and objective evaluation process. Accurate and reliable data is paramount to the integrity of clinical study reports. Manual review processes are often prone to human errors. And automated quality control systems can analyse large volumes of data efficiently, identifying discrepancies, outliers, and anomalies. By flagging potential data inconsistencies, these systems help ensure the accuracy and completeness of the CSR. ## **Let’s analyse these Data Insights** Automated quality control systems offer advanced data analysis capabilities, enabling researchers to extract valuable insights from clinical trial data. With patterns, trends, and correlations within the data, automation can facilitate a deeper understanding of study outcomes. Also, with visual interpretation of clinical data, it is much easier to see flagged inconsistencies, and make better and informed decisions. ## **Want to know how Geninvo is providing innovation to these inconsistencies?** Geninvo has been in the industry providing rich experience and bringing innovation to life. With unique combination of expertise in Life Sciences, leading-edge technologies, and software development, we bring a unique problem-solving approach in automating the Life Sciences industry. Hours of manual review can be done by [DocQC](https://geninvo.com/our-products/docqc-medical-writers-automation-tool/) in just 4 working hours. DocQC not only checks for the presence of cited references, but also reports the accuracy of the data and flags the discrepancies, outliers or anomalies. Discrepancies, which you can validate in real time or at a later stage using Offline Reports. Great news! It still doesn’t end; you can also provide your review comments or update the CSR inside DocQC and download the upgraded version of your CSR or share with your team. Integrating DocQC, you can get your final draft of CSR with such ease within such a short period of time. ## **Now, what tasks can medical reviewers perform?** To answer this question, let’s look at the critical thinking medical reviewers bring to the study reports. DocQC can generate the discrepancies or outliers, summarising the report for medical reviewers to make better decisions based on the visual reports. DocQC and critical thinking by medical reviewers, can revolutionize the medical industry. While DocQC can serve as a valuable tool to generate the findings, the judgement and expertise of human reviewers still remain a crucial aspect in the completion of the CSR. Reviewers can now spend more time on evaluating critical relevance and interpretation of data, for better critical judgements, as per their expertise and experience. Automated quality control systems present significant advantages in the realm of clinical study report reviews. By streamlining processes, ensuring consistency, and enhancing data accuracy, these systems optimize the efficiency and effectiveness of CSR evaluations. As the demand for robust clinical research continues to grow, leveraging automated quality control systems can help researchers, sponsors, and regulatory authorities achieve reliable, compliant, and high-quality clinical study reports. ***By Hargun Kaur Sethi Software Development and Business Growth, GENINVO*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, DocQC --- ### [Clinical Study Results: Quality Control on study findings and outcomes](https://geninvo.com/clinical-study-results-quality-control-on-study-findings-and-outcomes/) **Published:** January 16, 2024 **Author:** admin **Content:** Clinical Study Reports, or the CSRs, are comprehensive documents providing detailed information about the design, methodology, results, and analysis of clinical trials. The result section specifically, is a critical component that presents the findings and outcomes of the clinical trial in a comprehensive and structured manner. It provides a detailed analysis of the data collected during the study, including the efficacy and safety results, statistical analysis, and other relevant findings. ## **Components of the Result Section:** - **Study Population and Demographics:** This section provides an overview of the study participants, including the number of subjects enrolled, demographic information like age, gender, etc, and baseline characteristics like disease severity, treatment history, etc. - **Primary and Secondary Endpoints:** This section describes the endpoints of the study, which represent specific outcomes or measures used to evaluate the treatment effect. The primary endpoint is typically the main objective of the study, while secondary endpoints provide additional information. - **Statistical Analysis:** This describes the statistical methods used to analyse the study data. It includes a detailed explanation of the statistical tests employed, such as t-tests, chi-square tests, or regression analyses. - **Efficacy Results:** The efficacy results present the treatment outcomes and effectiveness of the investigational intervention. This includes measures such as response rates, changes in disease severity scores, survival rates, or any other relevant efficacy parameters. The results are typically presented in tables, figures, or graphs, along with statistical measures such as confidence intervals and p-values. - **Safety Results:** The safety results focus on the adverse events and side effects observed during the study. It includes the frequency, severity, seriousness, and relationship of adverse events to the investigational treatment. Other safety-related assessments, such as laboratory data, vital signs, and electrocardiograms, may also be included. The results are often summarized in tables or listings. - **Subgroup Analyses:** In some cases, subgroup analyses are conducted to explore the treatment effects in specific subpopulations. This section presents the results of subgroup analyses, which may include different age groups, genders, disease stages, or other relevant stratifications. - **Sensitivity Analyses:** Sensitivity analyses assess the robustness of the study results by examining the impact of different assumptions or statistical methods on the outcomes. - **Interpretation and Discussion:** The result section concludes with an interpretation and discussion of the findings. It provides an analysis of the results in the context of the study objectives, previous research, and clinical implications. This component may also include a comparison of the study results with relevant literature and a discussion of any discrepancies or limitations. ## **DocQC and the Result of clinical trial** The crucial result section of the study report should be accurate and reliable. It requires a thorough verification of data, independent review of statistical methods, and effective communication of the results. Quality control measures enhance the credibility and integrity of the study findings, allowing stakeholders to make informed decisions based on reliable information. DocQC helps with verification of this data by comparison with relevant sources, thus helping to maintain the quality of the document. With checks like In-text match post-text, SOF match data source including reverse check, Threshold Table, and many more DocQC checks that the findings are accurate by verifying the CSR content with the listed tables and also checking that the tables inserted in the CSR maintain the reliable information from the sources. As compared to multiple days of manual reviews, these checks take only about less than a day to QC the result section of the CSR. **Conclusion:** Overall, the result section of a CSR provides a comprehensive summary of the study findings, allowing researchers, regulators, and other stakeholders to evaluate the efficacy and safety of the investigational treatment and make informed decisions. ***By Hargun Kaur Sethi Software Development and Business Growth, GENINVO*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, DocQC --- ### [Big Save on Time > 60%, A case Study: DocQC™ Tested on 25 Studies.](https://geninvo.com/big-save-on-time-60-a-case-study-docqc-tested-on-25-studies/) **Published:** January 11, 2024 **Author:** admin **Content:** Medical Writers have provenly spent a lot of time historically, in reviewing the Clinical Study Reports. Clinical Study Reports, or the CSRs, are comprehensive documents providing detailed information about the design, methodology, results, and analysis of clinical trials. These study reports take about 40 hours to complete a round of quality check, and eventually multiple rounds of review are conducted. ## **Let’s get to know DocQC.** ### DocQC™– Medical Writing Automation Tool for Quality Control Checks DocQC™ is a tool that automates Quality Control or the QC checks, which historically required multiple, time-consuming cycles of manual review. The application is programmable for various complexities, supported by [AI and ML algorithms](https://www.unite.ai/ten-best-machine-learning-algorithms/), developed by your document SMEs. It increases the efficiency and effectiveness of your QC process with each use. DocQC™ enables your medical writers to maintain their focus on the science, analysis, and presentation of results. ## **THE 25 Studies!** The question – 25 studies? What are these and how these studies came into picture? During the development and testing of DocQC, 25 studies were selected. Downloaded from different websites, these 25 studies belonged to different pharmaceutical companies/clients, further containing different formats of documents. DocQC has been tested on these 25 sets of clinical study documents, to validate the artifacts and content, and check for the accuracy of the tool before its delivery. Ranging from TFLs to Narratives to CSR Protocols, and many more, DocQC is built to validate the consistency and accuracy of the clinical documents and reports. With different Quality Control Checks, DocQC caters to different sections of the CSR using different QC checks, few namely: - **In-text match post-text:** This is a text to table value comparison, for both internal CSR data and external source data. This saves about more than 18 hours of manual efforts; and can be performed in under maximum of 2 hours with DocQC. - **CSR Match Protocol SAP:** This works on the methodology section of the CSR against Protocol/Template/SAP. This is a very critical part of the CSR to focus on and provides an overview of what was planned and what happened in the study. Depending upon the length and complexity of the methodology section, DocQC can help save almost more than 5 hours of medical writers on this check; and can be performed within 2 hours. - **SOF match data source including reverse check/ Threshold Table:** These checks QCs the tables of the result section against the relative source tables. These checks save about 4 hours of the medical writer’s review time, enabling them to QC these tables within a maximum of 2 hours. - **Abbreviation Match List:** This manages the abbreviation listed in the List of Abbreviations and the CSR content along with the expanded forms. This simple yet time consuming check usually takes about 4-5 hours for a medical writer to perform manually, and DocQC reduces this time to less than even an hour. - **Reference Match Format List/ Reference Match Content:** These help to check for the listed references and related publications. These two checks combine the complete list of references, ranging from references listed in CSR to references from the reference list and the relative publications. DocQC helps save more than 3 hours on checking how accurately these references are maintained throughout the clinical documents. AND MANY MORE! ## **Let’s look at few more features of DocQC to ease Medical Writer’s life.** - DocQC helps automate QC checks to reduce time spend by medical writer on CSR review. More than 60% time is reduced by incorporating DocQC into reviewal process. - DocQC being tested on 25 studies, is robust and more accustomed to understanding different document formats and provide better results. - With offline reports, DocQC provides user with an option to QC the results during the run-time or at a later time. - DocQC also provides the user with ability to edit the study report and save the updated document. These changes by the user can also be tracked. - With the complete QC automated, the potential errors to human eye are highly reduced. - DocQC also has inbuilt configuration settings enabled to help provide user results as per their requirement. - With the process automated, medical writers have more time in hand to concentrate on more critical tasks, involving their expertise and critical thinking. - Medical writers can now conclude the results in better decision making, based on the generated results and visualizations. **To conclude,** DocQC caters to the multiple, time consuming cycles of manual review, reducing the medical writer’s review time by more than 60%. It is enabled with complex quality control checks to handle both internal and external QC checks. The technology is built by our document SMEs and supported by AI and ML algorithms, with a variety of complex checks, not just to reduce time, but also to maintain the consistency through automation, and QC the references and artifacts. ***By Hargun Kaur Sethi Software Development and Business Growth, GENINVO*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, DocQC --- ### [Data Anonymization in the Era of Artificial Intelligence: Balancing Privacy and Innovation](https://geninvo.com/data-anonymization-in-the-era-of-artificial-intelligence-balancing-privacy-and-innovation/) **Published:** January 10, 2024 **Author:** admin **Content:** Data anonymization plays a crucial role in balancing privacy and innovation in the era of artificial intelligence (AI). As AI technologies rely heavily on large-scale datasets, preserving privacy becomes a significant concern. Anonymization techniques offer a means to protect individuals’ identities while still enabling valuable data analysis and AI-driven innovation. ## **Here’s how [data anonymization](https://geninvo.com/our-products/data-anonymization-tool/) helps strike the balance:** **Preserving Privacy:** 1. **Pseudonymization:** Pseudonymization involves replacing personally identifiable information (PII) with pseudonyms or anonymized identifiers. This technique ensures that the original identity of individuals cannot be readily determined from the data. Pseudonymized data helps protect privacy while still allowing data analysis and AI model training. 2. **Generalization:** Generalization involves aggregating or grouping data to achieve a higher level of anonymity. For example, age ranges or regional information may be used instead of precise birth dates or exact geographic coordinates. By generalizing data, it becomes more challenging to identify specific individuals, reducing the risk of privacy breaches. 3. **Noise Addition:** Adding random noise to the data can help prevent re-identification. By injecting controlled randomness, it becomes difficult to link anonymized records back to specific individuals. Noise addition techniques can be applied to numeric data, textual data, or even images to safeguard privacy. 4. **Data Masking:** Masking techniques involve obfuscating or removing certain sensitive attributes from the dataset. For instance, social security numbers, phone numbers, or email addresses can be redacted or replaced with placeholder values. Data masking ensures that sensitive information is not exposed, reducing the risk of privacy violations. **Balancing Innovation:** 1. **Data Utility:** Anonymization techniques strive to strike a balance between privacy and data utility. The goal is to provide useful and meaningful data for analysis and AI applications while minimizing the risk of re-identification. Various anonymization methods focus on preserving the statistical properties, patterns, and relationships within the data to maintain its value for research and innovation. 2. **Differential Privacy**: Differential privacy, as discussed earlier, offers a rigorous framework for privacy preservation while allowing data analysis. It enables the release of aggregate statistical information while adding controlled noise to protect individual privacy. Differential privacy techniques are designed to balance the trade-off between privacy and data utility, ensuring that meaningful insights can still be derived from the data. 3. **Synthetic Data Generation**: Synthetic data generation is an emerging approach where artificial datasets are created that mimic the statistical properties of the original data. These synthetic datasets do not contain any real information, ensuring privacy, while still preserving the data’s statistical characteristics. Synthetic data can be used for AI model training, algorithm development, and other innovative applications without directly exposing sensitive information. 4. **Privacy-Preserving Machine Learning**: Advanced techniques, such as federated learning and secure multi-party computation, enable privacy-preserving machine learning. These approaches allow multiple parties to collaboratively train AI models without sharing their raw data. Privacy is maintained by only exchanging model updates or summary statistics, ensuring that individual data remains protected while fostering innovation through collaborative AI research. ## **Software tools play a vital role in balancing privacy and innovation in the era of artificial intelligence (AI) such as Shadow.** They can assist in implementing privacy-preserving techniques while enabling innovative AI applications. Here’s how software tools can help achieve this balance: 1. **Privacy-Preserving Data Analytics:** Software tools can provide privacy-enhancing techniques, such as secure computation and encrypted data processing, to perform data analytics while protecting sensitive information. These tools enable data to be analysed without exposing the raw data to unauthorized entities or compromising privacy. 2. **Secure Data Sharing:** Software tools can facilitate secure data sharing among different entities involved in AI research and development. They can employ encryption, secure file transfer protocols, and access control mechanisms to ensure that data is shared only with authorized parties and is protected from unauthorized access or breaches. 3. **Privacy Impact Assessments:** Software tools can assist in conducting privacy impact assessments (PIAs) to evaluate the potential privacy risks associated with AI projects. These tools can help organizations identify and mitigate privacy concerns early in the development process, enabling a proactive approach to privacy protection. 4. **Anonymization and De-identification:** Software tools can automate the anonymization and de-identification of data, removing or obfuscating personally identifiable information (PII) to protect privacy. These tools employ techniques such as pseudonymization, generalization, and data masking to balance data utility with privacy requirements. 5. **Model Explain ability and Interpretability:** AI models often operate on sensitive or personal data. Software tools can help in providing explanations and interpretations of AI model predictions without revealing the underlying sensitive information. Techniques such as model-agnostic interpretability and explainable AI can be employed to ensure transparency while protecting privacy. 6. **Consent Management:** Software tools can aid in managing user consent and preferences regarding data usage in AI applications. They can provide mechanisms for individuals to control how their data is collected, shared, and used in AI models. Consent management tools allow organizations to respect privacy preferences while still driving innovation through AI. 7. **Security and Data Governance:** Software tools can enforce strong security measures and data governance practices to protect against unauthorized access, data breaches, and misuse of sensitive information. These tools can include features like access controls, encryption, audit logging, and monitoring to ensure the security and integrity of data used in AI applications. **Conclusion** Data anonymization serves as a critical mechanism for balancing privacy and innovation in the era of artificial intelligence. By employing anonymization techniques, organizations can protect individuals’ identities while still harnessing the power of large-scale datasets for AI-driven advancements. Striking the right balance between privacy and innovation requires a thoughtful approach that incorporates robust anonymization methods, data utility considerations, and ongoing evaluation to adapt to evolving privacy challenges. By leveraging the capabilities of software tools, organizations can strike a balance between privacy and innovation in the era of artificial intelligence. These tools enable the implementation of privacy-preserving techniques, secure data sharing, and transparent AI practices, ensuring that privacy is respected while fostering innovation and advancement in AI applications. ***By Ramandeep Dhami, Business manager, GenInvo*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, Shadow --- ### [Automated Quality Control: Get the best out of your Clinical Study Report Review](https://geninvo.com/automated-quality-control-get-the-best-out-of-your-clinical-study-report-review/) **Published:** January 8, 2024 **Author:** admin **Content:** ## **What are Clinical Study Reports?** Clinical study reports (CSRs) are critical documents that summarize the results and findings of clinical trials. The different sections of CSR provide a comprehensive overview of the clinical trials and its results and serves as a record for further documentation and communication of the trial findings to the regulatory authorities, sponsors and other stakeholders. ## **Reason for Quality Control in CSR** The structure and content of a CSR may vary depending on the specific guidelines provided by regulatory authorities, but researchers and sponsors should adhere to the applicable guidelines when preparing a CSR to ensure regulatory compliance and transparency. To attain these guidelines, thorough review of CSR is mandatory before submission to regulatory authorities. Historically, performing quality control on CSR requires approximately 40 working hours. But introduction of automation has reduced the manual time, and human efforts to review CSR. ## **Conducting a Clinical Study Report Review** Conducting a thorough review of CSRs is essential to ensure the accuracy, integrity, and compliance of clinical trial data. However, manual review processes can be time-consuming, resource-intensive, and prone to human error. To address these challenges, automated quality control systems are emerging as valuable tools to streamline CSR review processes and optimize the efficiency and effectiveness of clinical research. ## **How can you enhance the efficiency of your CSR within minimal time?** CSR review, involving the careful assessment of numerous documents, data tables, and statistical analyses, through automation can save a lot of time for the reviewers. The 40 hours required to review different artifacts of CSR, can now be done within 4 hours through reports generated by Automation Tools. Automated quality control tools automate key aspects of the review process, significantly reducing the time and effort required. ## ****Can you tell how consistent and accurate CSR can be through automated quality control?**** Maintaining consistency and accuracy in CSR is crucial for ensuring accurate and reliable evaluations. Different reviewers might interpret evaluation criteria differently, leading to subjective assessments. But automated quality control systems can enforce predefined standards and criteria consistently, ensuring a fair and objective evaluation process. Accurate and reliable data is paramount to the integrity of clinical study reports. Manual review processes are often prone to human errors. And automated quality control systems can analyse large volumes of data efficiently, identifying discrepancies, outliers, and anomalies. By flagging potential data inconsistencies, these systems help ensure the accuracy and completeness of the CSR. ## **Let’s analyse these Data Insights** Automated quality control systems offer advanced data analysis capabilities, enabling researchers to extract valuable insights from clinical trial data. With patterns, trends, and correlations within the data, automation can facilitate a deeper understanding of study outcomes. Also, with visual interpretation of clinical data, it is much easier to see flagged inconsistencies, and make better and informed decisions. ## **Want to know how GenInvo is providing innovation to these inconsistencies?** Geninvo has been in the industry providing rich experience and bringing innovation to life. With unique combination of expertise in Life Sciences, leading-edge technologies, and software development, we bring a unique problem-solving approach in automating the Life Sciences industry. Hours of manual review can be done by [DocQC](https://geninvo.com/our-products/docqc-medical-writers-automation-tool/) in just 4 working hours. DocQC not only checks for the presence of cited references, but also reports the accuracy of the data and flags the discrepancies, outliers or anomalies. Discrepancies, which you can validate in real time or at a later stage using Offline Reports. Great news! It still doesn’t end; you can also provide your review comments or update the CSR inside DocQC and download the upgraded version of your CSR or share with your team. Integrating DocQC, you can get your final draft of CSR with such ease within such a short period of time. ## **Now, what tasks can medical reviewers perform?** To answer this question, let’s look at the critical thinking medical reviewers bring to the study reports. DocQC can generate the discrepancies or outliers, summarising the report for medical reviewers to make better decisions based on the visual reports. DocQC and critical thinking by medical reviewers, can revolutionize the medical industry. While DocQC can serve as a valuable tool to generate the findings, the judgement and expertise of human reviewers still remain a crucial aspect in the completion of the CSR. Reviewers can now spend more time on evaluating critical relevance and interpretation of data, for better critical judgements, as per their expertise and experience. **Now, let’s conclude:** Automated quality control systems present significant advantages in the realm of clinical study report reviews. By streamlining processes, ensuring consistency, and enhancing data accuracy, these systems optimize the efficiency and effectiveness of CSR evaluations. As the demand for robust clinical research continues to grow, leveraging automated quality control systems can help researchers, sponsors, and regulatory authorities achieve reliable, compliant, and high-quality clinical study reports. ***By Hargun Kaur Sethi Software Development and Business Growth, GENINVO*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, DocQC --- ### [Data Redaction: Safeguarding Sensitive Information in an Era of Data Sharing](https://geninvo.com/data-redaction-safeguarding-sensitive-information-in-an-era-of-data-sharing/) **Published:** January 2, 2024 **Author:** admin **Content:** Data redaction is a technique used to safeguard sensitive information in an era of data sharing. It involves selectively removing or obscuring sensitive data from documents, databases, or other sources of information before they are shared or made publicly accessible. The purpose of data redaction is to protect individuals’ privacy and prevent the disclosure of sensitive or confidential information. With the increasing volume of data being generated and shared, data redaction has become essential in various domains, including healthcare, finance, government, and legal sectors. It helps organizations comply with data protection regulations, such as the General Data Protection Regulation (GDPR) and the Health Insurance Portability and Accountability Act (HIPAA), which require the safeguarding of personal and sensitive information. Data redaction techniques can be applied to different types of data, including text documents, spreadsheets, databases, and even images. The specific approach to redaction may vary depending on the nature of the data and the requirements of the organization. ## **Here are some commonly used techniques:** 1. **Full Redaction:** In this approach, the sensitive information is entirely removed from the document or dataset. For example, a social security number or a credit card number may be completely blacked out or replaced with placeholder characters. 2. **Partial Redaction:** Partial redaction involves removing or obscuring only specific parts of the data while leaving the rest intact. For instance, in a document containing personal information, only the names and addresses may be redacted, while other non-sensitive information remains visible. 3. **Masking:** Masking involves replacing sensitive data with partially obscured values. For example, a credit card number may be masked by replacing some digits with asterisks or other symbols, such as “\*\*\*\* \*\*\*\* \*\*\*\* 1234.” 4. **Tokenization:** Tokenization replaces sensitive data with randomly generated unique identifiers called tokens. The tokens are then used as references to the original data. This technique ensures that the sensitive information is not directly exposed while maintaining the ability to perform certain operations with the data. 5. **Data Generalization:** Generalization involves transforming sensitive data into a more generalized or less specific form. For instance, ages may be grouped into age ranges, and precise location data may be generalized to city or regional levels. This technique helps protect privacy while still allowing meaningful analysis. ## **Safeguarding clinical data with software tools such as [Shadow](https://geninvo.com/our-products/data-anonymization-tool/)** Safeguarding clinical data is of utmost importance to protect patient privacy, ensure compliance with regulations, and maintain the integrity and confidentiality of sensitive healthcare information. Software tools play a vital role in helping healthcare organizations securely manage and protect clinical data. Here are some ways software tools can aid in safeguarding clinical data: 1. **Access Control:** Software tools can provide robust access control mechanisms to ensure that only authorized individuals can access specific clinical data. This includes user authentication, role-based access control (RBAC), and fine-grained permissions management. Access control can help prevent unauthorized access to sensitive patient information. 2. **Encryption:** Encryption is a fundamental technique for protecting clinical data. Software tools can facilitate the encryption of data both at rest (stored in databases or files) and in transit (during transmission over networks). Strong encryption algorithms and key management systems can be implemented to ensure that data remains secure even if it is intercepted or accessed by unauthorized parties. 3. **Audit Logs and Monitoring:** Software tools can generate audit logs that record all activities related to clinical data, including data access, modifications, and system events. These logs can be monitored and analysed to detect any suspicious or unauthorized activities. Real-time monitoring and alerting mechanisms can help promptly identify and respond to potential security breaches. 4. **Data Masking and De-identification:** Software tools can assist in masking or de-identifying clinical data to protect patient privacy. These tools can automatically remove or scramble personally identifiable information (PII) from datasets, replacing it with pseudonyms or anonymized identifiers. Data masking and de-identification techniques help reduce the risk of re-identification while preserving data utility for research and analysis purposes. 5. **Secure Data Transfer and Exchange:** Software tools can facilitate secure data transfer and exchange between healthcare providers, researchers, and other authorized entities. Secure file transfer protocols, such as Secure File Transfer Protocol (SFTP) or secure APIs (Application Programming Interfaces), can be employed to ensure that data is transmitted securely and protected from interception or unauthorized access. 6. **Data Backup and Disaster Recovery:** Software tools can automate regular data backups and provide disaster recovery mechanisms to ensure that clinical data is protected from loss or corruption. This includes features such as backup scheduling, incremental backups, off-site storage, and rapid data recovery in the event of system failures or disasters. 7. **Vulnerability Scanning and Patch Management:** Software tools can conduct regular vulnerability scans to identify potential security weaknesses in the systems and applications that handle clinical data. These tools can also assist in managing and applying software patches and updates to address known vulnerabilities promptly. 8. **Employee Training and Awareness:** Software tools can provide training modules and educational resources to healthcare staff on data security best practices, privacy regulations, and how to handle clinical data securely. This helps raise awareness and promote a culture of data privacy and security within healthcare organizations. **Conclusion** Data redaction is a crucial mechanism for safeguarding sensitive information in an era of data sharing. By selectively removing or obscuring sensitive data, organizations can protect individuals’ privacy and comply with data protection regulations. The choice of redaction technique depends on the specific requirements and context, and it’s essential to implement redaction carefully to ensure the integrity and privacy of the shared data. ***By Ramandeep Dhami, Business manager, GenInvo*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, Shadow --- ### [Building a Strong Foundation: Robust Metadata Repository (MDR) Framework for Automated Standard Compliant Data Mapping](https://geninvo.com/building-a-strong-foundation-robust-metadata-repository-mdr-framework-for-automated-standard-compliant-data-mapping/) **Published:** December 26, 2023 **Author:** admin **Content:** Pharmaceutical and biotechnology companies operate within a constantly evolving regulatory landscape, where adherence to standards set by organizations like the Clinical Data Interchange Standards Consortium (CDISC) is crucial for submitting clinical trial data. In the area of clinical trial data management, information can originate from various sources and be stored across different platforms, systems, and networks. This includes data stored in spreadsheets with edit checks and specifications, as well as PDF documents containing Case Report Forms (CRFs) and protocols, this list goes on and on. With the constant updates and creation of new versions, it becomes challenging to ensure utilization and access to the most up-to-date files/standards and use it effectively to map raw clinical data in standards-compliant datasets (such as CDISC-SDTM). GenInvo has leveraged use of Machine Learning to develop tool (ApoGI™) which offer a robust metadata repository framework (MDR Module) to address these issues. ## **[ApoGI™](https://geninvo.com/our-products/apogi/) – Metadata Repository (MDR)** **Module** The [ApoGI™](https://geninvo.com/our-products/apogi/) – MDR module helps users to set up project-specific metadata through an intuitive graphic user interface (GUI). The data transformation (ApoGI-DT™) module of the ApoGI converts trial-related information to CDISC or sponsor-specific data standards. The solution stores all metadata in a central registry, and automatically maps new study metadata with the existing database. By utilizing ApoGI™ – MDR, - One can easily track and manage the latest versions of files/standards, while also ensuring the integrity and quality of the data. - This framework acts as a centralized hub responsible for capturing and managing the metadata associated with clinical studies. - It efficiently manages various components such as source data, SDTM domain metadata, SDTM mapping specifications, and transformation rules etc… - By consolidating these elements within a single platform, organizations can streamline their data management processes, enhance data integrity, and facilitate efficient data transformation and mapping activities. Furthermore, this MDR module enhances collaboration and consistency among team members by offering a centralized repository for data transformations, serving as a single source of truth. It also provides the advantage of inheritability and scalability for future study creation, enabling organizations to efficiently build upon existing frameworks. By maintaining data integrity and traceability, the MDR module simplifies the validation process and expedites regulatory submission. The implementation of MDR module promotes transparency and facilitates efficient management of changes, ultimately resulting in the generation of accurate and standards-compliant datasets (such as CDISC-SDTM). ## **Key features of the ApoGI™ – MDR** - **Workflow management**: It automates workflows for creating new data standards or maintaining existing ones - **Automated study setup:** Importing both Legacy/CDISC Metadata into ApoGI system with autorecognition of CDISC standards. Automatically maps new study metadata with the central library. - Managing the Legacy/CDISC Metadata with any edits/updates to the domain/element. - **Governance model** to support Governance process - **Impact Analysis:** One of the key objectives of an MDR is to assess the potential impact of metadata changes before implementing them. This analysis involves evaluating all relevant standards and assets to let you know exactly what downstream and upstream metadata and processes that will be influenced by the proposed change. - **Change control:** MDR allow users to initiate change requests for existing standard objects. This functionality enables users to log requests for modifications, such as updating a form. The change control process, which follows a pre-defined workflow, governs the approval process and the tracking and management of these change requests. All changes are tracked from inception to completion. - Versioning - Traceability - Exporting functionality available for metadata. - **Reports and Dashboards:** Intuitive dashboard to reflect on the KPIs used in standards. The flexibility to define customized reports based on user preference. Tracks any addition, deletion, or change in each object by maintaining an audit trail - **User management:** Assigns roles and access privileges to users based on business needs - 21CFR Part 11 Compliance **ApoGI™ – MDR Flow:** ![](https://geninvo.com/wp-content/uploads/2023/12/apogi--1024x704.png "apogi- - GenInvo")***By Hitesh Raval, ***Principal Data Scientist & CDISC SME****** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** Apogi, blogs --- ### [Digitalization of Medical Writing: Balancing AI and Rule-based algorithms with Human Supervision in Medical Writing QC](https://geninvo.com/digitalization-of-medical-writing-balancing-ai-and-rule-based-algorithms-with-human-supervision-in-medical-writing-qc-2/) **Published:** December 22, 2023 **Author:** admin **Content:** ## **What is Digitalization of Medical Writing?** The digitalization of medical writing refers to using digital technologies and tools to create, edit, and review medical content. This includes various aspects of medical communication. In recent years, emergence of digitalization has led to a significant transformation int the field of medical writing. The integration of digital technologies and tools has revolutionized how medical content is created, managed, and published. This digital revolution has not only streamlined the workflow of medical writers but has also improved accessibility to accurate healthcare information for healthcare professionals and patients worldwide. The emergence of digitalization has significantly transformed the field of medical writing, offering numerous benefits and opportunities for both medical writers and healthcare professionals. Digitalization has also paved the way for improved accessibility to any individual on relevant medical information. Online content and the use of interactive educational materials, such as videos and graphics, has proven to be effective in enhancing patient comprehension and empowering them to make informed healthcare choices. ## **Promising future of Medical Writing:** As digitalization continues to evolve, the future of medical writing holds even more promise. AI and rule-based algorithms have made significant contributions to medical writing. Natural language processing (NLP) algorithms can analyse vast amounts of medical literature, extract relevant information, and assist in literature reviews, saving considerable time for medical writers. NLP can also assist in generating summaries and abstracts. Artificial intelligence (AI) and machine learning algorithms have the potential to automate certain aspects of medical writing, such as literature searching and reference formatting. AI-powered tools can aid in grammar and spell-checking, style consistency, and reference formatting, reducing errors and enhancing the overall quality of written content. An example of such tool is [DocQC](https://geninvo.com/our-products/docqc-medical-writers-automation-tool/), supported by [AI and ML algorithms](https://www.quinyx.com/blog/difference-between-ai-ml-algorithms) and developed by technological and subject matter experts to automate complex quality control checks. ## **Advantages of AI and Rule-based algorithms:** - Accuracy and Consistency: AI algorithms can contribute to the accuracy and consistency of medical writing. They can identify potential errors, inconsistencies, or deviations from established guidelines, ensuring that medical documents adhere to the highest standards. AI-powered tools can also assist in cross-referencing information, identifying redundant content, and maintaining consistency throughout the writing. [DocQC](https://geninvo.com/our-products/docqc-medical-writers-automation-tool/) ensures the accuracy and consistency of the data by automating the quality control checks and minimizing human errors and ambiguity. DocQC validates the data in the medical documents internally and externally and checks for the accurate facts. - Efficiency and Speed: The integration of AI and rule-based algorithms in medical writing has improved efficiency and speed. Automated processes can handle routine tasks, allowing medical writers to focus on higher-level tasks, such as data interpretation and critical analysis. This accelerates the writing process and enables faster broadcasting of medical information. Using DocQC, medical writers can reduce the manual efforts on multiple, time-consuming cycles of manual review and focus towards other high priority tasks involving critical thinking. DocQC provide the QC results within few minutes, enabling the medical writers to quickly evaluate the document quality. ## **Let’s merge digitalization with human supervision.** While AI and rule-based algorithms bring efficiency and accuracy, human supervision still remains a crucial element in medical writing. Human medical writers possess the expertise, clinical knowledge, and detailed understanding required to interpret medical data, contextual information, and ensure the quality of scientific content. They can critically analyse research findings, assess the clinical relevance, and provide valuable insights that AI algorithms may overlook. Medical writing involves ethical considerations and requires a deep understanding of the medical context. Human supervision is essential to navigate these details. Medical writers are responsible for ensuring the accuracy and appropriate interpretation of research findings, adhering to ethical guidelines, and presenting information in a way that is accessible, unbiased, and understandable to the target audience. Human supervision is crucial to maintain the ethical integrity of medical writing and mitigate potential biases. As AI continues to evolve, it is essential for medical writers to adapt and acquire new skills. Medical writers should familiarize themselves with AI technologies, understand their capabilities and limitations, and leverage them effectively in their work. There should be a healthy balance between the digital technologies with Medical Writer’s human supervision. They should also stay updated with the latest advancements in AI and rule-based algorithms to make informed decisions about when and how to incorporate them into their writing process. ## **The health balance and collaboration:** The optimal approach to balancing AI and rule-based algorithms with human supervision lies in collaboration. While these technologies enhance efficiency, accuracy, and productivity, human supervision remains essential to ensure the integrity, quality, and ethical standards of medical writing. By striking the right balance, medical writers can harness the power of AI while leveraging their expertise to produce high-quality, accurate, and contextually relevant medical content that meets the diverse needs of healthcare professionals and patients, empowering patients to actively engage in their healthcare journey. Medical writers and AI technologies can work collectively, with AI-powered tools assisting in routine tasks and human writers providing critical thinking, context, and expertise. Continuous learnings and developments are key to staying level to AI advancements and leveraging them effectively and efficiently. ***By Hargun Kaur Sethi Software Development and Business Growth, GENINVO*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, DocQC --- ### [The Rise of Differential Privacy: Ensuring Privacy in the Age of Big Data](https://geninvo.com/the-rise-of-differential-privacy-ensuring-privacy-in-the-age-of-big-data/) **Published:** December 21, 2023 **Author:** admin **Content:** The rise of differential privacy is a significant development in the field of data privacy, especially in the age of big data. With the increasing digitization of our lives and the proliferation of data-driven technologies, preserving privacy has become a critical concern. Differential privacy offers a framework and a set of techniques to address these concerns by allowing the analysis of large datasets while protecting the privacy of individuals. This has also led to the development of new algorithms and techniques that can provide privacy guarantees while preserving data utility. Researchers continue to explore and refine these techniques to enhance their practicality and applicability in real-world scenarios. Differential privacy has gained significant attention and adoption in recent years, driven by the need to balance data analysis and privacy protection. It has been embraced by both academia and industry, including major tech companies and government organizations. For example, Apple has incorporated differential privacy into its data collection practices protecting user privacy while still gaining insights from user data. Differential privacy is a concept that aims to strike a balance between data utility and privacy preservation. It provides a mathematical definition and a rigorous framework for quantifying the privacy guarantees of data analysis algorithms. The main idea behind differential privacy is to add a controlled amount of noise or randomness to the output of an algorithm to prevent the identification of specific individuals in the dataset. The core principle of differential privacy is that the presence or absence of any individual’s data should not significantly affect the results of a query or analysis. In other words, the output of a differentially private algorithm should be almost indistinguishable, regardless of whether an individual’s data is included or excluded from the dataset. To achieve differential privacy, various techniques are employed. One common approach is to introduce random noise into the data before performing computations. This noise makes it difficult to determine the specific contribution of any individual’s data, ensuring privacy. Another technique involves carefully controlling the release of aggregate statistical information to prevent the disclosure of sensitive details. ## **Differential privacy techniques like K-anonymity, L-diversity, and T-closeness** In the realm of data anonymization, techniques such as K-anonymity, L-diversity, and T-closeness have emerged as powerful tools to protect privacy and mitigate the risk of re-identification. These concepts go beyond traditional anonymization methods, providing enhanced guarantees of privacy preservation. In this blog post, we delve into the principles and applications of K-anonymity, L-diversity, and T-closeness, exploring how they strengthen data anonymization practices. ### **1.K-Anonymity:** - K-anonymity, a privacy model commonly applied to protect the data subjects’ privacy in data sharing scenarios, and the guarantees that k-anonymity can provide when used to anonymize data. In many privacy-preserving systems, the end goal is anonymity for the data subjects. Anonymity when taken at face value just means to be nameless, but a closer look makes it clear very quickly that only removing names from a dataset is not sufficient to achieve anonymization. Anonymized data can be re-identified by linking data with another dataset. The data may include pieces of information that are not themselves unique identifiers, but can become identifying when combined with other datasets, these are known as quasi-identifiers. **Each released record should be indistinguishable from at least (k-1) others on its QI attributes.** - Description of the generalization and suppression techniques used to achieve K-anonymity. - Examples of K-anonymity in action, highlighting its effectiveness in preventing identity disclosure. - There are two common method to achieve K-anonymity i:e suppression and generalization. ### **2. L-Diversity:** - Introduction to L-diversity, a refinement of K-anonymity that aims to protect against attribute disclosure. - The l-diversity model adds the promotion of intra-group diversity for sensitive values in the anonymization mechanism. - Discussion of practical techniques, such as adding noise or introducing fake records, to achieve L-diversity and preserve privacy. ### **3. T-Closeness:** - An equivalence class is said to have t-closeness if the distance between the distribution of a sensitive attribute in this class and the distribution of the attribute in the whole table is no more than a threshold t. A table is said to have t-closeness if all equivalence classes have t-closeness. - Description of the diversity-sensitive distance metric used in T-closeness to assess the closeness of attribute distributions. - Examples illustrating T-closeness and its impact on preserving privacy in different scenarios. **Conclusion** As data privacy becomes a critical concern, understanding and implementing advanced anonymization techniques like K-anonymity, L-diversity, and T-closeness is essential. These concepts provide robust privacy guarantees by preventing identity disclosure and attribute inference. By incorporating these techniques into data anonymization workflows, organizations can confidently share and analyse data while protecting the privacy of individuals. Remember, selecting the appropriate technique depends on the specific requirements and context of the data being anonymized. Stay informed, adapt to evolving privacy challenges, and ensure responsible data handling practices to safeguard privacy in the digital age. However, it’s worth noting that differential privacy is not a one-size-fits-all solution, and its implementation requires careful consideration and expertise. The level of privacy protection and data utility can be adjusted by tuning parameters, but there is an inherent trade-off between privacy and utility. Striking the right balance is crucial in different applications and contexts. ***By Ramandeep Dhami, Business Manager*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, Shadow --- ### [Role of Intelligent Automation: How Intelligent Automation transforms the Clinical Study Document Review in Real Time](https://geninvo.com/role-of-intelligent-automation-how-intelligent-automation-transforms-the-clinical-study-document-review-in-real-time/) **Published:** December 20, 2023 **Author:** admin **Content:** Clinical Study Reports play a critical role in assessing the safety and efficacy of new medical treatments. Review of these CSRs is a critical process in the healthcare industry, ensuring the accuracy, integrity, and compliance of clinical trial data. However, this process is often time-consuming, resource-intensive, and prone to human errors. To streamline and enhance this process, organizations are increasingly turning to intelligent automation technologies. Intelligent automation in CSR review uses Artificial Intelligence, Machine Learning, and automation tools to streamline the review process, extract relevant information, ensure compliance, enhance accuracy, and facilitate collaboration, leading to faster and more efficient analysis of clinical study reports. [DocQC](https://geninvo.com/our-products/docqc-medical-writers-automation-tool/) is an automated tool provided by Geninvo, that contributes towards reducing the CSR review time and decreasing the potential errors involved during human review. The introduction of [DocQC](https://geninvo.com/our-products/docqc-medical-writers-automation-tool/) has reduced the amount of time Medical Writer spends on reviewing the CSR in real time, enabling the reviewers to put their effort on more critical thinking. With quality control checks like data to table comparisons and comparisons between internal and external data/tables, which can be achieved in few hours, the reviewers have more time to focus on other complicated and required tasks. ## **Automated Data Extraction and Standardization:** Intelligent automation technologies, such as natural language processing (NLP), machine learning (ML), and optical character recognition (OCR), play a crucial role in automating data extraction from clinical study documents. These technologies can scan and extract relevant information from unstructured data sources, such as clinical trial protocols, investigator brochures, and patient records. By automating data extraction, intelligent automation ensures faster and more accurate capture of critical data points, reducing manual effort and minimizing the risk of human errors. Furthermore, intelligent automation enables standardization of data across multiple documents. It can identify and classify data elements consistently, ensuring uniformity in data representation and facilitating efficient data analysis. This standardization enhances data quality and integrity, making it easier for reviewers to interpret and compare information across different studies. Whether it is an internal document quality check, or an external document quality check with relevant source data/content, DocQC comes with algorithms to perform these complex quality checks in a timespan of few minutes. ## **Advantages of Intelligent Automation in Real Time:** ### **Efficient Data Analysis and Review:** Intelligent automation significantly improves the efficiency of data analysis and review processes in CSR review. By leveraging ML algorithms, automation tools can analyse large volumes of data, detect patterns, and identify anomalies in a matter of minutes. This enables reviewers to focus on critical data points and potential safety concerns, rather than spending excessive time on manual data analysis. Intelligent automation also empowers reviewers with real-time insights and decision support. By automating the identification of safety signals or adverse events, automation tools can alert reviewers to potential risks promptly. This proactive approach allows for timely intervention and ensures patient safety. Moreover, automation tools can generate summary reports or visualizations, presenting key findings and trends in a clear and concise manner, facilitating effective communication with stakeholders. With visual user interface of DocQC, reviewer can view the key findings, and move towards a better understanding of the potential risks. ### **Enhanced Compliance and Regulatory Oversight:** Compliance with regulatory requirements is paramount in the healthcare industry. Intelligent automation plays a vital role in ensuring compliance and regulatory oversight during CSR review. Automation tools can be trained on regulatory guidelines, enabling them to flag any deviations or inconsistencies in data, documentation, or processes. This not only helps maintain data integrity but also reduces the likelihood of regulatory non-compliance and potential penalties. Moreover, intelligent automation assists in the generation of regulatory submission documents. Automation tools can automate the compilation and formatting of data, creating submission-ready documents that meet the specific requirements of regulatory authorities. This streamlines the submission process and reduces the administrative burden on reviewers, allowing them to focus on the scientific and clinical aspects of the review. ### **Improved Collaboration and Knowledge Management:** Intelligent automation facilitates collaboration among reviewers and enhances knowledge management in CSR review. Automation tools can integrate with collaboration platforms, enabling seamless sharing of documents, comments, and annotations. This promotes effective communication and collaboration among reviewers, allowing for faster review cycles and efficient resolution of queries or discrepancies. Furthermore, intelligent automation enables the capture and retention of institutional knowledge. By automating the extraction and indexing of information from historical documents, automation tools create a centralized repository of knowledge. This repository can be accessed and utilized by reviewers for future reference, ensuring consistency and continuity in the review process even when personnel change. ### **Enhancing Accuracy and Consistency:** One of the critical challenges in CSR review is maintaining accuracy and consistency across multiple reviewers. Intelligent automation can address this challenge by providing standardized and consistent review processes. Automation tools can be trained on established guidelines and protocols, ensuring that the same criteria are applied consistently across all CSRs. This minimizes the risk of human error and improves the overall quality and reliability of the review process. ## **Accelerating Review Timelines:** The review of clinical study reports can be a time-consuming process, often leading to delays in regulatory approvals and the availability of new treatments. Intelligent automation can help expedite the review timelines by automating repetitive tasks and allowing reviewers to focus on more complex and critical aspects of the reports. By reducing manual effort and increasing efficiency, intelligent automation enables faster turnaround times while maintaining the necessary rigor and comprehensiveness of the review process. With DocQC, reviewers can save up to more than 60% of their time ideally spent on CSR review, and focus on more crucial tasks. **Conclusion:** Intelligent automation is revolutionizing the CSR review process in the real world, offering significant benefits to the healthcare industry. By automating data extraction and standardization, improving data analysis and review efficiency, enhancing compliance and regulatory oversight, and facilitating collaboration and knowledge management, intelligent automation transforms the way an time in which clinical trial data is reviewed and interpreted. As the healthcare industry continues to embrace technological advancements, leveraging intelligent automation will ultimately lead to faster, more accurate, and more reliable clinical study document review, contributing to improved patient safety, enhanced regulatory compliance, and accelerated development of life-saving treatments in reduced timespan. ***By Hargun Sethi – Software Development and Business Growth*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, DocQC --- ### [Automation on Clinical Study Report: Improve the Speed and Efficiency of document review. ](https://geninvo.com/automation-on-clinical-study-report-improve-the-speed-and-efficiency-of-document-review/) **Published:** December 19, 2023 **Author:** admin **Content:** Clinical Study Report (CSRs) are critical documents that summarize the findings and results of clinical trials. These reports require a thorough review process to ensure accuracy, compliance, and adherence to the regulatory guidelines. However, the manual review of CSRs can be multiple, time-consuming, resource-intensive, and prone to human errors. Fortunately, automation technologies have emerged as a valuable solution to enhance the speed and efficiency of document review in clinical research. Further, automation is transforming the review process of CSRs, leading to faster turnaround times, and improved overall efficiency. ## **Automation in Improving the Speed and Efficiency of Clinical Study Report** (**CSR) Review:** 1. **Automated Text Extraction and Search:** Automation tools are equipped with natural language processing (NLP) capabilities that can extract and analyse the content from CSRs. These tools can automatically identify and extract relevant data, such as study objectives, methodology, adverse events, and statistical analyses. By automating text extraction, reviewers can quickly locate specific information within the document, saving time and effort. [DocQC](https://geninvo.com/our-products/docqc-medical-writers-automation-tool/) provides different quality control checks to cater to different sections of the CSR, to validate the accuracy and consistency of the data/content. Additionally, automated search functionalities enable reviewers to conduct comprehensive searches across multiple CSRs, facilitating cross-referencing and data comparison, further improving the efficiency of the review process. [DocQC](https://geninvo.com/our-products/docqc-medical-writers-automation-tool/) is also built with cross-referencing quality control checks to conduct the search between CSR and relative sources. For example, it checks whether the content of the methodology section is accurately listed as per the Template, Protocol or Statistical Analysis Plan, or whether the references and citations are accurately listed throughout. 2. **Quality Control and Consistency:** Automation helps ensure consistent review practices and adherence to predefined quality control measures. By implementing automated review workflows, organizations can establish standardized review processes, ensuring that all reviewers follow the same guidelines and evaluation criteria, thus maintaining consistency. Automation tools can also flag potential errors, inconsistencies, or missing information, allowing reviewers to focus on addressing these issues instead of spending time on routine checks. This streamlines the review process, reduces the risk of oversights, and enhances the overall quality and accuracy of CSRs. Using DocQC, reviewers can spend more quality time on critical thinking and addressing all the flagged issues listed as per quality check reports. With automation tools like DocQC, it also helps to omit ambiguity and human errors in comparison with manual review. 3. **Regulatory Compliance and Standardization:** Reviewing CSRs for regulatory compliance is a critical aspect of the document review process. Automation tools can assist in identifying and flagging potential non-compliance issues by comparing the content of CSRs against predefined regulatory guidelines and industry standards. This automated compliance check minimizes the risk of overlooking regulatory requirements and ensures that CSRs meet the necessary regulatory criteria. Furthermore, automation enables the standardization of review practices, ensuring consistency across different reviewers and reducing the chances of subjective interpretations. The AI and ML enabled algorithms in DocQC provide consistency between the results of the CSR reviews. 4. **Collaboration and Version Control:** Automation facilitates seamless collaboration and version control among reviewers and stakeholders involved in the document review process. Cloud-based platforms allow multiple reviewers to access and review CSRs simultaneously, eliminating the need for manual exchange of documents. Version control features ensure that reviewers work on the most up-to-date version of the CSR, avoiding confusion and reducing the risk of errors resulting from working on outdated information. Automation also enables real-time tracking of changes and comments, streamlining the review process and enhancing communication and collaboration among team members. With offline reports in DocQC, user can track the changes done in CSR by comparing the downloaded excel reports. 5. **Enhanced Decision-Making:** Automation empowers reviewers with data-driven insights and decision-making support. Through advanced analytics and visualization tools, automation platforms can generate interactive reports, highlighting key findings, trends, and patterns within CSRs. These insights enable reviewers to make informed decisions and recommendations based on comprehensive data analysis, ultimately enhancing the quality and accuracy of the review process. DocQC’s user friendly interface brings the analysis of content comparison along with the highlighted key findings and patterns, enabling the reviewers to view the discrepancies and make better decisions and recommendations. **Conclusion:** Automation technologies are revolutionizing the review process of clinical study reports, offering significant improvements in speed, efficiency, and accuracy. By automating text extraction, ensuring regulatory compliance, promoting collaboration, and providing decision-making support, automation tools streamline the review process and enable faster turnaround times without compromising quality. As the field of clinical research continues to embrace automation, the adoption of these technologies will undoubtedly bring about transformative changes, enhancing the overall efficiency and effectiveness of document review in clinical study reports. ***Hargun Sethi – Software Development and Business Growth*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, DocQC --- ### [Digitalization of Quality Control in Medical Writing: Advantages Digitalization brings for the critical aspects of Quality Control](https://geninvo.com/digitalization-of-quality-control-in-medical-writing-advantages-digitalization-brings-for-the-critical-aspects-of-quality-control/) **Published:** December 19, 2023 **Author:** admin **Content:** Quality control in medical writing is a critical aspect of ensuring the accuracy, clarity, and reliability of medical documents. It involves a systematic and rigorous review process to identify and correct errors, inconsistencies, and deficiencies in the content. However, it is a time-consuming process involving multiple cycles of manual review of the medical documents. In the recent years, the digitalization has had a profound impact on almost every aspect. One field that has experienced significant changes due to digitalization is the realm of quality control. Digitalization has revolutionized the way quality control is conducted in medical writing, thus offering numerous benefits. Different technologies have been designed to handle the digitalization of medical documents, one such technology being [DocQC](https://geninvo.com/our-products/docqc-medical-writers-automation-tool/) – developed to handle the consistency, accuracy, and the quality of the documents in minimal time frame. With the help of Technology Experts and Subject Matter Experts, [DocQC](https://geninvo.com/our-products/docqc-medical-writers-automation-tool/) has been designed to handle even the different sections of medical document, thus enabling the medical writers to reduce their manual efforts with a relatively simple user interface and be involved in more crucial aspects of the medical writing. ## **Critical Aspects of Quality Control in Medical Writing:** - **Scientific Accuracy:** QC includes cross-checking data with original sources, verifying study findings, and ensuring accurate representation of scientific concepts and terminology. DocQC helps handle the accuracy between QC documents and source documents. - **Clarity and Coherence:** QC focuses on the clarity and coherence of the document, ensuring that ideas are presented in a clear and organized manner. - **Language and Grammar:** QC ensures that the language is precise, concise, and adheres to grammatical rules. It also involves checking for appropriate use of medical terminology and abbreviations. - **Consistency:** QC ensures consistent use of terminology, abbreviations, acronyms, and formatting throughout the document. It also involves checking for consistency in referencing style, citation format, and table and figure labelling.[ DocQC](https://geninvo.com/our-products/docqc-medical-writers-automation-tool/) helps maintain the consistency within the document for the data/content. - **Compliance with Guidelines and Regulations:** QC involves ensuring compliance with relevant guidelines and regulations. It also ensures compliance with regulatory requirements for documents like regulatory submissions or clinical study reports. - **Ethical Considerations:** QC includes reviewing the document for ethical considerations, ensuring the protection of patient confidentiality, proper disclosure of conflicts of interest, and adherence to ethical guidelines related to human subjects’ research, such as informed consent and ethical review board approvals. - **Reference and Citation Accuracy:** QC ensures that references are properly cited, consistent, and relevant to support scientific claims. It also includes cross-referencing in-text citations with the reference list to ensure accuracy and completeness. DocQC helps check the accuracy of the references and citations listed in the QC document. - **Formatting and Presentation:** QC involves proper use of headings, subheadings, tables, figures, and captions, as well as adherence to font styles, spacing, and page layout guidelines. - **Reviewer Feedback and Revisions:** QC involves reviewing and addressing comments, suggestions, and revisions provided by subject matter experts or peer reviewers. It ensures that all revisions are appropriately incorporated, and the document meets the reviewers’ expectations. By focusing on these critical aspects, quality control in medical writing helps to ensure that the final document is accurate, clear, reliable, and aligned with the highest scientific and ethical standards. It ensures that medical information is effectively communicated and contributes to the advancement of knowledge and healthcare practices. ## **Advantages of Digitalization of Quality Control in Medical Writing:** - **Improved Accuracy:** Digitalization automates the process of grammar and spell checking, significantly reducing the chances of human error, ensuring that the final document is accurate and error-free. - **Enhanced Efficiency:** Digitalization streamlines the QC process, saving significant time and effort to focus more on critical thinking. With automated tools, medical writers can quickly identify and correct errors, format documents according to guidelines, and manage revisions efficiently. DocQC helps the medical writers to reduce their manual efforts on reviewing the documents by automating complex quality checks. - **Real-time Collaboration:** Multiple individuals can work on the same document simultaneously, making it easier to incorporate feedback, track changes, and manage revisions. This enhances collaboration and reduces the time required for document review cycles. - **Access to Digital Resources:** Digitalization provides medical writers with access to a vast array of digital resources, such as online databases, electronic journals, and research tools which enable writers to gather relevant scientific literature efficiently, verify facts, and maintain scientific rigor. - **Plagiarism Detection:** Digitalization offers powerful plagiarism detection software that can scan documents and compare them against extensive databases of scientific literature to help medical writers identify potential instances of plagiarism, ensuring the originality and credibility of their work. - **Reference Management:** Digital reference management software tools allow medical writers to organize their references, automatically generate citations and bibliographies, and ensure consistency in referencing styles. This streamlines the referencing process, saves time, and reduces errors in citing scientific literature. DocQC provides quality checks to ensure the consistency of the data cited in the document and in the source documents. - **Integration of Regulatory Requirements:** Digitalization has made it easier to integrate specific regulatory guidelines and requirements into the writing process. Templates and software applications tailored to specific regulatory submissions, help writers structure their documents correctly and address the necessary sections, improving efficiency and adherence to regulatory standards. - **Audit Trail and Version Control:** Digital platforms provide an audit trail and version control ensuring transparency and accountability throughout the quality control process, making it easier to track the evolution of the document and address any discrepancies. With the offline reports provided on DocQC, it makes it very easy to track the document changes. The digitalization of quality control in medical writing offers significant advantages and DocQC is designed to automate the complex quality control checks to increase the efficiency and effectiveness of the QC process with each use. **Conclusion:** Overall, quality control in medical writing aims to produce accurate, reliable, and well-structured documents that meet the highest scientific and ethical standards. It involves a combination of expert review, thorough proofreading, adherence to guidelines, and attention to detail at every stage of the writing process. Along with the SMEs and technological experts, GENINVO has designed [DocQC](https://geninvo.com/our-products/docqc-medical-writers-automation-tool/) to help reduce the intervention of manual efforts and time and at the same time maintain the quality of the medical documents. As medical writing continues to evolve, embracing digitalization and leveraging these technologies will be crucial for ensuring the production of high-quality, accurate, and reliable medical documents that meet the rigorous standards of the industry. ***By Hargun Sethi – Software Development and Business Growth*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, DocQC --- ### [The “What” and “Why” of Clinical Data Anonymization](https://geninvo.com/the-what-and-why-of-clinical-data-anonymization/) **Published:** December 15, 2023 **Author:** admin **Content:** Clinical data anonymization is the process of transforming or modifying sensitive clinical-related information in a way that protects the privacy of individuals while still allowing for meaningful analysis and research. Here’s a closer look at the “What” and “Why” of [clinical data anonymization](https://geninvo.com/our-products/data-anonymization-tool/): ## **What is Clinical Data Anonymization?** [Clinical data anonymization](https://geninvo.com/our-products/data-anonymization-tool/) involves applying various techniques to de-identify or remove personally identifiable information (PII) from clinical-related datasets. This includes data such as medical history, genomic data, clinical trial data, or health surveys. The goal is to reduce the risk of re-identification, ensuring that individuals cannot be directly or indirectly identified from the anonymized data. ### **Anonymization techniques commonly used in Clinical data include:** 1. ***Generalization:*** Specific values are categorized into groups or ranges. For example, exact ages with age groups, countries into continents, etc. 2. ***Suppression:*** Removing or redacting sensitive attributes entirely. This can involve removing names, addresses, or other directly identifiable information. 3. ***Masking:*** Replacing parts of the data with symbols like (\*, $, #). For example, replacing zip code using hash i.e. 40\*\*\*\*\*. 4. ***Perturbation:*** Adding random noise or statistical noise to the data to make it more challenging to link to specific individuals. ## **Why is Clinical data anonymization important?** Clinical data contains highly sensitive information that can directly or indirectly identify individuals. Anonymization is crucial for several reasons: 1. **Privacy protection:** Anonymization safeguards the privacy and confidentiality of individuals by reducing the risk of re-identification. It helps prevent unauthorized access or disclosure of personal clinical information, complying with regulations like [HIPAA (Health Insurance Portability and Accountability Act)](https://www.cdc.gov/phlp/publications/topic/hipaa.html) in the United States and GDPR (General Data Protection Regulation) in the European Union. 2. **Research and analysis:** Anonymized clinical data allows researchers, analysts, and organizations to conduct studies, perform statistical analysis, and gain insights without compromising individual privacy. It enables population clinical analysis, medical research, public clinical initiatives, and the development of healthcare policies and interventions. 3. **Data sharing and collaboration**: Anonymization facilitates the sharing of clinical data among researchers, institutions, and stakeholders, promoting collaboration and knowledge exchange. It enables the pooling of data from multiple sources while preserving privacy, leading to more comprehensive and robust research outcomes. 4. **Ethical considerations:** Anonymization addresses ethical concerns related to the use of personal clinical information. It ensures that individuals’ sensitive data is protected and not exploited for unauthorized purposes, fostering trust between data custodians and individuals. **Conclusion** It’s important to note that achieving effective clinical data anonymization requires a thoughtful and careful approach. Anonymization methods must balance privacy protection and data utility, ensuring that the anonymized data remains useful for analysis and research while minimizing the risk of re-identification of individual. Compliance with relevant privacy regulations and guidelines is crucial when dealing with clinical data anonymization. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, Shadow --- ### [Driving Innovation: Accelerating Standard Compliant Data Generation through AI and Machine Learning](https://geninvo.com/driving-innovation-accelerating-standard-compliant-data-generation-through-ai-and-machine-learning/) **Published:** December 14, 2023 **Author:** admin **Content:** ***By Hitesh Raval, ***Principal Data Scientist & CDISC SME****** When submitting clinical trial data to regulatory agencies such as the FDA (U.S.) and PMDA (Japan), it is crucial to follow submission data standards, such as CDISC standards to ensure compliance. The manual mapping of data fields from a clinical trial database to the corresponding compliant standards, like CDISC-SDTM, has resulted in a significant increase in statistical programming resources required for a clinical trial. To address this issue, GenInvo has leveraged use of Machine Learning to develop tool ([ApoGI-DT™](https://geninvo.com/our-products/apogi-dt/)) that helps in automating this process, reducing the time and resources needed to develop high-quality, standards-compliant datasets (such as SDTM) for regulatory submission. ## **Traditional approach to standard compliant data transformation** The traditional approach of standard compliant data transformation (such as CDISC-SDTM) typically involves manual and rule-based procedures that are not only time-consuming but also prone to errors, necessitating specialized technical expertise. This approach frequently entails the development of customized programs to extract data from various sources, manually mapping the raw clinical data to standards-compliant data (such as CDISC-SDTM) domains and elements and validating the data against the established standards. Below mentioned are few of the current challenges in mapping process: - Laborious and time-consuming - Manual processing of codelist mapping, unit conversion and other similar task - Manual errors concerning the accuracy and completeness. - Inconsistency in mapping across studies - Necessity to understand raw data/metadata as precursor to manual mapping. ## Automating the data transformation with Natural Language Processing: Natural Language Processing along with Human in Loop approach (HIL) offers an opportunity to automate and optimize data transformation to generate standards-compliant datasets (such as CDISC-SDTM) for regulatory submission. This can be achieved through the below mention steps. **Standards-Compliant Dataset Generation Flow:** ![](https://geninvo.com/wp-content/uploads/2023/12/AI-and-ML-ingographics-1-1024x618.jpg "AI-and-ML-ingographics-1 - GenInvo")### **Mapping Automation** Utilizing modern Machine Learning and Pattern Recognition Algorithms, variable mapping has become as seamless as it can ever be. - **ML Model Training:** The model is trained using existing standards-compliant datasets (such as CDISC-SDTM) and their associated metadata. Throughout the training process, the model acquires knowledge of the relationships and patterns between the raw clinical trial data and the corresponding standard domains, variables, and values. This training enables the model to comprehend how various variables in the raw data align with specific standards-compliant data (such as CDISC-SDTM) components. - **Provide Input Raw Data:** The ML model is exceptionally generalized and can accept raw data in various formats such as spreadsheets, databases or any other structured data format. - **Automated Mapping to output Standard Data:** The model leverages its acquired knowledge in autonomously mapping the raw data variables with the relevant standards-compliant data (such as CDISC-SDTM) domains and variables. Through the analysis of learned patterns and associations during the training process, the model accurately identifies the corresponding standards-compliant data (such as CDISC-SDTM) components for each variable within the raw data and finally outputs the mapped standards-compliant datasets (such as CDISC-SDTM) based on the input raw data. Through the automation of the mapping process, the model effectively minimizes the need for manual intervention and mitigates the risk of human errors. This automated mapping capability proves especially advantageous for studies encompassing extensive datasets or projects that frequently undergo updates to the source structure. Nevertheless, it is essential to acknowledge that while AI offers a substantial advantage in mapping standards-compliant data (such as CDISC-SDTM), human review/validation remains indispensable. With Human in Loop approach (HIL), Domain Experts review the generated mappings to ensure precision and make any essential modifications based on their domain expertise and the specific demands of their therapeutic areas. ### **Validating and Standardizing Data** In the process of generating standards-compliant data (such as CDISC-SDTM), data validation and standardization are crucial steps that guarantee accuracy, consistency, and reliability of the data used in the study. AI models can play a significant role in automating and improving these steps when working with clinical data standards (such as CDISC). - **Error Identification:** By harnessing the power of machine learning algorithms, AI models have the capability to swiftly analyse standards-compliant datasets (such as CDISC-SDTM) and detect potential errors or inconsistencies present within the data. These errors may include missing values, incorrect date formats, and other similar issues. - **Inconsistency Resolution**: Through the analysis of patterns and relationships within standard data, AI models has the capability to detect instances where data entries exhibit contradictions. An illustrative example would be if a patient’s death information is inconsistent across standard domains (like AE, DM, DD domains of SDTM). In such cases, AI models can promptly flag these potential inconsistencies, drawing attention to the need for further investigation. By automating the identification of such inconsistencies, AI plays a crucial role in upholding the integrity and reliability of the data. - **Missing Data Handling**: AI models have the capability to utilize data query techniques to identify missing values by analysing the existing data patterns. This functionality proves valuable for statistical programmers and data managers as it enables them to proactively raise queries and expedite the data cleaning process. By leveraging this feature, data cleaning can be accomplished more efficiently and effectively. - **Data Standardization**: Clinical data standards (such as CDISC SDTM) provide standardized structures and variable definitions for clinical trial data. However, when working with real-world data, inconsistencies in data representation can arise. AI models offers valuable assistance in standardizing the data by aligning it with the clinical data standards. It possesses the capability to map and convert the data, ensuring adherence to the standards and promoting consistency and compatibility. AI models plays a crucial role by automating the detection of errors, resolving inconsistencies, handle missing data and ensuring compliance with clinical data standards. By leveraging the capabilities of machine learning and pattern recognition, AI provides valuable assistance and enabling to generate standards-compliant datasets (such as CDISC-SDTM) that is of high quality and reliable. ## **Conclusion** The utilization of Clinical Data Standards & Machine Learning techniques along with Human in loop (HIL) approach for clinical data transformation is emerging as promising solution to address the challenges of traditional manual processes. It offers significant advantages in terms of efficiency, accuracy and standardization. ML empowers researchers and data managers to optimize standards-compliant data (such as CDISC-SDTM) generation processes. However, human oversight and interaction remain critical to ensure the accuracy and compliance of the generated standards-compliant datasets (such as CDISC-SDTM). Additionally, these approaches can handle various data formats and sources, making them more flexible and adaptable to the variability in clinical trial data. With automation through AI, Statistical programmers can manage more studies and free up team members for higher-value activities which ultimately accelerate the entire process of clinical data reporting. We, At GenInvo developed tool that can help you to accelerate generating standards-compliant datasets (such as CDISC-SDTM) by reducing manual efforts and automating the entire process. Looking for Better Option to transform your clinical data to standards-compliant data, visit our product [ApoGI-DT™](https://geninvo.com/our-products/apogi-dt/) ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs --- ### [Journey from developer to innovator for generating clinical trial artifacts](https://geninvo.com/journey-from-developer-to-innovator-for-generating-clinical-trial-artifacts/) **Published:** December 14, 2023 **Author:** admin **Content:** ***By Amit Gupta, Technical Lead- Software Development*** My name is Amit Gupta, and currently I am working as a full stack developer and innovator at GenInvo for generating clinical trial artifacts with overall 10+ years of extensive IT experience. Interest in technology from the school days made me into the bachelor’s in computer science and engineering. I am firm believer that technology can impact lives at a level and scale that has never been realized in the history of mankind. The idea that something I create can impact people across the world right now or in the future is what drives my passion for Technology. I am passionate about technology because it’s about building better tools to ease people’s life. I started my professional journey as software developer with Tata Consultancy Services. During my time there I learnt multiple technologies and project in different domain. My experience with multiple technologies majorly revolves around Java and its frameworks, tools and services along with other popular backend and frontend technologies like Python, PHP, Angular, Different types of Databases, Mobile Application Development, Internet of Things, and others. Having interest in solving real world problems, learning new technologies and tools made me to start exploring the Artificial Intelligence and Machine Learning technologies. I started spending time to understand how smart system works and, how we can build new tools that can help us in solving problems dynamically. I got the understanding that with technology continues to evolve, the journey into the realm of AI/ML promises not only personal and professional growth but also provide the opportunity to shape the future of how we live, work, and interact with world. Saying all these my interest in working with mind blowing AI/ML technologies got increased and I started liking all these. This goes with famous quote from W.Clement stone **“When you discover your mission, you will feel its demand. It will fill you with enthusiasm and a burning desire to get to work on it.”** Back in 2020, I got an exciting opportunity to work with one of the most innovative software companies in the field of Clinical Research, i.e. GenInvo whose mission fascinated me that state ## **Our vision is the digitalization of the Clinical Research industry.** GenInvo is a product-based company that develops innovative software products for clinical research & life sciences. We have multiple products that help in automating different functions across different stage of the clinical trials using AI/ML technologies. Currently conducting clinical trials by pharma companies is a very time consuming, complex, and high money-oriented process. These trials involve multiple phases and many kinds of artifacts generations such as Protocols, CRFs, SAP, TLF, Standard-compliant datasets (such as SDTM & ADAM), Metadata and other reports. I started developing innovative tools in GenInvo which help in generating these artifacts using technologies like python, R, AI/ML, and others. While working on these we generated multiple algorithms to implement the automations in the clinical trials process. We are working with common goal to make innovation in clinical trial artifacts generation to accelerate various stages of clinical trials that ultimately speed up the entire process and benefit patients with new drug availability. Being an innovator, I am continuously working toward developing many new tools with the help of AI/ML models and algorithm that can generate automate generation of more clinical trials artifacts in less time with least manual intervention. ## **Conclusion** In conclusion, the journey from a software developer to become an innovator is a dynamic odyssey marked by continue learning, collaboration, and the pursuit of innovation. As we navigate through the ever-evolving landscape of technology, let us remember that the challenges we face are opportunities for growth. To all who are in this genre or going to come, just keep in mind that you must make your hands open to accept all knowledge coming and think out the box. ### Below mentioned are the innovative tool that we developed at GenInvo, [visit our products](https://geninvo.com/our-products/) to explore and get the insights. ### [**Shadow** ](https://geninvo.com/our-products/data-anonymization-tool/) Shadow is a leader in automating data and document de-identification and anonymization technology. Our team of Life Sciences and software development professionals built it with a commitment to producing innovative and long-standing solutions. ### [**DocQC** ](https://geninvo.com/our-products/docqc-medical-writers-automation-tool/) DocQC is a tool for automation of Quality Control (QC) checks that have historically required multiple, time-consuming cycles of manual review. Checks of various complexities are programmed leveraging cutting‒edge technologies. DocQC enables your Medical Writers to maintain their focus on the science, analyses, and presentation of results. ### [**ApoGI** ](https://geninvo.com/our-products/apogi/) ApoGI is an integrated, automation platform that leverages AI and ML, focusing on standards and metadata management to streamline processes and the generation of artifacts, typically associated with the clinical study lifecycle. ### [**ApoGI Data Transformation** ](https://geninvo.com/our-products/apogi-dt/) The SDTM (Study Data Tabulation Model) and ADaM (Analysis Data Model) are standards for human clinical trials (research) data tables and non-clinical data tables submitted by researchers to health authorities. It aligns with the specification developed by the Federation of Clinical Data Exchange Standards (CDISC). ApoGI is AI and meta-data driven designed for automation of end-to-end drug development process. ### **[DocGen](https://geninvo.com/our-products/docgen/)** DocGen – a document generation software for healthcare industry that revolutionizes the way life science companies generate and review standard documents. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs --- ### [Data anonymization tools: What are they and how do they work.](https://geninvo.com/data-anonymization-tools-what-are-they-and-how-do-they-work/) **Published:** December 13, 2023 **Author:** admin **Content:** ***By Ramandeep Dhami, Business Manager*** [Data anonymization tools](https://geninvo.com/our-products/data-anonymization-tool/) are software applications or platforms designed to implement data anonymization techniques and protect sensitive information while preserving data utility. These tools automate the process of anonymizing datasets, making it easier for organizations to apply privacy measures to their data. ## Here’s how data anonymization tools work: 1. **Data discovery and identification:** Data anonymization tools often provide features for data discovery and identification. They scan datasets to identify sensitive attributes or personally identifiable information (PII). These attributes can include names, addresses, social security numbers, and other data elements that can potentially identify individuals. 2. **Anonymization techniques selection:** Once sensitive attributes are identified, the tools offer a range of anonymization techniques to choose from. These techniques include generalization, suppression, masking, noise addition, and data perturbation. Users can select the appropriate anonymization methods based on the specific privacy requirements and data characteristics. 3. **Anonymization algorithms and transformations:** Data anonymization tools employ algorithms and transformations to apply the selected anonymization techniques to the sensitive attributes. These algorithms alter or remove the original data in a way that minimizes the risk of re-identification while maintaining the analytical usefulness of the data. For example, generalization replaces specific values with more general categories, and suppression removes sensitive attributes entirely. 4. **Privacy and utility assessments:** Data anonymization tools often provide assessment features to evaluate the effectiveness of the anonymization process. They measure the level of privacy achieved by the anonymization techniques and assess the impact on data utility. These assessments help users understand the trade-off between privacy protection and data usability, allowing them to fine-tune the anonymization parameters if needed. 5. **Metadata management**: Anonymization tools may include features for managing metadata associated with the anonymized datasets. Metadata includes information about the anonymization methods applied, the rationale behind the choices, and any additional documentation relevant to the privacy protection process. Managing metadata ensures transparency and facilitates compliance with privacy regulations. 6. **Data quality and validation:** Data anonymization tools may incorporate data quality and validation checks to ensure that the anonymized datasets meet certain standards. These checks help identify any anomalies or errors introduced during the anonymization process, such as data inconsistencies or violations of privacy constraints. Data quality checks ensure that the anonymized datasets are accurate and reliable for subsequent analysis. 7. **Export and secure sharing:** Once the anonymization process is complete, data anonymization tools often provide options for exporting or securely sharing the anonymized datasets. These tools may include encryption or access control mechanisms to protect the privacy of the data during storage or transmission. Secure sharing features allow organizations to collaborate or share data while still maintaining privacy. ## **How software application works such as [Shadow (Data anonymization tool)](https://geninvo.com/our-products/data-anonymization-tool/)** Data anonymization software works by applying various techniques to modify or transform sensitive data in a way that reduces the risk of re-identification while preserving the utility of the data for analysis or research purposes. Here’s a general overview of how data anonymization software typically works: 1. **Data identification:** The software scans and identifies sensitive attributes or personally identifiable information (PII) within the dataset. This can include attributes such as names, addresses, social security numbers, or any other information that can potentially identify individuals. 2. **Anonymization technique selection:** The software provides a range of anonymization techniques to choose from based on the specific privacy requirements and data characteristics. These techniques can include generalization, suppression, masking, perturbation, or pseudonymization. 3. **Data transformation:** The software applies the selected anonymization techniques to the sensitive attributes. The transformation process alters or removes the original data in a way that minimizes the risk of re-identification. For example, generalization replaces specific values with more general categories, suppression removes sensitive attributes entirely, masking replaces parts of the data with symbols or placeholders, and perturbation adds random noise to the data. 4. **Privacy and utility assessment:** The software often includes features to assess the privacy protection and data utility achieved through the anonymization process. It measures the level of privacy achieved by the applied techniques and evaluates the impact on data quality and usefulness. These assessments help users understand the trade-off between privacy protection and data utility and adjust if necessary. 5. **Metadata management:** Data anonymization software may also assist in managing metadata associated with the anonymized datasets. This metadata includes information about the anonymization methods applied, the rationale behind the choices, and any additional documentation relevant to the privacy protection process. Managing metadata ensures transparency and facilitates compliance with privacy regulations. 6. **Data quality validation:** The software may include checks to ensure the quality and integrity of the anonymized datasets. These checks help identify any anomalies or errors introduced during the anonymization process, such as data inconsistencies or violations of privacy constraints. Ensuring data quality is important to maintain the accuracy and reliability of the anonymized data for subsequent analysis. 7. **Export and secure sharing:** Once the anonymization process is complete, the software typically provides options for exporting or securely sharing the anonymized datasets. This may involve encryption or access control mechanisms to protect the privacy of the data during storage or transmission. Secure sharing features enable organizations to collaborate or share data while still maintaining privacy. It’s important to note that the specific workings of data anonymization software can vary depending on the tool or platform. Different software solutions may offer additional features, customization options, or specialized techniques to address specific privacy requirements or data types. **Conclusion** Data anonymization tools simplify and automate the anonymization process, enabling organizations to implement privacy measures effectively. They provide a user-friendly interface, a range of anonymization techniques, and assessment features to achieve an optimal balance between privacy protection and data utility. These tools are essential for organizations that handle sensitive data and need to comply with privacy regulations or protect the privacy of individuals in their datasets. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, Shadow **Tags:** Confidentiality, Data Anonymization, Data Security, De-identification, GDPR Compliance, Personal Data Protection, Privacy Protection, Privacy Regulations, Pseudonymization --- ### [Emerging Challenges and Innovations in Data Anonymization](https://geninvo.com/emerging-challenges-and-innovations-in-data-anonymization/) **Published:** December 13, 2023 **Author:** admin **Content:** ***By Ramandeep Dhami, Business Manager*** While [data anonymization ](https://geninvo.com/our-products/data-anonymization-tool/)is an essential technique for protecting privacy, there are several emerging challenges that need to be addressed: 1. **Re-identification attacks:** As adversaries become more sophisticated, there is an increasing risk of re-identification attacks. Attackers can combine anonymized datasets with external information sources or use advanced techniques, such as machine learning algorithms, to re-identify individuals. Addressing these attacks requires developing more robust anonymization methods that can withstand sophisticated re-identification attempts. 2. **Contextual information:** Traditional anonymization approaches focus primarily on removing or altering direct identifiers, such as names and social security numbers. However, contextual information, such as combinations of indirect identifiers or background knowledge, can still lead to re-identification. Protecting against these contextual risks requires considering the relationships and interdependencies between data attributes during the anonymization process. 3. **Data linkage:** Anonymized datasets can still be vulnerable to data linkage attacks, where an attacker combines multiple datasets to re-identify individuals. As data sharing and integration become more common, it is crucial to develop techniques that can mitigate the risk of data linkage and preserve privacy across linked datasets. 4. **Big data and high-dimensional data:** The increasing volume, variety, and dimensionality of data pose unique challenges for anonymization. Traditional anonymization methods may not be scalable or effective in handling big data or high-dimensional datasets. Developing scalable and efficient anonymization techniques that can handle large-scale and complex data is crucial for addressing these challenges. 5. **Emerging data types and sources:** With the proliferation of new data types and sources, such as IoT devices, social media, and sensor data, anonymization techniques need to adapt and evolve. These new data types often contain rich and unique information that can pose additional privacy risks. Anonymization methods must be updated to handle these emerging data types effectively. 6. **Regulatory compliance:** Privacy regulations, such as the General Data Protection Regulation (GDPR) and the California Consumer Privacy Act (CCPA), impose strict requirements for data anonymization. Ensuring compliance with these regulations can be challenging, as the interpretation and enforcement of anonymization standards may vary. Organizations must stay up to date with evolving regulatory frameworks and implement anonymization techniques that meet the compliance requirements. ## **Software Solutions such as[ Shadow ](https://geninvo.com/our-products/data-anonymization-tool/)**(Data Anonymization Tool) Software tools play a crucial role in overcoming challenges in data anonymization. They provide practical solutions and techniques to implement effective anonymization methods. Here are some ways software tools can help overcome challenges in data anonymization: 1. **Advanced anonymization algorithms:** Software tools often incorporate advanced anonymization algorithms that can withstand de-identification attacks and provide stronger privacy guarantees. These algorithms employ techniques such as generalization, suppression, noise addition, and data perturbation to anonymize sensitive attributes while preserving data utility. These tools automate the anonymization process and ensure that the resulting dataset maintains a good balance between privacy and utility. 2. **Differential privacy libraries**: Differential privacy has gained popularity as a robust privacy framework. Software tools often provide libraries or modules that implement differential privacy mechanisms. These libraries allow data analysts and researchers to apply differential privacy directly to their datasets and queries. They handle the mathematical calculations and noise addition required to achieve differential privacy, making it easier for users to incorporate this privacy-enhancing technique into their workflow. 3. **Synthetic data generation tools:** Synthetic data generation has emerged as an innovative approach to data anonymization. Software tools that specialize in synthetic data generation leverage generative models like Variational Autoencoders (VAEs) and Generative Adversarial Networks (GANs). These tools allow users to generate realistic synthetic datasets that preserve the statistical properties of the original data while ensuring privacy. Synthetic data generation tools provide options for customizing the level of privacy and enabling data users to work with representative datasets without accessing sensitive information. 4. **Privacy-preserving machine learning frameworks:** Software tools are being developed to facilitate privacy-preserving machine learning. These frameworks employ techniques like secure multi-party computation, federated learning, and homomorphic encryption. They allow multiple parties to collaborate on model training while preserving the privacy of their individual data. Privacy-preserving machine learning tools handle the complexities of secure computation and encryption, enabling users to train models on sensitive data without exposing the underlying information. 5. **Data anonymization platforms:** Dedicated data anonymization platforms provide end-to-end solutions for anonymizing datasets. These platforms often offer a range of features, including automated data discovery, sensitive attribute identification, anonymization algorithm selection, and data utility assessment. They provide a user-friendly interface to define privacy policies, configure anonymization techniques, and monitor the effectiveness of the anonymization process. Data anonymization platforms streamline the anonymization workflow, making it easier for organizations to implement privacy measures. 6. **Privacy impact assessment tools:** To ensure compliance with privacy regulations and standards, software tools are available for conducting privacy impact assessments (PIAs). These tools help organizations assess the privacy risks associated with their data processing activities and evaluate the effectiveness of their anonymization techniques. PIAs often include features for identifying potential re-identification risks, evaluating data utility, and generating reports to demonstrate compliance. Privacy impact assessment tools assist organizations in making informed decisions about data anonymization and ensuring that privacy risks are effectively managed. ## **Conclusion Overall, the emerging challenges and innovations in data anonymization aim to address the evolving privacy landscape and provide robust solutions for protecting sensitive information while enabling valuable data analysis and research. [Software tools](https://blog.gramener.com/10-best-data-anonymization-tools-and-techniques-to-protect-sensitive-information/) play a vital role in overcoming challenges in data anonymization by providing efficient and scalable solutions. They simplify the anonymization process, enable the application of advanced privacy techniques, and assist organizations in achieving a balance between privacy protection and data utility. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, Shadow **Tags:** Anonymization Tools, Confidentiality, Data Anonymization, Data Security, De-identification, GDPR Compliance, Personal Data Protection, Privacy Protection, Privacy Regulations, Pseudonymization --- ### [The Future of Data Anonymization: Trends and Predictions](https://geninvo.com/the-future-of-data-anonymization-trends-and-predictions/) **Published:** October 27, 2023 **Author:** admin **Content:** **Introduction** In the ever-evolving landscape of data privacy and security, data anonymization has emerged as a critical component. As businesses and individuals become more conscious of data protection, the demand for effective [data anonymization tools](https://geninvo.com/our-products/data-anonymization-tool/) and techniques is on the rise. In this blog, we’ll delve into the future of data anonymization, exploring the trends and predictions that will shape its development in the years to come. ## **The Growing Significance of Data Anonymization** Data anonymization, often referred to as de-identification, is the process of removing or altering personally identifiable information (PII) from datasets, ensuring that the data remains useful for analysis while protecting the privacy of individuals. The growing significance of data anonymization can be attributed to several factors: **1. Stringent Data Privacy Regulations:** The enforcement of data privacy regulations like the General Data Protection Regulation (GDPR) and the [California Consumer Privacy Act](https://oag.ca.gov/privacy/ccpa) (CCPA) has forced organizations to take data privacy seriously. Data anonymization helps businesses comply with these regulations by mitigating the risks associated with data breaches and privacy violations. **2. Increasing Data Breaches:** Data breaches have become alarmingly common, causing severe financial and reputational damage to organizations. Anonymizing data reduces the attractiveness of databases to cybercriminals, as they are less likely to find valuable PII. **3. Ethical Considerations:** There is a growing ethical awareness surrounding data usage. Individuals are more concerned about how their data is handled, making it essential for businesses to prioritize data anonymization to build trust with their customers. ## **Current Trends in Data Anonymization** Before we dive into predictions, let’s examine the current trends in data anonymization: **1. Machine Learning Integration:** Machine learning algorithms are increasingly being integrated into data anonymization tools. These algorithms can automate the identification and anonymization of sensitive information, making the process more efficient and accurate. **2. Differential Privacy:** Differential privacy is a mathematical framework that quantifies the privacy risk of an individual in a dataset. This approach is gaining traction as it provides a rigorous way to measure and control privacy while preserving data utility. **3. Secure Multi-Party Computation:** This cryptographic technique allows multiple parties to jointly analyze their data without revealing the underlying information. It is a promising trend for privacy-preserving data sharing in collaborative environments. **4. Homomorphic Encryption:** Homomorphic encryption enables computations on encrypted data without decrypting it first. This technology is advancing, making it possible to perform complex analyses on sensitive data while keeping it encrypted. ## **Predictions for the Future** Now, let’s look ahead and explore some predictions for the future of data anonymization: **1. Increased Adoption of AI and Machine Learning** As AI and machine learning continue to advance, they will play a more significant role in data anonymization. These technologies will become integral in automating the anonymization process, identifying sensitive data patterns, and adapting to new threats and vulnerabilities. **2. Integration with Big Data Analytics** Data anonymization will become tightly integrated with big data analytics tools. Organizations will seek solutions that allow them to extract valuable insights from large datasets while preserving privacy. This integration will enable more efficient and powerful data-driven decision-making. **3. Enhanced Privacy Controls for Individuals** Individuals will have greater control over their data through decentralized identity management systems and consent mechanisms. Data anonymization tools will incorporate these features, allowing individuals to decide how their data is used and shared. **4. Cross-Border Data Privacy Solutions** With data being a global commodity, data anonymization solutions will need to comply with various international data privacy regulations. We can expect the development of standardized anonymization protocols that cater to the diverse legal requirements of different regions. **5. Collaboration and Data Sharing** Secure multi-party computation and federated learning will facilitate secure collaboration and data sharing among organizations without compromising privacy. This will be particularly valuable in healthcare, finance, and other sectors where data sharing can drive innovation while protecting sensitive information. **6. Privacy-Preserving AI** Advancements in privacy-preserving AI will enable organizations to train machine learning models on sensitive data without exposing the data itself. This will have applications in healthcare research, fraud detection, and more, without risking data breaches or privacy violations. ## **Conclusion** The future of data anonymization is promising, as it aligns with the increasing awareness of data privacy and the demand for secure data-driven insights. As technology continues to advance, data anonymization will evolve to meet new challenges and opportunities. To stay ahead in this evolving landscape, organizations should invest in cutting-edge data anonymization tools, adopt best practices, and keep a close eye on emerging trends and innovations. By doing so, they can ensure the protection of sensitive information while harnessing the power of data for growth and innovation in the years to come. In conclusion, data anonymization is not just a trend; it’s a necessity for businesses looking to thrive in a privacy-focused world. The future of data anonymization holds tremendous potential, and those who embrace it will be better prepared to navigate the ever-changing data privacy landscape. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, Shadow --- ### [Data Anonymization Tools and Techniques to auto detect and protect sensitive information in clinical data.](https://geninvo.com/data-anonymization-tools-and-techniques-to-auto-detect-and-protect-sensitive-information-in-clinical-data/) **Published:** November 15, 2023 **Author:** admin **Content:** **Introduction to Sensitive information in Clinical Data** Protecting sensitive information in clinical data is of utmost importance to ensure patient privacy and comply with data protection regulations such as the [Health Insurance Portability and Accountability Act (HIPAA)](https://www.cdc.gov/phlp/publications/topic/hipaa.html) in the United States or the General Data Protection Regulation (GDPR) in the European Union. ![](https://geninvo.com/wp-content/uploads/2023/11/sensitive-data.jpeg "sensitive-data - GenInvo")Sensitive information in clinical data refers to any data elements that are considered private, confidential, or personally identifiable, and have the potential to harm individuals if accessed or disclosed without proper authorization. In the context of healthcare and clinical data, sensitive information typically includes: 1. **Personally identifiable information (PII):** This includes data elements that can directly or indirectly identify an individual, such as names, addresses, dates of birth, social security numbers, or patient identification numbers. 2. **Medical history and diagnoses**: Clinical data may contain sensitive information about a patient’s medical conditions, treatments, medication history, surgical procedures, or mental health conditions. Such information is considered highly private and should be protected. 3. **Genetic and genomic data**: Genetic information, including DNA sequences, genotypic or phenotypic data, or family medical history, is highly sensitive due to its potential implications for an individual’s health and privacy. 4. **Laboratory test results**: Clinical data often includes information on laboratory tests, such as blood tests, imaging reports, or pathology results. These results may reveal sensitive health information and should be safeguarded. 5. **Billing and payment information**: Healthcare data may include details related to insurance, billing, and financial transactions, such as insurance policy numbers, credit card information, or billing records. Protection of these data elements is crucial to prevent financial fraud or identity theft. 6. **Biometric data**: Some clinical data may involve biometric information, such as fingerprints, voiceprints, or retinal scans. These data elements are highly sensitive and require strict protection. 7. **Patient communications**: Electronic health records or clinical data systems may contain sensitive information from patient-doctor communications, including emails, messages, or notes discussing personal medical conditions, treatment plans, or sensitive discussions. ## **Data Anonymization** Data anonymization is the process of transforming data in such a way that it can no longer be linked to a specific individual or entity. This is done to protect privacy and comply with data protection regulations. ![](https://geninvo.com/wp-content/uploads/2023/11/Data-anonymization-1024x576.jpg "Data-anonymization - GenInvo")**Tools and Techniques** There are several tools and techniques available for data anonymization. Here are some commonly used ones: 1. **Masking:** Masking involves replacing sensitive data with fake or pseudonymous values. For example, replacing names with random strings or replacing identifying numbers with randomly generated numbers. 2. **Generalization:** Generalization involves replacing specific values with a more general or less precise value. For example, replacing exact ages with age ranges or replacing specific dates with years. 3. **Perturbation:** Perturbation involves adding random noise or altering the values of data slightly to make it harder to identify individuals. For numerical data, this can be achieved by adding random values within a certain range. 4. **Encryption:** Encryption involves transforming data using cryptographic techniques, making it unreadable without the appropriate decryption key. This can be used to protect data both at rest and in transit. 5. **Data Swapping:** Data swapping involves exchanging values between different individuals or entities while preserving statistical properties. This technique ensures that the data remains useful for analysis while preventing the identification of specific individuals. 6. **Tokenization:** Tokenization involves replacing sensitive data with unique tokens or identifiers. The mapping between the original data and the tokens is securely stored and used to reconstruct the original data when necessary. 7. **Data Masking:** Data masking involves hiding sensitive information by partially or completely obscuring it. This can be done through techniques such as blurring, pixelation, or redaction. 8. **Differential Privacy:** Differential privacy is a privacy-preserving framework that adds noise to query results or statistical analysis. It ensures that the presence or absence of an individual’s data does not significantly impact the outcome of the analysis. When selecting [data anonymization tools](https://geninvo.com/our-products/data-anonymization-tool/) or techniques, it’s important to consider the specific requirements of your use case, the sensitivity of the data, and the applicable data protection regulations. Additionally, it’s crucial to evaluate the effectiveness of the chosen technique in preserving privacy while maintaining data utility for the intended analysis or use. ## **Automation in Data Anonymization** Automation plays a crucial role in data anonymization, as it enables organizations to apply consistent and scalable techniques to protect privacy. Here are some ways automation can be applied in data anonymization: 1. **Pseudonymization:** Pseudonymization involves replacing identifying information with pseudonyms or aliases. Automation can be used to pseudonymize data by applying consistent algorithms or methods to replace personal identifiers with non-identifying values. This can be done automatically across large datasets, ensuring efficiency and accuracy. 2. **Generalization and suppression:** Generalization involves replacing specific values with more generalized or less precise values, while suppression involves removing or masking certain data elements. Automation can be used to apply predefined rules or algorithms to generalize or suppress sensitive data automatically. For example, automated techniques can be employed to replace specific birth dates with age ranges or to suppress or redact names or addresses based on predefined criteria. 3. **Data masking and tokenization:** Data masking involves replacing sensitive data with fictitious or obfuscated values, while tokenization involves replacing sensitive data with randomly generated tokens. Automation can be used to mask or tokenize data at scale, ensuring consistent and secure anonymization. This is particularly useful when sharing data with third parties or using data for non-production purposes while preserving privacy. 4. **Anonymization rule engines:** Automation can be employed to develop rule engines that apply a set of predefined anonymization rules to data. These rules can be based on legal or regulatory requirements, organizational policies, or privacy best practices. Anonymization rule engines enable organizations to automate the anonymization process, ensuring that all data is treated consistently and in compliance with privacy regulations. 5. **Machine learning-assisted anonymization:** Automation can leverage machine learning techniques to assist in the anonymization process. For instance, automated algorithms can be trained to identify and redact sensitive information, such as personally identifiable information (PII), based on patterns and context. This can help organizations automate the detection and anonymization of sensitive data across large and diverse datasets. **Conclusion** In conclusion, data anonymization is a crucial process for protecting sensitive information and ensuring privacy in various domains, including clinical data. By removing or obfuscating personally identifiable information (PII), data anonymization helps mitigate the risk of unauthorized access, identity theft, and other privacy breaches. Through techniques such as masking, generalization, perturbation, encryption, data swapping, tokenization, and data masking, sensitive data can be transformed in a way that it becomes difficult or impossible to link it back to individuals. These anonymization techniques help strike a balance between preserving privacy and maintaining the utility of the data for analysis and research purposes. Overall, data anonymization plays a vital role in safeguarding privacy and enabling the responsible use of data for research, analysis, and innovation while reducing the risks associated with the unauthorized disclosure of sensitive information. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, Shadow **Tags:** Anonymization Tools, Confidentiality, Data Anonymization, Data Security, De-identification, GDPR Compliance, Personal Data Protection, Privacy Protection, Privacy Regulations, Pseudonymization --- ### [How Synthetic Data Accelerates Drug Discovery in the Pharmaceutical Industry ](https://geninvo.com/how-synthetic-data-accelerates-drug-discovery-in-the-pharmaceutical-industry/) **Published:** November 24, 2023 **Author:** admin **Content:** The pharmaceutical sector leads the way in scientific innovation, continuously striving to develop life changing medications and treatments. But there are many obstacles in the way of discovery, and innovative approaches are needed to get beyond them. With its ability to solve major issues with clinical data management, biometrics, and statistical programming, synthetic data is rapidly becoming a revolutionary force in pharmaceutical research. Using GenInvo’s [Datalution](https://geninvo.com/our-products/datalution/) platform and insights from NCBI, we will examine how meaningful synthetic data is changing drug discovery and talk about its technical aspects in this blog. ## **The Complexities of Drug Discovery** Drug discovery is a resource-intensive, complex process that requires a lot of resources. Identifying wonder drugs, evaluating their safety, and deciphering enormous datasets are just a few of the many difficulties faced by researchers. Although they have their own set of drawbacks, clinical data management, biometrics, and statistical programming have historically been essential to this procedure. ## **Pain Points in Clinical Data Management** Clinical data management involves the collection, validation, and analysis of data from clinical trials. Pain points include: Presenter mode **Data Entry and Cleaning (EDC):** Electronic Data Capture is efficient but requires rigorous data cleaning. **Data Quality:** Ensuring the accuracy and integrity of data is a significant challenge. **Data Standardization (SDTM):** Converting data into the Standard Data Tabulation Model format can be time-consuming. **Pain Points in Biometrics** Biometrics, the science of identifying individuals based on their unique characteristics, plays a critical role in clinical trials and patient identification. Pain points include: **Data Privacy:** Protecting sensitive patient information is essential. **Data Testing:** Rigorous testing of biometric systems can be complex and privacy-sensitive. **Data Security:** Biometric data requires robust security measures. **Pain Points in Statistical Programming** Statistical programming is vital for analyzing and interpreting data. Pain points include: **Data Diversity:** Ensuring diverse datasets for analysis is challenging. **Data Volume:** Handling massive datasets efficiently is a technical challenge. **Data Integrity:** Maintaining data integrity during analysis is crucial. **Enter Meaningful Synthetic Data** Meaning Synthetic data is the innovative solution to these pain points. It is artificially generated data that mirrors real data while preserving statistical properties. Let’s delve into how synthetic data is revolutionizing these areas: ## **Clinical Data Management** Even before collecting actual data the meaning Synthetic data helps in clinical data management by: **Improving Data Quality:** Meaningful Synthetic data can be used to validate EDC and SDTM processes, ensuring high data quality. **Data Testing:** Researchers can test data management systems and software without real patient data, mitigating privacy concerns. **Cost Reduction:** Synthetic data reduces costs associated with data acquisition and maintenance. **Biometrics** In biometrics, synthetic data offers: **Privacy Preservation:** Synthetic biometric datasets protect patient privacy while allowing for thorough system testing. **Enhanced Security:** Robust security testing using synthetic data helps identify vulnerabilities without risking real patient data. **Algorithm Development:** Researchers can develop and refine algorithms using synthetic data before real-world deployment. **Statistical Programming** Statistical programming benefits from synthetic data by: **Data Diversity:** Synthetic data provides a broad range of datasets for diverse analyses. **Scalability:** Handling large datasets efficiently is easier with synthetic data. **Data Integrity:** Synthetic data helps ensure data integrity throughout the analysis process. ## **GenInvo’s Datalution Platform – Meaningful Synthetic Data Generation Solution** Leading the way in synthetic data services is GenInvo’s Datalution platform, which provides cutting-edge clinical data management, biometrics, and statistical programming solutions. Pharmaceutical businesses may speed up research, cut expenses, and protect patient privacy and security by using Datalution’s synthetic data. It is a powerful instrument in the arsenal of pharmaceutical companies striving to discover drugs quickly. ## **The Future of Drug Discovery** Synthetic data has the potential to become a vital tool in pharmaceutical research as technology advances. It is a game-changer in the drug discovery process because it can handle the issues with statistical programming, biometrics, and clinical data management while guaranteeing data security and privacy. GenInvo’s Datalution platform is paving the way for the use of meaningful synthetic data in pharmaceutical research, which will speed up the advancement of drugs and therapies that can save lives. Datalution is all in one solution for generating meaningful synthetic data for testing electronic data capture, edit checks, data management (as part of UAT Process), programming, and statistical setup activities for Dry Run (mapping/transformation, TLFs & visualization ) and more. Advantages of using Datalution: - Easy to use user interface - Generate Real like synthetic data for upcoming or ongoing clinical trials integrated with patient journey - Zero risk of identifying patients - Allow stake holders to have data at right time and increase the trial efficiency by performing data operations quickly without hick-ups To conclude, synthetic data is changing the way the pharmaceutical sector conducts drug research. It’s not only a matter of accelerating the process; it’s also about resolving the crucial issues that have long impeded advancement. The future of pharmaceutical research looks brighter than ever, with cutting-edge tools like GenInvo’s Datalution platform promising faster, safer, and more effective drug discovery. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, Datalution **Tags:** AI Development, Data Augmentation, Data Generation, Data Privacy, Data Science, Machine Learning, Model Training, Privacy Preservation, Synthetic data, Synthetic Dataset --- ### [Accelerating the Medical Writing Process with Automation ](https://geninvo.com/accelerating-the-medical-writing-process-with-automation/) **Published:** November 29, 2023 **Author:** admin **Content:** In the field of medical writing, the efficient creation and sharing of accurate and high-quality scientific content is crucial. Medical writers play a vital role in creating various documents, including research papers, regulatory submissions, clinical trial reports, and educational content. However, the medical writing process can be time-consuming and complex, requiring extensive research, data analysis, and adherence to strict guidelines. In recent years, the automation has revolutionized the medical writing landscape, offering significant benefits in terms of speed, accuracy, and productivity, thus accelerating the medical writing process and transforming the industry. ## **How Automation helps in Saving Medical Writer’s time:** One of the most time-consuming tasks in medical writing is conducting a comprehensive literature review. [Automation tools](https://geninvo.com/our-products/docqc-medical-writers-automation-tool/) can significantly expedite this process by automatically extracting relevant information from vast databases of scientific literature. Advanced algorithms and natural language processing techniques enable tools to identify key articles, summarize their content, and extract significant data, saving medical writers hours or even days of manual review. Automation tools can also streamline the data analysis process, which is essential for generating evidence-based content. By leveraging machine learning algorithms, these tools can analyse large datasets, identify trends, and highlight significant findings. This enables medical writers to focus on interpreting the results and drawing meaningful conclusions, rather than spending excessive time on data organization and analysis. ## **Advantages of Automation in Medical Writing to accelerate the process:** - **Automation in maintaining the Consistency:** Consistency and adherence to guidelines are crucial in medical writing. Automation can ensure that documents adhere to specific formatting requirements, such as those outlined by regulatory bodies or scientific journals. By using standardized templates, medical writers can save time and effort in formatting documents, allowing them to focus on the content itself. Automated tools can also perform quality checks, identifying and flagging potential errors or inconsistencies, thereby improving the overall accuracy and quality of the documents. - **Automation helping in collaborative work:** Medical writing often involves collaboration among multiple authors, which can be challenging to manage. Automation tools provide a centralized platform for collaborative writing, allowing multiple authors to work simultaneously on a document. These tools enable real-time editing, version control, and seamless integration of contributions, facilitating efficient collaboration and reducing the time spent on merging and reconciling different versions of the document. - **Automation helping in effective communication:** In a globalized world, medical documents often require translation into multiple languages. Automation tools equipped with machine translation capabilities can accelerate the translation process while maintaining accuracy. Additionally, these tools can assist in localizing the content to adhere to cultural and linguistic nuances, ensuring that the information is effectively communicated to diverse audiences. ### **Conclusion** Automation has become a game-changer in the medical writing process, offering significant benefits in terms of speed, accuracy, and productivity. By leveraging advanced technologies such as machine learning, natural language processing, and collaborative platforms, medical writers can streamline tasks such as literature review, data analysis, formatting, collaboration, and translation. As automation continues to evolve, it will likely have an even more profound impact on the medical writing landscape, enabling professionals to focus their efforts on critical thinking, interpretation, and the generation of high-quality scientific content. Embracing automation in medical writing is essential for keeping pace with the rapidly advancing field of healthcare and ensuring the efficient dissemination of knowledge to benefit patients, healthcare professionals, and the scientific community as a whole. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, DocQC **Tags:** Academic Medicine, Clinical Communication, Health Informatics, Healthcare Documentation, Literature Review, Medical Research, Medical Terminology, Medical Writing, Scientific Writing, Writing Tools --- ### [Pharmaceuticals/CRO's reducing the time spent on data protection by 50% with the help of Anonymization tools.](https://geninvo.com/pharmaceuticals-cros-reducing-the-time-spent-on-data-protection-by-50-with-the-help-of-anonymization-tools/) **Published:** November 29, 2023 **Author:** admin **Content:** Pharmaceutical companies and Contract Research Organizations (CROs) are increasingly using [anonymization tools](https://geninvo.com/our-products/data-anonymization-tool/) to reduce the time spent on data protection. Anonymization is the process of protecting private or sensitive information by erasing or modifying personally identifiable information from datasets, documents and DICOM Images. while still maintaining the usefulness and integrity of the data for analysis and research purposes. ## **By implementing anonymization tools, pharmaceuticals and CROs can achieve several benefits, including:** 1. **Enhanced data privacy:** Anonymizing sensitive data helps protect the privacy of individuals whose information is included in the datasets. This is particularly important in the healthcare and pharmaceutical sectors, where patient confidentiality is critical. 2. **Simplified compliance with regulations:** Anonymization tools can assist organizations in complying with data protection regulations, such as the General Data Protection Regulation (GDPR) in the European Union and the [Health Insurance Portability and Accountability Act ](https://www.cdc.gov/phlp/publications/topic/hipaa.html)(HIPAA) in the United States. These tools help mitigate the risk of data breaches and non-compliance penalties. 3. **Streamlined data sharing:** Organizations can share the valuable data for research collaborations and for public domain by complying with the rules and regulations given by regulatory agencies, and this can be done through the process of anonymization of personal sensitive identifiable information. 4. **Accelerated data analysis:** [Anonymization tools](https://geninvo.com/our-products/data-anonymization-tool/) allow organizations to focus on data analysis rather than spending excessive time on data protection measures. By automating the anonymization process, repetitive tasks can be handled efficiently, freeing up resources for more advanced data analytics and research activities. ## **How pharmaceutical companies save time by using anonymization techniques in several ways:** 1. **Automated anonymization**: Anonymization tools automate the process of hiding or modifying personally identifiable information from datasets, documents and DICOM images. This eliminates the need for manual identification and removal of sensitive data, saving significant time and effort. 2. **Efficient data masking:** Anonymization techniques, such as data masking or pseudonymization, replace sensitive information with Randomly generated information for variables in data that retains the statistical properties of the original dataset. This process can be done quickly and efficiently, ensuring the protection of privacy while maintaining data utility. 3. **Streamlined regulatory compliance:** Anonymization techniques help pharmaceutical companies comply with stringent data protection regulations, such as GDPR and HIPAA. By anonymizing data, organizations can demonstrate their commitment to privacy and ensure compliance without the need for lengthy manual review processes. 4. **Simplified data sharing**: Anonymized data can be shared more easily with external partners, research organizations, and regulatory authorities. This streamlined sharing process eliminates the need for extensive legal and administrative negotiations, saving time and resources. 5. **Accelerated research and analysis:** With sensitive data already anonymized, researchers and analysts can focus more directly on the analysis and interpretation of the data. This accelerates research timelines and enables faster decision-making processes. 6. **Facilitated collaboration:** Anonymization techniques enable collaboration between pharmaceutical companies and external stakeholders, such as academic researchers or CROs. By anonymizing data, organizations can safely share datasets while maintaining confidentiality and intellectual property rights, fostering collaboration and knowledge sharing. 7. **Reduced data breach risk:** Anonymization helps mitigate the risk of data breaches by hiding personally identifiable information. This reduces the potential harm that could result from unauthorized access to sensitive data, saving companies time, effort, and reputational damage associated with data breach investigations and mitigation. The time saved by pharmaceutical companies using automation techniques in data anonymization can vary depending on several factors, including the size and complexity of the datasets, the specific anonymization methods employed, and the level of automation implemented. While it is challenging to provide an exact figure, automation can significantly reduce the time spent on data anonymization compared to manual approaches. ## **Here are some potential time-saving benefits of automation in data anonymization:** 1. **Speed and efficiency:** Automation tools can process large datasets quickly and efficiently. Tasks that would require significant manual effort, such as identifying and hiding personal identifiable information, can be automated, resulting in substantial time savings. 2. **Scalability:** Automation allows pharmaceutical companies to handle increasing volumes of data without a proportional increase in time and resources. As the size of datasets grows, automation can handle the anonymization process more effectively, ensuring consistent and efficient application of anonymization techniques. 3. **Repetitive task automation:** Anonymization often involves repetitive tasks, such as hiding specific data fields or applying consistent transformations. Automation tools can perform these tasks consistently and accurately, reducing the time spent on manual data handling. 4. **Standardization:** Automation techniques can enforce standardization in the anonymization process. Once an anonymization workflow is defined and automated, it can be applied consistently across multiple datasets, reducing the time required for manual intervention and decision-making. 5. **Iterative improvements:** Automation allows for iterative improvements in the anonymization process. As new techniques or best practices emerge, automation tools can be updated and refined to incorporate these advancements, leading to more efficient and effective anonymization over time. ## **Conclusion** While the specific time savings can vary, pharmaceutical companies that implement automation techniques in data anonymization can typically expect significant reductions in the time required for data processing, enabling them to allocate resources more efficiently, accelerate research initiatives, and streamline data sharing processes. Overall, anonymization techniques save time for pharmaceutical companies by automating and streamlining the data protection process, facilitating compliance, enabling efficient data sharing, and accelerating research and analysis efforts. While the extent of time savings may vary depending on the specific context and datasets involved, it is plausible that the use of anonymization tools could reduce the Significant amount of time spent on data protection. However, it’s important to note that the implementation of such tools should be accompanied by robust security measures and thorough evaluation to ensure the effectiveness of anonymization techniques and compliance with applicable regulations. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, Shadow **Tags:** Clinical dataset anonymization, Data De-identification, risk of re-identification, shadow --- ### [Digitalization of Medical Writing: Balancing AI and Rule-based algorithms with Human Supervision in Medical Writing QC ](https://geninvo.com/digitalization-of-medical-writing-balancing-ai-and-rule-based-algorithms-with-human-supervision-in-medical-writing-qc/) **Published:** December 11, 2023 **Author:** admin **Content:** **Introduction** The digitalization of medical writing refers to using digital technologies and tools to create, edit, and review medical content. This includes various aspects of medical communication. In recent years, emergence of digitalization has led to a significant transformation int the field of medical writing. The integration of digital technologies and tools has revolutionized how medical content is created, managed, and published. This digital revolution has not only streamlined the workflow of medical writers but has also improved accessibility to accurate healthcare information for healthcare professionals and patients worldwide. The emergence of digitalization has significantly transformed the field of medical writing, offering numerous benefits and opportunities for both medical writers and healthcare professionals. Digitalization has also paved the way for improved accessibility to any individual on relevant medical information. Online content and the use of interactive educational materials, such as videos and graphics, has proven to be effective in enhancing patient comprehension and empowering them to make informed healthcare choices. ## **Future of Medical Writing:** As digitalization continues to evolve, the future of medical writing holds even more promise. AI and rule-based algorithms have made significant contributions to medical writing. Natural language processing (NLP) algorithms can analyse vast amounts of medical literature, extract relevant information, and assist in literature reviews, saving considerable time for medical writers. NLP can also assist in generating summaries and abstracts. Artificial intelligence (AI) and machine learning algorithms have the potential to automate certain aspects of medical writing, such as literature searching and reference formatting. AI-powered tools can aid in grammar and spell-checking, style consistency, and reference formatting, reducing errors and enhancing the overall quality of written content. An example of such tool is [DocQC](https://geninvo.com/our-products/docqc-medical-writers-automation-tool/), supported by AI and ML algorithms and developed by technological and subject matter experts to automate complex quality control checks. ## **Advantages of AI and Rule-based algorithms:** - **Accuracy and Consistency:** AI algorithms can contribute to the accuracy and consistency of medical writing. They can identify potential errors, inconsistencies, or deviations from established guidelines, ensuring that medical documents adhere to the highest standards. AI-powered tools can also assist in cross-referencing information, identifying redundant content, and maintaining consistency throughout the writing. DocQC ensures the accuracy and consistency of the data by automating the quality control checks and minimizing human errors and ambiguity. DocQC validates the data in the medical documents internally and externally and checks for the accurate facts. - **Efficiency and Speed:** The integration of AI and rule-based algorithms in medical writing has improved efficiency and speed. Automated processes can handle routine tasks, allowing medical writers to focus on higher-level tasks, such as data interpretation and critical analysis. This accelerates the writing process and enables faster broadcasting of medical information. Using DocQC, medical writers can reduce the manual efforts on multiple, time-consuming cycles of manual review and focus towards other high priority tasks involving critical thinking. DocQC provide the QC results within few minutes, enabling the medical writers to quickly evaluate the document quality. ![](https://geninvo.com/wp-content/uploads/2023/12/Digitalization-of-Medical-Writing-2.jpg "Digitalization-of-Medical-Writing-2 - GenInvo") ## **Intervention of Human Supervision:** While AI and rule-based algorithms bring efficiency and accuracy, human supervision still remains a crucial element in medical writing. Human medical writers possess the expertise, clinical knowledge, and detailed understanding required to interpret medical data, contextual information, and ensure the quality of scientific content. They can critically analyse research findings, assess the clinical relevance, and provide valuable insights that AI algorithms may overlook. Medical writing involves ethical considerations and requires a deep understanding of the medical context. Human supervision is essential to navigate these details. Medical writers are responsible for ensuring the accuracy and appropriate interpretation of research findings, adhering to ethical guidelines, and presenting information in a way that is accessible, unbiased, and understandable to the target audience. Human supervision is crucial to maintain the ethical integrity of medical writing and mitigate potential biases. As AI continues to evolve, it is essential for medical writers to adapt and acquire new skills. Medical writers should familiarize themselves with AI technologies, understand their capabilities and limitations, and leverage them effectively in their work. There should be a healthy balance between the digital technologies with Medical Writer’s human supervision. They should also stay updated with the latest advancements in AI and rule-based algorithms to make informed decisions about when and how to incorporate them into their writing process. **Conclusion:** The optimal approach to balancing AI and rule-based algorithms with human supervision lies in collaboration. While these technologies enhance efficiency, accuracy, and productivity, human supervision remains essential to ensure the integrity, quality, and ethical standards of medical writing. By striking the right balance, medical writers can harness the power of AI while leveraging their expertise to produce high-quality, accurate, and contextually relevant medical content that meets the diverse needs of healthcare professionals and patients, empowering patients to actively engage in their healthcare journey. Medical writers and AI technologies can work collectively, with AI-powered tools assisting in routine tasks and human writers providing critical thinking, context, and expertise. Continuous learnings and developments are key to staying level to AI advancements and leveraging them effectively and efficiently. ***Hargun Kaur Sethi*** ***Software Development and Business Growth, GENINVO*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, DocQC **Tags:** Academic Medicine, Clinical Communication, Health Informatics, Healthcare Documentation, Medical Research, Medical Terminology, Medical Writing, Scientific Writing, Writing Tools --- ### [Ensuring GDPR Compliance with Advanced Data Anonymization Solutions](https://geninvo.com/ensuring-gdpr-compliance-with-advanced-data-anonymization-solutions/) **Published:** August 18, 2023 **Author:** admin **Content:** **Introduction** In an increasingly interconnected world, where every digital interaction leaves a trace, safeguarding personal data has become a paramount concern. The General Data Protection Regulation (GDPR), a comprehensive legal framework enacted by the European Union, stands as a sentinel of individual privacy rights. In this era of data-driven insights, organizations are not only tasked with harnessing the power of information but also ensuring that it is wielded responsibly and ethically. This is where advanced data anonymization solutions emerge as vital tools, bridging the gap between data utility and privacy protection in the pursuit of[ GDPR compliance](https://gdpr.eu/compliance/). GDPR, a beacon of data protection, mandates stringent standards for organizations handling personal data of EU citizens. Its principles demand transparency, accountability, and the implementation of robust measures to mitigate data breaches and unauthorized access. Central to GDPR compliance is the concept of data anonymization—a process that transforms personal information into an irreversible, de-identified form, rendering it impervious to re-identification. Yet, as the volume and complexity of data continue to surge, basic anonymization methods might fall short of achieving the desired privacy thresholds. This is where advanced data anonymization solutions emerge as beacons of innovation, enabling organizations to uphold GDPR mandates while extracting meaningful insights from their datasets. In this comprehensive exploration, we delve into the intricate synergy between GDPR compliance and advanced data anonymization solutions. We dissect the pivotal GDPR articles that underscore the significance of data protection and privacy preservation. With a keen focus on advanced techniques such as k-anonymity, differential privacy, and secure multi-party computation, we illuminate how these cutting-edge methodologies transcend traditional approaches. Join us on a journey that navigates the complex landscape of data anonymization, guiding organizations towards the pinnacle of GDPR compliance while harnessing the full potential of their data-driven endeavors. ## **Understanding GDPR and Data Anonymization** In the digital age, where the exchange of personal information has become the currency of modern commerce, the General Data Protection Regulation (GDPR) stands as a sentinel, championing the rights of individuals and setting the stage for responsible data management. Enacted by the European Union in 2018, GDPR is more than a legal framework; it embodies a paradigm shift that compels organizations to tread the fine line between data-driven innovation and the protection of individual privacy. At its core, GDPR is an intricate tapestry woven with threads of consent, transparency, and accountability. It bestows individuals with the right to know how their data is being used, and more importantly, the authority to grant or withhold permission. Organizations, in turn, are entrusted with the responsibility to handle personal data with utmost care, ensuring that the digital footprints left by users are safeguarded against prying eyes and malicious intent. This is where the notion of data anonymization takes center stage, offering a potent mechanism to adhere to GDPR’s mandates. Data anonymization is not a mere process; it is a transformational journey that pivots on the principle of irreversibility. By stripping personal data of identifiers and contextual cues, this technique renders information impotent in the hands of malevolent actors. Yet, its significance extends beyond the mere veiling of information. Data anonymization is the cornerstone upon which organizations build their GDPR compliance strategy. It underscores the commitment to individual privacy while ensuring that the deluge of data continues to fuel innovation and drive informed decision-making. As we delve deeper into the intricate layers of GDPR and data anonymization, we unravel the symbiotic relationship between these two concepts. We dissect the GDPR articles that provide the philosophical underpinnings of data protection and delve into the mechanisms through which data anonymization fortifies compliance. Embark on this intellectual voyage, where knowledge becomes the beacon guiding organizations towards a harmonious coexistence of data utility and privacy preservation in the ever-evolving landscape of digital transformation. ## **Key GDPR Articles Relating to Data Anonymization** In the intricate tapestry of the General Data Protection Regulation (GDPR), certain articles stand as pillars, fortifying the edifice of data protection and privacy preservation. These articles form the bedrock upon which organizations must construct their strategies for compliance, particularly when it comes to the art and science of data anonymization. ### **Article 5: Principles of Lawfulness, Fairness, and Transparency** At the heart of GDPR lies the foundational Article 5, a manifesto of principles that set the stage for ethical data handling. Lawfulness, fairness, and transparency dictate that personal data shall be processed with explicit purpose and consent. When contemplating data anonymization, this article crystallizes the need to ensure that the transformation is not only for the organization’s benefit but aligns with the original purpose for which the data was collected. Transparency takes on a new dimension, urging organizations to communicate their anonymization practices clearly to users, allowing them to grasp the intricacies of how their data is being treated. ### **Article 6: Lawfulness of Processing** Article 6 introduces the concept of legal grounds for processing personal data. When data anonymization is the chosen path, organizations must ensure that the anonymized data remains within the legal bounds of processing. The transformed data should be detached from identifiers in a manner that adheres to the principles of purpose limitation and minimization. Compliance with Article 6 becomes not only a matter of legality but a testament to an organization’s commitment to ethical data stewardship. ### **Article 25: Data Protection by Design and by Default** Embedded within Article 25 is the mandate for incorporating privacy-enhancing measures from the inception of data processing activities. [Data anonymization](https://geninvo.com/our-services/anonymization-as-a-service/) emerges as a champion of this principle, encapsulating privacy within the very fabric of data architecture. By applying anonymization techniques as a default, organizations manifest their dedication to protecting user privacy, creating an environment where personal data can thrive without compromising individual rights. ### **Article 32: Security of Processing** Article 32 reverberates with the call for security, urging organizations to adopt measures that safeguard personal data against breaches and vulnerabilities. In the realm of data anonymization, this extends beyond mere pseudonyms; it necessitates the deployment of advanced techniques that render re-identification an insurmountable challenge. Organizations must ensure that their chosen anonymization methods are robust enough to withstand evolving cyber threats, ultimately upholding the integrity of the anonymized data. As we traverse the intricate corridors of these key GDPR articles, we illuminate the fundamental principles that weave data anonymization into the fabric of compliance. These articles offer a compass that guides organizations in their journey towards reconciling data utility with the sanctity of individual privacy, and through them, we unearth the transformative potential of data anonymization in the modern era of digital responsibility. ## **Advanced Data Anonymization Solutions for GDPR Compliance** In the ever-evolving landscape of data protection and privacy, where traditional methods of safeguarding information are increasingly challenged, a new wave of guardians emerges advanced data anonymization solutions. These innovative techniques go beyond the realm of conventional data obfuscation, providing a robust shield against the prying eyes of unauthorized entities while empowering organizations to navigate the labyrinthine corridors of the General Data Protection Regulation (GDPR) with confidence. ### **K-Anonymity: Redefining the Threshold of Privacy** At the forefront of advanced data anonymization stands the ingenious concept of k-anonymity. This transformative technique ensures that individual data points within a dataset are indistinguishable from at least ‘k-1’ other data points. By introducing sufficient noise and variability, k-anonymity effectively shrouds the uniqueness of individuals, making re-identification a formidable challenge. This innovation not only aligns with GDPR’s mandates of data minimization but also establishes a new standard for privacy protection in an era where de-identification alone may fall short. ### **Differential Privacy: Guarding Against Intrusive Analysis** Venturing further into the realm of innovation, differential privacy emerges as a beacon of protection against even the most sophisticated intrusions. This technique injects calibrated noise into queries made against a dataset, rendering statistical analysis incapable of singling out specific individuals. Differential privacy finds resonance within GDPR’s core principles by ensuring that the insights gleaned from data are meaningful while never jeopardizing the identities of those who contributed to the pool of information. ### **Secure Multi-Party Computation: Collaboration Without Compromise** In an interconnected world, collaboration often transcends organizational boundaries. However, sharing data while upholding GDPR’s tenets can be a delicate dance. Enter secure multi-party computation, an advanced technique that enables multiple entities to analyze their collective data without ever exposing individual records. This innovative solution harmonizes the collaborative spirit of modern enterprises with the imperative of safeguarding privacy, presenting a tangible path toward GDPR compliance without sacrificing insights. As organizations embark on the quest for GDPR compliance, these advanced data anonymization solutions illuminate a new trajectory—one where privacy and utility are not adversaries but allies. In the symphony of k-anonymity, differential privacy, and secure multi-party computation, organizations discover the harmonious chords that resonate with the essence of responsible data stewardship. By harnessing these solutions, they emerge as vanguards of privacy, fortifying their position on the vanguard of the GDPR landscape, all while harnessing the transformative power of their data assets. ## **Benefits of Implementing Advanced Data Anonymization** In the delicate dance between data utilization and the imperative of safeguarding individual privacy, organizations often find themselves at a crossroads. As the custodians of vast repositories of information, they bear the responsibility of striking a delicate balance—one that upholds the tenets of the General Data Protection Regulation (GDPR) while harnessing the transformative potential of data-driven insights. Enter advanced data anonymization solutions, not as mere guardians of anonymity, but as catalysts for a harmonious coalescence of data utility and privacy preservation. - **Upholding Customer Trust and Regulatory Compliance** At the heart of the GDPR mandate lies the principle of engendering trust—a trust that the personal data entrusted to organizations will be handled responsibly and ethically. Implementing advanced data anonymization solutions serves as a potent testament to an organization’s commitment to this trust. By deploying techniques like k-anonymity and differential privacy, companies demonstrate their dedication to safeguarding customer privacy, not as an afterthought, but as a foundational principle woven into the fabric of their operations. This unwavering commitment to ethical data stewardship not only fosters goodwill among customers but also ensures compliance with GDPR regulations, shielding organizations from the punitive repercussions of privacy breaches. - **Maximizing Data Utility without Sacrificing Privacy** In a world where insights are the currency of progress, organizations are in a perpetual pursuit of extracting the most value from their data assets. Advanced data anonymization solutions facilitate this quest by unleashing the full potential of datasets while keeping individual identities shielded from prying eyes. This delicate interplay between utility and privacy, once considered an insurmountable challenge, is now navigated with finesse through techniques like secure multi-party computation. Organizations can collaborate, glean insights, and innovate—all without relinquishing control over sensitive information, thereby achieving the coveted equilibrium of data-driven advancement and uncompromised privacy. - **Mitigating Risks and Elevating Reputation** The digital landscape is rife with risks, from cyber threats to regulatory audits. In this milieu, the deployment of advanced data anonymization solutions serves as a proactive shield against potential pitfalls. By fortifying datasets with techniques beyond basic anonymization, organizations mitigate the risk of data breaches and re-identification attacks, safeguarding themselves from reputational damage and legal repercussions. This not only instills confidence among stakeholders but also enhances an organization’s standing as a guardian of data ethics, reinforcing its image as a responsible custodian of personal information. As organizations embark on a journey guided by the luminous principles of advanced data anonymization, they embark on a path of harmonious coexistence—where data becomes a wellspring of insights, innovation, and progress, while individual privacy stands unassailable, bolstered by cutting-edge techniques. In embracing these solutions, organizations embrace a future where trust is unwavering, utility is maximized, and privacy is honored—a future that resonates with the spirit and letter of GDPR compliance. ## **Best Practices for Implementing Advanced Data Anonymization** In the intricate choreography of data management and privacy protection, the realm of advanced data anonymization emerges not as a standalone act but as a symphony of strategy, precision, and commitment. As organizations step onto this stage to align with the symphony of the General Data Protection Regulation (GDPR), a meticulous dance of best practices becomes paramount, guiding every move towards compliance and data-driven excellence. - **Choose Anonymization Techniques Aligned with Purpose** Central to the art of advanced data anonymization is the selection of techniques that align with the organization’s goals. K-anonymity, differential privacy, and secure multi-party computation offer distinct advantages; therefore, an informed choice based on the nature of data, the intended analysis, and the risk profile is essential. This choice resonates with GDPR’s principle of purpose limitation, ensuring that data transformation is a deliberate step towards both compliance and meaningful insights. - **Assess Quality and Anonymization Effectiveness** Effective anonymization is not a binary outcome but a nuanced balance between data utility and privacy preservation. Rigorous assessment of anonymization effectiveness is a core tenet of best practice. By quantifying the degree of privacy protection achieved, organizations can ascertain that the transformed data meets the thresholds necessary for GDPR compliance. Regular audits and validation mechanisms become the hallmarks of an organization that values not only the process but the outcome of data anonymization. - **Integrate Anonymization by Design** Just as a masterpiece is born from inception, advanced data anonymization solutions must be woven into the very fabric of data processing. The GDPR principle of “Data Protection by Design and by Default” resonates here. Anonymization should not be an afterthought but an integral aspect of data architecture. By weaving it into the DNA of data pipelines, organizations ensure that every touchpoint adheres to the sanctity of privacy, forming a cohesive defense against unauthorized intrusion. - **Stay Abreast of Evolving Threats and Techniques** In the dynamic landscape of data privacy and security, standing still is akin to regression. Best practices extend beyond implementation—they encompass an ongoing commitment to adapt and evolve. Staying informed about emerging threats, vulnerabilities, and new anonymization techniques is vital. This knowledge equips organizations to fortify their defenses against the ever-shifting sands of the digital frontier, ensuring that GDPR compliance remains a continuous journey rather than a one-time destination. As organizations embrace the best practices of advanced data anonymization, they emerge as virtuosos—conducting a symphony where the harmonies of data utility, privacy preservation, and GDPR compliance converge seamlessly. Each practice, a deliberate note played with precision, contributes to an opus that resonates with the spirit of ethical data management—a masterpiece where privacy finds its crescendo, and data transforms into an instrument of empowerment and innovation. **Conclusion** In the grand tapestry of modern data management, where the threads of innovation and responsibility are intricately woven, the harmonious interplay between GDPR compliance and advanced data anonymization emerges as a symphony of progress and protection. As the curtains draw close on our exploration, the resounding crescendo of insights and understanding echoes, revealing a landscape where individual privacy thrives hand in hand with the quest for knowledge. In the realm of GDPR, advanced data anonymization solutions stand as more than a mere shield against regulatory repercussions; they become the embodiment of an organization’s commitment to integrity. With the precision of k-anonymity, the subtlety of differential privacy, and the collaborative spirit of secure multi-party computation, organizations become guardians not only of data but of the trust bestowed upon them by individuals. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs **Tags:** Advanced Data Techniques, Anonymization Strategies, Data Anonymization, Data Governance, Data Insights, Data Privacy, Data Security, Data Stewardship, Differential Privacy, Ethical Data Management, GDPR Compliance, GDPR Guidelines, K-Anonymity, Personal Data Protection, Privacy by Design, Privacy Protection, Privacy Regulations, regulatory compliance, Responsible Data Use, Secure Multi-Party Computation --- ### [Digital Marketing Manager](https://geninvo.com/digital-marketing-manager/) **Published:** October 19, 2023 **Author:** admin **Content:** ## **Responsibilities** - Plan and execute all digital marketing, including SEO/SEM, marketing database, email, social media and display advertising campaigns. - Design, build and maintain our social media presence. - Manage and train the rest of the team. - Measure and report performance of all digital marketing campaigns, and assess against goals (ROI and KPIs) - Identify trends and insights and optimize spend and performance based on the insights. - Brainstorm new and creative growth strategies - Plan, execute, and measure experiments and conversion tests. - Collaborate with internal teams to create landing pages and optimize user experience. - Utilize strong analytical ability to evaluate end-to-end customer experience across multiple channels and customer touch points. - Instrument conversion points and optimize user funnels. - Collaborate with agencies and other vendor partners. - Evaluate emerging technologies. Provide thought leadership and perspective for adoption where appropriate. ## **Requirements and skills** - BS/MS degree in marketing or a related field - Proven working experience in digital marketing. - Demonstrable experience leading and managing SEO/SEM, marketing database, email, social media and/or display advertising campaigns. - Highly creative with experience in identifying target audiences and devising digital campaigns that engage, inform and motivate. - Experience in optimizing landing pages and user funnels. - Experience with A/B and multivariate experiments - Solid knowledge of website analytics tools - Experience in setting up and optimizing Google Adwords campaigns - Working knowledge of HTML, CSS, and JavaScript development and constraints - Strong analytical skills and data-driven thinking - Up-to-date with the latest trends and best practices in online marketing and measurement ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** job --- ### [What is KUBERNETES (k8s)? ](https://geninvo.com/what-is-kubernetes-k8s/) **Published:** August 19, 2022 **Author:** admin **Content:** In this digital era, every project needs to be built in less time with more flexible and resilience manner. Being a startup in pharmaceuticals, enterprises strive to innovate fast where team rolls out new feature, collects feedback from clients, and introduces changes until they find their product-market fit. After covid – a global pandemic outbreak, enterprises looking towards new technologies which leads them to get task done rapidly without loosing focus on overall value. Solving these challenges isn’t easy, here Kubernetes (or k8s) comes into role, the leading platform for managing and orchestrating containerized workloads and services. Traditionally SDLC use waterfall model for software development which incurs lot of time and cost as well it follows rigid model. [Kubernetes](https://www.mirantis.com/cloud-native-concepts/getting-started-with-kubernetes/what-is-kubernetes/) is a portable, extensible, open-source container orchestration system that helps systems administrators automate computer application deployment, scaling and management. As healthcare innovation has paced rapidly in recent years, it becomes important innovation must come with security, reliability, availability, scalability with artificial intelligence. Health organization consists crucial medical records and trial research of patients, healthcare software is required to analyze properly having reliable strategies running at backend. Software built over Kubernetes replaces the traditional approach of SDLC, now shifting for micro-services, a software developing method having many APIs and services build independently each other, make software reliable and resilient to use. ## What are containers? Containers are packages of software that contain all the necessary elements that combine application source code with the required operating system (OS) dependencies and libraries to run in any machine. Containers make it easy to share CPU, memory, storage, and network resources at the operating systems level and offer a logical packaging mechanism in which applications can be abstracted from the environment in which they actually run. ## How [Geninvo](https://geninvo.com/) use kubernetes? We, at Geninvo, always seek to look forward using latest technological enhancement. Yet Kubernetes is still young platform, a deeper look at the technology reveals how it can help healthcare organizations innovate, providing them with greater security, faster application deployment, lower costs and scalability. As an organization served to healthcare, we face increase pressure to innovate more quickly and be more customer-focused while simultaneously minimizing downtime and its impact. Our expert DevOps team build cloud based infrastructure using K8s, easier the automating application testing and deployment which further can reduce time to market and offer more transparency into production pipelines. Kubernetes allows our organizations to: - Deploy applications quickly and predictably - Scale applications on the fly - Roll out new features seamlessly - Limit hardware usage to required resources only. Our aim is to create a power-house innovation for our clients that is ready for enterprise deployment. Let’s innovate together. **By: Manish Anupam *Sr. Manager-IT & Database, Innovative Solutions & Strategist*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, IT --- ### [The Importance of Automation in Clinical Trials ](https://geninvo.com/the-importance-of-automation-in-clinical-trials/) **Published:** September 26, 2023 **Author:** admin **Content:** **Introduction** Clinical trials are the backbone of medical research and innovation. They play a pivotal role in advancing healthcare, developing new treatments, and improving patient outcomes. However, conducting clinical trials is a complex and resource-intensive process, often plagued by challenges such as data inaccuracies, time constraints, and regulatory compliance. This is where automation steps in as a game-changer. In this article, we will explore the profound significance of automation in clinical trials and how it revolutionizes the field. ## **Use case of using Automation within Clinical trials** ### **Streamlining the Process** 1. **Efficient Patient Recruitment and Enrollment:** One of the most critical aspects of a clinical trial is the recruitment and enrollment of eligible participants. This process can be time-consuming, costly, and prone to errors when done manually. Automation tools, such as patient databases and electronic health record integration, streamline this process. They help identify suitable candidates quickly, ensuring that trials get underway faster and efficiently, ultimately expediting the development of potential treatments. 2. **Data Collection and Management:** Clinical trials generate vast amounts of data, including patient records, lab results, and adverse event reports. Managing this data manually is not only labor-intensive but also prone to errors. Automated Electronic Data Capture (EDC) systems and Clinical Trial Management Systems (CTMS) centralize data collection and storage, improving accuracy, traceability, and accessibility. Researchers can focus more on data analysis and less on data entry, significantly accelerating the research process. ### **Enhancing Data Accuracy** 1. **Reducing Human Error:** Clinical trials demand precise and error-free data. Even the smallest mistake can have far-reaching consequences, potentially delaying the approval of life-saving treatments. Automation reduces the risk of human error by minimizing manual data entry and automating data validation processes. This ensures data accuracy and integrity, instilling confidence in the research findings and regulatory authorities. 2. **Real-time Monitoring and Safety:** Patient safety is paramount in clinical trials. Automated systems can continuously monitor patient data, detecting adverse events and trends in real time. This early detection allows for swift intervention when necessary, ensuring the safety and well-being of trial participants. It also helps maintain compliance with stringent regulatory requirements, ultimately expediting the trial’s progress. ### **Accelerating Time-to-Market** 1. **Faster Data Analysis:** Traditional data analysis methods can be time-consuming and require extensive manual effort. Automation tools for data analysis, such as machine learning algorithms, can process large datasets at remarkable speeds, identifying trends and patterns that may have been missed through manual analysis. This accelerated data analysis expedites decision-making and allows researchers to make informed choices about the trial’s direction. 2. **Regulatory Compliance:** Regulatory approval is a critical milestone in the clinical trial journey. Automation aids in ensuring that all regulatory requirements are met, from data security to documentation and reporting. By automating regulatory compliance processes, sponsors can reduce delays caused by administrative hurdles and expedite the path to market approval. ### **Cost-effectiveness and Resource Optimization** 1. **Resource Allocation:** Clinical trials often require substantial financial and human resources. Automation optimizes resource allocation by reducing the need for manual labor in data entry, monitoring, and administrative tasks. This enables organizations to allocate their resources more efficiently, directing them toward essential aspects of the trial, such as patient care, research, and development. 2. **Remote Monitoring:** Automation also facilitates remote monitoring of clinical trials, reducing the need for constant on-site visits. This is especially valuable in global trials or during unforeseen events like pandemics, where travel restrictions can impede the monitoring process. Remote monitoring not only enhances trial efficiency but also offers greater convenience for both patients and researchers. ### **Challenges and Considerations** While automation holds great promise for clinical trials, it is not without its challenges and considerations. 1. **Initial Investment:** Implementing automation systems can require a significant initial investment in terms of technology, training, and infrastructure. However, the long-term benefits in terms of time and cost savings often outweigh these initial costs. 2. **Data Security:** With the increasing reliance on digital systems, data security becomes a paramount concern. Protecting sensitive patient data from cyber threats and breaches is critical. Robust cybersecurity measures are essential to maintaining trust and regulatory compliance. 3. **Integration with Existing Systems:** Integration of automation systems with existing healthcare infrastructure and electronic health records can be complex. Ensuring seamless interoperability is crucial to realizing the full benefits of automation. ## **Conclusion** Automation in clinical trials is not merely a technological advancement; it is a paradigm shift that has the potential to reshape the landscape of medical research and healthcare. By streamlining processes, enhancing data accuracy, accelerating time-to-market, and optimizing resources, automation improves the efficiency and effectiveness of clinical trials. It offers hope to patients by expediting the development of innovative treatments and therapies. As we continue to embrace automation in clinical trials, it is imperative that we remain vigilant about ethical considerations, data security, and the ongoing need for human expertise and oversight. By striking a balance between automation and human involvement, we can maximize the benefits of this transformative technology while ensuring the safety and well-being of trial participants and the integrity of research outcomes. The future of clinical trials is undoubtedly automated, and it holds the promise of a brighter and healthier tomorrow for all. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs --- ### [Quick Look at Software Testing](https://geninvo.com/quick-look-at-software-testing/) **Published:** September 8, 2023 **Author:** admin **Content:** **Introduction** Software testing plays a vital part of the software development lifecycle that ensures the quality, reliability, and performance of all products. It involves evaluating a software application or system to identify defects, errors, or gaps that may impact its functionality. In this blog, we will explore the fundamentals of software testing, discuss the importance of testing, and differentiate between manual testing and automation testing, that are two widely used testing practices followed in the industry. **What is the Importance of Software Testing** - **Ensuring Quality**: Software testing is crucial for delivering a high-quality product. By identifying and resolving defects, testing ensures that the software functions correctly, meets user expectations, and provides a seamless experience. - **Enhancing User Satisfaction**: Through testing, usability issues, compatibility problems, or performance bottlenecks can be identified and addressed. This results in improved user satisfaction and a positive user experience. - **Reducing Risks and Costs**: Early detection and resolution of defects during the testing phase help mitigate risks and reduce the likelihood of expensive fixes or rework later in the software development lifecycle. This saves time, effort, and costs associated with fixing issues post-release. - **Security and Reliability**: Software testing plays a critical role in identifying vulnerabilities and security loopholes. By performing security testing, organizations can ensure the confidentiality, integrity, and availability of user data and protect against potential cyber threats. **7 Building Blocks of Effective Software Testing** ![](https://geninvo.com/wp-content/uploads/2023/09/MicrosoftTeams-image-147-1024x919.png "MicrosoftTeams-image-147 - GenInvo")These seven principles serve as fundamental guidelines for effective software testing, helping testing teams make informed decisions about where and how to focus their efforts to deliver high-quality software products. **Testing Shows Presence of Defects:** The first principle emphasizes that the primary purpose of testing is to identify defects or issues within the software. It demonstrates the existence of problems that could potentially affect the functionality, performance, or user experience. However, even if testing doesn’t find defects, it doesn’t guarantee that no defects exist. Testing provides valuable information about the quality of the software, but it can’t guarantee its perfection. **Exhaustive Testing is Impossible:** It’s practically impossible to test every single input, scenario, or combination within a software application. The potential number of test cases is often immense, and time and resources are limited. Therefore, testing efforts need to be targeted toward the most critical and high-risk areas of the software. The goal is to achieve a balance between the level of testing and the level of risk tolerance. **Early Testing**: This principle stresses the importance of starting testing as early as possible in the software development lifecycle. Detecting defects early helps in reducing the cost of fixing them later. It’s more cost-effective to identify and rectify issues during the initial stages of development than after the software has progressed further. Early testing also provides faster feedback to the development team, enabling them to make improvements before more work is added. **Defect Clustering:** This principle suggests that defects are not evenly distributed across all parts of the software. In many cases, a small number of modules or components tend to contain most defects. By focusing testing efforts on these critical areas, testers can maximize the chances of identifying and fixing significant issues, thus improving the overall quality of the software. **Pesticide Paradox:** The pesticide paradox warns that using the same set of test cases repeatedly can lead to a decrease in the effectiveness of testing. Over time, these tests become less effective and finding new defects because the software evolves. To address this, testers need to continually update and create new test cases to ensure that different aspects of the software are being examined thoroughly. **Testing is Context-Dependent:** This principle acknowledges that testing effectiveness is influenced by the context in which the software operates. Factors like the software’s complexity, its intended use, the environment it will be used in, and user requirements all play a role in shaping the testing strategy. Different software projects may require different testing approaches based on their unique contexts. **Absence-of-Errors Fallacy:** Just because a specific aspect of the software has been tested and no errors were found does not imply that the software is entirely free of defects. Testing should cover both functional and non-functional aspects of the software, and a comprehensive testing approach is needed to gain confidence in the software’s quality and reliability. **What is Manual Testing?** Manual testing is a process in which test cases are executed manually without the help of any automated tool. It ensures that all the functions in the application are working, as defined in the requirement document. Since no tools are involved in Manual Testing, it is slow, repetitive, costly, and time-consuming. Manual testing is helpful where human interaction is required and better suited. For example, User [Acceptance testing ](https://testsigma.com/blog/acceptance-test-vs-system-test/)is a type of manual testing performed when human intervention is necessary to test the ready-to-use product before releasing it in the market. Manual testing always takes place when human intervention is needed and needs to test the application from a user perspective. Let’s look at an example below to understand better how Manual Testing works. **What is Automation Testing?** Automation testing involves using specialized software tools and scripts to perform repetitive test cases, validations, and verifications automatically. Unlike manual testing, which relies on human intervention, automation leverages pre-written scripts to execute tests, simulating user interactions and evaluating application responses. This approach streamlines the testing process, enhances accuracy, and significantly reduces the time required for repetitive tasks. **Manual Testing vs Automated Testing – Key Differences** The difference between manual testing and automated testing is that in manual testing, you perform the tests step by step without the help of tools, whereas in automated testing, tests are executed automatically using automation tools & frameworks. **Criteria****Automation Testing****Manual Testing**SpeedAutomation Testing is faster than a manual testing.Manual testing requires human resources and is time consuming as well.Exploratory TestingAutomation will not allow any random testing.It is possible in case of Manual TestingInvestmentThe initial investment for automation testing is higher.The initial investment for manual testing is lower.ReliabilityAutomation Testing is more reliable, as it is performed by tools and scripts.Manual testing won’t be as accurate as there is a possibility of the human error.Investment TypeInvestment is needed for testing tools and automation engineers.Investment is needed for human resources.Cost-effectiveAutomation Testing is cost effective.Manual Testing is not cost effective as ROI is lower.Test ReportsIn automation testing, all stakeholders check test execution results by logging into automation system.Manual Tests are usually updated in an Excel/Word, and test results are not readily available.Performance TestingPerformance Tests like Stress Testing, Load Testing, Spike Testing, etc. must be done by an automation tool only.Performance Testing is difficult to do manually.Set upIt needs less complex test execution set up.Manual testing needs have a straightforward test execution setup.DeadlinesAutomated Tests will not have risks of missing out any test deadlines.Manual Testing has a higher chance of missing out the test deadlines.FrameworkAutomation testing employs frameworks like Data Driven, Keyword, and Hybrid to speed up the automation process.Manual Testing won’t have frameworks but may use guidelines, checklists, and strict processes.When to Use?It is well suited for Regression Testing, Load Testing, Performance Testing, or repeatable functional test cases.It will be suitable for Usability, Exploratory, and Adhoc Testing.**Automation Testing Life Cycle** ![](https://geninvo.com/wp-content/uploads/2023/09/MicrosoftTeams-image-148-1024x919.png "MicrosoftTeams-image-148 - GenInvo")- **Scope of Test Automation:** Identifying which test cases are suitable for automation based on complexity, repeatability, and business impact. - **Selection of the Automation Tool:** Choosing the appropriate automation tool that aligns with the application’s technology stack, features, and testing requirements. - **Test Plan Design and Strategy:** Creating a comprehensive test plan that outlines objectives, scope, testing goals, resource allocation, and the overall strategy for automation testing. - **Test Environment Set Up:** Establishing the necessary test environment, including hardware, software, databases, and configurations, to replicate real-world scenarios. - Test Script and its Execution: Developing test scripts using the chosen automation tool, incorporating test logic, data, and interactions. Executing these scripts to perform automated tests. - **Test Results and Reports:** Collecting and analysing test results to determine whether the application meets desired quality standards. Generating reports that provide insights into test coverage, pass/fail status, and any defects identified. **Why Automation Testing?** Automation testing offers numerous advantages over manual testing due to its ability to streamline the testing process, enhance efficiency, and improve the overall quality of software products. Unlike manual testing, automation can execute a large number of test cases rapidly, providing quicker feedback on code changes and accelerating release cycles. It significantly reduces human errors inherent in repetitive tasks, ensuring consistent and reliable results. Automated tests can be run 24/7, allowing for continuous testing even during non-working hours. Moreover, automation enhances test coverage by executing tests across different platforms, configurations, and scenarios that would be impractical to cover manually. While manual testing is essential for exploratory and user-centric testing, automation excels in regression testing, complex scenarios, and non-functional testing. Overall, automation testing enables teams to optimize resources, detect defects early, and deliver high-quality software efficiently in today’s fast-paced development landscape. **Automation Testing Offers Several Benefits** ![](https://geninvo.com/wp-content/uploads/2023/09/MicrosoftTeams-image-149-1004x1024.png "MicrosoftTeams-image-149 - GenInvo")- Automation testing allows for the rapid execution of many test cases, greatly accelerating the testing process. Automated tests can perform tasks in parallel and run 24/7, delivering quicker feedback on software quality and enabling faster release cycles. - Automation eliminates the human factor from repetitive and monotonous tasks, reducing the likelihood of errors caused by fatigue, distractions, or oversight. Tests are executed consistently and precisely as programmed, minimizing the risk of manual mistakes. - Automated tests can cover a wide range of scenarios and configurations that would be time-consuming or impractical to test manually. This comprehensive coverage ensures that various aspects of the application are thoroughly tested. - Automated tests provide consistent and repeatable results every time they are executed. This consistency ensures that tests are not influenced by human emotions, biases, or variations in execution. - Although there’s an initial investment in setting up and maintaining automation, the long-term cost savings are significant. Automated tests can be reused across projects and versions, reducing the need for extensive manual testing resources. - Automation frees up human testers from repetitive and time-consuming tasks, allowing them to focus on higher-value testing activities that require critical thinking and analysis. This optimization of resources enhances overall efficiency. - Automated tests are designed to detect defects precisely and consistently. They can identify subtle issues that might be missed during manual testing, leading to higher software quality and a lower chance of defects reaching production. - Automation promotes collaboration between development, testing, and other cross-functional teams. It ensures that all team members have access to the same set of automated tests, leading to a shared understanding of the application’s behaviour. - Automated tests can be integrated into the development process from the start, catching defects early in the development lifecycle. This early detection reduces the cost and effort of fixing bugs in later stages of development. **Stages of Automation Testing Life Cycle** 1\. **Deciding the scope of Test Automation:** It refers to the ability to recognize the viability of automation. When assessing the feasibility, each point of view should be considered. The following items should be dealt with without disappointment at this stage: - At this point, we determine which application modules can be automated and which cannot. - Which test cases can be mechanized and how to mechanize them. - Variables such as cost, team size, and ability should all be taken under consideration. 2\. **Choosing the Right Automation Tool:** Selecting the correct automation testing device is a basic stage for a Test Automation Life Cycle as testing profoundly relies upon automation devices. At the point when you are searching for the right tool you must remember the following things: - Financial plan - Advancements being utilized in the venture. - Knowledge of the tool which will be used. **3. Plan, Design and Strategy** It is the most fundamental level of the automated testing life cycle technique, defining how to approach and achieve the goal of test automation. We create an Automation procedure and plan at this step. We must consider the following factors when creating this: - Tools which we choose for automation. - Recognize which design framework to be utilized after understanding the upsides and downsides of the testing tool. - Construct a test suite for the Automation experiment in the device to test the executives. **4. Set Up Test Environment** Setting up a machine or a remote machine where test scripts will be executed is part of this phase of the Test Automation Life Cycle. The following are some of the most important aspects of the test environment to consider: - Test Data - Multiple Browser - Automation Framework - Tool configuration and license - Selection of environment whether staging or live **5. Test Script Execution** It’s a great time to run the test script after we’ve set up the test environment. It is critical to ensure that all test cases are executed correctly. When the test content is properly developed, it should be implemented by keeping the following in mind: - A test content ought to involve all practical angles as indicated by the experiment. - It is important to run scripts in numerous conditions and over different stages. - Batch execution can be performed to retain time and attempt. - If the non-fulfilment happens because of some Error, compose a bug report. **6. Examine & Maintenance Approach** It’s the final phase of the automation testing process. After a wide range of testing is carried out, the testing team examines to determine specific segments that experience an overall number of issue reports. The outcome of the examination proposes whether it requires an extra test attempt or not. The maintenance approach is an automation testing stage that is used to check whether the new software functionality added to the product is working properly or not. It is used whenever new scripts have been added that need to be inspected and maintained to improve the power of automation scripts. **Automation Software Testing in the Life Science Domain** ![](https://geninvo.com/wp-content/uploads/2023/09/MicrosoftTeams-image-150-992x1024.png "MicrosoftTeams-image-150 - GenInvo")Automation software testing plays a crucial role in the life science domain, where accuracy, compliance, and safety are of paramount importance. The life science industry includes pharmaceuticals, biotechnology, medical devices, and clinical research, all of which require rigorous testing to ensure the quality and safety of products. Here’s how automation testing is utilized in the life science domain: - **Regulatory Compliance:** The life science industry is heavily regulated by agencies like the FDA (Food and Drug Administration) and EMEA (Covering Europe, Middle East, and Africa, called as European Medicines Agency). Automated testing helps ensure that software systems adhere to regulatory requirements, reducing the risk of non-compliance and associated penalties. - **Data Integrity:** Automated tests can verify data integrity within software applications, ensuring that critical patient and research data remains accurate and secure. This is vital for maintaining trust and complying with data protection regulations. - **Validation and Verification:** Automated testing assists in the validation and verification of software systems used in research, manufacturing, and clinical trials. These tests confirm that software functions as intended, minimizing the potential for errors that could impact patient safety or research outcomes. - **Clinical Trials Management:** Automation can streamline the testing of electronic data capture (EDC) systems used in clinical trials. Automated tests can simulate and validate data collection processes, ensuring that clinical trial data is accurate and reliable. - **Data Analysis and Reporting:** Automated tests can validate the accuracy of data analysis algorithms used in medical research, preventing errors that could lead to incorrect conclusions or decisions. - **Efficiency and Time Savings:** Automating repetitive testing tasks accelerates the testing process, allowing life science professionals to focus on high-value tasks like analysis, research, and decision-making. **Summary** Manual testing helps to identify minute issues easily, whereas automation testing would require complete test scripting and execution. Also, Automated testing assists in readily writing and running test cases for redundant tasks. **Which one, in such a case, should be your go-to testing approach, then**? You need to focus on a few requisites before deciding if the manual is right for you or if automation tools are your saviour. In almost every case, the combination of both works the best. Though Manual testing is time-consuming, repetitive, and costly, it can still be helpful in some cases. But automation helps you deal with multiple scenarios faster, and it is economical as well. We at GenInvo, use both the techniques in all our Software Development products as part of our product testing activities. Our mission is to use the best of technology to revolutionize the Life Sciences industry. We do this by providing innovative solutions and services within Testing areas to pharmaceutical companies and other players in the industry. This will help deliver high-quality treatments to patients faster and with greater accuracy, cost effectiveness to our partner organizations. We know the global pharmaceutical market and understand that a culmination of the Software Testing team SMEs would best provide services to these organizations and provide efficient and effective services to the software development. ***By: Abhinav Soni, Senior Analyst -Software Testing*** ***and*** ***Sahil Sharma, Associate- Software Testing, GENINVO*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, Uncategorized --- ### [Shake hands with GENINVO at PHUSE CSS 2023! ](https://geninvo.com/shake-hands-with-geninvo-at-phuse-css-2023/) **Published:** August 18, 2023 **Author:** admin **Content:** Date: 18th – 20th Sep 2023 This year, we showcase key industry related information through an interesting poster. We invite you to meet our subject matter expert & share your thoughts on our **poster presentation**. Topic: Insight into growing use of R, R-Shiny and Python Presenter: Pinku Hooda, Associate Director-Project Management The event will unite attendees from industry, regulatory and academia to support health, product development and regulatory review. It will facilitate collaboration to share experiences, solve problems and explore new concepts to drive future innovation. Looking forward to seeing you there! ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [EMWA](https://geninvo.com/emwa/) **Published:** September 23, 2019 **Author:** admin **Content:** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** 2019, events --- ### [Meet GENINVO at DPHARM 2023 in Boston, MA!](https://geninvo.com/meet-geninvo-at-dpharm-2023-in-boston-ma/) **Published:** August 18, 2023 **Author:** admin **Content:** **Date- 20th – 22nd Sep 2023** DPHARM 2023 reports on the latest innovations in clinical trials driving efficiencies in clinical operations and reducing patient, sites and physician burden to participate in research. We will be **exhibiting** at the event & look forward to seeing you there! Stay tuned for more details. ![](https://geninvo.com/wp-content/uploads/2023/08/MicrosoftTeams-image-134-1.jpg "MicrosoftTeams-image-134-1 - GenInvo")![](https://geninvo.com/wp-content/uploads/2023/08/MicrosoftTeams-image-133-2-1024x576.jpg "MicrosoftTeams-image-133-2 - GenInvo") ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [GENINVO is delighted to exhibit at Informa Connect 2023! You can visit us at Booth #4.](https://geninvo.com/informa-connect-2023/) **Published:** February 17, 2023 **Author:** admin **Content:** GENINVO is aware and up to date with evolving data privacy rules across the globe and, In Informa connect 2023 we are looking forward to present on: **“SMEs and machines working together to fuel the automation of anonymization.”** - Evolution of anonymization process from manual to automation. - SME’s role in building the automated anonymization tool. - ROI of manual to automated anonymization process. - Innovations that helped in automation. - What is expected in future innovations for Data Transparency field? Let’s have insightful conversations to help understand your gap areas and further develop our products to perfectly fit into your organization. Our team is producing transformational software solutions using years of experience in life sciences industry, collaboration with industry forums, leading edge technologies and our software development capabilities, data-engineering practices, cloud expertise, and artificial intelligence research. ## Let’s discuss our product [Shadow™](https://geninvo.com/our-products/data-anonymization-tool/). Shadow is a data anonymization tool, which helps in data transparency, data masking, data and document anonymization. Our team has created this tool to produce solutions that allow you to focus on science and results. Shadow™ alleviates the pain points of homegrown software utilities that often prove to be inefficient, difficult to maintain, and slow to match quickly evolving requirements. Anonymization of documents has been challenging for Life Sciences companies as they look to comply with Health Canada, France’s MR001-MR004, and EMA Policy 0070 (Phase 1 and 2). Shadow™ enables our clients to address these issues now and into the future. Shadow™ is a 21 CFR 11 and GDPR compliant solution to support global data sharing and de-identification requirements. **Clinical Data Disclosure, Transparency & Plain Language Summaries 2023** *Join us at the [physical live event](https://informaconnect.com/) (Informa connect 2023!) from 21st to 22ndMarch 2023, in Hilton Philadelphia at Penn’s Landing, Philadelphia*. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** Uncategorized --- ### [EMA policy 0070 Relaunch in September 2023 - What you should need to know! ](https://geninvo.com/ema-policy-0070-relaunch-in-september-2023-what-you-should-need-to-know/) **Published:** May 30, 2023 **Author:** admin **Content:** EMA Policy 0070 is to be relaunched in September 2023. This was announced by the European Medicines Agency during a webinar held on May 16, 2023. All Marketing Authorization Holders who submit packages to EMA should immediately implement document [anonymization](https://geninvo.com/our-products/data-anonymization-tool/) processes. EMA Policy 0070, which was originally implemented on January 1, 2015, has been around for almost a decade. The suspension of EMA Policy 0070 in December 2018 was due to the COVID Pandemic. But now, EMA Policy 0070 will be reactivated. ![](https://geninvo.com/wp-content/uploads/2023/06/key-milestones.png "key milestones - GenInvo")## **What is the scope of this document?** Sponsors should be aware that EMA Policy 0070 has remained largely unchanged, but some changes have been made to the procedures. The scope of relaunch includes - New Active Substances (NAS), September 2023 - Negative and withdrawn goods - COVID-19 (and other Public Health Emergency Clinical Data) - MAHs affected will receive detailed, specific letters inviting them to request the packages - Meetings to discuss the scope of publication, anonymization strategy, and commercially sensitive information CCI strategy. Changes to improve efficiency and continue collaboration with Health Canada. ## **What’s new in EMA Policy 0070 relaunch?** The EMA Policy 0070 Team will work closely with the Clinical Trial Information System team (CTIS) to ensure that both efforts are uniform and consistent. The EMA wants to complete package preparation as soon as possible – as soon as the sponsors receive a letter of invitation from EMA in relation to EMA Policy 0070. Pre-submission meetings will be tailored to each product. The scope of publication as well as anonymization will be discussed at this meeting. The EMA will develop new templates for anonymization reports in collaboration with [Health Canada](https://www.trialassure.com/resources/blog/health-canada-guidelines-for-clinical-trial-registration-and-results-posting-to-be-released/). It will also draft a list for the marketing authorization holder of the documents that are eligible for anonymization. Re-launching EMA Policy 0070 enhances transparency and public trust in clinical research by allowing researchers and healthcare professionals access to clinical data. This policy will enhance the scientific integrity and safety of healthcare decisions by ensuring efficient and safe clinical trials. ## **Key Points from Webinar** - Any submission getting decision from September 2023 would be eligible to submit the anonymized package as per Policy 0070. - Submission done after suspension of Policy 0070 after Brexit and before September 2023 would not need to be published immediately but it would be done based on request and proper planning to avoid burden on Sponsors and EMA. - Invitation letters will be sent if your product is in scope. - Emphasis on 1) early preparation of packages for submission – prior to Opinion and 2) Complete QC check prior to submission – all documents present. - EMA worked collaboratively with Health Canada to create a common template for anonymization report. - EMA Policy 0070 Team will work closely with the Clinical Trial Information System team (CTIS) to ensure that both efforts are uniform and consistent. However, anything redacted as CCI for CTIS does not make it eligible for CCI for Policy 0070. Following were the major reasons of rejection of CCI and shall be considered for future: - Information is already in public domain. - Specific details shall be redacted as CCI in place of complete paragraphs. - Lack of Proper justification for CCI to explain how it impacts economic benefit of the sponsor. - Covid-19 projects are still of interest to the public and will continue to be published under Policy 0070 even if a decision on it is made before September 2023. - Timelines have been revised from 60 days to 120 days for publishing the anonymized package from the date of CHMP opinion on initial marketing authorization applications. Important Links: [\[1\]](https://www.ema.europa.eu/en/human-regulatory/research-development/clinical-trials/clinical-trial-regulation%20%20%20https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/clinical-data-publication%20%20%20%20https://www.canada.ca/en/health-canada/services/drug-health-product-review-approval/profile-public-release-clinical-information-guidance/document.html) [\[2\]](https://rlsciences.com/blog-insights-data-anonymization-real-world-evidence/2021/6/21/the-upcoming-clinical-trial-regulation-and-ema-policy-0070-restart-are-you-ready#_ftnref2) [\[3\]](https://rlsciences.com/blog-insights-data-anonymization-real-world-evidence/2021/6/21/the-upcoming-clinical-trial-regulation-and-ema-policy-0070-restart-are-you-ready#_ftnref3) \[4\] [Clinical Data Publication (Policy 0070) re-launch – EMA webinar | European Medicines Agency (europa.eu)](https://www.ema.europa.eu/en/events/clinical-data-publication-policy-0070-re-launch-ema-webinar) ***By Parveen Kumar *–* Head of Data Transparency & Product Owner, GENINVO*** *For questions on this article, please [contact ](https://geninvo.com/contact-us/)*[*us.*](https://geninvo.com/contact-us/) ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs **Tags:** anonymization of structured and unstructured data, Clinical Data Anonymization services, Clinical Data Disclosure, Clinical Data Privacy, Clinical dataset anonymization, Clinical Document anonymization, CTIS, CTIS redaction services, Data De-identification, Data Transparency, Document Redaction, EU CTR, GDPR, HC PRCI, HIPPA, HITRUST, Policy 0070 relaunch, pseudonymization vs anonymization, Qualitative risk assessment, Quantitative risk assessment, Redaction vs anonymization, Reference population, risk of re-identification --- ### [Managing Product Development Amidst Regulatory Changes Landscape ](https://geninvo.com/managing-product-development-amidst-regulatory-changes-landscape/) **Published:** August 1, 2023 **Author:** admin **Content:** **Introduction** In today’s fast-paced business environment, product development is a critical aspect of staying competitive and meeting consumer demands. However, the landscape of product development has been significantly influenced by an ever-changing regulatory environment. Companies across various industries are required to comply with an array of regulations that affect product design, safety, manufacturing, marketing, and distribution. In this blog, we will explore the challenges and opportunities of managing product development amidst regulatory changes and the strategies that businesses can adopt to navigate this complex landscape. ## **The Impact of Regulatory Changes on Product Development** ### **Evolving Compliance Standards:** [Regulatory agencies](https://en.wikipedia.org/wiki/List_of_regulators_in_India) continuously update and revise compliance standards to ensure consumer safety, protect the environment, and maintain industry integrity. These changes can have a significant impact on product development timelines and processes. Companies must stay vigilant to identify and integrate the latest compliance requirements into their product development strategies. ### **Increased Time and Cost:** As regulatory requirements become more stringent, the product development cycle may lengthen, resulting in increased development costs. Companies need to allocate resources effectively, plan for longer development cycles, and streamline processes to manage costs efficiently. ### **Market Access and Expansion:** New regulatory changes can affect market access and expansion plans. Companies may face barriers to enter new regions or introduce products in certain markets if they fail to meet specific regulatory requirements. Staying up to date with regional and global regulatory changes is crucial for successful market penetration. ### **Impact on Innovation:** Strict regulatory requirements can sometimes hinder innovation by imposing limitations on certain product features or technologies. Balancing innovation with compliance is a delicate act that requires proactive research and collaboration with regulatory authorities. ## **Strategies for Managing Product Development amidst Regulatory Changes** ### **Proactive Regulatory Intelligence:** Establish a dedicated regulatory intelligence team that closely monitors relevant [regulatory bodies](https://geninvo.com/regulatory-bodies-in-life-sciences/) and industry developments. Early identification of potential changes allows companies to plan and adjust their product development strategies accordingly. ### **Agile Product Development Processes:** Adopt agile methodologies in product development to be more responsive to regulatory changes. Agile practices enable companies to adapt to evolving compliance standards and market requirements quickly. ### **Cross-Functional Collaboration:** Effective communication and collaboration between product development teams and regulatory experts are critical. Involving regulatory experts from the early stages of product development ensures that potential compliance issues are addressed promptly and integrated into the design. ### **Robust Risk Management:** Implement a comprehensive risk management framework that evaluates potential regulatory risks throughout the product development lifecycle. Identify and mitigate risks early to avoid costly delays or compliance issues during later stages. ### **Compliance by Design:** Incorporate compliance considerations directly into the product design process. This approach ensures that regulatory requirements are an inherent part of the product, reducing the need for extensive modifications later. ### **Regular Training and Education:** Equip your product development teams with the knowledge and skills required to understand and navigate regulatory changes effectively. Regular training sessions and workshops help create a compliance-aware culture within the organization. ### **Utilize Technology Solutions:** Leverage technology solutions like AI-powered compliance tools to automate regulatory monitoring and compliance checks. These tools can streamline the process of identifying and implementing necessary changes in response to new regulations. ### **Engage with Regulatory Authorities:** Establish a positive working relationship with regulatory authorities. Engaging in regular dialogue can help companies gain insights into upcoming changes and potentially influence the development of regulations that impact their industry. ## **Conclusion** Managing product development amidst a constantly changing regulatory landscape is a formidable challenge, but it presents significant opportunities for companies that approach it strategically. By proactively monitoring regulatory changes, embracing agile practices, fostering cross-functional collaboration, and integrating compliance considerations into product design, organizations can navigate the regulatory maze successfully. With the right strategies in place, businesses can not only ensure compliance but also turn regulatory challenges into a competitive advantage, fostering innovation and sustainable growth in the long run. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs **Tags:** Agile Product Development, AI-powered Compliance Tools, Business Strategy, Compliance, Cross-Functional Collaboration, Innovation, Market Access, Market Dynamics, Market Expansion, Market Penetration, Pharmaceutical Industry (if applicable), Product Design, Product Development, Regulatory Authorities, Regulatory Changes, regulatory compliance, Regulatory Intelligence, Risk Management, Technology Solutions, Training and Education --- ### [Data Protection ](https://geninvo.com/data-protection/) **Published:** December 9, 2022 **Author:** admin **Content:** The impact of globalization on privacy of identity is growing. The fact that more and more Data Protection, comprising data security and data privacy, has emerged as a major challenge in cross-border data flows means that data breaches often affect people in multiple countries and may result in financial frauds. Customers are demanding more security as their worries about privacy and user identity of the data that are being processed or used. For a global organization, [experts recommend having a data protection policy](https://www.techtarget.com/searchdatabackup/tip/6-business-benefits-of-data-protection-and-GDPR-compliance) that complies with the most stringent set of rules the business faces, while at the same time using a security and compliance framework that covers a broad set of requirements. The guidelines for data protection and privacy apply across the board and include the following: - safeguarding data; - getting consent from the person whose data is being collected; - identifying the regulations that apply to the organization and the data it collects; and - ensuring employees are fully trained in the nuances of data privacy and security Although some businesses use the terms data protection, data security and data privacy, they have different purposes: - **Data protection** safeguards information from loss through backup and recovery. Data protection is the process of safeguarding important information from corruption, compromise or loss. The importance of data protection increases as the amount of data created and stored continues to grow at unprecedented rates. Consequently, a large part of a data protection strategy is ensuring that data can be restored quickly after any corruption or loss. Protecting data from compromise and ensuring data privacy are other key components of data protection - **Data security refers** specifically to measures taken to protect the integrity of the data itself against manipulation and malware. It provides security from internal and external threats by implementing controls by different Regulatory agencies using framework. - **Data privacy** refers to controlling access to the data. Organizations must determine who has access to data. Understandably, a privacy breach can lead to data security issues. **Data Protection and Privacy Laws and Regulations** are vary from country to country, and even from state to state — and there’s a constant stream of new ones. China’s data privacy law went into effect June 1, 2017. The European Union’s General Data Protection Regulation (GDPR) went into effect in May 2018. In the United States, the California Consumer Privacy Act supports the right for individuals to control their own personally identifiable information. Compliance with any one set of rules is complicated and challenging. The GDPR defines an array of legal terms at length. Below are some of the most important ones are: ‘Data processing’ or ‘Processing’ means any automated or manual operation(s) carried out on personal data. In essence, this covers almost any relevant action word that could possibly be performed on information including collecting, recording, organising, classifying, storing, modifying, amending, retrieving, using or revealing such data by broadcasting, publishing, transmitting, making available to others, integrating, blocking, deleting or destroying. Personal Information (PI) is generally defined as any information relating to an identified or identifiable natural person. It may be referred to as personal data, personal information, non-public personal information, etc. Examples include, Name, Address, Date of Birth, Telephone Number, Fax Number, Email Address, Government Identifier (e.g., PAN Number, PF account number, etc.), Account Number (Bank Account, Credit Card, etc.), Driving License Number, IP Address, Biometric Identifier, Photograph or Video Identifiable to an Individual and any other unique identifying number, characteristic or code. A definition of Privacy, on the other hand is “the claim of individuals, groups, or institutions to determine when, how, and to what extent information about them is communicated to others” by Dr. Alan F. Westin (Privacy and Freedom, 1967) A ‘Data Subject’ or ‘Individual’ is defined as the person to whom the personal data relates ‘Data protection authority’ or ‘Authority’ is the national body established to be responsible for upholding the rights of individuals to the protection of their personal data through the enforcement and monitoring of compliance with the local data privacy laws. ‘Sensitive personal data’ is a subset of personal data and is defined as information that directly or indirectly reveals a person’s race, ethnicity, political or philosophical views, religious beliefs, union affiliation, criminal record or any data related to their health or sexual life Controllers ‘determine the purpose of the processings’. This means that they make decisions about what information is captured and why Processors process personal data on behalf of a controller and in line with the given instructions. If a processor subcontract some or all of the processing to another organisation, the latter is referred to as a sub-processor. The Data Protection Officer, or DPO, is an organization’s GDPR focal point and will have to possess expert knowledge of data protection law and practices ## **Data protection Principles** The key principles of data protection are to safeguard and make available data under all circumstances. If you process data, you have to do so according to seven protection and accountability principles: 1. **Lawfulness, fairness and transparency** — Processing must be lawful, fair, and transparent to the data subject. 2. **Purpose limitation** — You must process data for the legitimate purposes specified explicitly to the data subject when you collected it. 3. **Data minimization** — You should collect and process only as much data as necessary for the purposes specified. 4. **Accuracy** — You must keep personal data accurate and up to date. 5. **Storage limitation** — You may only store personally identifying data for as long as necessary for the specified purpose. 6. **Integrity and confidentiality** — Processing must be done in such a way as to ensure appropriate security, integrity, and confidentiality (e.g., by using encryption). 7. **Accountability** — The data controller is responsible for being able to demonstrate GDPR compliance with all of these principles. **Accountability** - Designate data protection responsibilities to your team. - Maintain detailed documentation of the data you’re collecting, how it’s used, where it’s stored, which employee is responsible for it, etc. - Train your staff and implement technical and organizational security measures. - Have Data Processing Agreement contracts in place with third parties you contract to process data for you. - Appoint a Data Protection Officer. **Data Security** The protection of the rights and freedoms of natural persons with regard to the processing of personal data require that appropriate technical and organisational measures be taken to ensure that the requirements of this Regulation are met. In order to be able to demonstrate compliance with this Regulation, the controller should adopt internal policies and implement measures which meet in particular the principles of data protection by design and data protection by default. Technical measures mean anything from requiring your employees to use two-factor authentication on accounts where personal data are stored to contracting with cloud providers that use end-to-end encryption. Organizational measures are things like staff trainings, adding a data privacy policy to your employee handbook, or limiting access to personal data to only those employees in your organization who need it. **Consent** There are strict new rules about what constitutes **consent from a data subject** to process their information. - Consent must be “freely given, specific, informed and unambiguous.” - Requests for consent must be “clearly distinguishable from the other matters” and presented in “clear and plain language.” - Data subjects can withdraw previously given consent whenever they want, and you have to honor their decision. You can’t simply change the legal basis of the processing to one of the other justifications. - Children under 13 can only give consent with permission from their parent. - You need to keep documentary evidence of consent. **GENINVO & it’s Privacy Principles** The underlying philosophy of privacy protection is that that the data subject be informed about the Personal Information (PI) that may be collected by the processor whose services one is availing of, or the website that one is visiting. The company is expected to do so by declaring its privacy policy. We at GENINVO follow the general principles & ensure a transparent privacy policy. Generally, the following eight principles cut across all geographies: Notice, Consent, Collection Limitation, Use Limitation, Access & Corrections, Security/Safeguards, Data Quality and Openness. APEC, EU, and Canada include two more principles namely, Accountability and Enforcement. US Safe Harbour Program also includes these principles. The GDPR recognizes a litany of new [privacy rights for data subjects](https://gdpr.eu/tag/chapter-3/), which aim to give individuals more control over the data they loan to organizations. As an organization, it’s important to understand these rights to ensure you are GDPR compliant. Below is a rundown of data subjects’ privacy rights: 1. The right to be informed 2. The right of access 3. The right to rectification 4. The right to erasure 5. The right to restrict processing 6. The right to data portability 7. The right to object 8. Rights in relation to automated decision making and profiling. **Conclusion** Any organization that is processing any Personal Information, It is strongly recommend to be GDPR compliant. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, QA/CSV **Tags:** data protection --- ### [Overview of Clinical Data Sharing and Data Anonymization](https://geninvo.com/overview-of-clinical-data-sharing-and-data-anonymization/) **Published:** June 20, 2023 **Author:** admin **Content:** ## Need for Data Sharing For biomedical research, Clinical trials are essential components as they lay down the foundation for the researchers to investigate the significance of various treatments and interventions given to humans for disease cures. The urgency for Clinical Trial Transparency is highlighted by the Declaration of Helsinki and the World Health Organization. It is rapidly making an appearance in the analytic domain of organizations, academicians, and the general public. The listing of Clinical Trials on the public database has opened new avenues to check the operations inculcated by the drug manufacturing enterprise in obeying the regulation used for Good Clinical Practices. Clinical Trial Transparency also helps external scientific and medical investigators to collaborate with firms and strengthen the advantages to improve drug development for mankind’s well-being. In spite of continuous efforts of authorities aimed at ensuring the following of regulation and clinical data transparency for all clinical trials, fewer than half of trials are published/disclosed in the public domain. In general, the absence of transparency can result in significant consequences for healthcare systems, patients, and medical practitioners. ## The advantages of Data Transparency in Clinical Trials are listed as: - The opportunity to reuse clinical data and documents (CSRs (Clinical Study Report)), which might speed up the development of drugs. - Increased transparency could raise interest and awareness among trial participants and researchers. - Transparency raises the scope to track the development of new treatments for unmet medical needs in our healthcare system. - Additionally, it is possible to aggregate participant-level data from different trials to infer more than what can be derived from the results of a single trial. - It tends to prevent sponsors from severe penalties imposed by regulatory bodies. ## Needs and Scenarios on Clinical Data Disclosures - EMA Policy 0070 - Health Canada PRCI - EU CTR regulations - Voluntary Data Sharing - Registries such as CT.GOV etc. ## Need for Data Anonymization In contrast to Data Sharing needs there are data privacy regulations which binds the sponsor to make sure that personal data should not be shared. If shared, there shall not be any possibility of identifying individuals and their personal information from shared clinical data. Clinical trial dataset contains personal and identifying information as mentioned below: **Direct Identifiers** in dataset like Subject IDs, Investigator Name etc could lead to identification of subjects. This violates Data Protection Acts worldwide to protect personal information of individuals. **Quasi-identifiers** are identifiers that by themselves do not identify a specific individual but can be aggregated and “linked” with other information to identify data subjects. For example, age, sex, race, adverse events etc. This leads to need for anonymizing the clinical data so that there is no possibility to identify any individual. As[ ARTICLE 29 DATA PROTECTION PARTY](https://en.wikipedia.org/wiki/Article_29_Data_Protection_Working_Party) states that data is anonymized if there is no possibility to single out an individual, link the information to identify and infer any information on particular individual with some probability above acceptable threshold: - *Singling out*, which corresponds to the possibility to isolate some or all records which identify an individual in the dataset; - *Linkability*, which is the ability to link, at least, two records concerning the same data subject or a group of data subjects (either in the same database or in two different databases). If an attacker can establish (e.g. by means of correlation analysis) that two records are assigned to a same group of individuals but cannot single out individuals in this group, the technique provides resistance against “singling out” but not against linkability; - *Inference*, which is the possibility to deduce, with significant probability, the value of an attribute from the values of a set of other attributes ## Identifying Identifiers and Anonymization Techniques ![](https://geninvo.com/wp-content/uploads/2023/06/Anonymization-techniques-e1687251994604.png "Anonymization-techniques - GenInvo") **Identifiers are:** - Replicable (i.e. its values must be stable over time), - Distinguishable (possess sufficient variation to distinguish it from other individuals in the data set), and - Knowable (it must characterise information that an adversary can know and then use to re-identify the records in the data set) ### **Identifiers in Clinical Trial Data are:** ![](https://geninvo.com/wp-content/uploads/2023/06/Picture2.png "Picture2 - GenInvo") ## Anonymization Methods ![](https://geninvo.com/wp-content/uploads/2023/06/Picture3.png "Picture3 - GenInvo") ![](https://geninvo.com/wp-content/uploads/2023/06/Picture4.png "Picture4 - GenInvo") ![](https://geninvo.com/wp-content/uploads/2023/06/Picture5.png "Picture5 - GenInvo") ![](https://geninvo.com/wp-content/uploads/2023/06/Picture6.png "Picture6 - GenInvo") ## **Need for Automation Tool** Anonymization of clinical data is not something which interests sponsor as it is not helping in their own research but for general public and researcher. But sponsors are responsible from the Data Privacy regulations perspective to protect the privacy of individuals involved in clinical trials. Hence, sponsors need a robust tool to automate the process and minimize the risk of re-identification. Clinical Data includes structured and unstructured form of data. It needs an automation tool to anonymize clinical data uniformly for structured and unstructured forms. GenInvo has developed an automation tool named **[Shadow™ (Data Anonymization Tool)](https://geninvo.com/our-products/data-anonymization-tool/)** which has all the required anonymization techniques available to anonymize clinical data. ![Data Anonymization ](https://geninvo.com/wp-content/uploads/2023/06/Picture7-1024x568.png "Picture7 - GenInvo") ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs **Tags:** Clinical Data Disclosure, Clinical Data Privacy, Clinical dataset anonymization, Clinical Document anonymization, Data De-identification, Document Redaction, risk of re-identification, shadow --- ### [Synthetic Patient Data in Clinical Trials: Why it's important to have meaningful synthetic data. ](https://geninvo.com/synthetic-patient-data-in-clinical-trials-why-its-important-to-have-meaningful-synthetic-data/) **Published:** June 19, 2023 **Author:** admin **Content:** It is time consuming and difficult to manually generate the test data to support Clinical Programming (CP)/Biostatistics and statistical processes and the differences in the quality and coverage of only limited type of scenario in test data causes the delay in the quality check processes. To overcome these challenges, we should have the capability to generate the artificial data automatically with the use of synthetic data generation software that can be utilized to support these processes. Data which is not collected from real world event(s) and generated artificially is referred as synthetic data. ## Just Synthetic Data or should it be Meaningful Synthetic Data? **Does it make difference?** Yes! To fulfil the requirements to support Clinical Programming (CP)/Biostatistics and statistical processes, the availability of synthetic data which is not meaningful won’t be sufficient. To cover all the scenarios of the real clinical trial data there are several points those needs to be considered and taken care of. Such as, links between the forms/datasets i.e. concomitant medication (CM) given for an adverse even (AE) is not matching or not entered; results of pregnancy test should be available for females not males, etc. There are several such instances where synthetic data which is not meaningful will fail to serve the purpose. On the other hand, meaningful synthetic data covers all the scenarios required to boost Clinical Programming (CP)/programming/statistical processes. ## **How can GENINVO help you generate “meaningful” synthetic data?** GENINVO’s [Datalution™](https://geninvo.com/our-products/datalution/) is all in one solution for generating meaningful synthetic data for testing electronic data capture, edit checks, data management (as part of [UAT Process](https://www.panaya.com/blog/testing/what-is-uat-testing/#:~:text=User%20Acceptance%20Testing%20(UAT)%2C,do%20in%20real%2Dworld%20situations.)), programming, and statistical setup activities for Dry Run (mapping/transformation, TLFs & visualization ) and more. ### Advantages of using[ Datalution™](https://geninvo.com/our-products/datalution/): - Easy to use user interface. - Generate Real like synthetic data for upcoming or ongoing clinical trials integrated with patient journey. - Zero risk of de-identifying patients - Allow stake holders to have data at right time and increase the trial efficiency by performing data operations quickly without hick-ups. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs --- ### [White List & Black List: Enhanced NER Model](https://geninvo.com/white-list-black-list-enhanced-ner-model/) **Published:** September 17, 2021 **Author:** admin **Content:** ![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-10-Case-Study-WB-List_v3_Strona_1-scaled.jpg "Case Studies-10-Case Study WB List_v3_Strona_1 - GenInvo")![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-10-Case-Study-WB-List_v3_Strona_2-scaled.jpg "Case Studies-10-Case Study WB List_v3_Strona_2 - GenInvo")![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-10-Case-Study-WB-List_v3_Strona_3-scaled.jpg "Case Studies-10-Case Study WB List_v3_Strona_3 - GenInvo")![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-10-Case-Study-WB-List_v3_Strona_4-scaled.jpg "Case Studies-10-Case Study WB List_v3_Strona_4 - GenInvo")![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-10-Case-Study-WB-List_v3_Strona_5-scaled.jpg "Case Studies-10-Case Study WB List_v3_Strona_5 - GenInvo")![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-10-Case-Study-WB-List_v3_Strona_6-scaled.jpg "Case Studies-10-Case Study WB List_v3_Strona_6 - GenInvo")![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-10-Case-Study-WB-List_v3_Strona_7-scaled.jpg "Case Studies-10-Case Study WB List_v3_Strona_7 - GenInvo") ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** Apogi, case studies **Tags:** apogi --- ### [Automation within Medical Writing](https://geninvo.com/automation-within-medical-writing/) **Published:** May 17, 2023 **Author:** admin **Content:** ## **What does medical writing function do?** Medical writing is a highly specialized field that involves content writing and clinical research on scientific documents of different types which include regulatory and research-related documents, disease or drug-related educational and promotional literature, periodicals, publication articles like journal manuscripts and abstracts, content for healthcare websites, health-related magazines, or news. These texts can be read by anyone from a layperson to a highly qualified medical professional. ![](https://geninvo.com/wp-content/uploads/2023/05/Picture1.png "Picture1 - GenInvo") Medical writing is an umbrella term that refers to both technical and scientific writing in health, medicine, and other life science disciplines. The profession includes communicating composite data and ideas in a clear, brief, plausible, absolute, and convincing manner. It’s all about developing materials about medicine and health by collecting, organizing, interpreting, and presenting information in a manner appropriate for the target audience. Medical writers help to analyse, organize, and present the data into a variety of formats with creative work involving research, analysis, and communication for different audiences, including, but not limited to, regulatory authorities, public, patients and their caregivers, and physicians. ## **Trends of using Technology within Pharma and Life sciences Industry.** Many pharmaceutical and Life Sciences sectors have been seeing the regulatory standards constantly changing and evolving quickly, and spending on research and development has been rising constantly. Necessity to continuously adapt, produce, maintain, and update medical material has evolved. There is a steady shift toward accepting automation in managing these changes, the medical writing industry is also trying to adapt to this situation and is moving towards using innovative solutions which can ease the process using AI/ML/NLP/NLG solutions. Several companies are now assessing and employing AI solutions to automate conventional writing processes that are time-consuming and tedious. As these companies have realized the importance of automation in the medical writing space, they have agreed that AI solutions can save up to 80% of the medical writer’s time and can process and manipulate large amounts of data within few minutes. Companies are adopting multiple approaches with automation. They are either developing internal automation capabilities for QC, data structuring, analysis, and generating documents, etc., or they are partnering with companies that have automation platforms. ## **Building AI System for Medical Writing** Increasingly, building AI systems is becoming less complex and cheaper. The principle behind making a good AI is collecting relevant data to train the AI model. AI models are programs or algorithms that enable the AI to recognize specific patterns in large datasets. The better you make AI technology, the more wisely it can analyse vast amounts of data to learn how to perform a particular task. The process of analysing data and performing tasks is called machine learning (ML). For example, [Natural language processing](https://medium.datadriveninvestor.com/natural-language-processing-in-the-near-future-a-blog-around-the-latest-developments-in-nlp-895d56c62ec4) (NLP) gives machines the ability to read, understand human languages, and mimic that behaviour. The most promising AI apps rely on ML and deep learning. The latter operates based on neural networks built similarly to those in the human brain. Example of real-world applications of AI include Speech recognition, Computer vision, discovery of data trends, Fraud prevention etc. ## **Medical Writing and Technology** To build [AI powered solution](https://geninvo.com/our-products/docqc-medical-writers-automation-tool/), one must identify the problem that needs to be solved, collect the right data, create algorithms, train the AI model, choose the right platform, pick a programming language, and, finally, deploy and monitor the operation of the respective AI system. ![](https://geninvo.com/wp-content/uploads/2023/05/Picture2-1024x595.jpg "Picture2 - GenInvo")Medical Writing field also has a need for Automation in the industry now and want to leverage the techniques and algorithms of Natural Language Processing (NLP) and Natural Language Generation (NLG) to generate content in their areas. The data that is being currently worked on are transforming into Artificial Intelligence (AI) has made major strides in producing, processing, and mining text. These AI-powered engines can understand the context and suggest appropriate terminology. The technology is also helpful when creating intuitive material. The algorithms should be programmed properly, so that computer displays no bias. Based on its training, it offers its predictions and recommendations. Medical writers can use computer innovation and the rise of AI in the fields of NLP and NLG to their advantage while producing medical documentation. The technology of AI/ML/NLP/NLG has certain criteria and steps as a process to create the platform. From Medical writing perspective, this may include identifying and analysing the word structure, check the syntax/grammar, make meaningful words, mapping these words to appropriate dictionaries, and setting the context of the words with the meaning of the sentence, and then interpretating the actual meaning of the sentence. AI, when clubbed with NLP and NLG, automatically extracts information from a variety of data sets, whether they are organized (structured) or unstructured. It can then analyse the extracted data to comprehend and categorize the content’s substance and context and stores the content and context data in a dynamic semantic model as per the requirement. ![](https://geninvo.com/wp-content/uploads/2023/05/Picture3-1024x468.jpg "Picture3 - GenInvo")To meet the needs of various stakeholders, the system should be built to reflect the context of the material when it needs to be reused or repurposed. The solution needs to maintain a database of data that is conveniently searchable with natural language queries. Additionally, impact analysis needs to be done to enhance change management anytime new content is made available or updated. ## **Traditional Approach vs Recent Technology** With advance technology, a system can provide repeated operations with a high degree of redundancy. The time and resource that is needed to create these documents are mostly spent on gathering data from already existing sources (such as Study documents like Protocol, CSR, SAP, Narratives, Publications etc) and organizing them under appropriate section headings (as per the respective templates). AI/ML/NLP solution can put all these contents and can start creating the necessary outputs and can reduce 50-80% as compared to manual traditional approach. ![](https://geninvo.com/wp-content/uploads/2023/05/Picture4-1024x696.jpg "Picture4 - GenInvo")Medical writing expertise would be required to assist in refining the finished documents/articles and offer an expert guidance and making sure the meaning has proper scientific interpretation. Speeding up the content generation can enable submissions and marketing authorizations faster and produce complex documents faster as compared to traditional approach (days instead of weeks for example). The capabilities of AI/ML are constantly expanding and can be used to generate documents that need higher degree of editorial expertise such as peer reviewed articles/journals, abstracts, presentations, posters, manuscripts etc. ## **GENINVO’s assistance with Automation** Due to advances in data collection/processing/reporting systems, there always has been real-time demand on the availability of “clean data,” for further processing, which leads to better time management. With advancements in technology, multiple options became available to the medical writers that provided meaningful alternatives to speed up the medical writing process. With enhanced communication systems and automation opportunities, the said challenges are addressable in today’s world with GENINVO’s automation. GENINVO automation tools help to check the document readiness for submission within minutes and lets the medical writers to focus on the scientific content. GENINVO also provides AI/ML/NLP/NLG enabled tools/solutions for generating and content authoring medical writing deliverables with good quality and in quick time. GENINVO’s DocQC™ is a tool for automation of Quality Control (QC) checks that have historically required multiple, time-consuming cycles of manual review. Checks of various complexities are programmed leveraging cutting‒edge technologies. DocQC™ enables your Medical Writers to maintain their focus on the science, analyses, and presentation of results. **Summing up** **Automation and AI Techniques (NLP/NLG) are both real and here to stay. They have exciting prospects in the future of Medical Writing and is not a threat but can only support in getting the deliverables faster with Quality.** ***By Ramesh Venkataramana, Director Innovative solutions and strategy, GENINVO*** *19th May, 2023* ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs **Tags:** Clinical Trial Automation, Data Extraction and Analysis, Machine Learning in Medical Writing, Medical Writing Automation Automated Medical Writing AI in Medical Writing Natural Language Processing (NLP), Mining in Medical Writing --- ### [Synthetic Data Vs Real Data ](https://geninvo.com/synthetic-data-vs-real-data/) **Published:** May 8, 2023 **Author:** admin **Content:** There has been an increase in interest in synthetic data over the past few years for various applications such as machine learning and data analytics. Research predicts that synthetic data will surpass real data by 2030. However, some executives and business leaders may not be familiar with the concept due to its differences from real data. **GENINVO** uses Datalution™, the all-in-one solution for generating synthetic data for testing electronic data capture screens, edit checks, Data management activities (as part of UAT Process), programming, and statistical setup activities. ## **What is Synthetic data? How is it created?** Synthetic data is artificially generated data that is created using computer algorithms and models rather than being collected from real-world observations. It can be used to replace or augment real-world data in various applications, such as testing and training machine learning models, conducting simulations, or generating new data for research purposes. **The process of creating synthetic data typically involves the following steps:** **Defining the data requirements**: This involves specifying the characteristics and properties of the data to be generated, such as the size, format, structure, and distribution of the data. **Designing the model:** Based on the data requirements, a computer model is designed to simulate the generation of synthetic data. The model may incorporate statistical, probabilistic, or machine learning algorithms, depending on the type of data being generated. **Generating the data:** Once the model is designed, it can be used to generate synthetic data by simulating various scenarios and events. The data can be generated in batches or in real-time, depending on the application. **Validating the data:** Before using synthetic data for any application, it is important to validate its quality and accuracy. This involves comparing the statistical properties of synthetic data with those of real-world data to ensure that they match. There are several tools and platforms available for creating synthetic data, ranging from open-source software to commercial products. Some popular methods for generating synthetic data include generative adversarial networks (GANs), variational autoencoders (VAEs), and Monte Carlo simulations. ## **What are the key benefits of synthetic data over real data?** Synthetic data is generated by computer programs or algorithms that simulate the statistical properties of real data without containing any personal or confidential information. Here are some potential benefits of using synthetic data over real data: **Privacy Protection:** Synthetic patient data can be generated to replace sensitive or personal data, protecting individual privacy and reducing the risk of data breaches. **Cost-Effectiveness:** Synthetic data can be generated at a lower cost than collecting and processing real data, especially for large datasets or data with high variability. **Availability:** In some cases, real data may not be available or difficult to obtain due to legal, ethical, or practical reasons. Synthetic data can be generated quickly and easily, providing a viable alternative. **Control over Data Properties:** Synthetic data can be tailored to meet specific research needs or scenarios by controlling data properties such as distribution, noise, and correlation. **Reproducibility:** Synthetic data can be generated repeatedly with the same statistical properties, ensuring reproducibility and consistency of results. However, synthetic data may not always be suitable or replaceable for real data in certain applications or domains, especially when the data needs to capture the complexity and richness of real-world phenomena or behaviors. Additionally, the accuracy and validity of synthetic data depend on the quality and representativeness of the underlying algorithms used for generation. ## **What are the challenges with using synthetic data against real data?** Using synthetic data instead of real data has its advantages in certain situations, such as when the real data is sensitive or unavailable. However, there are also several challenges with using synthetic data that need to be considered. Some of the key challenges include: **Lack of variability:** Synthetic data may not be able to capture the full range of variability present in the real data. This can result in models trained on synthetic data being less accurate or less robust than models trained on real data. **Bias:** Synthetic data can be biased in ways that are not representative of the real data. This can occur when the synthetic data is generated based on assumptions that do not hold in the real world or when the synthetic data is not diverse enough to capture the full range of variation present in the real data. **Data quality:** Synthetic data may not be of the same quality as real data. This can lead to models trained on synthetic data performing poorly when applied to real data. **Limited applicability:** Synthetic data may only be applicable to certain contexts or scenarios and may not generalize well to other situations. **Ethical considerations:** Using synthetic data can raise ethical concerns, particularly if it is used to simulate sensitive or personal data. This can include issues around privacy, consent, and data ownership. Overall, while synthetic data has its advantages, it is important to carefully consider the potential challenges and limitations before deciding to use it instead of real data. ## **Which type of data should be used for specific applications? Synthetic or Real?** The choice between synthetic and real data depends on the specific application and the goals of the project. **Here are some general guidelines:** If the goal is to train a machine learning model to perform a specific task, such as image recognition, natural language processing, or speech recognition, then both synthetic and real data can be useful. Synthetic data can be generated in large quantities and can be labeled more easily than real data. Real data, on the other hand, can provide a more realistic representation of the problem domain. If the application involves safety-critical systems, such as autonomous vehicles or medical devices, then real data is generally preferred. This is because real data can capture the complexity and unpredictability of the real world, which is crucial for ensuring the safety and reliability of such systems. If the goal is to perform simulations or virtual testing, then synthetic data may be more appropriate. Synthetic data can be generated to represent a wide range of scenarios and can be used to test the system under different conditions. In summary, the choice between synthetic and real data depends on the specific application and the goals of the project. In general, a combination of both synthetic and real data can be beneficial for training machine learning models and testing systems. ## **How can GENINVO help you generate ‘meaningful’ synthetic data?** Introducing Datalution ™, A Meaningful [Synthetic Data Generation Solution ](https://geninvo.com/our-products/datalution/) - Leverages clinical study documents - Ensures data are representative of the “Patient Journey” - Generates “Meaningful” test data: 1. Chronological order of the dates/visits. 2. Generates the test/assessments based on the protocol. Feel free to reach out at: [Contact us – GENINVO](https://geninvo.com/contact-us/) to know more about Datalution™ technology and services. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs **Tags:** real data, Synthetic data, Synthetic data solutions, Synthetic data technology --- ### [GENINVO is delighted to exhibit and present again at the PHUSE US Connect 2023! You can visit us at Booth #7.](https://geninvo.com/phuse-us-connect-2023/) **Published:** February 17, 2023 **Author:** admin **Content:** PHUSE US Connect 2023, Let’s have insightful conversations to help understand your gap areas and further develop our products to perfectly fit into your organization. Our team is producing transformational software solutions using years of experience in life sciences industry, collaboration with industry forums, leading edge technologies and our software development capabilities, data-engineering practices, cloud expertise, and artificial intelligence research. ### Come join us for insightful presentations by GENINVO’s subject matter experts: 1\. Beyond k-anonymity for [Clinical Trial Data Anonymization ](https://geninvo.com/our-products/data-anonymization-tool/) 2\. Handling Multiple Adaptations in One Clinical Trial 3\. Introduction to Machine Learning Models, How to Train Them and What to Do If They Become Sassy 4\. The Role of Al in the Biometrics and Medical Writing functions We are proud to share the many life science solutions that we have created with the support of our talented resources. Our team has created innovative tools and solutions that help [life science companies](https://www.sigmaaldrich.com/) achieve the desired result with greater performance and efficiency. Connect events, which are a result of PHUSE’s culture for information sharing and strong purpose to unite talents, serve as a hub for tackling healthcare problems and advancing life sciences. Get inspired by the PHUSE community and learn from industry experts. You will have many opportunities to network with the right people and make connections. ***Don’t forget to join us in PHUSE US Connect 2023 at Booth #7 on 5th to 8th March 2023, in Renaissance Orlando at Seaworld Florida.*** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [Shadow for EU-CTR Compliance](https://geninvo.com/shadow-for-eu-ctr-compliance/) **Published:** November 29, 2022 **Author:** admin **Content:** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** videos --- ### [American Medical Writers Association (AMWA 2022)](https://geninvo.com/american-medical-writers-association-amwa-2022/) **Published:** October 14, 2022 **Author:** admin **Content:** The 2022 Medical Writing & Communication Conference program will elevate health and well-being through medical communication. ![](https://geninvo.com/wp-content/uploads/2022/11/MicrosoftTeams-image-36-1024x899.jpg "MicrosoftTeams-image-36 - GenInvo") We are happy to exhibit at [AMWA 2022](https://www.amwa.org/)! Talk to our expert team members and let’s discuss how our medical writer’s automation tool for advanced quality checks, [DocQC](https://geninvo.com/our-products/docqc/) can aid you. Also, achieve data anonymization with ease, with our Health Canada & EMA policy 0070 compliant and industry leading solution, [Shadow](https://geninvo.com/our-products/shadow-a-data-anonymization-tool/). Join us on table no.18 at the “Premier Educational Event for Medical Communicators” organized by AMWA’s 2022 Medical Writing & Communication Conference in Denver, CO. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events **Tags:** AMWA's 2022 --- ### [PHUSE EU Connect 2022](https://geninvo.com/phuse-eu-connect-2022/) **Published:** October 14, 2022 **Author:** admin **Content:** PHUSE EU Connect 2022 events bring together our global community to collaborate on hot topics, share perspectives and discuss different approaches to guiding the healthcare industry landscape, both now and in the future. GenInvo is delighted to exhibit again at the [PHUSE EU Connect](https://www.phuse-events.org/)! Let’s have insightful conversations to help understand your gap areas and further develop our products to perfectly fit into your organization. Our team is producing [transformational software](https://geninvo.com/our-services/) solutions using years of experience in life sciences industry, collaboration with industry forums, leading edge technologies and our software development capabilities, data-engineering practices, cloud expertise, and artificial intelligence research. Meet us at the EU Connect 2022 for four unforgettable days in the heart of Belfast’s city center, 13th–16th November. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events **Tags:** PHUSE EU Connect 2022 --- ### [PHUSE US Connect 2022](https://geninvo.com/phuse-us-connect-2022/) **Published:** October 8, 2021 **Author:** admin **Content:** - We are excited to showcase the various [life science solutions we have developed](https://geninvo.com/our-products/) with the help of our talented resources. - Our team has developed impactful tools and solutions which help life science businesses to acheive the desired result with higher performance and greater efficiency. - We would also be showcasing the various Data Science Applications we have developed in our CoE. ![](https://geninvo.com/wp-content/uploads/2022/10/Phuse-event--1024x819.png "Phuse-event- - GenInvo") *Join us at the physical live event from 1st to 4th May in Atlanta at the Marriott Marquis.* ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [R/Shiny Developer/Lead](https://geninvo.com/r-shiny-developer-lead/) **Published:** December 14, 2021 **Author:** admin **Content:** ##### **Job Description:** - We are looking for a candidate for a Senior/Lead RShiny Developer, who can drive the strategy and can direct and lead the team. - Project Management skills would be more focused on what are the projects, understanding of the stakeholders, being in the part of these meetings etc. - The candidate would be hands on code development with R and Rshiny skills - Candidate must have hands on working experience with R Code development & RShiny. - Must have experience of Publishing packages to internal company repository. - Candidate should have experience in implementing RShiny app in docker on Kubernetes. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** job --- ### [EU-CTR New regulations are here - Are you ready for the changes?](https://geninvo.com/eu-ctr-new-regulations-are-here-are-you-ready-for-the-changes/) **Published:** September 21, 2022 **Author:** admin **Content:** Join GenInvo’s live webinar on ‘How our Anonymization tools & services help you meet new regulatory regulations and more stringent timelines of EU-CTR’ Date- Sep 22nd, 2022 ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [ISMS Implementation ](https://geninvo.com/isms-implementation/) **Published:** August 30, 2022 **Author:** admin **Content:** Every technology-driven business process is exposed to security and privacy threats. Modern technologies are capable of preventing cybersecurity attacks, but these aren’t enough, organizations must ensure that business processes, policies, and workforce behaviour minimize or mitigate these risks. # **What is an ISMS?** [ISMS](https://isms.mponline.gov.in/Portal/) (ISO 27001) is an International Standard has been given by International Standards Organization (ISO) to provide a model for establishing, implementing, operating, monitoring, reviewing, maintaining and improving an Information Security Management System (ISMS). The adoption of an ISMS should be a strategic decision for an organization. The design and implementation of an organization’s ISMS is influenced by their needs and objectives, security requirements, the processes employed and the size and structure of the organization. ## **How to Implement an ISMS?** This International Standard adopts the “Plan-Do-Check-Act” (PDCA) model, which is applied to structure all ISMS processes. ISMS takes as input the information security requirements and expectations of the interested parties and through the necessary actions and processes produces information security outcomes that meets those requirements and expectations. **The PDCA Model:** ![](https://geninvo.com/wp-content/uploads/2022/08/PDCA-model.png "PDCA-model - GenInvo") - **Plan –** Identify the problems and collect useful information to evaluate security risk. Define the policies and processes that can be used to address problem root causes. Develop methods to establish continuous improvement in information security management capabilities. - **Do –** Implement the planned security policies and procedures. The implementation follows the ISO standards, but actual implementation is based on the resources available to organization. - **Check** **–** Monitor the effectiveness of ISMS policies and controls. Evaluate tangible outcomes as well as behavioural aspects associated with the ISMS processes. - **Act –** Focus on continuous improvement. Take corrective and preventive actions, based on the results of the internal ISMS audit and management review or other relevant information, to achieve continual improvement of the ISMS. ## **How Geninvo Implemented an ISMS?** In [Geninvo](https://www.geninvo.com/), ISMS security controls for all the information assets associated with customers, employees, and business partners. The below are the policies implemented at [Geninvo](https://www.geninvo.com/) for security controls. - **Organization Security Policy:** Security Policy defines the process/approach of Geninvo towards establishing and implementing information security measures, adopting the industry best practices/regulations such as the ISO270001 security standards and GDPR. - **Human Resource Policy:** Security roles and responsibilities of employees, contractors and third-party users shall be aligned with organization’s information security policy. - **Physical and Environmental Security:** Organization’s sensitive information processing facilities is housed in secure areas. Physical or System Security protection is implemented to safeguard the information data against natural and man-made disasters. - **Equipment/System Security:** Equipment’s/ System shall be protected to reduce the risks from environmental threats and unauthorized access. Power and telecommunication cables shall be appropriately protected from interception or damage. - **Communications and Operations Management:** Management and operations of all information processing facilities shall be controlled to reduce the risk of negligent or deliberate misuse. Services delivered by third parties shall be managed according to Organization’s information security requirements. - **Mobile Computing Policy:** Appropriate security measures have been adopted to protect mobile computing facilities. Personnel are trained on the usage of these facilities in public places and when connecting to networks. - **Business Continuity Management:** A business continuity management process has been implemented to minimize the impact on the Organization and recover from the loss of information assets to an acceptable level. Business Continuity plan has been developed and implemented to ensure the timely resumption of critical functions*.* - **User Access Management:** Allocation of access rights to information systems, network and services is controlled. User is made aware of the responsibilities for maintaining effective access controls. - **Security Requirements in Application:** Appropriate controls are established to ensure the data protection and data integrity while enhancement or updating or installing new information system, maintenance or management to protect the application and processing data through various validation checks in applications. - **Cryptographic Controls:** Based on periodic risk assessments Geninvo shall identify information assets, which require to be protected by cryptographic controls. Appropriate cryptographic controls have applied to protect such information assets - **Network Security Management:** Controls has established to safeguard the confidentiality and integrity of data passing over public and internal networks, and the users are provided access to the network services that have been specifically authorized. - **E-mail Security Policy:** The information exchanged by emails is appropriately protected from unauthorized access, modification or denial of service. - **Internet/Intranet Security:** Controls are established to safeguard the confidentiality and integrity of data passing over Internet/Intranet. - **Asset Management:** All assets is accounted for and have a nominated owner. Acceptable use of assets is established. Information is classified to indicate the need, priorities and expected degree of protection. - **Information System Acquisition, Development and Maintenance:** Security requirements is identified and agreed prior to the development and / or implementation of information systems. - **Information Security Incident Management:** Appropriate controls is established to ensure a quick, effective, and orderly management of information security incidents and weaknesses. - **Compliance:** Compliance with legislative, regulatory, and contractual security requirements for the design, operation, use, and management of information systems shall be ensured. **Conclusion:** These Policies and procedures offer best practices towards Geninvo success for systematically managing security of sensitive data. Though these may vary slightly from one framework to another, considering and aligning with these policies will provide much in the way of information security. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, QA/CSV **Tags:** ISMS, Security Policy --- ### [Regulatory Bodies in Life Sciences](https://geninvo.com/regulatory-bodies-in-life-sciences/) **Published:** March 26, 2021 **Author:** admin **Excerpt:** Regulatory bodies (or regulatory agencies) in Life Sciences as we have come to know them have been around since the 1900’s, and they drive how we perform our work. This article is an introduction for those new to the industry and for others interested in the impact of these authorities on innovation. **Content:** *Thomas Kalfas – Sr Innovation Officer* *22nd Jan, 2021* Regulatory bodies (or regulatory agencies) in Life Sciences as we have come to know them have been around since the 1900’s, and they drive how we perform our work. This article is an introduction for those new to the industry and for others interested in the impact of these authorities on innovation. ## **What purpose does a [regulatory agency](https://wdra.gov.in/) serve?** Regulatory bodies, or agencies, are independent governmental bodies established by legislative acts in order to set standards in a specific field of activity, or operations, in the private sector of the economy and then to enforce those standards\[1\]. Naturally, as problems became more prevalent and complex in the 20th century, these agencies became necessary as a means for promoting fair trade and for protecting consumers. In Life Sciences, these agencies regulate how new products, i.e., drugs, biologics and medical devices, are tested in animals and in humans, and subsequently either rejected or approved for use\[1\]. Regulations over time have led to the development of GxPs, short for Good Practices, as controls/processes needing to be in place to ensure compliance with regulatory requirements. GxPs include mostly: - **GCPs** – Good Clinical Practices (for proper conduct in collecting, cleaning, analyzing and reporting information from pre-clinical and clinical trials); - **GLPs** – Good Laboratory Practices (for proper conduct of laboratories in maintaining standards and production of laboratory test results); and, - **GMPs** – Good Manufacturing Practices (for proper conduct in the making of new drugs, biologics, and medical devices) Regulatory agencies monitor product development activities (from discovery, manufacturing and marketing) inclusive if the execution of clinical trials to ensure that standard processes are being followed, and most importantly that patients are not being unnecessarily exposed to potentially harmful and/or ineffective products. **What are some examples of agencies globally?** **US: FDA (the Food and Drug Administration)** In 1906, because of the passing of the Pure Food and Drugs Act, the Bureau of Chemistry became the FDA \[2\]. The FDA is responsible for \[3\]: - Protecting the public health by **ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices**; and by ensuring the safety of our nation’s food supply, cosmetics, and products that emit radiation. - Regulating the manufacturing, marketing, and distribution of tobacco products to protect the public health and to reduce tobacco use by minors. - Advancing the public health by **helping to speed innovations that make medical products more effective, safer, and more affordable** and by helping the public get the accurate, science-based information they need to use medical products and foods to maintain and improve their health. - Ensuring the security of the food supply and by fostering development of medical products to respond to deliberate and naturally emerging public health threats. **EU: EMA (the European Medicines Agency)** Established in 1995, the EMA’s mission is to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health in the European Union (EU). The EMA is responsible for\[4\]: - Facilitating development and access to medicines - Evaluating applications for marketing authorization - Monitoring the safety of medicines across their lifecycle - Providing information to healthcare professionals and patients **Canada: Health Canada** Health Canada is responsible for Canada’s national health policy. They work with other federal health-related agencies including the Canadian Food Inspection Agency (CFIA) and the Public Health Agency of Canada (PHAC) to \[5\]: - Preserve and modernize Canada’s health care system - Enhance and protect the health of Canadians - Work in partnership with others - Communicate health promotion and disease prevention **Japan: PMDA (the Pharmaceuticals and Medical Devices Agency)** Established in 2004, the PMDA is the government organization in Japan in charge of reviewing drugs and medical devices, overseeing post-market safety, and providing relief for adverse health effects \[6\]. **How is our work influenced by these agencies?** Life Science companies need to be able to demonstrate regulatory compliance. This is determined via audits or inspections. Regulatory agencies can perform audits proactively by the company itself, using internal and/or contract auditors, and as part of a standard vendor qualification process when considering outsourcing with potential vendors. The results of an audit highlight areas requiring further explanation/clarification to the auditor’s satisfaction. It will also highlight those that require improvement to address gaps or to ensure existing processes are fully compliant. The results of the audit typically come in the form of a CAPA (Corrective Action and Preventative Action). The CAPA is an opportunity to understand the auditor’s feedback, identify and discuss any errors in observations, and ask any clarifying questions to ensure a proper approach and response to any remaining findings. Following the initial report, a CAPA response is expected to detail a plan/timeline addressing any audit findings. In most cases, audit findings are manageable and addressed in short order. However, if it finds major and systemic findings that are not addressed in a timely fashion, the penalties can be quite severe and impact business. Given the importance of regulatory compliance, Regulatory Affairs departments are established in Life Science companies to: - Stay abreast of changes in legislation (rules and regulations) of drug research, manufacturing, and marketing - Ensure effective communications internally to their organizations for assurance of regulatory compliance across all departments/functions - Ensure effective communications externally with the regulatory agencies themselves to comply or show evidence of organizational regulatory compliance So, regulatory agencies significantly impact how Life Sciences operate daily. **What role do they play in facilitating innovation?** As mentioned above, best practices and standard operating procedures aligned with regulations assist with compliance. Limiting ambiguity, variability, and changes to these processes facilitates compliance and gives well-trained staff the ability to respond with confidence to questions/concerns raised by staff and/or auditors. Even the strongest and most established processes require periodic assessment and updates. However, similar to changes in software/hardware systems, the impact of these updates can be both time consuming and costly. Consider not only the process changes but also potential systems/data changes and certainly the retraining of staff. Consequently, process enhancements/revisions might be limited by some to only address high priority items (retroactive in nature). Does this discourage innovation? Perhaps. Do regulatory agencies discourage innovation for fear that it could make compliance across industry organizations more difficult? By evaluating their websites and their proclamations and policies in action, it would appear they do encourage innovation. While policing the industry is a large portion of what regulatory agencies do, innovation is vital to enhancing future discovery, development, and marketing. Over the past decade, agencies have declared their stance on innovation. Furthermore, the agencies listed above helped to spur innovation actively in the following ways \[7\]\[8\]\[9\]\[10\]: - Publicly declaring innovation policies and strategies. - Incentivizing innovations in the industry by offering “fast-track” or in the case of the FDA “breakthrough therapy” designations for therapies offering significant improvement over available therapies for patients with serious or life-threatening diseases. - Collaborating and engaging with stakeholders, advisory panels, and task forces (including patients, drug development sponsors, and IT professionals) to learn about the impact of diseases on patients, and to gather input from industry experts in health information technology to pave the way for faster delivery of new products. **Conclusion** Regulatory bodies play a pivotal role in establishing fair trade and protecting the rights and safety of consumers. Most of their efforts historically focused on this. However, as technological advancements open new doors, regulatory agencies, to better serve patients, are open to and contribute to collaborative innovation efforts to speed new product approval and delivery while maintaining safety standards. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs --- ### [What is Password Protection?](https://geninvo.com/what-is-password-protection/) **Published:** August 22, 2022 **Author:** admin **Content:** *Damanjeet Singh – Technical Lead- IT & Infrastructure* Passwords provide the first line of defense against unauthorized access to your computer and personal information. Once a password protects the data, only the person with the passwords will access the information or accounts. Another user cannot read, change, or delete your data set without knowing the password. The three different levels used in the 3-level password authentication scheme are image ordering, color pixels and the one-time password (OTP). ## **Some ways in which you can make the most out of your password protection include:** 1. Don’t share your password or relevant usernames with anyone. If anyone may need access to your data, be present and allow them access. 2\. Don’t use one password for all your various data accounts, be creative and have different passwords. Also, sharpen your memory and remember all of them. 3\. A stronger password is not only one that contains numbers, letters, and symbols. Make [your password even stronger](https://cybernews.com/best-password-managers/how-to-create-a-strong-password/) by creating a passphrase unique and crazy enough for you. 4\. Strengthen your password using multi-factor authentication, which will require your permission from another device to grant access. [GenInvo](https://geninvo.com/) has an MFA system for all applications; GenInvo protects your company’s data and makes management easier. The system requires a person to provide a username and password and afterward allow access from the MFA app on your android or iOS phone. The second authentication process uses the one-time password method to grant access. ## **Why You Need Password Protection**: Without a password, all your information will be open and available to anyone who tries to access it. In a business setting, this leaves critical data such as personal or client information exposed. Passwords are the first secure entry point to your information; therefore, anyone without it can easily experience a breach in their security system. ## **Benefits of Using Password Protection for Your Business** Passwords can be very beneficial for your company when implemented in the best ways. Here are some benefits of password protection for your business: With password protection and MFA, you allow instant, user-friendly and secure access to accounts or data. Instead of risking valuable business information, coming up with passwords keeps everyone’s work well protected beyond the administrators. The use of passwords and MFA have also reduced the possibility of hacking and brute force attacks on companies’ data. **Top 5 tips for good password security!** 1\. Make your password long 2\. Include numbers, symbols, uppercase, and lowercase letters 3\. Avoid using obvious personal information 4\. Do NOT reuse passwords 5\. Do NOT keep the same password for all accounts ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, IT **Tags:** password protection --- ### [WHAT IS ISO CERTIFICATION AND WHY DOES IT MATTER?](https://geninvo.com/what-is-iso-certification-and-why-does-it-matter/) **Published:** August 17, 2022 **Author:** admin **Content:** *Gurjeet Dhaunsi – Analyst- QA/CSV* **ISO (International Organization of Standardization)** is non-profit organization which is setup with a goal to achieve standardization across global markets for same products in terms of consistency & quality. [ISO](https://www.iso.org/about-us.html) was inaugurated in 1946 in London & today more than 24000 standards are in force, published by ISO in various fields ranging from environment to safety, ethical standards, and safety protocols, to quality and risk management. These standards are widely used by organizations all over the world to conform to international standards, streamline their business operations and to compete more effectively with others. **ISO Certification** is mark of quality and credibility for any organization. No matter how big or small a company is, an **ISO certification** is always an asset for the organization. ISO certification certifies that a management system, manufacturing process, any service, or documentation procedure has all the requirements for standardization and quality assurance. **Benefits of ISO certification** are not just limited to standardization but also helps in proper functioning & efficiency improvement. Following would be key benefits while relevant ISO certification is achieved: ## **Benefits of ISO certification** - **Save Resources:** Organizations that are ISO certified often must analyse their business processes to identify bottlenecks, which in turn enables them to resolve the same and speed up their various processes so that they are able to meet the desired target on schedule. This is most important especially when it comes to large-scale companies but all companies that are ISO certified generally can streamline their functioning and, in the process, hence enabling them to deliver ahead of schedule. - **Improving customer satisfaction:** With the relevant ISO certification, organizations can provide services to their customers with better satisfaction. To remain compliant, they must generally be quick to get back to their customers on all their queries and all issues are handled by the organization at the highest level and resolved in the shortest time possible. By doing so, the organization manages to build up a reputation of providing customers with enhanced service and these results in better publicity and more visibility, which in turn enables them to retain their clients and attract new ones with ease. - **Resources utilization planning:** It is a fact that most organizations often waste valuable environmental resources without ever utilizing the same. With the right ISO certification, organizations must evaluate their various business processes, limiting any such wastage, and even eliminating the same altogether. One such example would be the use of carbon paper and since we are in a digital age, there is no need for companies to use carbon paper anymore to make manual copies of the content. It is always a good idea to run manual checks to see if there is any wastage of resources and seek to eliminate the same. - **Risk management:** With ISO certification, organizations would have to assess all internal and external threats, take measures to mitigate the same and set in place certain protocols which can help to better protect the organization and all its key assets. Often, most organizations do take many measures when it comes to protecting proprietary information related to their organization but often such measures do not extend to client data and information. However, with the requisite of ISO certification, companies must enforce a strict protocol, regulate access to valuable information and key data, ensuring that random checks are carried out and ensure that various protocols are in place to protect their data. By ensuring better data protection, organizations can gain better in terms of credibility and as a result, are able to attract new customers with ease. - **Better Work environment:** Organizations that are ISO compliant can provide their employees with better working conditions and would have various measures in place to guarantee their safety. Recently, a check revealed that most organizations often do not allocate enough resources to train their employees in safety nor do they have adequate evacuation protocols in place. However, with ISO certification, organizations must be required to have fire escape plans in place, ensure that their employees are better protected and have random safety checks done periodically as well. - **Environment resources Protection**: With relevant ISO certification, organizations would be required to reduce their carbon footprint. This can include various activities from recycling to migrating from paper to digital mode. All of these can enable a company to reduce its carbon footprint, use more plants in the office, go green and essentially promote the idea of doing something for the protection of environment. - **Decision making**: One of the key things that are imperative for any organization is the right decision making. Organizations must decide based on an analysis of the information and processes that are followed rather than a gut feeling. ISO standards offers a structured framework for quality management, thus, ensuring the right decision making in case of being ISO certified. - **Meet the requirements specified by the government: Grabbing the government contract could be a big deal for any organization. Organization that wishes to apply for the same needs to be equipped well so that it can match the criteria specified by the government. Government tenders usually mention the ISO certification as qualifying criteria. Hence, having this certification makes your company eligible to apply for government contracts. - **Empowered Employees: One of the key criteria that any organization needs to match to get ISO certification is the training of the staff. It also provides the necessary tools for them to perform their tasks like metrics, procedures, and the right protocol. It eventually helps in making the employees more knowledgeable, and they can perform their tasks more efficiently and without flaws. - **Detailed report of the functioning of your organization: The ISO certification requires that any organization going for this must-have documented a detailed process using business metrics. The objective is to have a detailed guideline for the functioning of the organization. Moreover, this can also become a protocol for reference in the future. Also, it guarantees customers about the credibility of the organization. - **International Quality recognition: As ISO is a globally recognized quality standard, and any organization that has this certification matches up to the international quality standards. The protocol of quality management, production management or services remains the same globally. Hence, organization can approach global clients with ease. **Conclusion:** From all above discussed benefits it is certainly imperative that organizations having ISO certifications would have edge than other organizations in terms of quality, business processes, environmental aspects and many more. Hence in turn providing more business opportunities across globe. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs, QA/CSV **Tags:** ISO Certification --- ### [PHUSE's Data Transparency Winter Event - virtual](https://geninvo.com/phuses-data-transparency-winter-event-virtual/) **Published:** February 7, 2022 **Author:** admin **Content:** We are participating in the Phuse Data Transparency Virtual Event. Get in touch with us to learn more about Shadow By GENINVO, our solution to rising Data Transparency requirements. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [Youth Initiative – Introduction to Robotics Workshop](https://geninvo.com/youth-initiative-introduction-to-robotics-workshop/) **Published:** September 9, 2020 **Author:** admin **Content:** BLOOMINGTON, IL. – Sept, 2019. GENINVO believes in using technology as a catalyst to empower people and communities. Among a few of the initiatives taken, the “Introductions to Robotics” program gained momentum and became quite popular. The workshop introduced various applications of Robotics and concepts of AI/Machine Learning to youth at an early age. GENINVO hopes to inculcate a culture of curiosity in these young adults. This workshop would force them to be inclined towards science and technology from a very early age. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** news --- ### [Project Management to support GENINVO Innovation efforts](https://geninvo.com/project-management-to-support-geninvo-innovation-efforts/) **Published:** March 26, 2021 **Author:** admin **Excerpt:** Given the growth of the pharmaceutical segment, the industry needs to become increasingly better at managing pharmaceutical projects for more treatment options to become available to patient populations. **Content:** *Bhavani Jallepalli – Senior Manager, PMO* *7th Dec, 2020* Given the growth of the pharmaceutical segment, the industry needs to become increasingly better at managing projects for more treatment options to become available to patient populations. The objective of any project management pursuit is to complete the project on time, within budget, and at the required quality or performance parameters. Given the complexity and intense regulatory demands of the pharmaceutical industry, project management is more difficult than many other segments. A project is a temporary undertaking to achieve a defined outcome. Effective project management organizes and manages resources in a way that achieves project completion within the defined scope, quality, time, and budget. The temporary nature of a project, including well-defined beginning and end points, differs from permanent or semi-permanent ongoing processes used to create a pharmaceutical product repeatedly. The management of projects versus the management of ongoing processes is typically quite different. Projects begin and end to enact some sort of change within a pharmaceutical organization, such as a new product, production suite, process, etc. Therefore, pharmaceutical project managers must be effective managers of discrete change, whereas ongoing process managers need to be skillful at maintaining operations and making subtler changes over time. Mainly Project management comprises of the following steps: Step #1 – Clearly Establish Project Definition and Impacting Constraints Step #2 – Project Execution Planning Step #3 – Project Execution Step # 4 – Project Completion The traditional role of project management is to put a process in place that prevents failure. It is a linear methodology where all the phases of a process occur in sequence. Its concept depends on predictable tools and experience. Each project follows the same life cycle which includes the stages such as feasibility, planning, designing, building, testing, production, and support. Teams plan the entire project upfront without any scope for changing requirements. The rigidity of this method is the reason why it is not meant for large projects and leaves no room for changing the requirements once the project development starts. **Current Scenario** Project management is getting more demanding and agile. It is how organizations go to market sooner, deliver faster value and make customers happier bringing in higher importance to the Agile methodology. The basic concept behind Agile software development is that it delves into evolving changes and collaborative effort to bring out results rather than a predefined process. Adaptive planning is perhaps the top feature of Agile and one that makes it a favorite among project managers, worldwide. Scaled Agile frameworks like Disciplined Agile and SAFe combine Agile with Lean practices, indicating that Agile is reaching maturity. As the global pandemic disrupts our regular way of working, we see a world that demands innovation in managing our projects, our processes, and people. Virtual project management is now pertinent, as project managers spend more than half of their time on coordination and monitoring. ****The GENINVO Difference**** We make the best use of project management software that helps increase communication and collaboration. These tools empower employees to self-organize projects from start to finish and turn their own innovative ideas into reality. We provide [Custom Application Development](https://geninvo.com/our-services/custom-application-development/) services where our technical teams support solutions development in key projects and other areas. As an organization focused on innovation, we are working on building innovation and intelligence into the project management culture. Our specialized AI and ML teams built AI bots that can take care of the PM tasks in some of the following areas: - Finding innovative ways to obtain quantified customer feedback and implement the lessons learnt in the completed and ongoing projects. - Predictive analytics using data, algorithms, and AI to forecast future outcomes. Organizations can use predictive analysis to rebuild, manage future risks, and be truly resilient in the face of radical changes happening in the industry. - Employing AI to sort emails and meetings and set aside time for productive work. - Using AI to do most of the repetitive work, including compare, analyze, and approve working hours, and leave applications based on set rules. - Proposing and assigning resources to the right tasks based on their skill set. - There is still lot more opportunity for AI to help the PMO office get more organized, reduce redundancy, and increase predictability. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs --- ### [Innovation in Medical Writing](https://geninvo.com/innovation-in-pharmaceutical-area-of-medical-writing/) **Published:** March 26, 2021 **Author:** admin **Excerpt:** Innovation’ denotes new, better, more effective ways of solving problems. An innovation must be something truly new or at least significantly different, and provide a benefit to the field, with patients at the centre within healthcare domain. **Content:** *Aarti Tatke, Technical Lead – Medical Writer, GENINVO* *24th Dec, 2020* With Innovation and AI (artificial intelligence) making way into clinical research, it took time to establish a place in the medical writing domain. The process began with an attempt to automate the generation of documents that reuse clinical information. However, medical writers were not comfortable with the use of cumbersome software versus the quality of output generated. With advancements in technology, multiple options became available to the medical writers that provided meaningful alternatives to speed up the medical writing process. **Current Scenario** So far, the exercise to automate the document quality check (QC) or review process have yielded partial success. Tools today, only offer to check grammar, punctuation, language consistency and a few mere metrics. There were few challenges in bringing automation and gaining efficiency in the medical writing process: - Due to the nature of the documents, there are multiple ways of representing the data-heavy documents and no standardized format - Knowing what to focus on while performing Quality Checks in limited time is equally challenging - As requirement for each document is usually different, consistency and time allocation are tough, although they must be delivered at the earliest although QC is the last step - And finally, the QC process needs to be documented and findings need to be addressed and annotated with a justification as well. All these challenges have existed for a long time, as the amount of data gathered during clinical trials is also huge and needs to be reported in a concise manner. There are also other factors such as urgency, lack of sufficient time, changing regulatory requirements and human dependency that impact the quality of Quality Checks for Medical Writing Documents. **How we bring in the GENINVO Difference** As solution**,** due to advances in data capture, there is real-time availability of “clean data,” which leads to better time management. With enhanced communication systems and automation opportunities, the said challenges are addressable in today’s world. To be able to fully overcome the problems, organizations require a dedicated software. And that is where **[DocQC](https://geninvo.com/our-products/docqc/)** fills the gap. With DocQC, you have the following advantage: - Checks are programmable and runnable in the background so the scope of QC is defined, and writers can focus on other tasks at hand. - It can run complex checks within minutes, to verify consistency of data against source documents as well as across documents representing the same data. - Since the checks are programmable, human error is negated. Users train and test the system in advance. - For the future, simplified sequential autorun checks and the ability to read and verify data in text against respective sources should be a priority. The user should also be able to configure specific requirements on their own, as per individual project requirements. Observing the effects of change in Innovation, whether it results in failure or success, is one of the keys to improvements and developments in healthcare. When the change is something new or involves the process of introducing something new, the results should benefit healthcare. The criteria for innovation in health is then achieved. Beyond satisfying these criteria, newly introduced ideas, methods, products, and/or the process of introducing something new in healthcare face the additional burden of adoption in the field. In addition to these hurdles, external demands of stakeholders, funders, regulators, competitors, consumers, and general accountability must be met. By understanding what is innovative and what is not, as well as the barriers to adoption and implementation, we are better able to conceptualize what is necessary in the field to bring about long-lasting and large-scale developments for increased efficiency and effectiveness in various areas of healthcare. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** blogs --- ### [GENINVO Launches Centre of Excellence for Data Science and Analytics](https://geninvo.com/geninvo-launches-centre-of-excellence-for-data-science-and-analytics/) **Published:** November 16, 2021 **Author:** admin **Content:** **GENINVO Launches Centre of Excellence for Data Science and Analytics to Help Clients Unlock Insights using Data Science** **Bloomington, 16th November 2021:** GENINVO a leading provider of life sciences product and business solutions organization, announced the launch of a Centre of Excellence for Data Science and Analytics (DSA CoE). The DSA is a resolute team of experts comprising of life science and technology domains. Data Science and Analytics CoE will focus on research and development of futuristic smart technologies and creation of next-generation products and solutions for its global customers in the life science and pharmaceutical space. The CoE aims to uncover unmet needs and create solutions to overcome them as GENINVO values both, people, and innovative technologies. The primary focus of the Data Science and Analytics CoE is on leveraging technologies such as Artificial Intelligence, Machine Learning Algorithms, Deep Learning to derive actionable insights using the various data science models and concepts. GENINVO’s Scientific community can develop deep learning models to derive Image analysis and processing, help in anomaly detection amongst patterns, and develop automated solutions for life sciences. The team also excels in creating NLP pipelines powered by deep learning to extract insights from unstructured text, voice, and audio patterns. GENINVO SMEs are also working on recommendation systems that predict user preferences and provides personalized item recommendations. GENINVO has an experienced team for generation of Data Visualization charts with use of tools such as SAS, R, Tableau, Spotfire, Qlik Sense, and Power-BI. With chatbot development module, human-like conversations are now possible which would help save time and operational costs. Speaking about the importance of the Data Science and Analytics CoE, Shweta Shukla, CEO, GENINVO said, “Data science is an emerging field of science and has multiple aspects which our CoE utilizes. Intellectual capital is the greatest asset and digital transformation in medical science requires integration of people and knowledge. Data science is the bedrock of our solutions & services, and the advanced technology of AI/ML infused with data science helps draw informed insights so we can predict difficulties. The main purpose is to accelerate discoveries in our industry and help solve for future and existing long-standing challenges. Our team of Genius innovators continue to walk on a separate journey and think beyond what already exists to deliver unexpected results and innovations.” The Data Science and Analytics CoE at GENINVO will participate in various industry forums and with standardized bodies in defining the future standards for Data Science and Analytics. The CoE will collaborate with various partners such as leading Academic Institutes and open-source communities to shape up the evolution and adoption of these next-generation technologies. #### **Media References** --- [![](https://geninvo.com/wp-content/uploads/2021/08/logo-2.png "logo-2 - GenInvo")](https://www.prlog.org/12893675-geninvo-launches-centre-of-excellence-for-data-science-and-analytics-to-help-clients-unlock-insights.html) [![](https://geninvo.com/wp-content/uploads/2021/11/cropped-Black-white-gold-logo.png "cropped-Black-white-gold-logo - GenInvo")](https://onlineprnews.com/news/50014891-1637089242-geninvo-launches-centre-of-excellence-in-data-science-and-analytics-to-help-clients-unlock-insights.html/) [![](https://geninvo.com/wp-content/uploads/2021/11/logo-pr-base.png "logo-pr-base - GenInvo")](https://www.pr.com/press-release/849170) [![](https://geninvo.com/wp-content/uploads/2021/08/1888pressrelease-pr-logo.jpg "1888pressrelease-pr-logo - GenInvo")](https://www.1888pressrelease.com/geninvo-launches-centre-of-excellence-for-data-science-and-a-pr-699745.html) ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** news --- ### [PHUSE EU Connect 2021](https://geninvo.com/phuse-eu-connect-2021/) **Published:** October 8, 2021 **Author:** admin **Content:** We are here to make a dent at the PHUSE EU Connect 2021! This event is going to be in a hybrid mode, We are excited to be presenting at the Event this time. Watch out for our exciting presentataion ont the solution that is revolutionizing the life science business around the globe. Join in and drop by our representatives to say hello or even Book your personalized demos with us if you think our solutions are what your business or your customers could benefit from. [Get in touch](https://geninvo.com/contact-us/) Today! ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [How a Global Medical Writing CRO Increased Functional Capability with Shadow™](https://geninvo.com/how-a-global-medical-writing-cro-increased-functional-capability-with-shadowtm/) **Published:** March 26, 2021 **Author:** admin **Content:** - ![](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-1_Page_1-1024x576.jpg "Case Studies-1_Page_1 - GenInvo") - ![](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-1_Page_2-1024x576.jpg "Case Studies-1_Page_2 - GenInvo") - ![](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-1_Page_3-1024x576.jpg "Case Studies-1_Page_3 - GenInvo") - ![](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-1_Page_4-1024x576.jpg "Case Studies-1_Page_4 - GenInvo") - ![](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-1_Page_5-1024x576.jpg "Case Studies-1_Page_5 - GenInvo") ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** case studies **Tags:** shadow --- ### [NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) **Published:** September 17, 2021 **Author:** admin **Content:** - ![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity_Strona_1-1024x576.jpg "Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity_Strona_1.jpg - GenInvo") - ![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity_Strona_2-1024x576.jpg "Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity_Strona_2.jpg - GenInvo") - ![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity_Strona_3-1024x576.jpg "Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity_Strona_3.jpg - GenInvo") - ![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity_Strona_4-1024x576.jpg "Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity_Strona_4.jpg - GenInvo") - ![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity_Strona_5-1024x576.jpg "Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity_Strona_5.jpg - GenInvo") - ![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity_Strona_6-1024x576.jpg "Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity_Strona_6.jpg - GenInvo") - ![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity_Strona_7-1024x576.jpg "Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity_Strona_7.jpg - GenInvo") ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** Apogi, case studies **Tags:** apogi --- ### [Big Pharma Company Achieves Compliance with EMA 0070 Policy](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-ema-0070-policy-with-a-tight-deadline/) **Published:** March 26, 2021 **Author:** admin **Content:** - ![](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-2_Page_1-1024x576.jpg "Case Studies-2_Page_1 - GenInvo") - ![](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-2_Page_2-1024x576.jpg "Case Studies-2_Page_2 - GenInvo") - ![](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-2_Page_3-1024x576.jpg "Case Studies-2_Page_3 - GenInvo") - ![](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-2_Page_4-1024x576.jpg "Case Studies-2_Page_4 - GenInvo") - ![](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-2_Page_5-1024x576.jpg "Case Studies-2_Page_5 - GenInvo") ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** case studies **Tags:** shadow --- ### [DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) **Published:** September 17, 2021 **Author:** admin **Content:** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** Apogi, case studies **Tags:** apogi --- ### [Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) **Published:** September 17, 2021 **Author:** admin **Content:** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** Apogi, case studies **Tags:** apogi --- ### [Lung Cancer Detection](https://geninvo.com/lung-cancer-detection/) **Published:** September 17, 2021 **Author:** admin **Content:** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** Apogi, case studies **Tags:** apogi --- ### [Breast Cancer Detection Using Machine Learning](https://geninvo.com/breast-cancer-detection-using-machine-learning/) **Published:** September 17, 2021 **Author:** admin **Content:** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** Apogi, case studies **Tags:** apogi --- ### [Doc QC tool as a one-stop solution for all Quality Control (QC) needs of a medical writer](https://geninvo.com/doc-qc-tool-as-a-one-stop-solution-for-all-quality-control-qc-needs-of-a-medical-writer/) **Published:** August 10, 2021 **Author:** admin **Content:** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** case studies **Tags:** docqc --- ### [How a Pharmaceutical Firm Established Anonymization Process](https://geninvo.com/how-a-pharmaceutical-firm-established-anonymization-process/) **Published:** March 26, 2021 **Author:** admin **Content:** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** case studies **Tags:** shadow --- ### [How a Big Pharma Company Achieved Compliance with Health Canada Under Tight Deadlines](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-health-canada-under-tight-deadlines/) **Published:** March 26, 2021 **Author:** admin **Content:** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** case studies **Tags:** shadow --- ### [Provide ApoGI as a Metadata Driven Platform](https://geninvo.com/provide-apogitmas-a-metadatadriven-platform/) **Published:** April 27, 2021 **Author:** admin **Content:** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** Apogi, case studies **Tags:** apogi --- ### [Provide ApoGI as a MDR Visualization](https://geninvo.com/provide-apogitmas-a-mdrvisualization/) **Published:** April 27, 2021 **Author:** admin **Content:** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** Apogi, case studies **Tags:** apogi --- ### [Provide ApoGI as a Metadata Driven Transformations](https://geninvo.com/provide-apogitm-asa-metadata-driventransformations/) **Published:** April 27, 2021 **Author:** admin **Content:** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** Apogi, case studies **Tags:** apogi --- ### [NEW WEBSITE LAUNCH ANNOUNCEMENT](https://geninvo.com/new-website-launch-announcement-geninvo-launches-updated-website/) **Published:** June 15, 2021 **Author:** admin **Excerpt:** GENINVO Launches updated website **Content:** **GENINVO Launches updated website** After months of hard work and dedication, GENINVO is pleased to announce the new and updated website launch! The primary goal of the redesign process was to create a user-focused design, add improved functionality, and provide easy access to information about GENINVO’s products and services. Additionally, the design will highlight to users the dynamic and technology-driven approach to show how GENINVO is driving the Digital Transformation wave in the life sciences industry. The information is structured into various services and products categories. Case studies to highlight successful business outcome and the value add created for its clients. A new Blog section is also added to showcase industry knowledge and exhibit the technical expertise of the skilled workforce at GENINVO. “We are thrilled to debut our new company website to our clients, referral partners, and employer visitors who are looking to understand the breadth of GENINVO’s products and services,” said Shweta Shukla, GENINVO’s CEO. She further added, “This website redesign ties together all the offerings into one place and allows our clients to visualize the positive business outcome GENINVO can bring to their organizational goals.” GENINVO’s new website will be updated regularly with news of product launches, engaging blog articles, insightful case studies, and corporate milestones. Visitors are encouraged to explore the website and enquire about any of the interesting offerings at [www.geninvo.com/contact-us](https://www.geninvo.com/contact-us/). **About GENINVO** GENINVO is the go-to partner for those looking to better leverage technology in the life science industry. Our expertise in life sciences, leading-edge technologies, and software development enable us to provide innovative and transformative solutions and services to our sponsors. Our mission is to help revolutionize the industry to bring life-changing treatments to patients faster. For more information, visit https://www.geninvo.com/ Keep up to date with the latest GENINVO workshops, trade shows, seminars/webinars participation and company announcements in our Insights section. For any suggestions, questions, comments please drop a line. #### **Media References** --- [![](https://geninvo.com/wp-content/uploads/2021/08/1888pressrelease-pr-logo.jpg "1888pressrelease-pr-logo - GenInvo")](https://www.1888pressrelease.com/geninvo-new-website-launch-announcement-pr-692908.html) [![](https://geninvo.com/wp-content/uploads/2021/08/logo-2.png "logo-2 - GenInvo")](https://www.prlog.org/12878850-geninvo-launches-engaging-new-website.html) ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** news --- ### [See the Impact of Innovation](https://geninvo.com/see-the-impact-of-innovation/) **Published:** April 8, 2020 **Author:** admin **Excerpt:** Bloomington, IL- GenInvo provides a unique combination of expertise in life sciences, leading-edge technologies **Content:** GENINVO provides a unique combination of expertise in Life Sciences, leading-edge technologies, and software development. That enables us to provide innovative and transformative products, solutions, and services. During the COVID-19 pandemic, we are supporting our clients who develop, screen, and test drugs to find a treatment for this disease as fast as possible. We are proud to be a part of the solution. We see the impact of innovation up close daily, from our client’s perspective. We strive to develop efficient, innovative products and solutions for our clients to make the drug development process smarter, faster, and more cost-effective. Innovation is an essential element of our mission and success for clients. We support their journey, working collaboratively to understand the needs of their systems and processes and their current challenges within these areas. We have a strong pipeline of innovative products, built using advanced technologies to support the unmet gaps and launched state-of-the-art products, such as Shadow and DocQC. We continue to build new, robust products. ApoGI is an example of an integrated automation platform that leverages AI (artificial intelligence) and ML (machine learning) to focus on standards in metadata management. It streamlines processes and the generation of artefacts, typically associated with the clinical study lifecycle. As the Director of Innovation Solutions and Strategy, Ramesh Venkataramana said, “With many years of experience in various pharma organizations, there are gaps within the current landscape of Process/Systems/Tools usage within the respective organizations’ current legacy drug development portfolio. From study setup to closure, pharma companies look for futuristic, long-term, and efficient to deliver on time with quality on an advanced platform within a regulated environment. GENINVO has a like-minded group of talented people who understand the client’s perspective and develop innovative solutions to address these gaps sooner.” We understand the demand for people with knowledge and skills in AI and ML exceeds the supply. We continue searching for talented, experienced professionals to join us. At this critical time as COVID-19 spreads around the globe, we consider the safety of all employees and advised them to work from home. Regardless of the situation, the product development timeline is still on track. This shows the dedication of our employees and their commitment, while allowing employees to balance work and personal time spent. We support communities around the Bloomington-Normal area recently providing hundreds of lunches to a nearby school and are ready to support many more. Over the next few months, we will continue to invest advanced technology to build strong products for the Life Sciences domain while scaling to other industries. Email us with questions at . ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** news --- ### [GENINVO provides technological solutions to the problems in Life Sciences and Pharmaceutical Industry.](https://geninvo.com/geninvo-provides-technological-solutions-to-the-problems-in-life-sciences-and-pharmaceutical-industry/) **Published:** May 12, 2020 **Author:** admin **Excerpt:** The Life Sciences and Pharmaceutical works in a highly regulated environment. **Content:** The Life Sciences and pharmaceutical industry is a highly regulated environment. The regulations demand stringent quality standards achievable through technology. GENINVO does that. We deliver technological solutions for the Life Sciences and pharmaceutical Industry. Personalized service, coupled with large company capabilities, ensure we are flexible, consistent, responsive, and provide high-quality services. Because of this niche approach, we are constantly looking for ways to add value to our clients in all aspects of clinical studies. We help the pharmaceutical industry solve problems at every stage of their work. Our innovative technologies and services make research at pharmaceutical organizations simpler, faster, and safer. Innovation is our key driver as we continue developing processes, tools, and technology that accelerate data gathering, analysis, and the submission phases. Our latest innovations include Shadow™ (EMA Policy 0070 Solution), ApoGI, Outlier Detection Software, and DocQC, a medical writing tool for QC checks. Our people have years of experience in developing innovative tools and providing IT solutions services to Life Sciences companies. The Innovation and IT teams have expertise across multiple domains, including developing various tools and services and its deployment through Infrastructure-as-a-Service (IaaS), Software-as-a-Service (SaaS), or as Platform-as-a-Service (PaaS). We also offer on-premises and cloud for our products. All products have an open API system with the potential of providing different integration modules to connect. We are in an exceptional position with a dedicated, multi-talented group comprised of business, technology, project management, and software development experts. This unique combination of expertise in Life Sciences, leading-edge technologies, and software development enables teams to provide innovative and transformative solutions and services. We understand the business needs and challenges of our clients and can translate these as requirements and to address them thoroughly in our software solutions Our experience includes working with large, midsize and small clients across diverse therapeutic areas. Team members have interacted with different functions of clinical trials and delivery of fit for purpose software solutions. Our unique product-based services and commitment towards the best interest of clients makes us a trusted advisor and strategic partner. While the world is struggling to cope up with COVID-19, we are working hard to ensure our commitments and deliverables are met. We’ve supported our associates by providing opportunities to upgrade their skills, encouraging them to take online courses to keep up pace with the technological developments, and involving them in all the products in production. We will continue to invest in advanced technology to build strong products for the Life Sciences domain, while scaling to other industries. Email us with questions at . ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** news --- ### [GENINVO Celebrates Anniversary](https://geninvo.com/geninvo-anniversary/) **Published:** July 9, 2020 **Author:** admin **Excerpt:** A year ago, GENINVO was carved out of a CRO to provide innovative technology solutions **Content:** A year ago, we launched GENINVO to provide innovative technology solutions and services to the Life Sciences industry. The objective was to enable them to deliver drugs faster with higher quality and cost-efficiency. Today GENINVO partners with all sizes of biopharma companies around the world, and we are on our way to being the number one recognized partner for software solutions and services for the Biopharma industry. GENINVO CEO Shweta said, “We are excited to be headquartered in Bloomington, IL. This town is a great fit for our company, and I see a long-lasting relationship with the community. GENINVO’s journey from inception as an independent company has been a remarkable one. We set an exemplary standard with our work ethic and dedication. The successful growth of our company is a direct result of our employees and their passion to excel. It is their sheer commitment that drives our operations and has built enormous confidence in our clients.” Asked about her plans for the future, Mrs. Shukla said, “Modernizing the pharmaceutical industry is the mission of the company. We are growing each day and working hard on enhancing our products and developing new solutions to achieve the mission for pharmaceutical companies located all around the world. Our team is a perfect combination of professionals with expertise in Life Sciences, leading-edge technologies, and software development. This gives us the edge to provide truly innovative and transformative solutions and services to our clients and to the entire industry, to help bring life-changing treatments to patients faster.” By choosing our headquarters in Central Illinois, GENINVO puts Bloomington on the map for providing a home for a one-of-a-kind company known for their technology all around the world. [](https://www.geninvo.com/wp-content/uploads/2020/07/gi_shadow_july_anniv.pdf) ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** news --- ### [COVID-19](https://geninvo.com/covid-19/) **Published:** March 13, 2020 **Author:** admin **Excerpt:** GenInvo is taking steps to keep our employees safe while continuing to serve our customers. **Content:** **GENINVO** is taking steps to keep our employees safe while continuing to serve our customers. In response to concerns about the spread of **COVID-19**, we are implementing social distancing in the workplace and instructing employees who can, to work from home. **COVID-19** is a disease caused by a specific virus **(SARS-CoV-2)** and labeled in the press as “coronavirus” or “novel coronavirus.” Much about the disease is not currently known. While public health officials are still determining the medical impacts of the virus along with certain key characteristics, such as the incubation period, we believe the economic impact will, in part, depend on how the public reacts to the virus. Public reaction could allow the disease to spread more quickly and widely, or it could create unnecessary costs. ###### Useful links: [World Health Organization: WHO](https://www.who.int/emergencies/diseases/novel-coronavirus-2019)[Centers for Disease Control and Prevention](https://www.cdc.gov/) ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** news --- ### [Standing strong with Community](https://geninvo.com/standing-strong-with-community/) **Published:** March 18, 2020 **Author:** admin **Excerpt:** In these trying times, the GenInvo team is ensuring school kids don’t go hungry. **Content:** In these trying times, the **GENINVO** team is ensuring school kids don’t go hungry. In our hometown, there are many kids who depend on schools for providing their lunch for free every day. With school closures due to COVID-19, we provided several hundred lunch packets to a nearby school. If you are in Bloomington/Normal (IL) area, and if you read this message, please make sure to reach out to your nearby schools and find out how each one of you can help ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** news --- ### [GENINVO Announces Upcoming Version Launch of Shadow™](https://geninvo.com/geninvo-announces-upcoming-launch-of-shadow-version-2/) **Published:** June 16, 2020 **Author:** admin **Excerpt:** GenInvo's CEO Shweta Shukla, announces the upcoming launch of Shadow™ Version 2 **Content:** GENINVO CEO Shweta Shukla, announced the upcoming launch of Shadow™ Version 2. Shweta took this opportunity to thank the team. “I would like to thank our teams for staying on track during these stressful times. While it is easier to lose focus of what is important during COVID-19 pandemic, our teams are working from home and using this as an opportunity to bond with their teammates and collaborate with one another. As we build our business, we continue to work relentlessly, while taking care of our loved ones at this time of need. COVID-19 brought new challenges, but our teams have done a spectacular job in adapting to these unexpected situations and supporting our clients.” She further added, “We have adapted quickly and successfully with this changing economy and working conditions. We continuously focus on becoming a strong company and even stronger employees that already know how to work productively from home. Taking advantage of best in the class collaborative tools, internal webinars, newsletters, and social posts, we stayed in touch and collaborated. We continue to address the safety of our employees, as business operates as usual.” We would also like to announce the upcoming launch of [Shadow™](https://www.geninvo.com/shadow/) Version 2 of data transparency solution. [Shadow™](https://www.geninvo.com/shadow/) is a leader in automating data and document de-identification and anonymization technology. This robust technology can determine risk for re-identification of patients and determination of data utility after anonymization. It also can generate an anonymization report. With Version 2, it will be AI/ML enabled and address the need of different health authorities including Health Canada. We are supporting customers with submissions to Health Canada. Additionally, we have more SMEs on our team to support our pharmaceutical clients in agile fashion. GENINVO has other technologies including DocQC™ for automated QC of documents and ApoGI, a platform for managing data and metadata while interacting with different functions in pharmaceuticals. GENINVO will continue to enable and support our clients in their journey, working collaboratively to understand the needs of their systems, processes, and current challenges within the Life Sciences industry. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** news --- ### [GENINVO Launches Shadow™ Version 2](https://geninvo.com/geninvo-launches-shadow-version-2/) **Published:** November 6, 2020 **Author:** admin **Excerpt:** On behalf of GenInvo and our Innovative Solutions team, I am very excited **Content:** GENINVO Senior Innovation Officer, Tom Kalfas, announced the launch of Shadow™ Version 2. He said, “On behalf of GENINVO and our Innovative Solutions Team, I am very excited to announce the launch of the second major release of Shadow, our data transparency solution.” Since its first release, Shadow has already become an industry-leading software innovation, automating the anonymization of clinical trial data and documents in support of global data transparency initiatives, such as EMA Policy 0070 and Health Canada’s PRCI (Public Release of Clinical Information). In the second generation, we introduced several new time and cost-saving efficiencies to streamline the anonymization process further for our users. We also introduced new key capabilities such as “Auto RA,” a data-driven method for quickly determining the most effective combination of anonymization methods to apply and a CCI Justification Table generator (supporting both EMA and Health Canada formats) to complete the anonymization package for our users. With leading-edge technologies, including AI and ML, Shadow 2 was designed to become increasingly more intelligent and easier to use based on the feedback of its user community. Shadow enhances the speed and efficiency of anonymization activity by reducing manual intervention and minimizing the risk of patient reidentification while maintaining data utility. Shadow addresses the evolving global data transparency requirements, allowing its users and their teams to focus on innovative science and results. While we are all quite proud of the what the team has achieved, we are even more excited about the opportunities this new design makes possible and the innovations already in progress to support additional anonymization use cases and next-gen capabilities. GENINVO has other technologies including DocQC™ for automated QC of documents and ApoGI, a platform for managing data and metadata while interacting with different functions in pharmaceuticals. GENINVO will continue to enable and support our clients in their journey, working collaboratively to understand the needs of their systems, processes, and current challenges within the Life Sciences industry. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** news --- ### [PHUSE US Connect 2021](https://geninvo.com/phuse-us-connect-2021/) **Published:** May 19, 2021 **Author:** admin **Content:** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [PHUSE Data Transparency Summer Event](https://geninvo.com/phuse-data-transparency-summer-event/) **Published:** May 19, 2021 **Author:** admin **Content:** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [Analyst/Lead – CSV/QA](https://geninvo.com/analyst-lead-csv-qa/) **Published:** March 31, 2021 **Author:** admin **Content:** ##### **MAIN DUTIES/RESPONSIBILITIES:** - At a minimum, following activities are required to be performed; - Validation and Qualification activities for the infrastructure, systems and processes for GxP compliance throughout GENINVO. - Oversee the Organization’s quality assurance organization to insure efficiency, quality, service, and cost-effective management of resources. - Work Closely with QA Manager on GxP audit programs for internal and external facilities as well as vendors and sub-contractors. This will include all study/project audits, any deviations, CAPA and subsequent reporting programs that advise the study/project director for potential impact. - Work Closely with QA Manager on managing client issues and expectations with regards to organizational quality systems. - Review of Project/Study documents for accuracy and completeness. - Co-ordinate with the development staff to assure that the quality level and standard operating procedures within the organisation are implemented into the study/project from inception till end. - Investigating customer complaints. - Perform other roles and responsibilities as assigned by the senior management ##### **SKILLS & EXPERIENCE** - Bachelor’s degree from a reputed university preferably in life science related fields - Must have excellent knowledge of cGxPs, Quality standards, industry best practices and regulatory affairs for life sciences and IT processes. - Expertise in regulatory affairs and requirements for clinical research processes. - Sound knowledge of aspects of SAS programming, project management, pharmacovigilance systems, clinical data management, data submissions, clinical trial monitoring. - Strong capability to execute audits, facilitate and drive investigations, root cause analysis, and corrective and preventive actions. - Good understanding of quality and project management methodologies. - Excellent knowledge of SDLC methodologies, software testing and validation & verification ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** job --- ### [Analyst/Engineer-AI/ML](https://geninvo.com/analyst-engineer-ai-ml/) **Published:** March 31, 2021 **Author:** admin **Content:** ##### **MAIN DUTIES/RESPONSIBILITIES** - Study and transform data science prototypes - Design machine learning systems - Research and implement appropriate ML algorithms and tools - Develop machine learning applications according to requirements - Select appropriate datasets and data representation methods - Run machine learning tests and experiments - Perform statistical analysis and fine-tuning using test results - Train and retrain systems when necessary - Extend existing ML libraries and frameworks - Keep abreast of developments in the field ##### **SKILLS & EXPERIENCE** - BSc in Computer Science, Mathematics or similar field; Master’s degree is a plus - Junior to Senior Level, 2+ Years of relevant field Experience - Proven experience as a Machine Learning Engineer or similar role - Understanding of data structures, data modeling and software architecture - Deep knowledge of math, probability, statistics and algorithms - Ability to write robust code in Python, Java and R ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** job --- ### [Analyst–IT and Security Compliance](https://geninvo.com/analyst-it-and-security-compliance/) **Published:** March 31, 2021 **Author:** admin **Content:** ##### **MAIN DUTIES/RESPONSIBILITIES** - In the role of Security Compliance Analyst you will be involved in activities such as: - Delivery of and reporting on the status of all IT audit recommendations - Developing the security and compliance strategy - Assist with the development of control frameworks to meet business and regulatory requirements - Establish current security baseline and 3 year rolling business plan - Assisting in developing security and compliance strategy ##### **SKILLS & EXPERIENCE** - Must have a Bachelor’s degree in Computer Science / Bachelor’s in Engineering or equivalent - Successful design and management of security compliance programmes - Proven portfolio within security compliance - Good to have Certified with CISSP, CISM, CISA etc - In depth understanding of standards including ISO ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** job --- ### [GENINVO Anniversary](https://geninvo.com/geninvo-anniversary-2/) **Published:** April 6, 2021 **Author:** admin **Content:** GENINVO Celebrates another year of achieving business excellence in Pharmaceutical and Life-sciences businesses around the world. Learn more about our industry breakthrough products at www.geninvo.com ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** videos --- ### [Shadow- Risk Analysis Tool](https://geninvo.com/shadow-risk-analysis-tool/) **Published:** April 6, 2021 **Author:** admin **Content:** Determine the risk for re-identification of your data before and after de-identification to ensure you meet required thresholds. It’s Your Solution to Evolving Data Transparency Requirements. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** videos --- ### [GENINVO](https://geninvo.com/geninvo-video/) **Published:** April 6, 2021 **Author:** admin **Content:** Go-to life sciences partner for innovative software solutions ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** videos --- ### [GENINVO - Covid-19](https://geninvo.com/geninvo-covid-19/) **Published:** April 6, 2021 **Author:** admin **Content:** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** videos --- ### [Architect – Data Science (Deep Learning and NLP Expert)](https://geninvo.com/architect-data-science-deep-learning-and-nlp-expert/) **Published:** March 31, 2021 **Author:** admin **Content:** We are solving today’s most complex analytics problems, making the lives of our colleagues easier and more productive, and driving our mission to deliver exceptional solutions to our customers. We are passionate about learning new ways to get the most value from our massive data resources. We are partnering to incorporate analytics into every aspect of the enterprise. Developing ourselves and others is key to our success. ##### **RESPONSIBILITIES** As a Sr. Data Scientist authority in these areas you will be responsible for researching, developing, and improving algorithms that help computers learn from text. Our goal is to reduce the time and expense of performing traditionally manual tasks, growing efficiency and reducing costs. By extracting data sets containing millions of documents, you will help to develop NLP capabilities to improve the speed and ease with which we service our client. Additionally, you will be able to responsible for: - Conducting state of the art research in Natural Language Processing (NLP and NER) - Research and application of state-of-the-art deep learning techniques to inform key strategic recommendations and decisions - Advising/mentoring data scientists and business partners on applying NLP in their work - Training staff and clients on AI/ML and ML/DL techniques ##### **QUALIFICATIONS** - Expertise developing natural language processing/understanding algorithms/models required - Expertise applying deep learning techniques to NLP/U problems required including thorough knowledge of the theory and practice of NLP and deep-learning techniques - Strong experience in other machine learning, or artificial intelligence algorithms/models required - Strong coder, with experience building models and analyzing data using machine learning tools (Python, Matlab) and deep learning tools (TensorFlow, Keras). Software development experience a plus. - Strong experience implementing models in production - Ability to craft new concepts and stay current with academic research. Published research a plus. - Strong experience working with non-technical stakeholders. - Ability to summarize research and analysis for audiences with varying levels of expertise. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** job --- ### [Analyst/Architect – Data Science](https://geninvo.com/analyst-architect-data-science/) **Published:** March 24, 2021 **Author:** admin **Content:** ##### **RESPONSIBILITIES:** As a Data Scientist, you will be responsible for: - Proactively assisting in management of several clients, while reporting to management across multiple levels of our organization - Training and leading staff for your assigned projects and initiatives - Establish effective working relationships directly with clients - Contribute to the development of your own and team’s technical expertise - Keep up on research related to data science, trends, and potential applications/products - Support of business development activities to help identify and research opportunities on new and existing clients and products ##### **QUALIFICATIONS:** - Bachelor’s degree - Computer and Information Science, Management Information Systems or related degree - 4 years’ experience in Computer Science, Mathematics, or Statistics or related field/industry ##### **PREFERRED QUALIFICATIONS** - Demonstrates thorough knowledge of contributing on client engagement teams that design and develop business intelligence (BI) and predictive models for data warehouse (DW) information management architecture - Evaluating enterprise DW architecture feasibility, risk and technologies related to business change (i.e. assessing, identifying and recommending BI and related business stakeholders’ data requirements; BI solution prototyping and development; processes and performance from business and technical standpoints; and the impact of data changes on business and IT processes) - Advising CXO’s on emerging BI/DW technologies and strategies consistent with clients’ business strategies - Prioritizing, preparing and implementing BI and/or DW architectural improvements (i.e. developing and recommending alternative DW technical and data management solutions, methodologies, strategies and architectural improvement plans) - Developing and validating business stakeholders’ conceptual data models, including socializing and implementing logical and physical DW/data mart data models; identifying data sources and metadata (including business rules, definitions, attributes) to deliver analytic requirements - Demonstrates thorough abilities to interact with end users to understand and document business and functional requirements for complex projects, including full software development life cycle, DW/BI/ETL tools and other related technologies - Enterprise data management, data warehousing and/or business intelligence; data modeling, integration and/or synchronization, quality, security, conversion and analysis; database administration; enterprise data management policies, procedures, compliance and risk management. This includes a minimum of having participated in two full life cycle implementations. - Architecture, design and development of enterprise business intelligence and data warehousing solutions, including utilizing leading ETL/BI tools and the ability to engineer a solution - Design and development of data cleansing routines utilizing typical data quality functions involving standardization, transformation, rationalization, linking and matching that leverages knowledge within data, master data, metadata and technology management - Demonstrates proven thorough skills and success participating in consulting-related projects within a professional services environment that utilize creative thinking skills and individual initiative: - Collaborates and contributes as a team member, understanding personal and team roles, contributing to a positive working environment by building solid relationships with team members, proactively seeking guidance, clarification and feedback - Identifies and addresses client needs, building solid relationships with clients, developing an awareness of GenInvo services, approaching clients in an organized manner, delivering clear requests for information, demonstrating flexibility in prioritizing and completing tasks, communicating potential conflicts to upper management - Prioritizes and handles multiple tasks, researching and analyzing pertinent client, industry, and technical matters, utilizing problem-solving skills, communicating effectively in written and verbal formats to various audiences (including various levels of management and external clients) in a professional business environment ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** job --- ### [Architect/Analyst – Fullstack](https://geninvo.com/architect-analyst-fullstack/) **Published:** April 6, 2021 **Author:** admin **Content:** ##### **MAIN DUTIES/RESPONSIBILITIES** - Work with development teams and product managers to ideate software solutions - Design client-side and server-side architecture - Build the front-end of applications through appealing visual design - Develop and manage well-functioning databases and applications - Write effective APIs - Test software to ensure responsiveness and efficiency - Troubleshoot, debug and upgrade software - Create security and data protection settings - Build features and applications with a mobile responsive design - Write technical documentation - Work with data scientists and analysts to improve software ##### **SKILLS & EXPERIENCE** - BSc in Computer Science, Technology, Mathematics or similar field; Master’s degree is a plus - Junior to Senior Level, 0- 8+ Years of relevant field Experience. - Knowledge of multiple front-end languages and libraries ,JAVA, J2EE, Spring, Spring boot, Webservices(soap/restful), Serverless, NodeJS, JavaScript, Typescript, jQuery, AngularJS (1.X), Angular, XML, HTML/HTML5, BOOTSTRAP, CSS, PYTHON and or R, CI/CD Tools, SQL/NoSQL, Hibernate, JPA. - Knowledge of multiple back-end languages (e.g. C#, Java, Python) and JavaScript frameworks (e.g. Angular, React, Node.js) - Familiarity with databases (e.g. MySQL, MongoDB), web servers (e.g. Apache) and UI/UX design ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** job --- ### [Business Development Executive/Manager](https://geninvo.com/business-development-executive-manager/) **Published:** April 6, 2021 **Author:** admin **Content:** ##### **MAIN DUTIES/RESPONSIBILITIES:** - Contacting potential clients to establish rapport and arrange meetings. - Planning and overseeing new marketing initiatives. - Researching organizations and individuals to find new opportunities. - Increasing the value of current customers while attracting new ones. - Finding and developing new markets and improving sales. - Attending conferences, meetings, and industry events. - Developing quotes and proposals for clients. - Developing goals for the development team and business growth and ensuring they are met. - Training personnel and helping team members develop their skills. ##### **SKILLS & EXPERIENCE** - Bachelor’s degree in business, marketing or related field. - Experience in sales, marketing or related field. - Strong communication skills and IT fluency. - Ability to manage complex projects and multi-task. - Excellent organizational skills. - Ability to flourish with minimal guidance, be proactive, and handle uncertainty. - Proficient in Word, Excel, Outlook, and PowerPoint. - Comfortable using a computer for various tasks. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** job --- ### [Project Manager](https://geninvo.com/project-manager/) **Published:** April 6, 2021 **Author:** admin **Content:** ##### **MAIN DUTIES/RESPONSIBILITIES** - Coordinate internal resources and third parties/vendors for the flawless execution of projects - Ensure that all projects are delivered on-time, within scope and within budget - Developing project scopes and objectives, involving all relevant stakeholders and ensuring technical feasibility - Ensure resource availability and allocation - Develop a detailed project plan to track progress - Use appropriate verification techniques to manage changes in project scope, schedule and costs - Measure project performance using appropriate systems, tools and techniques - Report and escalate to management as needed - Manage the relationship with the client and all stakeholders - Perform risk management to minimize project risks - Establish and maintain relationships with third parties/vendors - Create and maintain comprehensive project documentation ##### **SKILLS & EXPERIENCE** - Great educational background, preferably in the fields of computer science or engineering. - 10+ Years, Senior Level - Project managers should have a background in business skills, management, budgeting and analysis.. - Proven working experience as a project administrator in the information technology sector - Solid technical background, with understanding or hands-on experience in software development and web technologies - Excellent client-facing and internal communication skills - Excellent written and verbal communication skills - Solid organizational skills including attention to detail and multi-tasking skills - Strong working knowledge of Microsoft Office - PMP / PRINCE II certification is a plus ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** job --- ### [DocQC](https://geninvo.com/docqc-video/) **Published:** April 6, 2021 **Author:** admin **Content:** Medical Writers automation tool for QC checks ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** videos --- ### [ApoGI](https://geninvo.com/apogi-video/) **Published:** April 6, 2021 **Author:** admin **Content:** Automated Metadata Management at your fingertips ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** videos --- ### [Shadow](https://geninvo.com/shadow-video/) **Published:** April 6, 2021 **Author:** admin **Content:** Your Solution to Evolving Data Transparency Requirements ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** videos --- ### [Machine Learning - Shadow](https://geninvo.com/machine-learning-shadow/) **Published:** April 6, 2021 **Author:** admin **Content:** While Unstructured Content remains ‘Challenge’ for many, we took as an ‘Opportunity’. GenInvo’s very own in-house product Shadow™ utilizes advanced Deep Learning and NLP libraries for complex tasks. NLP leverages cognitive algorithms while Deep learning excels at identifying patterns with the help of its neural network structure. All of this leads to enhanced user experience. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** videos --- ### [Shadow - Solution to Evolving Data Transparency Requirements](https://geninvo.com/shadow-solution-to-evolving-data-transparency-requirements/) **Published:** April 6, 2021 **Author:** admin **Content:** Built from the ground up by the innovative time at GenInvo, a team comprised of both Life Sciences and software development professionals ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** videos --- ### [Shadow - Health Canada, France’s MR001-MR004, EMA Policy 0070 (Phase 1 and 2), compliant](https://geninvo.com/shadow-health-canada-frances-mr001-mr004-ema-policy-0070-phase-1-and-2-compliant/) **Published:** April 6, 2021 **Author:** admin **Content:** Shadow™ alleviates the pain points of homegrown software utilities that often prove to be inefficient, difficult to maintain, and slow to match quickly evolving requirements. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** videos --- ### [DocQc - Medical Writer's Best Friend](https://geninvo.com/docqc-medical-writers-best-friend/) **Published:** April 6, 2021 **Author:** admin **Content:** Medical Writing – Quality Control Tool ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** videos --- ### [Shadow- Data Anonymization Tool](https://geninvo.com/shadow-data-anonymization-tool/) **Published:** April 6, 2021 **Author:** admin **Content:** Know Shadow With Geninvo – Shadow is a leader in automating Data and Document De-Identification and Anonymization technology. It’s Your Solution to Evolving Data Transparency Requirements. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** videos --- ### [DocQC - Medical Writers automation tool for QC checks](https://geninvo.com/docqc-medical-writers-automation-tool-for-qc-checks/) **Published:** April 6, 2021 **Author:** admin **Content:** DocQC is a standalone software-as-a-service application, also available in platform-as-a-service, or on-premise configurations. The accuracy and consistency of clinical trial documentation is key to successful submissions. With so many different source documents contributing to a single clinical study report, checking accuracy and traceability is mandatory. Manual document checking, particularly of embedded tables and listings, is particularly time consuming.. DocQC automates the checking of your submission document quality, saving valuable time for you to focus on the scientific integrity and regulatory compliance. This short video shows how DocQC can be integrated into your document quality control freeing you to concentrate on content. ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** videos --- ### [Phuse EU Connect](https://geninvo.com/phuse-eu-connect/) **Published:** November 23, 2019 **Author:** admin **Content:** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [CBI - Clinical Trial Disclosure and Data Transparency DBA: Informa Connect](https://geninvo.com/cbi-clinical-trial-disclosure-and-data-transparency-dba-informa-connect/) **Published:** January 23, 2020 **Author:** admin **Content:** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [ISCR Conference 2020](https://geninvo.com/iscr-conference-2020/) **Published:** January 25, 2020 **Author:** admin **Content:** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [PhUSE US Connect 2020](https://geninvo.com/phuse-us-connect-2020/) **Published:** March 5, 2020 **Author:** admin **Content:** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [DIA's Digital Technology in Clinical Trials conference](https://geninvo.com/dias-digital-technology-in-clinical-trials-conference/) **Published:** March 27, 2020 **Author:** admin **Content:** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [ACRP - Association of Clinical Research Professionals](https://geninvo.com/acrp-association-of-clinical-research-professionals/) **Published:** April 30, 2020 **Author:** admin **Content:** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [EMWA Prague 2020](https://geninvo.com/emwa-prague-2020/) **Published:** May 2, 2020 **Author:** admin **Content:** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [PHUSE Data Transparency 2020 Multi-day - Virtual Meeting](https://geninvo.com/phuse-data-transparency-2020-multi-day-virtual-meeting/) **Published:** June 2, 2020 **Author:** admin **Content:** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [DIA 2020 Global Annual Meeting - Virtual Meeting](https://geninvo.com/dia-2020-global-annual-meeting-virtual-meeting/) **Published:** June 10, 2020 **Author:** admin **Content:** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [DIA's Digital Technology in Clinical Trials - Virtual Meeting](https://geninvo.com/dias-digital-technology-in-clinical-trials-virtual-meeting/) **Published:** September 1, 2020 **Author:** admin **Content:** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [Publication & Clinical Trial Transparency - Virtual](https://geninvo.com/publication-clinical-trial-transparency-virtual/) **Published:** September 22, 2020 **Author:** admin **Content:** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ### [Global Clinical Trial Disclosure & Data Transparency Conference - Virtual Event](https://geninvo.com/global-clinical-trial-disclosure-data-transparency-conference-virtual-event/) **Published:** October 12, 2020 **Author:** admin **Content:** ![author avatar](https://secure.gravatar.com/avatar/68b7883710357528860fd6d284e85de9ad0ea12e195c25e1fa1ccec8b0c4d1ce?s=300&d=mm&r=g) admin [See Full Bio](https://geninvo.com/author/admin/) [ ](https://geninvo.com/author/admin/) **Categories:** events --- ## Pages ### [GENINVO](https://geninvo.com/) **Published:** February 14, 2022 **Author:** admin **Content:** # Redefining The Clinical Study Landscape Through Next-Gen AI Powered Solutions [ Explore Solutions ](https://geninvo.com/our-products/) ## Industry Leadership and Certificates for Compliance ![](https://geninvo.com/wp-content/uploads/2021/03/SOC-2-Compliance-Badge_Dark.svg "SOC 2 Compliance Badge_Dark - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/03/ISO-27001-Compliance-Badge_Dark.svg "ISO 27001 Compliance Badge_Dark - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2026/03/ISO-9001-Compliance-Badge_Dark-1024x1024.png "ISO 9001 Compliance Badge_Dark - GenInvo - GenInvo") ## Our Products ## Experience our Product Portfolio All GENINVO products are scalable, secure, and customizable. Our industry-leading Life Science products also come with plug-and-play modules and off-the-shelf licensing for hassle-free deployment with existing infrastructure. [![](https://geninvo.com/wp-content/uploads/2024/12/Shadow.webp "Shadow - GenInvo - GenInvo")](https://geninvo.com/our-products/data-anonymization-tool/)### [Data and Document Anonymization Solution](https://geninvo.com/our-products/data-anonymization-tool/) [![Badge Showing a Teal Shield with a White Circular Emblem and a Bright Green Checkmark, Labeled Confidential Information Scanner. 1/2/3? (informative Badge)](https://geninvo.com/wp-content/uploads/2026/06/CIS-3d-logo-24-V1.png "CIS-3d-logo-24-V1 - GenInvo - GenInvo")](https://geninvo.com/cis-confidential-information-scanner/)### [AI-Powered CCI Redaction Tool for Regulatory Compliance](https://geninvo.com/cis-confidential-information-scanner/) [![](https://geninvo.com/wp-content/uploads/2024/12/Datalution.webp "Datalution - GenInvo - GenInvo")](https://geninvo.com/our-products/datalution/)### [Automation of Synthetic Data Generation](https://geninvo.com/our-products/datalution/) [![](https://geninvo.com/wp-content/uploads/2024/12/DocQC.webp "DocQC - GenInvo - GenInvo")](https://geninvo.com/our-products/docqc-medical-writing-automation/)### [Quality Checks Automation Tool for Medical Writers](https://geninvo.com/our-products/docqc-medical-writing-automation/) [![](https://geninvo.com/wp-content/uploads/2026/06/image-33-scaled.png "image 33 - GenInvo - GenInvo")](https://geninvo.com/codemagic/)### [AI Statistical Programming Automation Tool](https://geninvo.com/codemagic/) [![](https://geninvo.com/wp-content/uploads/2024/12/DocWright.webp "DocWright - GenInvo - GenInvo")](https://geninvo.com/our-products/docwrightai/)### [Document Generation Software](https://geninvo.com/our-products/docwrightai/) [![](https://geninvo.com/wp-content/uploads/2026/06/GI-DC-3d-logo-24-V1.png "GI-DC 3d-logo-24-V1 - GenInvo - GenInvo")](https://geninvo.com/our-products/data-collaboration/)### [Data Collaboration Platform](https://geninvo.com/our-products/data-collaboration/) ## Upcoming Events [ ![Geninvo at Dpharm 2026 Banner: Sept 15–16, 2026 in Boston, Usa; Sheraton Boston Hotel Exhibition Booth #116.](https://geninvo.com/wp-content/uploads/2026/06/DPHARM-1.png "Meet Geninvo at DPHARM 2026 — Booth 116, Boston - GenInvo - GenInvo") ](https://geninvo.com/dpharm-2026/) ###### [Meet GenInvo at DPHARM 2026, Booth 116, Boston](https://geninvo.com/dpharm-2026/) - [ June 4, 2026 ](https://geninvo.com/2026/06/04/) - 11:59 am [ Read More ](https://geninvo.com/dpharm-2026/) [ ![Geninvo Booth 10 at Emwa 61st Spring Conference 2026 Barcelona.](https://geninvo.com/wp-content/uploads/2026/04/539-X-334-1.png "539 X 334 1 - GenInvo - GenInvo") ](https://geninvo.com/emwa-2026-barcelona/) ###### [Meet GENINVO at the EMWA 61st Spring Conference 2026](https://geninvo.com/emwa-2026-barcelona/) - [ April 21, 2026 ](https://geninvo.com/2026/04/21/) - 10:13 am [ Read More ](https://geninvo.com/emwa-2026-barcelona/) [ ![](https://geninvo.com/wp-content/uploads/2026/04/539-X-334.png "539 X 334 - GenInvo - GenInvo") ](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) ###### [GenInvo at PharmaSUG 2026 SDE Conference](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) - [ April 10, 2026 ](https://geninvo.com/2026/04/10/) - 12:18 pm [ Read More ](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) « PreviousPage1[Page2](https://geninvo.com/wp-cron.php/page/2/?doing_wp_cron=1783869150.2234899997711181640625)[Page3](https://geninvo.com/wp-cron.php/page/3/?doing_wp_cron=1783869150.2234899997711181640625)[Page4](https://geninvo.com/wp-cron.php/page/4/?doing_wp_cron=1783869150.2234899997711181640625)[Page5](https://geninvo.com/wp-cron.php/page/5/?doing_wp_cron=1783869150.2234899997711181640625)[Next »](https://geninvo.com/?e-page-5a15dfe=2) ## Latest Blogs [ ![](https://geninvo.com/wp-content/uploads/2025/10/Blog-12.jpg "Blog-12 - GenInvo - GenInvo") ](https://geninvo.com/quantitative-risk-assessment-a-smarter-approach-to-clinical-data-anonymization/) ###### [Quantitative Risk Assessment: A Smarter Approach to Clinical Data Anonymization ](https://geninvo.com/quantitative-risk-assessment-a-smarter-approach-to-clinical-data-anonymization/) - [ October 27, 2025 ](https://geninvo.com/2025/10/27/) - 3:30 pm [ Read More ](https://geninvo.com/quantitative-risk-assessment-a-smarter-approach-to-clinical-data-anonymization/) [ ![](https://geninvo.com/wp-content/uploads/2025/09/Blog-11.jpg "Blog-11 - GenInvo - GenInvo") ](https://geninvo.com/secure-scanning-with-confidential-information-scanner-safeguarding-your-ccis-during-clinical-research/) ###### [Secure Scanning with Confidential Information Scanner: Safeguarding Your CCIs During Clinical Research](https://geninvo.com/secure-scanning-with-confidential-information-scanner-safeguarding-your-ccis-during-clinical-research/) - [ September 16, 2025 ](https://geninvo.com/2025/09/16/) - 11:52 am [ Read More ](https://geninvo.com/secure-scanning-with-confidential-information-scanner-safeguarding-your-ccis-during-clinical-research/) [ ![Clinical Trials](https://geninvo.com/wp-content/uploads/2025/08/Blog-8.jpg "Blog-8 - GenInvo - GenInvo") ](https://geninvo.com/pythons-future-in-clinical-trials-innovations-and-collaborative-advancements/) ###### [Python’s Future in Clinical Trials: Innovations and Collaborative Advancements](https://geninvo.com/pythons-future-in-clinical-trials-innovations-and-collaborative-advancements/) - [ August 13, 2025 ](https://geninvo.com/2025/08/13/) - 6:41 am [ Read More ](https://geninvo.com/pythons-future-in-clinical-trials-innovations-and-collaborative-advancements/) « PreviousPage1[Page2](https://geninvo.com/wp-cron.php/page/2/?doing_wp_cron=1783869150.2234899997711181640625)[Page3](https://geninvo.com/wp-cron.php/page/3/?doing_wp_cron=1783869150.2234899997711181640625)[Page4](https://geninvo.com/wp-cron.php/page/4/?doing_wp_cron=1783869150.2234899997711181640625)[Page5](https://geninvo.com/wp-cron.php/page/5/?doing_wp_cron=1783869150.2234899997711181640625)[Next »](https://geninvo.com/?e-page-f6ad6b2=2) ## Our Locations ## Global Reach Accross 3+ Countries ![](https://geninvo.com/wp-content/uploads/2026/04/MAP.webp "MAP - GenInvo - GenInvo") ![animated gif](https://geninvo.com/wp-content/uploads/2025/10/location.gif)**US OFFICE** info@geninvo.com +1 309-807-5006 ![animated gif](https://geninvo.com/wp-content/uploads/2025/10/location.gif)**INDIA OFFICE** info@geninvo.com 0171-26604-10 ![animated gif](https://geninvo.com/wp-content/uploads/2025/10/location.gif)**UK OFFICE** info@geninvo.com 0171-26604-10 ![animated gif](https://geninvo.com/wp-content/uploads/2025/10/location.gif)**CANADA OFFICE** info@geninvo.com 0171-26604-10 --- ### [Shadow](https://geninvo.com/our-products/data-anonymization-tool/) **Published:** March 19, 2021 **Author:** admin **Content:** ![](//geninvo.com/wp-content/uploads/2026/04/Top-section.webp) image-1 [![](//geninvo.com/wp-content/uploads/2024/06/Sha-c-1-1.png)](https://geninvo.com/our-products/data-anonymization-tool/) [Shadow™](https://geninvo.com/our-products/data-anonymization-tool/) Your Solution to Evolving Data Transparency Requirements [View Brochure](https://geninvo.com/wp-content/uploads/2026/06/Shadow.pdf) [Anonymization As a Service](https://geninvo.com/our-services/anonymization-as-a-service/) [Shadow™](https://geninvo.com/our-products/data-anonymization-tool/) Your Solution to Evolving Data Transparency Requirements [View Brochure](https://geninvo.com/wp-content/uploads/2026/06/Shadow.pdf) [CIS Tool](https://geninvo.com/cis-confidential-information-scanner/) [Anonymization As a Service](https://geninvo.com/our-services/anonymization-as-a-service/) [![](//geninvo.com/wp-content/uploads/2024/06/Sha-c-1-1.png)](https://geninvo.com/our-products/data-anonymization-tool/) # Shadow™ Clinical Data De-Identification & Anonymization Tool Shadow™ is an advanced clinical data de-identification tool for CROs, designed to help Life Sciences organizations accelerate regulatory submissions while maintaining complete compliance, control, and data integrity. As a next-generation data anonymization tool pharma companies trust, Shadow™ unifies [EMA Policy 0070 compliance software](https://www.ema.europa.eu/en/homepage), 21 CFR Part 11 data masking, CDISC SDTM anonymization, and clinical document redaction software into a single enterprise-grade platform. Built for scalability and precision, Shadow™ enables CROs and pharma teams to reduce turnaround times, eliminate manual inefficiencies, and deliver submission ready outputs with confidence while remaining fully compliant with all major regulatory frameworks. It automates the de-identification of structured clinical datasets (CDISC SDTM, ADaM), unstructured clinical documents (CSRs, protocols), and DICOM medical images, ensuring compliance with global data transparency regulations including **EMA Policy 0070 (Initial and Revised), [Health Canada](https://www.canada.ca/), PHUSE GTP and De-Identification Standards, 21 CFR Part 11, and GDPR & TransCelerate Guidance** Developed and maintained by GENINVO, Shadow™ is backed by ISO 27001, ISO 9001, and SOC 2 certifications. ## Book Your Demo Now! Full Name Work Email Message Request Demo ## What Is Shadow™? Shadow™ is a purpose-built clinical data de-identification tool for CROs that transforms how organizations approach anonymization. Instead of relying on fragmented tools or manual processes, Shadow™ delivers an integrated platform that combines data anonymization tool pharma capabilities with automated clinical document redaction software. With built-in EMA Policy 0070 compliance software and 21 CFR Part 11 data masking, Shadow™ ensures that every dataset, document, and image is processed in accordance with global regulatory requirements. Its native CDISC SDTM anonymization capabilities allow teams to handle structured datasets efficiently while maintaining analytical integrity. ## Built for Global Regulatory Compliance Regulation / Framework Scope Shadow™ Status **EMA Policy 0070 (Initial & Revised)** Clinical data transparency for EU submissions. ✔ Fully Compliant **Health Canada** Health Canada public release of clinical Information ✔ Fully Compliant **EU CTR (Clinical Trials Regulation)** EU Clinical Trials Regulation data transparency and public disclosure obligations for clinical trial results ✔ Fully Compliant **21 CFR Part 11 (FDA)** Electronic records & electronic signatures for US submissions ✔ Validated **GDPR** EU personal data protection clinical data and patient records ✔ Compliant **PHUSE GTP and De-Identification Standards** Industry guidance for clinical data de-identification strategy application ✔ Fully Compliant **TransCelerate Guidance** Cross-industry de-identification guidance for pharma R&D transparency ✔ Fully Compliant ## The Real Cost of Manual De-Identification CROs and medical writers managing clinical data transparency face critical operational and compliance challenges that directly impact timelines, costs, and regulatory confidence—challenges that Shadow™ is purpose-built to solve as a leading **clinical data de-identification tool for CROs**: - **Homegrown scripts limit scale and reliability** — In-house de-identification utilities are difficult to maintain, poorly documented, and unable to keep pace with evolving regulatory requirements such as EMA Policy 0070 Revised Phase 2. - **Manual redaction slows time-to-submission** — Document-level redaction of Clinical Study Reports is resource-intensive, error-prone, and creates costly bottlenecks ahead of regulatory deadlines. - **Re-identification risk lacks visibility and control** — Without a formal risk analysis framework, organizations cannot accurately quantify or demonstrate compliance with required regulatory thresholds. Shadow™ by GENINVO solves all three challenges as a purpose-built clinical data de-identification tool for CROs. Organizations using Shadow™ report significant reductions in the time required to complete clinical document redaction compared to manual or script-based approaches. Teams managing large CDISC SDTM and ADaM portfolios benefit from pre-built strategy repositories that eliminate the need to rebuild de-identification rules from scratch for every study. And because Shadow™ generates audit-ready re-identification risk reports automatically, regulatory reviewers receive the documentation they expect without additional manual effort from your team. ## Shadow™ Key Features Looking to enhance your organization’s impact? GENINVO’s technology-empowered experts are available to assist you in the following areas: ### [ Document +Data + DICOM images Anonymization ](https://geninvo.com/our-services/anonymization-as-a-service/) Anonymize structured datasets (CDISC SDTM, ADaM), clinical documents (CSRs, protocols), and DICOM medical images in a single unified platform. ### Dynamic Strategy Repository Store and apply de-identification strategies at Global, Therapeutic Area, Compound, Study, and Project levels. Comes with pre-built CDISC SDTM and ADaM strategies out of the box. ### Template Driven Anonymization Define reusable templates to apply large sets of strategies in one action — dramatically reducing time and effort across recurring studies. ### Dual Frame Before & After View See the live effect of each de-identification rule applied to your data or document in real time before finalizing, eliminating costly errors. ### CCI Open Search Search a continuously updated repository of already-published Commercially Confidential Information (CCI) to inform redaction decisions before starting a new project. ### Re-Identification Risk Analysis Quantify re-identification risk before and after de-identification to demonstrate compliance with EMA and Health Canada thresholds with full audit trail. ### Data Utility Analysis Measure the impact of anonymization on analytical utility so downstream consumers can still reproduce key analyses from de-identified datasets. ### Performance Metrics Track and report on de-identification team precision, strategy effectiveness, and workflow throughput to optimize resource allocation. ### Multi-Language Strategy Import Apply de-identification strategies created for an English document directly to foreign-language versions of the same document saving significant time for global submissions. ### Anonymization Reports & Redaction Proposals Automatically generate Redaction Proposals and Anonymization Reports required for regulatory submissions fully audit-ready. ### Process Workflow Guidance Step-by-step workflow guidance for your entire project team through de-identification, review, approval, and final anonymization stages. ### 21 CFR Part 11 Validation Package Shadow™ ships with full validation documentation to support GxP deployment in regulated environments without burdening your IT or QA team. ## Who Uses Shadow™? Shadow™ is a purpose-built clinical data de-identification tool for CROs, designed for Life Sciences professionals working at the intersection of data transparency, regulatory compliance, and clinical science. ### Contract Research Organizations (CROs) Manage de-identification programs across multiple sponsors, TAs, and studies on a single platform with shared strategy repositories and team performance tracking. ### Pharma & Biotech Companies Meet EMA, Health Canada, and FDA data transparency obligations across your full drug development portfolio including CDISC datasets, clinical documents, and DICOM images. ### Medical Writers Redact Clinical Study Reports with real-time dual-frame review, auto-generated redaction proposals, and regulatory-ready anonymization reports without manual copy-paste workflows. ### Regulatory Affairs Teams Generate audit-ready anonymization plans, re-identification risk reports, and redaction proposals that regulators expect directly from the platform. Shadow™ by GENINVO is a globally deployed clinical data de-identification tool for CROs, supporting Life Sciences organizations across North America, Europe, and Asia-Pacific. Its compliance coverage spans all major regulatory jurisdictions where clinical data sharing obligations apply: the European Union (EMA Policy 0070), the United States (21 CFR Part 11, FDA), Canada (Health Canada). Whether your team is headquartered in the US, EU, or operates across multiple regions, Shadow™ provides a single validated platform for all your clinical data transparency requirements. ## How Shadow™ Works: The De-Identification Workflow As a purpose built clinical data de-identification tool for CROs, Shadow™ guides entire team through a structured, auditable workflow from strategy definition to submission-ready output ensuring speed, consistency, and regulatory confidence at every stage: Step 1 **Define Strategy:** Quickly select or configure de-identification strategies using the built-in CDISC SDTM / ADaM repository, or create custom rules at the Global, TA, Compound, Study, or Project level to standardize processes across programs. Step 2 **Apply & Preview:** Apply rules with an intuitive dual-frame, before-and-after view, allowing your team to validate changes in real time and eliminate errors before finalization. Step 3 **Risk Analysis:** Instantly assess re-identification risk to ensure your anonymized datasets meet EMA Policy 0070 and Health Canada thresholds with confidence. Step 4 **Validate Utility:** Leverage data utility analysis tools to maintain the analytical value of your datasets, ensuring downstream usability without compromising compliance. Step 5 **Generate Reports:** Automatically generate Redaction Proposals, Anonymization Plans, and Anonymization Reports—fully audit-ready and formatted for seamless regulatory submission. Step 6 **Review & Approve:** Streamline collaboration with built-in workflows that route content for review and sign-off by QA, regulatory, and leadership teams. ## Ready to Eliminate Manual De-Identification From Your Workflow? Shadow™ is trusted by Life Sciences companies and CROs globally to deliver compliant, auditable, and scalable clinical data anonymization. See how Shadow™ can replace your homegrown scripts, accelerate your EMA 0070 submissions, and give your team confidence in every de-identified dataset. [ Book a Demo ](#demo) [ Download the Shadow™ Brochure ](https://geninvo.com/wp-content/uploads/2026/06/Shadow.pdf) [ Contact Us ](https://geninvo.com/contact-us/) ## Frequently Asked Questions: Shadow™ by GENINVO What is Shadow™ and who makes it? Shadow™ is a clinical data de-identification and anonymization software developed by GENINVO, a Life Sciences technology company. It is purpose-built for CROs, pharmaceutical companies, and medical writers who need to comply with EMA Policy 0070, Health Canada, 21 CFR Part 11, and GDPR data transparency requirements. GENINVO designed Shadow™ to replace inefficient homegrown scripts and manual redaction workflows with an enterprise-validated, audit-ready platform. Does Shadow™ support EMA Policy 0070 Phase 1 and Phase 2 (Revised)? Shadow™ by GENINVO is fully compliant with both the Initial and Revised phases of EMA Policy 0070, covering both document-level Clinical Study Report (CSR) redaction and structured dataset de-identification. This means organizations can use a single platform to address all EMA 0070 obligations — from preparing the anonymized CSR for public disclosure to generating the required Anonymization Plan and re-identification risk documentation. Is Shadow™ 21 CFR Part 11 compliant? Shadow™ is a validated 21 CFR Part 11 compliant solution, and it ships with a complete validation documentation package. This means your IT and QA teams do not need to build validation infrastructure from scratch — the evidence required for GxP deployment is provided as part of the product. GENINVO’s Shadow™ is also GDPR compliant and certified to ISO 27001 and SOC 2 standards. Can Shadow™ handle both clinical datasets and documents like CSRs? Shadow™ handles three types of content in a single integrated platform: structured clinical datasets (CDISC SDTM and ADaM), unstructured clinical documents (CSRs, protocols, synopses), and DICOM medical images. This makes Shadow™ by GENINVO one of the few clinical de-identification tools that eliminates the need for separate systems for data and document anonymization — a key advantage for CROs managing complex, multi-format de-identification programs. How is Shadow™ different from ARX, the open-source de-identification tool? Shadow™ by GENINVO is an enterprise-validated platform built specifically for Life Sciences regulatory compliance; ARX is a free, open-source, research-oriented tool that requires significant IT configuration and has no built-in regulatory workflow. Shadow™ includes pre-built CDISC SDTM and ADaM strategies, document-level CSR redaction, DICOM image anonymization, 21 CFR Part 11 validation, regulatory report generation, multi-language strategy support, and team performance metrics — none of which are available in ARX. For organizations with GxP requirements and regulatory submission deadlines, Shadow™ is the purpose-fit alternative. Does Shadow™ support multi-language document de-identification? Shadow™ by GENINVO includes a Multi-Language Strategy Import feature that allows de-identification strategies created for an English document to be imported and applied to the same document in any other language. For global pharmaceutical submissions where the same CSR is submitted in multiple languages, this capability can reduce the effort required to anonymize non-English document versions by a significant margin. Can we apply different de-identification strategies at the study or compound level? Shadow™ stores and applies de-identification strategies at five hierarchical levels: Global, Therapeutic Area (TA), Compound, Study, and Project. This means organizations can maintain a master strategy library while allowing study-level customizations — a critical capability for CROs managing multiple sponsors with different de-identification requirements on the same platform. What regulatory reports does Shadow™ generate automatically? Shadow™ by GENINVO automatically generates Redaction Proposals, Anonymization Plans, and Anonymization Reports formatted for regulatory submission to the EMA, Health Canada, and other authorities. It also produces performance metrics reports for internal quality governance. These auto-generated documents eliminate the manual effort of assembling submission-ready documentation and ensure consistency across every project. Can Shadow™ replace our existing homegrown de-identification scripts? Replacing homegrown de-identification scripts is one of Shadow™’s most common deployment use cases. Homegrown utilities are difficult to validate for 21 CFR Part 11, hard to maintain as regulations evolve, and rarely generate the audit documentation regulators expect. Shadow™ by GENINVO provides a governed, validated replacement that keeps pace with regulatory changes — including EMA Policy 0070 revisions — without requiring your team to maintain custom code. --- ### [DocQC](https://geninvo.com/our-products/docqc-medical-writing-automation/) **Published:** March 25, 2021 **Author:** admin **Content:** ![DocQC medical writing automation tool dashboard for clinical QC checks](//geninvo.com/wp-content/uploads/2026/04/Top-section.webp "DocQC medical writing automation tool dashboard for clinical QC checks") GI-DocQC-page-image ![](//geninvo.com/wp-content/uploads/2024/04/DocQC-b.png) # DocQC™​ - Medical Writing Automation for Clinical QC # DocQC™​ Medical Writing Automation for Clinical QC [View Brochure](https://geninvo.com/wp-content/uploads/2022/05/DocQC_brochure_8-5x5-5-V5.2-14-04-Final.pdf) [View Brochure](https://geninvo.com/wp-content/uploads/2025/03/DocQC_brochure_5.5x8.5-Inches-V5.2-14-04-Final-V1-1-3.pdf) ![](//geninvo.com/wp-content/uploads/2024/04/DocQC-b.png) ## What is Medical Writing Automation? **Medical writing automation** is the use of specialized software, Artificial Intelligence (AI), and Natural Language Generation (NLG) to streamline the creation of high-stakes clinical and regulatory documents. In an industry where a single New Drug Application (NDA) can exceed 100,000 pages, automation acts as a force multiplier. It transitions the role of a medical writer from manual data entry and formatting to strategic “human-in-the-loop” oversight. ## Book Your Demo Now! Full Name Work Email Message Request Demo ## How DocQC™ Automates QC Checks? DocQC™ is a tool that automates QC checks, which historically required multiple, time-consuming cycles of manual review. The application is programmable for various complexities, supported by [AI and ML algorithms](https://www.unite.ai/ten-best-machine-learning-algorithms/), developed by your document SMEs. It increases the efficiency and effectiveness of your QC process with each use. DocQC™ enables your medical writers to maintain their focus on the science, analysis, and presentation of results. ## Essential Quality Checks for Clinical Documents ### Reference Match Format List Lists in-text literature cross-references and checks conformance to AMA and Harvard styles. List in text literature cross references and checks for corresponding full citations in the list of references and vice-versa. ### Reference Match Content Checks in-text literature cross-references (titles and content) to ensure relevance and consistency with the source (titles and content) found in the appendices. ### Abbreviation Match List Lists in-text abbreviations and checks for corresponding entries in the list of abbreviations and vice-versa. Checks whether abbreviations from the list of abbreviations are correctly introduced at the first instance of their full-forms ### Post-text TFL Content Checks the post-text TFLs content (titles and column headers) to ensure they are relevant to the content of the section where they are referenced. (Note that this check excludes post-text TFLs referenced in the in-text tables). ### In-text Match Post-text Checks the CSR data/text against the referred source tables (in-text tables/post-text tables) to ensure relevance and consistency. ### Threshold Table Checks data of Intext Tables based on the criteria mentioned in the Title of Tables against its corresponding Post-Text TFLs (source) and vice versa. ### SOF Citation Lists post-text TFLs (aka “statements of fact”) and checks for corresponding entries in the appropriate appendices. ### SOF Match Data Source including Reverse check Checks content of in-text tables against corresponding post-text TFLs and vice-versa. ### Multiple Documents Keyword Check Shows content in CSR synopsis, relevant sections of CSR body, and appendices, using certain keywords. ### CSR Match Protocol SAP Checks methods section of CSR against the corresponding section of the template or the Protocol/SAP. ### CSR Match Narrative Checks in-text patient (or subject) numbers in the CSR to ensure that there are corresponding entries in the patient narratives section. ### CSR Match Template Checks CSR against its standard template to confirm all required sections are present with appropriate section title. ## Key Features of DocQC™ Automation **DocQC™ features support your efforts with** - Removes time-consuming multiple cycles of manual review. - Omits ambiguity by minimizing human error. - AI enabled algorithms - Reduction in time in CSR finalization from Last Patient – Last Visit - DocQC quality check’s while cross referencing other study artifacts including Protocol, SAP, and TLFs. - User-friendly interface for viewing and managing your QC check repository across several levels (Global Study). - Repository contains standard “out of the box” checks. ## DocQC™ Product Videos [ Request Demo ](#docqc) ## Functionality of Our Quality Checks Automation tool Looking to enhance your organization’s impact? See how DocQC™ can help: [ Request Demo ](https://geninvo.com/contact-us/) ![Medical Writers Automation Tool](https://geninvo.com/wp-content/uploads/2021/03/laptop-docqc.png "laptop-docqc - GenInvo - GenInvo") ## Frequently Asked Questions What is medical writing automation software? Medical writing automation software is a technology platform that uses AI and rule-based algorithms to automate clinical documents — such as CSRs, protocols, and SAPs — automatically, replacing time-consuming manual cycles. How does DocQC™ automate QC checks for medical writers? DocQC™ cross-references in-text citations, abbreviations, TFL data, and CSR content against source documents using configurable AI algorithms. It generates QC reports highlighting errors, mismatches, and missing entries — all without manual comparison. What document types does DocQC™ support? DocQC™ supports Clinical Study Reports (CSRs), Templates, Protocols, Statistical Analysis Plans (SAPs), Publications, TFLs and Narrative documents, in PDF and Word (.docx) formats. How much time can DocQC™ save in CSR finalization? DocQC™ significantly reduces the number of manual QC cycles required during CSR finalization, cutting the time upto >60% between Last Patient Last Visit (LPLV) and submission. --- ### [Contact us](https://geninvo.com/contact-us/) **Published:** March 25, 2021 **Author:** admin **Content:** ![](//geninvo.com/wp-content/uploads/2024/12/BG-contact-1.jpg) image-1 Contact us Contact us ## Contact Us [ View Our Services ](https://geninvo.com/our-services/) [ View Our Products ](https://geninvo.com/our-products/) [ Who we are ](https://geninvo.com/who-we-are/) ![](https://geninvo.com/wp-content/uploads/2021/03/contact-top.jpg "contact-top - GenInvo - GenInvo") To know more about how our Products and Services can help your business be more effective and efficient, get in touch with us today! Full Name Work Email Phone Number Company Region/Country Interested in Shadow DocQC DocWrightAI CodeMagic Datalution Data Collaboration Platform CIS-Confidential Information Scanner ApoGI Automation of Data Conversion Anonymization As a Service Innovation As a Service Cloud Managed Services Custom Application Development General Enquiries Collaborative Innovation Talent Resource Hub How did you hear about us? Google search Career Portal - Indeed Career Portal- Naukri Virtual Events Recruiter Reach out Word of Mouth Referral from Employee Email Campaigns Social Media - LinkedIn Social Media - Twitter Social Media - Facebook Message I consent to my submitted data being collected and stored. Send ## NORTH AMERICA ## USA, Bloomington Illinois, (Global Headquarter) 1408 East Empire Street 61701 Bloomington (Illinois), United States. Email – info@geninvo.com +1 309-807-5006 ![](https://geninvo.com/wp-content/uploads/2024/12/USA.webp "USA - GenInvo - GenInvo") ## Vancouver, Canada 1383 West 8th Avenue Vancouver, British Columbia, Canada – V6H 3W4 Email – info@geninvo.com ![](https://geninvo.com/wp-content/uploads/2024/12/USA.webp "USA - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2024/12/Vancouver.webp "Vancouver - GenInvo - GenInvo") ## EUROPE ## United Kingdom Geninvo, Inc. Limited Acre House 11/15 William Road London NWI 3ER Email – info@geninvo.com ![](https://geninvo.com/wp-content/uploads/2024/12/UK-1024x441.webp "UK - GenInvo - GenInvo") ## INDIA ## Haryana, India \#41/5-B, Dayal Bagh, Babyal Road, Ambala Cant -133001 (Haryana) India. Email – info@geninvo.com 0171-2660410 ![](https://geninvo.com/wp-content/uploads/2024/12/Haryana.webp "Haryana - GenInvo - GenInvo") ## Mohali, India Unit 912, Tower B, Bestech Business Tower, Sector 66, Mohali-160062 Email – info@geninvo.com ![](https://geninvo.com/wp-content/uploads/2024/12/Haryana.webp "Haryana - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2024/12/Mohali.webp "Mohali - GenInvo - GenInvo") --- ### [Who We Are](https://geninvo.com/who-we-are/) **Published:** March 22, 2021 **Author:** admin **Content:** ![](//geninvo.com/wp-content/uploads/2024/08/About-Us-image.jpg) image-1 About Us About US A team of highly talented people who bring insights & Innovation. A team of highly talented people who bring insights & Innovation. GENINVO is an independent organization that emerged from its parent company, a biometric-focused CRO. With a niche background, we bring a wealth of experience in delivering technology-focused services and championing automation. Every day, we witness firsthand the profound impact of innovation, integrating it into our business ethos as a vital force for our clients and societal progress alike. Our success recipe revolves around breathing life into innovation, ensuring that we not only deliver value to our customers but also pave the way for growth opportunities. Through tailor-made software solutions and services, coupled with an unwavering commitment to understanding and addressing our clients’ needs, we’ve earned the trust of our clients as a dependable advisor and strategically. ## Who We Are At GENINVO, we’re defined by our fusion of expertise in Life Sciences, cutting-edge technologies, and software development. This unique blend empowers us to offer truly innovative and transformative solutions, attuned to the clinical, technological, and business landscapes our clients navigate. Our handpicked teams, comprising technology mavens and Life Science subject matter experts, bring a distinctive problem-solving approach to the pharmaceutical industry. Transparency lies at the core of our client relationships, with excellence in clinical trials as our hallmark. We provide automation tools like DocQC, Shadow, Data Transformation Package, ApoGI, and more, catering to evolving needs with a promise of further advancements. Our forte lies not only in technological implementation but also in clinical technology and the caliber of our people. With a global footprint spanning the USA, Canada, Europe, the UK, and India, we transcend geographical barriers to forge strategic partnerships with our clients. Continual investment in cutting-edge technologies underscores our commitment to optimizing services and solutions, ensuring we remain at the forefront of industry innovation. GENINVO is an independent organization launched from its parent company (a biometric-focused CRO). This background put us in a niche position with rich experience in providing technology-focused services and working on enabling automation. ![](https://geninvo.com/wp-content/uploads/2024/08/Mission.png "Mission - GenInvo - GenInvo") ## Our Mission ##### **Our mission is to be the go-to partner for our clients and an industry leader in Life Sciences.** We support our clients in their innovation journey by working collaboratively to understand their needs. Using our expertise in several areas including business, software development, and technology, we provide innovative and transformative solutions and services to bring life-changing products and treatments to patients faster. ![](https://geninvo.com/wp-content/uploads/2024/08/Mission.png "Mission - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2024/08/Vision.png "Vision - GenInvo - GenInvo") ## Our Vision ##### **Our vision is the digitalization of the pharmaceutical industry.** We believe in innovating for a better world and providing a utilitarian benefit to our users. > ***Our mission is to be the go-to partner for our clients and an industry leader in Life Sciences.*** We support our clients in their innovation journey by working collaboratively to understand their needs. Using our expertise in several areas including business, software development, and technology, we provide innovative and transformative solutions and services to bring life-changing products and treatments to patients faster. > ***Our vision is the digitalization of the pharmaceutical industry.*** We believe in innovating for a better world and providing a utilitarian benefit to our users. ![](https://geninvo.com/wp-content/uploads/2021/10/mandv-arrow.png "mandv-arrow - GenInvo - GenInvo") # Our Leadership Team Our leaders are transformative and innovative; they possess expertise allowing them to fill variety of roles and responsibilities while having a vision of the future to attain long term goals. They recognize each member’s strength through their character as well as skills and focus on embracing the differences to cultivate a workplace environment of continuous improvements and initiative. ![CEO](https://geninvo.com/wp-content/uploads/elementor/thumbs/CEO-1-qwoviyxzua48wgwmylhdtvj1kqfqy8tk8xxsxyipgc.png "CEO") ### **Shweta Shukla** **CEO** [ In ](https://www.linkedin.com/in/shwetageninvo/) ![CO-FOUNDER](https://geninvo.com/wp-content/uploads/elementor/thumbs/CO-FOUNDER-2-qwovizvu145j82v9t3w0edai64b45xxal2laf8hba4.png "CO-FOUNDER") ### **Nalin Gupta** **Co-Founder & Strategic Advisor** [ In ](https://www.linkedin.com/in/nalingupta-av/) ![CO-FOUNDER-1](https://geninvo.com/wp-content/uploads/elementor/thumbs/CO-FOUNDER-1-1-qwovj0to7y6tjotwnmamyv1yri6hdn10x78rwifx3w.png "CO-FOUNDER-1") ### **Neha Aggrawal** **Co-Founder** [ In ](https://www.linkedin.com/in/naggarwalav/) ![GI-rohit-bajaj](https://geninvo.com/wp-content/uploads/elementor/thumbs/GI-rohit-bajaj-r36w29f3xc2v0706jyub4w69vfp6l5gotv03snczto.png "GI-rohit-bajaj") ### **Rohit Bajaj** **Associate Director QA/IT CSV** [ In ](https://www.linkedin.com/in/rohit-bajaj-a315a02/) ![Durgaprasad-G-new](https://geninvo.com/wp-content/uploads/elementor/thumbs/Durgaprasad-G-new-r4turaclct86430esnbdmbn6bpwm1hrbv0so3v2p98.png "Durgaprasad-G-new") ### **Durga Gudivaka** **Global Head- Technology and Innovation** [ In ](https://www.linkedin.com/in/durgaprasad-gudivaka-0a3b234) ![Sunita-GI](https://geninvo.com/wp-content/uploads/elementor/thumbs/Sunita-GI-r8i5uahgva3r4tt7kfkeupnxkp5jkeralox95bb3vg.jpg "Sunita-GI") ### **Sunita Poojary** **Senior Director – Operations and Growth** [ In ](https://www.linkedin.com/in/sunita-poojary-0aa46bb/) ![DaraghRyan](https://geninvo.com/wp-content/uploads/elementor/thumbs/DaraghRyan-rehwiol1xfymqon4nqn05109tceufdxjr54kxb0qxo.jpg "DaraghRyan") ### **Daragh Ryan** **Global Head of Client Consultancy** [ In ](https://www.linkedin.com/in/daraghryan/) ![James](https://geninvo.com/wp-content/uploads/elementor/thumbs/James-rehwr39323gyl4fhkdgvfwmp3ez19xb48r6xgejza4.png "James") ### **James Gallagher** **Advisor** [ In ](https://www.linkedin.com/in/daraghryan/) --- ### [CodeMagic](https://geninvo.com/codemagic/) **Published:** April 28, 2026 **Author:** admin **Content:** ![](//geninvo.com/wp-content/uploads/2026/04/Top-section.webp) ![](//geninvo.com/wp-content/uploads/2026/04/Logo-Icon_0004_CodeMagic-3d-logo-2025.webp) CodeMagic™​ CodeMagic™​ AI statistical programming automation AI statistical programming automation ![](//geninvo.com/wp-content/uploads/2026/04/Logo-Icon_0004_CodeMagic-3d-logo-2025.webp) # CodeMagic AI-Assisted Code Generation for Statistical Programming CodeMagic is Geninvo’s AI statistical programming automation platform. It converts your ADaM specifications and TLF mock shells into ready-to-execute R code automatically. As a result, your statistical programming team delivers results up to 50% faster, with 85% code accuracy. Furthermore, every output is GxP-compliant and CDISC-aligned out of the box. In addition, CodeMagic integrates directly into your existing Statistical Computing Environment (SCE). Therefore, you can start automating on day one without disrupting your workflow. Code Accuracy 0 % Faster Delivery ~ 0 % Core Modules: ADaM · TLF · SDTM 0 # CodeMagic's Three Core Automation Modules Feature 1 Feature 2 Feature 3 Feature 1 Automated ADaM Code Generation CodeMagic reads your variable-level ADaM specification metadata and derivation logic. As a result, it produces complete, CDISC-compliant ADaM dataset code instantly. No more manually translating specifications into R scripts. Furthermore, your programmers can review and run the output immediately saving days of manual work per dataset. Feature 2 TLF Automation for Clinical Trials Upload your Tables, Listings, and Figures mock shells alongside your ADaM specs. CodeMagic generates structured, execution-ready R code for every output. In addition, the formatting follows your organisation’s conventions — consistently applied across all 200–500 TLFs in your study. Therefore, your team delivers a complete TLF package in a fraction of the usual time. Feature 3 Raw Data to SDTM — Automated CodeMagic converts raw clinical data to SDTM-compliant datasets using your detailed mapping specifications. As a result, a process that traditionally took 4–6 weeks is completed in days. Furthermore, the outputs are audit-ready and submission-standard from the start not after a lengthy QC cycle. ## The AI Engineering Behind CodeMagic CodeMagic is not a general-purpose AI code generator. It is purpose-built for clinical data statistical programming. As a result, it understands the exact complexity of CDISC standards, regulatory requirements, and pharmaceutical programming conventions. Four core technologies power the platform: ## Ready to Cut Statistical Programming Time by 50%? ## Book Your Demo Now! Full Name Work Email Message Request Demo --- ### [ApoGI](https://geninvo.com/our-products/apogi/) **Published:** March 25, 2021 **Author:** admin **Content:** ![](//geninvo.com/wp-content/uploads/2026/04/Top-section.webp) image-1 ![](//geninvo.com/wp-content/uploads/2024/04/GI-case-study-oct23-V2.png) ApoGI™ ApoGI™ Next-Gen End to End Platform Automating your Clinical Study Deliverables Next-Gen End to End Platform Automating your Clinical Study Deliverables [View Brochure](https://geninvo.com/wp-content/uploads/2022/05/ApoGI_8-5x5-5-V3-14-04-Final.pdf) [View Brochure](https://geninvo.com/wp-content/uploads/2025/09/ApoGI_5.5x8.5-Inches-V3-14-04-Final-V1-1-2-1.pdf) ![](//geninvo.com/wp-content/uploads/2024/04/ApoGI-logo-animation-for-hero-page-V3.mp4.gif) ## ApoGI™ Product Videos ## Book Your Demo Now! Full Name Work Email Message Request Demo ## ApoGI™- Metadata Management Tool ApoGI™- Metadata Management Tool, is an integrated, automation platform that leverages AI (Artificial Intelligence) and ML ([Machine Learning](https://en.wikipedia.org/wiki/Machine_learning)) and puts focus on standards and metadata management to streamline processes and the generation of artifacts typically associated with the clinical study lifecycle. Ensuring process/artifact consistency, streamlining and automating repetitive tasks and artifact generation to allow subject matter experts to focus on science and deriving additional value/insights from clinical trial data. ![](https://geninvo.com/wp-content/uploads/2024/04/ApoGI-logo-gif-animation.gif "ApoGI logo gif animation - GenInvo - GenInvo") # ApoGI™- Metadata Management Tool ApoGI™- Metadata Management Tool, is an integrated, automation platform that leverages AI (Artificial Intelligence) and ML ([Machine Learning](https://en.wikipedia.org/wiki/Machine_learning)) and puts focus on standards and metadata management to streamline processes and the generation of artifacts typically associated with the clinical study lifecycle. Ensuring process/artifact consistency, streamlining and automating repetitive tasks and artifact generation to allow subject matter experts to focus on science and deriving additional value/insights from clinical trial data. ### **Key Features** Life Science SMEs drive our custom application development services, supported by leading-edge technologists and software development experts seasoned in delivering solutions and services that resonate with our sponsors. Our technical teams support solutions development and services in the following areas: - Next generation enterprise platform - Ability to integrate and leverage data from multiple sources - Anonymization of data for sharing it internally or externally in real time - Leveraging new technologies to support artifact generation from protocol to CSR - Automated process workflows to facilitate Governance, Artifact Generation, Review / Approval / Sign-off - ApoGI has developed Data Visualization module to analyze information related to Clinical Metadata and Data and provide data insights in the form of visual elements like charts, graphs and maps to understand the trends, outliers and patterns in data. - Availability of Structured Governance Framework to track metadata at multiple hierarchical levels. - Impact Analysis/Traceability Tool (across all levels) ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ## Key Features Life Science SMEs drive our custom application development services, supported by leading-edge technologists and software development experts seasoned in delivering solutions and services that resonate with our sponsors. Our technical teams support solutions development and services in the following areas: - Next generation enterprise platform - Ability to integrate and leverage data from multiple sources - Anonymization of data for sharing it internally or externally in real time - Leveraging new technologies to support artifact generation from protocol to CSR - Automated process workflows to facilitate Governance, Artifact Generation, Review / Approval / Sign-off - ApoGI has developed Data Visualization module to analyze information related to Clinical Metadata and Data and provide data insights in the form of visual elements like charts, graphs and maps to understand the trends, outliers and patterns in data. - Availability of Structured Governance Framework to track metadata at multiple hierarchical levels - Impact Analysis/Traceability Tool (across all levels) ![](https://geninvo.com/wp-content/uploads/2022/05/apogi-icons-03.png "apogi-icons-03 - GenInvo - GenInvo") # STUDY DESIGN EXTRACTOR - Platform for Extracting Protocol Information like Trial Design Elements, Study level Information, Visit Assessment schedules along with Domains that need to be collected for the study from the Protocol Document. - Identify existing Metadata availability from MDR and identifying new Domains that would need to be created for the study for Data collection Elements USP: Unmet needs in the Industry to automate extracting information from the Protocol Document to reduce Study Build timelines. ![](https://geninvo.com/wp-content/uploads/2022/05/apogi-icons-04.png "apogi-icons-04 - GenInvo - GenInvo") # STUDY BUILD - Managing Study level metadata, copying from Global. - Creating new metadata at study level from scratch for Data collection Elements - Change request by Study user for Global Metadata Governance - File system USP: Meeting unmet Industry needs to manage all Study Level Metadata in one place from Data collection to Data reporting. ![](https://geninvo.com/wp-content/uploads/2022/05/apogi-icons-02.png "apogi-icons-02 - GenInvo - GenInvo") # DATA TRANSFORMATION - Importing the raw datasets/non-clinical study data and their classification with tags - Providing the framework for source to target mapping with user interface screen - Providing the basic default functions for mapping datasets & supports custom mapping - Automap functionality to demonstrate current mapping techniques, supports manual mapping - Execution logs, method usability report and impact assessment, mapping coverage report and export - Exporting the transformed data and mapping spec generation and file system USP: Data Transformation/Data conversions made easy by applying Automapping, Machine learning algorithms to reduce Submission Timelines. ![](https://geninvo.com/wp-content/uploads/2022/05/apogi-icons-01.png "apogi-icons-01 - GenInvo - GenInvo") # TLF SHELL GENERATOR - Platform for facilitating the finalization of all the templates for generating Tables, Listings and Figures as part of setting up the expectations between the Statisticians and the Statistical Programmers. - Product supports to create TLF from scratch, allows to import existing TLF shells/catalog from existing library and generate metadata to be stored back in MDR. - Supports various formats in both Import and Export functionality. USP: Product will be used to generate the actual study artifacts: Tables, Listings and Figures using SDTM/AdAM dataset ## ApoGI™ -Product Suite [ ![](https://geninvo.com/wp-content/uploads/2024/04/ApoGI™-Product-Suite-info-V1-1024x576.png "ApoGI™--Product-Suite-info-V1 - GenInvo - GenInvo") ](https://geninvo.com/wp-content/uploads/2024/04/ApoGI™-Product-Suite-info-V1.png) ## ApoGI™ -Platform Modules **ApoGI platform consist of ADMIN, MDR, Study Build, Data transformation and TLF Shell/ Report Generator** ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ## Key Benefits of ApoGI™- Metadata Automation Platform ### Our product ApoGI™ is a one stop metadata solution platform. Looking to enhance your organization’s impact? Our technology-empowered experts are available to assist you in the following areas: - ApoGI offers one stop platform-based solution which helps reduce multiple hops between systems and ensures data and document traceability - ApoGI is future ready with AI enabled Automation platform with “Innovation as Service” model for custom needs as required - Plug-n-Play modules in the ApoGI platform help manage industry requirements along with legacy products - Focus consequently enhances the value of the metadata and related transformations making it possible to extend the capabilities of the platform to cover additional artifacts, processes, and use cases. [ Request Demo ](#apogi) ![](https://geninvo.com/wp-content/uploads/2024/04/laptop-1.png "laptop-1 - GenInvo - GenInvo") ## Key Benefits of ApoGI™- Metadata Automation Platform ### Our product ApoGI™ is a one stop metadata solution platform. Looking to enhance your organization’s impact? Our technology-empowered experts are available to assist you in the following areas: - ApoGI offers one stop platform-based solution which helps reduce multiple hops between systems and ensures data and document traceability - ApoGI is future ready with AI enabled Automation platform with “Innovation as Service” model for custom needs as required - Plug-n-Play modules in the ApoGI platform help manage industry requirements along with legacy products - Focus consequently enhances the value of the metadata and related transformations making it possible to extend the capabilities of the platform to cover additional artifacts, processes, and use cases. [ Request Demo ](https://geninvo.com/contact-us/) ![](https://geninvo.com/wp-content/uploads/2021/03/laptop-apogi.png "laptop-apogi - GenInvo - GenInvo") --- ### [CIS- Confidential Information Scanner](https://geninvo.com/cis-confidential-information-scanner/) **Published:** January 24, 2025 **Author:** admin **Content:** ![](//geninvo.com/wp-content/uploads/2026/04/Top-section.webp) image-1 ![](//geninvo.com/wp-content/uploads/2025/01/CIS-banner-logo.png) ![](//geninvo.com/wp-content/uploads/2024/08/Untitled-1.png) CIS Confidential Information Scanner CIS Confidential Information Scanner Your Shield To Confidential Information for Regulatory Compliance, Economic Risks and Data Breaches. Your Shield To Confidential Information for Regulatory Compliance, Economic Risks and Data Breaches. [View Brochure](#) ![](//geninvo.com/wp-content/uploads/2025/01/CIS-banner-logo.png) ## CIS™ # AI-Powered CCI Redaction Tool for Regulatory Compliance & Data Protection in Clinical Trials CIS™ is an AI-powered solution that safeguards commercially confidential information (CCI) in anonymized clinical documents and ensures compliance with global regulatory standards. Built specifically for the life sciences industry, CIS™ combines Artificial Intelligence and Machine Learning to accurately detect, classify, and protect confidential data and information across documents and repositories. Traditional manual redaction and homegrown utilities are slow, error-prone, and unable to keep pace with regulatory requirements eg. EU-Clinical Trial Regulation, EMA Policy 0070, Health Canada Public Release of Clinical Information etc. CIS™ changes that by delivering automated, intelligent scanning across 50+ life sciences specific categories of confidential information, enabling faster, more reliable protection of data in regulatory submissions, clinical trial documents, and research records. ## Book Your Demo Now! Full Name Work Email Message Request Demo With seamless integration into document repositories and scanning across custom portals, CIS™ provides a centralized, secure way to manage and protect sensitive information throughout its lifecycle. Whether it’s meeting EMA Policy 0070, Health Canada MR001-MR004, HIPAA, GDPR, or 21 CFR Part 11 requirements, CIS™ empowers organizations to stay compliant while focusing on science, innovation, and results. By leveraging sophisticated hybrid AI algorithms, CIS™ not only reduces compliance risks but also strengthens regulatory guidance on CCI, enhances data security, and preserves organizational trust in a complex data transparency landscape. Sharing sensitive data doesn’t have to compromise security. With [Shadow](https://geninvo.com/our-products/data-anonymization-tool/), de-identify your information before collaboration, ensuring your data remains protected. Paired with our [CCI Tool](https://geninvo.com/cis-confidential-information-scanner/), which securely identifies and manages confidential company data using AI and rules-based algorithms, these tools allow efficient, secure collaboration. Key Features CIS™ is a fully featured, user-friendly, compliance-driven solution built to protect confidential and sensitive information during the clinical development of the drug molecule while maintaining compliance with data-sharing regulations. - **50+ Confidentiality Categories** across drug discovery, development, and regulatory workflows. - **Customized Scanning** across internal repositories, web sources, and regulatory documents. - **Automated Re-Scanning** to detect updates and ensure continued protection of confidential information. - **Document Scanning** for internal documents, clinical trial reports, and regulatory submission. - **Reports** that generates human-like, well-structured outputs for review and compliance records of CCI management. - **CCI Source Navigation** to quickly locate the exact page, section, or PDF where confidential information is identified. [ Request Demo ](#cis) ![](https://geninvo.com/wp-content/uploads/2025/08/lap-2.png "lap-2 - GenInvo - GenInvo") ## Category Features Confidentiality Obligations Track and safeguard sensitive commercial information, payment agreements and confidentiality clauses with precision. CIS™ ensures contractual obligations remain protected and compliant with industry regulations. Projected Key Dates & Development Milestones Protect critical study timelines, trial milestones, and projected development dates from unintended disclosure. CIS™ keeps your strategic plans secure while maintaining transparency where required. Facilities & Third-Party Involvement Confidential details about research facilities, labs, and third-party vendors are securely scanned and monitored. CIS™ helps you protect sensitive operational data without slowing collaboration. Asset & Study Information Safeguard asset pipelines and study-related details throughout the drug development lifecycle. With CIS™, sensitive asset intelligence remains secure across internal and external exchanges. Other Sponsor Medicines or Vaccines When your studies involve sponsor medicines or vaccines in combination or as comparators, CIS™ protects this sensitive information from exposure. This reduces risks of competitive intelligence leaks. Other Non-Sponsor Medicines or Vaccines Confidential references to non-sponsor drugs or vaccines in trials or comparative studies are scanned and secured. CIS™ ensures protection while preserving regulatory clarity in submissions. Sponsor-Supported Studies CIS™ identifies and protects confidential information in sponsor-backed studies, from protocols to trial results. This safeguards sponsor interests while supporting compliance across submissions. Supported Collaborative Studies Protect sensitive details in multi-sponsor or collaborative research projects with ease. CIS™ ensures that confidentiality obligations are honoured without slowing down innovation. ## The Latest Industry Breakthrough Looking to enhance your organization’s impact? GENINVO’s technology-empowered experts are available to assist you in the following areas: ### Industry-Specific Confidentiality Categories CIS™ comes preloaded with 50+ categories tailored for life sciences, covering every stage from drug discovery to regulatory submission. This ensures you capture the right confidential elements, no matter where you are in the development lifecycle. ### Customized Scanning Across Sources Easily configure CIS™ to scan across internal repositories, regulatory portals, and the open web information. Flexible customization means the tool adapts to your specific workflows, not the other way around. ### Automated Re-Scanning for Updates Stay ahead of evolving compliance requirements with scheduled and automated re-scanning. CIS™ continuously checks for updates, ensuring your data remains protected and compliant over time. ### Intelligent Document Scanning CIS™ scans clinical trial reports, submissions, and internal documents with AI-powered precision. It reduces manual effort and minimizes the risk of overlooking sensitive information. ### Customizable Reporting Generate well-formatted Excel reports that present findings clearly for compliance and audit teams. Designed to look natural and easy to review, reports save time and speed up decision-making. ### Source Navigation Made Simple Pinpoint confidential information instantly with CCI source navigation, linking directly to the page, section, or PDF where data was found. This transparency builds confidence and streamlines the review process. ### Centralized CCI Database for Redactions Leverage the Asset CCI Database to apply consistent redactions across all documents. By storing and reusing CCI intelligence, CIS™ ensures efficiency and compliance in every project. --- ### [data-collaboration](https://geninvo.com/our-products/data-collaboration/) **Published:** May 23, 2024 **Author:** admin **Content:** ![](//geninvo.com/wp-content/uploads/2026/04/Top-section.webp) image-1 ![](//geninvo.com/wp-content/uploads/2024/10/DC-banner-logo-1.png) ![](//geninvo.com/wp-content/uploads/2024/08/Untitled-1.png) Data Collaboration Data Collaboration Data Sharing Platform in Clinical Research [View Brochure](https://geninvo.com/wp-content/uploads/2025/01/Data-Collabration-Brochure.pdf) ![](//geninvo.com/wp-content/uploads/2024/10/DC-banner-logo-1.png) ## Data Collaboration Product Videos ## Book Your Demo Now! Full Name Work Email Message Request Demo # Introduction to Data Collaboration ## Data Collaboration Platform Empowers Researchers with Seamless Clinical Data Sharing. In response to the growing emphasis on open science, the Data Collaboration platform is transforming the landscape of clinical research by empowering researchers to request, access, and analyze clinical data with unprecedented ease. Designed to foster transparency and collaboration, the platform offers a secure and user-friendly environment for data sharing. Researchers can now unlock the potential of existing clinical data, facilitating innovative research and accelerating advancements in healthcare. With features that prioritize both security and accessibility, the [Data Collaboration ](https://geninvo.com/our-products/data-collaboration/)platform is set to revolutionize how clinical data is utilized, driving forward the mission of open science and improving patient outcomes. Our mission is to advance open, responsible, and impactful sharing of clinical research data by building a sustainable, globally connected data ecosystem. We enable seamless collaboration and data reuse by serving as a trusted, independent intermediary—connecting data contributors, researchers, and the broader data-sharing community to accelerate scientific discovery and improve health outcomes worldwide. ## How Data Collaboration Works​ ## How Data Collaboration Works​ **1. Data Request Process:** ​ - Sponsors (pharmaceutical companies, academic institutions) submit anonymized data from completed trials.​ - Data must meet specific quality and ethical standards before being uploaded to the platform. ​ **2. Data Access Process:**​ - Researchers submit requests for access to datasets relevant to their research.​ - Access is granted based on predefined criteria, including the scientific merit of the proposal. ​ **3. User-Friendly Interface:**​ - A streamlined platform allows users to search for data using various filters (e.g., disease area, trial phase).​ - Users can view metadata about datasets to understand their context before requesting access.​ ![](https://geninvo.com/wp-content/uploads/2024/10/Gi-dc-data-collaboration-works-image-1024x851.webp "Gi-dc-data-collaboration-works-image - GenInvo - GenInvo") ## Privacy & Security ## Privacy & Security ![](https://geninvo.com/wp-content/uploads/2024/10/GI-data-collaboration-page-security-privacy-image-1024x851.webp "GI-data-collaboration-page-security-&-privacy-image - GenInvo - GenInvo") [ Request Demo ](#data) --- ### [DocWrightAI](https://geninvo.com/our-products/docwrightai-document-generation-software/) **Published:** March 14, 2023 **Author:** admin **Content:** ![](//geninvo.com/wp-content/uploads/2026/04/Top-section.webp) ![](//geninvo.com/wp-content/uploads/2024/04/DocWrightAI-b.png) DocWrightAI™​ DocWrightAI™​ Document Generation Made Easy Document Generation Made Easy ![](//geninvo.com/wp-content/uploads/2024/04/DocWrightAI-b.png) DocWrightAI™ Document Generation Made Easy View Brochure ## DocWrightAI™ Product Videos [ Request Demo ](https://geninvo.com/contact-us/) ## DocWrightAI™ -Document Generation Software Welcome to GENINVO’s latest innovation, DocWrightAI™ – a document generation software for healthcare industry that revolutionizes the way life science companies generate and review standard documents. **It is designed specifically to meet the complex documentation requirements of the life sciences** industry, automating much of the document creation process while maintaining accuracy and compliance. With DocWrightAI™, you can **build a document template library and leverage this to streamline the creation of various documents**, including clinical study reports, investigator brochures, regulatory submissions, patient information leaflets, labeling, and other technical documents as well. DocWrightAI™ features a user-friendly interface and integrates with various data sources, including electronic health records, patient registries, clinical databases, study datasets, etc., to **generate documents automatically from structured data.** With validation and verification features **powered by DocWrightAI™,** DocWrightAI™ ensures that all generated **documents meet both internal & regulatory standards and guidelines.** ## Book Your Demo Now! Full Name Work Email Message Request Demo ## DocWrightAI's ability to enable Multi-site, multi-region and multi-language support increases the teams’ efficiency and reduces the time-to-completion, all while ensuring compliance. With DocWrightAI™, you can be rest assured that your documents will be accurate, consistent, and compliant, while reducing time and cost, minimizing errors, and improving the efficiency of the document creation process. **The solution is customizable,** and you can create templates, workflows, and business rules according to your requirements. **The tool is built for teams**, **facilitating collaborative document creation** and review in real-time, ensuring faster approvals and reducing review cycles. DocWrightAI™’s ability to enable - multi-site, - multi-region and - multi-language support increases the teams’ efficiency and reduces the time-to-completion, all while ensuring compliance. ![](https://geninvo.com/wp-content/uploads/2024/04/writing-1024x846.png "writing - GenInvo - GenInvo") # DocWrightAI™ Feature Summary ### Natural Language Processing (NLP) ### Collaborative Workflows ### Conditional Statements/Templates ### Machine Learning ### Content Libraries ### Auto Formatting ### Integrated Validation and Verification ### Customizable Templates ### Electronic Signatures ### Multi-Language Support *Not seeing what you are looking for? Contact us at the link below to share your team’s particular challenges and requirements, and to schedule an interactive demo.* [ Request Demo ](#docwightai) --- ### [Datalution](https://geninvo.com/our-products/datalution/) **Published:** March 14, 2023 **Author:** admin **Content:** ![](//geninvo.com/wp-content/uploads/2026/04/Top-section.webp) image-1 ![](//geninvo.com/wp-content/uploads/2024/06/Datalution-b.png) Datalution™ Datalution™ A Meaningful Synthetic Data Generation Solution A Meaningful Synthetic Data Generation Solution [View Brochure](https://geninvo.com/wp-content/uploads/2024/06/Datalution-new-Brochure-Final-V2.1-2.pdf) [View Brochure](https://geninvo.com/wp-content/uploads/2024/06/Datalution-new-Brochure-Final-V2.1-2.pdf) ![](//geninvo.com/wp-content/uploads/2024/06/Datalution-b.png) # Datalution™ - Meaningful Synthetic Data Generation Solution ​ Introducing Datalution – Your Solution for Synthetic Data Generation Generate Meaningful Synthetic Data for Testing and Analysis Introducing Datalution, **the all-in-one solution for generating synthetic data** for testing electronic data capture screens, edit checks, Data management activities (as part of UAT Process), programming, and statistical setup activities. Our product generates “meaningful” synthetic data that simulates real-world scenarios, enabling you to test such things as your **edit checks, [CDISC (SDTM)](https://www.cdisc.org/standards/foundational/sdtm) dataset generation programs, data visualizations, and TFL (Tables, Figures, and Listings) generation programs** under a wide range of conditions. It makes clinical trial simulation and synthetic data generation for healthcare easier. With our product, you can create large and **diverse datasets quickly and cost-effectively**, without the need to first collect real data. Clean data is crucial for the accuracy, safety, regulatory compliance, efficiency, cost-effectiveness, and reproducibility of clinical trial analysis. To ensure the quality of the data, it is **important to have appropriate data cleaning and quality control procedures in place.** ## Book Your Demo Now! Full Name Work Email Message Request Demo ## Datalution™ offers a range of features that make it the ideal solution for testing database, programming, and statistical setup activities: ### Our product: - Provides **customizable data generation,** allowing you to tailor the data to meet your specific testing requirements. - Supports a **variety of data types**, including numeric, text (utilizing expected categorical values or realistically expected values as appropriate), and date/time data, making it easy to create complex datasets. - Generates data that is **statistically representative of the real-world**, allowing you to test your delivery programs and processes in a way that accurately reflects the “Patient Journey”, i.e., the typical behavior of clinical trial patients. ![](https://geninvo.com/wp-content/uploads/2024/06/Images-set-1024x846.png "Images-set - GenInvo - GenInvo") ## Datalution™ - Synthetic Data Generation for Healthcare Feature Summary ### Synthetic Data for Medical Research and Drug Development **Leverages clinical study documents, including:** - Clinical Trial Protocol - eDC/CDMS specifications such as Medidata Rave’s ALS - eCRF Completion Guidelines **Generates “Meaningful” test data:** - Categorical variables have values that comply with their associated code lists - Continuous variables have values that comply with their normal ranges - Outliers and bad values can be optionally introduced to test these lists/ranges - Dates and time values are set in chronological order in compliance with the protocol’s visit schedule - Ability to ensure specific number of patients in treatment and demographic groups **Ensures data are representative of the “Patient Journey”:** Configurable test data groups to represent: - Screen failures - Completed patients - Ongoing patients - Early withdrawal/discontinued patients Completion of data forms in compliance with the above groups [ Request Demo ](#datalution) ![](https://geninvo.com/wp-content/uploads/2024/06/lapp.png "lapp - GenInvo - GenInvo") --- ### [Innovation As a Service](https://geninvo.com/our-services/innovation-as-a-service/) **Published:** May 26, 2022 **Author:** admin **Content:** ![](//geninvo.com/wp-content/uploads/2026/04/Top-section.webp) image-1 ![](//geninvo.com/wp-content/uploads/2024/08/Untitled-1.png) Innovation As a Service Innovation As a service ![](//geninvo.com/wp-content/uploads/2024/09/innovation-as-a-service-1.png) ## Innovation As a Service [ View Brochure ](#) ![](https://geninvo.com/wp-content/uploads/2022/05/innov-as.jpg "innov-as - GenInvo - GenInvo") Discoveries and investments in next-generation medicines as well as technology have seen an increase in the pharma space. The ability to develop and deploy medications is a tedious process as a typical drug development cycle is complex and approximately takes 10-15 years for completion. We have team across the globe and the good news is that you can tap into this pool and use as a transformation force to cultivate your idea. Due to the pandemic, the pharma industry has been compelled to expedite the trials and faced multiple challenges such as drug approval market decrease and increasing costs. To overcome these issues, we at GENINVO identified opportunities and disruptive methods that aid and accelerate the drug development timelines. Innovation acts as our core value and we intend to provide sustainable solutions that emerge from novel ideas to bring a difference in our society/ healthcare. ## What you Gain - ● Agility and flexibility approach. - ● A solutions build in shorter time. - ● Access to highly skilled workforce. - ● Technology partnership. - ● A new robust product for your internal process and drug development enhancement. ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ## What you gain - Agility and flexibility approach - A solutions build in shorter time - Access to highly skilled workforce - Technology partnership - A new robust product for your internal process and drug development enhancement. --- ### [Thank You!](https://geninvo.com/thank-you/) **Published:** April 14, 2026 **Author:** admin **Content:** ## Thank You for Reaching Out! We’ve received your message and our team is already reviewing it. [ Explore Our Products ](https://geninvo.com/our-products/) --- ### [Work with Us](https://geninvo.com/work-with-us/) **Published:** March 24, 2021 **Author:** admin **Content:** ![](//geninvo.com/wp-content/uploads/2025/10/image-Work-with-us-page-24-V1.jpg) image-Work-with-us-page-24-V1 Your Launchpad for Innovation is Right Here! Your Launchpad for Innovation is Right Here! ## Work with Us [ Who we are ](https://geninvo.com/who-we-are/) [ GENINVO Insights ](https://geninvo.com/insights/) ![](https://geninvo.com/wp-content/uploads/2023/03/Untitled-design.png "Untitled design - GenInvo - GenInvo") ##### [Analyst/Architect – Data Science](https://geninvo.com/analyst-architect-data-science/) Location: Multiple Location in USA, UK & India Job Type: Full-time/Contract Experience: 3-10 Years [ ](https://geninvo.com/analyst-architect-data-science/) ##### [Analyst/Engineer-AI/ML](https://geninvo.com/analyst-engineer-ai-ml/) Location: Multiple Location in USA, UK & India Job Type: Full-time/Contract Experience: 5-10 Years [ ](https://geninvo.com/analyst-engineer-ai-ml/) ##### [Analyst/Lead – CSV/QA](https://geninvo.com/analyst-lead-csv-qa/) Location: Multiple Locations in India Job Type: Full-time/Contract Experience: 8 Years [ ](https://geninvo.com/analyst-lead-csv-qa/) ##### [Analyst–IT and Security Compliance](https://geninvo.com/analyst-it-and-security-compliance/) Location: Multiple Locations in India Job Type: Full-time Experience: 8 Years [ ](https://geninvo.com/analyst-it-and-security-compliance/) ##### [Architect – Data Science (Deep Learning and NLP Expert)](https://geninvo.com/architect-data-science-deep-learning-and-nlp-expert/) Location: India, US, UK Job Type: Full-time Experience: 8 Years+ [ ](https://geninvo.com/architect-data-science-deep-learning-and-nlp-expert/) ##### [Architect/Analyst – Fullstack](https://geninvo.com/architect-analyst-fullstack/) Location: Multiple Location in USA, UK & India Job Type: Full-time/Contract Experience: 4-10 Years [ ](https://geninvo.com/architect-analyst-fullstack/) ##### [Business Development Executive/Manager](https://geninvo.com/business-development-executive-manager/) Location: India and EU Job Type: Full-time/Contract Experience: 10 Years [ ](https://geninvo.com/business-development-executive-manager/) ##### [Project Manager](https://geninvo.com/project-manager/) Location: Multiple Location in USA, UK & India Job Type: Full-time/Contract Experience: 10 Years [ ](https://geninvo.com/project-manager/) ##### [R/Shiny Developer/Lead](https://geninvo.com/r-shiny-developer-lead/) Location: USA, UK & India Job Type: Full Time Experience: 4-10 Years [ ](https://geninvo.com/r-shiny-developer-lead/) ##### [Digital Marketing Manager](https://geninvo.com/digital-marketing-manager/) Location: Mohali Job Type: Fulltime Experience: 7+ Years [ ](https://geninvo.com/digital-marketing-manager/) ##### [Associate Python Developer](https://geninvo.com/role-description/) Location: Athens, Greece (Remote) Job Type: Full-time/Contract Experience: 0-1 Year [ ](https://geninvo.com/role-description/) ##### [SME: Data Transparency and Medical Writing](https://geninvo.com/sme-medical-writing/) Location: Remote Job Type: Full time Experience: 10+ [ ](https://geninvo.com/sme-medical-writing/) ##### [Business Analyst/Senior Business Analyst](https://geninvo.com/business-analyst-senior-business-analyst/) Location: Mohali Job Type: Full Time Experience: 5-7 Years [ ](https://geninvo.com/business-analyst-senior-business-analyst/) ##### [Launch Your Career with GenInvo – Internship Opportunity](https://geninvo.com/launch-your-career-with-geninvo-internship-opportunity/) Location: Job Type: Experience: [ ](https://geninvo.com/launch-your-career-with-geninvo-internship-opportunity/) ##### [Head / Associate / Senior Director – Product Adoption](https://geninvo.com/head-associate-senior-director-product-adoption/) Location: US / Canada / EU (On-Site or Remote) Job Type: Full Time Experience: 15+ years [ ](https://geninvo.com/head-associate-senior-director-product-adoption/) ##### [Senior Analyst / Lead – Google Cloud Development](https://geninvo.com/senior-analyst-lead-google-cloud-development/) Location: Remote (Anywhere in USA/Canada/EU/India Job Type: Fulltime Experience: 10+ years [ ](https://geninvo.com/senior-analyst-lead-google-cloud-development/) ##### [Senior/Lead Analyst – DevOps](https://geninvo.com/senior-lead-analyst-devops/) Location: Chandigarh / Remote (India) Job Type: Full Time Experience: 7+ Years [ ](https://geninvo.com/senior-lead-analyst-devops/) ##### [Product Adoption Specialist ](https://geninvo.com/product-adoption-specialist/) Location: Remote (Anywhere in US) Job Type: Full Time Experience: 8+ years [ ](https://geninvo.com/product-adoption-specialist/) --- ### [termsandcondition](https://geninvo.com/our-products/data-collaboration/termsandcondition/) **Published:** May 22, 2024 **Author:** admin **Content:** ## Terms & Conditions ![](https://geninvo.com/wp-content/uploads/2024/05/image-4.png "image (4) - GenInvo - GenInvo") ## One Place Solution for Clinical Studies and Research ## **Policy** The GenInvo Privacy and related policies ensure that the processing of Personal Information by GenInvo as part of our business and service offerings is collected, stored and used in compliance with all applicable laws and regulations. “Personal Information” is any Information relating to an identified or identifiable natural person. The policy applies to all situations where Personal Information is collected, stored and processed by GenInvo: - For its own business use (primarily marketing), - To support business operations (e.g. contractual arrangements, administrative functions), and - To comply with all privacy regulations when providing software, services and support to our customers ## **What and How we collect Personal Information** Our websites collect a range of general Information and data when in use. This includes browser types, operating system details, IP addresses, clickstream details for the pages you visit, etc., in order to both enhance your experience on the site and to ensure the security and integrity of our IT infrastructure. Our websites offer the opportunity to register interest in GenInvo products and services. Personal Information is captured from our website when you participate in any of the following activities: - Registering on our site - Subscribing to a newsletter - Responding to a survey - Filling out a form - Providing feedback on our products or services - Signing up for a webinar - Attending a webinar The Personal Information we collect from you will depend on which activity you are using in the list above and may include your: - Name - Title - Company name - Address - Phone number(s) - Email address This information is stored and processed only for the purpose for which it was collected ## **Our use of cookies** Cookies are small files that a site or its service provider transfers to your computer’s hard drive through your web browser (if you allow) that enables the site’s or service provider’s systems to recognize your browser and capture and remember certain Information. We use cookies to: - Keep track of advertisements, and - Compile aggregate data (not Personal Information) about our site traffic and site interactions in order to offer better site experiences and tools in the future. - We may also use trusted third-party services that track this Information on our behalf. You can choose to have your computer warn you each time a cookie is being sent, or you can choose to turn off all cookies. You do this through your browser settings. Since each browser is a little different, look at your browser’s Help Menu to learn the correct way to modify your cookies. If you turn cookies off, it will not prevent you from using our website. ## **How we use your Personal Information** When you provide us with Personal Information, it is stored in secure databases and may be used for: - Sending newsletters - Sending notices about upcoming webinars, - Contacting you when submitting your Information for employment opportunities, - Including you in marketing campaigns and sending promotional materials of interest, and - Sending you emails of surveys. ## **How we protect your Personal Information** As GenInvo is a global company, we process and store Personal Information using secure cloud-based products and services which may or may not be located within your country. GenInvo securely collects and transfers your Personal Information using encrypted processes. GenInvo stores your Personal Information using products provided by companies that have privacy and security management certifications. Your Personal Information is only accessible by a limited number of GenInvo persons whose access is controlled through unique user IDs and password-protected accounts. Personal Information is only stored for the period necessary to achieve the purpose for which the data was provided, and to comply with legal or statutory requirements. GenInvo is both a Data Controller and a Data Processor of Personal Information depending on the detailed circumstances for which it was collected. ## **Consent and access** Each time you provide Personal Information via our website or attend one of our webinars, you will be presented with a list of opt-in selections. By selecting a given opt-in selection, you are consenting to the collection the Personal Information being collected, and the use of that data described above. You may unsubscribe at any time by clicking the unsubscribe link in the footer of all marketing communication emails or by mailing [privacy@geninvo.com](mailto:info@geninvo.com). ## **Your rights** As an individual whose Personal Information has been collected and stored by our site, you may at any time: - Request confirmation as to how your Personal Information is being processed - Request copies of the Personal Information we hold as a company - Request your Personal Information be updated, corrected or blocked from further processing - Request deletion of your Personal Information - Restrict the reasons for processing your Personal Information - Receive the Personal Information we hold in common computer-readable form - Request your Personal Information is not used to make automated decisions about you - Withdraw consent to the processing of your Personal Information **Requests for the above can be submitted by email to** [**privacy@geninvo.com**](mailto:privacy@geninvo.com) **or by mail to the address below.** We have a defined process for the privacy and confidential data breach, and you can query or provide feedback to us at privacy@geninvo.com about your any dissatisfaction regarding your rights management or confidentiality violation. You have the right to complain to a Data Protection Authority/Supervisory Authority about Our collection and use of Your Personal Data. For example, if You are in the European Economic Area (EEA), please contact Your local data protection authority in the EEA. ## **Notification of changes** We keep our Privacy Policy under regular review, and we will place any updates on this web page. ## **Contact information** If you have any questions regarding our Privacy Policy, you can contact our Data Privacy Officer at [dpo@geninvo.com](mailto:info@geninvo.com) or write to us at: GenInvo, Inc1408 East Empire Street Bloomington, Illinois 61701, USA --- ### [People, Diversity & Culture](https://geninvo.com/people-diversity-culture/) **Published:** July 16, 2021 **Author:** admin **Content:** image-1 ![](//geninvo.com/wp-content/uploads/2024/08/Untitled-1.png) People People Diversity Diversity & Culture & Culture ![](//geninvo.com/wp-content/uploads/2024/09/Tree-with-shadow.png) ## People, Diversity & Culture [ Who We Are ](https://geninvo.com/who-we-are/) [ Contact Us ](https://geninvo.com/contact-us/) [ GENINVO Global Policies​ ](#policy) ![Company-culture](https://geninvo.com/wp-content/uploads/2021/07/Agile-e1626934378637.jpg "People Overview - GenInvo - GenInvo") ### GENINVO Thrives on a Culture of Innovation Innovation is always characterized by a tolerance for failure and a level playing field for creativity. Every business innovation is encouraged to be collaborative, agile and be non-hierarchical at its heart. ### GENINVO thrives on a culture of Innovation Innovation is always characterized by a tolerance for failure and a level playing field for creativity. Every business innovation is encouraged to be collaborative, agile and be non-hierarchical at its heart. ![](https://geninvo.com/wp-content/uploads/2024/09/Creavtive-image-1.png "Creavtive-image 1 - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ## Creative The first step of innovation is thinking outside the box. It’s essential as creativity acts as a differentiator and we value every idea because it fosters inspiring individuals within the organization. ## Agile Businesses in our industry work in an environment of constant change. Hence, we believe in creating a culture that embraces change. At GENINVO, we always want to turn uncertainty into an opportunity to flourish even in difficult times. ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2024/09/Aglie-image-1.png "Aglie-image 1 - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/08/kalfas-300x300.jpg "kalfas - GenInvo - GenInvo") > Hi, I’m Tom Kalfas, one of the founders of GENINVO and currently its Senior Innovation Officer. GENINVO has thrived from the start by leveraging opportunities in the industry where other, longer-established companies were unable meet the challenge. GENINVO was born of innovation, and to be successful in this space we have had to be extremely agile. Our combination of expertise in Life Sciences, leading edge technology, and software development affords us the ability to be agile, to quickly assess and meet challenges as opportunities for innovation, to blaze new trails, and to help revolutionize the industry to speed the development of new products for the patients and families who desperately need them. ![](https://geninvo.com/wp-content/uploads/2021/03/Ramesh_Venkataramana-300x300.jpg "Ramesh_Venkataramana - GenInvo - GenInvo") > Hello everyone, It’s Ramesh Venkataramana and I’m the Senior Director- IS & Strategies. Our culture thrives on transparency and open communication. GENINVO aims to make a positive impact in the society through purposeful innovation which acts as a stimulating factor and motivates each member to go the extra mile. The teams have flexibility and ownership in their workspace, so each one recognizes their task and individual value. We all are provided with employee benefits which significantly boosts morale and to be part of a company that emphasises on employee well-being creates a unified workforce. What matters is, we re-imagine, re-invent, and grow while being ourselves completely at GENINVO. ![](https://geninvo.com/wp-content/uploads/2024/09/Transparent-image-1.png "Transparent-image 1 - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ## Transparent Transparency breeds trust which acts as a foundation of efficient teamwork. We encourage our teams to work collaboratively in order to harbour an environment of cohesiveness and continuous improvement. # GENINVO Global Policies Prohibition of Child and Forced Labor Policy​​ Code of Conduct and Ethics​ GENINVO Promise to Sustainable Goals Prohibition of Child and Forced Labor Policy​​ GENINVO is an international organization that has accepted responsibility for setting minimum standards for itself and its business partners. The foundation of GENINVO’s ‘Prohibition of Child and Forced Labor Policy’ is based on the Company’s commitment to find practical, meaningful and culturally appropriate responses to support the elimination of such labor practices. It thus endorses the need for appropriate initiatives to progressively eliminate these abuses. In order to achieve the minimum level of protection as stated by the [International Labour Standards on Forced labour (ilo.org)](https://www.ilo.org/global/standards/subjects-covered-by-international-labour-standards/forced-labour/lang--en/index.htm "https://www.ilo.org/global/standards/subjects-covered-by-international-labour-standards/forced-labour/lang--en/index.htm"), and [ILO Conventions on child labour (IPEC)](https://www.ilo.org/ipec/facts/ILOconventionsonchildlabour/lang--en/index.htm "https://www.ilo.org/ipec/facts/iloconventionsonchildlabour/lang--en/index.htm"). GENINVO standards provide the basis for collaboration with all suppliers and ensure that they have appropriate provisions and prohibit child and forced labor. apibus leo. Code of Conduct and Ethics​ One of the core values at GENINVO is ethical approach to business conduct. GENINVO believes in equal employment opportunities to all employees and applicants for employment without regard to race, color, religion, sex, national origin, caste, age, disability, genetics or veterans’ status. GENINVO commits adherence with all applicable laws, regulations and guidelines for the business. GENINVO strictly prohibits non-discrimination, harassment, any form of corruptions, bribery, fraud and extortion directly or indirectly within the company by the employees and our business partners. In order to conduct day to day business, GENINVO protects confidentiality of the information and ensure secure flow of data for the business including intellectual property, study data and documents including personal information. GENINVO believes in maintaining a strong and healthy relationships with all its business parties (including vendors or contractors) and expects all of them to adhere to these policies laid down by the company. GENINVO provides and expects from business partners to ensure healthy, safe and ethical work environment. Please report if any suspected violations of this code to GENINVO Promise to Sustainable Goals Our strength lies in our people, and the diversity of our global workforce. We have a distributed workforce spanning across all major continents who help create a positive impact for our clients. Quality Education is a basic human right, from hiring fresh graduates and upskilling them for the industry to creating continued education opportunities for experienced professionals. When the Covid-19 pandemic struck, it led to unprecedented disruptions at work, which we complemented by immediately rolling out Work-From-Home policies along with Covid insurance packages for all employees. And as the lockdowns hit, for the families who depend on school mealsfor daily nutrition, were provided with support food packages. Beyond providing support for basic nutrition and livelihood, GENINVO believes in using technology as a catalyst to empower people and communities. Among a few of the initiatives taken, the Robotics Applications Initiative program has gathered momentum, which introduces the various applications of Robotics and concepts of Artificial Intelligence and Machine Learning to youth at an early age. Good health and well Being is a perennial area of focus for our workforce. We have introduced the Virtual Fitness and Exercise Challenge that helps maintain a balance between a healthy mental and physical state for all individuals. GENINVO is committed to empowering the youth in our community to solve complex societal challenges, and we continue to run several programs through which we inculcate a culture of technologically focused entrepreneurship, innovation and collaboration. # GENINVO Global Policies ### Prohibition of Child and Forced Labor Policy​ ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") GENINVO is an international organization that has accepted responsibility for setting minimum standards for itself and its business partners. The foundation of GENINVO’s ‘Prohibition of Child and Forced Labor Policy’ is based on the Company’s commitment to find practical, meaningful and culturally appropriate responses to support the elimination of such labor practices. It thus endorses the need for appropriate initiatives to progressively eliminate these abuses. In order to achieve the minimum level of protection as stated by the [International Labour Standards on Forced labour (ilo.org)](https://www.ilo.org/global/standards/subjects-covered-by-international-labour-standards/forced-labour/lang--en/index.htm "https://www.ilo.org/global/standards/subjects-covered-by-international-labour-standards/forced-labour/lang--en/index.htm"), and [ILO Conventions on child labour (IPEC)](https://www.ilo.org/ipec/facts/ILOconventionsonchildlabour/lang--en/index.htm "https://www.ilo.org/ipec/facts/iloconventionsonchildlabour/lang--en/index.htm"). GENINVO standards provide the basis for collaboration with all suppliers and ensure that they have appropriate provisions and prohibit child and forced labor. ### Code of Conduct and Ethics ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") One of the core values at GENINVO is ethical approach to business conduct. GENINVO believes in equal employment opportunities to all employees and applicants for employment without regard to race, color, religion, sex, national origin, caste, age, disability, genetics or veterans’ status. GENINVO commits adherence with all applicable laws, regulations and guidelines for the business. GENINVO strictly prohibits non-discrimination, harassment, any form of corruptions, bribery, fraud and extortion directly or indirectly within the company by the employees and our business partners. In order to conduct day to day business, GENINVO protects confidentiality of the information and ensure secure flow of data for the business including intellectual property, study data and documents including personal information. GENINVO believes in maintaining a strong and healthy relationships with all its business parties (including vendors or contractors) and expects all of them to adhere to these policies laid down by the company. GENINVO provides and expects from business partners to ensure healthy, safe and ethical work environment. Please report if any suspected violations of this code to ### GENINVO Promise to Sustainable Goals ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") Our strength lies in our people, and the diversity of our global workforce. We have a distributed workforce spanning across all major continents who help create a positive impact for our clients. Quality Education is a basic human right, from hiring fresh graduates and upskilling them for the industry to creating continued education opportunities for experienced professionals. When the Covid-19 pandemic struck, it led to unprecedented disruptions at work, which we complemented by immediately rolling out Work-From-Home policies along with Covid insurance packages for all employees. And as the lockdowns hit, for the families who depend on school mealsfor daily nutrition, were provided with support food packages. Beyond providing support for basic nutrition and livelihood, GENINVO believes in using technology as a catalyst to empower people and communities. Among a few of the initiatives taken, the Robotics Applications Initiative program has gathered momentum, which introduces the various applications of Robotics and concepts of Artificial Intelligence and Machine Learning to youth at an early age. Good health and well Being is a perennial area of focus for our workforce. We have introduced the Virtual Fitness and Exercise Challenge that helps maintain a balance between a healthy mental and physical state for all individuals. GENINVO is committed to empowering the youth in our community to solve complex societal challenges, and we continue to run several programs through which we inculcate a culture of technologically focused entrepreneurship, innovation and collaboration. ![](https://geninvo.com/wp-content/uploads/2024/09/No-poverty-251x300.png "No-poverty - GenInvo - GenInvo") ## NO POVERTY ![](https://geninvo.com/wp-content/uploads/2024/09/Zero-hunger-251x300.png "Zero-hunger - GenInvo - GenInvo") ## ZERO HUNGER ![](https://geninvo.com/wp-content/uploads/2024/09/Good-health-251x300.png "Good-health - GenInvo - GenInvo") ## GOOD HEALTH & WELL - BEING ![](https://geninvo.com/wp-content/uploads/2024/09/Quality-education-251x300.png "Quality-education - GenInvo - GenInvo") ## QUALITY WORK ![](https://geninvo.com/wp-content/uploads/2024/09/Gender-quality-251x300.png "Gender-quality - GenInvo - GenInvo") ## GENDER EQUALITY ![](https://geninvo.com/wp-content/uploads/2024/09/Decent-work-251x300.png "Decent-work - GenInvo - GenInvo") ## DECENT WORK& ECOMONIC GROWTH ![](https://geninvo.com/wp-content/uploads/2024/09/Reduced-inequalities-251x300.png "Reduced-inequalities - GenInvo - GenInvo") ## REDUCED INEQUALITIES ![](https://geninvo.com/wp-content/uploads/2024/09/Climate-action-251x300.png "Climate-action - GenInvo - GenInvo") ## CLIMATE ACTION ![](https://geninvo.com/wp-content/uploads/2024/09/Partnership-251x300.png "Partnership - GenInvo - GenInvo") ## PARTNERSHIPS FOR THE GOALS ### End poverty in all its forms everywhere ### End hunger, achieve food security and improved nutrition and promote sustainable agriculture ### Ensure healthy lives and promote well-being for all at all ages ### Ensure inclusive and equitable quality education and promote lifelong learning opportunities for all ### Achieve gender equality and empower all women and girls ### Promote sustained, inclusive and sustainable economic growth, full and productive employment and decent work for all ### Reduce inequality within and among countries ### Take urgent action to combat climate change and its impacts ### Strengthen the means of implementation and revitalize the global partnership for sustainable development --- ### [Our Services](https://geninvo.com/our-services/) **Published:** March 19, 2021 **Author:** admin **Content:** ![](//geninvo.com/wp-content/uploads/2025/03/Service-page-BG.png) image-1 ![](//geninvo.com/wp-content/uploads/2025/03/Service-page-image.png) What We Do What We DO GENINVO offers a wide range of services tailor-made for our client’s success. We understand the business challenges of organizations big and small. Whether you’re a startup or a multinational firm with data centers around the globe, our services can handle scale and complexity as well as create innovative tools for the future. GENINVO offers a wide range of services tailor-made for our client’s success. We understand the business challenges of organizations big and small. Whether you’re a startup or a multinational firm with data centers around the globe, our services can handle scale and complexity as well as create innovative tools for the future. ![](//geninvo.com/wp-content/uploads/2025/03/Service-page-image.png) ## Anonymization As a service ![](https://geninvo.com/wp-content/uploads/2025/04/anonymization-as-a-ser-1-1024x791.png "anonymization-as-a-ser-1 - GenInvo - GenInvo") GENINVO enables data sharing and anonymization processes, providing a redaction only approach. We anonymize clinical data set, documents, and DICOM images in sync for one study and perform qualitative/quantitative risk assessments. [ Find Out More ](https://geninvo.com/our-services/anonymization-as-a-service/) ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2025/04/anonymization-as-a-ser-1-1024x791.png "anonymization-as-a-ser-1 - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2024/03/innovation-as-a-service.png) ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ## Innovation As a service ![](https://geninvo.com/wp-content/uploads/2024/03/innovation-as-a-service.png) Discoveries and investments in next-generation medicines as well as technology have seen an increase in the pharma space. The ability to develop and deploy medications is a tedious process as a typical drug development cycle is complex and approximately takes 10-15 years for completion. We have team across the globe and the good news is that you can tap into this pool and use as a transformation force to cultivate your idea. [ Find Out More ](https://geninvo.com/our-services/innovation-as-a-service/) ## Collaborative Innovation ![](https://geninvo.com/wp-content/uploads/2024/03/Collbartive-inno-1024x791.png "Collbartive-inno - GenInvo - GenInvo") The need for new drugs is significant to our everyday lives and companies must comply to the current regulatory processes. One of the main challenges pharma industry faces is the lengthy timeline of 10 years’ or more for developing medicines, the continuous pressure on pricing, and ever-changing guidelines. At the same time, another major challenge is the high degree of uncertainty for drug approval. [ Find Out More ](https://geninvo.com/our-services/anonymization-as-a-service/) ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2024/03/Collbartive-inno-1024x791.png "Collbartive-inno - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2024/02/CAD-1024x791.jpg "CAD - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ## Custom Application Development ![](https://geninvo.com/wp-content/uploads/2024/02/CAD-1024x791.jpg "CAD - GenInvo - GenInvo") Life Science SMEs, leading technologists, and software development experts drive our services. They support clients in several areas, including custom integration and development projects, business and technical project management, DevOps, R-Shiny development, Data visualization, UI/UX development, and AI and technical platforms. [ Find Out More ](https://geninvo.com/our-services/custom-application-development/) ## Cloud managed Service ![](https://geninvo.com/wp-content/uploads/2024/02/cloud-mana-1024x791.jpg "cloud-mana - GenInvo - GenInvo") GENINVO helps you manage IT, databases, and enterprise applications, including the integration of Citrix, Azure AD, Octa, and SQL. We convert from a CAPEX to an OPEX model, freeing up your IT resources to drive innovation. Our experts outline how you can improve efficiency and realize cost savings versus traditional on-premises environments. [ Find Out More ](https://geninvo.com/our-services/cloud-managed-services/) ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2024/02/cloud-mana-1024x791.jpg "cloud-mana - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2024/02/Talent-resource-1024x791.jpg "Talent-resource - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ## Resource Hub ![](https://geninvo.com/wp-content/uploads/2024/02/Talent-resource-1024x791.jpg "Talent-resource - GenInvo - GenInvo") Today’s business environment is volatile, competitive, and complex. To stay ahead, businesses need innovative ways to optimize resources while remaining competitive and agile. We are dedicated to fostering diverse and promising talent to contribute to the innovative pipeline and product development within the Life Science domain. This involves the orchestration of holistic and end-to-end offerings, including digital, analytics, applications, and cloud services. [ Find Out More ](https://geninvo.com/our-services/talent-resource-hub/) --- ### [Our Products](https://geninvo.com/our-products/) **Published:** March 19, 2021 **Author:** admin **Content:** ![](//geninvo.com/wp-content/uploads/2024/06/Sh-image.jpg) image-1 ![](https://geninvo.com/wp-content/uploads/2021/04/Product-over.gif) Our Product Portfolio Our Product Portfolio All our products are scalable, secure, and customizable. Our industry-leading Life Science products also come with plug-and-play modules and off-the-shelf licensing for hassle-free deployment with your existing infrastructure. All our products are scalable, secure, and customizable. Our industry-leading Life Science products also come with plug-and-play modules and off-the-shelf licensing for hassle-free deployment with your existing infrastructure. ![](https://geninvo.com/wp-content/uploads/2021/04/Product-over.gif) ## Our Product Portfolio All our products are scalable, secure, and customizable. Our industry-leading Life Science products also come with plug-and-play modules and off-the-shelf licensing for hassle-free deployment with your existing infrastructure. ![](https://geninvo.com/wp-content/uploads/2021/04/Product-over.gif) ![](https://geninvo.com/wp-content/uploads/2024/06/ApoGI-box-1.png "ApoGI-box-1 - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ## ApoGI™ #### Next-Gen End to End Platform, Automating your Clinical Study Deliverables ![](https://geninvo.com/wp-content/uploads/2024/06/ApoGI-box-1.png "ApoGI-box-1 - GenInvo - GenInvo") ApoGI™ is an integrated, automation platform that leverages AI and ML, focusing on standards and metadata management to streamline processes and the generation of artifacts, typically associated with the clinical study lifecycle. [ Find Out More ](https://geninvo.com/our-products/apogi/) ## DocQC™ #### Medical Writers automation tool for QC checks ![](https://geninvo.com/wp-content/uploads/2024/06/DocQC-box.1.png "DocQC-box.1 - GenInvo - GenInvo") DocQC™ is a tool for automation of Quality Control (QC) checks that have historically required multiple, time-consuming cycles of manual review. Checks of various complexities are programmed leveraging cutting‒edge technologies. DocQC™enables your Medical Writers to maintain their focus on the science, analyses, and presentation of results. [ Find Out More ](https://geninvo.com/our-products/docqc-medical-writers-automation-tool/) ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2024/06/DocQC-box.1.png "DocQC-box.1 - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2024/06/Shadow-box.1.png "Shadow-box.1 - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ## Shadow™ #### Your Solution to Evolving Data Transparency Requirements ![](https://geninvo.com/wp-content/uploads/2024/06/Shadow-box.1.png "Shadow-box.1 - GenInvo - GenInvo") Shadow™ is a leader in automating data and document de-identification and anonymization technology. Our team of Life Sciences and software development professionals built it with a commitment to producing innovative and long-standing solutions. [ Find Out More ](https://geninvo.com/our-products/data-anonymization-tool/) ## DocWrightAI™ #### A Document Generation Software ![](https://geninvo.com/wp-content/uploads/2024/06/DocWrightAI-box-1.png "DocWrightAI-box-1 - GenInvo - GenInvo") DocWrightAI™ – a document generation software for healthcare industry that revolutionizes the way life science companies generate and review standard documents. **It is designed specifically to meet the complex documentation requirements of the life sciences** industry, automating much of the document creation process while maintaining accuracy and compliance. [ Find Out More ](https://geninvo.com/our-products/docwrightai/) ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2024/06/DocWrightAI-box-1.png "DocWrightAI-box-1 - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2025/02/Datalution-box.1.webp "Datalution-box.1 - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ## Datalution™ #### Your Solution for Synthetic Data Generation ![](https://geninvo.com/wp-content/uploads/2025/02/Datalution-box.1.webp "Datalution-box.1 - GenInvo - GenInvo") Our product generates “meaningful” synthetic data that simulates real-world scenarios, enabling you to test such things as your **edit checks, [CDISC (SDTM)](https://www.cdisc.org/standards/foundational/sdtm) dataset generation programs, data visualizations, and TFL (Tables, Figures, and Listings) generation programs** under a wide range of conditions. It makes clinical trial simulation and synthetic data generation for healthcare easier. [ Find Out More ](https://geninvo.com/our-products/datalution/) ## CIS - Confidential Information Scanner #### AI-powered discovery across web and document resources. ![](https://geninvo.com/wp-content/uploads/2025/02/CIS-Product-page-image-1-1024x851.png "CIS-Product-page-image (1) - GenInvo - GenInvo") GenInvo’s CIS Tool is an advanced AI-driven solution that efficiently uncovers confidential business information over web and in publicly available documents, covering over 100 standard categories. Combine it with **[Shadow](https://geninvo.com/our-products/data-anonymization-tool/)** to remove sensitive identifiers and use our **[Data Collaboration Platform](https://geninvo.com/our-products/data-collaboration/)** to share your processed data with confidence. [ Find Out More ](https://geninvo.com/cis-confidential-information-scanner/) ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2025/02/CIS-Product-page-image-1-1024x851.png "CIS-Product-page-image (1) - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2025/02/Data-collaboration-Product-page-image-1-1024x851.webp "Data-collaboration-Product-page-image (1) - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ## Data Collaboration Platform #### Data Collaboration Platform Empowers Researchers with Seamless Clinical Data Sharing. ![](https://geninvo.com/wp-content/uploads/2025/02/Data-collaboration-Product-page-image-1-1024x851.webp "Data-collaboration-Product-page-image (1) - GenInvo - GenInvo") In response to the growing emphasis on open science, the Data Collaboration platform is transforming the landscape of clinical research by empowering researchers to request, access, and analyze clinical data with unprecedented ease. Designed to foster transparency and collaboration, the platform offers a secure and user-friendly environment for data sharing. Researchers can now unlock the potential of existing clinical data, facilitating innovative research and accelerating advancements in healthcare. [ Find Out More ](https://geninvo.com/our-products/data-collaboration/) ## Automation of Data Conversion™ #### Automation of Data Conversion ![](https://geninvo.com/wp-content/uploads/2024/06/Data-Conversion-box-1.png "Data-Conversion-box-1 - GenInvo - GenInvo") The SDTM (Study Data Tabulation Model) and ADaM (Analysis Data Model) are standards for human clinical trials (research) data tables and non-clinical data tables submitted by researchers to health authorities. It aligns with the specification developed by the Federation of Clinical Data Exchange Standards (CDISC). ApoGI is AI and meta-data driven designed for automation of end-to-end drug development process. [ Find Out More ](https://geninvo.com/our-products/automation-of-data-conversion/) ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2024/06/Data-Conversion-box-1.png "Data-Conversion-box-1 - GenInvo - GenInvo") --- ### [Webinar Registration](https://geninvo.com/modernizing-clinical-document-qc-from-manual-chaos-to-al-enabled-efficiency-with-docqc/) **Published:** October 30, 2023 **Author:** admin **Content:** ## Webinar Topic ## Synthetic Data for Secure Innovation: Balancing Utility and Privacy ## SPEAKER: Jaskaran Saini September 30th, 2025 | 12:00 PM - 12:30 PM ET ## Webinar Registration Full Name Work Email Company Name Phone Number Register Now --- ### [DSA](https://geninvo.com/our-services/dsa/) **Published:** September 8, 2021 **Author:** admin **Content:** Machine Learning GENINVO Machine Learning expert team helps in creating a system that can assist you with critical business decisions [View More](#machl) Why DS&A-CoE? This Centre of Excellence forms the bed rock for innovation at GENINVO [View More](#dsa-coe) Case Studies Learn how our products and services are solving business problems across industries​ [View More](#casestudies) [ ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjY3MzUiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D) ## What is Data Science? Data Science Data science entails analyzing data to find patterns and characteristics. A combination of mathematics, statistics, and computer science are involved here. A variety of visualization techniques are used to make the data understandable. The focus here is to gain insights that can make a positive difference to the organization by understanding and using the data. Artificial Intelligence Like natural intelligence, artificial intelligence enables computers to mimic the human intelligence and behavior. Machine Learning Machine Learning is a branch of Artificial Intelligence that focuses on learning. In order to learn autonomously from data, algorithms and statistical models are developed without explicit instructions being given up front. Deep Learning Deep Learning is part of Machine Learning that uses artificial neural networks. Models of this type are based on the structure and function of the human brain. ![](https://geninvo.com/wp-content/uploads/2021/09/graph.jpg "graph - GenInvo - GenInvo") Technologies at DS&A-CoE ## Generate better Insights with Cutting-edge Technologies ![](https://geninvo.com/wp-content/uploads/2021/08/icons-dsa-02.svg) Machine Learning ![](https://geninvo.com/wp-content/uploads/2021/08/icons-dsa-04.svg) Deep Learning ![](https://geninvo.com/wp-content/uploads/2021/08/icons-dsa-01.svg) Natural Language Processing ![](https://geninvo.com/wp-content/uploads/2021/08/icons-dsa-03.svg) Recommendation Engine ![](https://geninvo.com/wp-content/uploads/2021/09/icons-dsa-05.svg) Visualization ![](https://geninvo.com/wp-content/uploads/2021/09/icons-dsa-06.svg) Chatbot Development ![](https://geninvo.com/wp-content/uploads/2021/08/icons-dsa-02.svg) Machine Learning ## Machine Learning By partnering with GenInvo’s Machine Learning expert team, you can build a system that helps you make better business decisions. ML techniques are revolutionizing clinical development, delivering time and cost savings and providing better insights to inform better decisions. ![](https://geninvo.com/wp-content/uploads/2021/08/icons-dsa-04.svg) Deep Learning ## Deep Learning From labeling, training dataset assessment, and image processing, to custom deep learning pipelines, GenInvo Scientific develops deep learning for video/Image analytics, anomaly detection, and automation solutions in life science. ![](https://geninvo.com/wp-content/uploads/2021/08/icons-dsa-01.svg) Natural Language Processing ## Natural Language Processing Utilize natural language processing pipelines powered by deep learning to extract meaning and insights from unstructured text, voice, and audio. ![](https://geninvo.com/wp-content/uploads/2021/08/icons-dsa-03.svg) Recommendation Engine ## Recommendation Engines Information systems that predict user preferences and presents product/item/service recommendations that are personalized and subjective. ![](https://geninvo.com/wp-content/uploads/2021/09/icons-dsa-05.svg) Visualization ## Visualization We have an experienced team for generation of Data Visualization charts with use of latest tools such as SAS, R, Tableau, Spotfire, Qlik Sense, and Power-BI. ![](https://geninvo.com/wp-content/uploads/2021/09/icons-dsa-06.svg) Chatbot Development ## Chatbot Development With our chatbot development services, you can offer customer support through human-like conversations to your customers, saving time and operational costs. Why DS&A-CoE? ## "Our aim is to accelerate discoveries and the development of life sciences worldwide using AI/ML" ### Boost Innovation The DS&A-COE is the GenInvo pillar and go-to place for AI. Our aim to accelerate discoveries and the development of life sciences across the worldwide using AI/ML. Our experienced and highly skilled business strategists, life science experts, data scientist’s and others understand tide of AI. We can assist in designing and implementing customized strategies to help traverse your business through a swift transition. ### Increase Efficiency & Discover Insights Faster Enables life sciences organizations to reduce time, eliminate data & process redundancies, minimize costs, wastages, and outflows. Enables you to drive efficiency in the business processes by delivering results in near real time, select the right target audience, and automatically classify and mine text for key insights. Real time results have made insight discovery faster than ever before. AI/ML generated results are more accurate and freer of any human induced errors or biases. ### Mitigate Risks AI where computer algorithms improve over time through their experience of using data – plays an increasingly prominent role in enterprise risk management. We create sophisticated tools to monitor and analyze behavior and activities in real time. Case studies ## Learn how our products and services are solving business problems across industries [ ![Building a Strong Foundation: Robust Metadata Repository (MDR) Framework for Automated Standard Compliant Data Mapping](https://geninvo.com/wp-content/uploads/2023/12/Building-a-Strong-Foundation-300x169.png) ](https://geninvo.com/building-a-strong-foundation-robust-metadata-repository-mdr-framework-for-automated-standard-compliant-data-mapping/) ## [Building a Strong Foundation: Robust Metadata Repository (MDR) Framework for Automated Standard Compliant Data Mapping](https://geninvo.com/building-a-strong-foundation-robust-metadata-repository-mdr-framework-for-automated-standard-compliant-data-mapping/) [ ![Importance of “Table, Listing and Figures” Automation in Clinical Trials](https://geninvo.com/wp-content/uploads/2023/12/acl-v1-300x169.jpg) ](https://geninvo.com/importance-of-table-listing-and-figures-automation-in-clinical-trials/) ## [Importance of “Table, Listing and Figures” Automation in Clinical Trials](https://geninvo.com/importance-of-table-listing-and-figures-automation-in-clinical-trials/) [ ![White List & Black List: Enhanced NER Model](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-10-Case-Study-WB-List_v3-300x169.jpg) ](https://geninvo.com/white-list-black-list-enhanced-ner-model/) ## [White List & Black List: Enhanced NER Model](https://geninvo.com/white-list-black-list-enhanced-ner-model/) [ ![NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity-300x169.jpg) ](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) ## [NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) [ ![DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-12-Eprotocol-presentation-300x169.jpg) ](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) ## [DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) [ ![Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-13-Shadow-Recommendation-Engine-300x169.jpg) ](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) ## [Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) [ ![Lung Cancer Detection](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-8-Lung-Cancer-Detection-use-cases-300x169.jpg) ](https://geninvo.com/lung-cancer-detection/) ## [Lung Cancer Detection](https://geninvo.com/lung-cancer-detection/) [ ![Breast Cancer Detection Using Machine Learning](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-9-Case-Study-Breast-Cancer-Detection_v3-use-cases-300x169.jpg) ](https://geninvo.com/breast-cancer-detection-using-machine-learning/) ## [Breast Cancer Detection Using Machine Learning](https://geninvo.com/breast-cancer-detection-using-machine-learning/) [ ![Provide ApoGI as a Metadata Driven Transformations](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-5-300x169.jpg) ](https://geninvo.com/provide-apogitm-asa-metadata-driventransformations/) ## [Provide ApoGI as a Metadata Driven Transformations](https://geninvo.com/provide-apogitm-asa-metadata-driventransformations/) [ ![Provide ApoGI as a MDR Visualization](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-6-300x169.jpg) ](https://geninvo.com/provide-apogitmas-a-mdrvisualization/) ## [Provide ApoGI as a MDR Visualization](https://geninvo.com/provide-apogitmas-a-mdrvisualization/) [ ![Provide ApoGI as a Metadata Driven Platform](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-7-300x169.jpg) ](https://geninvo.com/provide-apogitmas-a-metadatadriven-platform/) ## [Provide ApoGI as a Metadata Driven Platform](https://geninvo.com/provide-apogitmas-a-metadatadriven-platform/) Building Solutions ## Using AI/ML techniques, currently our experts are working on to build solutions from scratch ![](https://geninvo.com/wp-content/uploads/2021/08/bs-icons-01.jpg "bs-icons-01 - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/08/bs-icons-02.jpg "bs-icons-02 - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/08/bs-icons-03.jpg "bs-icons-03 - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/08/bs-icons-04.jpg "bs-icons-04 - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/08/bs-icons-07.jpg "bs-icons-07 - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/08/bs-icons-06.jpg "bs-icons-06 - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/08/bs-icons-05.jpg "bs-icons-05 - GenInvo - GenInvo") --- ### [Anonymization As a Service](https://geninvo.com/our-services/anonymization-as-a-service/) **Published:** March 19, 2021 **Author:** admin **Content:** ![](//geninvo.com/wp-content/uploads/2026/04/Top-section.webp) image-1 ![](//geninvo.com/wp-content/uploads/2024/08/Untitled-1.png) Anonymization As a Service Anonymization As a service ![](//geninvo.com/wp-content/uploads/2025/04/anonymization-as-a-ser-1.png) ## Anonymization As a Service [ View case studies ](https://geninvo.com/insights/case-studies/) ![](https://geninvo.com/wp-content/uploads/2021/03/anonym-top.jpg) ## Learn more about our data anonymization tool. ![](https://geninvo.com/wp-content/uploads/2024/10/Shadow-3d-logo-24-V1.webp "Shadow-3d-logo-24-V1 - GenInvo - GenInvo") [ Read More ](https://geninvo.com/our-products/data-anonymization-tool/) Clinical Data sharing for transparency is a hot discussion topic since the Policy 0070 and Health Canada publishing requirements have been implemented. Pharmaceutical companies need to redact their clinical documents to support submission for market authorization, but regulatory bodies are motivating sponsors to maintain higher data utility through anonymization. It is not only regulatory groups, but also other associations/big pharmaceutical firms that are moving towards mandating of clinical data sharing. For example, in July 2013, Pharmaceutical Researchers and Manufacturers of America (PhRMA) & European Federation of Pharmaceutical Industries and Associations (EFPIA) member companies demonstrated commitment and shared complete Clinical Study Reports (CSRs) along with Individual patient data (IPD). In June 2017, International Committee of Medical Journal Editors (ICMJE) introduced a requirement for data sharing statements of clinical trials before publishing any articles in journals abiding to ICMJE. Multiple scenarios for data sharing exist. ## Sharing Gain Clinical data such as dataset, clinical study reports, clinical summary reports and images may need sharing. - ● Sharing data under Health Canada and EMA Policy 0070 - ● Sharing data externally with researchers. - ● Sharing data internally for exploratory analysis. ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ## Sharing Data Clinical data such as dataset, clinical study reports, clinical summary reports and images may need sharing. - Sharing data under Health Canada and EMA Policy 0070 - Sharing data externally with researchers - Sharing data internally for exploratory analysis # Risk Assessement for Anonymization Pharmaceutical companies have been submitting anonymized clinical reports to the EMA/Health Canada with redaction of any text meeting the criteria of personal information or Companies Confidential Information (CCI). EMA/Health Canada is also interested in alternative techniques for data anonymization. Those include replacement, generalization, date offsetting, etc., that have a more clearly established method for calculating the quantitative risk of re-identification. The industry is using quantitative risk assessment for anonymization and maintaining the balance between the risk of re-identification and data utility. Hence, with the release of Phase 2 of Policy 0070, you can expect growth in anonymization as the industry recognizes the importance of data sharing. GENINVO understands this necessity and has developed Shadow™, a solution compliant with Health Canada, EMA Policy 0070 (Phase 1 & 2), and France’s MR001-MR004. ## Type of Services provided As a business that safeguards data, we ensure the accurate redaction and anonymization of all information. Every organization has different requirements for data retention, along with unique redaction needs. Business subject matter expertise balanced with leading edge technologies and software developers is critical in delivering solutions and services that resonate with our clients. Here are some of the SME groups and strategic consulting services we provide: We are SMEs with a wealth of experience from the Life Science domains. We have in-depth knowledge and offer guidance to product development teams, resulting in innovative-oriented products like Shadow™, DocQC™, ApoGI™, etc. ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ## Variety of Anonymization Business subject matter expertise balanced with leading edge technologies and software developers is critical in delivering solutions and services that resonate with our clients. Here are some of the SME groups and strategic consulting services we provide: Anonymization with redaction only approach and Qualitative/ Quantitative risk assessment Support with setting up data sharing and anonymization processes Anonymization with redaction and transformation of identifying information with Quantitative risk assessment Anonymization of clinical dataset, documents and DICOM images in sync for one study Anonymization with redaction only approach and Qualitative/ Quantitative risk assessment As a business that safeguards data, we ensure the accurate redaction and anonymization of all information. Every organization has different requirements for data retention, along with unique redaction needs. We put our customers at ease by properly handling sensitive information. Quantitative risk analysis works on objective understanding as it relies on precise statistical data. In comparison, qualitative risk analysis works on expert subjective understanding, as it depends on the probability of an event and its level of impact. We provide actionable insights and help minimize uncertainty so the focus can be on high-priority risks. Support with setting up data sharing and anonymization processes Our technical teams provide guidance and simplify the complexities of sharing data by employing efficient process generation techniques. Thus, enabling protection of confidential data during sharing data. Anonymization with redaction and transformation of identifying information with Quantitative risk assessment We anonymize each data set while meeting regulatory requirements to protect our data subjects’ privacy and personal information. Risk assessment is one of the most critical and complex parts of risk management. Quantitative assessments deliver clear data and determine threat levels and loss expectancies. As a result, we understand risk and provide the right technology to mitigate potential issues. Anonymization of clinical dataset, documents and DICOM images in sync for one study Data anonymization is crucial for clinical data transparency. Personally identifiable data is removed or encrypted to ensure the protection of patient privacy during data sharing. In addition, data access is available that safeguards the confidentiality of research participants. Medical image data also needs to be anonymized, along with datasets and documents. We recognize that need and follow the DICOM (Digital Imaging and Communications in Medicine) format for transmitting medical images while preserving their utility. However, anonymizing healthcare data while applying GDPR compliant techniques is not a one-off task. Rather, we synchronize the complex processes for you and eliminate the various challenges of data sharing. --- ### [Collaborative Innovation](https://geninvo.com/our-services/collaborative-innovation/) **Published:** May 24, 2022 **Author:** admin **Content:** ![](//geninvo.com/wp-content/uploads/2026/04/Top-section.webp) image-1 ![](//geninvo.com/wp-content/uploads/2024/08/Untitled-1.png) Collaborative Innovation Collaborative Innovation ![](//geninvo.com/wp-content/uploads/2024/11/CI-iamge.png) ## Collaborative Innovation [ View Brochure ](#) ![](https://geninvo.com/wp-content/uploads/2022/10/collaborative-innovation.jpg "collaborative innovation - GenInvo - GenInvo") The need for new drugs is significant to our everyday lives and companies must comply to the current regulatory processes. One of the main challenges pharma industry faces is the lengthy timeline of 10 years’ or more for developing medicines, the continuous pressure on pricing, and ever-changing guidelines. At the same time, another major challenge is the high degree of uncertainty for drug approval. In the wake of pandemic, the need to expedite the Drug Development process has escalated. ## Collaborative Innovation Model Collaboration between the right stakeholders is a foundation to innovation. Every pharma company has their unique needs and challenges, so ‘one size fits all’ solution wouldn’t be feasible to overcome them. Our team is producing transformational software solutions using years of experience in life sciences industry, collaboration with industry forums, leading edge technologies and our software development capabilities, data-engineering practices, cloud expertise, and artificial intelligence research. Under our ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") --- ### [Cloud Managed Services](https://geninvo.com/our-services/cloud-managed-services/) **Published:** March 26, 2021 **Author:** admin **Content:** ![](//geninvo.com/wp-content/uploads/2026/04/Top-section.webp) image-1 ![](//geninvo.com/wp-content/uploads/2024/08/Untitled-1.png) Cloud managed Services Cloud managed Service [View Case Studies](https://geninvo.com/insights/case-studies/) ![](//geninvo.com/wp-content/uploads/2024/12/CMS-image.png) Where to Start: - Do you have a plan to move your applications to the cloud and achieve the business outcomes? - Do you have a solution to convert from a CAPEX to an OPEX model? We help you manage your IT, databases, and enterprise applications, including the integration of Citrix, Azure AD, Octa, and SQL. We enable conversion from a CAPEX to an OPEX model, freeing up your IT resources to drive innovation. Our experts will outline how you can improve efficiency, delivering cost savings versus traditional on-premises environments. ## Managed Services Managed services offer you a roadmap to reach your cloud potential: - ● Get clear assessments and advice when migrating to the cloud. - ● Access Microsoft Azure and AWS environments without added CAPEX. - ● Leverage service levels with consistent application performance. - ● Enhance security with policy driven SSO. - ● Reduce risk and cost with usage-based pricing. - ● Deploy and manage critical enterprise workloads and data. - ● Manage your DevOps tools, activities such as install/upgrade, configuration, backup/restore of data, performance, and security. - ● Support the underlying compute, storage, and network resources. - ● Build business agility through multiple management options. ## Cloud Database Management # Why Adopt DevOps DevOps is a powerful option for enterprises, accelerating their transformation journey and centrally managing their software and delivery foundation. Your infrastructure is a perpetually evolving series of challenges. From mastering diverse tools to evolving software tools, from a functional and technical standpoint, DevOps is dynamic. Its impact includes technological trends, such as containers or micro-services. Let us answer these questions with you: - *How can you speed up DevOps initiatives?* - *How do you to start?* - *Where should you standardize?* - *How can you customize DevOps processes, practices, and tools?* ## Key offerings for DevOps managed services include: ##### Continuous integration The speed and scale at which DevOps moves and manages the process to ensure quick and error-free releases. ##### Release management We assist in managing your releases to reduce the risk of failed deployments ##### Security management We provide comprehensive protection for your environment and embrace a DevSecOps Model ##### Monitoring We actively check real user interactions monitoring of the system, infrastructure, application security, and more. ##### Policy & Governance Create transparent cybersecurity policies and procedures that are easy for developers and other team members to understand and adopt. This enables teams to develop code that meets security requirements. ## Benefits ## The benefits of switching to a managed services provider include reducing costs to a flat monthly rate and saving time. If your business isn’t tapping into the benefits of the cloud yet, we can help. GENINVO can assess your business’ cloud readiness and determine which cloud IT solutions support your goals most effectively. We provide customizable packages of managed IT services ­(a client can choose any components and services) with flexible pricing.​​ The subscription fee for managed IT services involves following factors: - IT infrastructure type (cloud, on-premises). - IT infrastructure complexity. - Scope of infrastructure projects. - Support package (time coverage, number of issues included). --- ### [Custom Application Development](https://geninvo.com/our-services/custom-application-development/) **Published:** March 19, 2021 **Author:** admin **Content:** ![](//geninvo.com/wp-content/uploads/2026/04/Top-section.webp) image-1 ![](//geninvo.com/wp-content/uploads/2024/08/Untitled-1.png) Custom Application Development Custom Application Development ![](//geninvo.com/wp-content/uploads/2024/10/CAD-image.png) Life science tools companies are under increasing pressure to reduce time-to-market and the cost of introducing new products. As product lifecycles continue to decrease, compressing development cycles and accelerating new product introductions are becoming critical. Companies that fail to consistently launch new products will lose ground to more innovative competitors who invest in new and improved solutions to advance their customers’ research. But new products alone are not enough – they need to be successful new products. To compete with the Life Science industry’s ever-increasing demands, enterprises must optimize cost and align IT with business outcomes. In addition, end markets and end-customers are ever more engaged and more critical as the healthcare industry trends toward connectivity, personalization, and self-service. To meet these needs, you’ll find custom application development an attractive choice, providing preconfigured solutions to meet challenging demands and help transform business. ## Diverse Technical Capabilities Life Science SMEs drive our custom application development supported by technology and development experts. Our technical teams support you in these ways: - JavaScript, Java, Python, Shell Scripting,and C++ Development - Project Management (General service projects and both Agile and Waterfall Software Development Methodologies) - R & R-Shiny Development - Relational and Graph Database Technologies - Strong IT Team to support the Technical Platform (Platform as Service, Infra as Service, Software as Service) etc - Data Visualization (Spotfire, Tableau) - UI/UX Development (AngularJS) - Big Data and Data Lakes (Hadoop, MS Insight, Spark, MongoDB) - Artificial Intelligence (Machine Learning, Natural Language Processing (NLP), Computer Vision, Voice Recognition, Chatbots, Recommendation Engines, Data/Document Recognition, Auto-Analytics, Robotic Process Automation (RPA)) ## Custom Application Development [ View case studies ](https://geninvo.com/insights/case-studies/) ![](https://geninvo.com/wp-content/uploads/2021/03/cad-top.jpg) ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ## Diverse Technical Capabilities Life Science SMEs drive our custom application development supported by technology and development experts. Our technical teams support you in these ways: - JavaScript, Java, Python, Shell Scripting, and C++ Development - Relational and Graph Database Technologies - Big Data and Data Lakes (Hadoop, MS Insight, Spark, MongoDB) - R & R-Shiny Development - Data Visualization (Spotfire, Tableau) - UI/UX Development (AngularJS) # The GENINVO Difference Looking to enhance your organization’s impact? GENINVO’s technology-empowered experts are available to assist you in the following areas: ##### Software Architects and Developers to support custom integrations and development projects and act as an extended arm for your development teams ##### Business Project Management Help effectively manage key projects from pharma functional knowledge background ##### Technical Project Management Govern your software projects including Waterfall and Agile software development methodologies ##### DevOps Enhance your software solutions environments, development systems, and software validation and release capabilities ##### QA/Computer Systems Validation Consultants Evaluate and extend support for your software/systems development and implementation processes ##### Testing & Test Automation Assess and support for your software testing processes, including the development of scripts to automate testing procedures ##### Technical Documentation & Training Specialists Compile and maintain your Software Development Life Cycle (SDLC)-related documentation, including the creation of owner/user manuals and training materials ##### Qualified Subject Matter experts Delivery projects in the Life Sciences domain # Solutions GENINVO provides anonymization services for variety of anonymization needs including the following: --- ### [Resource Hub​](https://geninvo.com/our-services/talent-resource-hub/) **Published:** March 19, 2021 **Author:** admin **Content:** ![](//geninvo.com/wp-content/uploads/2026/04/Top-section.webp) image-1 ![](//geninvo.com/wp-content/uploads/2024/08/Untitled-1.png) Resource Hub Resource Hub ![](//geninvo.com/wp-content/uploads/2025/01/RH-image.png) Today’s business environment is volatile, competitive, and complex. To stay ahead, Life Sciences requires innovative ways to optimize resources while managing agility. We foster diverse, promising talent in Life Science with great opportunities for these graduates. We believe that convergence of the ecosystem is the future and are consequently working to create unique customer experiences. This process involves innovative orchestration of holistic and end-to-end offerings, including digital, analytics, applications, and cloud services. Life Science companies are increasingly seeking to truncate the process. They want an integrated end-to-end approach with a single vendor to minimize hops, maximize productivity, and accelerate product launches and go-to-market. ## Development and Delivery Expertise We provide development and delivery expertise with biometric knowledge in the following areas: - Data Visualization (R, R Shiny, Spotfire, Tableau, Python) - QA/CSV – Assess, enhance and extend support for your software/systems development and implementation processes - Custom Software Development Services (Full Stack Java, Python, Shell Scripting, C++, Angular JS, UI-UX Design & Development) - Business Process Optimization and Modernization - Software evaluation, implementation, and maintenance - Solutions for Big Data and Data Lakes (Hadoop, Spark) using Graph Databases. Build and implement AI/ML/NLP/Bot’s techniques around processes & tools - Project Management and Delivery Services # Clinical Data Disclosure and Data Sharing capabilities Our services range from custom application development for your specific needs to anonymization services for attaining clinical data disclosure to data sharing capabilities. Our product line is a result of the highly skilled SMEs and their in-depth knowledge to understand the industry’s requirements. [![](https://geninvo.com/wp-content/uploads/2024/12/ApoGI.webp "ApoGI - GenInvo - GenInvo")](https://geninvo.com/our-products/apogi/)### [ApoGI](https://geninvo.com/our-products/apogi/) Next-generation platform for automation of your clinical study lifecycle deliverables [![](https://geninvo.com/wp-content/uploads/2024/12/DocQC.webp "DocQC - GenInvo - GenInvo")](https://geninvo.com/our-products/docqc-medical-writing-automation/)### [DocQC](https://geninvo.com/our-products/docqc-medical-writing-automation/) Medical Writers automation tool for QC checks [![](https://geninvo.com/wp-content/uploads/2024/12/Shadow.webp "Shadow - GenInvo - GenInvo")](https://geninvo.com/our-products/data-anonymization-tool/)### [Shadow](https://geninvo.com/our-products/data-anonymization-tool/) Your Solution to Evolving Data Transparency Requirements. Ensures Data Protection and Enables Data Sharing [![](https://geninvo.com/wp-content/uploads/2025/01/GI-all-products-3d-logo-24-V1.webp "GI-all-products-3d-logo-24-V1 - GenInvo - GenInvo")](https://geninvo.com/our-products/automation-of-data-conversion/)### [Automation of Data Conversion](https://geninvo.com/our-products/automation-of-data-conversion/) Handling SDTM (Study Data Tabulation Model) and ADaM as standards for human clinical trials. ## Solutions Business SME balanced with leading-edge technologies and software developers is critical in delivering solutions and services for our clients. Here are some of the SME groups and strategic consulting services we provide: --- ### [Videos](https://geninvo.com/insights/videos/) **Published:** March 31, 2021 **Author:** admin **Content:** ![](//geninvo.com/wp-content/uploads/2024/09/image-5.jpg) image-1 ![](//geninvo.com/wp-content/uploads/2024/08/Untitled-1.png) ![](//geninvo.com/wp-content/uploads/2025/05/Videos.png) GENINVO Videos GENINVO Videos Dive into the world of GENINVO. Learn more about our products and get to know us better in our engaging video section. Dive into the world of GENINVO. Learn more about our products and get to know us better in our engaging video section. ![](//geninvo.com/wp-content/uploads/2025/05/Videos.png) ## GENINVO Videos Dive into the world of GENINVO. Learn more about our products and get to know us better in our engaging video section. [ Back ](https://geninvo.com/insights/) ![](https://geninvo.com/wp-content/uploads/2021/04/videos-top.jpg "videos-top - GenInvo - GenInvo") [ ![](https://geninvo.com/wp-content/uploads/2022/11/2022-11-29T20_55_50-1024x575.png "2022-11-29T20_55_50 - GenInvo - GenInvo") ](https://geninvo.com/shadow-for-eu-ctr-compliance/) #### [Shadow for EU-CTR Compliance](https://geninvo.com/shadow-for-eu-ctr-compliance/) [ Watch Video ](https://geninvo.com/shadow-for-eu-ctr-compliance/) [ ![](https://geninvo.com/wp-content/uploads/2021/04/docqc-img-overlay.png "docqc-img-overlay - GenInvo - GenInvo") ](https://geninvo.com/docqc-medical-writers-automation-tool-for-qc-checks/) #### [DocQC – Medical Writers automation tool for QC checks](https://geninvo.com/docqc-medical-writers-automation-tool-for-qc-checks/) [ Watch Video ](https://geninvo.com/docqc-medical-writers-automation-tool-for-qc-checks/) [ ![](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-shadow-1-1024x717.jpg "Mockups Design - GenInvo - GenInvo") ](https://geninvo.com/shadow-risk-analysis-tool/) #### [Shadow- Risk Analysis Tool](https://geninvo.com/shadow-risk-analysis-tool/) [ Watch Video ](https://geninvo.com/shadow-risk-analysis-tool/) [ ![](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-shadow-2-e1617726656616-1024x492.jpg "Mockups Design - GenInvo - GenInvo") ](https://geninvo.com/shadow-data-anonymization-tool/) #### [Shadow- Data Anonymization Tool](https://geninvo.com/shadow-data-anonymization-tool/) [ Watch Video ](https://geninvo.com/shadow-data-anonymization-tool/) [ ![](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-docqc-1024x717.jpg "Mockups Design - GenInvo - GenInvo") ](https://geninvo.com/docqc-medical-writers-best-friend/) #### [DocQc – Medical Writer’s Best Friend](https://geninvo.com/docqc-medical-writers-best-friend/) [ Watch Video ](https://geninvo.com/docqc-medical-writers-best-friend/) [ ![](https://geninvo.com/wp-content/uploads/2021/04/overlay_annv-1024x573.jpg "overlay_annv - GenInvo - GenInvo") ](https://geninvo.com/geninvo-anniversary-2/) #### [GENINVO Anniversary](https://geninvo.com/geninvo-anniversary-2/) [ Watch Video ](https://geninvo.com/geninvo-anniversary-2/) « PreviousPage1[Page2](https://geninvo.com/insights/videos/2/?doing_wp_cron=1783869150.2234899997711181640625)[Page3](https://geninvo.com/insights/videos/3/?doing_wp_cron=1783869150.2234899997711181640625)[Next »](https://geninvo.com/insights/videos/2/) --- ### [Blogs](https://geninvo.com/insights/blog/) **Published:** March 26, 2021 **Author:** admin **Content:** ![](//geninvo.com/wp-content/uploads/2024/09/image-5.jpg) image-1 ![](//geninvo.com/wp-content/uploads/2024/08/Untitled-1.png) ![](//geninvo.com/wp-content/uploads/2025/05/Blog.png) GENINVO Blogs GENINVO Blogs Explore our blogs. Hear from our SMEs, data scientists, AI/ML Experts, Product Owners, researchers, industry leaders, and other experts on trending topics Explore our blogs. Hear from our SMEs, data scientists, AI/ML Experts, Product Owners, researchers, industry leaders, and other experts on trending topics. ![](//geninvo.com/wp-content/uploads/2025/05/Blog.png) ## GENINVO Blogs Explore our blogs. Hear from our SMEs, data scientists, AI/ML Experts, Product Owners, researchers, industry leaders, and other experts on trending topics. [ Back ](https://geninvo.com/insights/) ![](https://geninvo.com/wp-content/uploads/2021/04/blogstop.jpg "blogstop - GenInvo - GenInvo") [ ![](https://geninvo.com/wp-content/uploads/2025/10/Blog-12.jpg "Blog-12 - GenInvo - GenInvo") ](https://geninvo.com/quantitative-risk-assessment-a-smarter-approach-to-clinical-data-anonymization/) ###### [Quantitative Risk Assessment: A Smarter Approach to Clinical Data Anonymization ](https://geninvo.com/quantitative-risk-assessment-a-smarter-approach-to-clinical-data-anonymization/) - [ October 27, 2025 ](https://geninvo.com/2025/10/27/) - 3:30 pm [ Read More ](https://geninvo.com/quantitative-risk-assessment-a-smarter-approach-to-clinical-data-anonymization/) [ ![](https://geninvo.com/wp-content/uploads/2025/09/Blog-11.jpg "Blog-11 - GenInvo - GenInvo") ](https://geninvo.com/secure-scanning-with-confidential-information-scanner-safeguarding-your-ccis-during-clinical-research/) ###### [Secure Scanning with Confidential Information Scanner: Safeguarding Your CCIs During Clinical Research](https://geninvo.com/secure-scanning-with-confidential-information-scanner-safeguarding-your-ccis-during-clinical-research/) - [ September 16, 2025 ](https://geninvo.com/2025/09/16/) - 11:52 am [ Read More ](https://geninvo.com/secure-scanning-with-confidential-information-scanner-safeguarding-your-ccis-during-clinical-research/) [ ![Clinical Trials](https://geninvo.com/wp-content/uploads/2025/08/Blog-8.jpg "Blog-8 - GenInvo - GenInvo") ](https://geninvo.com/pythons-future-in-clinical-trials-innovations-and-collaborative-advancements/) ###### [Python’s Future in Clinical Trials: Innovations and Collaborative Advancements](https://geninvo.com/pythons-future-in-clinical-trials-innovations-and-collaborative-advancements/) - [ August 13, 2025 ](https://geninvo.com/2025/08/13/) - 6:41 am [ Read More ](https://geninvo.com/pythons-future-in-clinical-trials-innovations-and-collaborative-advancements/) [ ![Open-source Clinical Programming](https://geninvo.com/wp-content/uploads/2025/07/Blog-7.jpg "Blog-7 - GenInvo - GenInvo") ](https://geninvo.com/the-changing-role-of-the-clinical-programmer-in-an-open-source-world/) ###### [The Changing Role of the Clinical Programmer in an Open-Source World](https://geninvo.com/the-changing-role-of-the-clinical-programmer-in-an-open-source-world/) - [ July 29, 2025 ](https://geninvo.com/2025/07/29/) - 9:29 am [ Read More ](https://geninvo.com/the-changing-role-of-the-clinical-programmer-in-an-open-source-world/) [ ![Ai and Machine Learning Tools for Life Sciences](https://geninvo.com/wp-content/uploads/2025/07/Blog-6.jpg "Blog-6 - GenInvo - GenInvo") ](https://geninvo.com/ai-ml-tools-life-sciences-geninvo/) ###### [Beyond the Buzzwords: How GenInvo’s AI/ML Tools Are Transforming Life Sciences](https://geninvo.com/ai-ml-tools-life-sciences-geninvo/) - [ July 24, 2025 ](https://geninvo.com/2025/07/24/) - 5:48 am [ Read More ](https://geninvo.com/ai-ml-tools-life-sciences-geninvo/) [ ![Docwrightai](https://geninvo.com/wp-content/uploads/2025/06/Blog-5.jpg "DocWrightAI - GenInvo - GenInvo") ](https://geninvo.com/empowering-the-future-of-life-sciences-a-geninvo-perspective-from-the-inside/) ###### [Empowering the Future of Life Sciences: A GenInvo Perspective from the Inside](https://geninvo.com/empowering-the-future-of-life-sciences-a-geninvo-perspective-from-the-inside/) - [ June 30, 2025 ](https://geninvo.com/2025/06/30/) - 3:34 pm [ Read More ](https://geninvo.com/empowering-the-future-of-life-sciences-a-geninvo-perspective-from-the-inside/) [ ![](https://geninvo.com/wp-content/uploads/2025/06/Blog-4.jpg "Blog-4 - GenInvo - GenInvo") ](https://geninvo.com/geninvos-cis-tool-safeguarding-confidential-company-information-in-life-sciences/) ###### [GenInvo’s CIS Tool: Safeguarding Confidential Company Information in Life Sciences.](https://geninvo.com/geninvos-cis-tool-safeguarding-confidential-company-information-in-life-sciences/) - [ June 20, 2025 ](https://geninvo.com/2025/06/20/) - 12:21 pm [ Read More ](https://geninvo.com/geninvos-cis-tool-safeguarding-confidential-company-information-in-life-sciences/) [ ![](https://geninvo.com/wp-content/uploads/2025/06/Blog-3.jpg "Blog-3 - GenInvo - GenInvo") ](https://geninvo.com/why-clinical-data-transparency-matters-benefits-for-patients-researchers-and-industry/) ###### [Why Clinical Data Transparency Matters: Benefits for Patients, Researchers, and Industry](https://geninvo.com/why-clinical-data-transparency-matters-benefits-for-patients-researchers-and-industry/) - [ June 13, 2025 ](https://geninvo.com/2025/06/13/) - 12:52 pm [ Read More ](https://geninvo.com/why-clinical-data-transparency-matters-benefits-for-patients-researchers-and-industry/) [ ![](https://geninvo.com/wp-content/uploads/2025/01/Blog-2.jpg "Blog-2 - GenInvo - GenInvo") ](https://geninvo.com/how-meaningful-synthetic-data-generation-tools-are-transforming-ai-development/) ###### [How Meaningful Synthetic Data Generation Tools Are Transforming AI Development ](https://geninvo.com/how-meaningful-synthetic-data-generation-tools-are-transforming-ai-development/) - [ January 2, 2025 ](https://geninvo.com/2025/01/02/) - 2:14 pm [ Read More ](https://geninvo.com/how-meaningful-synthetic-data-generation-tools-are-transforming-ai-development/) [ ![](https://geninvo.com/wp-content/uploads/2024/10/Untitled-1-1.webp "Untitled-1 1 - GenInvo - GenInvo") ](https://geninvo.com/empowering-clinical-and-regulatory-writing-harnessing-ai-as-your-assistant/) ###### [Empowering Clinical and Regulatory Writing: Harnessing AI as Your Assistant ](https://geninvo.com/empowering-clinical-and-regulatory-writing-harnessing-ai-as-your-assistant/) - [ October 11, 2024 ](https://geninvo.com/2024/10/11/) - 11:11 am [ Read More ](https://geninvo.com/empowering-clinical-and-regulatory-writing-harnessing-ai-as-your-assistant/) [ ![](https://geninvo.com/wp-content/uploads/2024/09/mdw-1.jpg "mdw-1 - GenInvo - GenInvo") ](https://geninvo.com/the-impact-of-ai-on-medical-writing-how-artificial-intelligence-is-revolutionizing-medical-content-creation/) ###### [The Impact of AI on Medical Writing: How Artificial Intelligence is Revolutionizing Medical Content Creation ](https://geninvo.com/the-impact-of-ai-on-medical-writing-how-artificial-intelligence-is-revolutionizing-medical-content-creation/) - [ September 13, 2024 ](https://geninvo.com/2024/09/13/) - 8:56 am [ Read More ](https://geninvo.com/the-impact-of-ai-on-medical-writing-how-artificial-intelligence-is-revolutionizing-medical-content-creation/) [ ![](https://geninvo.com/wp-content/uploads/2024/07/dtct-1.webp "CDISC Standards and Data Transformation in Clinical Trial - GenInvo - GenInvo") ](https://geninvo.com/cdisc-standards-and-data-transformation-in-clinical-trial/) ###### [CDISC Standards and Data Transformation in Clinical Trial.](https://geninvo.com/cdisc-standards-and-data-transformation-in-clinical-trial/) - [ July 23, 2024 ](https://geninvo.com/2024/07/23/) - 1:12 pm [ Read More ](https://geninvo.com/cdisc-standards-and-data-transformation-in-clinical-trial/) « PreviousPage1[Page2](https://geninvo.com/insights/blog/2/?doing_wp_cron=1783869150.2234899997711181640625)[Page3](https://geninvo.com/insights/blog/3/?doing_wp_cron=1783869150.2234899997711181640625)[Page4](https://geninvo.com/insights/blog/4/?doing_wp_cron=1783869150.2234899997711181640625)[Page5](https://geninvo.com/insights/blog/5/?doing_wp_cron=1783869150.2234899997711181640625)[Next »](https://geninvo.com/insights/blog/2/) --- ### [Case Studies](https://geninvo.com/insights/case-studies/) **Published:** March 26, 2021 **Author:** admin **Content:** ![](//geninvo.com/wp-content/uploads/2024/09/image-5.jpg) image-1 ![](//geninvo.com/wp-content/uploads/2024/08/Untitled-1.png) ![](//geninvo.com/wp-content/uploads/2025/05/Case-study.png) GENINVO Case Studies GENINVO Case Studies Learn how our products and services are solving business problems across industries. These studies offer real-world evidence of how we move metrics including reducing complexity, enhancing process functionality and creating positive business impact. Learn how our products and services are solving business problems across industries. These studies offer real-world evidence of how we move metrics including reducing complexity, enhancing process functionality and creating positive business impact. ![](//geninvo.com/wp-content/uploads/2025/05/Case-study.png) ## GENINVO Case Studies Learn how our products and services are solving business problems across industries. These studies offer real-world evidence of how we move metrics including reducing complexity, enhancing process functionality and creating positive business impact. [ Back ](https://geninvo.com/insights/) ![](https://geninvo.com/wp-content/uploads/2021/04/case-studies-top.jpg "case-studies-top - GenInvo - GenInvo") [ ![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-10-Case-Study-WB-List_v3.jpg "Case-Studies-10-Case-Study-WB-List_v3 - GenInvo - GenInvo") ](https://geninvo.com/white-list-black-list-enhanced-ner-model/) ###### [White List & Black List: Enhanced NER Model](https://geninvo.com/white-list-black-list-enhanced-ner-model/) [ Read More ](https://geninvo.com/white-list-black-list-enhanced-ner-model/) [ ![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity.jpg "Case-Studies-11-DocQc-Table-41---NLP-for-Text-Similarity - GenInvo - GenInvo") ](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) ###### [NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) [ Read More ](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) [ ![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-12-Eprotocol-presentation.jpg "Case-Studies-12-Eprotocol-presentation - GenInvo - GenInvo") ](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) ###### [DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) [ Read More ](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) [ ![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-13-Shadow-Recommendation-Engine.jpg "Case-Studies-13-Shadow---Recommendation-Engine - GenInvo - GenInvo") ](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) ###### [Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) [ Read More ](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) [ ![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-8-Lung-Cancer-Detection-use-cases.jpg "Case-Studies-8-Lung-Cancer-Detection-use-cases - GenInvo - GenInvo") ](https://geninvo.com/lung-cancer-detection/) ###### [Lung Cancer Detection](https://geninvo.com/lung-cancer-detection/) [ Read More ](https://geninvo.com/lung-cancer-detection/) « PreviousPage1[Page2](https://geninvo.com/insights/case-studies/2/?doing_wp_cron=1783869150.2234899997711181640625)[Page3](https://geninvo.com/insights/case-studies/3/?doing_wp_cron=1783869150.2234899997711181640625)[Next »](https://geninvo.com/insights/case-studies/2/) --- ### [News](https://geninvo.com/insights/news/) **Published:** March 24, 2021 **Author:** admin **Content:** ![](//geninvo.com/wp-content/uploads/2024/09/image-5.jpg) image-1 ![](//geninvo.com/wp-content/uploads/2024/08/Untitled-1.png) ![](//geninvo.com/wp-content/uploads/2025/05/News.png) GENINVO News GENINVO News Follow this section to stay updated with all the exciting news about GENINVO. Follow this section to stay updated with all the exciting news about GENINVO. ![](//geninvo.com/wp-content/uploads/2025/05/News.png) ## GENINVO News Follow this section to stay updated with all the exciting news about GENINVO. [ Back ](https://geninvo.com/insights/) ![](https://geninvo.com/wp-content/uploads/2021/04/news-top.jpg "news-top - GenInvo - GenInvo") [ ![](https://geninvo.com/wp-content/uploads/2021/11/dsa-coe.jpg "dsa-coe - GenInvo - GenInvo") ](https://geninvo.com/geninvo-launches-centre-of-excellence-for-data-science-and-analytics/) ##### [GENINVO Launches Centre of Excellence for Data Science and Analytics](https://geninvo.com/geninvo-launches-centre-of-excellence-for-data-science-and-analytics/) [ Read More ](https://geninvo.com/geninvo-launches-centre-of-excellence-for-data-science-and-analytics/) [ ![](https://geninvo.com/wp-content/uploads/2021/06/feat-ns.jpg "feat-ns - GenInvo - GenInvo") ](https://geninvo.com/new-website-launch-announcement-geninvo-launches-updated-website/) ##### [NEW WEBSITE LAUNCH ANNOUNCEMENT](https://geninvo.com/new-website-launch-announcement-geninvo-launches-updated-website/) GENINVO Launches updated website [ Read More ](https://geninvo.com/new-website-launch-announcement-geninvo-launches-updated-website/) [ ![](https://geninvo.com/wp-content/uploads/2021/03/feat-shadow.jpg "feat-shadow - GenInvo - GenInvo") ](https://geninvo.com/geninvo-launches-shadow-version-2/) ##### [GENINVO Launches Shadow™ Version 2](https://geninvo.com/geninvo-launches-shadow-version-2/) On behalf of GenInvo and our Innovative Solutions team, I am very excited [ Read More ](https://geninvo.com/geninvo-launches-shadow-version-2/) « PreviousPage1[Page2](https://geninvo.com/insights/news/2/?doing_wp_cron=1783869150.2234899997711181640625)[Page3](https://geninvo.com/insights/news/3/?doing_wp_cron=1783869150.2234899997711181640625)[Page4](https://geninvo.com/insights/news/4/?doing_wp_cron=1783869150.2234899997711181640625)[Next »](https://geninvo.com/insights/news/2/) --- ### [Events](https://geninvo.com/insights/events/) **Published:** March 24, 2021 **Author:** admin **Content:** ![](//geninvo.com/wp-content/uploads/2024/09/image-5.jpg) image-1 ![](//geninvo.com/wp-content/uploads/2024/08/Untitled-1.png) ![](//geninvo.com/wp-content/uploads/2025/04/Event.png) GENINVO Events GENINVO Events Join us at exclusive events, as we present the best of industry insights and form ground breaking partnerships at events around the world. Join us at exclusive events, as we present the best of industry insights and form ground breaking partnerships at events around the world. ![](//geninvo.com/wp-content/uploads/2025/04/Event.png) ## GENINVO Events Join us at exclusive events, as we present the best of industry insights and form ground breaking partnerships at events around the world. [ Back ](https://geninvo.com/insights/) ![](https://geninvo.com/wp-content/uploads/2021/04/events-top.jpg "events-top - GenInvo - GenInvo") [ ![Geninvo at Dpharm 2026 Banner: Sept 15–16, 2026 in Boston, Usa; Sheraton Boston Hotel Exhibition Booth #116.](https://geninvo.com/wp-content/uploads/2026/06/DPHARM-1.png "Meet Geninvo at DPHARM 2026 — Booth 116, Boston - GenInvo - GenInvo") ](https://geninvo.com/dpharm-2026/) ###### [Meet GenInvo at DPHARM 2026, Booth 116, Boston](https://geninvo.com/dpharm-2026/) - [ June 4, 2026 ](https://geninvo.com/2026/06/04/) - 11:59 am [ Read More ](https://geninvo.com/dpharm-2026/) [ ![Geninvo Booth 10 at Emwa 61st Spring Conference 2026 Barcelona.](https://geninvo.com/wp-content/uploads/2026/04/539-X-334-1.png "539 X 334 1 - GenInvo - GenInvo") ](https://geninvo.com/emwa-2026-barcelona/) ###### [Meet GENINVO at the EMWA 61st Spring Conference 2026](https://geninvo.com/emwa-2026-barcelona/) - [ April 21, 2026 ](https://geninvo.com/2026/04/21/) - 10:13 am [ Read More ](https://geninvo.com/emwa-2026-barcelona/) [ ![](https://geninvo.com/wp-content/uploads/2026/04/539-X-334.png "539 X 334 - GenInvo - GenInvo") ](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) ###### [GenInvo at PharmaSUG 2026 SDE Conference](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) - [ April 10, 2026 ](https://geninvo.com/2026/04/10/) - 12:18 pm [ Read More ](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) [ ![](https://geninvo.com/wp-content/uploads/2026/03/image-16.png "image (16) - GenInvo - GenInvo") ](https://geninvo.com/geninvo-phuse-us-connect-2026/) ###### [GenInvo @ PHUSE US Connect 2026](https://geninvo.com/geninvo-phuse-us-connect-2026/) - [ March 16, 2026 ](https://geninvo.com/2026/03/16/) - 2:57 pm [ Read More ](https://geninvo.com/geninvo-phuse-us-connect-2026/) [ ![](https://geninvo.com/wp-content/uploads/2025/08/Blog-9.jpg "Blog-9 - GenInvo - GenInvo") ](https://geninvo.com/live-webinar-accelerating-authoring-and-qc-of-clinical-documents-with-ai-powered-automation/) ###### [Live Webinar: Accelerating Authoring and QC of Clinical Documents with AI-Powered Automation](https://geninvo.com/live-webinar-accelerating-authoring-and-qc-of-clinical-documents-with-ai-powered-automation/) - [ August 19, 2025 ](https://geninvo.com/2025/08/19/) - 7:26 am [ Read More ](https://geninvo.com/live-webinar-accelerating-authoring-and-qc-of-clinical-documents-with-ai-powered-automation/) [ ![](https://geninvo.com/wp-content/uploads/2025/08/GI-AMWA-conference-blog-2025.jpg "GI-&-AMWA-conference-blog-2025 - GenInvo - GenInvo") ](https://geninvo.com/geninvo-is-powering-the-future-of-medical-writing-at-amwa-2025/) ###### [GenInvo is Powering the Future of Medical Writing at AMWA 2025!](https://geninvo.com/geninvo-is-powering-the-future-of-medical-writing-at-amwa-2025/) - [ August 7, 2025 ](https://geninvo.com/2025/08/07/) - 1:09 pm [ Read More ](https://geninvo.com/geninvo-is-powering-the-future-of-medical-writing-at-amwa-2025/) [ ![](https://geninvo.com/wp-content/uploads/2025/07/Blog-GI-Phusevirtualevent-Sept-2025.jpg "Blog-GI-Phusevirtualevent-Sept-2025 - GenInvo - GenInvo") ](https://geninvo.com/geninvo-sponsors-phuse-data-transparency-autumn-event-2025/) ###### [GENINVO™ Sponsors PHUSE Data Transparency Autumn Event 2025](https://geninvo.com/geninvo-sponsors-phuse-data-transparency-autumn-event-2025/) - [ July 30, 2025 ](https://geninvo.com/2025/07/30/) - 2:56 pm [ Read More ](https://geninvo.com/geninvo-sponsors-phuse-data-transparency-autumn-event-2025/) [ ![](https://geninvo.com/wp-content/uploads/2025/02/GI-US-PHUSE-connect-2025.jpg "GI-&-US-PHUSE-connect-2025 - GenInvo - GenInvo") ](https://geninvo.com/geninvo-at-phuse-us-connect-2025/) ###### [GENINVO™ at PHUSE US Connect 2025](https://geninvo.com/geninvo-at-phuse-us-connect-2025/) - [ February 18, 2025 ](https://geninvo.com/2025/02/18/) - 11:56 am [ Read More ](https://geninvo.com/geninvo-at-phuse-us-connect-2025/) [ ![](https://geninvo.com/wp-content/uploads/2025/02/GI-DIA-blogpost-mar2025.webp "GI-&-DIA-blogpost-mar2025 - GenInvo - GenInvo") ](https://geninvo.com/join-geninvo-at-the-dia-medical-affairs-and-scientific-communications-forum/) ###### [Join GENINVO™ at the DIA Medical Affairs and Scientific Communications Forum](https://geninvo.com/join-geninvo-at-the-dia-medical-affairs-and-scientific-communications-forum/) - [ February 18, 2025 ](https://geninvo.com/2025/02/18/) - 11:46 am [ Read More ](https://geninvo.com/join-geninvo-at-the-dia-medical-affairs-and-scientific-communications-forum/) [ ![](https://geninvo.com/wp-content/uploads/2024/11/blog-post-AMWA-24nov.webp "blog-post-AMWA-24nov - GenInvo - GenInvo") ](https://geninvo.com/thank-you-for-attending-the-geninvos-amwa-webinar/) ###### [Thank You for Attending the GENINVO’s AMWA Webinar](https://geninvo.com/thank-you-for-attending-the-geninvos-amwa-webinar/) - [ November 8, 2024 ](https://geninvo.com/2024/11/08/) - 1:44 pm [ Read More ](https://geninvo.com/thank-you-for-attending-the-geninvos-amwa-webinar/) [ ![](https://geninvo.com/wp-content/uploads/2024/10/GI-AMWA-blog-AI-writers-24-V2.webp "GI-&-AMWA-blog-AI-writers-24-V2 - GenInvo - GenInvo") ](https://geninvo.com/join-our-free-webinar/) ###### [Join Our Free Webinar!](https://geninvo.com/join-our-free-webinar/) - [ October 4, 2024 ](https://geninvo.com/2024/10/04/) - 11:58 am [ Read More ](https://geninvo.com/join-our-free-webinar/) [ ![](https://geninvo.com/wp-content/uploads/2024/04/GI-and-sha-DIA-V1-3.jpg "GI-and-sha-DIA-V1 3 - GenInvo - GenInvo") ](https://geninvo.com/shake-hands-with-geninvo-at-dias-global-clinical-trial-disclosure-and-data-transparency-conference/) ###### [Shake hands with GENINVO at DIA’s Global Clinical Trial Disclosure and Data Transparency Conference](https://geninvo.com/shake-hands-with-geninvo-at-dias-global-clinical-trial-disclosure-and-data-transparency-conference/) - [ April 18, 2024 ](https://geninvo.com/2024/04/18/) - 9:58 am [ Read More ](https://geninvo.com/shake-hands-with-geninvo-at-dias-global-clinical-trial-disclosure-and-data-transparency-conference/) « PreviousPage1[Page2](https://geninvo.com/insights/events/2/?doing_wp_cron=1783869150.2234899997711181640625)[Page3](https://geninvo.com/insights/events/3/?doing_wp_cron=1783869150.2234899997711181640625)[Next »](https://geninvo.com/insights/events/2/) --- ### [Insights](https://geninvo.com/insights/) **Published:** March 22, 2021 **Author:** admin **Content:** ![](//geninvo.com/wp-content/uploads/2025/04/Insight-image.jpg) image-1 GENINVO Insights GENINVO Insights Welcome to the world of GENINVO. These resources focusses on "How" we are paving the way forward for the Pharmaceutical industry using Passion and Technology as our driving force. Welcome to the world of GENINVO. These resources focusses on "How" we are paving the way forward for the Pharmaceutical industry using Passion and Technology as our driving force. ## GENINVO Insights Welcome to the world of GENINVO. These resources focusses on “How” we are paving the way forward for the Pharmaceutical industry using Passion and Technology as our driving force. ![](https://geninvo.com/wp-content/uploads/2021/03/insights-top.jpg) All Blogs Case Studies Events News Videos All ## Blogs [ ![Quantitative Risk Assessment: A Smarter Approach to Clinical Data Anonymization ](https://geninvo.com/wp-content/uploads/2025/10/Blog-12-300x189.jpg) ](https://geninvo.com/quantitative-risk-assessment-a-smarter-approach-to-clinical-data-anonymization/) ## [Quantitative Risk Assessment: A Smarter Approach to Clinical Data Anonymization ](https://geninvo.com/quantitative-risk-assessment-a-smarter-approach-to-clinical-data-anonymization/) [ ![Secure Scanning with Confidential Information Scanner: Safeguarding Your CCIs During Clinical Research](https://geninvo.com/wp-content/uploads/2025/09/Blog-11-300x189.jpg) ](https://geninvo.com/secure-scanning-with-confidential-information-scanner-safeguarding-your-ccis-during-clinical-research/) ## [Secure Scanning with Confidential Information Scanner: Safeguarding Your CCIs During Clinical Research](https://geninvo.com/secure-scanning-with-confidential-information-scanner-safeguarding-your-ccis-during-clinical-research/) [ ![Python’s Future in Clinical Trials: Innovations and Collaborative Advancements](https://geninvo.com/wp-content/uploads/2025/08/Blog-8-300x189.jpg) ](https://geninvo.com/pythons-future-in-clinical-trials-innovations-and-collaborative-advancements/) ## [Python’s Future in Clinical Trials: Innovations and Collaborative Advancements](https://geninvo.com/pythons-future-in-clinical-trials-innovations-and-collaborative-advancements/) [ ![The Changing Role of the Clinical Programmer in an Open-Source World](https://geninvo.com/wp-content/uploads/2025/07/Blog-7-300x189.jpg) ](https://geninvo.com/the-changing-role-of-the-clinical-programmer-in-an-open-source-world/) ## [The Changing Role of the Clinical Programmer in an Open-Source World](https://geninvo.com/the-changing-role-of-the-clinical-programmer-in-an-open-source-world/) [ ![Beyond the Buzzwords: How GenInvo’s AI/ML Tools Are Transforming Life Sciences](https://geninvo.com/wp-content/uploads/2025/07/Blog-6-300x189.jpg) ](https://geninvo.com/ai-ml-tools-life-sciences-geninvo/) ## [Beyond the Buzzwords: How GenInvo’s AI/ML Tools Are Transforming Life Sciences](https://geninvo.com/ai-ml-tools-life-sciences-geninvo/) [ ![Empowering the Future of Life Sciences: A GenInvo Perspective from the Inside](https://geninvo.com/wp-content/uploads/2025/06/Blog-5-300x196.jpg) ](https://geninvo.com/empowering-the-future-of-life-sciences-a-geninvo-perspective-from-the-inside/) ## [Empowering the Future of Life Sciences: A GenInvo Perspective from the Inside](https://geninvo.com/empowering-the-future-of-life-sciences-a-geninvo-perspective-from-the-inside/) [ ![GenInvo’s CIS Tool: Safeguarding Confidential Company Information in Life Sciences.](https://geninvo.com/wp-content/uploads/2025/06/Blog-4-300x196.jpg) ](https://geninvo.com/geninvos-cis-tool-safeguarding-confidential-company-information-in-life-sciences/) ## [GenInvo’s CIS Tool: Safeguarding Confidential Company Information in Life Sciences.](https://geninvo.com/geninvos-cis-tool-safeguarding-confidential-company-information-in-life-sciences/) [ ![Why Clinical Data Transparency Matters: Benefits for Patients, Researchers, and Industry](https://geninvo.com/wp-content/uploads/2025/06/Blog-3-300x196.jpg) ](https://geninvo.com/why-clinical-data-transparency-matters-benefits-for-patients-researchers-and-industry/) ## [Why Clinical Data Transparency Matters: Benefits for Patients, Researchers, and Industry](https://geninvo.com/why-clinical-data-transparency-matters-benefits-for-patients-researchers-and-industry/) [ ![How Meaningful Synthetic Data Generation Tools Are Transforming AI Development ](https://geninvo.com/wp-content/uploads/2025/01/Blog-2-300x169.jpg) ](https://geninvo.com/how-meaningful-synthetic-data-generation-tools-are-transforming-ai-development/) ## [How Meaningful Synthetic Data Generation Tools Are Transforming AI Development ](https://geninvo.com/how-meaningful-synthetic-data-generation-tools-are-transforming-ai-development/) [ ![Empowering Clinical and Regulatory Writing: Harnessing AI as Your Assistant  ](https://geninvo.com/wp-content/uploads/2024/10/Untitled-1-1-300x189.webp) ](https://geninvo.com/empowering-clinical-and-regulatory-writing-harnessing-ai-as-your-assistant/) ## [Empowering Clinical and Regulatory Writing: Harnessing AI as Your Assistant ](https://geninvo.com/empowering-clinical-and-regulatory-writing-harnessing-ai-as-your-assistant/) [ ![The Impact of AI on Medical Writing: How Artificial Intelligence is Revolutionizing Medical Content Creation ](https://geninvo.com/wp-content/uploads/2024/09/mdw-1-300x169.jpg) ](https://geninvo.com/the-impact-of-ai-on-medical-writing-how-artificial-intelligence-is-revolutionizing-medical-content-creation/) ## [The Impact of AI on Medical Writing: How Artificial Intelligence is Revolutionizing Medical Content Creation ](https://geninvo.com/the-impact-of-ai-on-medical-writing-how-artificial-intelligence-is-revolutionizing-medical-content-creation/) [ ![CDISC Standards and Data Transformation in Clinical Trial.](https://geninvo.com/wp-content/uploads/2024/07/dtct-1-300x169.webp) ](https://geninvo.com/cdisc-standards-and-data-transformation-in-clinical-trial/) ## [CDISC Standards and Data Transformation in Clinical Trial.](https://geninvo.com/cdisc-standards-and-data-transformation-in-clinical-trial/) [ ![Transforming Document Creation in Life Sciences with DocWrightAI™ – GenInvo’s Advanced AI Assistant!](https://geninvo.com/wp-content/uploads/2024/06/DocWright-lifscience-300x169.jpg) ](https://geninvo.com/transforming-document-creation-in-life-sciences-with-docwrightai-geninvos-advanced-ai-assistant/) ## [Transforming Document Creation in Life Sciences with DocWrightAI™ – GenInvo’s Advanced AI Assistant!](https://geninvo.com/transforming-document-creation-in-life-sciences-with-docwrightai-geninvos-advanced-ai-assistant/) [ ![Embracing the Digital Era: The Transformative Power of Digitalization in Medical Writing](https://geninvo.com/wp-content/uploads/2024/03/1672114503523rf-1-300x169.jpg) ](https://geninvo.com/embracing-the-digital-era-the-transformative-power-of-digitalization-in-medical-writing/) ## [Embracing the Digital Era: The Transformative Power of Digitalization in Medical Writing](https://geninvo.com/embracing-the-digital-era-the-transformative-power-of-digitalization-in-medical-writing/) [ ![Data Masking and Data Anonymization: The need for healthcare companies](https://geninvo.com/wp-content/uploads/2024/03/data-m-300x169.jpg) ](https://geninvo.com/data-masking-and-data-anonymization-the-need-for-healthcare-companies/) ## [Data Masking and Data Anonymization: The need for healthcare companies](https://geninvo.com/data-masking-and-data-anonymization-the-need-for-healthcare-companies/) [ ![Artificial Intelligence in the Healthcare Domain: How AI Reviews Clinical Documents](https://geninvo.com/wp-content/uploads/2024/03/maxresdefault.jpgr_-300x169.jpg) ](https://geninvo.com/artificial-intelligence-in-the-healthcare-domain-how-ai-reviews-clinical-documents/) ## [Artificial Intelligence in the Healthcare Domain: How AI Reviews Clinical Documents](https://geninvo.com/artificial-intelligence-in-the-healthcare-domain-how-ai-reviews-clinical-documents/) [ ![Importance and examples of usage of Data Anonymization in Healthcare & Other sectors](https://geninvo.com/wp-content/uploads/2024/02/dah-sector-300x169.jpg) ](https://geninvo.com/importance-and-examples-of-usage-of-data-anonymization-in-healthcare-other-sectors/) ## [Importance and examples of usage of Data Anonymization in Healthcare & Other sectors](https://geninvo.com/importance-and-examples-of-usage-of-data-anonymization-in-healthcare-other-sectors/) [ ![Data Anonymization and HIPAA Compliance: Protecting Health Information Privacy](https://geninvo.com/wp-content/uploads/2024/02/Untitled-1df-300x169.jpg) ](https://geninvo.com/data-anonymization-and-hipaa-compliance-protecting-health-information-privacy/) ## [Data Anonymization and HIPAA Compliance: Protecting Health Information Privacy](https://geninvo.com/data-anonymization-and-hipaa-compliance-protecting-health-information-privacy/) [ ![Automation of Unstructured Clinical Data: A collaboration of automation and Medical Writers](https://geninvo.com/wp-content/uploads/2024/01/cdf-300x169.png) ](https://geninvo.com/automation-of-unstructured-clinical-data-a-collaboration-of-automation-and-medical-writers/) ## [Automation of Unstructured Clinical Data: A collaboration of automation and Medical Writers](https://geninvo.com/automation-of-unstructured-clinical-data-a-collaboration-of-automation-and-medical-writers/) [ ![Quality Control of the Methods and Procedures of Clinical Study](https://geninvo.com/wp-content/uploads/2024/01/quloi-300x169.jpg) ](https://geninvo.com/quality-control-of-the-methods-and-procedures-of-clinical-study/) ## [Quality Control of the Methods and Procedures of Clinical Study](https://geninvo.com/quality-control-of-the-methods-and-procedures-of-clinical-study/) ## Case Studies [ ![White List & Black List: Enhanced NER Model](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-10-Case-Study-WB-List_v3-300x169.jpg) ](https://geninvo.com/white-list-black-list-enhanced-ner-model/) ## [White List & Black List: Enhanced NER Model](https://geninvo.com/white-list-black-list-enhanced-ner-model/) [ ![NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity-300x169.jpg) ](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) ## [NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) [ ![DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-12-Eprotocol-presentation-300x169.jpg) ](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) ## [DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) [ ![Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-13-Shadow-Recommendation-Engine-300x169.jpg) ](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) ## [Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) [ ![Lung Cancer Detection](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-8-Lung-Cancer-Detection-use-cases-300x169.jpg) ](https://geninvo.com/lung-cancer-detection/) ## [Lung Cancer Detection](https://geninvo.com/lung-cancer-detection/) [ ![Breast Cancer Detection Using Machine Learning](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-9-Case-Study-Breast-Cancer-Detection_v3-use-cases-300x169.jpg) ](https://geninvo.com/breast-cancer-detection-using-machine-learning/) ## [Breast Cancer Detection Using Machine Learning](https://geninvo.com/breast-cancer-detection-using-machine-learning/) [ ![Doc QC tool as a one-stop solution for all Quality Control (QC) needs of a medical writer](https://geninvo.com/wp-content/uploads/2021/08/Case-Studies-8-DocQC-300x169.jpg) ](https://geninvo.com/doc-qc-tool-as-a-one-stop-solution-for-all-quality-control-qc-needs-of-a-medical-writer/) ## [Doc QC tool as a one-stop solution for all Quality Control (QC) needs of a medical writer](https://geninvo.com/doc-qc-tool-as-a-one-stop-solution-for-all-quality-control-qc-needs-of-a-medical-writer/) [ ![Provide ApoGI as a Metadata Driven Platform](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-7-300x169.jpg) ](https://geninvo.com/provide-apogitmas-a-metadatadriven-platform/) ## [Provide ApoGI as a Metadata Driven Platform](https://geninvo.com/provide-apogitmas-a-metadatadriven-platform/) [ ![Provide ApoGI as a MDR Visualization](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-6-300x169.jpg) ](https://geninvo.com/provide-apogitmas-a-mdrvisualization/) ## [Provide ApoGI as a MDR Visualization](https://geninvo.com/provide-apogitmas-a-mdrvisualization/) [ ![Provide ApoGI as a Metadata Driven Transformations](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-5-300x169.jpg) ](https://geninvo.com/provide-apogitm-asa-metadata-driventransformations/) ## [Provide ApoGI as a Metadata Driven Transformations](https://geninvo.com/provide-apogitm-asa-metadata-driventransformations/) [ ![How a Big Pharma Company Achieved Compliance with Health Canada Under Tight Deadlines](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-4-300x169.jpg) ](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-health-canada-under-tight-deadlines/) ## [How a Big Pharma Company Achieved Compliance with Health Canada Under Tight Deadlines](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-health-canada-under-tight-deadlines/) [ ![How a Pharmaceutical Firm Established Anonymization Process](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-3-300x169.jpg) ](https://geninvo.com/how-a-pharmaceutical-firm-established-anonymization-process/) ## [How a Pharmaceutical Firm Established Anonymization Process](https://geninvo.com/how-a-pharmaceutical-firm-established-anonymization-process/) [ ![Big Pharma Company Achieves Compliance with EMA 0070 Policy](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-2-300x169.jpg) ](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-ema-0070-policy-with-a-tight-deadline/) ## [Big Pharma Company Achieves Compliance with EMA 0070 Policy](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-ema-0070-policy-with-a-tight-deadline/) [ ![How a Global Medical Writing CRO Increased Functional Capability with Shadow™](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-1-300x169.jpg) ](https://geninvo.com/how-a-global-medical-writing-cro-increased-functional-capability-with-shadowtm/) ## [How a Global Medical Writing CRO Increased Functional Capability with Shadow™](https://geninvo.com/how-a-global-medical-writing-cro-increased-functional-capability-with-shadowtm/) ## Events [ ![Meet GenInvo at DPHARM 2026, Booth 116, Boston](https://geninvo.com/wp-content/uploads/2026/06/DPHARM-1-300x186.png) ](https://geninvo.com/dpharm-2026/) ## [Meet GenInvo at DPHARM 2026, Booth 116, Boston](https://geninvo.com/dpharm-2026/) [ ![Meet GENINVO at the EMWA 61st Spring Conference 2026](https://geninvo.com/wp-content/uploads/2026/04/539-X-334-1-300x186.png) ](https://geninvo.com/emwa-2026-barcelona/) ## [Meet GENINVO at the EMWA 61st Spring Conference 2026](https://geninvo.com/emwa-2026-barcelona/) [ ![GenInvo at PharmaSUG 2026 SDE Conference](https://geninvo.com/wp-content/uploads/2026/04/539-X-334-300x186.png) ](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) ## [GenInvo at PharmaSUG 2026 SDE Conference](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) [ ![GenInvo @ PHUSE US Connect 2026](https://geninvo.com/wp-content/uploads/2026/03/image-16-300x186.png) ](https://geninvo.com/geninvo-phuse-us-connect-2026/) ## [GenInvo @ PHUSE US Connect 2026](https://geninvo.com/geninvo-phuse-us-connect-2026/) [ ![Live Webinar: Accelerating Authoring and QC of Clinical Documents with AI-Powered Automation](https://geninvo.com/wp-content/uploads/2025/08/Blog-9-300x186.jpg) ](https://geninvo.com/live-webinar-accelerating-authoring-and-qc-of-clinical-documents-with-ai-powered-automation/) ## [Live Webinar: Accelerating Authoring and QC of Clinical Documents with AI-Powered Automation](https://geninvo.com/live-webinar-accelerating-authoring-and-qc-of-clinical-documents-with-ai-powered-automation/) [ ![GenInvo is Powering the Future of Medical Writing at AMWA 2025!](https://geninvo.com/wp-content/uploads/2025/08/GI-AMWA-conference-blog-2025-300x186.jpg) ](https://geninvo.com/geninvo-is-powering-the-future-of-medical-writing-at-amwa-2025/) ## [GenInvo is Powering the Future of Medical Writing at AMWA 2025!](https://geninvo.com/geninvo-is-powering-the-future-of-medical-writing-at-amwa-2025/) [ ![GENINVO™ Sponsors PHUSE Data Transparency Autumn Event 2025](https://geninvo.com/wp-content/uploads/2025/07/Blog-GI-Phusevirtualevent-Sept-2025-300x189.jpg) ](https://geninvo.com/geninvo-sponsors-phuse-data-transparency-autumn-event-2025/) ## [GENINVO™ Sponsors PHUSE Data Transparency Autumn Event 2025](https://geninvo.com/geninvo-sponsors-phuse-data-transparency-autumn-event-2025/) [ ![GENINVO™ at PHUSE US Connect 2025](https://geninvo.com/wp-content/uploads/2025/02/GI-US-PHUSE-connect-2025-300x186.jpg) ](https://geninvo.com/geninvo-at-phuse-us-connect-2025/) ## [GENINVO™ at PHUSE US Connect 2025](https://geninvo.com/geninvo-at-phuse-us-connect-2025/) [ ![Join GENINVO™ at the DIA Medical Affairs and Scientific Communications Forum](https://geninvo.com/wp-content/uploads/2025/02/GI-DIA-blogpost-mar2025-300x186.webp) ](https://geninvo.com/join-geninvo-at-the-dia-medical-affairs-and-scientific-communications-forum/) ## [Join GENINVO™ at the DIA Medical Affairs and Scientific Communications Forum](https://geninvo.com/join-geninvo-at-the-dia-medical-affairs-and-scientific-communications-forum/) [ ![Thank You for Attending the GENINVO’s AMWA Webinar](https://geninvo.com/wp-content/uploads/2024/11/blog-post-AMWA-24nov-300x169.webp) ](https://geninvo.com/thank-you-for-attending-the-geninvos-amwa-webinar/) ## [Thank You for Attending the GENINVO’s AMWA Webinar](https://geninvo.com/thank-you-for-attending-the-geninvos-amwa-webinar/) [ ![Join Our Free Webinar!](https://geninvo.com/wp-content/uploads/2024/10/GI-AMWA-blog-AI-writers-24-V2-300x169.webp) ](https://geninvo.com/join-our-free-webinar/) ## [Join Our Free Webinar!](https://geninvo.com/join-our-free-webinar/) [ ![Shake hands with GENINVO at DIA’s Global Clinical Trial Disclosure and Data Transparency Conference](https://geninvo.com/wp-content/uploads/2024/04/GI-and-sha-DIA-V1-3-300x169.jpg) ](https://geninvo.com/shake-hands-with-geninvo-at-dias-global-clinical-trial-disclosure-and-data-transparency-conference/) ## [Shake hands with GENINVO at DIA’s Global Clinical Trial Disclosure and Data Transparency Conference](https://geninvo.com/shake-hands-with-geninvo-at-dias-global-clinical-trial-disclosure-and-data-transparency-conference/) [ ![Meet GENINVO at DPHARM 2023 in Boston, MA!](https://geninvo.com/wp-content/uploads/2023/08/MicrosoftTeams-image-142-300x169.jpg) ](https://geninvo.com/meet-geninvo-at-dpharm-2023-in-boston-ma/) ## [Meet GENINVO at DPHARM 2023 in Boston, MA!](https://geninvo.com/meet-geninvo-at-dpharm-2023-in-boston-ma/) [ ![Shake hands with GENINVO at PHUSE CSS 2023! ](https://geninvo.com/wp-content/uploads/2023/08/MicrosoftTeams-image-151-300x169.jpg) ](https://geninvo.com/shake-hands-with-geninvo-at-phuse-css-2023/) ## [Shake hands with GENINVO at PHUSE CSS 2023! ](https://geninvo.com/shake-hands-with-geninvo-at-phuse-css-2023/) [ ![GENINVO is delighted to exhibit and present again at the PHUSE US Connect 2023! You can visit us at Booth #7.](https://geninvo.com/wp-content/uploads/2023/02/MicrosoftTeams-image-53-300x169.jpg) ](https://geninvo.com/phuse-us-connect-2023/) ## [GENINVO is delighted to exhibit and present again at the PHUSE US Connect 2023! You can visit us at Booth #7.](https://geninvo.com/phuse-us-connect-2023/) [ ![American Medical Writers Association (AMWA 2022)](https://geninvo.com/wp-content/uploads/2022/10/MicrosoftTeams-image-24-300x170.jpg) ](https://geninvo.com/american-medical-writers-association-amwa-2022/) ## [American Medical Writers Association (AMWA 2022)](https://geninvo.com/american-medical-writers-association-amwa-2022/) [ ![PHUSE EU Connect 2022](https://geninvo.com/wp-content/uploads/2022/10/MicrosoftTeams-image-23-300x170.jpg) ](https://geninvo.com/phuse-eu-connect-2022/) ## [PHUSE EU Connect 2022](https://geninvo.com/phuse-eu-connect-2022/) [ ![EU-CTR New regulations are here – Are you ready for the changes?](https://geninvo.com/wp-content/uploads/2022/09/MicrosoftTeams-image-8-300x172.jpg) ](https://geninvo.com/eu-ctr-new-regulations-are-here-are-you-ready-for-the-changes/) ## [EU-CTR New regulations are here – Are you ready for the changes?](https://geninvo.com/eu-ctr-new-regulations-are-here-are-you-ready-for-the-changes/) [ ![PHUSE’s Data Transparency Winter Event – virtual](https://geninvo.com/wp-content/uploads/2022/02/GI_phuse-8-10-feb-22-01-300x172.jpg) ](https://geninvo.com/phuses-data-transparency-winter-event-virtual/) ## [PHUSE’s Data Transparency Winter Event – virtual](https://geninvo.com/phuses-data-transparency-winter-event-virtual/) [ ![PHUSE US Connect 2022](https://geninvo.com/wp-content/uploads/2021/10/Phuse-event-US-May-300x169.png) ](https://geninvo.com/phuse-us-connect-2022/) ## [PHUSE US Connect 2022](https://geninvo.com/phuse-us-connect-2022/) ## News [ ![GENINVO Launches Centre of Excellence for Data Science and Analytics](https://geninvo.com/wp-content/uploads/2021/11/dsa-coe-300x170.jpg) ](https://geninvo.com/geninvo-launches-centre-of-excellence-for-data-science-and-analytics/) ## [GENINVO Launches Centre of Excellence for Data Science and Analytics](https://geninvo.com/geninvo-launches-centre-of-excellence-for-data-science-and-analytics/) [ ![NEW WEBSITE LAUNCH ANNOUNCEMENT](https://geninvo.com/wp-content/uploads/2021/06/feat-ns-300x170.jpg) ](https://geninvo.com/new-website-launch-announcement-geninvo-launches-updated-website/) ## [NEW WEBSITE LAUNCH ANNOUNCEMENT](https://geninvo.com/new-website-launch-announcement-geninvo-launches-updated-website/) [ ![GENINVO Launches Shadow™ Version 2](https://geninvo.com/wp-content/uploads/2021/03/feat-shadow-300x170.jpg) ](https://geninvo.com/geninvo-launches-shadow-version-2/) ## [GENINVO Launches Shadow™ Version 2](https://geninvo.com/geninvo-launches-shadow-version-2/) [ ![Youth Initiative – Introduction to Robotics Workshop](https://geninvo.com/wp-content/uploads/2021/10/event-feature-2020-300x170.jpg) ](https://geninvo.com/youth-initiative-introduction-to-robotics-workshop/) ## [Youth Initiative – Introduction to Robotics Workshop](https://geninvo.com/youth-initiative-introduction-to-robotics-workshop/) [ ![GENINVO Celebrates Anniversary](https://geninvo.com/wp-content/uploads/2021/05/feat-annivers-300x170.jpg) ](https://geninvo.com/geninvo-anniversary/) ## [GENINVO Celebrates Anniversary](https://geninvo.com/geninvo-anniversary/) [ ![GENINVO Announces Upcoming Version Launch of Shadow™](https://geninvo.com/wp-content/uploads/2021/03/feat-shadow-300x170.jpg) ](https://geninvo.com/geninvo-announces-upcoming-launch-of-shadow-version-2/) ## [GENINVO Announces Upcoming Version Launch of Shadow™](https://geninvo.com/geninvo-announces-upcoming-launch-of-shadow-version-2/) [ ![GENINVO provides technological solutions to the problems in Life Sciences and Pharmaceutical Industry.](https://geninvo.com/wp-content/uploads/2021/05/feat-lsp-300x170.jpg) ](https://geninvo.com/geninvo-provides-technological-solutions-to-the-problems-in-life-sciences-and-pharmaceutical-industry/) ## [GENINVO provides technological solutions to the problems in Life Sciences and Pharmaceutical Industry.](https://geninvo.com/geninvo-provides-technological-solutions-to-the-problems-in-life-sciences-and-pharmaceutical-industry/) [ ![See the Impact of Innovation](https://geninvo.com/wp-content/uploads/2021/05/feat-impact-300x170.jpg) ](https://geninvo.com/see-the-impact-of-innovation/) ## [See the Impact of Innovation](https://geninvo.com/see-the-impact-of-innovation/) [ ![Standing strong with Community](https://geninvo.com/wp-content/uploads/2021/03/feat-stand-str-300x170.jpg) ](https://geninvo.com/standing-strong-with-community/) ## [Standing strong with Community](https://geninvo.com/standing-strong-with-community/) [ ![COVID-19](https://geninvo.com/wp-content/uploads/2021/03/feat-covid-300x170.jpg) ](https://geninvo.com/covid-19/) ## [COVID-19](https://geninvo.com/covid-19/) ## Videos [ ![Shadow for EU-CTR Compliance](https://geninvo.com/wp-content/uploads/2022/11/2022-11-29T20_55_50-300x168.png) ](https://geninvo.com/shadow-for-eu-ctr-compliance/) ## [Shadow for EU-CTR Compliance](https://geninvo.com/shadow-for-eu-ctr-compliance/) [ ![DocQC – Medical Writers automation tool for QC checks](https://geninvo.com/wp-content/uploads/2021/04/docqc-img-overlay-300x171.png) ](https://geninvo.com/docqc-medical-writers-automation-tool-for-qc-checks/) ## [DocQC – Medical Writers automation tool for QC checks](https://geninvo.com/docqc-medical-writers-automation-tool-for-qc-checks/) [ ![Shadow- Risk Analysis Tool](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-shadow-1-e1617726618274-300x168.jpg) ](https://geninvo.com/shadow-risk-analysis-tool/) ## [Shadow- Risk Analysis Tool](https://geninvo.com/shadow-risk-analysis-tool/) [ ![Shadow- Data Anonymization Tool](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-shadow-2-e1617726656616-300x144.jpg) ](https://geninvo.com/shadow-data-anonymization-tool/) ## [Shadow- Data Anonymization Tool](https://geninvo.com/shadow-data-anonymization-tool/) [ ![DocQc – Medical Writer’s Best Friend](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-docqc-300x210.jpg) ](https://geninvo.com/docqc-medical-writers-best-friend/) ## [DocQc – Medical Writer’s Best Friend](https://geninvo.com/docqc-medical-writers-best-friend/) [ ![GENINVO Anniversary](https://geninvo.com/wp-content/uploads/2021/04/overlay_annv-300x168.jpg) ](https://geninvo.com/geninvo-anniversary-2/) ## [GENINVO Anniversary](https://geninvo.com/geninvo-anniversary-2/) [ ![Shadow – Health Canada, France’s MR001-MR004, EMA Policy 0070 (Phase 1 and 2), compliant](https://geninvo.com/wp-content/uploads/2021/04/overlay_sh-300x168.jpg) ](https://geninvo.com/shadow-health-canada-frances-mr001-mr004-ema-policy-0070-phase-1-and-2-compliant/) ## [Shadow – Health Canada, France’s MR001-MR004, EMA Policy 0070 (Phase 1 and 2), compliant](https://geninvo.com/shadow-health-canada-frances-mr001-mr004-ema-policy-0070-phase-1-and-2-compliant/) [ ![Shadow – Solution to Evolving Data Transparency Requirements](https://geninvo.com/wp-content/uploads/2021/04/healthcanadapolicy-over-300x170.jpg) ](https://geninvo.com/shadow-solution-to-evolving-data-transparency-requirements/) ## [Shadow – Solution to Evolving Data Transparency Requirements](https://geninvo.com/shadow-solution-to-evolving-data-transparency-requirements/) [ ![Machine Learning – Shadow](https://geninvo.com/wp-content/uploads/2021/04/overlay_ml-300x168.jpg) ](https://geninvo.com/machine-learning-shadow/) ## [Machine Learning – Shadow](https://geninvo.com/machine-learning-shadow/) [ ![GENINVO – Covid-19](https://geninvo.com/wp-content/uploads/2021/04/covid-over-300x170.jpg) ](https://geninvo.com/geninvo-covid-19/) ## [GENINVO – Covid-19](https://geninvo.com/geninvo-covid-19/) [ ![Shadow](https://geninvo.com/wp-content/uploads/2021/04/shadow-over-300x170.jpg) ](https://geninvo.com/shadow-video/) ## [Shadow](https://geninvo.com/shadow-video/) [ ![ApoGI](https://geninvo.com/wp-content/uploads/2021/04/apogi-over-300x170.jpg) ](https://geninvo.com/apogi-video/) ## [ApoGI](https://geninvo.com/apogi-video/) [ ![DocQC](https://geninvo.com/wp-content/uploads/2021/04/docqc-over-300x170.jpg) ](https://geninvo.com/docqc-video/) ## [DocQC](https://geninvo.com/docqc-video/) [ ![GENINVO](https://geninvo.com/wp-content/uploads/2021/04/self_animation-300x169.jpg) ](https://geninvo.com/geninvo-video/) ## [GENINVO](https://geninvo.com/geninvo-video/) Blogs ## Blogs [ ![Quantitative Risk Assessment: A Smarter Approach to Clinical Data Anonymization ](https://geninvo.com/wp-content/uploads/2025/10/Blog-12-300x189.jpg) ](https://geninvo.com/quantitative-risk-assessment-a-smarter-approach-to-clinical-data-anonymization/) ## [Quantitative Risk Assessment: A Smarter Approach to Clinical Data Anonymization ](https://geninvo.com/quantitative-risk-assessment-a-smarter-approach-to-clinical-data-anonymization/) [ ![Secure Scanning with Confidential Information Scanner: Safeguarding Your CCIs During Clinical Research](https://geninvo.com/wp-content/uploads/2025/09/Blog-11-300x189.jpg) ](https://geninvo.com/secure-scanning-with-confidential-information-scanner-safeguarding-your-ccis-during-clinical-research/) ## [Secure Scanning with Confidential Information Scanner: Safeguarding Your CCIs During Clinical Research](https://geninvo.com/secure-scanning-with-confidential-information-scanner-safeguarding-your-ccis-during-clinical-research/) [ ![Python’s Future in Clinical Trials: Innovations and Collaborative Advancements](https://geninvo.com/wp-content/uploads/2025/08/Blog-8-300x189.jpg) ](https://geninvo.com/pythons-future-in-clinical-trials-innovations-and-collaborative-advancements/) ## [Python’s Future in Clinical Trials: Innovations and Collaborative Advancements](https://geninvo.com/pythons-future-in-clinical-trials-innovations-and-collaborative-advancements/) [ ![The Changing Role of the Clinical Programmer in an Open-Source World](https://geninvo.com/wp-content/uploads/2025/07/Blog-7-300x189.jpg) ](https://geninvo.com/the-changing-role-of-the-clinical-programmer-in-an-open-source-world/) ## [The Changing Role of the Clinical Programmer in an Open-Source World](https://geninvo.com/the-changing-role-of-the-clinical-programmer-in-an-open-source-world/) [ ![Beyond the Buzzwords: How GenInvo’s AI/ML Tools Are Transforming Life Sciences](https://geninvo.com/wp-content/uploads/2025/07/Blog-6-300x189.jpg) ](https://geninvo.com/ai-ml-tools-life-sciences-geninvo/) ## [Beyond the Buzzwords: How GenInvo’s AI/ML Tools Are Transforming Life Sciences](https://geninvo.com/ai-ml-tools-life-sciences-geninvo/) [ ![Empowering the Future of Life Sciences: A GenInvo Perspective from the Inside](https://geninvo.com/wp-content/uploads/2025/06/Blog-5-300x196.jpg) ](https://geninvo.com/empowering-the-future-of-life-sciences-a-geninvo-perspective-from-the-inside/) ## [Empowering the Future of Life Sciences: A GenInvo Perspective from the Inside](https://geninvo.com/empowering-the-future-of-life-sciences-a-geninvo-perspective-from-the-inside/) [ ![GenInvo’s CIS Tool: Safeguarding Confidential Company Information in Life Sciences.](https://geninvo.com/wp-content/uploads/2025/06/Blog-4-300x196.jpg) ](https://geninvo.com/geninvos-cis-tool-safeguarding-confidential-company-information-in-life-sciences/) ## [GenInvo’s CIS Tool: Safeguarding Confidential Company Information in Life Sciences.](https://geninvo.com/geninvos-cis-tool-safeguarding-confidential-company-information-in-life-sciences/) [ ![Why Clinical Data Transparency Matters: Benefits for Patients, Researchers, and Industry](https://geninvo.com/wp-content/uploads/2025/06/Blog-3-300x196.jpg) ](https://geninvo.com/why-clinical-data-transparency-matters-benefits-for-patients-researchers-and-industry/) ## [Why Clinical Data Transparency Matters: Benefits for Patients, Researchers, and Industry](https://geninvo.com/why-clinical-data-transparency-matters-benefits-for-patients-researchers-and-industry/) [ ![How Meaningful Synthetic Data Generation Tools Are Transforming AI Development ](https://geninvo.com/wp-content/uploads/2025/01/Blog-2-300x169.jpg) ](https://geninvo.com/how-meaningful-synthetic-data-generation-tools-are-transforming-ai-development/) ## [How Meaningful Synthetic Data Generation Tools Are Transforming AI Development ](https://geninvo.com/how-meaningful-synthetic-data-generation-tools-are-transforming-ai-development/) [ ![Empowering Clinical and Regulatory Writing: Harnessing AI as Your Assistant  ](https://geninvo.com/wp-content/uploads/2024/10/Untitled-1-1-300x189.webp) ](https://geninvo.com/empowering-clinical-and-regulatory-writing-harnessing-ai-as-your-assistant/) ## [Empowering Clinical and Regulatory Writing: Harnessing AI as Your Assistant ](https://geninvo.com/empowering-clinical-and-regulatory-writing-harnessing-ai-as-your-assistant/) [ ![The Impact of AI on Medical Writing: How Artificial Intelligence is Revolutionizing Medical Content Creation ](https://geninvo.com/wp-content/uploads/2024/09/mdw-1-300x169.jpg) ](https://geninvo.com/the-impact-of-ai-on-medical-writing-how-artificial-intelligence-is-revolutionizing-medical-content-creation/) ## [The Impact of AI on Medical Writing: How Artificial Intelligence is Revolutionizing Medical Content Creation ](https://geninvo.com/the-impact-of-ai-on-medical-writing-how-artificial-intelligence-is-revolutionizing-medical-content-creation/) [ ![CDISC Standards and Data Transformation in Clinical Trial.](https://geninvo.com/wp-content/uploads/2024/07/dtct-1-300x169.webp) ](https://geninvo.com/cdisc-standards-and-data-transformation-in-clinical-trial/) ## [CDISC Standards and Data Transformation in Clinical Trial.](https://geninvo.com/cdisc-standards-and-data-transformation-in-clinical-trial/) [ ![Transforming Document Creation in Life Sciences with DocWrightAI™ – GenInvo’s Advanced AI Assistant!](https://geninvo.com/wp-content/uploads/2024/06/DocWright-lifscience-300x169.jpg) ](https://geninvo.com/transforming-document-creation-in-life-sciences-with-docwrightai-geninvos-advanced-ai-assistant/) ## [Transforming Document Creation in Life Sciences with DocWrightAI™ – GenInvo’s Advanced AI Assistant!](https://geninvo.com/transforming-document-creation-in-life-sciences-with-docwrightai-geninvos-advanced-ai-assistant/) [ ![Embracing the Digital Era: The Transformative Power of Digitalization in Medical Writing](https://geninvo.com/wp-content/uploads/2024/03/1672114503523rf-1-300x169.jpg) ](https://geninvo.com/embracing-the-digital-era-the-transformative-power-of-digitalization-in-medical-writing/) ## [Embracing the Digital Era: The Transformative Power of Digitalization in Medical Writing](https://geninvo.com/embracing-the-digital-era-the-transformative-power-of-digitalization-in-medical-writing/) [ ![Data Masking and Data Anonymization: The need for healthcare companies](https://geninvo.com/wp-content/uploads/2024/03/data-m-300x169.jpg) ](https://geninvo.com/data-masking-and-data-anonymization-the-need-for-healthcare-companies/) ## [Data Masking and Data Anonymization: The need for healthcare companies](https://geninvo.com/data-masking-and-data-anonymization-the-need-for-healthcare-companies/) [ ![Artificial Intelligence in the Healthcare Domain: How AI Reviews Clinical Documents](https://geninvo.com/wp-content/uploads/2024/03/maxresdefault.jpgr_-300x169.jpg) ](https://geninvo.com/artificial-intelligence-in-the-healthcare-domain-how-ai-reviews-clinical-documents/) ## [Artificial Intelligence in the Healthcare Domain: How AI Reviews Clinical Documents](https://geninvo.com/artificial-intelligence-in-the-healthcare-domain-how-ai-reviews-clinical-documents/) [ ![Importance and examples of usage of Data Anonymization in Healthcare & Other sectors](https://geninvo.com/wp-content/uploads/2024/02/dah-sector-300x169.jpg) ](https://geninvo.com/importance-and-examples-of-usage-of-data-anonymization-in-healthcare-other-sectors/) ## [Importance and examples of usage of Data Anonymization in Healthcare & Other sectors](https://geninvo.com/importance-and-examples-of-usage-of-data-anonymization-in-healthcare-other-sectors/) [ ![Data Anonymization and HIPAA Compliance: Protecting Health Information Privacy](https://geninvo.com/wp-content/uploads/2024/02/Untitled-1df-300x169.jpg) ](https://geninvo.com/data-anonymization-and-hipaa-compliance-protecting-health-information-privacy/) ## [Data Anonymization and HIPAA Compliance: Protecting Health Information Privacy](https://geninvo.com/data-anonymization-and-hipaa-compliance-protecting-health-information-privacy/) [ ![Automation of Unstructured Clinical Data: A collaboration of automation and Medical Writers](https://geninvo.com/wp-content/uploads/2024/01/cdf-300x169.png) ](https://geninvo.com/automation-of-unstructured-clinical-data-a-collaboration-of-automation-and-medical-writers/) ## [Automation of Unstructured Clinical Data: A collaboration of automation and Medical Writers](https://geninvo.com/automation-of-unstructured-clinical-data-a-collaboration-of-automation-and-medical-writers/) [ ![Quality Control of the Methods and Procedures of Clinical Study](https://geninvo.com/wp-content/uploads/2024/01/quloi-300x169.jpg) ](https://geninvo.com/quality-control-of-the-methods-and-procedures-of-clinical-study/) ## [Quality Control of the Methods and Procedures of Clinical Study](https://geninvo.com/quality-control-of-the-methods-and-procedures-of-clinical-study/) Case Studies ## Case Studies [ ![White List & Black List: Enhanced NER Model](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-10-Case-Study-WB-List_v3-300x169.jpg) ](https://geninvo.com/white-list-black-list-enhanced-ner-model/) ## [White List & Black List: Enhanced NER Model](https://geninvo.com/white-list-black-list-enhanced-ner-model/) [ ![NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity-300x169.jpg) ](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) ## [NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) [ ![DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-12-Eprotocol-presentation-300x169.jpg) ](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) ## [DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) [ ![Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-13-Shadow-Recommendation-Engine-300x169.jpg) ](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) ## [Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) [ ![Lung Cancer Detection](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-8-Lung-Cancer-Detection-use-cases-300x169.jpg) ](https://geninvo.com/lung-cancer-detection/) ## [Lung Cancer Detection](https://geninvo.com/lung-cancer-detection/) [ ![Breast Cancer Detection Using Machine Learning](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-9-Case-Study-Breast-Cancer-Detection_v3-use-cases-300x169.jpg) ](https://geninvo.com/breast-cancer-detection-using-machine-learning/) ## [Breast Cancer Detection Using Machine Learning](https://geninvo.com/breast-cancer-detection-using-machine-learning/) [ ![Doc QC tool as a one-stop solution for all Quality Control (QC) needs of a medical writer](https://geninvo.com/wp-content/uploads/2021/08/Case-Studies-8-DocQC-300x169.jpg) ](https://geninvo.com/doc-qc-tool-as-a-one-stop-solution-for-all-quality-control-qc-needs-of-a-medical-writer/) ## [Doc QC tool as a one-stop solution for all Quality Control (QC) needs of a medical writer](https://geninvo.com/doc-qc-tool-as-a-one-stop-solution-for-all-quality-control-qc-needs-of-a-medical-writer/) [ ![Provide ApoGI as a Metadata Driven Platform](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-7-300x169.jpg) ](https://geninvo.com/provide-apogitmas-a-metadatadriven-platform/) ## [Provide ApoGI as a Metadata Driven Platform](https://geninvo.com/provide-apogitmas-a-metadatadriven-platform/) [ ![Provide ApoGI as a MDR Visualization](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-6-300x169.jpg) ](https://geninvo.com/provide-apogitmas-a-mdrvisualization/) ## [Provide ApoGI as a MDR Visualization](https://geninvo.com/provide-apogitmas-a-mdrvisualization/) [ ![Provide ApoGI as a Metadata Driven Transformations](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-5-300x169.jpg) ](https://geninvo.com/provide-apogitm-asa-metadata-driventransformations/) ## [Provide ApoGI as a Metadata Driven Transformations](https://geninvo.com/provide-apogitm-asa-metadata-driventransformations/) [ ![How a Big Pharma Company Achieved Compliance with Health Canada Under Tight Deadlines](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-4-300x169.jpg) ](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-health-canada-under-tight-deadlines/) ## [How a Big Pharma Company Achieved Compliance with Health Canada Under Tight Deadlines](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-health-canada-under-tight-deadlines/) [ ![How a Pharmaceutical Firm Established Anonymization Process](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-3-300x169.jpg) ](https://geninvo.com/how-a-pharmaceutical-firm-established-anonymization-process/) ## [How a Pharmaceutical Firm Established Anonymization Process](https://geninvo.com/how-a-pharmaceutical-firm-established-anonymization-process/) [ ![Big Pharma Company Achieves Compliance with EMA 0070 Policy](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-2-300x169.jpg) ](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-ema-0070-policy-with-a-tight-deadline/) ## [Big Pharma Company Achieves Compliance with EMA 0070 Policy](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-ema-0070-policy-with-a-tight-deadline/) [ ![How a Global Medical Writing CRO Increased Functional Capability with Shadow™](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-1-300x169.jpg) ](https://geninvo.com/how-a-global-medical-writing-cro-increased-functional-capability-with-shadowtm/) ## [How a Global Medical Writing CRO Increased Functional Capability with Shadow™](https://geninvo.com/how-a-global-medical-writing-cro-increased-functional-capability-with-shadowtm/) Events ## Events [ ![Meet GenInvo at DPHARM 2026, Booth 116, Boston](https://geninvo.com/wp-content/uploads/2026/06/DPHARM-1-300x186.png) ](https://geninvo.com/dpharm-2026/) ## [Meet GenInvo at DPHARM 2026, Booth 116, Boston](https://geninvo.com/dpharm-2026/) [ ![Meet GENINVO at the EMWA 61st Spring Conference 2026](https://geninvo.com/wp-content/uploads/2026/04/539-X-334-1-300x186.png) ](https://geninvo.com/emwa-2026-barcelona/) ## [Meet GENINVO at the EMWA 61st Spring Conference 2026](https://geninvo.com/emwa-2026-barcelona/) [ ![GenInvo at PharmaSUG 2026 SDE Conference](https://geninvo.com/wp-content/uploads/2026/04/539-X-334-300x186.png) ](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) ## [GenInvo at PharmaSUG 2026 SDE Conference](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) [ ![GenInvo @ PHUSE US Connect 2026](https://geninvo.com/wp-content/uploads/2026/03/image-16-300x186.png) ](https://geninvo.com/geninvo-phuse-us-connect-2026/) ## [GenInvo @ PHUSE US Connect 2026](https://geninvo.com/geninvo-phuse-us-connect-2026/) [ ![Live Webinar: Accelerating Authoring and QC of Clinical Documents with AI-Powered Automation](https://geninvo.com/wp-content/uploads/2025/08/Blog-9-300x186.jpg) ](https://geninvo.com/live-webinar-accelerating-authoring-and-qc-of-clinical-documents-with-ai-powered-automation/) ## [Live Webinar: Accelerating Authoring and QC of Clinical Documents with AI-Powered Automation](https://geninvo.com/live-webinar-accelerating-authoring-and-qc-of-clinical-documents-with-ai-powered-automation/) [ ![GenInvo is Powering the Future of Medical Writing at AMWA 2025!](https://geninvo.com/wp-content/uploads/2025/08/GI-AMWA-conference-blog-2025-300x186.jpg) ](https://geninvo.com/geninvo-is-powering-the-future-of-medical-writing-at-amwa-2025/) ## [GenInvo is Powering the Future of Medical Writing at AMWA 2025!](https://geninvo.com/geninvo-is-powering-the-future-of-medical-writing-at-amwa-2025/) [ ![GENINVO™ Sponsors PHUSE Data Transparency Autumn Event 2025](https://geninvo.com/wp-content/uploads/2025/07/Blog-GI-Phusevirtualevent-Sept-2025-300x189.jpg) ](https://geninvo.com/geninvo-sponsors-phuse-data-transparency-autumn-event-2025/) ## [GENINVO™ Sponsors PHUSE Data Transparency Autumn Event 2025](https://geninvo.com/geninvo-sponsors-phuse-data-transparency-autumn-event-2025/) [ ![GENINVO™ at PHUSE US Connect 2025](https://geninvo.com/wp-content/uploads/2025/02/GI-US-PHUSE-connect-2025-300x186.jpg) ](https://geninvo.com/geninvo-at-phuse-us-connect-2025/) ## [GENINVO™ at PHUSE US Connect 2025](https://geninvo.com/geninvo-at-phuse-us-connect-2025/) [ ![Join GENINVO™ at the DIA Medical Affairs and Scientific Communications Forum](https://geninvo.com/wp-content/uploads/2025/02/GI-DIA-blogpost-mar2025-300x186.webp) ](https://geninvo.com/join-geninvo-at-the-dia-medical-affairs-and-scientific-communications-forum/) ## [Join GENINVO™ at the DIA Medical Affairs and Scientific Communications Forum](https://geninvo.com/join-geninvo-at-the-dia-medical-affairs-and-scientific-communications-forum/) [ ![Thank You for Attending the GENINVO’s AMWA Webinar](https://geninvo.com/wp-content/uploads/2024/11/blog-post-AMWA-24nov-300x169.webp) ](https://geninvo.com/thank-you-for-attending-the-geninvos-amwa-webinar/) ## [Thank You for Attending the GENINVO’s AMWA Webinar](https://geninvo.com/thank-you-for-attending-the-geninvos-amwa-webinar/) [ ![Join Our Free Webinar!](https://geninvo.com/wp-content/uploads/2024/10/GI-AMWA-blog-AI-writers-24-V2-300x169.webp) ](https://geninvo.com/join-our-free-webinar/) ## [Join Our Free Webinar!](https://geninvo.com/join-our-free-webinar/) [ ![Shake hands with GENINVO at DIA’s Global Clinical Trial Disclosure and Data Transparency Conference](https://geninvo.com/wp-content/uploads/2024/04/GI-and-sha-DIA-V1-3-300x169.jpg) ](https://geninvo.com/shake-hands-with-geninvo-at-dias-global-clinical-trial-disclosure-and-data-transparency-conference/) ## [Shake hands with GENINVO at DIA’s Global Clinical Trial Disclosure and Data Transparency Conference](https://geninvo.com/shake-hands-with-geninvo-at-dias-global-clinical-trial-disclosure-and-data-transparency-conference/) [ ![Meet GENINVO at DPHARM 2023 in Boston, MA!](https://geninvo.com/wp-content/uploads/2023/08/MicrosoftTeams-image-142-300x169.jpg) ](https://geninvo.com/meet-geninvo-at-dpharm-2023-in-boston-ma/) ## [Meet GENINVO at DPHARM 2023 in Boston, MA!](https://geninvo.com/meet-geninvo-at-dpharm-2023-in-boston-ma/) [ ![Shake hands with GENINVO at PHUSE CSS 2023! ](https://geninvo.com/wp-content/uploads/2023/08/MicrosoftTeams-image-151-300x169.jpg) ](https://geninvo.com/shake-hands-with-geninvo-at-phuse-css-2023/) ## [Shake hands with GENINVO at PHUSE CSS 2023! ](https://geninvo.com/shake-hands-with-geninvo-at-phuse-css-2023/) [ ![GENINVO is delighted to exhibit and present again at the PHUSE US Connect 2023! You can visit us at Booth #7.](https://geninvo.com/wp-content/uploads/2023/02/MicrosoftTeams-image-53-300x169.jpg) ](https://geninvo.com/phuse-us-connect-2023/) ## [GENINVO is delighted to exhibit and present again at the PHUSE US Connect 2023! You can visit us at Booth #7.](https://geninvo.com/phuse-us-connect-2023/) [ ![American Medical Writers Association (AMWA 2022)](https://geninvo.com/wp-content/uploads/2022/10/MicrosoftTeams-image-24-300x170.jpg) ](https://geninvo.com/american-medical-writers-association-amwa-2022/) ## [American Medical Writers Association (AMWA 2022)](https://geninvo.com/american-medical-writers-association-amwa-2022/) [ ![PHUSE EU Connect 2022](https://geninvo.com/wp-content/uploads/2022/10/MicrosoftTeams-image-23-300x170.jpg) ](https://geninvo.com/phuse-eu-connect-2022/) ## [PHUSE EU Connect 2022](https://geninvo.com/phuse-eu-connect-2022/) [ ![EU-CTR New regulations are here – Are you ready for the changes?](https://geninvo.com/wp-content/uploads/2022/09/MicrosoftTeams-image-8-300x172.jpg) ](https://geninvo.com/eu-ctr-new-regulations-are-here-are-you-ready-for-the-changes/) ## [EU-CTR New regulations are here – Are you ready for the changes?](https://geninvo.com/eu-ctr-new-regulations-are-here-are-you-ready-for-the-changes/) [ ![PHUSE’s Data Transparency Winter Event – virtual](https://geninvo.com/wp-content/uploads/2022/02/GI_phuse-8-10-feb-22-01-300x172.jpg) ](https://geninvo.com/phuses-data-transparency-winter-event-virtual/) ## [PHUSE’s Data Transparency Winter Event – virtual](https://geninvo.com/phuses-data-transparency-winter-event-virtual/) [ ![PHUSE US Connect 2022](https://geninvo.com/wp-content/uploads/2021/10/Phuse-event-US-May-300x169.png) ](https://geninvo.com/phuse-us-connect-2022/) ## [PHUSE US Connect 2022](https://geninvo.com/phuse-us-connect-2022/) News ## News [ ![GENINVO Launches Centre of Excellence for Data Science and Analytics](https://geninvo.com/wp-content/uploads/2021/11/dsa-coe-300x170.jpg) ](https://geninvo.com/geninvo-launches-centre-of-excellence-for-data-science-and-analytics/) ## [GENINVO Launches Centre of Excellence for Data Science and Analytics](https://geninvo.com/geninvo-launches-centre-of-excellence-for-data-science-and-analytics/) [ ![NEW WEBSITE LAUNCH ANNOUNCEMENT](https://geninvo.com/wp-content/uploads/2021/06/feat-ns-300x170.jpg) ](https://geninvo.com/new-website-launch-announcement-geninvo-launches-updated-website/) ## [NEW WEBSITE LAUNCH ANNOUNCEMENT](https://geninvo.com/new-website-launch-announcement-geninvo-launches-updated-website/) [ ![GENINVO Launches Shadow™ Version 2](https://geninvo.com/wp-content/uploads/2021/03/feat-shadow-300x170.jpg) ](https://geninvo.com/geninvo-launches-shadow-version-2/) ## [GENINVO Launches Shadow™ Version 2](https://geninvo.com/geninvo-launches-shadow-version-2/) [ ![Youth Initiative – Introduction to Robotics Workshop](https://geninvo.com/wp-content/uploads/2021/10/event-feature-2020-300x170.jpg) ](https://geninvo.com/youth-initiative-introduction-to-robotics-workshop/) ## [Youth Initiative – Introduction to Robotics Workshop](https://geninvo.com/youth-initiative-introduction-to-robotics-workshop/) [ ![GENINVO Celebrates Anniversary](https://geninvo.com/wp-content/uploads/2021/05/feat-annivers-300x170.jpg) ](https://geninvo.com/geninvo-anniversary/) ## [GENINVO Celebrates Anniversary](https://geninvo.com/geninvo-anniversary/) [ ![GENINVO Announces Upcoming Version Launch of Shadow™](https://geninvo.com/wp-content/uploads/2021/03/feat-shadow-300x170.jpg) ](https://geninvo.com/geninvo-announces-upcoming-launch-of-shadow-version-2/) ## [GENINVO Announces Upcoming Version Launch of Shadow™](https://geninvo.com/geninvo-announces-upcoming-launch-of-shadow-version-2/) [ ![GENINVO provides technological solutions to the problems in Life Sciences and Pharmaceutical Industry.](https://geninvo.com/wp-content/uploads/2021/05/feat-lsp-300x170.jpg) ](https://geninvo.com/geninvo-provides-technological-solutions-to-the-problems-in-life-sciences-and-pharmaceutical-industry/) ## [GENINVO provides technological solutions to the problems in Life Sciences and Pharmaceutical Industry.](https://geninvo.com/geninvo-provides-technological-solutions-to-the-problems-in-life-sciences-and-pharmaceutical-industry/) [ ![See the Impact of Innovation](https://geninvo.com/wp-content/uploads/2021/05/feat-impact-300x170.jpg) ](https://geninvo.com/see-the-impact-of-innovation/) ## [See the Impact of Innovation](https://geninvo.com/see-the-impact-of-innovation/) [ ![Standing strong with Community](https://geninvo.com/wp-content/uploads/2021/03/feat-stand-str-300x170.jpg) ](https://geninvo.com/standing-strong-with-community/) ## [Standing strong with Community](https://geninvo.com/standing-strong-with-community/) [ ![COVID-19](https://geninvo.com/wp-content/uploads/2021/03/feat-covid-300x170.jpg) ](https://geninvo.com/covid-19/) ## [COVID-19](https://geninvo.com/covid-19/) Videos ## Videos [ ![Shadow for EU-CTR Compliance](https://geninvo.com/wp-content/uploads/2022/11/2022-11-29T20_55_50-300x168.png) ](https://geninvo.com/shadow-for-eu-ctr-compliance/) ## [Shadow for EU-CTR Compliance](https://geninvo.com/shadow-for-eu-ctr-compliance/) [ ![DocQC – Medical Writers automation tool for QC checks](https://geninvo.com/wp-content/uploads/2021/04/docqc-img-overlay-300x171.png) ](https://geninvo.com/docqc-medical-writers-automation-tool-for-qc-checks/) ## [DocQC – Medical Writers automation tool for QC checks](https://geninvo.com/docqc-medical-writers-automation-tool-for-qc-checks/) [ ![Shadow- Risk Analysis Tool](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-shadow-1-e1617726618274-300x168.jpg) ](https://geninvo.com/shadow-risk-analysis-tool/) ## [Shadow- Risk Analysis Tool](https://geninvo.com/shadow-risk-analysis-tool/) [ ![Shadow- Data Anonymization Tool](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-shadow-2-e1617726656616-300x144.jpg) ](https://geninvo.com/shadow-data-anonymization-tool/) ## [Shadow- Data Anonymization Tool](https://geninvo.com/shadow-data-anonymization-tool/) [ ![DocQc – Medical Writer’s Best Friend](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-docqc-300x210.jpg) ](https://geninvo.com/docqc-medical-writers-best-friend/) ## [DocQc – Medical Writer’s Best Friend](https://geninvo.com/docqc-medical-writers-best-friend/) [ ![GENINVO Anniversary](https://geninvo.com/wp-content/uploads/2021/04/overlay_annv-300x168.jpg) ](https://geninvo.com/geninvo-anniversary-2/) ## [GENINVO Anniversary](https://geninvo.com/geninvo-anniversary-2/) [ ![Shadow – Health Canada, France’s MR001-MR004, EMA Policy 0070 (Phase 1 and 2), compliant](https://geninvo.com/wp-content/uploads/2021/04/overlay_sh-300x168.jpg) ](https://geninvo.com/shadow-health-canada-frances-mr001-mr004-ema-policy-0070-phase-1-and-2-compliant/) ## [Shadow – Health Canada, France’s MR001-MR004, EMA Policy 0070 (Phase 1 and 2), compliant](https://geninvo.com/shadow-health-canada-frances-mr001-mr004-ema-policy-0070-phase-1-and-2-compliant/) [ ![Shadow – Solution to Evolving Data Transparency Requirements](https://geninvo.com/wp-content/uploads/2021/04/healthcanadapolicy-over-300x170.jpg) ](https://geninvo.com/shadow-solution-to-evolving-data-transparency-requirements/) ## [Shadow – Solution to Evolving Data Transparency Requirements](https://geninvo.com/shadow-solution-to-evolving-data-transparency-requirements/) [ ![Machine Learning – Shadow](https://geninvo.com/wp-content/uploads/2021/04/overlay_ml-300x168.jpg) ](https://geninvo.com/machine-learning-shadow/) ## [Machine Learning – Shadow](https://geninvo.com/machine-learning-shadow/) [ ![GENINVO – Covid-19](https://geninvo.com/wp-content/uploads/2021/04/covid-over-300x170.jpg) ](https://geninvo.com/geninvo-covid-19/) ## [GENINVO – Covid-19](https://geninvo.com/geninvo-covid-19/) [ ![Shadow](https://geninvo.com/wp-content/uploads/2021/04/shadow-over-300x170.jpg) ](https://geninvo.com/shadow-video/) ## [Shadow](https://geninvo.com/shadow-video/) [ ![ApoGI](https://geninvo.com/wp-content/uploads/2021/04/apogi-over-300x170.jpg) ](https://geninvo.com/apogi-video/) ## [ApoGI](https://geninvo.com/apogi-video/) [ ![DocQC](https://geninvo.com/wp-content/uploads/2021/04/docqc-over-300x170.jpg) ](https://geninvo.com/docqc-video/) ## [DocQC](https://geninvo.com/docqc-video/) [ ![GENINVO](https://geninvo.com/wp-content/uploads/2021/04/self_animation-300x169.jpg) ](https://geninvo.com/geninvo-video/) ## [GENINVO](https://geninvo.com/geninvo-video/) ## Blogs [ ![Quantitative Risk Assessment: A Smarter Approach to Clinical Data Anonymization ](https://geninvo.com/wp-content/uploads/2025/10/Blog-12-300x189.jpg) ](https://geninvo.com/quantitative-risk-assessment-a-smarter-approach-to-clinical-data-anonymization/) ## [Quantitative Risk Assessment: A Smarter Approach to Clinical Data Anonymization ](https://geninvo.com/quantitative-risk-assessment-a-smarter-approach-to-clinical-data-anonymization/) [ ![Secure Scanning with Confidential Information Scanner: Safeguarding Your CCIs During Clinical Research](https://geninvo.com/wp-content/uploads/2025/09/Blog-11-300x189.jpg) ](https://geninvo.com/secure-scanning-with-confidential-information-scanner-safeguarding-your-ccis-during-clinical-research/) ## [Secure Scanning with Confidential Information Scanner: Safeguarding Your CCIs During Clinical Research](https://geninvo.com/secure-scanning-with-confidential-information-scanner-safeguarding-your-ccis-during-clinical-research/) [ ![Python’s Future in Clinical Trials: Innovations and Collaborative Advancements](https://geninvo.com/wp-content/uploads/2025/08/Blog-8-300x189.jpg) ](https://geninvo.com/pythons-future-in-clinical-trials-innovations-and-collaborative-advancements/) ## [Python’s Future in Clinical Trials: Innovations and Collaborative Advancements](https://geninvo.com/pythons-future-in-clinical-trials-innovations-and-collaborative-advancements/) [ ![The Changing Role of the Clinical Programmer in an Open-Source World](https://geninvo.com/wp-content/uploads/2025/07/Blog-7-300x189.jpg) ](https://geninvo.com/the-changing-role-of-the-clinical-programmer-in-an-open-source-world/) ## [The Changing Role of the Clinical Programmer in an Open-Source World](https://geninvo.com/the-changing-role-of-the-clinical-programmer-in-an-open-source-world/) [ ![Beyond the Buzzwords: How GenInvo’s AI/ML Tools Are Transforming Life Sciences](https://geninvo.com/wp-content/uploads/2025/07/Blog-6-300x189.jpg) ](https://geninvo.com/ai-ml-tools-life-sciences-geninvo/) ## [Beyond the Buzzwords: How GenInvo’s AI/ML Tools Are Transforming Life Sciences](https://geninvo.com/ai-ml-tools-life-sciences-geninvo/) [ ![Empowering the Future of Life Sciences: A GenInvo Perspective from the Inside](https://geninvo.com/wp-content/uploads/2025/06/Blog-5-300x196.jpg) ](https://geninvo.com/empowering-the-future-of-life-sciences-a-geninvo-perspective-from-the-inside/) ## [Empowering the Future of Life Sciences: A GenInvo Perspective from the Inside](https://geninvo.com/empowering-the-future-of-life-sciences-a-geninvo-perspective-from-the-inside/) [ ![GenInvo’s CIS Tool: Safeguarding Confidential Company Information in Life Sciences.](https://geninvo.com/wp-content/uploads/2025/06/Blog-4-300x196.jpg) ](https://geninvo.com/geninvos-cis-tool-safeguarding-confidential-company-information-in-life-sciences/) ## [GenInvo’s CIS Tool: Safeguarding Confidential Company Information in Life Sciences.](https://geninvo.com/geninvos-cis-tool-safeguarding-confidential-company-information-in-life-sciences/) [ ![Why Clinical Data Transparency Matters: Benefits for Patients, Researchers, and Industry](https://geninvo.com/wp-content/uploads/2025/06/Blog-3-300x196.jpg) ](https://geninvo.com/why-clinical-data-transparency-matters-benefits-for-patients-researchers-and-industry/) ## [Why Clinical Data Transparency Matters: Benefits for Patients, Researchers, and Industry](https://geninvo.com/why-clinical-data-transparency-matters-benefits-for-patients-researchers-and-industry/) [ ![How Meaningful Synthetic Data Generation Tools Are Transforming AI Development ](https://geninvo.com/wp-content/uploads/2025/01/Blog-2-300x169.jpg) ](https://geninvo.com/how-meaningful-synthetic-data-generation-tools-are-transforming-ai-development/) ## [How Meaningful Synthetic Data Generation Tools Are Transforming AI Development ](https://geninvo.com/how-meaningful-synthetic-data-generation-tools-are-transforming-ai-development/) [ ![Empowering Clinical and Regulatory Writing: Harnessing AI as Your Assistant  ](https://geninvo.com/wp-content/uploads/2024/10/Untitled-1-1-300x189.webp) ](https://geninvo.com/empowering-clinical-and-regulatory-writing-harnessing-ai-as-your-assistant/) ## [Empowering Clinical and Regulatory Writing: Harnessing AI as Your Assistant ](https://geninvo.com/empowering-clinical-and-regulatory-writing-harnessing-ai-as-your-assistant/) [ ![The Impact of AI on Medical Writing: How Artificial Intelligence is Revolutionizing Medical Content Creation ](https://geninvo.com/wp-content/uploads/2024/09/mdw-1-300x169.jpg) ](https://geninvo.com/the-impact-of-ai-on-medical-writing-how-artificial-intelligence-is-revolutionizing-medical-content-creation/) ## [The Impact of AI on Medical Writing: How Artificial Intelligence is Revolutionizing Medical Content Creation ](https://geninvo.com/the-impact-of-ai-on-medical-writing-how-artificial-intelligence-is-revolutionizing-medical-content-creation/) [ ![CDISC Standards and Data Transformation in Clinical Trial.](https://geninvo.com/wp-content/uploads/2024/07/dtct-1-300x169.webp) ](https://geninvo.com/cdisc-standards-and-data-transformation-in-clinical-trial/) ## [CDISC Standards and Data Transformation in Clinical Trial.](https://geninvo.com/cdisc-standards-and-data-transformation-in-clinical-trial/) [ ![Transforming Document Creation in Life Sciences with DocWrightAI™ – GenInvo’s Advanced AI Assistant!](https://geninvo.com/wp-content/uploads/2024/06/DocWright-lifscience-300x169.jpg) ](https://geninvo.com/transforming-document-creation-in-life-sciences-with-docwrightai-geninvos-advanced-ai-assistant/) ## [Transforming Document Creation in Life Sciences with DocWrightAI™ – GenInvo’s Advanced AI Assistant!](https://geninvo.com/transforming-document-creation-in-life-sciences-with-docwrightai-geninvos-advanced-ai-assistant/) [ ![Embracing the Digital Era: The Transformative Power of Digitalization in Medical Writing](https://geninvo.com/wp-content/uploads/2024/03/1672114503523rf-1-300x169.jpg) ](https://geninvo.com/embracing-the-digital-era-the-transformative-power-of-digitalization-in-medical-writing/) ## [Embracing the Digital Era: The Transformative Power of Digitalization in Medical Writing](https://geninvo.com/embracing-the-digital-era-the-transformative-power-of-digitalization-in-medical-writing/) [ ![Data Masking and Data Anonymization: The need for healthcare companies](https://geninvo.com/wp-content/uploads/2024/03/data-m-300x169.jpg) ](https://geninvo.com/data-masking-and-data-anonymization-the-need-for-healthcare-companies/) ## [Data Masking and Data Anonymization: The need for healthcare companies](https://geninvo.com/data-masking-and-data-anonymization-the-need-for-healthcare-companies/) [ ![Artificial Intelligence in the Healthcare Domain: How AI Reviews Clinical Documents](https://geninvo.com/wp-content/uploads/2024/03/maxresdefault.jpgr_-300x169.jpg) ](https://geninvo.com/artificial-intelligence-in-the-healthcare-domain-how-ai-reviews-clinical-documents/) ## [Artificial Intelligence in the Healthcare Domain: How AI Reviews Clinical Documents](https://geninvo.com/artificial-intelligence-in-the-healthcare-domain-how-ai-reviews-clinical-documents/) [ ![Importance and examples of usage of Data Anonymization in Healthcare & Other sectors](https://geninvo.com/wp-content/uploads/2024/02/dah-sector-300x169.jpg) ](https://geninvo.com/importance-and-examples-of-usage-of-data-anonymization-in-healthcare-other-sectors/) ## [Importance and examples of usage of Data Anonymization in Healthcare & Other sectors](https://geninvo.com/importance-and-examples-of-usage-of-data-anonymization-in-healthcare-other-sectors/) [ ![Data Anonymization and HIPAA Compliance: Protecting Health Information Privacy](https://geninvo.com/wp-content/uploads/2024/02/Untitled-1df-300x169.jpg) ](https://geninvo.com/data-anonymization-and-hipaa-compliance-protecting-health-information-privacy/) ## [Data Anonymization and HIPAA Compliance: Protecting Health Information Privacy](https://geninvo.com/data-anonymization-and-hipaa-compliance-protecting-health-information-privacy/) [ ![Automation of Unstructured Clinical Data: A collaboration of automation and Medical Writers](https://geninvo.com/wp-content/uploads/2024/01/cdf-300x169.png) ](https://geninvo.com/automation-of-unstructured-clinical-data-a-collaboration-of-automation-and-medical-writers/) ## [Automation of Unstructured Clinical Data: A collaboration of automation and Medical Writers](https://geninvo.com/automation-of-unstructured-clinical-data-a-collaboration-of-automation-and-medical-writers/) [ ![Quality Control of the Methods and Procedures of Clinical Study](https://geninvo.com/wp-content/uploads/2024/01/quloi-300x169.jpg) ](https://geninvo.com/quality-control-of-the-methods-and-procedures-of-clinical-study/) ## [Quality Control of the Methods and Procedures of Clinical Study](https://geninvo.com/quality-control-of-the-methods-and-procedures-of-clinical-study/) ## Case Studies [ ![White List & Black List: Enhanced NER Model](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-10-Case-Study-WB-List_v3-300x169.jpg) ](https://geninvo.com/white-list-black-list-enhanced-ner-model/) ## [White List & Black List: Enhanced NER Model](https://geninvo.com/white-list-black-list-enhanced-ner-model/) [ ![NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity-300x169.jpg) ](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) ## [NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) [ ![DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-12-Eprotocol-presentation-300x169.jpg) ](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) ## [DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) [ ![Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-13-Shadow-Recommendation-Engine-300x169.jpg) ](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) ## [Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) [ ![Lung Cancer Detection](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-8-Lung-Cancer-Detection-use-cases-300x169.jpg) ](https://geninvo.com/lung-cancer-detection/) ## [Lung Cancer Detection](https://geninvo.com/lung-cancer-detection/) [ ![Breast Cancer Detection Using Machine Learning](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-9-Case-Study-Breast-Cancer-Detection_v3-use-cases-300x169.jpg) ](https://geninvo.com/breast-cancer-detection-using-machine-learning/) ## [Breast Cancer Detection Using Machine Learning](https://geninvo.com/breast-cancer-detection-using-machine-learning/) [ ![Doc QC tool as a one-stop solution for all Quality Control (QC) needs of a medical writer](https://geninvo.com/wp-content/uploads/2021/08/Case-Studies-8-DocQC-300x169.jpg) ](https://geninvo.com/doc-qc-tool-as-a-one-stop-solution-for-all-quality-control-qc-needs-of-a-medical-writer/) ## [Doc QC tool as a one-stop solution for all Quality Control (QC) needs of a medical writer](https://geninvo.com/doc-qc-tool-as-a-one-stop-solution-for-all-quality-control-qc-needs-of-a-medical-writer/) [ ![Provide ApoGI as a Metadata Driven Platform](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-7-300x169.jpg) ](https://geninvo.com/provide-apogitmas-a-metadatadriven-platform/) ## [Provide ApoGI as a Metadata Driven Platform](https://geninvo.com/provide-apogitmas-a-metadatadriven-platform/) [ ![Provide ApoGI as a MDR Visualization](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-6-300x169.jpg) ](https://geninvo.com/provide-apogitmas-a-mdrvisualization/) ## [Provide ApoGI as a MDR Visualization](https://geninvo.com/provide-apogitmas-a-mdrvisualization/) [ ![Provide ApoGI as a Metadata Driven Transformations](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-5-300x169.jpg) ](https://geninvo.com/provide-apogitm-asa-metadata-driventransformations/) ## [Provide ApoGI as a Metadata Driven Transformations](https://geninvo.com/provide-apogitm-asa-metadata-driventransformations/) [ ![How a Big Pharma Company Achieved Compliance with Health Canada Under Tight Deadlines](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-4-300x169.jpg) ](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-health-canada-under-tight-deadlines/) ## [How a Big Pharma Company Achieved Compliance with Health Canada Under Tight Deadlines](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-health-canada-under-tight-deadlines/) [ ![How a Pharmaceutical Firm Established Anonymization Process](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-3-300x169.jpg) ](https://geninvo.com/how-a-pharmaceutical-firm-established-anonymization-process/) ## [How a Pharmaceutical Firm Established Anonymization Process](https://geninvo.com/how-a-pharmaceutical-firm-established-anonymization-process/) [ ![Big Pharma Company Achieves Compliance with EMA 0070 Policy](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-2-300x169.jpg) ](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-ema-0070-policy-with-a-tight-deadline/) ## [Big Pharma Company Achieves Compliance with EMA 0070 Policy](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-ema-0070-policy-with-a-tight-deadline/) [ ![How a Global Medical Writing CRO Increased Functional Capability with Shadow™](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-1-300x169.jpg) ](https://geninvo.com/how-a-global-medical-writing-cro-increased-functional-capability-with-shadowtm/) ## [How a Global Medical Writing CRO Increased Functional Capability with Shadow™](https://geninvo.com/how-a-global-medical-writing-cro-increased-functional-capability-with-shadowtm/) ## Events [ ![Meet GenInvo at DPHARM 2026, Booth 116, Boston](https://geninvo.com/wp-content/uploads/2026/06/DPHARM-1-300x186.png) ](https://geninvo.com/dpharm-2026/) ## [Meet GenInvo at DPHARM 2026, Booth 116, Boston](https://geninvo.com/dpharm-2026/) [ ![Meet GENINVO at the EMWA 61st Spring Conference 2026](https://geninvo.com/wp-content/uploads/2026/04/539-X-334-1-300x186.png) ](https://geninvo.com/emwa-2026-barcelona/) ## [Meet GENINVO at the EMWA 61st Spring Conference 2026](https://geninvo.com/emwa-2026-barcelona/) [ ![GenInvo at PharmaSUG 2026 SDE Conference](https://geninvo.com/wp-content/uploads/2026/04/539-X-334-300x186.png) ](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) ## [GenInvo at PharmaSUG 2026 SDE Conference](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) [ ![GenInvo @ PHUSE US Connect 2026](https://geninvo.com/wp-content/uploads/2026/03/image-16-300x186.png) ](https://geninvo.com/geninvo-phuse-us-connect-2026/) ## [GenInvo @ PHUSE US Connect 2026](https://geninvo.com/geninvo-phuse-us-connect-2026/) [ ![Live Webinar: Accelerating Authoring and QC of Clinical Documents with AI-Powered Automation](https://geninvo.com/wp-content/uploads/2025/08/Blog-9-300x186.jpg) ](https://geninvo.com/live-webinar-accelerating-authoring-and-qc-of-clinical-documents-with-ai-powered-automation/) ## [Live Webinar: Accelerating Authoring and QC of Clinical Documents with AI-Powered Automation](https://geninvo.com/live-webinar-accelerating-authoring-and-qc-of-clinical-documents-with-ai-powered-automation/) [ ![GenInvo is Powering the Future of Medical Writing at AMWA 2025!](https://geninvo.com/wp-content/uploads/2025/08/GI-AMWA-conference-blog-2025-300x186.jpg) ](https://geninvo.com/geninvo-is-powering-the-future-of-medical-writing-at-amwa-2025/) ## [GenInvo is Powering the Future of Medical Writing at AMWA 2025!](https://geninvo.com/geninvo-is-powering-the-future-of-medical-writing-at-amwa-2025/) [ ![GENINVO™ Sponsors PHUSE Data Transparency Autumn Event 2025](https://geninvo.com/wp-content/uploads/2025/07/Blog-GI-Phusevirtualevent-Sept-2025-300x189.jpg) ](https://geninvo.com/geninvo-sponsors-phuse-data-transparency-autumn-event-2025/) ## [GENINVO™ Sponsors PHUSE Data Transparency Autumn Event 2025](https://geninvo.com/geninvo-sponsors-phuse-data-transparency-autumn-event-2025/) [ ![GENINVO™ at PHUSE US Connect 2025](https://geninvo.com/wp-content/uploads/2025/02/GI-US-PHUSE-connect-2025-300x186.jpg) ](https://geninvo.com/geninvo-at-phuse-us-connect-2025/) ## [GENINVO™ at PHUSE US Connect 2025](https://geninvo.com/geninvo-at-phuse-us-connect-2025/) [ ![Join GENINVO™ at the DIA Medical Affairs and Scientific Communications Forum](https://geninvo.com/wp-content/uploads/2025/02/GI-DIA-blogpost-mar2025-300x186.webp) ](https://geninvo.com/join-geninvo-at-the-dia-medical-affairs-and-scientific-communications-forum/) ## [Join GENINVO™ at the DIA Medical Affairs and Scientific Communications Forum](https://geninvo.com/join-geninvo-at-the-dia-medical-affairs-and-scientific-communications-forum/) [ ![Thank You for Attending the GENINVO’s AMWA Webinar](https://geninvo.com/wp-content/uploads/2024/11/blog-post-AMWA-24nov-300x169.webp) ](https://geninvo.com/thank-you-for-attending-the-geninvos-amwa-webinar/) ## [Thank You for Attending the GENINVO’s AMWA Webinar](https://geninvo.com/thank-you-for-attending-the-geninvos-amwa-webinar/) [ ![Join Our Free Webinar!](https://geninvo.com/wp-content/uploads/2024/10/GI-AMWA-blog-AI-writers-24-V2-300x169.webp) ](https://geninvo.com/join-our-free-webinar/) ## [Join Our Free Webinar!](https://geninvo.com/join-our-free-webinar/) [ ![Shake hands with GENINVO at DIA’s Global Clinical Trial Disclosure and Data Transparency Conference](https://geninvo.com/wp-content/uploads/2024/04/GI-and-sha-DIA-V1-3-300x169.jpg) ](https://geninvo.com/shake-hands-with-geninvo-at-dias-global-clinical-trial-disclosure-and-data-transparency-conference/) ## [Shake hands with GENINVO at DIA’s Global Clinical Trial Disclosure and Data Transparency Conference](https://geninvo.com/shake-hands-with-geninvo-at-dias-global-clinical-trial-disclosure-and-data-transparency-conference/) [ ![Meet GENINVO at DPHARM 2023 in Boston, MA!](https://geninvo.com/wp-content/uploads/2023/08/MicrosoftTeams-image-142-300x169.jpg) ](https://geninvo.com/meet-geninvo-at-dpharm-2023-in-boston-ma/) ## [Meet GENINVO at DPHARM 2023 in Boston, MA!](https://geninvo.com/meet-geninvo-at-dpharm-2023-in-boston-ma/) [ ![Shake hands with GENINVO at PHUSE CSS 2023! ](https://geninvo.com/wp-content/uploads/2023/08/MicrosoftTeams-image-151-300x169.jpg) ](https://geninvo.com/shake-hands-with-geninvo-at-phuse-css-2023/) ## [Shake hands with GENINVO at PHUSE CSS 2023! ](https://geninvo.com/shake-hands-with-geninvo-at-phuse-css-2023/) [ ![GENINVO is delighted to exhibit and present again at the PHUSE US Connect 2023! You can visit us at Booth #7.](https://geninvo.com/wp-content/uploads/2023/02/MicrosoftTeams-image-53-300x169.jpg) ](https://geninvo.com/phuse-us-connect-2023/) ## [GENINVO is delighted to exhibit and present again at the PHUSE US Connect 2023! You can visit us at Booth #7.](https://geninvo.com/phuse-us-connect-2023/) [ ![American Medical Writers Association (AMWA 2022)](https://geninvo.com/wp-content/uploads/2022/10/MicrosoftTeams-image-24-300x170.jpg) ](https://geninvo.com/american-medical-writers-association-amwa-2022/) ## [American Medical Writers Association (AMWA 2022)](https://geninvo.com/american-medical-writers-association-amwa-2022/) [ ![PHUSE EU Connect 2022](https://geninvo.com/wp-content/uploads/2022/10/MicrosoftTeams-image-23-300x170.jpg) ](https://geninvo.com/phuse-eu-connect-2022/) ## [PHUSE EU Connect 2022](https://geninvo.com/phuse-eu-connect-2022/) [ ![EU-CTR New regulations are here – Are you ready for the changes?](https://geninvo.com/wp-content/uploads/2022/09/MicrosoftTeams-image-8-300x172.jpg) ](https://geninvo.com/eu-ctr-new-regulations-are-here-are-you-ready-for-the-changes/) ## [EU-CTR New regulations are here – Are you ready for the changes?](https://geninvo.com/eu-ctr-new-regulations-are-here-are-you-ready-for-the-changes/) [ ![PHUSE’s Data Transparency Winter Event – virtual](https://geninvo.com/wp-content/uploads/2022/02/GI_phuse-8-10-feb-22-01-300x172.jpg) ](https://geninvo.com/phuses-data-transparency-winter-event-virtual/) ## [PHUSE’s Data Transparency Winter Event – virtual](https://geninvo.com/phuses-data-transparency-winter-event-virtual/) [ ![PHUSE US Connect 2022](https://geninvo.com/wp-content/uploads/2021/10/Phuse-event-US-May-300x169.png) ](https://geninvo.com/phuse-us-connect-2022/) ## [PHUSE US Connect 2022](https://geninvo.com/phuse-us-connect-2022/) ## News [ ![GENINVO Launches Centre of Excellence for Data Science and Analytics](https://geninvo.com/wp-content/uploads/2021/11/dsa-coe-300x170.jpg) ](https://geninvo.com/geninvo-launches-centre-of-excellence-for-data-science-and-analytics/) ## [GENINVO Launches Centre of Excellence for Data Science and Analytics](https://geninvo.com/geninvo-launches-centre-of-excellence-for-data-science-and-analytics/) [ ![NEW WEBSITE LAUNCH ANNOUNCEMENT](https://geninvo.com/wp-content/uploads/2021/06/feat-ns-300x170.jpg) ](https://geninvo.com/new-website-launch-announcement-geninvo-launches-updated-website/) ## [NEW WEBSITE LAUNCH ANNOUNCEMENT](https://geninvo.com/new-website-launch-announcement-geninvo-launches-updated-website/) [ ![GENINVO Launches Shadow™ Version 2](https://geninvo.com/wp-content/uploads/2021/03/feat-shadow-300x170.jpg) ](https://geninvo.com/geninvo-launches-shadow-version-2/) ## [GENINVO Launches Shadow™ Version 2](https://geninvo.com/geninvo-launches-shadow-version-2/) [ ![Youth Initiative – Introduction to Robotics Workshop](https://geninvo.com/wp-content/uploads/2021/10/event-feature-2020-300x170.jpg) ](https://geninvo.com/youth-initiative-introduction-to-robotics-workshop/) ## [Youth Initiative – Introduction to Robotics Workshop](https://geninvo.com/youth-initiative-introduction-to-robotics-workshop/) [ ![GENINVO Celebrates Anniversary](https://geninvo.com/wp-content/uploads/2021/05/feat-annivers-300x170.jpg) ](https://geninvo.com/geninvo-anniversary/) ## [GENINVO Celebrates Anniversary](https://geninvo.com/geninvo-anniversary/) [ ![GENINVO Announces Upcoming Version Launch of Shadow™](https://geninvo.com/wp-content/uploads/2021/03/feat-shadow-300x170.jpg) ](https://geninvo.com/geninvo-announces-upcoming-launch-of-shadow-version-2/) ## [GENINVO Announces Upcoming Version Launch of Shadow™](https://geninvo.com/geninvo-announces-upcoming-launch-of-shadow-version-2/) [ ![GENINVO provides technological solutions to the problems in Life Sciences and Pharmaceutical Industry.](https://geninvo.com/wp-content/uploads/2021/05/feat-lsp-300x170.jpg) ](https://geninvo.com/geninvo-provides-technological-solutions-to-the-problems-in-life-sciences-and-pharmaceutical-industry/) ## [GENINVO provides technological solutions to the problems in Life Sciences and Pharmaceutical Industry.](https://geninvo.com/geninvo-provides-technological-solutions-to-the-problems-in-life-sciences-and-pharmaceutical-industry/) [ ![See the Impact of Innovation](https://geninvo.com/wp-content/uploads/2021/05/feat-impact-300x170.jpg) ](https://geninvo.com/see-the-impact-of-innovation/) ## [See the Impact of Innovation](https://geninvo.com/see-the-impact-of-innovation/) [ ![Standing strong with Community](https://geninvo.com/wp-content/uploads/2021/03/feat-stand-str-300x170.jpg) ](https://geninvo.com/standing-strong-with-community/) ## [Standing strong with Community](https://geninvo.com/standing-strong-with-community/) [ ![COVID-19](https://geninvo.com/wp-content/uploads/2021/03/feat-covid-300x170.jpg) ](https://geninvo.com/covid-19/) ## [COVID-19](https://geninvo.com/covid-19/) ## Videos [ ![Shadow for EU-CTR Compliance](https://geninvo.com/wp-content/uploads/2022/11/2022-11-29T20_55_50-300x168.png) ](https://geninvo.com/shadow-for-eu-ctr-compliance/) ## [Shadow for EU-CTR Compliance](https://geninvo.com/shadow-for-eu-ctr-compliance/) [ ![DocQC – Medical Writers automation tool for QC checks](https://geninvo.com/wp-content/uploads/2021/04/docqc-img-overlay-300x171.png) ](https://geninvo.com/docqc-medical-writers-automation-tool-for-qc-checks/) ## [DocQC – Medical Writers automation tool for QC checks](https://geninvo.com/docqc-medical-writers-automation-tool-for-qc-checks/) [ ![Shadow- Risk Analysis Tool](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-shadow-1-e1617726618274-300x168.jpg) ](https://geninvo.com/shadow-risk-analysis-tool/) ## [Shadow- Risk Analysis Tool](https://geninvo.com/shadow-risk-analysis-tool/) [ ![Shadow- Data Anonymization Tool](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-shadow-2-e1617726656616-300x144.jpg) ](https://geninvo.com/shadow-data-anonymization-tool/) ## [Shadow- Data Anonymization Tool](https://geninvo.com/shadow-data-anonymization-tool/) [ ![DocQc – Medical Writer’s Best Friend](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-docqc-300x210.jpg) ](https://geninvo.com/docqc-medical-writers-best-friend/) ## [DocQc – Medical Writer’s Best Friend](https://geninvo.com/docqc-medical-writers-best-friend/) [ ![GENINVO Anniversary](https://geninvo.com/wp-content/uploads/2021/04/overlay_annv-300x168.jpg) ](https://geninvo.com/geninvo-anniversary-2/) ## [GENINVO Anniversary](https://geninvo.com/geninvo-anniversary-2/) [ ![Shadow – Health Canada, France’s MR001-MR004, EMA Policy 0070 (Phase 1 and 2), compliant](https://geninvo.com/wp-content/uploads/2021/04/overlay_sh-300x168.jpg) ](https://geninvo.com/shadow-health-canada-frances-mr001-mr004-ema-policy-0070-phase-1-and-2-compliant/) ## [Shadow – Health Canada, France’s MR001-MR004, EMA Policy 0070 (Phase 1 and 2), compliant](https://geninvo.com/shadow-health-canada-frances-mr001-mr004-ema-policy-0070-phase-1-and-2-compliant/) [ ![Shadow – Solution to Evolving Data Transparency Requirements](https://geninvo.com/wp-content/uploads/2021/04/healthcanadapolicy-over-300x170.jpg) ](https://geninvo.com/shadow-solution-to-evolving-data-transparency-requirements/) ## [Shadow – Solution to Evolving Data Transparency Requirements](https://geninvo.com/shadow-solution-to-evolving-data-transparency-requirements/) [ ![Machine Learning – Shadow](https://geninvo.com/wp-content/uploads/2021/04/overlay_ml-300x168.jpg) ](https://geninvo.com/machine-learning-shadow/) ## [Machine Learning – Shadow](https://geninvo.com/machine-learning-shadow/) [ ![GENINVO – Covid-19](https://geninvo.com/wp-content/uploads/2021/04/covid-over-300x170.jpg) ](https://geninvo.com/geninvo-covid-19/) ## [GENINVO – Covid-19](https://geninvo.com/geninvo-covid-19/) [ ![Shadow](https://geninvo.com/wp-content/uploads/2021/04/shadow-over-300x170.jpg) ](https://geninvo.com/shadow-video/) ## [Shadow](https://geninvo.com/shadow-video/) [ ![ApoGI](https://geninvo.com/wp-content/uploads/2021/04/apogi-over-300x170.jpg) ](https://geninvo.com/apogi-video/) ## [ApoGI](https://geninvo.com/apogi-video/) [ ![DocQC](https://geninvo.com/wp-content/uploads/2021/04/docqc-over-300x170.jpg) ](https://geninvo.com/docqc-video/) ## [DocQC](https://geninvo.com/docqc-video/) [ ![GENINVO](https://geninvo.com/wp-content/uploads/2021/04/self_animation-300x169.jpg) ](https://geninvo.com/geninvo-video/) ## [GENINVO](https://geninvo.com/geninvo-video/) --- ### [Technology Support](https://geninvo.com/our-services/cloud-infrastructure-services/) **Published:** February 25, 2025 **Author:** admin **Content:** ![](//geninvo.com/wp-content/uploads/2026/04/Top-section.webp) image-1 ![](//geninvo.com/wp-content/uploads/2024/08/Untitled-1.png) Cloud Infrastructure Services Cloud Infrastructure Services ![](//geninvo.com/wp-content/uploads/2025/02/Your-Collaborative-Partner-for-Technology-Support-2.png) # GENINVO Your Collaborative Partner for Technology Support GENINVO is recognized as a collaborative and strategic technology partner by our clients rather than simply a vendor. Considering no two strategic partnerships are identical, we custom tailor each relationship to meet the business needs of our clients while maintaining economies of scale. Our presence in North America, UK, Europe, and India helps us to leverage talent globally and support different time zones. As a socially responsible company, we actively participate in initiatives that contribute to the betterment of society. We believe in giving back to the community, supporting charitable causes, and promoting diversity and inclusion within our workforce. We work with the goal of supporting our clients in their journey of success and delivering advanced solutions by working collaboratively to understand the needs of their systems, processes, and challenges. ## GENINVO Service Level Commitment The objective of this Service Level Agreement (SLA) is to define the expectations and responsibilities between the client and the service provider regarding **helpdesk support services**, available during the agreed operational hours of 24/5. Here’s a breakdown of the key points: ## GENINVO Expertise At GENINVO, we specialize in delivering tailored solutions across a wide range of industries and technology domains. Below is an overview of our expertise: **GENINVO Comprehensive Technology Specializations and Solutions for Modern Business Needs.** --- ### [ApoGI-DT™](https://geninvo.com/our-products/apogi-dt/) **Published:** March 14, 2023 **Author:** admin **Content:** ApoGI-DT™ Automated Data Transformations View Brochure ## Fill the details below to request demo. Full Name Work Email Company Name Phone Number Request Demo ![](https://geninvo.com/wp-content/uploads/2022/09/Data-Conversion-logo-01-257x300.png "Data Conversion logo-01 - GenInvo - GenInvo") # Introducing ApoGI-DT™ - Data Transformation Software for Clinical Trials and Life Science Industry GENINVO is proud to present ApoGI-DT™ a data transformation software for clinical trials and life science industry. ApoGI-DT™ is an innovative **automated dataset generation solution** that will revolutionize the Life Science industry for life science data management. ApoGI-DT™ is designed to **produce compliant CDISC datasets from raw clinical trial data** with unparalleled efficiency and accuracy. ApoGI-DT™ is another of the latest GENINVO innovations, and we’re excited to offer this groundbreaking solution to the Life Science industry. We believe that it will transform the way clinical trial data is processed and analyzed, improving efficiency, reducing costs, and increasing the speed of clinical trial data analysis. With ApoGI-DT™, you can **transform heterogeneous and complex clinical trial data into structured and compliant datasets** in a fraction of the time compared to traditional manual methods. This will enable your team to focus on more critical aspects of your clinical trial data analysis, improving efficiency, and reducing costs. ## Your Solution for Compliant CDISC Dataset Generation! At GENINVO, we understand the importance of adhering to regulatory standards, which is why we’ve developed ApoGI-DT™ to ensure your clinical trial data is fully compliant with [CDISC standards](https://www.cdisc.org/standards). With ApoGI-DT™, you can be rest assured that datasets are of the highest quality, meeting all regulatory requirements. Our team of experts has developed ApoGI-DT™ with flexibility in mind, allowing it to **integrate with a range of data sources, including EDC and Third-Party data.** This means that regardless of the data source or format, ApoGI-DT™ can transform your raw data into structured and compliant datasets, ready for analysis. ***Contact us today to learn more about ApoGI-DT™ and how it can help your organization. We look forward to hearing from you!*** [ Contact Us ](https://geninvo.com/contact-us/) ![Data Management Software](https://geninvo.com/wp-content/uploads/2023/03/DT-2.jpg "data management software - GenInvo - GenInvo") ## ApoGI-DT™ Feature Summary ### User-friendly Interface: ### Integration with Multiple Data Sources: ### Automated Transformation: ### Quality Control and Data Validation: ### Support for Multiple Standards: ### Customization: ### Real-time Reporting: ### Automated Documentation: ### Compliance with Regulatory Standards: ### Scalability: ### Cost Savings: *Not seeing what you are looking for? Contact us at the link below to share your team’s particular challenges and requirements, and to schedule an interactive demo.* [ Request Demo ](https://geninvo.com/contact-us/) --- ### [Automation of Data Conversion](https://geninvo.com/our-products/automation-of-data-conversion/) **Published:** March 19, 2021 **Author:** admin **Content:** ## Automation of Data Conversion™ Automation of data conversion made easy [ View Brochure ](#) ![](https://geninvo.com/wp-content/uploads/2021/04/data-conversion-2-01.jpg) [ Request Demo ](https://geninvo.com/contact-us/) ![](https://geninvo.com/wp-content/uploads/2022/05/MicrosoftTeams-image-91-e1663328795792-225x300.png "MicrosoftTeams-image (91) - GenInvo - GenInvo") Our experts simplify the data transformation process, standardize data goals, ensure consistency of attributes, define files and programming specifications, and avoid wastage of time and resources. Our tool also supports SDTM conversion and meets the requirements described in its Implementation Guide and internal standards. ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ## The SDTM and ADaM The SDTM (Study Data Tabulation Model) and ADaM (Analysis Data Model) are standards for human clinical trials (research) data tables and non-clinical data tables submitted by researchers to health authorities. The Federation of Clinical data Exchange Standards (CDISC) developed this specification. ApoGI is AI and meta-data driven solution designed for automation of the end-to-end drug development process. Its data transformation feature automates the generation of datasets in various standard structures like SDTM+/-, SDTM, ADaM, or any other data standard as defined by regulatory authorities. ![](https://geninvo.com/wp-content/uploads/2021/04/dc-img-01.png "dc-img-01 - GenInvo - GenInvo") [ ![](https://geninvo.com/wp-content/uploads/2021/03/data_conversion-904x1024.jpg "ata_conversion - GenInvo - GenInvo") ](https://geninvo.com/wp-content/uploads/2021/03/data_conversion.jpg) ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") # Conversion Process Our experts simplify the process of converting from SDTM/ADaM to NDA electronic submission, standardize data goals, ensure consistency of attributes for each variable between data sets, define files and programming specifications, and avoid wasting time and resources to verify late consistency. The programming specification document is a key part of the SDTM conversion process because of its programming and verification capabilities, writing definition PDFs, and defining the generation of the main parts of the XML. There is a great need for a cost-effective way to ensure SDTM conversion meets the requirements described in the SDTM Implementation Guide and internal standards, and to ensure consistency between SDTM data sets, programming specifications, and definition files. ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ## Mapping datasets Mapping datasets, e.g., raw to SDTM (or SDTM to ADaM), is a time-consuming task supported by this automation platform. With AI-enabled technology, automapping (or automated generation of dataset specifications to get from source to target) is possible. Additionally, it also becomes increasingly intelligent via guided, supervised learning with use over time, reducing time to generation as well as the QC cycles required. The platform has considered functionalities to automate the process of generating both ADaM and TFLs platform macros and transformational metadata to support ETL-like conversion ![](https://geninvo.com/wp-content/uploads/2021/04/dc-img-02.png "dc-img-02 - GenInvo - GenInvo") --- ### [Date wise events](https://geninvo.com/insights/date-wise-events/) **Published:** September 6, 2023 **Author:** admin **Content:** ## GENINVO Events Join us at exclusive events, as we present the best of industry insights and form ground breaking partnerships at events around the world. [ Back ](https://geninvo.com/insights/) ![](https://geninvo.com/wp-content/uploads/2021/04/events-top.jpg "events-top - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/plugins/elementor/assets/images/placeholder.png) ## 2023 ![](https://geninvo.com/wp-content/plugins/elementor/assets/images/placeholder.png) ## 2022 ![](https://geninvo.com/wp-content/plugins/elementor/assets/images/placeholder.png) ## 2021 ![](https://geninvo.com/wp-content/plugins/elementor/assets/images/placeholder.png) ## 2020 ![](https://geninvo.com/wp-content/plugins/elementor/assets/images/placeholder.png) ## 2019 --- ### [Parental permission form](https://geninvo.com/consent-form/) **Published:** February 6, 2023 **Author:** admin **Content:** Congratulations! Your ward has been selected for the Live Webinar with Kids hosted by GENINVO. Kindly sign the consent form below. I grant permission to GENINVO for utilizing my child’s image/photograph for social media promotion of the Live Webinar with Kids. I also grant permission to GENINVO for using the images of my child resulting from the Live webinar on their official social media handles. Child's Name Age Educational Institution's Name Parent's Name Parent’s Signature Date Send --- ### [Geninvo](https://geninvo.com/geninvo/) **Published:** March 16, 2021 **Author:** admin **Content:** OUR Products ## Experience our Product Portfolio All GENINVO products are scalable, secure, and customizable. Our industry-leading Life Science products also come with plug-and-play modules and off-the-shelf licensing for hassle-free deployment with existing infrastructure. [ ![Shadow - Data Anonymization Tool.](https://geninvo.com/wp-content/uploads/2021/03/shadow_logo-300x216.png "shadow_logo - GenInvo - GenInvo") ](https://geninvo.com/our-products/data-anonymization-tool/) ## [Data and Document Anonymization Solution](https://geninvo.com/our-products/data-anonymization-tool/) [ ![Medical Writers Automation Tool](https://geninvo.com/wp-content/uploads/2021/03/docqc_logo-e1631023185935.png "docqc_logo - GenInvo - GenInvo") ](https://geninvo.com/our-products/docqc-medical-writing-automation/) ## [Document QC Automation](https://geninvo.com/our-products/docqc-medical-writing-automation/) [ ![Metadata Management Tool](https://geninvo.com/wp-content/uploads/2021/03/metaworks_logo-300x209.png "metaworks_logo - GenInvo - GenInvo") ](https://geninvo.com/our-products/apogi/) ## [Next Generation Enterprise Platform](https://geninvo.com/our-products/apogi/) [ ![](https://geninvo.com/wp-content/uploads/2022/05/Data-Conversion-logo-01-e1653650398868-223x300.png "Data Conversion logo-01 - GenInvo - GenInvo") ](https://geninvo.com/our-products/automation-of-data-conversion/) ## [Automation of Data Conversion](https://geninvo.com/our-products/automation-of-data-conversion/) ###### OUR SERVICES # Our Service Offerings Experience the GENINVO Difference with our services, tailored to meet your specific demands. We offer highly skilled, innovative, and adaptable teams who help our partners flourish and attain business success in a variety of industries. [ READ MORE ](https://geninvo.com/our-services/) ## Innovation As a Services Discoveries and investments in next-generation medicines as well as technology have seen an increase in the pharma space. [ ](https://geninvo.com/our-services/innovation-as-a-service/) ## Anonymization As a Service We provide a variety of customized anonymization services to support global data sharing and transparency services, along with redaction and risk assessment options. [ ](https://geninvo.com/our-services/anonymization-as-a-service/) ## Resource Hub Our Life Science SME and software and technology experts support solutions in a variety of areas including data visualization, custom software development, and more. [ ](https://geninvo.com/our-services/talent-resource-hub/) ## Custom Application Development Expert teams, Personalised tools and process – We deliver exactly what our customer needs. [ ](https://geninvo.com/our-services/custom-application-development/) ![](https://geninvo.com/wp-content/uploads/2021/10/our-story.jpg "our-story - GenInvo - GenInvo") ![our-story-pic](https://geninvo.com/wp-content/uploads/2021/10/our-story-pic-e1634036208103.png "our-story-pic") ![](https://geninvo.com/wp-content/uploads/2021/10/our-story-cog.png "our-story-cog - GenInvo - GenInvo") ## [Learn about our Vision, Mission, and Leadership Team](https://geninvo.com/who-we-are/) Learn more about the group working toward bringing a technological revolution to the Life Sciences industry. [ READ MORE ](https://geninvo.com/who-we-are/) ## Testimonials Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. ![John Doe](https://geninvo.com/wp-content/plugins/elementor/assets/images/placeholder.png) John DoeCEO Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. ![John Doe](https://geninvo.com/wp-content/plugins/elementor/assets/images/placeholder.png) John DoeCEO Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. ![John Doe](https://geninvo.com/wp-content/plugins/elementor/assets/images/placeholder.png) John DoeCEO ## Join Us We always welcome the right talent. If AI/ML, NLP, Automation, Cloud and Big Data excite you, then GENINVO is the place for you! [ Find opportunities ](https://geninvo.com/work-with-us/) ![](https://geninvo.com/wp-content/uploads/2022/06/MicrosoftTeams-image.png "MicrosoftTeams-image - GenInvo - GenInvo") [ **US HEAD OFFICE** 1408 East Empire Street 61701 Bloomington (Illinois) info@geninvo.com +1 309-807-5006 ](https://geninvo.com/contact-us/) [ **INDIA HEAD OFFICE** 6269/4, Nicholson Road, Ambala Cantt 13301, (Haryana) India info@geninvo.com 0171-26604-10 ](https://geninvo.com/contact-us/) [ **CANADA HEAD OFFICE** 1383 West 8th Avenue Vancouver, British Columbia, Canada - V6H 3W4 info@geninvo.com ](https://geninvo.com/contact-us/) [custom-twitter-feeds buttontextcolor="#ffffff" buttoncolor="#00393f"] --- ### [Shadow for EU-CTR Compliance](https://geninvo.com/shadow-for-eu-ctr-compliance/) **Published:** November 29, 2022 **Author:** admin **Content:** --- ### [Prohibition of Child and Forced Labor Policy](https://geninvo.com/prohibition-of-child-and-forced-labor-policy/) **Published:** September 21, 2021 **Author:** admin **Content:** ## Prohibition of Child and Forced Labor Policy [ Contact us ](https://geninvo.com/contact-us/) ![](https://geninvo.com/wp-content/uploads/2021/09/GenInvo-Policy.png "GenInvo--Policy - GenInvo - GenInvo") GENINVO is an international organization that has accepted responsibility for setting minimum standards for itself and its business partners. The foundation of GENINVO’s ‘Prohibition of Child and Forced Labor Policy’ is based on the Company’s commitment to find practical, meaningful and culturally appropriate responses to support the elimination of such labor practices. It thus endorses the need for appropriate initiatives to progressively eliminate these abuses. In order to achieve the minimum level of protection as stated by the [International Labour Standards on Forced labour (ilo.org)](https://www.ilo.org/global/standards/subjects-covered-by-international-labour-standards/forced-labour/lang--en/index.htm "https://www.ilo.org/global/standards/subjects-covered-by-international-labour-standards/forced-labour/lang--en/index.htm"), and [ILO Conventions on child labour (IPEC)](https://www.ilo.org/ipec/facts/ILOconventionsonchildlabour/lang--en/index.htm "https://www.ilo.org/ipec/facts/iloconventionsonchildlabour/lang--en/index.htm"). GENINVO standards provide the basis for collaboration with all suppliers and ensure that they have appropriate provisions and prohibit child and forced labor. ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") [ ](#top-section) - [Policy](#policy) - [What and how we collect Personal Information](#howwecollect) - [Our use of Cookies](#cookies) - [How we use your Personal Information](#usepersonalinformation) - [How we protect your Personal Information](#protectpersonalinformation) - [Consent and Access](#consentandaccess) - [Your Rights](#yourrights) - [Notification of Changes Contact Information](#notificationofchanges) - [Policy](#policy) - [What and how we collect Personal Information](#howwecollect) - [Our use of Cookies](#cookies) - [How we use your Personal Information](#usepersonalinformation) - [How we protect your Personal Information](#protectpersonalinformation) - [Consent and Access](#consentandaccess) - [Your Rights](#yourrights) - [Notification of Changes Contact Information](#notificationofchanges) ## **Policy** The GenInvo Privacy and related policies ensure that the processing of Personal Information by GenInvo as part of our business and service offerings is collected, stored and used in compliance with all applicable laws and regulations. “Personal Information” is any Information relating to an identified or identifiable natural person. The policy applies to all situations where Personal Information is collected, stored and processed by GenInvo: - For its own business use (primarily marketing), - To support business operations (e.g. contractual arrangements, administrative functions), and - To comply with all privacy regulations when providing software, services and support to our customers ## **What and How we collect Personal Information** Our websites collect a range of general Information and data when in use. This includes browser types, operating system details, IP addresses, clickstream details for the pages you visit, etc., in order to both enhance your experience on the site and to ensure the security and integrity of our IT infrastructure. Our websites offer the opportunity to register interest in GenInvo products and services. Personal Information is captured from our website when you participate in any of the following activities: - Registering on our site - Subscribing to a newsletter - Responding to a survey - Filling out a form - Providing feedback on our products or services - Signing up for a webinar - Attending a webinar The Personal Information we collect from you will depend on which activity you are using in the list above and may include your: - Name - Title - Company name - Address - Phone number(s) - Email address This information is stored and processed only for the purpose for which it was collected ## **Our use of cookies** Cookies are small files that a site or its service provider transfers to your computer’s hard drive through your web browser (if you allow) that enables the site’s or service provider’s systems to recognize your browser and capture and remember certain Information. We use cookies to: - Keep track of advertisements, and - Compile aggregate data (not Personal Information) about our site traffic and site interactions in order to offer better site experiences and tools in the future. - We may also use trusted third-party services that track this Information on our behalf. You can choose to have your computer warn you each time a cookie is being sent, or you can choose to turn off all cookies. You do this through your browser settings. Since each browser is a little different, look at your browser’s Help Menu to learn the correct way to modify your cookies. If you turn cookies off, it will not prevent you from using our website. ## **How we use your Personal Information** When you provide us with Personal Information, it is stored in secure databases and may be used for: - Sending newsletters - Sending notices about upcoming webinars, - Contacting you when submitting your Information for employment opportunities, - Including you in marketing campaigns and sending promotional materials of interest, and - Sending you emails of surveys. ## **How we protect your Personal Information** As GenInvo is a global company, we process and store Personal Information using secure cloud-based products and services which may or may not be located within your country. GenInvo securely collects and transfers your Personal Information using encrypted processes. GenInvo stores your Personal Information using products provided by companies that have privacy and security management certifications. Your Personal Information is only accessible by a limited number of GenInvo persons whose access is controlled through unique user IDs and password-protected accounts. Personal Information is only stored for the period necessary to achieve the purpose for which the data was provided, and to comply with legal or statutory requirements. GenInvo is both a Data Controller and a Data Processor of Personal Information depending on the detailed circumstances for which it was collected. ## **Consent and access** Each time you provide Personal Information via our website or attend one of our webinars, you will be presented with a list of opt-in selections. By selecting a given opt-in selection, you are consenting to the collection the Personal Information being collected, and the use of that data described above. You may unsubscribe at any time by clicking the unsubscribe link in the footer of all marketing communication emails or by mailing [privacy@geninvo.com](mailto:info@geninvo.com). ## **Your rights** As an individual whose Personal Information has been collected and stored by our site, you may at any time: - Request confirmation as to how your Personal Information is being processed - Request copies of the Personal Information we hold as a company - Request your Personal Information be updated, corrected or blocked from further processing - Request deletion of your Personal Information - Restrict the reasons for processing your Personal Information - Receive the Personal Information we hold in common computer-readable form - Request your Personal Information is not used to make automated decisions about you - Withdraw consent to the processing of your Personal Information **Requests for the above can be submitted by email to** [**privacy@geninvo.com**](mailto:privacy@geninvo.com) **or by mail to the address below.** We have a defined process for the privacy and confidential data breach, and you can query or provide feedback to us at privacy@geninvo.com about your any dissatisfaction regarding your rights management or confidentiality violation. You have the right to complain to a Data Protection Authority/Supervisory Authority about Our collection and use of Your Personal Data. For example, if You are in the European Economic Area (EEA), please contact Your local data protection authority in the EEA. ## **Notification of changes** We keep our Privacy Policy under regular review, and we will place any updates on this web page. ## **Contact information** If you have any questions regarding our Privacy Policy, you can contact our Data Privacy Officer at [dpo@geninvo.com](mailto:info@geninvo.com) or write to us at: GenInvo, Inc1408 East Empire Street Bloomington, Illinois 61701, USA --- ### [Code of Conduct and Ethics](https://geninvo.com/code-of-conduct-and-ethics/) **Published:** September 21, 2021 **Author:** admin **Content:** ## Code of Conduct and Ethics [ Contact us ](https://geninvo.com/contact-us/) ![](https://geninvo.com/wp-content/uploads/2021/09/GenInvo-Policy.png "GenInvo--Policy - GenInvo - GenInvo") One of the core values at GENINVO is ethical approach to business conduct. GENINVO believes in equal employment opportunities to all employees and applicants for employment without regard to race, color, religion, sex, national origin, caste, age, disability, genetics or veterans’ status. GENINVO commits adherence with all applicable laws, regulations and guidelines for the business. GENINVO strictly prohibits non-discrimination, harassment, any form of corruptions, bribery, fraud and extortion directly or indirectly within the company by the employees and our business partners. In order to conduct day to day business, GENINVO protects confidentiality of the information and ensure secure flow of data for the business including intellectual property, study data and documents including personal information. GENINVO believes in maintaining a strong and healthy relationships with all its business parties (including vendors or contractors) and expects all of them to adhere to these policies laid down by the company. GENINVO provides and expects from business partners to ensure healthy, safe and ethical work environment. Please report if any suspected violations of this code to privacy@geninvo.com ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ## Topics in this Policy GENINVO provides anonymization services for variety of anonymisation needs including the following: [ ](#top-section) - [Policy](#policy) - [What and how we collect Personal Information](#howwecollect) - [Our use of Cookies](#cookies) - [How we use your Personal Information](#usepersonalinformation) - [How we protect your Personal Information](#protectpersonalinformation) - [Consent and Access](#consentandaccess) - [Your Rights](#yourrights) - [Notification of Changes Contact Information](#notificationofchanges) - [Policy](#policy) - [What and how we collect Personal Information](#howwecollect) - [Our use of Cookies](#cookies) - [How we use your Personal Information](#usepersonalinformation) - [How we protect your Personal Information](#protectpersonalinformation) - [Consent and Access](#consentandaccess) - [Your Rights](#yourrights) - [Notification of Changes Contact Information](#notificationofchanges) ## **Policy** The GenInvo Privacy and related policies ensure that the processing of Personal Information by GenInvo as part of our business and service offerings is collected, stored and used in compliance with all applicable laws and regulations. “Personal Information” is any Information relating to an identified or identifiable natural person. The policy applies to all situations where Personal Information is collected, stored and processed by GenInvo: - For its own business use (primarily marketing), - To support business operations (e.g. contractual arrangements, administrative functions), and - To comply with all privacy regulations when providing software, services and support to our customers ## **What and How we collect Personal Information** Our websites collect a range of general Information and data when in use. This includes browser types, operating system details, IP addresses, clickstream details for the pages you visit, etc., in order to both enhance your experience on the site and to ensure the security and integrity of our IT infrastructure. Our websites offer the opportunity to register interest in GenInvo products and services. Personal Information is captured from our website when you participate in any of the following activities: - Registering on our site - Subscribing to a newsletter - Responding to a survey - Filling out a form - Providing feedback on our products or services - Signing up for a webinar - Attending a webinar The Personal Information we collect from you will depend on which activity you are using in the list above and may include your: - Name - Title - Company name - Address - Phone number(s) - Email address This information is stored and processed only for the purpose for which it was collected ## **Our use of cookies** Cookies are small files that a site or its service provider transfers to your computer’s hard drive through your web browser (if you allow) that enables the site’s or service provider’s systems to recognize your browser and capture and remember certain Information. We use cookies to: - Keep track of advertisements, and - Compile aggregate data (not Personal Information) about our site traffic and site interactions in order to offer better site experiences and tools in the future. - We may also use trusted third-party services that track this Information on our behalf. You can choose to have your computer warn you each time a cookie is being sent, or you can choose to turn off all cookies. You do this through your browser settings. Since each browser is a little different, look at your browser’s Help Menu to learn the correct way to modify your cookies. If you turn cookies off, it will not prevent you from using our website. ## **How we use your Personal Information** When you provide us with Personal Information, it is stored in secure databases and may be used for: - Sending newsletters - Sending notices about upcoming webinars, - Contacting you when submitting your Information for employment opportunities, - Including you in marketing campaigns and sending promotional materials of interest, and - Sending you emails of surveys. ## **How we protect your Personal Information** As GenInvo is a global company, we process and store Personal Information using secure cloud-based products and services which may or may not be located within your country. GenInvo securely collects and transfers your Personal Information using encrypted processes. GenInvo stores your Personal Information using products provided by companies that have privacy and security management certifications. Your Personal Information is only accessible by a limited number of GenInvo persons whose access is controlled through unique user IDs and password-protected accounts. Personal Information is only stored for the period necessary to achieve the purpose for which the data was provided, and to comply with legal or statutory requirements. GenInvo is both a Data Controller and a Data Processor of Personal Information depending on the detailed circumstances for which it was collected. ## **Consent and access** Each time you provide Personal Information via our website or attend one of our webinars, you will be presented with a list of opt-in selections. By selecting a given opt-in selection, you are consenting to the collection the Personal Information being collected, and the use of that data described above. You may unsubscribe at any time by clicking the unsubscribe link in the footer of all marketing communication emails or by mailing [privacy@geninvo.com](mailto:info@geninvo.com). ## **Your rights** As an individual whose Personal Information has been collected and stored by our site, you may at any time: - Request confirmation as to how your Personal Information is being processed - Request copies of the Personal Information we hold as a company - Request your Personal Information be updated, corrected or blocked from further processing - Request deletion of your Personal Information - Restrict the reasons for processing your Personal Information - Receive the Personal Information we hold in common computer-readable form - Request your Personal Information is not used to make automated decisions about you - Withdraw consent to the processing of your Personal Information **Requests for the above can be submitted by email to** [**privacy@geninvo.com**](mailto:privacy@geninvo.com) **or by mail to the address below.** We have a defined process for the privacy and confidential data breach, and you can query or provide feedback to us at privacy@geninvo.com about your any dissatisfaction regarding your rights management or confidentiality violation. You have the right to complain to a Data Protection Authority/Supervisory Authority about Our collection and use of Your Personal Data. For example, if You are in the European Economic Area (EEA), please contact Your local data protection authority in the EEA. ## **Notification of changes** We keep our Privacy Policy under regular review, and we will place any updates on this web page. ## **Contact information** If you have any questions regarding our Privacy Policy, you can contact our Data Privacy Officer at [dpo@geninvo.com](mailto:info@geninvo.com) or write to us at: GenInvo, Inc1408 East Empire Street Bloomington, Illinois 61701, USA --- ### [Privacy Policy](https://geninvo.com/privacy-policy/) **Published:** March 25, 2021 **Author:** admin **Content:** ## Geninvo Privacy Policy [ Contact us ](https://geninvo.com/contact-us/) ![Geninvo Privacy Policy](https://geninvo.com/wp-content/uploads/2021/04/GenInvo-Privacy-Policy.png "GenInvo-Privacy-Policy - GenInvo - GenInvo") GenInvo understands the importance of protecting the privacy rights of individuals. This document explains the basic details of our data privacy policy, and how it is implemented at GenInvo. It explains the following: - How and What information may be collected and stored - How we use that information - How we protect that information - Whom to contact if there are any questions concerning data privacy and protection at GenInvo ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ## Topics in this Policy GENINVO provides anonymization services for variety of anonymisation needs including the following: [ ](#top-section) - [Policy](#policy) - [What and how we collect Personal Information](#howwecollect) - [Our use of Cookies](#cookies) - [How we use your Personal Information](#usepersonalinformation) - [How we protect your Personal Information](#protectpersonalinformation) - [Consent and Access](#consentandaccess) - [Your Rights](#yourrights) - [Notification of Changes Contact Information](#notificationofchanges) - [Policy](#policy) - [What and how we collect Personal Information](#howwecollect) - [Our use of Cookies](#cookies) - [How we use your Personal Information](#usepersonalinformation) - [How we protect your Personal Information](#protectpersonalinformation) - [Consent and Access](#consentandaccess) - [Your Rights](#yourrights) - [Notification of Changes Contact Information](#notificationofchanges) ## **Policy** The GenInvo Privacy and related policies ensure that the processing of Personal Information by GenInvo as part of our business and service offerings is collected, stored and used in compliance with all applicable laws and regulations. “Personal Information” is any Information relating to an identified or identifiable natural person. The policy applies to all situations where Personal Information is collected, stored and processed by GenInvo: - For its own business use (primarily marketing), - To support business operations (e.g. contractual arrangements, administrative functions), and - To comply with all privacy regulations when providing software, services and support to our customers ## **What and How we collect Personal Information** Our websites collect a range of general Information and data when in use. This includes browser types, operating system details, IP addresses, clickstream details for the pages you visit, etc., in order to both enhance your experience on the site and to ensure the security and integrity of our IT infrastructure. Our websites offer the opportunity to register interest in GenInvo products and services. Personal Information is captured from our website when you participate in any of the following activities: - Registering on our site - Subscribing to a newsletter - Responding to a survey - Filling out a form - Providing feedback on our products or services - Signing up for a webinar - Attending a webinar The Personal Information we collect from you will depend on which activity you are using in the list above and may include your: - Name - Title - Company name - Address - Phone number(s) - Email address This information is stored and processed only for the purpose for which it was collected ## **Our use of cookies** Cookies are small files that a site or its service provider transfers to your computer’s hard drive through your web browser (if you allow) that enables the site’s or service provider’s systems to recognize your browser and capture and remember certain Information. We use cookies to: - Keep track of advertisements, and - Compile aggregate data (not Personal Information) about our site traffic and site interactions in order to offer better site experiences and tools in the future. - We may also use trusted third-party services that track this Information on our behalf. You can choose to have your computer warn you each time a cookie is being sent, or you can choose to turn off all cookies. You do this through your browser settings. Since each browser is a little different, look at your browser’s Help Menu to learn the correct way to modify your cookies. If you turn cookies off, it will not prevent you from using our website. ## **How we use your Personal Information** When you provide us with Personal Information, it is stored in secure databases and may be used for: - Sending newsletters - Sending notices about upcoming webinars, - Contacting you when submitting your Information for employment opportunities, - Including you in marketing campaigns and sending promotional materials of interest, and - Sending you emails of surveys. ## **How we protect your Personal Information** As GenInvo is a global company, we process and store Personal Information using secure cloud-based products and services which may or may not be located within your country. GenInvo securely collects and transfers your Personal Information using encrypted processes. GenInvo stores your Personal Information using products provided by companies that have privacy and security management certifications. Your Personal Information is only accessible by a limited number of GenInvo persons whose access is controlled through unique user IDs and password-protected accounts. Personal Information is only stored for the period necessary to achieve the purpose for which the data was provided, and to comply with legal or statutory requirements. GenInvo is both a Data Controller and a Data Processor of Personal Information depending on the detailed circumstances for which it was collected. ## **Consent and access** Each time you provide Personal Information via our website or attend one of our webinars, you will be presented with a list of opt-in selections. By selecting a given opt-in selection, you are consenting to the collection the Personal Information being collected, and the use of that data described above. You may unsubscribe at any time by clicking the unsubscribe link in the footer of all marketing communication emails or by mailing [privacy@geninvo.com](mailto:info@geninvo.com). ## **Your rights** As an individual whose Personal Information has been collected and stored by our site, you may at any time: - Request confirmation as to how your Personal Information is being processed - Request copies of the Personal Information we hold as a company - Request your Personal Information be updated, corrected or blocked from further processing - Request deletion of your Personal Information - Restrict the reasons for processing your Personal Information - Receive the Personal Information we hold in common computer-readable form - Request your Personal Information is not used to make automated decisions about you - Withdraw consent to the processing of your Personal Information **Requests for the above can be submitted by email to** [**privacy@geninvo.com**](mailto:privacy@geninvo.com) **or by mail to the address below.** We have a defined process for the privacy and confidential data breach, and you can query or provide feedback to us at privacy@geninvo.com about your any dissatisfaction regarding your rights management or confidentiality violation. You have the right to complain to a Data Protection Authority/Supervisory Authority about Our collection and use of Your Personal Data. For example, if You are in the European Economic Area (EEA), please contact Your local data protection authority in the EEA. ## **Notification of changes** We keep our Privacy Policy under regular review, and we will place any updates on this web page. ## **Contact information** If you have any questions regarding our Privacy Policy, you can contact our Data Privacy Officer at [dpo@geninvo.com](mailto:info@geninvo.com) or write to us at: GenInvo, Inc1408 East Empire Street Bloomington, Illinois 61701, USA --- ## My Templates ### [gi-new-footer](https://geninvo.com/?elementor_library=gi-new-footer) **Published:** March 16, 2021 **Author:** admin **Content:** Content area --- ### [menu-white](https://geninvo.com/?elementor_library=menu-white) **Published:** April 8, 2021 **Author:** admin **Content:** Content area --- ### [events-single](https://geninvo.com/?elementor_library=events-single) **Published:** March 23, 2021 **Author:** admin **Content:** ## GENINVO Events [ Back ](https://geninvo.com/insights/events/) # events-single ###### More Events [ ![Meet GenInvo at DPHARM 2026, Booth 116, Boston](https://geninvo.com/wp-content/uploads/2026/06/DPHARM-1-300x186.png) ](https://geninvo.com/dpharm-2026/) ## [Meet GenInvo at DPHARM 2026, Booth 116, Boston](https://geninvo.com/dpharm-2026/) [ ![Meet GENINVO at the EMWA 61st Spring Conference 2026](https://geninvo.com/wp-content/uploads/2026/04/539-X-334-1-300x186.png) ](https://geninvo.com/emwa-2026-barcelona/) ## [Meet GENINVO at the EMWA 61st Spring Conference 2026](https://geninvo.com/emwa-2026-barcelona/) [ ![GenInvo at PharmaSUG 2026 SDE Conference](https://geninvo.com/wp-content/uploads/2026/04/539-X-334-300x186.png) ](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) ## [GenInvo at PharmaSUG 2026 SDE Conference](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) [ ![GenInvo @ PHUSE US Connect 2026](https://geninvo.com/wp-content/uploads/2026/03/image-16-300x186.png) ](https://geninvo.com/geninvo-phuse-us-connect-2026/) ## [GenInvo @ PHUSE US Connect 2026](https://geninvo.com/geninvo-phuse-us-connect-2026/) [ ![Live Webinar: Accelerating Authoring and QC of Clinical Documents with AI-Powered Automation](https://geninvo.com/wp-content/uploads/2025/08/Blog-9-300x186.jpg) ](https://geninvo.com/live-webinar-accelerating-authoring-and-qc-of-clinical-documents-with-ai-powered-automation/) ## [Live Webinar: Accelerating Authoring and QC of Clinical Documents with AI-Powered Automation](https://geninvo.com/live-webinar-accelerating-authoring-and-qc-of-clinical-documents-with-ai-powered-automation/) [ ![GenInvo is Powering the Future of Medical Writing at AMWA 2025!](https://geninvo.com/wp-content/uploads/2025/08/GI-AMWA-conference-blog-2025-300x186.jpg) ](https://geninvo.com/geninvo-is-powering-the-future-of-medical-writing-at-amwa-2025/) ## [GenInvo is Powering the Future of Medical Writing at AMWA 2025!](https://geninvo.com/geninvo-is-powering-the-future-of-medical-writing-at-amwa-2025/) [ ![GENINVO™ Sponsors PHUSE Data Transparency Autumn Event 2025](https://geninvo.com/wp-content/uploads/2025/07/Blog-GI-Phusevirtualevent-Sept-2025-300x189.jpg) ](https://geninvo.com/geninvo-sponsors-phuse-data-transparency-autumn-event-2025/) ## [GENINVO™ Sponsors PHUSE Data Transparency Autumn Event 2025](https://geninvo.com/geninvo-sponsors-phuse-data-transparency-autumn-event-2025/) [ ![GENINVO™ at PHUSE US Connect 2025](https://geninvo.com/wp-content/uploads/2025/02/GI-US-PHUSE-connect-2025-300x186.jpg) ](https://geninvo.com/geninvo-at-phuse-us-connect-2025/) ## [GENINVO™ at PHUSE US Connect 2025](https://geninvo.com/geninvo-at-phuse-us-connect-2025/) [ ![Join GENINVO™ at the DIA Medical Affairs and Scientific Communications Forum](https://geninvo.com/wp-content/uploads/2025/02/GI-DIA-blogpost-mar2025-300x186.webp) ](https://geninvo.com/join-geninvo-at-the-dia-medical-affairs-and-scientific-communications-forum/) ## [Join GENINVO™ at the DIA Medical Affairs and Scientific Communications Forum](https://geninvo.com/join-geninvo-at-the-dia-medical-affairs-and-scientific-communications-forum/) [ ![Thank You for Attending the GENINVO’s AMWA Webinar](https://geninvo.com/wp-content/uploads/2024/11/blog-post-AMWA-24nov-300x169.webp) ](https://geninvo.com/thank-you-for-attending-the-geninvos-amwa-webinar/) ## [Thank You for Attending the GENINVO’s AMWA Webinar](https://geninvo.com/thank-you-for-attending-the-geninvos-amwa-webinar/) [ ![Join Our Free Webinar!](https://geninvo.com/wp-content/uploads/2024/10/GI-AMWA-blog-AI-writers-24-V2-300x169.webp) ](https://geninvo.com/join-our-free-webinar/) ## [Join Our Free Webinar!](https://geninvo.com/join-our-free-webinar/) [ ![Shake hands with GENINVO at DIA’s Global Clinical Trial Disclosure and Data Transparency Conference](https://geninvo.com/wp-content/uploads/2024/04/GI-and-sha-DIA-V1-3-300x169.jpg) ](https://geninvo.com/shake-hands-with-geninvo-at-dias-global-clinical-trial-disclosure-and-data-transparency-conference/) ## [Shake hands with GENINVO at DIA’s Global Clinical Trial Disclosure and Data Transparency Conference](https://geninvo.com/shake-hands-with-geninvo-at-dias-global-clinical-trial-disclosure-and-data-transparency-conference/) [ ![Meet GENINVO at DPHARM 2023 in Boston, MA!](https://geninvo.com/wp-content/uploads/2023/08/MicrosoftTeams-image-142-300x169.jpg) ](https://geninvo.com/meet-geninvo-at-dpharm-2023-in-boston-ma/) ## [Meet GENINVO at DPHARM 2023 in Boston, MA!](https://geninvo.com/meet-geninvo-at-dpharm-2023-in-boston-ma/) [ ![Shake hands with GENINVO at PHUSE CSS 2023! ](https://geninvo.com/wp-content/uploads/2023/08/MicrosoftTeams-image-151-300x169.jpg) ](https://geninvo.com/shake-hands-with-geninvo-at-phuse-css-2023/) ## [Shake hands with GENINVO at PHUSE CSS 2023! ](https://geninvo.com/shake-hands-with-geninvo-at-phuse-css-2023/) [ ![GENINVO is delighted to exhibit and present again at the PHUSE US Connect 2023! You can visit us at Booth #7.](https://geninvo.com/wp-content/uploads/2023/02/MicrosoftTeams-image-53-300x169.jpg) ](https://geninvo.com/phuse-us-connect-2023/) ## [GENINVO is delighted to exhibit and present again at the PHUSE US Connect 2023! You can visit us at Booth #7.](https://geninvo.com/phuse-us-connect-2023/) [ ![American Medical Writers Association (AMWA 2022)](https://geninvo.com/wp-content/uploads/2022/10/MicrosoftTeams-image-24-300x170.jpg) ](https://geninvo.com/american-medical-writers-association-amwa-2022/) ## [American Medical Writers Association (AMWA 2022)](https://geninvo.com/american-medical-writers-association-amwa-2022/) [ ![PHUSE EU Connect 2022](https://geninvo.com/wp-content/uploads/2022/10/MicrosoftTeams-image-23-300x170.jpg) ](https://geninvo.com/phuse-eu-connect-2022/) ## [PHUSE EU Connect 2022](https://geninvo.com/phuse-eu-connect-2022/) [ ![EU-CTR New regulations are here – Are you ready for the changes?](https://geninvo.com/wp-content/uploads/2022/09/MicrosoftTeams-image-8-300x172.jpg) ](https://geninvo.com/eu-ctr-new-regulations-are-here-are-you-ready-for-the-changes/) ## [EU-CTR New regulations are here – Are you ready for the changes?](https://geninvo.com/eu-ctr-new-regulations-are-here-are-you-ready-for-the-changes/) [ ![PHUSE’s Data Transparency Winter Event – virtual](https://geninvo.com/wp-content/uploads/2022/02/GI_phuse-8-10-feb-22-01-300x172.jpg) ](https://geninvo.com/phuses-data-transparency-winter-event-virtual/) ## [PHUSE’s Data Transparency Winter Event – virtual](https://geninvo.com/phuses-data-transparency-winter-event-virtual/) [ ![PHUSE US Connect 2022](https://geninvo.com/wp-content/uploads/2021/10/Phuse-event-US-May-300x169.png) ](https://geninvo.com/phuse-us-connect-2022/) ## [PHUSE US Connect 2022](https://geninvo.com/phuse-us-connect-2022/) --- ### [gi-contact-header](https://geninvo.com/?elementor_library=gi-contact-header) **Published:** March 26, 2021 **Author:** admin **Content:** Content area --- ### [Blog post crousal](https://geninvo.com/?elementor_library=elementor-loop-item-2) **Published:** June 1, 2026 **Author:** admin --- ### [gi-new-header](https://geninvo.com/?elementor_library=gi-new-header) **Published:** March 16, 2021 **Author:** admin **Content:** Content area --- ### [job-popup](https://geninvo.com/?elementor_library=job-popup) **Published:** April 7, 2021 **Author:** admin **Content:** Content area --- ### [blog-single](https://geninvo.com/?elementor_library=blog-single) **Published:** March 22, 2021 **Author:** admin **Content:** ## GENINVO Blogs [ Back ](https://geninvo.com/insights/blog/) # blog-single - [ March 22, 2021 ](https://geninvo.com/2021/03/22/) - 12:08 pm ## Advancing Clinical Research Innovation | DPHARM 2026 | September 15–16, 2026 | Sheraton Boston Hotel **Geninvo is exhibiting at [DPHARM 2026](https://www.dpharmconference.com/)** the industry’s premier conference for disruptive innovations in clinical research taking place **September 15–16, 2026** at the **Sheraton Boston Hotel, Boston, MA**. Find our team at **Booth 116** and discover how GenInvo is transforming the fields like Data Analytics, Biometrics, Regulatory Writing and Data Transparency with cutting-edge technologies. 📅 **September 15–16, 2026** 📍 Sheraton Boston Hotel, Boston, MA 🏷️ **Booth 116** 👥 Contacts: Craig | James | Daragh **[Book a Meeting at DPHARM 2026](https://geninvo.com/contact-us/)** ## ABOUT THE EVENT About DPHARM 2026: Disruptive Innovations to Advance Clinical Research [DPHARM 2026 ](https://www.dpharmconference.com/)is the leading conference bringing together **senior clinical operations executives, R&D innovators, technology leaders, and patient advocates** to explore the future of clinical trials. Hosted at the **Sheraton Boston Hotel, September 15–16, 2026**, the event features TED-style talks, fireside chats, quick-fire demos, and the renowned **DPHARM Idol Disrupt** startup pitch competition all focused on driving efficiencies in clinical trial operations and improving outcomes for patients. Key themes at DPHARM 2026 include: - Decentralized and hybrid clinical trials - AI and data-driven trial design - Patient-centric research models - Disruptive technologies accelerating drug development - Operational excellence in clinical research ## WHY VISIT GENINVO AT BOOTH 116? At DPHARM 2026, the Geninvo team will be showcasing our full suite of AI-powered clinical research and data science solutions purpose-built for pharma sponsors, biotech firms, CROs, and clinical operations teams. Stop by **Booth 116** for live demonstrations of five transformative products: - ✅ **Live product demonstrations** — see all five GenInvo solutions in action - ✅ **One-on-one consultations** with clinical research and data science experts - ✅ **Real-world use cases** — how GenInvo is helping teams cut timelines, reduce errors, and stay compliant - ✅ **Exclusive conference offers** for DPHARM 2026 attendees - ✅ **Meet Craig, James, and Daragh** — our senior team on-site at Booth 116 Whether you are a pharma sponsor, CRO, statistical programmer, medical writer, or data manager — Geninvo has a solution built for your challenge. ## GENINVO PRODUCTS AT DPHARM 2026 Discover Geninvo’s AI-Powered Clinical Research Solutions Geninvo is the go-to partner for the life sciences industry, delivering innovative software solutions and data science services. Our unique combination of deep expertise in life sciences, cutting-edge AI, software development, data engineering, and cloud technologies helps bring life-changing treatments to patients faster. At DPHARM 2026, we are showcasing five products solving the toughest challenges in clinical research today. --- #### [CodeMagic™](https://geninvo.com/codemagic/) — AI-Assisted Code Generation for Statistical Programming *Stop writing SDTM, ADaM, and TFL code from scratch. CodeMagic generates it for you.* **CodeMagic™** is Geninvo’s AI-assisted code generation platform that automates statistical programming using structured specifications and mock shells. Designed for pharma statisticians and programmers, it generates **SDTM, ADaM, and TFL code** in open-source languages like R — delivering predictable, controlled, GxP-compliant, audit-ready programs with full documentation. **Key Capabilities:** - Automated ADaM generation with variable-level metadata mapping and derivation logic - TFL code generation from mock shells and ADaM specifications - Raw to SDTM conversion using detailed study specifications - Reusable global standard programs for common derivations - Seamless integration with client Statistical Computing Environments (SCEs) - Human-in-the-Loop framework ensuring accuracy, quality, and compliance throughout **Strategic Benefits for Your Team:** - Accelerate time-to-insight and shorten development timelines - Reduce manual coding errors through intelligent, structured prompts - Ensure CDISC standards and Good Programming Practices in every output - Free up programmer capacity for strategic analysis and innovation - Help SAS programmers transition to R with built-in learning support - Code is production-ready for validation or QC purposes **On the Roadmap:** SAS to R migration, Python/SAS/multi-language support, model-agnostic LLM compatibility. --- #### [Datalution™](https://geninvo.com/our-products/datalution/) — Intelligent Synthetic Data Platform for Clinical Trials *Start analytics before the first patient walks in the door.* **Datalution™** is Geninvo’s intelligent synthetic data platform that enables clinical trial teams to activate downstream analytics, testing, and validation workflows — all **before First-Patient-In**. With privacy guaranteed by design (zero patient re-identification risk), Datalution accelerates study configuration and early programming activation without compromising data security. **What Synthetic Data Enables:** - De-risking system validation and programming before trial start - Validating reconciliation, coding, and data cleaning processes - Eliminating patient exposure risk entirely - Testing QTL programs and pre-building TLF shells and analysis programs - Conducting realistic UAT for EDC, IRT, ePRO, and vendor systems - Achieving time and cost efficiency across the study lifecycle **Key Highlights:** - Privacy-guaranteed synthetic data infrastructure with zero re-identification risk by design - Accelerated study configuration and early programming activation - Unlocks early testing, validation, and system readiness across all trial systems --- #### [Shadow™](https://geninvo.com/our-products/data-anonymization-tool/) — Achieve Anonymization with Ease *Anonymize documents, datasets, and DICOM files — fast, accurately, and compliantly.* **Shadow™** is Geninvo’s AI-powered anonymization platform covering DICOM, clinical data, and regulatory documents. Using custom **NLP and Computer Vision (CV) models** to identify Personally Identifiable Information (PII) with precision, Shadow significantly reduces the time and manual effort required for anonymization — while eliminating human error. **Core Capabilities:** - DICOM + Data + Document De-identification in one platform - PII identification using custom NLP and CV models - Risk Analysis to assess re-identification risk before and after anonymization - Anonymization Reports with real-time results - Data Utility measurement to ensure anonymized data remains analytically useful **Compliance Coverage:** - GDPR, 21 CFR, and HIPAA compliant - Health Canada and EMA Policy 0070 aligned - Scalable, customizable Anonymization as a Service model --- #### [DocWrightAI™](https://geninvo.com/our-products/docwrightai-document-generation-software/) — AI-Driven Authoring of Clinical & Regulatory Documents *Create your most complex regulatory documents in minutes — without compromising accuracy or compliance.* **DocWrightAI™** is Geninvo’s advanced AI writing assistant for collaborative and efficient authoring of clinical and regulatory documents. Trained on official regulatory rules and medical knowledge, it accelerates document timelines from weeks to minutes while keeping human experts in control at every step. **Why It Stands Out:** - Accelerates document authoring timelines from weeks to minutes - Ensures compliance by design with built-in regulatory intelligence - AI-assisted, human-approved workflows keep your team in control - Built-in inconsistency checker catches errors before submission - Generates documents weeks ahead of schedule - Collaborative authoring allows multiple team members to work simultaneously - Customized user prompts generate content tailored to specific study needs - Human-in-Loop control ensures oversight and validation at every stage **Ideal For:** CSRs, protocols, INDs, NDAs, regulatory briefing documents, and all clinical/regulatory writing workflows. --- #### [DocQC™](https://geninvo.com/our-products/docqc-medical-writing-automation/) — Automated Medical Writing Review & QC *Cut review cycles. Cut costs. Never compromise on quality.* **DocQC™** is Geninvo’s automation tool that streamlines medical writing reviews, dramatically reducing manual effort and time-consuming review cycles. It solves the five biggest pain points in document QC: manual review burden, repetitive tasks causing fatigue, scalability challenges across multiple studies, delayed turnaround slowing regulatory submissions, and high cost per document. **Key Functionalities:** - Document Editing & Review Comments — real-time feedback and document revisions - Dashboard and Repository — central hub for managing and accessing all documents - Quality Review — document accuracy and compliance through predefined checklists - Collaborative Workspace — shared reviewing and editing for enhanced team productivity - Audit Trails — full change and access tracking to maintain document integrity - Queue Management System — organizes and prioritizes document review tasks efficiently **Two Flexible Business Models:** - **Service Model:** Geninvo FSP delivers Clinical & Regulatory Documents directly to clients - **Licensing Model:** Clients onboard and operate the DocQC platform independently within their own environment ## BOOK A MEETING Book a Meeting with Geninvo at DPHARM 2026 Don’t leave your DPHARM 2026 schedule to chance. Pre-book a dedicated **15 or 30-minute meeting** with our team at Booth 116 and make the most of your time in Boston. Email us directly: [**info@geninvo.com**](mailto:events@geninvo.com) ## FAQ SECTION **Where is DPHARM 2026 being held?** DPHARM 2026 takes place at the Sheraton Boston Hotel, Boston, Massachusetts, on September 15–16, 2026. **What booth number is Geninvo at DPHARM 2026?** Geninvo is exhibiting at **Booth 116** at DPHARM 2026. **How can I meet the Geninvo team at DPHARM 2026?** You can visit us directly at Booth 116, or email at [info@geninvo.com](mailto:events@geninvo.com). **What does Geninvo do?** Geninvo is a life sciences technology company delivering AI-powered software solutions and data science services for clinical research. Their product portfolio includes CodeMagic™ (AI-assisted statistical programming), Datalution™ (intelligent synthetic data for clinical trials), Shadow™ (data and document anonymization), DocWrightAI™ (AI-driven regulatory document authoring), and DocQC™ (automated medical writing QC). Geninvo helps pharma sponsors, biotech firms, and CROs accelerate drug development and bring life-changing treatments to patients faster. **What products will Geninvo demonstrate at DPHARM 2026?** At Booth 116, the Geninvo team will demonstrate five solutions: CodeMagic™ for AI-assisted SDTM/ADaM/TFL code generation; Datalution™ for synthetic clinical trial data; Shadow™ for DICOM, data, and document anonymization; DocWrightAI™ for AI-powered clinical and regulatory document authoring; and DocQC™ for automated medical writing review and quality control. **What is DPHARM?** DPHARM (Disruptive Innovations to Advance Clinical Research) is an annual conference organized by The Conference Forum (TCF), focused on transformative technologies and innovations modernizing clinical trials. **Is Geninvo exhibiting or sponsoring at DPHARM 2026?** Geninvo is exhibiting at DPHARM 2026 at Booth 116, September 15–16, 2026, in Boston. ## Subscribe for Newsletter Name Email Message Send ###### More Blogs [ ![Quantitative Risk Assessment: A Smarter Approach to Clinical Data Anonymization ](https://geninvo.com/wp-content/uploads/2025/10/Blog-12-300x189.jpg) ](https://geninvo.com/quantitative-risk-assessment-a-smarter-approach-to-clinical-data-anonymization/) ## [Quantitative Risk Assessment: A Smarter Approach to Clinical Data Anonymization ](https://geninvo.com/quantitative-risk-assessment-a-smarter-approach-to-clinical-data-anonymization/) [ ![Secure Scanning with Confidential Information Scanner: Safeguarding Your CCIs During Clinical Research](https://geninvo.com/wp-content/uploads/2025/09/Blog-11-300x189.jpg) ](https://geninvo.com/secure-scanning-with-confidential-information-scanner-safeguarding-your-ccis-during-clinical-research/) ## [Secure Scanning with Confidential Information Scanner: Safeguarding Your CCIs During Clinical Research](https://geninvo.com/secure-scanning-with-confidential-information-scanner-safeguarding-your-ccis-during-clinical-research/) [ ![Python’s Future in Clinical Trials: Innovations and Collaborative Advancements](https://geninvo.com/wp-content/uploads/2025/08/Blog-8-300x189.jpg) ](https://geninvo.com/pythons-future-in-clinical-trials-innovations-and-collaborative-advancements/) ## [Python’s Future in Clinical Trials: Innovations and Collaborative Advancements](https://geninvo.com/pythons-future-in-clinical-trials-innovations-and-collaborative-advancements/) [ ![The Changing Role of the Clinical Programmer in an Open-Source World](https://geninvo.com/wp-content/uploads/2025/07/Blog-7-300x189.jpg) ](https://geninvo.com/the-changing-role-of-the-clinical-programmer-in-an-open-source-world/) ## [The Changing Role of the Clinical Programmer in an Open-Source World](https://geninvo.com/the-changing-role-of-the-clinical-programmer-in-an-open-source-world/) [ ![Beyond the Buzzwords: How GenInvo’s AI/ML Tools Are Transforming Life Sciences](https://geninvo.com/wp-content/uploads/2025/07/Blog-6-300x189.jpg) ](https://geninvo.com/ai-ml-tools-life-sciences-geninvo/) ## [Beyond the Buzzwords: How GenInvo’s AI/ML Tools Are Transforming Life Sciences](https://geninvo.com/ai-ml-tools-life-sciences-geninvo/) [ ![Empowering the Future of Life Sciences: A GenInvo Perspective from the Inside](https://geninvo.com/wp-content/uploads/2025/06/Blog-5-300x196.jpg) ](https://geninvo.com/empowering-the-future-of-life-sciences-a-geninvo-perspective-from-the-inside/) ## [Empowering the Future of Life Sciences: A GenInvo Perspective from the Inside](https://geninvo.com/empowering-the-future-of-life-sciences-a-geninvo-perspective-from-the-inside/) [ ![GenInvo’s CIS Tool: Safeguarding Confidential Company Information in Life Sciences.](https://geninvo.com/wp-content/uploads/2025/06/Blog-4-300x196.jpg) ](https://geninvo.com/geninvos-cis-tool-safeguarding-confidential-company-information-in-life-sciences/) ## [GenInvo’s CIS Tool: Safeguarding Confidential Company Information in Life Sciences.](https://geninvo.com/geninvos-cis-tool-safeguarding-confidential-company-information-in-life-sciences/) [ ![Why Clinical Data Transparency Matters: Benefits for Patients, Researchers, and Industry](https://geninvo.com/wp-content/uploads/2025/06/Blog-3-300x196.jpg) ](https://geninvo.com/why-clinical-data-transparency-matters-benefits-for-patients-researchers-and-industry/) ## [Why Clinical Data Transparency Matters: Benefits for Patients, Researchers, and Industry](https://geninvo.com/why-clinical-data-transparency-matters-benefits-for-patients-researchers-and-industry/) [ ![How Meaningful Synthetic Data Generation Tools Are Transforming AI Development ](https://geninvo.com/wp-content/uploads/2025/01/Blog-2-300x169.jpg) ](https://geninvo.com/how-meaningful-synthetic-data-generation-tools-are-transforming-ai-development/) ## [How Meaningful Synthetic Data Generation Tools Are Transforming AI Development ](https://geninvo.com/how-meaningful-synthetic-data-generation-tools-are-transforming-ai-development/) [ ![Empowering Clinical and Regulatory Writing: Harnessing AI as Your Assistant  ](https://geninvo.com/wp-content/uploads/2024/10/Untitled-1-1-300x189.webp) ](https://geninvo.com/empowering-clinical-and-regulatory-writing-harnessing-ai-as-your-assistant/) ## [Empowering Clinical and Regulatory Writing: Harnessing AI as Your Assistant ](https://geninvo.com/empowering-clinical-and-regulatory-writing-harnessing-ai-as-your-assistant/) [ ![The Impact of AI on Medical Writing: How Artificial Intelligence is Revolutionizing Medical Content Creation ](https://geninvo.com/wp-content/uploads/2024/09/mdw-1-300x169.jpg) ](https://geninvo.com/the-impact-of-ai-on-medical-writing-how-artificial-intelligence-is-revolutionizing-medical-content-creation/) ## [The Impact of AI on Medical Writing: How Artificial Intelligence is Revolutionizing Medical Content Creation ](https://geninvo.com/the-impact-of-ai-on-medical-writing-how-artificial-intelligence-is-revolutionizing-medical-content-creation/) [ ![CDISC Standards and Data Transformation in Clinical Trial.](https://geninvo.com/wp-content/uploads/2024/07/dtct-1-300x169.webp) ](https://geninvo.com/cdisc-standards-and-data-transformation-in-clinical-trial/) ## [CDISC Standards and Data Transformation in Clinical Trial.](https://geninvo.com/cdisc-standards-and-data-transformation-in-clinical-trial/) [ ![Transforming Document Creation in Life Sciences with DocWrightAI™ – GenInvo’s Advanced AI Assistant!](https://geninvo.com/wp-content/uploads/2024/06/DocWright-lifscience-300x169.jpg) ](https://geninvo.com/transforming-document-creation-in-life-sciences-with-docwrightai-geninvos-advanced-ai-assistant/) ## [Transforming Document Creation in Life Sciences with DocWrightAI™ – GenInvo’s Advanced AI Assistant!](https://geninvo.com/transforming-document-creation-in-life-sciences-with-docwrightai-geninvos-advanced-ai-assistant/) [ ![Embracing the Digital Era: The Transformative Power of Digitalization in Medical Writing](https://geninvo.com/wp-content/uploads/2024/03/1672114503523rf-1-300x169.jpg) ](https://geninvo.com/embracing-the-digital-era-the-transformative-power-of-digitalization-in-medical-writing/) ## [Embracing the Digital Era: The Transformative Power of Digitalization in Medical Writing](https://geninvo.com/embracing-the-digital-era-the-transformative-power-of-digitalization-in-medical-writing/) [ ![Data Masking and Data Anonymization: The need for healthcare companies](https://geninvo.com/wp-content/uploads/2024/03/data-m-300x169.jpg) ](https://geninvo.com/data-masking-and-data-anonymization-the-need-for-healthcare-companies/) ## [Data Masking and Data Anonymization: The need for healthcare companies](https://geninvo.com/data-masking-and-data-anonymization-the-need-for-healthcare-companies/) [ ![Artificial Intelligence in the Healthcare Domain: How AI Reviews Clinical Documents](https://geninvo.com/wp-content/uploads/2024/03/maxresdefault.jpgr_-300x169.jpg) ](https://geninvo.com/artificial-intelligence-in-the-healthcare-domain-how-ai-reviews-clinical-documents/) ## [Artificial Intelligence in the Healthcare Domain: How AI Reviews Clinical Documents](https://geninvo.com/artificial-intelligence-in-the-healthcare-domain-how-ai-reviews-clinical-documents/) [ ![Importance and examples of usage of Data Anonymization in Healthcare & Other sectors](https://geninvo.com/wp-content/uploads/2024/02/dah-sector-300x169.jpg) ](https://geninvo.com/importance-and-examples-of-usage-of-data-anonymization-in-healthcare-other-sectors/) ## [Importance and examples of usage of Data Anonymization in Healthcare & Other sectors](https://geninvo.com/importance-and-examples-of-usage-of-data-anonymization-in-healthcare-other-sectors/) [ ![Data Anonymization and HIPAA Compliance: Protecting Health Information Privacy](https://geninvo.com/wp-content/uploads/2024/02/Untitled-1df-300x169.jpg) ](https://geninvo.com/data-anonymization-and-hipaa-compliance-protecting-health-information-privacy/) ## [Data Anonymization and HIPAA Compliance: Protecting Health Information Privacy](https://geninvo.com/data-anonymization-and-hipaa-compliance-protecting-health-information-privacy/) [ ![Automation of Unstructured Clinical Data: A collaboration of automation and Medical Writers](https://geninvo.com/wp-content/uploads/2024/01/cdf-300x169.png) ](https://geninvo.com/automation-of-unstructured-clinical-data-a-collaboration-of-automation-and-medical-writers/) ## [Automation of Unstructured Clinical Data: A collaboration of automation and Medical Writers](https://geninvo.com/automation-of-unstructured-clinical-data-a-collaboration-of-automation-and-medical-writers/) [ ![Quality Control of the Methods and Procedures of Clinical Study](https://geninvo.com/wp-content/uploads/2024/01/quloi-300x169.jpg) ](https://geninvo.com/quality-control-of-the-methods-and-procedures-of-clinical-study/) ## [Quality Control of the Methods and Procedures of Clinical Study](https://geninvo.com/quality-control-of-the-methods-and-procedures-of-clinical-study/) --- ### [Book Demo](https://geninvo.com/?elementor_library=book-demo) **Published:** April 7, 2026 **Author:** admin **Content:** Content area --- ### [Elementor Loop Item #23048](https://geninvo.com/?elementor_library=elementor-loop-item) **Published:** April 6, 2026 **Author:** admin **Content:** ![](https://geninvo.com/wp-content/uploads/2026/04/Anonymization.webp "Anonymization - GenInvo - GenInvo") #### **Anonymization As a Service** We provide a variety of customized anonymization services to support global data sharing and transparency services, along with redaction and risk assessment options. [ Read More ](https://geninvo.com/our-services/anonymization-as-a-service/) ![](https://geninvo.com/wp-content/uploads/2026/04/Innovation.webp "Innovation - GenInvo - GenInvo") #### **Innovation As a Service** Discoveries and investments in next-generation medicines as well as technology have seen an increase in the pharma space. [ Read More ](https://geninvo.com/our-services/innovation-as-a-service/) ![](https://geninvo.com/wp-content/uploads/2026/04/Custom-Application.webp "Custom Application - GenInvo - GenInvo") #### **Custom Application Development** Expert teams, Personalized tools, and Processes - We deliver exactly what our customers need. [ Read More ](https://geninvo.com/our-services/custom-application-development/) ![](https://geninvo.com/wp-content/uploads/2026/04/Collaborative-Innovation.webp "Collaborative Innovation - GenInvo - GenInvo") #### **Collaborative Innovation** Collaboration between the right stakeholders is a foundation to innovation. Every pharma company has their unique needs and challenges, so ‘one size fits all’ solution wouldn’t be feasible to overcome them. [ Read More ](https://geninvo.com/our-services/collaborative-innovation) ![](https://geninvo.com/wp-content/uploads/2026/04/Data-Science-CoE.webp "Data Science CoE - GenInvo - GenInvo") #### **Data Science CoE** Our Life Science SME and software and technology experts support solutions in a variety of areas including data visualization, custom software development, and more. [ Read More ](https://geninvo.com/our-services/dsa/) ![](https://geninvo.com/wp-content/uploads/2026/04/Cloud-Managed-Service.webp "Cloud Managed Service - GenInvo - GenInvo") #### **Cloud Managed Service** In today’s dynamic environment, it is necessary to have a clear path to achieve the business outcomes you desire. [ Read More ](https://geninvo.com/our-services/cloud-managed-services/) ![](https://geninvo.com/wp-content/uploads/2026/04/Talent-Resource-Hub.webp "Talent Resource Hub - GenInvo - GenInvo") #### **Talent Resource Hub** Our Life Science SME and software and technology experts support solutions in a variety of areas including data visualization, custom software development, and more. [ Read More ](https://geninvo.com/our-services/talent-resource-hub/) --- ### [Default Kit](https://geninvo.com/?elementor_library=default-kit) **Published:** March 16, 2021 **Author:** admin --- ### [leaders-carousel](https://geninvo.com/?elementor_library=leaders-carousel-2) **Published:** April 6, 2026 **Author:** admin **Content:** ![CEO-1.png](https://geninvo.com/wp-content/uploads/elementor/thumbs/CEO-1-rlllblejoshvjqzzli5ck87gohice1f5yrw2e53nmk.png "CEO-1.png") ### **Shweta Shukla** **CEO** [ In ](https://www.linkedin.com/in/shwetageninvo/) ![CO-FOUNDER-2.png](https://geninvo.com/wp-content/uploads/elementor/thumbs/CO-FOUNDER-2-rlllbmcdvmj5vcymg0jz4pyx9vdplqiwawjjvf29gc.png "CO-FOUNDER-2.png") ### **Nalin Gupta** **Co-Founder & Strategic Advisor** [ In ](https://www.linkedin.com/in/nalingupta-av/) ![CO-FOUNDER-1-1.png](https://geninvo.com/wp-content/uploads/elementor/thumbs/CO-FOUNDER-1-1-rlllbmcdvmj5vcymg0jz4pyx9vdplqiwawjjvf29gc.png "CO-FOUNDER-1-1.png") ### **Neha Aggrawal** **Co-Founder** [ In ](https://www.linkedin.com/in/naggarwalav/) ![GI-rohit-bajaj.png](https://geninvo.com/wp-content/uploads/elementor/thumbs/GI-rohit-bajaj-rlllbna82gkg6yx9aiylp7qdv992tfmmn171cp0va4.png "GI-rohit-bajaj.png") ### **Rohit Bajaj** **Associate Director QA/IT CSV** [ In ](https://www.linkedin.com/in/rohit-bajaj-a315a02/) ![Durgaprasad-G-new.png](https://geninvo.com/wp-content/uploads/elementor/thumbs/Durgaprasad-G-new-rlllbna82gkg6yx9aiylp7qdv992tfmmn171cp0va4.png "Durgaprasad-G-new.png") ### **Durga Gudivaka** **Global Head- Technology and Innovation** [ In ](https://www.linkedin.com/in/durgaprasad-gudivaka-0a3b234) ![Sunita-GI.jpg](https://geninvo.com/wp-content/uploads/elementor/thumbs/Sunita-GI-rlllbna82gkg6yx9aiylp7qdv992tfmmn171cp0va4.jpg "Sunita-GI.jpg") ### **Sunita Poojary** **Senior Director - Operations and Growth** [ In ](https://www.linkedin.com/in/sunita-poojary-0aa46bb/) ![DaraghRyan.jpg](https://geninvo.com/wp-content/uploads/elementor/thumbs/DaraghRyan-rlllbna82gkg6yx9aiylp7qdv992tfmmn171cp0va4.jpg "DaraghRyan.jpg") ### **Daragh Ryan** **Global Head of Client Consultancy** [ In ](https://www.linkedin.com/in/daraghryan/) ![James.png](https://geninvo.com/wp-content/uploads/elementor/thumbs/James-rlllbo829alqikvw51d89phugn4g14qcz5uityzh3w.png "James.png") ### **James Gallagher** **Advisor** [ In ](https://www.linkedin.com/in/daraghryan/) --- ### [contact-form](https://geninvo.com/?elementor_library=contact-form) **Published:** March 26, 2021 **Author:** admin **Content:** Content area --- ### [leaders-carousel](https://geninvo.com/?elementor_library=leaders-carousel) **Published:** April 12, 2021 **Author:** admin **Content:** ![CEO](https://geninvo.com/wp-content/uploads/elementor/thumbs/CEO-1-qwoviyxzua48wgwmylhdtvj1kqfqy8tk8xxsxyipgc.png "CEO") ### **Shweta Shukla** **CEO** [ In ](https://www.linkedin.com/in/shwetageninvo/) ![CO-FOUNDER](https://geninvo.com/wp-content/uploads/elementor/thumbs/CO-FOUNDER-2-qwovizvu145j82v9t3w0edai64b45xxal2laf8hba4.png "CO-FOUNDER") ### **Nalin Gupta** **Co-Founder & Strategic Advisor** [ In ](https://www.linkedin.com/in/nalingupta-av/) ![CO-FOUNDER-1](https://geninvo.com/wp-content/uploads/elementor/thumbs/CO-FOUNDER-1-1-qwovj0to7y6tjotwnmamyv1yri6hdn10x78rwifx3w.png "CO-FOUNDER-1") ### **Neha Aggrawal** **Co-Founder** [ In ](https://www.linkedin.com/in/naggarwalav/) ![GI-rohit-bajaj](https://geninvo.com/wp-content/uploads/elementor/thumbs/GI-rohit-bajaj-r36w29f3xc2v0706jyub4w69vfp6l5gotv03snczto.png "GI-rohit-bajaj") ### **Rohit Bajaj** **Associate Director QA/IT CSV** [ In ](https://www.linkedin.com/in/rohit-bajaj-a315a02/) ![Durgaprasad-G-new](https://geninvo.com/wp-content/uploads/elementor/thumbs/Durgaprasad-G-new-r4turaclct86430esnbdmbn6bpwm1hrbv0so3v2p98.png "Durgaprasad-G-new") ### **Durga Gudivaka** **Global Head- Technology and Innovation** [ In ](https://www.linkedin.com/in/durgaprasad-gudivaka-0a3b234) ![Sunita-GI](https://geninvo.com/wp-content/uploads/elementor/thumbs/Sunita-GI-r8i5uahgva3r4tt7kfkeupnxkp5jkeralox95bb3vg.jpg "Sunita-GI") ### **Sunita Poojary** **Senior Director - Operations and Growth** [ In ](https://www.linkedin.com/in/sunita-poojary-0aa46bb/) ![DaraghRyan](https://geninvo.com/wp-content/uploads/elementor/thumbs/DaraghRyan-rehwiol1xfymqon4nqn05109tceufdxjr54kxb0qxo.jpg "DaraghRyan") ### **Daragh Ryan** **Global Head of Client Consultancy** [ In ](https://www.linkedin.com/in/daraghryan/) ![James](https://geninvo.com/wp-content/uploads/elementor/thumbs/James-rehwr39323gyl4fhkdgvfwmp3ez19xb48r6xgejza4.png "James") ### **James Gallagher** **Advisor** [ In ](https://www.linkedin.com/in/daraghryan/) --- ### [job-single-post](https://geninvo.com/?elementor_library=job-single-post) **Published:** March 24, 2021 **Author:** admin **Content:** ![](//geninvo.com/wp-content/uploads/2025/10/image-Work-with-us-info-page-24-V1.jpg) image-Work-with-us-info page Rewrite your future Search and apply for a job today Rewrite your future Search and apply for a job today ## Work with Us [ Who we are ](https://geninvo.com/who-we-are/) [ GENINVO Insights ](https://geninvo.com/insights/) [ Other Jobs ](https://geninvo.com/work-with-us/) ![](https://geninvo.com/wp-content/uploads/2021/03/wwu-top.jpg) Job Type: Location: Experience: Salary: ## Advancing Clinical Research Innovation | DPHARM 2026 | September 15–16, 2026 | Sheraton Boston Hotel **Geninvo is exhibiting at [DPHARM 2026](https://www.dpharmconference.com/)** the industry’s premier conference for disruptive innovations in clinical research taking place **September 15–16, 2026** at the **Sheraton Boston Hotel, Boston, MA**. Find our team at **Booth 116** and discover how GenInvo is transforming the fields like Data Analytics, Biometrics, Regulatory Writing and Data Transparency with cutting-edge technologies. 📅 **September 15–16, 2026** 📍 Sheraton Boston Hotel, Boston, MA 🏷️ **Booth 116** 👥 Contacts: Craig | James | Daragh **[Book a Meeting at DPHARM 2026](https://geninvo.com/contact-us/)** ## ABOUT THE EVENT About DPHARM 2026: Disruptive Innovations to Advance Clinical Research [DPHARM 2026 ](https://www.dpharmconference.com/)is the leading conference bringing together **senior clinical operations executives, R&D innovators, technology leaders, and patient advocates** to explore the future of clinical trials. Hosted at the **Sheraton Boston Hotel, September 15–16, 2026**, the event features TED-style talks, fireside chats, quick-fire demos, and the renowned **DPHARM Idol Disrupt** startup pitch competition all focused on driving efficiencies in clinical trial operations and improving outcomes for patients. Key themes at DPHARM 2026 include: - Decentralized and hybrid clinical trials - AI and data-driven trial design - Patient-centric research models - Disruptive technologies accelerating drug development - Operational excellence in clinical research ## WHY VISIT GENINVO AT BOOTH 116? At DPHARM 2026, the Geninvo team will be showcasing our full suite of AI-powered clinical research and data science solutions purpose-built for pharma sponsors, biotech firms, CROs, and clinical operations teams. Stop by **Booth 116** for live demonstrations of five transformative products: - ✅ **Live product demonstrations** — see all five GenInvo solutions in action - ✅ **One-on-one consultations** with clinical research and data science experts - ✅ **Real-world use cases** — how GenInvo is helping teams cut timelines, reduce errors, and stay compliant - ✅ **Exclusive conference offers** for DPHARM 2026 attendees - ✅ **Meet Craig, James, and Daragh** — our senior team on-site at Booth 116 Whether you are a pharma sponsor, CRO, statistical programmer, medical writer, or data manager — Geninvo has a solution built for your challenge. ## GENINVO PRODUCTS AT DPHARM 2026 Discover Geninvo’s AI-Powered Clinical Research Solutions Geninvo is the go-to partner for the life sciences industry, delivering innovative software solutions and data science services. Our unique combination of deep expertise in life sciences, cutting-edge AI, software development, data engineering, and cloud technologies helps bring life-changing treatments to patients faster. At DPHARM 2026, we are showcasing five products solving the toughest challenges in clinical research today. --- #### [CodeMagic™](https://geninvo.com/codemagic/) — AI-Assisted Code Generation for Statistical Programming *Stop writing SDTM, ADaM, and TFL code from scratch. CodeMagic generates it for you.* **CodeMagic™** is Geninvo’s AI-assisted code generation platform that automates statistical programming using structured specifications and mock shells. Designed for pharma statisticians and programmers, it generates **SDTM, ADaM, and TFL code** in open-source languages like R — delivering predictable, controlled, GxP-compliant, audit-ready programs with full documentation. **Key Capabilities:** - Automated ADaM generation with variable-level metadata mapping and derivation logic - TFL code generation from mock shells and ADaM specifications - Raw to SDTM conversion using detailed study specifications - Reusable global standard programs for common derivations - Seamless integration with client Statistical Computing Environments (SCEs) - Human-in-the-Loop framework ensuring accuracy, quality, and compliance throughout **Strategic Benefits for Your Team:** - Accelerate time-to-insight and shorten development timelines - Reduce manual coding errors through intelligent, structured prompts - Ensure CDISC standards and Good Programming Practices in every output - Free up programmer capacity for strategic analysis and innovation - Help SAS programmers transition to R with built-in learning support - Code is production-ready for validation or QC purposes **On the Roadmap:** SAS to R migration, Python/SAS/multi-language support, model-agnostic LLM compatibility. --- #### [Datalution™](https://geninvo.com/our-products/datalution/) — Intelligent Synthetic Data Platform for Clinical Trials *Start analytics before the first patient walks in the door.* **Datalution™** is Geninvo’s intelligent synthetic data platform that enables clinical trial teams to activate downstream analytics, testing, and validation workflows — all **before First-Patient-In**. With privacy guaranteed by design (zero patient re-identification risk), Datalution accelerates study configuration and early programming activation without compromising data security. **What Synthetic Data Enables:** - De-risking system validation and programming before trial start - Validating reconciliation, coding, and data cleaning processes - Eliminating patient exposure risk entirely - Testing QTL programs and pre-building TLF shells and analysis programs - Conducting realistic UAT for EDC, IRT, ePRO, and vendor systems - Achieving time and cost efficiency across the study lifecycle **Key Highlights:** - Privacy-guaranteed synthetic data infrastructure with zero re-identification risk by design - Accelerated study configuration and early programming activation - Unlocks early testing, validation, and system readiness across all trial systems --- #### [Shadow™](https://geninvo.com/our-products/data-anonymization-tool/) — Achieve Anonymization with Ease *Anonymize documents, datasets, and DICOM files — fast, accurately, and compliantly.* **Shadow™** is Geninvo’s AI-powered anonymization platform covering DICOM, clinical data, and regulatory documents. Using custom **NLP and Computer Vision (CV) models** to identify Personally Identifiable Information (PII) with precision, Shadow significantly reduces the time and manual effort required for anonymization — while eliminating human error. **Core Capabilities:** - DICOM + Data + Document De-identification in one platform - PII identification using custom NLP and CV models - Risk Analysis to assess re-identification risk before and after anonymization - Anonymization Reports with real-time results - Data Utility measurement to ensure anonymized data remains analytically useful **Compliance Coverage:** - GDPR, 21 CFR, and HIPAA compliant - Health Canada and EMA Policy 0070 aligned - Scalable, customizable Anonymization as a Service model --- #### [DocWrightAI™](https://geninvo.com/our-products/docwrightai-document-generation-software/) — AI-Driven Authoring of Clinical & Regulatory Documents *Create your most complex regulatory documents in minutes — without compromising accuracy or compliance.* **DocWrightAI™** is Geninvo’s advanced AI writing assistant for collaborative and efficient authoring of clinical and regulatory documents. Trained on official regulatory rules and medical knowledge, it accelerates document timelines from weeks to minutes while keeping human experts in control at every step. **Why It Stands Out:** - Accelerates document authoring timelines from weeks to minutes - Ensures compliance by design with built-in regulatory intelligence - AI-assisted, human-approved workflows keep your team in control - Built-in inconsistency checker catches errors before submission - Generates documents weeks ahead of schedule - Collaborative authoring allows multiple team members to work simultaneously - Customized user prompts generate content tailored to specific study needs - Human-in-Loop control ensures oversight and validation at every stage **Ideal For:** CSRs, protocols, INDs, NDAs, regulatory briefing documents, and all clinical/regulatory writing workflows. --- #### [DocQC™](https://geninvo.com/our-products/docqc-medical-writing-automation/) — Automated Medical Writing Review & QC *Cut review cycles. Cut costs. Never compromise on quality.* **DocQC™** is Geninvo’s automation tool that streamlines medical writing reviews, dramatically reducing manual effort and time-consuming review cycles. It solves the five biggest pain points in document QC: manual review burden, repetitive tasks causing fatigue, scalability challenges across multiple studies, delayed turnaround slowing regulatory submissions, and high cost per document. **Key Functionalities:** - Document Editing & Review Comments — real-time feedback and document revisions - Dashboard and Repository — central hub for managing and accessing all documents - Quality Review — document accuracy and compliance through predefined checklists - Collaborative Workspace — shared reviewing and editing for enhanced team productivity - Audit Trails — full change and access tracking to maintain document integrity - Queue Management System — organizes and prioritizes document review tasks efficiently **Two Flexible Business Models:** - **Service Model:** Geninvo FSP delivers Clinical & Regulatory Documents directly to clients - **Licensing Model:** Clients onboard and operate the DocQC platform independently within their own environment ## BOOK A MEETING Book a Meeting with Geninvo at DPHARM 2026 Don’t leave your DPHARM 2026 schedule to chance. Pre-book a dedicated **15 or 30-minute meeting** with our team at Booth 116 and make the most of your time in Boston. Email us directly: [**info@geninvo.com**](mailto:events@geninvo.com) ## FAQ SECTION **Where is DPHARM 2026 being held?** DPHARM 2026 takes place at the Sheraton Boston Hotel, Boston, Massachusetts, on September 15–16, 2026. **What booth number is Geninvo at DPHARM 2026?** Geninvo is exhibiting at **Booth 116** at DPHARM 2026. **How can I meet the Geninvo team at DPHARM 2026?** You can visit us directly at Booth 116, or email at [info@geninvo.com](mailto:events@geninvo.com). **What does Geninvo do?** Geninvo is a life sciences technology company delivering AI-powered software solutions and data science services for clinical research. Their product portfolio includes CodeMagic™ (AI-assisted statistical programming), Datalution™ (intelligent synthetic data for clinical trials), Shadow™ (data and document anonymization), DocWrightAI™ (AI-driven regulatory document authoring), and DocQC™ (automated medical writing QC). Geninvo helps pharma sponsors, biotech firms, and CROs accelerate drug development and bring life-changing treatments to patients faster. **What products will Geninvo demonstrate at DPHARM 2026?** At Booth 116, the Geninvo team will demonstrate five solutions: CodeMagic™ for AI-assisted SDTM/ADaM/TFL code generation; Datalution™ for synthetic clinical trial data; Shadow™ for DICOM, data, and document anonymization; DocWrightAI™ for AI-powered clinical and regulatory document authoring; and DocQC™ for automated medical writing review and quality control. **What is DPHARM?** DPHARM (Disruptive Innovations to Advance Clinical Research) is an annual conference organized by The Conference Forum (TCF), focused on transformative technologies and innovations modernizing clinical trials. **Is Geninvo exhibiting or sponsoring at DPHARM 2026?** Geninvo is exhibiting at DPHARM 2026 at Booth 116, September 15–16, 2026, in Boston. [ APPLY ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjQxNzQiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D) ##### Share Job --- ### [job-loop](https://geninvo.com/?elementor_library=job-loop) **Published:** March 24, 2021 **Author:** admin **Content:** ##### [job-loop](https://geninvo.com/?elementor_library=job-loop) Location: Job Type: Experience: [ ](https://geninvo.com/?elementor_library=job-loop) --- ### [new-blog-loop](https://geninvo.com/?elementor_library=elementor-loop-9407) **Published:** August 29, 2022 **Author:** admin **Content:** ###### [new-blog-loop](https://geninvo.com/?elementor_library=elementor-loop-9407) - [ August 29, 2022 ](https://geninvo.com/2022/08/29/) - 6:24 am [ Read More ](https://geninvo.com/?elementor_library=elementor-loop-9407) --- ### [Year loop](https://geninvo.com/?elementor_library=year-loop) **Published:** September 6, 2023 **Author:** admin **Content:** - [ September 6, 2023 ](https://geninvo.com/2023/09/06/) - 6:58 am --- ### [show more](https://geninvo.com/?elementor_library=show-more) **Published:** March 15, 2023 **Author:** admin **Content:** ![Shadow - Data Anonymization Tool.](https://geninvo.com/wp-content/uploads/2021/03/shadow_logo-300x216.png "shadow_logo - GenInvo - GenInvo") # Shadow – Data Anonymization Tool. ## Shadow™ is a leader in automating data and document de-identification and data anonymization tool. Our team created this data anonymization tool to produce solution that allow you to focus on science and results. Shadow™ alleviates the pain points of homegrown software utilities that often prove to be inefficient, difficult to maintain, and slow to match quickly evolving requirements. --- ### [docgen](https://geninvo.com/?elementor_library=docgen) **Published:** March 14, 2023 **Author:** admin **Content:** [ ](https://geninvo.com/our-services/anonymization-as-a-service/) ### [ Document +Data Anonymization ](https://geninvo.com/our-services/anonymization-as-a-service/) Shadow™ is a comprehensive solution to address the evolving landscape for data and/or document de-identification and anonymization ### Anonymization Reports Reports to drive, describe and monitor your anonymization project and the effectiveness of your teams. ### Risk Analysis Determination of the risk for re-identification of your data before and after de-identification to ensure you meet required thresholds. --- ### [clone product page](https://geninvo.com/?elementor_library=clone-product-page) **Published:** March 14, 2023 **Author:** admin **Content:** ## ApoGI™ Next-Gen End to End Platform, Automating your Clinical Study Deliverables [ View Brochure ](https://geninvo.com/wp-content/uploads/2022/05/ApoGI_8-5x5-5-V3-14-04-Final.pdf) [ Request Demo ](https://geninvo.com/contact-us/) ![Metadata Management Tool](https://geninvo.com/wp-content/uploads/2021/03/metaworks_logo-300x209.png "metaworks_logo - GenInvo - GenInvo") ApoGI™ is an integrated, automation platform that leverages AI (Artificial Intelligence) and ML (Machine Learning) and puts focus on standards and metadata management to streamline processes and the generation of artifacts typically associated with the clinical study lifecycle. Ensuring process/artifact consistency, streamlining and automating repetitive tasks and artifact generation to allow subject matter experts to focus on science and deriving additional value/insights from clinical trial data. ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ## Key Features Life Science SMEs drive our custom application development services, supported by leading-edge technologists and software development experts seasoned in delivering solutions and services that resonate with our sponsors. Our technical teams support solutions development and services in the following areas: - Next generation enterprise platform - Ability to integrate and leverage data from multiple sources - Anonymization of data for sharing it internally or externally in real time - Leveraging new technologies to support artifact generation from protocol to CSR - Automated process workflows to facilitate Governance, Artifact Generation, Review / Approval / Sign-off - ApoGI has developed Data Visualization module to analyze information related to Clinical Metadata and Data and provide data insights in the form of visual elements like charts, graphs and maps to understand the trends, outliers and patterns in data. - Availability of Structured Governance Framework to track metadata at multiple hierarchical levels - Impact Analysis/Traceability Tool (across all levels) ![](https://geninvo.com/wp-content/uploads/2022/05/apogi-icons-03.png "apogi-icons-03 - GenInvo - GenInvo") # STUDY DESIGN EXTRACTOR - Platform for Extracting Protocol Information like Trial Design Elements, Study level Information, Visit Assessment schedules along with Domains that need to be collected for the study from the Protocol Document. - Identify existing Metadata availability from MDR and identifying new Domains that would need to be created for the study for Data collection Elements USP: Unmet needs in the Industry to automate extracting information from the Protocol Document to reduce Study Build timelines. ![](https://geninvo.com/wp-content/uploads/2022/05/apogi-icons-04.png "apogi-icons-04 - GenInvo - GenInvo") # STUDY BUILD - Managing Study level metadata, copying from Global. - Creating new metadata at study level from scratch for Data collection Elements - Change request by Study user for Global Metadata Governance - File system USP: Meeting unmet Industry needs to manage all Study Level Metadata in one place from Data collection to Data reporting. ![](https://geninvo.com/wp-content/uploads/2022/05/apogi-icons-02.png "apogi-icons-02 - GenInvo - GenInvo") # DATA TRANSFORMATION - Importing the raw datasets/non-clinical study data and their classification with tags - Providing the framework for source to target mapping with user interface screen - Providing the basic default functions for mapping datasets & supports custom mapping - Automap functionality to demonstrate current mapping techniques, supports manual mapping - Execution logs, method usability report and impact assessment, mapping coverage report and export - Exporting the transformed data and mapping spec generation and file system USP: Data Transformation/Data conversions made easy by applying Automapping, Machine learning algorithms to reduce Submission Timelines. ![](https://geninvo.com/wp-content/uploads/2022/05/apogi-icons-01.png "apogi-icons-01 - GenInvo - GenInvo") # TLF SHELL GENERATOR - Platform for facilitating the finalization of all the templates for generating Tables, Listings and Figures as part of setting up the expectations between the Statisticians and the Statistical Programmers. - Product supports to create TLF from scratch, allows to import existing TLF shells/catalog from existing library and generate metadata to be stored back in MDR. - Supports various formats in both Import and Export functionality. USP: Product will be used to generate the actual study artifacts: Tables, Listings and Figures using SDTM/AdAM dataset ## ApoGI Product Suite [ ![](https://geninvo.com/wp-content/uploads/2022/05/apogi-schem-01-e1651831982113.png "apogi-schem-01 - GenInvo - GenInvo") ](https://geninvo.com/wp-content/uploads/2022/05/apogi-schem-01.png) ## ApoGI Platform Modules **ApoGI platform consist of ADMIN and MDR** ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ## ApoGI Products **ApoGI Productcs consist of ADMIN and MDR** # Key Benefits Looking to enhance your organization’s impact? Our technology-empowered experts are available to assist you in the following areas: - ApoGI offers one stop platform-based solution which helps reduce multiple hops between systems and ensures data and document traceability - ApoGI is future ready with AI enabled Automation platform with “Innovation as Service” model for custom needs as required - Plug-n-Play modules in the ApoGI platform help manage industry requirements along with legacy products - Focus consequently enhances the value of the metadata and related transformations making it possible to extend the capabilities of the platform to cover additional artifacts, processes, and use cases. [ Request Demo ](https://geninvo.com/contact-us/) ![](https://geninvo.com/wp-content/uploads/2021/03/laptop-apogi.png "laptop-apogi - GenInvo - GenInvo") --- ### [video-single](https://geninvo.com/?elementor_library=video-single) **Published:** March 22, 2021 **Author:** admin **Content:** ## GENINVO Videos [ Back ](https://geninvo.com/insights/videos/) DocQC is a standalone software-as-a-service application, also available in platform-as-a-service, or on-premise configurations. The accuracy and consistency of clinical trial documentation is key to successful submissions. With so many different source documents contributing to a single clinical study report, checking accuracy and traceability is mandatory. Manual document checking, particularly of embedded tables and listings, is particularly time consuming.. DocQC automates the checking of your submission document quality, saving valuable time for you to focus on the scientific integrity and regulatory compliance. This short video shows how DocQC can be integrated into your document quality control freeing you to concentrate on content. ###### More Videos [ ![Shadow for EU-CTR Compliance](https://geninvo.com/wp-content/uploads/2022/11/2022-11-29T20_55_50-300x168.png) ](https://geninvo.com/shadow-for-eu-ctr-compliance/) ## [Shadow for EU-CTR Compliance](https://geninvo.com/shadow-for-eu-ctr-compliance/) [ ![DocQC – Medical Writers automation tool for QC checks](https://geninvo.com/wp-content/uploads/2021/04/docqc-img-overlay-300x171.png) ](https://geninvo.com/docqc-medical-writers-automation-tool-for-qc-checks/) ## [DocQC – Medical Writers automation tool for QC checks](https://geninvo.com/docqc-medical-writers-automation-tool-for-qc-checks/) [ ![Shadow- Risk Analysis Tool](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-shadow-1-e1617726618274-300x168.jpg) ](https://geninvo.com/shadow-risk-analysis-tool/) ## [Shadow- Risk Analysis Tool](https://geninvo.com/shadow-risk-analysis-tool/) [ ![Shadow- Data Anonymization Tool](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-shadow-2-e1617726656616-300x144.jpg) ](https://geninvo.com/shadow-data-anonymization-tool/) ## [Shadow- Data Anonymization Tool](https://geninvo.com/shadow-data-anonymization-tool/) [ ![DocQc – Medical Writer’s Best Friend](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-docqc-300x210.jpg) ](https://geninvo.com/docqc-medical-writers-best-friend/) ## [DocQc – Medical Writer’s Best Friend](https://geninvo.com/docqc-medical-writers-best-friend/) [ ![GENINVO Anniversary](https://geninvo.com/wp-content/uploads/2021/04/overlay_annv-300x168.jpg) ](https://geninvo.com/geninvo-anniversary-2/) ## [GENINVO Anniversary](https://geninvo.com/geninvo-anniversary-2/) [ ![Shadow – Health Canada, France’s MR001-MR004, EMA Policy 0070 (Phase 1 and 2), compliant](https://geninvo.com/wp-content/uploads/2021/04/overlay_sh-300x168.jpg) ](https://geninvo.com/shadow-health-canada-frances-mr001-mr004-ema-policy-0070-phase-1-and-2-compliant/) ## [Shadow – Health Canada, France’s MR001-MR004, EMA Policy 0070 (Phase 1 and 2), compliant](https://geninvo.com/shadow-health-canada-frances-mr001-mr004-ema-policy-0070-phase-1-and-2-compliant/) [ ![Shadow – Solution to Evolving Data Transparency Requirements](https://geninvo.com/wp-content/uploads/2021/04/healthcanadapolicy-over-300x170.jpg) ](https://geninvo.com/shadow-solution-to-evolving-data-transparency-requirements/) ## [Shadow – Solution to Evolving Data Transparency Requirements](https://geninvo.com/shadow-solution-to-evolving-data-transparency-requirements/) [ ![Machine Learning – Shadow](https://geninvo.com/wp-content/uploads/2021/04/overlay_ml-300x168.jpg) ](https://geninvo.com/machine-learning-shadow/) ## [Machine Learning – Shadow](https://geninvo.com/machine-learning-shadow/) [ ![GENINVO – Covid-19](https://geninvo.com/wp-content/uploads/2021/04/covid-over-300x170.jpg) ](https://geninvo.com/geninvo-covid-19/) ## [GENINVO – Covid-19](https://geninvo.com/geninvo-covid-19/) [ ![Shadow](https://geninvo.com/wp-content/uploads/2021/04/shadow-over-300x170.jpg) ](https://geninvo.com/shadow-video/) ## [Shadow](https://geninvo.com/shadow-video/) [ ![ApoGI](https://geninvo.com/wp-content/uploads/2021/04/apogi-over-300x170.jpg) ](https://geninvo.com/apogi-video/) ## [ApoGI](https://geninvo.com/apogi-video/) [ ![DocQC](https://geninvo.com/wp-content/uploads/2021/04/docqc-over-300x170.jpg) ](https://geninvo.com/docqc-video/) ## [DocQC](https://geninvo.com/docqc-video/) [ ![GENINVO](https://geninvo.com/wp-content/uploads/2021/04/self_animation-300x169.jpg) ](https://geninvo.com/geninvo-video/) ## [GENINVO](https://geninvo.com/geninvo-video/) --- ### [dsa-menu](https://geninvo.com/?elementor_library=dsa-menu) **Published:** August 23, 2021 **Author:** admin **Content:** Content area --- ### [main-page](https://geninvo.com/?elementor_library=main-page) **Published:** February 14, 2022 **Author:** admin **Content:** OUR Products ## Experience our Product Portfolio All GENINVO products are scalable, secure, and customizable. Our industry-leading Life Science products also come with plug-and-play modules and off-the-shelf licensing for hassle-free deployment with existing infrastructure. [ ![Shadow - Data Anonymization Tool.](https://geninvo.com/wp-content/uploads/2021/03/shadow_logo-300x216.png "shadow_logo - GenInvo - GenInvo") ](https://geninvo.com/our-products/data-anonymization-tool/) ## [Data and Document Anonymization Solution](https://geninvo.com/our-products/data-anonymization-tool/) [ ![Medical Writers Automation Tool](https://geninvo.com/wp-content/uploads/2021/03/docqc_logo-e1631023185935.png "docqc_logo - GenInvo - GenInvo") ](https://geninvo.com/our-products/docqc-medical-writing-automation/) ## [Document QC Automation](https://geninvo.com/our-products/docqc-medical-writing-automation/) [ ![Metadata Management Tool](https://geninvo.com/wp-content/uploads/2021/03/metaworks_logo-300x209.png "metaworks_logo - GenInvo - GenInvo") ](https://geninvo.com/our-products/apogi/) ## [Next Generation Enterprise Platform](https://geninvo.com/our-products/apogi/) [ ![](https://geninvo.com/wp-content/uploads/2021/05/prod-logs-adc-e1621859458849.png "prod-logs-adc - GenInvo - GenInvo") ](https://geninvo.com/our-products/automation-of-data-conversion/) ## [Automation of Data Conversion](https://geninvo.com/our-products/automation-of-data-conversion/) ###### OUR SERVICES # Our Service Offerings Experience the GENINVO Difference with our services, tailored to meet your specific demands. We offer highly skilled, innovative, and adaptable teams who help our partners flourish and attain business success in a variety of industries. [ READ MORE ](https://geninvo.com/our-services/) ## Custom Application Development Expert teams, Personalized tools, and Processes – We deliver exactly what our customers need. [ ](https://geninvo.com/our-services/custom-application-development/) ## Anonymization As a Service We provide a variety of customized anonymization services to support global data sharing and transparency services, along with redaction and risk assessment options. [ ](https://geninvo.com/our-services/anonymization-as-a-service/) ## Talent Resource Hub Our Life Science SME and software and technology experts support solutions in a variety of areas including data visualization, custom software development, and more. [ ](https://geninvo.com/our-services/talent-resource-hub/) ## Cloud Managed Services In today’s dynamic environment, it is necessary to have a clear path to achieve the business outcomes you desire. [ ](https://geninvo.com/our-services/cloud-managed-services/) ![](https://geninvo.com/wp-content/uploads/2021/10/our-story.jpg "our-story - GenInvo - GenInvo") ![our-story-pic](https://geninvo.com/wp-content/uploads/2021/10/our-story-pic-e1634036208103.png "our-story-pic") ![](https://geninvo.com/wp-content/uploads/2021/10/our-story-cog.png "our-story-cog - GenInvo - GenInvo") ## [Learn about our Vision, Mission, and Leadership Team](https://geninvo.com/who-we-are/) Learn more about the group working toward bringing a technological revolution to the Life Sciences industry. [ READ MORE ](https://geninvo.com/who-we-are/) ## Join Us We always welcome the right talent. If AI/ML, NLP, Automation, Cloud and Big Data excite you, then GENINVO is the place for you! [ Find opportunities ](https://geninvo.com/work-with-us/) ![](https://geninvo.com/wp-content/uploads/2021/03/map-back-e1711595718989.jpg "map-back - GenInvo - GenInvo") [ **US HEAD OFFICE** 1408 East Empire Street 61701 Bloomington (Illinois) info@geninvo.com +1 309-807-5006 ](https://geninvo.com/contact-us/) [ **INDIA HEAD OFFICE** 6269/4, Nicholson Road, Ambala Cantt 13301, (Haryana) India info@geninvo.com 0171-26604-10 ](https://geninvo.com/contact-us/) [custom-twitter-feeds buttontextcolor="#ffffff" buttoncolor="#00393f"] --- ### [dsa-content-tab-viz](https://geninvo.com/?elementor_library=dsa-content-tab-viz) **Published:** September 9, 2021 **Author:** admin **Content:** ## Visualization We have an experienced team for generation of Data Visualization charts with use of latest tools such as SAS, R, Tableau, Spotfire, Qlik Sense, and Power-BI. --- ### [dsa-content-tab-chbot](https://geninvo.com/?elementor_library=dsa-content-tab-chbot) **Published:** September 9, 2021 **Author:** admin **Content:** ## Chatbot Development With our chatbot development services, you can offer customer support through human-like conversations to your customers, saving time and operational costs. --- ### [dsa-content-tab-re](https://geninvo.com/?elementor_library=dsa-content-tab-re) **Published:** August 10, 2021 **Author:** admin **Content:** ## Recommendation Engines Information systems that predict user preferences and presents product/item/service recommendations that are personalized and subjective. --- ### [case-studies-old](https://geninvo.com/?elementor_library=case-studies-old) **Published:** September 17, 2021 **Author:** admin **Content:** ## GENINVO Case Studies [ Back ](https://geninvo.com/insights/case-studies/) # case-studies-old ![Elementor-post-screenshot_7763_2022-08-02-10-29-02_7598bf68.png](https://geninvo.com/wp-content/uploads/elementor/screenshots/Elementor-post-screenshot_7763_2022-08-02-10-29-02_7598bf68.png) Download ###### Share Download ###### Share ###### More Case Studies [ ![White List & Black List: Enhanced NER Model](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-10-Case-Study-WB-List_v3-300x169.jpg) ](https://geninvo.com/white-list-black-list-enhanced-ner-model/) ## [White List & Black List: Enhanced NER Model](https://geninvo.com/white-list-black-list-enhanced-ner-model/) [ ![NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity-300x169.jpg) ](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) ## [NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) [ ![DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-12-Eprotocol-presentation-300x169.jpg) ](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) ## [DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) [ ![Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-13-Shadow-Recommendation-Engine-300x169.jpg) ](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) ## [Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) [ ![Lung Cancer Detection](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-8-Lung-Cancer-Detection-use-cases-300x169.jpg) ](https://geninvo.com/lung-cancer-detection/) ## [Lung Cancer Detection](https://geninvo.com/lung-cancer-detection/) [ ![Breast Cancer Detection Using Machine Learning](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-9-Case-Study-Breast-Cancer-Detection_v3-use-cases-300x169.jpg) ](https://geninvo.com/breast-cancer-detection-using-machine-learning/) ## [Breast Cancer Detection Using Machine Learning](https://geninvo.com/breast-cancer-detection-using-machine-learning/) [ ![Doc QC tool as a one-stop solution for all Quality Control (QC) needs of a medical writer](https://geninvo.com/wp-content/uploads/2021/08/Case-Studies-8-DocQC-300x169.jpg) ](https://geninvo.com/doc-qc-tool-as-a-one-stop-solution-for-all-quality-control-qc-needs-of-a-medical-writer/) ## [Doc QC tool as a one-stop solution for all Quality Control (QC) needs of a medical writer](https://geninvo.com/doc-qc-tool-as-a-one-stop-solution-for-all-quality-control-qc-needs-of-a-medical-writer/) [ ![Provide ApoGI as a Metadata Driven Platform](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-7-300x169.jpg) ](https://geninvo.com/provide-apogitmas-a-metadatadriven-platform/) ## [Provide ApoGI as a Metadata Driven Platform](https://geninvo.com/provide-apogitmas-a-metadatadriven-platform/) [ ![Provide ApoGI as a MDR Visualization](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-6-300x169.jpg) ](https://geninvo.com/provide-apogitmas-a-mdrvisualization/) ## [Provide ApoGI as a MDR Visualization](https://geninvo.com/provide-apogitmas-a-mdrvisualization/) [ ![Provide ApoGI as a Metadata Driven Transformations](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-5-300x169.jpg) ](https://geninvo.com/provide-apogitm-asa-metadata-driventransformations/) ## [Provide ApoGI as a Metadata Driven Transformations](https://geninvo.com/provide-apogitm-asa-metadata-driventransformations/) [ ![How a Big Pharma Company Achieved Compliance with Health Canada Under Tight Deadlines](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-4-300x169.jpg) ](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-health-canada-under-tight-deadlines/) ## [How a Big Pharma Company Achieved Compliance with Health Canada Under Tight Deadlines](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-health-canada-under-tight-deadlines/) [ ![How a Pharmaceutical Firm Established Anonymization Process](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-3-300x169.jpg) ](https://geninvo.com/how-a-pharmaceutical-firm-established-anonymization-process/) ## [How a Pharmaceutical Firm Established Anonymization Process](https://geninvo.com/how-a-pharmaceutical-firm-established-anonymization-process/) [ ![Big Pharma Company Achieves Compliance with EMA 0070 Policy](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-2-300x169.jpg) ](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-ema-0070-policy-with-a-tight-deadline/) ## [Big Pharma Company Achieves Compliance with EMA 0070 Policy](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-ema-0070-policy-with-a-tight-deadline/) [ ![How a Global Medical Writing CRO Increased Functional Capability with Shadow™](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-1-300x169.jpg) ](https://geninvo.com/how-a-global-medical-writing-cro-increased-functional-capability-with-shadowtm/) ## [How a Global Medical Writing CRO Increased Functional Capability with Shadow™](https://geninvo.com/how-a-global-medical-writing-cro-increased-functional-capability-with-shadowtm/) --- ### [cases-single](https://geninvo.com/?elementor_library=cases-single) **Published:** March 26, 2021 **Author:** admin **Content:** ## GENINVO Case Studies [ Back ](#) # cases-single ![Untitled-1sk-pdf](https://geninvo.com/wp-content/uploads/2021/03/Untitled-1sk-pdf.svg) ![Elementor-post-screenshot_3079_2022-05-26-11-09-11_9a20a94.png](https://geninvo.com/wp-content/uploads/elementor/screenshots/Elementor-post-screenshot_3079_2022-05-26-11-09-11_9a20a94.png) Download ###### Share ###### More Case Studies [ ![White List & Black List: Enhanced NER Model](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-10-Case-Study-WB-List_v3-300x169.jpg) ](https://geninvo.com/white-list-black-list-enhanced-ner-model/) ## [White List & Black List: Enhanced NER Model](https://geninvo.com/white-list-black-list-enhanced-ner-model/) [ ![NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity-300x169.jpg) ](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) ## [NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) [ ![DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-12-Eprotocol-presentation-300x169.jpg) ](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) ## [DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) [ ![Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-13-Shadow-Recommendation-Engine-300x169.jpg) ](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) ## [Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) [ ![Lung Cancer Detection](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-8-Lung-Cancer-Detection-use-cases-300x169.jpg) ](https://geninvo.com/lung-cancer-detection/) ## [Lung Cancer Detection](https://geninvo.com/lung-cancer-detection/) [ ![Breast Cancer Detection Using Machine Learning](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-9-Case-Study-Breast-Cancer-Detection_v3-use-cases-300x169.jpg) ](https://geninvo.com/breast-cancer-detection-using-machine-learning/) ## [Breast Cancer Detection Using Machine Learning](https://geninvo.com/breast-cancer-detection-using-machine-learning/) [ ![Doc QC tool as a one-stop solution for all Quality Control (QC) needs of a medical writer](https://geninvo.com/wp-content/uploads/2021/08/Case-Studies-8-DocQC-300x169.jpg) ](https://geninvo.com/doc-qc-tool-as-a-one-stop-solution-for-all-quality-control-qc-needs-of-a-medical-writer/) ## [Doc QC tool as a one-stop solution for all Quality Control (QC) needs of a medical writer](https://geninvo.com/doc-qc-tool-as-a-one-stop-solution-for-all-quality-control-qc-needs-of-a-medical-writer/) [ ![Provide ApoGI as a Metadata Driven Platform](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-7-300x169.jpg) ](https://geninvo.com/provide-apogitmas-a-metadatadriven-platform/) ## [Provide ApoGI as a Metadata Driven Platform](https://geninvo.com/provide-apogitmas-a-metadatadriven-platform/) [ ![Provide ApoGI as a MDR Visualization](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-6-300x169.jpg) ](https://geninvo.com/provide-apogitmas-a-mdrvisualization/) ## [Provide ApoGI as a MDR Visualization](https://geninvo.com/provide-apogitmas-a-mdrvisualization/) [ ![Provide ApoGI as a Metadata Driven Transformations](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-5-300x169.jpg) ](https://geninvo.com/provide-apogitm-asa-metadata-driventransformations/) ## [Provide ApoGI as a Metadata Driven Transformations](https://geninvo.com/provide-apogitm-asa-metadata-driventransformations/) [ ![How a Big Pharma Company Achieved Compliance with Health Canada Under Tight Deadlines](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-4-300x169.jpg) ](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-health-canada-under-tight-deadlines/) ## [How a Big Pharma Company Achieved Compliance with Health Canada Under Tight Deadlines](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-health-canada-under-tight-deadlines/) [ ![How a Pharmaceutical Firm Established Anonymization Process](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-3-300x169.jpg) ](https://geninvo.com/how-a-pharmaceutical-firm-established-anonymization-process/) ## [How a Pharmaceutical Firm Established Anonymization Process](https://geninvo.com/how-a-pharmaceutical-firm-established-anonymization-process/) [ ![Big Pharma Company Achieves Compliance with EMA 0070 Policy](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-2-300x169.jpg) ](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-ema-0070-policy-with-a-tight-deadline/) ## [Big Pharma Company Achieves Compliance with EMA 0070 Policy](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-ema-0070-policy-with-a-tight-deadline/) [ ![How a Global Medical Writing CRO Increased Functional Capability with Shadow™](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-1-300x169.jpg) ](https://geninvo.com/how-a-global-medical-writing-cro-increased-functional-capability-with-shadowtm/) ## [How a Global Medical Writing CRO Increased Functional Capability with Shadow™](https://geninvo.com/how-a-global-medical-writing-cro-increased-functional-capability-with-shadowtm/) --- ### [sustainable_goals](https://geninvo.com/?elementor_library=sustainable_goals) **Published:** September 21, 2021 **Author:** admin **Content:** ### End poverty in all its forms everywhere ### End hunger, achieve food security and improved nutrition and promote sustainable agriculture ### Ensure healthy lives and promote well-being for all at all ages --- ### [policies-site](https://geninvo.com/?elementor_library=policies-site) **Published:** September 21, 2021 **Author:** admin **Content:** ## Geninvo Privacy Policy [ Contact us ](https://geninvo.com/contact-us/) ![Geninvo Privacy Policy](https://geninvo.com/wp-content/uploads/2021/04/GenInvo-Privacy-Policy.png "GenInvo-Privacy-Policy - GenInvo - GenInvo") GenInvo understands the importance of protecting the privacy rights of individuals. This document explains the basic details of our data privacy policy, and how it is implemented at GenInvo. It explains the following: - How and What information may be collected and stored - How we use that information - How we protect that information - Whom to contact if there are any questions concerning data privacy and protection at GenInvo ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ## Topics in this Policy GENINVO provides anonymization services for variety of anonymisation needs including the following: [ ](#top-section) - [Policy](#policy) - [What and how we collect Personal Information](#howwecollect) - [Our use of Cookies](#cookies) - [How we use your Personal Information](#usepersonalinformation) - [How we protect your Personal Information](#protectpersonalinformation) - [Consent and Access](#consentandaccess) - [Your Rights](#yourrights) - [Notification of Changes Contact Information](#notificationofchanges) - [Policy](#policy) - [What and how we collect Personal Information](#howwecollect) - [Our use of Cookies](#cookies) - [How we use your Personal Information](#usepersonalinformation) - [How we protect your Personal Information](#protectpersonalinformation) - [Consent and Access](#consentandaccess) - [Your Rights](#yourrights) - [Notification of Changes Contact Information](#notificationofchanges) ## **Policy** The GenInvo Privacy and related policies ensure that the processing of Personal Information by GenInvo as part of our business and service offerings is collected, stored and used in compliance with all applicable laws and regulations. “Personal Information” is any Information relating to an identified or identifiable natural person. The policy applies to all situations where Personal Information is collected, stored and processed by GenInvo: - For its own business use (primarily marketing), - To support business operations (e.g. contractual arrangements, administrative functions), and - To comply with all privacy regulations when providing software, services and support to our customers ## **What and How we collect Personal Information** Our websites collect a range of general Information and data when in use. This includes browser types, operating system details, IP addresses, clickstream details for the pages you visit, etc., in order to both enhance your experience on the site and to ensure the security and integrity of our IT infrastructure. Our websites offer the opportunity to register interest in GenInvo products and services. Personal Information is captured from our website when you participate in any of the following activities: - Registering on our site - Subscribing to a newsletter - Responding to a survey - Filling out a form - Providing feedback on our products or services - Signing up for a webinar - Attending a webinar The Personal Information we collect from you will depend on which activity you are using in the list above and may include your: - Name - Title - Company name - Address - Phone number(s) - Email address This information is stored and processed only for the purpose for which it was collected ## **Our use of cookies** Cookies are small files that a site or its service provider transfers to your computer’s hard drive through your web browser (if you allow) that enables the site’s or service provider’s systems to recognize your browser and capture and remember certain Information. We use cookies to: - Keep track of advertisements, and - Compile aggregate data (not Personal Information) about our site traffic and site interactions in order to offer better site experiences and tools in the future. - We may also use trusted third-party services that track this Information on our behalf. You can choose to have your computer warn you each time a cookie is being sent, or you can choose to turn off all cookies. You do this through your browser settings. Since each browser is a little different, look at your browser’s Help Menu to learn the correct way to modify your cookies. If you turn cookies off, it will not prevent you from using our website. ## **How we use your Personal Information** When you provide us with Personal Information, it is stored in secure databases and may be used for: - Sending newsletters - Sending notices about upcoming webinars, - Contacting you when submitting your Information for employment opportunities, - Including you in marketing campaigns and sending promotional materials of interest, and - Sending you emails of surveys. ## **How we protect your Personal Information** As GenInvo is a global company, we process and store Personal Information using secure cloud-based products and services which may or may not be located within your country. GenInvo securely collects and transfers your Personal Information using encrypted processes. GenInvo stores your Personal Information using products provided by companies that have privacy and security management certifications. Your Personal Information is only accessible by a limited number of GenInvo persons whose access is controlled through unique user IDs and password-protected accounts. Personal Information is only stored for the period necessary to achieve the purpose for which the data was provided, and to comply with legal or statutory requirements. GenInvo is both a Data Controller and a Data Processor of Personal Information depending on the detailed circumstances for which it was collected. ## **Consent and access** Each time you provide Personal Information via our website or attend one of our webinars, you will be presented with a list of opt-in selections. By selecting a given opt-in selection, you are consenting to the collection the Personal Information being collected, and the use of that data described above. You may unsubscribe at any time by clicking the unsubscribe link in the footer of all marketing communication emails or by mailing [privacy@geninvo.com](mailto:info@geninvo.com). ## **Your rights** As an individual whose Personal Information has been collected and stored by our site, you may at any time: - Request confirmation as to how your Personal Information is being processed - Request copies of the Personal Information we hold as a company - Request your Personal Information be updated, corrected or blocked from further processing - Request deletion of your Personal Information - Restrict the reasons for processing your Personal Information - Receive the Personal Information we hold in common computer-readable form - Request your Personal Information is not used to make automated decisions about you - Withdraw consent to the processing of your Personal Information **Requests for the above can be submitted by email to** [**privacy@geninvo.com**](mailto:privacy@geninvo.com) **or by mail to the address below.** We have a defined process for the privacy and confidential data breach, and you can query or provide feedback to us at privacy@geninvo.com about your any dissatisfaction regarding your rights management or confidentiality violation. You have the right to complain to a Data Protection Authority/Supervisory Authority about Our collection and use of Your Personal Data. For example, if You are in the European Economic Area (EEA), please contact Your local data protection authority in the EEA. ## **Notification of changes** We keep our Privacy Policy under regular review, and we will place any updates on this web page. ## **Contact information** If you have any questions regarding our Privacy Policy, you can contact our Data Privacy Officer at [dpo@geninvo.com](mailto:info@geninvo.com) or write to us at: GenInvo, Inc1408 East Empire Street Bloomington, Illinois 61701, USA --- ### [dsa-apogi-tab-content-02](https://geninvo.com/?elementor_library=dsa-apogi-tab-content-02) **Published:** September 2, 2021 **Author:** admin **Content:** [ Download ](#) --- ### [dsa-content-tab-dl](https://geninvo.com/?elementor_library=dsa-content-tab-dl) **Published:** September 9, 2021 **Author:** admin **Content:** ## Deep Learning From labeling, training dataset assessment, and image processing, to custom deep learning pipelines, GenInvo Scientific develops deep learning for video/Image analytics, anomaly detection, and automation solutions in life science. --- ### [dsa-content-tab-ml](https://geninvo.com/?elementor_library=dsa-content-tab-ml) **Published:** August 10, 2021 **Author:** admin **Content:** ## Machine Learning By partnering with GenInvo’s Machine Learning expert team, you can build a system that helps you make better business decisions. ML techniques are revolutionizing clinical development, delivering time and cost savings and providing better insights to inform better decisions. --- ### [dsa-content-tab-nlp](https://geninvo.com/?elementor_library=dsa-content-tab) **Published:** August 10, 2021 **Author:** admin **Content:** ## Natural Language Processing Utilize natural language processing pipelines powered by deep learning to extract meaning and insights from unstructured text, voice, and audio. --- ### [DSandA](https://geninvo.com/?elementor_library=dsanda) **Published:** September 8, 2021 **Author:** admin **Content:** Machine Learning GenInvo Machine Learning expert team helps in creating a system that can assist you with critical business decisions. [View More](#machl) Why DS&A-CoE? The DS&A -COE is the GenInvo pillar and go-to place for AI [View More](#dsa-coe) Case Studies Learn how our products and services are solving business problems across industries​ [View More](#casestudies) [ ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjY3MzUiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D) Technologies at DS&A-CoE ## Generate better Insights with Cutting-edge Technologies - Machine Learning - Recommendation Engine - Natural Language Processing - Image Processing ## Machine Learning By partnering with GenInvo’s Machine Learning expert team, you can build a system that helps you make better business decisions. ML techniques are revolutionizing clinical development, delivering time and cost savings and providing better insights to inform better decisions. ## Recommendation Engines Information systems that predict user preferences and presents product/item/service recommendations that are personalized and subjective. ## Natural Language Processing Utilize natural language processing pipelines powered by deep learning to extract meaning and insights from unstructured text, voice, and audio. ## Recommendation Engines Our image processing services are meant to optimize production environments for Computer Vision , scale-up your Spatial Data Processing operations, and deploy solutions to the cloud or to the edge. Why DS&A-CoE? ## Our aim to accelerate discoveries and the development of life sciences across the worldwide using AI/ML. - Boost Innovation - Increase Efficiency & Discover Insights Faster - Mitigate Risks The DS&A -COE is the GenInvo pillar and go-to place for AI. Our aim to accelerate discoveries and the development of life sciences across the worldwide using AI/ML. Our experienced and highly skilled business strategists, life science experts, data scientist’s and others understand tide of AI. We can assist in designing and implementing customized strategies to help traverse your business through a swift transition. Enables life sciences organizations to reduce time, eliminate data & process redundancies, minimize costs, wastages, and outflows. Enables you to drive efficiency in the business processes by delivering results in near real time, select the right target audience, and automatically classify and mine text for key insights. Real time results have made insight discovery faster than ever before. AI/ML generated results are more accurate and freer of any human induced errors or biases. AI where computer algorithms improve over time through their experience of using data – plays an increasingly prominent role in enterprise risk management. We create sophisticated tools to monitor and analyze behavior and activities in real time. Case studies ## Learn how our products and services are solving business problems across industries [ ![Building a Strong Foundation: Robust Metadata Repository (MDR) Framework for Automated Standard Compliant Data Mapping](https://geninvo.com/wp-content/uploads/2023/12/Building-a-Strong-Foundation-300x169.png) ](https://geninvo.com/building-a-strong-foundation-robust-metadata-repository-mdr-framework-for-automated-standard-compliant-data-mapping/) ## [Building a Strong Foundation: Robust Metadata Repository (MDR) Framework for Automated Standard Compliant Data Mapping](https://geninvo.com/building-a-strong-foundation-robust-metadata-repository-mdr-framework-for-automated-standard-compliant-data-mapping/) [ ![Importance of “Table, Listing and Figures” Automation in Clinical Trials](https://geninvo.com/wp-content/uploads/2023/12/acl-v1-300x169.jpg) ](https://geninvo.com/importance-of-table-listing-and-figures-automation-in-clinical-trials/) ## [Importance of “Table, Listing and Figures” Automation in Clinical Trials](https://geninvo.com/importance-of-table-listing-and-figures-automation-in-clinical-trials/) [ ![White List & Black List: Enhanced NER Model](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-10-Case-Study-WB-List_v3-300x169.jpg) ](https://geninvo.com/white-list-black-list-enhanced-ner-model/) ## [White List & Black List: Enhanced NER Model](https://geninvo.com/white-list-black-list-enhanced-ner-model/) [ ![NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity-300x169.jpg) ](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) ## [NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) [ ![DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-12-Eprotocol-presentation-300x169.jpg) ](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) ## [DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) [ ![Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-13-Shadow-Recommendation-Engine-300x169.jpg) ](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) ## [Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) [ ![Lung Cancer Detection](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-8-Lung-Cancer-Detection-use-cases-300x169.jpg) ](https://geninvo.com/lung-cancer-detection/) ## [Lung Cancer Detection](https://geninvo.com/lung-cancer-detection/) [ ![Breast Cancer Detection Using Machine Learning](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-9-Case-Study-Breast-Cancer-Detection_v3-use-cases-300x169.jpg) ](https://geninvo.com/breast-cancer-detection-using-machine-learning/) ## [Breast Cancer Detection Using Machine Learning](https://geninvo.com/breast-cancer-detection-using-machine-learning/) [ ![Provide ApoGI as a Metadata Driven Transformations](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-5-300x169.jpg) ](https://geninvo.com/provide-apogitm-asa-metadata-driventransformations/) ## [Provide ApoGI as a Metadata Driven Transformations](https://geninvo.com/provide-apogitm-asa-metadata-driventransformations/) [ ![Provide ApoGI as a MDR Visualization](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-6-300x169.jpg) ](https://geninvo.com/provide-apogitmas-a-mdrvisualization/) ## [Provide ApoGI as a MDR Visualization](https://geninvo.com/provide-apogitmas-a-mdrvisualization/) [ ![Provide ApoGI as a Metadata Driven Platform](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-7-300x169.jpg) ](https://geninvo.com/provide-apogitmas-a-metadatadriven-platform/) ## [Provide ApoGI as a Metadata Driven Platform](https://geninvo.com/provide-apogitmas-a-metadatadriven-platform/) Building Solutions ## Using AI/ML techniques, currently our experts are working on to build solutions from scratch ![](https://geninvo.com/wp-content/uploads/2021/08/bs-icons-01.jpg "bs-icons-01 - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/08/bs-icons-02.jpg "bs-icons-02 - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/08/bs-icons-03.jpg "bs-icons-03 - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/08/bs-icons-04.jpg "bs-icons-04 - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/08/bs-icons-07.jpg "bs-icons-07 - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/08/bs-icons-06.jpg "bs-icons-06 - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/08/bs-icons-05.jpg "bs-icons-05 - GenInvo - GenInvo") --- ### [geninvo-error-page](https://geninvo.com/?elementor_library=geninvo-error-page) **Published:** April 7, 2021 **Author:** admin **Content:** 404 ### Page not found ### Here are some useful links: - [ApoGI](https://geninvo.com/our-products/apogi/) - [ApoGI-DT™](https://geninvo.com/our-products/apogi-dt/) - [Shadow](https://geninvo.com/our-products/data-anonymization-tool/) - [DocQC](https://geninvo.com/our-products/docqc-medical-writing-automation/) - [DocWrightAI](https://geninvo.com/our-products/docwrightai-document-generation-software/) - [Datalution](https://geninvo.com/our-products/datalution/) - [Automation of Data Conversion](https://geninvo.com/our-products/automation-of-data-conversion/) - [ApoGI](https://geninvo.com/our-products/apogi/) - [ApoGI-DT™](https://geninvo.com/our-products/apogi-dt/) - [Shadow](https://geninvo.com/our-products/data-anonymization-tool/) - [DocQC](https://geninvo.com/our-products/docqc-medical-writing-automation/) - [DocWrightAI](https://geninvo.com/our-products/docwrightai-document-generation-software/) - [Datalution](https://geninvo.com/our-products/datalution/) - [Automation of Data Conversion](https://geninvo.com/our-products/automation-of-data-conversion/) - [Innovation As a Service](https://geninvo.com/our-services/innovation-as-a-service/) - [Anonymization As a Service](https://geninvo.com/our-services/anonymization-as-a-service/) - [Custom Application Development](https://geninvo.com/our-services/custom-application-development/) - [Collaborative Innovation](https://geninvo.com/our-services/collaborative-innovation/) - [Data Science CoE](https://geninvo.com/our-services/dsa/) - [Cloud Managed Services](https://geninvo.com/our-services/cloud-managed-services/) - [Resource Hub​](https://geninvo.com/our-services/talent-resource-hub/) - [Innovation As a Service](https://geninvo.com/our-services/innovation-as-a-service/) - [Anonymization As a Service](https://geninvo.com/our-services/anonymization-as-a-service/) - [Custom Application Development](https://geninvo.com/our-services/custom-application-development/) - [Collaborative Innovation](https://geninvo.com/our-services/collaborative-innovation/) - [Data Science CoE](https://geninvo.com/our-services/dsa/) - [Cloud Managed Services](https://geninvo.com/our-services/cloud-managed-services/) - [Resource Hub​](https://geninvo.com/our-services/talent-resource-hub/) --- ### [search-results-page](https://geninvo.com/?elementor_library=search-results-page) **Published:** April 7, 2021 **Author:** admin **Content:** ## GENINVO [ Back ](https://geninvo.com/insights/) #### Template: search-results-page ### [ Meet GenInvo at DPHARM 2026, Booth 116, Boston ](https://geninvo.com/dpharm-2026/) Advancing Clinical Research Innovation | DPHARM 2026 | September 15–16, 2026 | Sheraton Boston Hotel Geninvo is exhibiting at DPHARM 2026 the industry’s premier conference [ Read More » ](https://geninvo.com/dpharm-2026/) ### [ CodeMagic ](https://geninvo.com/codemagic/) CodeMagic AI-Assisted Code Generation for Statistical Programming CodeMagic is Geninvo’s AI statistical programming automation platform. It converts your ADaM specifications and TLF mock shells into [ Read More » ](https://geninvo.com/codemagic/) ### [ Meet GENINVO at the EMWA 61st Spring Conference 2026 ](https://geninvo.com/emwa-2026-barcelona/) Barcelona is calling! As the medical writing landscape shifts toward an AI-integrated future, Geninvo is proud to be at the forefront as a sponsor and [ Read More » ](https://geninvo.com/emwa-2026-barcelona/) ### [ Thank You! ](https://geninvo.com/thank-you/) Thank You for Reaching Out! We’ve received your message and our team is already reviewing it. Explore Our Products [ Read More » ](https://geninvo.com/thank-you/) ### [ GenInvo at PharmaSUG 2026 SDE Conference ](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) Proud Bronze Sponsor GenInvo is proud to announce its participation as a Bronze Sponsor at the PharmaSUG 2026 SDE Conference a premier event bringing together [ Read More » ](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) ### [ GenInvo @ PHUSE US Connect 2026 ](https://geninvo.com/geninvo-phuse-us-connect-2026/) Join us in Austin! GenInvo is headed to Texas for PHUSE US Connect 2026. As industry innovators, we’re excited to share our expertise and present [ Read More » ](https://geninvo.com/geninvo-phuse-us-connect-2026/) ### [ Product Adoption Specialist ](https://geninvo.com/product-adoption-specialist/) Title: Product Adoption Specialist Experience: 8+ years Location: Remote (Anywhere in US) Job Type: Full time The role covers value realization management, change management, and may [ Read More » ](https://geninvo.com/product-adoption-specialist/) ### [ Senior/Lead Analyst – DevOps ](https://geninvo.com/senior-lead-analyst-devops/) Job Summary We are looking for an experienced Senior / Lead DevOps Engineer to design, implement, and manage robust CI/CD pipelines and cloud-native infrastructure. The ideal candidate [ Read More » ](https://geninvo.com/senior-lead-analyst-devops/) ### [ Senior Analyst / Lead – Google Cloud Development ](https://geninvo.com/senior-analyst-lead-google-cloud-development/) An immediate joiner will be preferred We are seeking a highly experienced Google Cloud Developer with strong expertise in GEN AI technologies. The ideal candidate will have 10+ years [ Read More » ](https://geninvo.com/senior-analyst-lead-google-cloud-development/) ### [ Head / Associate / Senior Director – Product Adoption ](https://geninvo.com/head-associate-senior-director-product-adoption/) Position Overview:Accelerate time-to-value and maximize ROI by driving seamless adoption of our solutions for clients, upskilling internal teams delivering services, and leading a specialist function [ Read More » ](https://geninvo.com/head-associate-senior-director-product-adoption/) « PreviousPage1[Page2](https://geninvo.com/?elementor_library=search-results-page%2F2%2F&doing_wp_cron=1783869150.2234899997711181640625)[Page3](https://geninvo.com/?elementor_library=search-results-page%2F3%2F&doing_wp_cron=1783869150.2234899997711181640625)[Page4](https://geninvo.com/?elementor_library=search-results-page%2F4%2F&doing_wp_cron=1783869150.2234899997711181640625)[Page5](https://geninvo.com/?elementor_library=search-results-page%2F5%2F&doing_wp_cron=1783869150.2234899997711181640625)[Next »](https://geninvo.com/?elementor_library=search-results-page/2/) --- ### [Insights](https://geninvo.com/?elementor_library=insights) **Published:** March 22, 2021 **Author:** admin **Content:** ## Geninvo Insights Your Solution to Evolving Data Transparency Requirements ![](https://geninvo.com/wp-content/uploads/2021/03/insights-top.jpg) --- ### [events-archive](https://geninvo.com/?elementor_library=events-archive) **Published:** March 24, 2021 **Author:** admin **Content:** ## Events Your Solution to Evolving Data Transparency Requirements [ View Brochure ](#) [ ![Geninvo at Dpharm 2026 Banner: Sept 15–16, 2026 in Boston, Usa; Sheraton Boston Hotel Exhibition Booth #116.](https://geninvo.com/wp-content/uploads/2026/06/DPHARM-1.png "Meet Geninvo at DPHARM 2026 — Booth 116, Boston - GenInvo - GenInvo") ](https://geninvo.com/dpharm-2026/) ###### [Meet GenInvo at DPHARM 2026, Booth 116, Boston](https://geninvo.com/dpharm-2026/) [ Read More ](https://geninvo.com/dpharm-2026/) [ ![Geninvo Booth 10 at Emwa 61st Spring Conference 2026 Barcelona.](https://geninvo.com/wp-content/uploads/2026/04/539-X-334-1.png "539 X 334 1 - GenInvo - GenInvo") ](https://geninvo.com/emwa-2026-barcelona/) ###### [Meet GENINVO at the EMWA 61st Spring Conference 2026](https://geninvo.com/emwa-2026-barcelona/) [ Read More ](https://geninvo.com/emwa-2026-barcelona/) [ ![](https://geninvo.com/wp-content/uploads/2026/04/539-X-334.png "539 X 334 - GenInvo - GenInvo") ](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) ###### [GenInvo at PharmaSUG 2026 SDE Conference](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) [ Read More ](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) [ ![](https://geninvo.com/wp-content/uploads/2026/03/image-16.png "image (16) - GenInvo - GenInvo") ](https://geninvo.com/geninvo-phuse-us-connect-2026/) ###### [GenInvo @ PHUSE US Connect 2026](https://geninvo.com/geninvo-phuse-us-connect-2026/) [ Read More ](https://geninvo.com/geninvo-phuse-us-connect-2026/) [ ![](https://geninvo.com/wp-content/uploads/2025/08/Blog-9.jpg "Blog-9 - GenInvo - GenInvo") ](https://geninvo.com/live-webinar-accelerating-authoring-and-qc-of-clinical-documents-with-ai-powered-automation/) ###### [Live Webinar: Accelerating Authoring and QC of Clinical Documents with AI-Powered Automation](https://geninvo.com/live-webinar-accelerating-authoring-and-qc-of-clinical-documents-with-ai-powered-automation/) [ Read More ](https://geninvo.com/live-webinar-accelerating-authoring-and-qc-of-clinical-documents-with-ai-powered-automation/) « PreviousPage1[Page2](https://geninvo.com/?elementor_library=events-archive%2F2%2F&doing_wp_cron=1783869150.2234899997711181640625)[Page3](https://geninvo.com/?elementor_library=events-archive%2F3%2F&doing_wp_cron=1783869150.2234899997711181640625)[Page4](https://geninvo.com/?elementor_library=events-archive%2F4%2F&doing_wp_cron=1783869150.2234899997711181640625)[Page5](https://geninvo.com/?elementor_library=events-archive%2F5%2F&doing_wp_cron=1783869150.2234899997711181640625)[Next »](https://geninvo.com/?elementor_library=events-archive/2/) --- ### [top-banner](https://geninvo.com/?elementor_library=top-banner) **Published:** March 22, 2021 **Author:** admin **Content:** ## Shadow™ Your Solution to Evolving Data Transparency Requirements [ View Brochure ](#) Shadow™ is a leader in automating Data and Document De-Identification and Anonymization technology. Built from the ground up by the innovative team at GenInvo, a team comprised of both life sciences and software development professionals committed to producing innovative and long-standing solutions that allow you to focus on innovative science and results. Shadow™ alleviates the pain points of homegrown software utilities that often prove to be inefficient, difficult to maintain, and slow to match quickly evolving requirements. ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ## Key Features Shadow™ is a fully featured, Health Canada, France’s MR001-MR004, EMA Policy 0070 (Phase 1 and 2) compliant solution \+ Data (and Document) De-Identification and Anonymization Workflow component \+ Risk Analysis Tools: Ability to determine risk for re-identification \+ Tools to determine data utility after de-ID \+ Ability to generate Redaction Proposal \+ Ability to generate Anonymization Plan # Key Benefits Shadow™ is a fully featured, Health Canada, France’s MR001-MR004, EMA Policy 0070 (Phase 1 and 2) compliant solution - Ability to store/Apply De-ID strategies in metadata repository at Global, TA, Compound, Study, and Project Levels - Ability to interactively Apply/Test Data and Doc Rules - Dual-frame before-n-after views of data and documents during de-ID process - Performance Metrics: evaluate precision/efficiency of strategy application and effectiveness of the de-ID teams/personnel - Health Canada, France’s MR001-MR004, EMA Policy 0070 (Phase 1 and 2), compliant [ Request Demo ](#) ![](https://geninvo.com/wp-content/uploads/2021/03/laptop-shadow.png "laptop-shadow - GenInvo - GenInvo") ## The Latest Industry Breakthrough Looking to enhance your organization’s impact? GenInvo’s technology-empowered experts are available to assist you in the following areas: ##### Data + Document Anonymization Shadow™ is a comprehensive solution to address the evolving landscape for data and/or document de-identification and anonymization ##### Anonymization Reports Reports to help drive, describe and monitor your anonymization project and the effectiveness of your teams. ##### Risk Analysis Determine the risk for re-identification of your data before and after de-identification to ensure you meet required thresholds. ##### Cutting Edge Solution Built from the ground up by the innovative time at GenInvo, a team comprised of both Life Sciences and software development professionals ##### Dynamic Strategy Repository Leverage the software’s “canned” (predefined) de-identification strategies for CDISC SDTM and ADaM along with those you develop to support your own data and document standards ##### Process Workflows​ Get right to work, or let Shadow™ guide you and your project team members through de-identification, review/approval and anonymization ##### Real-time Results See the effects of your de-identification strategies as you apply them so that you can determine and tailor their effectiveness ##### Data Utility Evaluate the impact of your applied de-identification strategies to ensure consumers’ ability to reproduce analyses ##### Performance Metrics Evaluate precision/efficiency of strategy application and effectiveness of the de-ID teams/personnel --- ### [product-page](https://geninvo.com/?elementor_library=product-page) **Published:** March 19, 2021 **Author:** admin **Content:** ## Shadow™ Your Solution to Evolving Data Transparency Requirements [ View Brochure ](#) ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ## Key Features Shadow™ is a fully featured, Health Canada, France’s MR001-MR004, EMA Policy 0070 (Phase 1 and 2) compliant solution \+ Data (and Document) De-Identification and Anonymization Workflow component \+ Risk Analysis Tools: Ability to determine risk for re-identification \+ Tools to determine data utility after de-ID \+ Ability to generate Redaction Proposal \+ Ability to generate Anonymization Plan --- ### [news-single](https://geninvo.com/?elementor_library=news-single) **Published:** March 22, 2021 **Author:** admin **Content:** ## GENINVO News [ Back ](https://geninvo.com/insights/news/) - March 22, 2021 #### news-single GENINVO Senior Innovation Officer, Tom Kalfas, announced the launch of Shadow™ Version 2. He said, “On behalf of GENINVO and our Innovative Solutions Team, I am very excited to announce the launch of the second major release of Shadow, our data transparency solution.” Since its first release, Shadow has already become an industry-leading software innovation, automating the anonymization of clinical trial data and documents in support of global data transparency initiatives, such as EMA Policy 0070 and Health Canada’s PRCI (Public Release of Clinical Information). In the second generation, we introduced several new time and cost-saving efficiencies to streamline the anonymization process further for our users. We also introduced new key capabilities such as “Auto RA,” a data-driven method for quickly determining the most effective combination of anonymization methods to apply and a CCI Justification Table generator (supporting both EMA and Health Canada formats) to complete the anonymization package for our users. With leading-edge technologies, including AI and ML, Shadow 2 was designed to become increasingly more intelligent and easier to use based on the feedback of its user community. Shadow enhances the speed and efficiency of anonymization activity by reducing manual intervention and minimizing the risk of patient reidentification while maintaining data utility. Shadow addresses the evolving global data transparency requirements, allowing its users and their teams to focus on innovative science and results. While we are all quite proud of the what the team has achieved, we are even more excited about the opportunities this new design makes possible and the innovations already in progress to support additional anonymization use cases and next-gen capabilities. GENINVO has other technologies including DocQC™ for automated QC of documents and ApoGI, a platform for managing data and metadata while interacting with different functions in pharmaceuticals. GENINVO will continue to enable and support our clients in their journey, working collaboratively to understand the needs of their systems, processes, and current challenges within the Life Sciences industry. ###### More News [ ![GENINVO Launches Centre of Excellence for Data Science and Analytics](https://geninvo.com/wp-content/uploads/2021/11/dsa-coe-300x170.jpg) ](https://geninvo.com/geninvo-launches-centre-of-excellence-for-data-science-and-analytics/) ## [GENINVO Launches Centre of Excellence for Data Science and Analytics](https://geninvo.com/geninvo-launches-centre-of-excellence-for-data-science-and-analytics/) [ ![NEW WEBSITE LAUNCH ANNOUNCEMENT](https://geninvo.com/wp-content/uploads/2021/06/feat-ns-300x170.jpg) ](https://geninvo.com/new-website-launch-announcement-geninvo-launches-updated-website/) ## [NEW WEBSITE LAUNCH ANNOUNCEMENT](https://geninvo.com/new-website-launch-announcement-geninvo-launches-updated-website/) [ ![GENINVO Launches Shadow™ Version 2](https://geninvo.com/wp-content/uploads/2021/03/feat-shadow-300x170.jpg) ](https://geninvo.com/geninvo-launches-shadow-version-2/) ## [GENINVO Launches Shadow™ Version 2](https://geninvo.com/geninvo-launches-shadow-version-2/) [ ![Youth Initiative – Introduction to Robotics Workshop](https://geninvo.com/wp-content/uploads/2021/10/event-feature-2020-300x170.jpg) ](https://geninvo.com/youth-initiative-introduction-to-robotics-workshop/) ## [Youth Initiative – Introduction to Robotics Workshop](https://geninvo.com/youth-initiative-introduction-to-robotics-workshop/) [ ![GENINVO Celebrates Anniversary](https://geninvo.com/wp-content/uploads/2021/05/feat-annivers-300x170.jpg) ](https://geninvo.com/geninvo-anniversary/) ## [GENINVO Celebrates Anniversary](https://geninvo.com/geninvo-anniversary/) [ ![GENINVO Announces Upcoming Version Launch of Shadow™](https://geninvo.com/wp-content/uploads/2021/03/feat-shadow-300x170.jpg) ](https://geninvo.com/geninvo-announces-upcoming-launch-of-shadow-version-2/) ## [GENINVO Announces Upcoming Version Launch of Shadow™](https://geninvo.com/geninvo-announces-upcoming-launch-of-shadow-version-2/) [ ![GENINVO provides technological solutions to the problems in Life Sciences and Pharmaceutical Industry.](https://geninvo.com/wp-content/uploads/2021/05/feat-lsp-300x170.jpg) ](https://geninvo.com/geninvo-provides-technological-solutions-to-the-problems-in-life-sciences-and-pharmaceutical-industry/) ## [GENINVO provides technological solutions to the problems in Life Sciences and Pharmaceutical Industry.](https://geninvo.com/geninvo-provides-technological-solutions-to-the-problems-in-life-sciences-and-pharmaceutical-industry/) [ ![See the Impact of Innovation](https://geninvo.com/wp-content/uploads/2021/05/feat-impact-300x170.jpg) ](https://geninvo.com/see-the-impact-of-innovation/) ## [See the Impact of Innovation](https://geninvo.com/see-the-impact-of-innovation/) [ ![Standing strong with Community](https://geninvo.com/wp-content/uploads/2021/03/feat-stand-str-300x170.jpg) ](https://geninvo.com/standing-strong-with-community/) ## [Standing strong with Community](https://geninvo.com/standing-strong-with-community/) [ ![COVID-19](https://geninvo.com/wp-content/uploads/2021/03/feat-covid-300x170.jpg) ](https://geninvo.com/covid-19/) ## [COVID-19](https://geninvo.com/covid-19/) --- ### [news-single-loop](https://geninvo.com/?elementor_library=news-single-loop) **Published:** March 22, 2021 **Author:** admin **Content:** - March 22, 2021 ##### [news-single-loop](https://geninvo.com/?elementor_library=news-single-loop) [ Read More ](https://geninvo.com/?elementor_library=news-single-loop) --- ### [events-single-loop](https://geninvo.com/?elementor_library=events-single-loop) **Published:** March 23, 2021 **Author:** admin **Content:** --- ### [event-archive-loop](https://geninvo.com/?elementor_library=event-archive-loop) **Published:** March 24, 2021 **Author:** admin **Content:** ###### [event-archive-loop](https://geninvo.com/?elementor_library=event-archive-loop) [ Read More ](https://geninvo.com/?elementor_library=event-archive-loop) --- ### [case-study-archive-loop](https://geninvo.com/?elementor_library=case-study-archive-loop) **Published:** March 24, 2021 **Author:** admin **Content:** ###### case-study-archive-loop [ Read More ](https://geninvo.com/?elementor_library=case-study-archive-loop) --- ### [news-archive-loop](https://geninvo.com/?elementor_library=news-archive-loop) **Published:** March 24, 2021 **Author:** admin **Content:** ##### [news-archive-loop](https://geninvo.com/?elementor_library=news-archive-loop) [ Read More ](https://geninvo.com/?elementor_library=news-archive-loop) --- ### [case-study-single-loop](https://geninvo.com/?elementor_library=case-study-single-loop) **Published:** March 24, 2021 **Author:** admin **Content:** - March 24, 2021 ##### [case-study-single-loop](https://geninvo.com/?elementor_library=case-study-single-loop) [ Read More ](https://geninvo.com/?elementor_library=case-study-single-loop) --- ### [blog-archive-loop](https://geninvo.com/?elementor_library=blog-archive-loop) **Published:** March 26, 2021 **Author:** admin **Content:** ##### blog-archive-loop [ Read More ](https://geninvo.com/?elementor_library=blog-archive-loop) --- ### [videos-single-loop](https://geninvo.com/?elementor_library=videos-single-loop) **Published:** April 6, 2021 **Author:** admin **Content:** [ Watch Video ](https://geninvo.com/?elementor_library=videos-single-loop) --- ### [videos-page-loop](https://geninvo.com/?elementor_library=videos-page-loop) **Published:** April 6, 2021 **Author:** admin **Content:** #### [videos-page-loop](https://geninvo.com/?elementor_library=videos-page-loop) [ Watch Video ](https://geninvo.com/?elementor_library=videos-page-loop) --- ### [cookie-popup](https://geninvo.com/?elementor_library=cookie-popup) **Published:** August 18, 2021 **Author:** admin **Content:** Content area --- ### [dsa-apogi-tab-content-04](https://geninvo.com/?elementor_library=dsa-apogi-tab-content-04) **Published:** September 2, 2021 **Author:** admin **Content:** ![Case Studies-5_Page_1](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-5_Page_1-768x432.jpg) ![Case Studies-5_Page_2](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-5_Page_2-768x432.jpg) ![Case Studies-5_Page_3](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-5_Page_3-768x432.jpg) ![Case Studies-5_Page_4](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-5_Page_4-768x432.jpg) ![Case Studies-5_Page_5](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-5_Page_5-768x432.jpg) [ Download ](#) --- ### [dsa-apogi-tab-content-03](https://geninvo.com/?elementor_library=dsa-apogi-tab-content-03) **Published:** September 2, 2021 **Author:** admin **Content:** ![Case Studies-7_Page_1](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-7_Page_1-768x432.jpg) ![Case Studies-7_Page_2](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-7_Page_2-768x432.jpg) ![Case Studies-7_Page_3](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-7_Page_3-768x432.jpg) ![Case Studies-7_Page_4](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-7_Page_4-768x432.jpg) ![Case Studies-7_Page_5](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-7_Page_5-768x432.jpg) [ Download ](#) --- ### [Typeform](https://geninvo.com/?elementor_library=typeform) **Published:** August 18, 2021 **Author:** admin **Content:** Content area --- ### [dsa-content-tab-ip](https://geninvo.com/?elementor_library=dsa-content-tab-ip) **Published:** August 10, 2021 **Author:** admin **Content:** ## Recommendation Engines Our image processing services are meant to optimize production environments for Computer Vision , scale-up your Spatial Data Processing operations, and deploy solutions to the cloud or to the edge. --- ### [case-studies-dsa](https://geninvo.com/?elementor_library=case-studies-dsa) **Published:** August 10, 2021 **Author:** admin **Content:** [ ![Building a Strong Foundation: Robust Metadata Repository (MDR) Framework for Automated Standard Compliant Data Mapping](https://geninvo.com/wp-content/uploads/2023/12/Building-a-Strong-Foundation-300x169.png) ](https://geninvo.com/building-a-strong-foundation-robust-metadata-repository-mdr-framework-for-automated-standard-compliant-data-mapping/) ## [Building a Strong Foundation: Robust Metadata Repository (MDR) Framework for Automated Standard Compliant Data Mapping](https://geninvo.com/building-a-strong-foundation-robust-metadata-repository-mdr-framework-for-automated-standard-compliant-data-mapping/) [ ![Importance of “Table, Listing and Figures” Automation in Clinical Trials](https://geninvo.com/wp-content/uploads/2023/12/acl-v1-300x169.jpg) ](https://geninvo.com/importance-of-table-listing-and-figures-automation-in-clinical-trials/) ## [Importance of “Table, Listing and Figures” Automation in Clinical Trials](https://geninvo.com/importance-of-table-listing-and-figures-automation-in-clinical-trials/) [ ![White List & Black List: Enhanced NER Model](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-10-Case-Study-WB-List_v3-300x169.jpg) ](https://geninvo.com/white-list-black-list-enhanced-ner-model/) ## [White List & Black List: Enhanced NER Model](https://geninvo.com/white-list-black-list-enhanced-ner-model/) [ ![NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity-300x169.jpg) ](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) ## [NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) [ ![DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-12-Eprotocol-presentation-300x169.jpg) ](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) ## [DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) [ ![Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-13-Shadow-Recommendation-Engine-300x169.jpg) ](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) ## [Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) [ ![Lung Cancer Detection](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-8-Lung-Cancer-Detection-use-cases-300x169.jpg) ](https://geninvo.com/lung-cancer-detection/) ## [Lung Cancer Detection](https://geninvo.com/lung-cancer-detection/) [ ![Breast Cancer Detection Using Machine Learning](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-9-Case-Study-Breast-Cancer-Detection_v3-use-cases-300x169.jpg) ](https://geninvo.com/breast-cancer-detection-using-machine-learning/) ## [Breast Cancer Detection Using Machine Learning](https://geninvo.com/breast-cancer-detection-using-machine-learning/) [ ![Provide ApoGI as a Metadata Driven Transformations](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-5-300x169.jpg) ](https://geninvo.com/provide-apogitm-asa-metadata-driventransformations/) ## [Provide ApoGI as a Metadata Driven Transformations](https://geninvo.com/provide-apogitm-asa-metadata-driventransformations/) [ ![Provide ApoGI as a MDR Visualization](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-6-300x169.jpg) ](https://geninvo.com/provide-apogitmas-a-mdrvisualization/) ## [Provide ApoGI as a MDR Visualization](https://geninvo.com/provide-apogitmas-a-mdrvisualization/) [ ![Provide ApoGI as a Metadata Driven Platform](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-7-300x169.jpg) ](https://geninvo.com/provide-apogitmas-a-metadatadriven-platform/) ## [Provide ApoGI as a Metadata Driven Platform](https://geninvo.com/provide-apogitmas-a-metadatadriven-platform/) --- ### [dsa-case-studies](https://geninvo.com/?elementor_library=dsa-case-studies) **Published:** August 10, 2021 **Author:** admin **Content:** [ ![White List & Black List: Enhanced NER Model](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-10-Case-Study-WB-List_v3-300x169.jpg) ](https://geninvo.com/white-list-black-list-enhanced-ner-model/) ## [White List & Black List: Enhanced NER Model](https://geninvo.com/white-list-black-list-enhanced-ner-model/) [ ![NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity-300x169.jpg) ](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) ## [NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) [ ![DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-12-Eprotocol-presentation-300x169.jpg) ](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) ## [DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) [ ![Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-13-Shadow-Recommendation-Engine-300x169.jpg) ](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) ## [Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) [ ![Lung Cancer Detection](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-8-Lung-Cancer-Detection-use-cases-300x169.jpg) ](https://geninvo.com/lung-cancer-detection/) ## [Lung Cancer Detection](https://geninvo.com/lung-cancer-detection/) [ ![Breast Cancer Detection Using Machine Learning](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-9-Case-Study-Breast-Cancer-Detection_v3-use-cases-300x169.jpg) ](https://geninvo.com/breast-cancer-detection-using-machine-learning/) ## [Breast Cancer Detection Using Machine Learning](https://geninvo.com/breast-cancer-detection-using-machine-learning/) [ ![Doc QC tool as a one-stop solution for all Quality Control (QC) needs of a medical writer](https://geninvo.com/wp-content/uploads/2021/08/Case-Studies-8-DocQC-300x169.jpg) ](https://geninvo.com/doc-qc-tool-as-a-one-stop-solution-for-all-quality-control-qc-needs-of-a-medical-writer/) ## [Doc QC tool as a one-stop solution for all Quality Control (QC) needs of a medical writer](https://geninvo.com/doc-qc-tool-as-a-one-stop-solution-for-all-quality-control-qc-needs-of-a-medical-writer/) [ ![Provide ApoGI as a Metadata Driven Platform](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-7-300x169.jpg) ](https://geninvo.com/provide-apogitmas-a-metadatadriven-platform/) ## [Provide ApoGI as a Metadata Driven Platform](https://geninvo.com/provide-apogitmas-a-metadatadriven-platform/) [ ![Provide ApoGI as a MDR Visualization](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-6-300x169.jpg) ](https://geninvo.com/provide-apogitmas-a-mdrvisualization/) ## [Provide ApoGI as a MDR Visualization](https://geninvo.com/provide-apogitmas-a-mdrvisualization/) [ ![Provide ApoGI as a Metadata Driven Transformations](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-5-300x169.jpg) ](https://geninvo.com/provide-apogitm-asa-metadata-driventransformations/) ## [Provide ApoGI as a Metadata Driven Transformations](https://geninvo.com/provide-apogitm-asa-metadata-driventransformations/) [ ![How a Big Pharma Company Achieved Compliance with Health Canada Under Tight Deadlines](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-4-300x169.jpg) ](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-health-canada-under-tight-deadlines/) ## [How a Big Pharma Company Achieved Compliance with Health Canada Under Tight Deadlines](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-health-canada-under-tight-deadlines/) [ ![How a Pharmaceutical Firm Established Anonymization Process](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-3-300x169.jpg) ](https://geninvo.com/how-a-pharmaceutical-firm-established-anonymization-process/) ## [How a Pharmaceutical Firm Established Anonymization Process](https://geninvo.com/how-a-pharmaceutical-firm-established-anonymization-process/) [ ![Big Pharma Company Achieves Compliance with EMA 0070 Policy](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-2-300x169.jpg) ](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-ema-0070-policy-with-a-tight-deadline/) ## [Big Pharma Company Achieves Compliance with EMA 0070 Policy](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-ema-0070-policy-with-a-tight-deadline/) [ ![How a Global Medical Writing CRO Increased Functional Capability with Shadow™](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-1-300x169.jpg) ](https://geninvo.com/how-a-global-medical-writing-cro-increased-functional-capability-with-shadowtm/) ## [How a Global Medical Writing CRO Increased Functional Capability with Shadow™](https://geninvo.com/how-a-global-medical-writing-cro-increased-functional-capability-with-shadowtm/) --- ### [old-top-main](https://geninvo.com/?elementor_library=old-top-main) **Published:** August 9, 2021 **Author:** admin **Content:** GENINVO Provides Services Custom Made to Your Needs Our SME’s and software development experts help you with complete End-to-End Application Development, Advisory Consulting Services, Enhancing Legacy Applications and more. [Learn More](https://geninvo.com/our-services/) Regulatory Bodies in Life Sciences Know more about the role of regulatory bodies and how they help shape a regulated Life Science industry around the world. [Explore GENINVO Blogs](https://geninvo.com/blog/) Your Solution to Automating Clinical Study Deliverables ApoGI™ ensures process consistency, automates repetitive tasks and artifact generation, and much more. Our AI-ML next-gen end-to-end platform does it all for you! [Discover ApoGI](https://geninvo.com/apogi/) GENINVO Believes in Leading through Innovation We are proud to be sponsors of insightful and innovative conferences around the globe. Join us from 14th - 18th June at the PHUSE US Connect 2021- Clinical Data Science Conference. [View Events](https://geninvo.com/events/) Our COVID-19 Measures In response to the COVID-19 pandemic, we implemented social distancing in the workplace and allow employees who can work from home. We are also following the measures recommended by WHO. [World Health Organization: WHO](https://www.who.int/emergencies/diseases/novel-coronavirus-2019) ###### OUR SERVICES # Our Service Offerings Experience the GENINVO Difference with our services, tailored to meet your specific demands. We offer highly skilled, innovative, and adaptable teams who help our partners flourish and attain business success in a variety of industries. [ READ MORE ](https://geninvo.com/our-services/) ## Custom Application Development Expert teams, Personalized tools, and Processes – We deliver exactly what our customers need. [ ](https://geninvo.com/our-services/custom-application-development/) ## Anonymization As a Service We provide a variety of customized anonymization services to support global data sharing and transparency services, along with redaction and risk assessment options. [ ](https://geninvo.com/our-services/anonymization-as-a-service/) ## Talent Mapping Our Life Science SME and software and technology experts support solutions in a variety of areas including data visualization, custom software development, and more. [ ](https://geninvo.com/our-services/talent-resource-hub/) ## Cloud Managed Services In today’s dynamic environment, it is necessary to have a clear path to achieve the business outcomes you desire. [ ](https://geninvo.com/our-services/cloud-managed-services/) OUR Products ## Experience our Product Portfolio All GENINVO products are scalable, secure, and customizable. Our industry-leading Life Science products also come with plug-and-play modules and off-the-shelf licensing for hassle-free deployment with existing infrastructure. [ ![Shadow - Data Anonymization Tool.](https://geninvo.com/wp-content/uploads/2021/03/shadow_logo-e1726059597494.png "shadow_logo - GenInvo - GenInvo") ](https://geninvo.com/our-products/data-anonymization-tool/) ## [Data and Document Anonymization Solution](https://geninvo.com/our-products/data-anonymization-tool/) [ ![Medical Writers Automation Tool](https://geninvo.com/wp-content/uploads/2021/03/docqc_logo-e1631023185935.png "docqc_logo - GenInvo - GenInvo") ](https://geninvo.com/our-products/docqc-medical-writing-automation/) ## [Document QC Automation](https://geninvo.com/our-products/docqc-medical-writing-automation/) [ ![Metadata Management Tool](https://geninvo.com/wp-content/uploads/2021/03/metaworks_logo-e1631023215361.png "metaworks_logo - GenInvo - GenInvo") ](https://geninvo.com/our-products/apogi/) ## [Next Generation Enterprise Platform](https://geninvo.com/our-products/apogi/) [ ![](https://geninvo.com/wp-content/uploads/2021/05/prod-logs-adc-e1621859458849.png "prod-logs-adc - GenInvo - GenInvo") ](https://geninvo.com/our-products/automation-of-data-conversion/) ## [Automation of Data Conversion](https://geninvo.com/our-products/automation-of-data-conversion/) ![](https://geninvo.com/wp-content/uploads/2021/03/our-story.jpg "our-story - GenInvo - GenInvo") ## [Learn about our Vision, Mission, and Leadership Team](https://geninvo.com/who-we-are/) Learn more about the group working toward bringing a technological revolution to the Life Sciences industry. [ READ MORE ](https://geninvo.com/who-we-are/) ## Join Us We always welcome the right talent. If AI/ML, NLP, Automation, Cloud and Big Data excite you, then GENINVO is the place for you! [ Find opportunities ](https://geninvo.com/work-with-us/) [custom-twitter-feeds buttontextcolor="#ffffff" buttoncolor="#00393f"] --- ### [blog-section-tab](https://geninvo.com/?elementor_library=blog-section-tab) **Published:** April 6, 2021 **Author:** admin **Content:** ## Blogs [ ![Quantitative Risk Assessment: A Smarter Approach to Clinical Data Anonymization ](https://geninvo.com/wp-content/uploads/2025/10/Blog-12-300x189.jpg) ](https://geninvo.com/quantitative-risk-assessment-a-smarter-approach-to-clinical-data-anonymization/) ## [Quantitative Risk Assessment: A Smarter Approach to Clinical Data Anonymization ](https://geninvo.com/quantitative-risk-assessment-a-smarter-approach-to-clinical-data-anonymization/) [ ![Secure Scanning with Confidential Information Scanner: Safeguarding Your CCIs During Clinical Research](https://geninvo.com/wp-content/uploads/2025/09/Blog-11-300x189.jpg) ](https://geninvo.com/secure-scanning-with-confidential-information-scanner-safeguarding-your-ccis-during-clinical-research/) ## [Secure Scanning with Confidential Information Scanner: Safeguarding Your CCIs During Clinical Research](https://geninvo.com/secure-scanning-with-confidential-information-scanner-safeguarding-your-ccis-during-clinical-research/) [ ![Python’s Future in Clinical Trials: Innovations and Collaborative Advancements](https://geninvo.com/wp-content/uploads/2025/08/Blog-8-300x189.jpg) ](https://geninvo.com/pythons-future-in-clinical-trials-innovations-and-collaborative-advancements/) ## [Python’s Future in Clinical Trials: Innovations and Collaborative Advancements](https://geninvo.com/pythons-future-in-clinical-trials-innovations-and-collaborative-advancements/) [ ![The Changing Role of the Clinical Programmer in an Open-Source World](https://geninvo.com/wp-content/uploads/2025/07/Blog-7-300x189.jpg) ](https://geninvo.com/the-changing-role-of-the-clinical-programmer-in-an-open-source-world/) ## [The Changing Role of the Clinical Programmer in an Open-Source World](https://geninvo.com/the-changing-role-of-the-clinical-programmer-in-an-open-source-world/) [ ![Beyond the Buzzwords: How GenInvo’s AI/ML Tools Are Transforming Life Sciences](https://geninvo.com/wp-content/uploads/2025/07/Blog-6-300x189.jpg) ](https://geninvo.com/ai-ml-tools-life-sciences-geninvo/) ## [Beyond the Buzzwords: How GenInvo’s AI/ML Tools Are Transforming Life Sciences](https://geninvo.com/ai-ml-tools-life-sciences-geninvo/) [ ![Empowering the Future of Life Sciences: A GenInvo Perspective from the Inside](https://geninvo.com/wp-content/uploads/2025/06/Blog-5-300x196.jpg) ](https://geninvo.com/empowering-the-future-of-life-sciences-a-geninvo-perspective-from-the-inside/) ## [Empowering the Future of Life Sciences: A GenInvo Perspective from the Inside](https://geninvo.com/empowering-the-future-of-life-sciences-a-geninvo-perspective-from-the-inside/) [ ![GenInvo’s CIS Tool: Safeguarding Confidential Company Information in Life Sciences.](https://geninvo.com/wp-content/uploads/2025/06/Blog-4-300x196.jpg) ](https://geninvo.com/geninvos-cis-tool-safeguarding-confidential-company-information-in-life-sciences/) ## [GenInvo’s CIS Tool: Safeguarding Confidential Company Information in Life Sciences.](https://geninvo.com/geninvos-cis-tool-safeguarding-confidential-company-information-in-life-sciences/) [ ![Why Clinical Data Transparency Matters: Benefits for Patients, Researchers, and Industry](https://geninvo.com/wp-content/uploads/2025/06/Blog-3-300x196.jpg) ](https://geninvo.com/why-clinical-data-transparency-matters-benefits-for-patients-researchers-and-industry/) ## [Why Clinical Data Transparency Matters: Benefits for Patients, Researchers, and Industry](https://geninvo.com/why-clinical-data-transparency-matters-benefits-for-patients-researchers-and-industry/) [ ![How Meaningful Synthetic Data Generation Tools Are Transforming AI Development ](https://geninvo.com/wp-content/uploads/2025/01/Blog-2-300x169.jpg) ](https://geninvo.com/how-meaningful-synthetic-data-generation-tools-are-transforming-ai-development/) ## [How Meaningful Synthetic Data Generation Tools Are Transforming AI Development ](https://geninvo.com/how-meaningful-synthetic-data-generation-tools-are-transforming-ai-development/) [ ![Empowering Clinical and Regulatory Writing: Harnessing AI as Your Assistant  ](https://geninvo.com/wp-content/uploads/2024/10/Untitled-1-1-300x189.webp) ](https://geninvo.com/empowering-clinical-and-regulatory-writing-harnessing-ai-as-your-assistant/) ## [Empowering Clinical and Regulatory Writing: Harnessing AI as Your Assistant ](https://geninvo.com/empowering-clinical-and-regulatory-writing-harnessing-ai-as-your-assistant/) [ ![The Impact of AI on Medical Writing: How Artificial Intelligence is Revolutionizing Medical Content Creation ](https://geninvo.com/wp-content/uploads/2024/09/mdw-1-300x169.jpg) ](https://geninvo.com/the-impact-of-ai-on-medical-writing-how-artificial-intelligence-is-revolutionizing-medical-content-creation/) ## [The Impact of AI on Medical Writing: How Artificial Intelligence is Revolutionizing Medical Content Creation ](https://geninvo.com/the-impact-of-ai-on-medical-writing-how-artificial-intelligence-is-revolutionizing-medical-content-creation/) [ ![CDISC Standards and Data Transformation in Clinical Trial.](https://geninvo.com/wp-content/uploads/2024/07/dtct-1-300x169.webp) ](https://geninvo.com/cdisc-standards-and-data-transformation-in-clinical-trial/) ## [CDISC Standards and Data Transformation in Clinical Trial.](https://geninvo.com/cdisc-standards-and-data-transformation-in-clinical-trial/) [ ![Transforming Document Creation in Life Sciences with DocWrightAI™ – GenInvo’s Advanced AI Assistant!](https://geninvo.com/wp-content/uploads/2024/06/DocWright-lifscience-300x169.jpg) ](https://geninvo.com/transforming-document-creation-in-life-sciences-with-docwrightai-geninvos-advanced-ai-assistant/) ## [Transforming Document Creation in Life Sciences with DocWrightAI™ – GenInvo’s Advanced AI Assistant!](https://geninvo.com/transforming-document-creation-in-life-sciences-with-docwrightai-geninvos-advanced-ai-assistant/) [ ![Embracing the Digital Era: The Transformative Power of Digitalization in Medical Writing](https://geninvo.com/wp-content/uploads/2024/03/1672114503523rf-1-300x169.jpg) ](https://geninvo.com/embracing-the-digital-era-the-transformative-power-of-digitalization-in-medical-writing/) ## [Embracing the Digital Era: The Transformative Power of Digitalization in Medical Writing](https://geninvo.com/embracing-the-digital-era-the-transformative-power-of-digitalization-in-medical-writing/) [ ![Data Masking and Data Anonymization: The need for healthcare companies](https://geninvo.com/wp-content/uploads/2024/03/data-m-300x169.jpg) ](https://geninvo.com/data-masking-and-data-anonymization-the-need-for-healthcare-companies/) ## [Data Masking and Data Anonymization: The need for healthcare companies](https://geninvo.com/data-masking-and-data-anonymization-the-need-for-healthcare-companies/) [ ![Artificial Intelligence in the Healthcare Domain: How AI Reviews Clinical Documents](https://geninvo.com/wp-content/uploads/2024/03/maxresdefault.jpgr_-300x169.jpg) ](https://geninvo.com/artificial-intelligence-in-the-healthcare-domain-how-ai-reviews-clinical-documents/) ## [Artificial Intelligence in the Healthcare Domain: How AI Reviews Clinical Documents](https://geninvo.com/artificial-intelligence-in-the-healthcare-domain-how-ai-reviews-clinical-documents/) [ ![Importance and examples of usage of Data Anonymization in Healthcare & Other sectors](https://geninvo.com/wp-content/uploads/2024/02/dah-sector-300x169.jpg) ](https://geninvo.com/importance-and-examples-of-usage-of-data-anonymization-in-healthcare-other-sectors/) ## [Importance and examples of usage of Data Anonymization in Healthcare & Other sectors](https://geninvo.com/importance-and-examples-of-usage-of-data-anonymization-in-healthcare-other-sectors/) [ ![Data Anonymization and HIPAA Compliance: Protecting Health Information Privacy](https://geninvo.com/wp-content/uploads/2024/02/Untitled-1df-300x169.jpg) ](https://geninvo.com/data-anonymization-and-hipaa-compliance-protecting-health-information-privacy/) ## [Data Anonymization and HIPAA Compliance: Protecting Health Information Privacy](https://geninvo.com/data-anonymization-and-hipaa-compliance-protecting-health-information-privacy/) [ ![Automation of Unstructured Clinical Data: A collaboration of automation and Medical Writers](https://geninvo.com/wp-content/uploads/2024/01/cdf-300x169.png) ](https://geninvo.com/automation-of-unstructured-clinical-data-a-collaboration-of-automation-and-medical-writers/) ## [Automation of Unstructured Clinical Data: A collaboration of automation and Medical Writers](https://geninvo.com/automation-of-unstructured-clinical-data-a-collaboration-of-automation-and-medical-writers/) [ ![Quality Control of the Methods and Procedures of Clinical Study](https://geninvo.com/wp-content/uploads/2024/01/quloi-300x169.jpg) ](https://geninvo.com/quality-control-of-the-methods-and-procedures-of-clinical-study/) ## [Quality Control of the Methods and Procedures of Clinical Study](https://geninvo.com/quality-control-of-the-methods-and-procedures-of-clinical-study/) --- ### [top-carousel-temp](https://geninvo.com/?elementor_library=top-carousel-temp) **Published:** April 15, 2021 **Author:** admin **Content:** ## GENINVO provides services custom made to your needs. Our SME’s and software development experts help you in Complete End-to-End Application Development, Advisory consulting services, Enhancing legacy applications and several more. [ Know More ](https://geninvo.com/our-services/) --- ### [leaders-old-part](https://geninvo.com/?elementor_library=leaders-old-part) **Published:** April 12, 2021 **Author:** admin **Content:** ![](https://geninvo.com/wp-content/uploads/2021/03/shweta_shukla.jpg "shweta_shukla - GenInvo - GenInvo") ### Shweta Shukla CEO [### in ](https://www.linkedin.com/in/shwetageninvo/) ![](https://geninvo.com/wp-content/uploads/2021/03/thomas_kalfas.jpg "thomas_kalfas - GenInvo - GenInvo") ### Thomas Kalfas Innovations Officer [### in ](https://www.linkedin.com/in/tom-kalfas-7813a5/) ![](https://geninvo.com/wp-content/uploads/2021/03/Ramesh_Venkataramana.jpg "Ramesh_Venkataramana - GenInvo - GenInvo") ### Ramesh Venkataramana Director Innovative Solutions and Strategy [### in ](https://www.linkedin.com/in/ramesh-venkataramana-52129719/) --- ### [all-section-tab](https://geninvo.com/?elementor_library=all-section-tab) **Published:** April 6, 2021 **Author:** admin **Content:** ## Blogs [ ![Quantitative Risk Assessment: A Smarter Approach to Clinical Data Anonymization ](https://geninvo.com/wp-content/uploads/2025/10/Blog-12-300x189.jpg) ](https://geninvo.com/quantitative-risk-assessment-a-smarter-approach-to-clinical-data-anonymization/) ## [Quantitative Risk Assessment: A Smarter Approach to Clinical Data Anonymization ](https://geninvo.com/quantitative-risk-assessment-a-smarter-approach-to-clinical-data-anonymization/) [ ![Secure Scanning with Confidential Information Scanner: Safeguarding Your CCIs During Clinical Research](https://geninvo.com/wp-content/uploads/2025/09/Blog-11-300x189.jpg) ](https://geninvo.com/secure-scanning-with-confidential-information-scanner-safeguarding-your-ccis-during-clinical-research/) ## [Secure Scanning with Confidential Information Scanner: Safeguarding Your CCIs During Clinical Research](https://geninvo.com/secure-scanning-with-confidential-information-scanner-safeguarding-your-ccis-during-clinical-research/) [ ![Python’s Future in Clinical Trials: Innovations and Collaborative Advancements](https://geninvo.com/wp-content/uploads/2025/08/Blog-8-300x189.jpg) ](https://geninvo.com/pythons-future-in-clinical-trials-innovations-and-collaborative-advancements/) ## [Python’s Future in Clinical Trials: Innovations and Collaborative Advancements](https://geninvo.com/pythons-future-in-clinical-trials-innovations-and-collaborative-advancements/) [ ![The Changing Role of the Clinical Programmer in an Open-Source World](https://geninvo.com/wp-content/uploads/2025/07/Blog-7-300x189.jpg) ](https://geninvo.com/the-changing-role-of-the-clinical-programmer-in-an-open-source-world/) ## [The Changing Role of the Clinical Programmer in an Open-Source World](https://geninvo.com/the-changing-role-of-the-clinical-programmer-in-an-open-source-world/) [ ![Beyond the Buzzwords: How GenInvo’s AI/ML Tools Are Transforming Life Sciences](https://geninvo.com/wp-content/uploads/2025/07/Blog-6-300x189.jpg) ](https://geninvo.com/ai-ml-tools-life-sciences-geninvo/) ## [Beyond the Buzzwords: How GenInvo’s AI/ML Tools Are Transforming Life Sciences](https://geninvo.com/ai-ml-tools-life-sciences-geninvo/) [ ![Empowering the Future of Life Sciences: A GenInvo Perspective from the Inside](https://geninvo.com/wp-content/uploads/2025/06/Blog-5-300x196.jpg) ](https://geninvo.com/empowering-the-future-of-life-sciences-a-geninvo-perspective-from-the-inside/) ## [Empowering the Future of Life Sciences: A GenInvo Perspective from the Inside](https://geninvo.com/empowering-the-future-of-life-sciences-a-geninvo-perspective-from-the-inside/) [ ![GenInvo’s CIS Tool: Safeguarding Confidential Company Information in Life Sciences.](https://geninvo.com/wp-content/uploads/2025/06/Blog-4-300x196.jpg) ](https://geninvo.com/geninvos-cis-tool-safeguarding-confidential-company-information-in-life-sciences/) ## [GenInvo’s CIS Tool: Safeguarding Confidential Company Information in Life Sciences.](https://geninvo.com/geninvos-cis-tool-safeguarding-confidential-company-information-in-life-sciences/) [ ![Why Clinical Data Transparency Matters: Benefits for Patients, Researchers, and Industry](https://geninvo.com/wp-content/uploads/2025/06/Blog-3-300x196.jpg) ](https://geninvo.com/why-clinical-data-transparency-matters-benefits-for-patients-researchers-and-industry/) ## [Why Clinical Data Transparency Matters: Benefits for Patients, Researchers, and Industry](https://geninvo.com/why-clinical-data-transparency-matters-benefits-for-patients-researchers-and-industry/) [ ![How Meaningful Synthetic Data Generation Tools Are Transforming AI Development ](https://geninvo.com/wp-content/uploads/2025/01/Blog-2-300x169.jpg) ](https://geninvo.com/how-meaningful-synthetic-data-generation-tools-are-transforming-ai-development/) ## [How Meaningful Synthetic Data Generation Tools Are Transforming AI Development ](https://geninvo.com/how-meaningful-synthetic-data-generation-tools-are-transforming-ai-development/) [ ![Empowering Clinical and Regulatory Writing: Harnessing AI as Your Assistant  ](https://geninvo.com/wp-content/uploads/2024/10/Untitled-1-1-300x189.webp) ](https://geninvo.com/empowering-clinical-and-regulatory-writing-harnessing-ai-as-your-assistant/) ## [Empowering Clinical and Regulatory Writing: Harnessing AI as Your Assistant ](https://geninvo.com/empowering-clinical-and-regulatory-writing-harnessing-ai-as-your-assistant/) [ ![The Impact of AI on Medical Writing: How Artificial Intelligence is Revolutionizing Medical Content Creation ](https://geninvo.com/wp-content/uploads/2024/09/mdw-1-300x169.jpg) ](https://geninvo.com/the-impact-of-ai-on-medical-writing-how-artificial-intelligence-is-revolutionizing-medical-content-creation/) ## [The Impact of AI on Medical Writing: How Artificial Intelligence is Revolutionizing Medical Content Creation ](https://geninvo.com/the-impact-of-ai-on-medical-writing-how-artificial-intelligence-is-revolutionizing-medical-content-creation/) [ ![CDISC Standards and Data Transformation in Clinical Trial.](https://geninvo.com/wp-content/uploads/2024/07/dtct-1-300x169.webp) ](https://geninvo.com/cdisc-standards-and-data-transformation-in-clinical-trial/) ## [CDISC Standards and Data Transformation in Clinical Trial.](https://geninvo.com/cdisc-standards-and-data-transformation-in-clinical-trial/) [ ![Transforming Document Creation in Life Sciences with DocWrightAI™ – GenInvo’s Advanced AI Assistant!](https://geninvo.com/wp-content/uploads/2024/06/DocWright-lifscience-300x169.jpg) ](https://geninvo.com/transforming-document-creation-in-life-sciences-with-docwrightai-geninvos-advanced-ai-assistant/) ## [Transforming Document Creation in Life Sciences with DocWrightAI™ – GenInvo’s Advanced AI Assistant!](https://geninvo.com/transforming-document-creation-in-life-sciences-with-docwrightai-geninvos-advanced-ai-assistant/) [ ![Embracing the Digital Era: The Transformative Power of Digitalization in Medical Writing](https://geninvo.com/wp-content/uploads/2024/03/1672114503523rf-1-300x169.jpg) ](https://geninvo.com/embracing-the-digital-era-the-transformative-power-of-digitalization-in-medical-writing/) ## [Embracing the Digital Era: The Transformative Power of Digitalization in Medical Writing](https://geninvo.com/embracing-the-digital-era-the-transformative-power-of-digitalization-in-medical-writing/) [ ![Data Masking and Data Anonymization: The need for healthcare companies](https://geninvo.com/wp-content/uploads/2024/03/data-m-300x169.jpg) ](https://geninvo.com/data-masking-and-data-anonymization-the-need-for-healthcare-companies/) ## [Data Masking and Data Anonymization: The need for healthcare companies](https://geninvo.com/data-masking-and-data-anonymization-the-need-for-healthcare-companies/) [ ![Artificial Intelligence in the Healthcare Domain: How AI Reviews Clinical Documents](https://geninvo.com/wp-content/uploads/2024/03/maxresdefault.jpgr_-300x169.jpg) ](https://geninvo.com/artificial-intelligence-in-the-healthcare-domain-how-ai-reviews-clinical-documents/) ## [Artificial Intelligence in the Healthcare Domain: How AI Reviews Clinical Documents](https://geninvo.com/artificial-intelligence-in-the-healthcare-domain-how-ai-reviews-clinical-documents/) [ ![Importance and examples of usage of Data Anonymization in Healthcare & Other sectors](https://geninvo.com/wp-content/uploads/2024/02/dah-sector-300x169.jpg) ](https://geninvo.com/importance-and-examples-of-usage-of-data-anonymization-in-healthcare-other-sectors/) ## [Importance and examples of usage of Data Anonymization in Healthcare & Other sectors](https://geninvo.com/importance-and-examples-of-usage-of-data-anonymization-in-healthcare-other-sectors/) [ ![Data Anonymization and HIPAA Compliance: Protecting Health Information Privacy](https://geninvo.com/wp-content/uploads/2024/02/Untitled-1df-300x169.jpg) ](https://geninvo.com/data-anonymization-and-hipaa-compliance-protecting-health-information-privacy/) ## [Data Anonymization and HIPAA Compliance: Protecting Health Information Privacy](https://geninvo.com/data-anonymization-and-hipaa-compliance-protecting-health-information-privacy/) [ ![Automation of Unstructured Clinical Data: A collaboration of automation and Medical Writers](https://geninvo.com/wp-content/uploads/2024/01/cdf-300x169.png) ](https://geninvo.com/automation-of-unstructured-clinical-data-a-collaboration-of-automation-and-medical-writers/) ## [Automation of Unstructured Clinical Data: A collaboration of automation and Medical Writers](https://geninvo.com/automation-of-unstructured-clinical-data-a-collaboration-of-automation-and-medical-writers/) [ ![Quality Control of the Methods and Procedures of Clinical Study](https://geninvo.com/wp-content/uploads/2024/01/quloi-300x169.jpg) ](https://geninvo.com/quality-control-of-the-methods-and-procedures-of-clinical-study/) ## [Quality Control of the Methods and Procedures of Clinical Study](https://geninvo.com/quality-control-of-the-methods-and-procedures-of-clinical-study/) ## Case Studies [ ![White List & Black List: Enhanced NER Model](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-10-Case-Study-WB-List_v3-300x169.jpg) ](https://geninvo.com/white-list-black-list-enhanced-ner-model/) ## [White List & Black List: Enhanced NER Model](https://geninvo.com/white-list-black-list-enhanced-ner-model/) [ ![NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity-300x169.jpg) ](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) ## [NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) [ ![DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-12-Eprotocol-presentation-300x169.jpg) ](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) ## [DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) [ ![Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-13-Shadow-Recommendation-Engine-300x169.jpg) ](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) ## [Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) [ ![Lung Cancer Detection](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-8-Lung-Cancer-Detection-use-cases-300x169.jpg) ](https://geninvo.com/lung-cancer-detection/) ## [Lung Cancer Detection](https://geninvo.com/lung-cancer-detection/) [ ![Breast Cancer Detection Using Machine Learning](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-9-Case-Study-Breast-Cancer-Detection_v3-use-cases-300x169.jpg) ](https://geninvo.com/breast-cancer-detection-using-machine-learning/) ## [Breast Cancer Detection Using Machine Learning](https://geninvo.com/breast-cancer-detection-using-machine-learning/) [ ![Doc QC tool as a one-stop solution for all Quality Control (QC) needs of a medical writer](https://geninvo.com/wp-content/uploads/2021/08/Case-Studies-8-DocQC-300x169.jpg) ](https://geninvo.com/doc-qc-tool-as-a-one-stop-solution-for-all-quality-control-qc-needs-of-a-medical-writer/) ## [Doc QC tool as a one-stop solution for all Quality Control (QC) needs of a medical writer](https://geninvo.com/doc-qc-tool-as-a-one-stop-solution-for-all-quality-control-qc-needs-of-a-medical-writer/) [ ![Provide ApoGI as a Metadata Driven Platform](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-7-300x169.jpg) ](https://geninvo.com/provide-apogitmas-a-metadatadriven-platform/) ## [Provide ApoGI as a Metadata Driven Platform](https://geninvo.com/provide-apogitmas-a-metadatadriven-platform/) [ ![Provide ApoGI as a MDR Visualization](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-6-300x169.jpg) ](https://geninvo.com/provide-apogitmas-a-mdrvisualization/) ## [Provide ApoGI as a MDR Visualization](https://geninvo.com/provide-apogitmas-a-mdrvisualization/) [ ![Provide ApoGI as a Metadata Driven Transformations](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-5-300x169.jpg) ](https://geninvo.com/provide-apogitm-asa-metadata-driventransformations/) ## [Provide ApoGI as a Metadata Driven Transformations](https://geninvo.com/provide-apogitm-asa-metadata-driventransformations/) [ ![How a Big Pharma Company Achieved Compliance with Health Canada Under Tight Deadlines](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-4-300x169.jpg) ](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-health-canada-under-tight-deadlines/) ## [How a Big Pharma Company Achieved Compliance with Health Canada Under Tight Deadlines](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-health-canada-under-tight-deadlines/) [ ![How a Pharmaceutical Firm Established Anonymization Process](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-3-300x169.jpg) ](https://geninvo.com/how-a-pharmaceutical-firm-established-anonymization-process/) ## [How a Pharmaceutical Firm Established Anonymization Process](https://geninvo.com/how-a-pharmaceutical-firm-established-anonymization-process/) [ ![Big Pharma Company Achieves Compliance with EMA 0070 Policy](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-2-300x169.jpg) ](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-ema-0070-policy-with-a-tight-deadline/) ## [Big Pharma Company Achieves Compliance with EMA 0070 Policy](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-ema-0070-policy-with-a-tight-deadline/) [ ![How a Global Medical Writing CRO Increased Functional Capability with Shadow™](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-1-300x169.jpg) ](https://geninvo.com/how-a-global-medical-writing-cro-increased-functional-capability-with-shadowtm/) ## [How a Global Medical Writing CRO Increased Functional Capability with Shadow™](https://geninvo.com/how-a-global-medical-writing-cro-increased-functional-capability-with-shadowtm/) ## Events [ ![Meet GenInvo at DPHARM 2026, Booth 116, Boston](https://geninvo.com/wp-content/uploads/2026/06/DPHARM-1-300x186.png) ](https://geninvo.com/dpharm-2026/) ## [Meet GenInvo at DPHARM 2026, Booth 116, Boston](https://geninvo.com/dpharm-2026/) [ ![Meet GENINVO at the EMWA 61st Spring Conference 2026](https://geninvo.com/wp-content/uploads/2026/04/539-X-334-1-300x186.png) ](https://geninvo.com/emwa-2026-barcelona/) ## [Meet GENINVO at the EMWA 61st Spring Conference 2026](https://geninvo.com/emwa-2026-barcelona/) [ ![GenInvo at PharmaSUG 2026 SDE Conference](https://geninvo.com/wp-content/uploads/2026/04/539-X-334-300x186.png) ](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) ## [GenInvo at PharmaSUG 2026 SDE Conference](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) [ ![GenInvo @ PHUSE US Connect 2026](https://geninvo.com/wp-content/uploads/2026/03/image-16-300x186.png) ](https://geninvo.com/geninvo-phuse-us-connect-2026/) ## [GenInvo @ PHUSE US Connect 2026](https://geninvo.com/geninvo-phuse-us-connect-2026/) [ ![Live Webinar: Accelerating Authoring and QC of Clinical Documents with AI-Powered Automation](https://geninvo.com/wp-content/uploads/2025/08/Blog-9-300x186.jpg) ](https://geninvo.com/live-webinar-accelerating-authoring-and-qc-of-clinical-documents-with-ai-powered-automation/) ## [Live Webinar: Accelerating Authoring and QC of Clinical Documents with AI-Powered Automation](https://geninvo.com/live-webinar-accelerating-authoring-and-qc-of-clinical-documents-with-ai-powered-automation/) [ ![GenInvo is Powering the Future of Medical Writing at AMWA 2025!](https://geninvo.com/wp-content/uploads/2025/08/GI-AMWA-conference-blog-2025-300x186.jpg) ](https://geninvo.com/geninvo-is-powering-the-future-of-medical-writing-at-amwa-2025/) ## [GenInvo is Powering the Future of Medical Writing at AMWA 2025!](https://geninvo.com/geninvo-is-powering-the-future-of-medical-writing-at-amwa-2025/) [ ![GENINVO™ Sponsors PHUSE Data Transparency Autumn Event 2025](https://geninvo.com/wp-content/uploads/2025/07/Blog-GI-Phusevirtualevent-Sept-2025-300x189.jpg) ](https://geninvo.com/geninvo-sponsors-phuse-data-transparency-autumn-event-2025/) ## [GENINVO™ Sponsors PHUSE Data Transparency Autumn Event 2025](https://geninvo.com/geninvo-sponsors-phuse-data-transparency-autumn-event-2025/) [ ![GENINVO™ at PHUSE US Connect 2025](https://geninvo.com/wp-content/uploads/2025/02/GI-US-PHUSE-connect-2025-300x186.jpg) ](https://geninvo.com/geninvo-at-phuse-us-connect-2025/) ## [GENINVO™ at PHUSE US Connect 2025](https://geninvo.com/geninvo-at-phuse-us-connect-2025/) [ ![Join GENINVO™ at the DIA Medical Affairs and Scientific Communications Forum](https://geninvo.com/wp-content/uploads/2025/02/GI-DIA-blogpost-mar2025-300x186.webp) ](https://geninvo.com/join-geninvo-at-the-dia-medical-affairs-and-scientific-communications-forum/) ## [Join GENINVO™ at the DIA Medical Affairs and Scientific Communications Forum](https://geninvo.com/join-geninvo-at-the-dia-medical-affairs-and-scientific-communications-forum/) [ ![Thank You for Attending the GENINVO’s AMWA Webinar](https://geninvo.com/wp-content/uploads/2024/11/blog-post-AMWA-24nov-300x169.webp) ](https://geninvo.com/thank-you-for-attending-the-geninvos-amwa-webinar/) ## [Thank You for Attending the GENINVO’s AMWA Webinar](https://geninvo.com/thank-you-for-attending-the-geninvos-amwa-webinar/) [ ![Join Our Free Webinar!](https://geninvo.com/wp-content/uploads/2024/10/GI-AMWA-blog-AI-writers-24-V2-300x169.webp) ](https://geninvo.com/join-our-free-webinar/) ## [Join Our Free Webinar!](https://geninvo.com/join-our-free-webinar/) [ ![Shake hands with GENINVO at DIA’s Global Clinical Trial Disclosure and Data Transparency Conference](https://geninvo.com/wp-content/uploads/2024/04/GI-and-sha-DIA-V1-3-300x169.jpg) ](https://geninvo.com/shake-hands-with-geninvo-at-dias-global-clinical-trial-disclosure-and-data-transparency-conference/) ## [Shake hands with GENINVO at DIA’s Global Clinical Trial Disclosure and Data Transparency Conference](https://geninvo.com/shake-hands-with-geninvo-at-dias-global-clinical-trial-disclosure-and-data-transparency-conference/) [ ![Meet GENINVO at DPHARM 2023 in Boston, MA!](https://geninvo.com/wp-content/uploads/2023/08/MicrosoftTeams-image-142-300x169.jpg) ](https://geninvo.com/meet-geninvo-at-dpharm-2023-in-boston-ma/) ## [Meet GENINVO at DPHARM 2023 in Boston, MA!](https://geninvo.com/meet-geninvo-at-dpharm-2023-in-boston-ma/) [ ![Shake hands with GENINVO at PHUSE CSS 2023! ](https://geninvo.com/wp-content/uploads/2023/08/MicrosoftTeams-image-151-300x169.jpg) ](https://geninvo.com/shake-hands-with-geninvo-at-phuse-css-2023/) ## [Shake hands with GENINVO at PHUSE CSS 2023! ](https://geninvo.com/shake-hands-with-geninvo-at-phuse-css-2023/) [ ![GENINVO is delighted to exhibit and present again at the PHUSE US Connect 2023! You can visit us at Booth #7.](https://geninvo.com/wp-content/uploads/2023/02/MicrosoftTeams-image-53-300x169.jpg) ](https://geninvo.com/phuse-us-connect-2023/) ## [GENINVO is delighted to exhibit and present again at the PHUSE US Connect 2023! You can visit us at Booth #7.](https://geninvo.com/phuse-us-connect-2023/) [ ![American Medical Writers Association (AMWA 2022)](https://geninvo.com/wp-content/uploads/2022/10/MicrosoftTeams-image-24-300x170.jpg) ](https://geninvo.com/american-medical-writers-association-amwa-2022/) ## [American Medical Writers Association (AMWA 2022)](https://geninvo.com/american-medical-writers-association-amwa-2022/) [ ![PHUSE EU Connect 2022](https://geninvo.com/wp-content/uploads/2022/10/MicrosoftTeams-image-23-300x170.jpg) ](https://geninvo.com/phuse-eu-connect-2022/) ## [PHUSE EU Connect 2022](https://geninvo.com/phuse-eu-connect-2022/) [ ![EU-CTR New regulations are here – Are you ready for the changes?](https://geninvo.com/wp-content/uploads/2022/09/MicrosoftTeams-image-8-300x172.jpg) ](https://geninvo.com/eu-ctr-new-regulations-are-here-are-you-ready-for-the-changes/) ## [EU-CTR New regulations are here – Are you ready for the changes?](https://geninvo.com/eu-ctr-new-regulations-are-here-are-you-ready-for-the-changes/) [ ![PHUSE’s Data Transparency Winter Event – virtual](https://geninvo.com/wp-content/uploads/2022/02/GI_phuse-8-10-feb-22-01-300x172.jpg) ](https://geninvo.com/phuses-data-transparency-winter-event-virtual/) ## [PHUSE’s Data Transparency Winter Event – virtual](https://geninvo.com/phuses-data-transparency-winter-event-virtual/) [ ![PHUSE US Connect 2022](https://geninvo.com/wp-content/uploads/2021/10/Phuse-event-US-May-300x169.png) ](https://geninvo.com/phuse-us-connect-2022/) ## [PHUSE US Connect 2022](https://geninvo.com/phuse-us-connect-2022/) ## News [ ![GENINVO Launches Centre of Excellence for Data Science and Analytics](https://geninvo.com/wp-content/uploads/2021/11/dsa-coe-300x170.jpg) ](https://geninvo.com/geninvo-launches-centre-of-excellence-for-data-science-and-analytics/) ## [GENINVO Launches Centre of Excellence for Data Science and Analytics](https://geninvo.com/geninvo-launches-centre-of-excellence-for-data-science-and-analytics/) [ ![NEW WEBSITE LAUNCH ANNOUNCEMENT](https://geninvo.com/wp-content/uploads/2021/06/feat-ns-300x170.jpg) ](https://geninvo.com/new-website-launch-announcement-geninvo-launches-updated-website/) ## [NEW WEBSITE LAUNCH ANNOUNCEMENT](https://geninvo.com/new-website-launch-announcement-geninvo-launches-updated-website/) [ ![GENINVO Launches Shadow™ Version 2](https://geninvo.com/wp-content/uploads/2021/03/feat-shadow-300x170.jpg) ](https://geninvo.com/geninvo-launches-shadow-version-2/) ## [GENINVO Launches Shadow™ Version 2](https://geninvo.com/geninvo-launches-shadow-version-2/) [ ![Youth Initiative – Introduction to Robotics Workshop](https://geninvo.com/wp-content/uploads/2021/10/event-feature-2020-300x170.jpg) ](https://geninvo.com/youth-initiative-introduction-to-robotics-workshop/) ## [Youth Initiative – Introduction to Robotics Workshop](https://geninvo.com/youth-initiative-introduction-to-robotics-workshop/) [ ![GENINVO Celebrates Anniversary](https://geninvo.com/wp-content/uploads/2021/05/feat-annivers-300x170.jpg) ](https://geninvo.com/geninvo-anniversary/) ## [GENINVO Celebrates Anniversary](https://geninvo.com/geninvo-anniversary/) [ ![GENINVO Announces Upcoming Version Launch of Shadow™](https://geninvo.com/wp-content/uploads/2021/03/feat-shadow-300x170.jpg) ](https://geninvo.com/geninvo-announces-upcoming-launch-of-shadow-version-2/) ## [GENINVO Announces Upcoming Version Launch of Shadow™](https://geninvo.com/geninvo-announces-upcoming-launch-of-shadow-version-2/) [ ![GENINVO provides technological solutions to the problems in Life Sciences and Pharmaceutical Industry.](https://geninvo.com/wp-content/uploads/2021/05/feat-lsp-300x170.jpg) ](https://geninvo.com/geninvo-provides-technological-solutions-to-the-problems-in-life-sciences-and-pharmaceutical-industry/) ## [GENINVO provides technological solutions to the problems in Life Sciences and Pharmaceutical Industry.](https://geninvo.com/geninvo-provides-technological-solutions-to-the-problems-in-life-sciences-and-pharmaceutical-industry/) [ ![See the Impact of Innovation](https://geninvo.com/wp-content/uploads/2021/05/feat-impact-300x170.jpg) ](https://geninvo.com/see-the-impact-of-innovation/) ## [See the Impact of Innovation](https://geninvo.com/see-the-impact-of-innovation/) [ ![Standing strong with Community](https://geninvo.com/wp-content/uploads/2021/03/feat-stand-str-300x170.jpg) ](https://geninvo.com/standing-strong-with-community/) ## [Standing strong with Community](https://geninvo.com/standing-strong-with-community/) [ ![COVID-19](https://geninvo.com/wp-content/uploads/2021/03/feat-covid-300x170.jpg) ](https://geninvo.com/covid-19/) ## [COVID-19](https://geninvo.com/covid-19/) ## Videos [ ![Shadow for EU-CTR Compliance](https://geninvo.com/wp-content/uploads/2022/11/2022-11-29T20_55_50-300x168.png) ](https://geninvo.com/shadow-for-eu-ctr-compliance/) ## [Shadow for EU-CTR Compliance](https://geninvo.com/shadow-for-eu-ctr-compliance/) [ ![DocQC – Medical Writers automation tool for QC checks](https://geninvo.com/wp-content/uploads/2021/04/docqc-img-overlay-300x171.png) ](https://geninvo.com/docqc-medical-writers-automation-tool-for-qc-checks/) ## [DocQC – Medical Writers automation tool for QC checks](https://geninvo.com/docqc-medical-writers-automation-tool-for-qc-checks/) [ ![Shadow- Risk Analysis Tool](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-shadow-1-e1617726618274-300x168.jpg) ](https://geninvo.com/shadow-risk-analysis-tool/) ## [Shadow- Risk Analysis Tool](https://geninvo.com/shadow-risk-analysis-tool/) [ ![Shadow- Data Anonymization Tool](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-shadow-2-e1617726656616-300x144.jpg) ](https://geninvo.com/shadow-data-anonymization-tool/) ## [Shadow- Data Anonymization Tool](https://geninvo.com/shadow-data-anonymization-tool/) [ ![DocQc – Medical Writer’s Best Friend](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-docqc-300x210.jpg) ](https://geninvo.com/docqc-medical-writers-best-friend/) ## [DocQc – Medical Writer’s Best Friend](https://geninvo.com/docqc-medical-writers-best-friend/) [ ![GENINVO Anniversary](https://geninvo.com/wp-content/uploads/2021/04/overlay_annv-300x168.jpg) ](https://geninvo.com/geninvo-anniversary-2/) ## [GENINVO Anniversary](https://geninvo.com/geninvo-anniversary-2/) [ ![Shadow – Health Canada, France’s MR001-MR004, EMA Policy 0070 (Phase 1 and 2), compliant](https://geninvo.com/wp-content/uploads/2021/04/overlay_sh-300x168.jpg) ](https://geninvo.com/shadow-health-canada-frances-mr001-mr004-ema-policy-0070-phase-1-and-2-compliant/) ## [Shadow – Health Canada, France’s MR001-MR004, EMA Policy 0070 (Phase 1 and 2), compliant](https://geninvo.com/shadow-health-canada-frances-mr001-mr004-ema-policy-0070-phase-1-and-2-compliant/) [ ![Shadow – Solution to Evolving Data Transparency Requirements](https://geninvo.com/wp-content/uploads/2021/04/healthcanadapolicy-over-300x170.jpg) ](https://geninvo.com/shadow-solution-to-evolving-data-transparency-requirements/) ## [Shadow – Solution to Evolving Data Transparency Requirements](https://geninvo.com/shadow-solution-to-evolving-data-transparency-requirements/) [ ![Machine Learning – Shadow](https://geninvo.com/wp-content/uploads/2021/04/overlay_ml-300x168.jpg) ](https://geninvo.com/machine-learning-shadow/) ## [Machine Learning – Shadow](https://geninvo.com/machine-learning-shadow/) [ ![GENINVO – Covid-19](https://geninvo.com/wp-content/uploads/2021/04/covid-over-300x170.jpg) ](https://geninvo.com/geninvo-covid-19/) ## [GENINVO – Covid-19](https://geninvo.com/geninvo-covid-19/) [ ![Shadow](https://geninvo.com/wp-content/uploads/2021/04/shadow-over-300x170.jpg) ](https://geninvo.com/shadow-video/) ## [Shadow](https://geninvo.com/shadow-video/) [ ![ApoGI](https://geninvo.com/wp-content/uploads/2021/04/apogi-over-300x170.jpg) ](https://geninvo.com/apogi-video/) ## [ApoGI](https://geninvo.com/apogi-video/) [ ![DocQC](https://geninvo.com/wp-content/uploads/2021/04/docqc-over-300x170.jpg) ](https://geninvo.com/docqc-video/) ## [DocQC](https://geninvo.com/docqc-video/) [ ![GENINVO](https://geninvo.com/wp-content/uploads/2021/04/self_animation-300x169.jpg) ](https://geninvo.com/geninvo-video/) ## [GENINVO](https://geninvo.com/geninvo-video/) --- ### [videos-section-tab](https://geninvo.com/?elementor_library=videos-section-tab) **Published:** April 6, 2021 **Author:** admin **Content:** ## Videos [ ![Shadow for EU-CTR Compliance](https://geninvo.com/wp-content/uploads/2022/11/2022-11-29T20_55_50-300x168.png) ](https://geninvo.com/shadow-for-eu-ctr-compliance/) ## [Shadow for EU-CTR Compliance](https://geninvo.com/shadow-for-eu-ctr-compliance/) [ ![DocQC – Medical Writers automation tool for QC checks](https://geninvo.com/wp-content/uploads/2021/04/docqc-img-overlay-300x171.png) ](https://geninvo.com/docqc-medical-writers-automation-tool-for-qc-checks/) ## [DocQC – Medical Writers automation tool for QC checks](https://geninvo.com/docqc-medical-writers-automation-tool-for-qc-checks/) [ ![Shadow- Risk Analysis Tool](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-shadow-1-e1617726618274-300x168.jpg) ](https://geninvo.com/shadow-risk-analysis-tool/) ## [Shadow- Risk Analysis Tool](https://geninvo.com/shadow-risk-analysis-tool/) [ ![Shadow- Data Anonymization Tool](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-shadow-2-e1617726656616-300x144.jpg) ](https://geninvo.com/shadow-data-anonymization-tool/) ## [Shadow- Data Anonymization Tool](https://geninvo.com/shadow-data-anonymization-tool/) [ ![DocQc – Medical Writer’s Best Friend](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-docqc-300x210.jpg) ](https://geninvo.com/docqc-medical-writers-best-friend/) ## [DocQc – Medical Writer’s Best Friend](https://geninvo.com/docqc-medical-writers-best-friend/) [ ![GENINVO Anniversary](https://geninvo.com/wp-content/uploads/2021/04/overlay_annv-300x168.jpg) ](https://geninvo.com/geninvo-anniversary-2/) ## [GENINVO Anniversary](https://geninvo.com/geninvo-anniversary-2/) [ ![Shadow – Health Canada, France’s MR001-MR004, EMA Policy 0070 (Phase 1 and 2), compliant](https://geninvo.com/wp-content/uploads/2021/04/overlay_sh-300x168.jpg) ](https://geninvo.com/shadow-health-canada-frances-mr001-mr004-ema-policy-0070-phase-1-and-2-compliant/) ## [Shadow – Health Canada, France’s MR001-MR004, EMA Policy 0070 (Phase 1 and 2), compliant](https://geninvo.com/shadow-health-canada-frances-mr001-mr004-ema-policy-0070-phase-1-and-2-compliant/) [ ![Shadow – Solution to Evolving Data Transparency Requirements](https://geninvo.com/wp-content/uploads/2021/04/healthcanadapolicy-over-300x170.jpg) ](https://geninvo.com/shadow-solution-to-evolving-data-transparency-requirements/) ## [Shadow – Solution to Evolving Data Transparency Requirements](https://geninvo.com/shadow-solution-to-evolving-data-transparency-requirements/) [ ![Machine Learning – Shadow](https://geninvo.com/wp-content/uploads/2021/04/overlay_ml-300x168.jpg) ](https://geninvo.com/machine-learning-shadow/) ## [Machine Learning – Shadow](https://geninvo.com/machine-learning-shadow/) [ ![GENINVO – Covid-19](https://geninvo.com/wp-content/uploads/2021/04/covid-over-300x170.jpg) ](https://geninvo.com/geninvo-covid-19/) ## [GENINVO – Covid-19](https://geninvo.com/geninvo-covid-19/) [ ![Shadow](https://geninvo.com/wp-content/uploads/2021/04/shadow-over-300x170.jpg) ](https://geninvo.com/shadow-video/) ## [Shadow](https://geninvo.com/shadow-video/) [ ![ApoGI](https://geninvo.com/wp-content/uploads/2021/04/apogi-over-300x170.jpg) ](https://geninvo.com/apogi-video/) ## [ApoGI](https://geninvo.com/apogi-video/) [ ![DocQC](https://geninvo.com/wp-content/uploads/2021/04/docqc-over-300x170.jpg) ](https://geninvo.com/docqc-video/) ## [DocQC](https://geninvo.com/docqc-video/) [ ![GENINVO](https://geninvo.com/wp-content/uploads/2021/04/self_animation-300x169.jpg) ](https://geninvo.com/geninvo-video/) ## [GENINVO](https://geninvo.com/geninvo-video/) --- ### [news-section-tab](https://geninvo.com/?elementor_library=news-section-tab) **Published:** April 6, 2021 **Author:** admin **Content:** ## News [ ![GENINVO Launches Centre of Excellence for Data Science and Analytics](https://geninvo.com/wp-content/uploads/2021/11/dsa-coe-300x170.jpg) ](https://geninvo.com/geninvo-launches-centre-of-excellence-for-data-science-and-analytics/) ## [GENINVO Launches Centre of Excellence for Data Science and Analytics](https://geninvo.com/geninvo-launches-centre-of-excellence-for-data-science-and-analytics/) [ ![NEW WEBSITE LAUNCH ANNOUNCEMENT](https://geninvo.com/wp-content/uploads/2021/06/feat-ns-300x170.jpg) ](https://geninvo.com/new-website-launch-announcement-geninvo-launches-updated-website/) ## [NEW WEBSITE LAUNCH ANNOUNCEMENT](https://geninvo.com/new-website-launch-announcement-geninvo-launches-updated-website/) [ ![GENINVO Launches Shadow™ Version 2](https://geninvo.com/wp-content/uploads/2021/03/feat-shadow-300x170.jpg) ](https://geninvo.com/geninvo-launches-shadow-version-2/) ## [GENINVO Launches Shadow™ Version 2](https://geninvo.com/geninvo-launches-shadow-version-2/) [ ![Youth Initiative – Introduction to Robotics Workshop](https://geninvo.com/wp-content/uploads/2021/10/event-feature-2020-300x170.jpg) ](https://geninvo.com/youth-initiative-introduction-to-robotics-workshop/) ## [Youth Initiative – Introduction to Robotics Workshop](https://geninvo.com/youth-initiative-introduction-to-robotics-workshop/) [ ![GENINVO Celebrates Anniversary](https://geninvo.com/wp-content/uploads/2021/05/feat-annivers-300x170.jpg) ](https://geninvo.com/geninvo-anniversary/) ## [GENINVO Celebrates Anniversary](https://geninvo.com/geninvo-anniversary/) [ ![GENINVO Announces Upcoming Version Launch of Shadow™](https://geninvo.com/wp-content/uploads/2021/03/feat-shadow-300x170.jpg) ](https://geninvo.com/geninvo-announces-upcoming-launch-of-shadow-version-2/) ## [GENINVO Announces Upcoming Version Launch of Shadow™](https://geninvo.com/geninvo-announces-upcoming-launch-of-shadow-version-2/) [ ![GENINVO provides technological solutions to the problems in Life Sciences and Pharmaceutical Industry.](https://geninvo.com/wp-content/uploads/2021/05/feat-lsp-300x170.jpg) ](https://geninvo.com/geninvo-provides-technological-solutions-to-the-problems-in-life-sciences-and-pharmaceutical-industry/) ## [GENINVO provides technological solutions to the problems in Life Sciences and Pharmaceutical Industry.](https://geninvo.com/geninvo-provides-technological-solutions-to-the-problems-in-life-sciences-and-pharmaceutical-industry/) [ ![See the Impact of Innovation](https://geninvo.com/wp-content/uploads/2021/05/feat-impact-300x170.jpg) ](https://geninvo.com/see-the-impact-of-innovation/) ## [See the Impact of Innovation](https://geninvo.com/see-the-impact-of-innovation/) [ ![Standing strong with Community](https://geninvo.com/wp-content/uploads/2021/03/feat-stand-str-300x170.jpg) ](https://geninvo.com/standing-strong-with-community/) ## [Standing strong with Community](https://geninvo.com/standing-strong-with-community/) [ ![COVID-19](https://geninvo.com/wp-content/uploads/2021/03/feat-covid-300x170.jpg) ](https://geninvo.com/covid-19/) ## [COVID-19](https://geninvo.com/covid-19/) --- ### [events-section-tab](https://geninvo.com/?elementor_library=events-section-tab) **Published:** April 6, 2021 **Author:** admin **Content:** ## Events [ ![Meet GenInvo at DPHARM 2026, Booth 116, Boston](https://geninvo.com/wp-content/uploads/2026/06/DPHARM-1-300x186.png) ](https://geninvo.com/dpharm-2026/) ## [Meet GenInvo at DPHARM 2026, Booth 116, Boston](https://geninvo.com/dpharm-2026/) [ ![Meet GENINVO at the EMWA 61st Spring Conference 2026](https://geninvo.com/wp-content/uploads/2026/04/539-X-334-1-300x186.png) ](https://geninvo.com/emwa-2026-barcelona/) ## [Meet GENINVO at the EMWA 61st Spring Conference 2026](https://geninvo.com/emwa-2026-barcelona/) [ ![GenInvo at PharmaSUG 2026 SDE Conference](https://geninvo.com/wp-content/uploads/2026/04/539-X-334-300x186.png) ](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) ## [GenInvo at PharmaSUG 2026 SDE Conference](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) [ ![GenInvo @ PHUSE US Connect 2026](https://geninvo.com/wp-content/uploads/2026/03/image-16-300x186.png) ](https://geninvo.com/geninvo-phuse-us-connect-2026/) ## [GenInvo @ PHUSE US Connect 2026](https://geninvo.com/geninvo-phuse-us-connect-2026/) [ ![Live Webinar: Accelerating Authoring and QC of Clinical Documents with AI-Powered Automation](https://geninvo.com/wp-content/uploads/2025/08/Blog-9-300x186.jpg) ](https://geninvo.com/live-webinar-accelerating-authoring-and-qc-of-clinical-documents-with-ai-powered-automation/) ## [Live Webinar: Accelerating Authoring and QC of Clinical Documents with AI-Powered Automation](https://geninvo.com/live-webinar-accelerating-authoring-and-qc-of-clinical-documents-with-ai-powered-automation/) [ ![GenInvo is Powering the Future of Medical Writing at AMWA 2025!](https://geninvo.com/wp-content/uploads/2025/08/GI-AMWA-conference-blog-2025-300x186.jpg) ](https://geninvo.com/geninvo-is-powering-the-future-of-medical-writing-at-amwa-2025/) ## [GenInvo is Powering the Future of Medical Writing at AMWA 2025!](https://geninvo.com/geninvo-is-powering-the-future-of-medical-writing-at-amwa-2025/) [ ![GENINVO™ Sponsors PHUSE Data Transparency Autumn Event 2025](https://geninvo.com/wp-content/uploads/2025/07/Blog-GI-Phusevirtualevent-Sept-2025-300x189.jpg) ](https://geninvo.com/geninvo-sponsors-phuse-data-transparency-autumn-event-2025/) ## [GENINVO™ Sponsors PHUSE Data Transparency Autumn Event 2025](https://geninvo.com/geninvo-sponsors-phuse-data-transparency-autumn-event-2025/) [ ![GENINVO™ at PHUSE US Connect 2025](https://geninvo.com/wp-content/uploads/2025/02/GI-US-PHUSE-connect-2025-300x186.jpg) ](https://geninvo.com/geninvo-at-phuse-us-connect-2025/) ## [GENINVO™ at PHUSE US Connect 2025](https://geninvo.com/geninvo-at-phuse-us-connect-2025/) [ ![Join GENINVO™ at the DIA Medical Affairs and Scientific Communications Forum](https://geninvo.com/wp-content/uploads/2025/02/GI-DIA-blogpost-mar2025-300x186.webp) ](https://geninvo.com/join-geninvo-at-the-dia-medical-affairs-and-scientific-communications-forum/) ## [Join GENINVO™ at the DIA Medical Affairs and Scientific Communications Forum](https://geninvo.com/join-geninvo-at-the-dia-medical-affairs-and-scientific-communications-forum/) [ ![Thank You for Attending the GENINVO’s AMWA Webinar](https://geninvo.com/wp-content/uploads/2024/11/blog-post-AMWA-24nov-300x169.webp) ](https://geninvo.com/thank-you-for-attending-the-geninvos-amwa-webinar/) ## [Thank You for Attending the GENINVO’s AMWA Webinar](https://geninvo.com/thank-you-for-attending-the-geninvos-amwa-webinar/) [ ![Join Our Free Webinar!](https://geninvo.com/wp-content/uploads/2024/10/GI-AMWA-blog-AI-writers-24-V2-300x169.webp) ](https://geninvo.com/join-our-free-webinar/) ## [Join Our Free Webinar!](https://geninvo.com/join-our-free-webinar/) [ ![Shake hands with GENINVO at DIA’s Global Clinical Trial Disclosure and Data Transparency Conference](https://geninvo.com/wp-content/uploads/2024/04/GI-and-sha-DIA-V1-3-300x169.jpg) ](https://geninvo.com/shake-hands-with-geninvo-at-dias-global-clinical-trial-disclosure-and-data-transparency-conference/) ## [Shake hands with GENINVO at DIA’s Global Clinical Trial Disclosure and Data Transparency Conference](https://geninvo.com/shake-hands-with-geninvo-at-dias-global-clinical-trial-disclosure-and-data-transparency-conference/) [ ![Meet GENINVO at DPHARM 2023 in Boston, MA!](https://geninvo.com/wp-content/uploads/2023/08/MicrosoftTeams-image-142-300x169.jpg) ](https://geninvo.com/meet-geninvo-at-dpharm-2023-in-boston-ma/) ## [Meet GENINVO at DPHARM 2023 in Boston, MA!](https://geninvo.com/meet-geninvo-at-dpharm-2023-in-boston-ma/) [ ![Shake hands with GENINVO at PHUSE CSS 2023! ](https://geninvo.com/wp-content/uploads/2023/08/MicrosoftTeams-image-151-300x169.jpg) ](https://geninvo.com/shake-hands-with-geninvo-at-phuse-css-2023/) ## [Shake hands with GENINVO at PHUSE CSS 2023! ](https://geninvo.com/shake-hands-with-geninvo-at-phuse-css-2023/) [ ![GENINVO is delighted to exhibit and present again at the PHUSE US Connect 2023! You can visit us at Booth #7.](https://geninvo.com/wp-content/uploads/2023/02/MicrosoftTeams-image-53-300x169.jpg) ](https://geninvo.com/phuse-us-connect-2023/) ## [GENINVO is delighted to exhibit and present again at the PHUSE US Connect 2023! You can visit us at Booth #7.](https://geninvo.com/phuse-us-connect-2023/) [ ![American Medical Writers Association (AMWA 2022)](https://geninvo.com/wp-content/uploads/2022/10/MicrosoftTeams-image-24-300x170.jpg) ](https://geninvo.com/american-medical-writers-association-amwa-2022/) ## [American Medical Writers Association (AMWA 2022)](https://geninvo.com/american-medical-writers-association-amwa-2022/) [ ![PHUSE EU Connect 2022](https://geninvo.com/wp-content/uploads/2022/10/MicrosoftTeams-image-23-300x170.jpg) ](https://geninvo.com/phuse-eu-connect-2022/) ## [PHUSE EU Connect 2022](https://geninvo.com/phuse-eu-connect-2022/) [ ![EU-CTR New regulations are here – Are you ready for the changes?](https://geninvo.com/wp-content/uploads/2022/09/MicrosoftTeams-image-8-300x172.jpg) ](https://geninvo.com/eu-ctr-new-regulations-are-here-are-you-ready-for-the-changes/) ## [EU-CTR New regulations are here – Are you ready for the changes?](https://geninvo.com/eu-ctr-new-regulations-are-here-are-you-ready-for-the-changes/) [ ![PHUSE’s Data Transparency Winter Event – virtual](https://geninvo.com/wp-content/uploads/2022/02/GI_phuse-8-10-feb-22-01-300x172.jpg) ](https://geninvo.com/phuses-data-transparency-winter-event-virtual/) ## [PHUSE’s Data Transparency Winter Event – virtual](https://geninvo.com/phuses-data-transparency-winter-event-virtual/) [ ![PHUSE US Connect 2022](https://geninvo.com/wp-content/uploads/2021/10/Phuse-event-US-May-300x169.png) ](https://geninvo.com/phuse-us-connect-2022/) ## [PHUSE US Connect 2022](https://geninvo.com/phuse-us-connect-2022/) --- ### [case-studies-section-tab](https://geninvo.com/?elementor_library=case-studies-section-tab) **Published:** April 6, 2021 **Author:** admin **Content:** ## Case Studies [ ![White List & Black List: Enhanced NER Model](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-10-Case-Study-WB-List_v3-300x169.jpg) ](https://geninvo.com/white-list-black-list-enhanced-ner-model/) ## [White List & Black List: Enhanced NER Model](https://geninvo.com/white-list-black-list-enhanced-ner-model/) [ ![NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity-300x169.jpg) ](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) ## [NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) [ ![DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-12-Eprotocol-presentation-300x169.jpg) ](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) ## [DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) [ ![Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-13-Shadow-Recommendation-Engine-300x169.jpg) ](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) ## [Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) [ ![Lung Cancer Detection](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-8-Lung-Cancer-Detection-use-cases-300x169.jpg) ](https://geninvo.com/lung-cancer-detection/) ## [Lung Cancer Detection](https://geninvo.com/lung-cancer-detection/) [ ![Breast Cancer Detection Using Machine Learning](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-9-Case-Study-Breast-Cancer-Detection_v3-use-cases-300x169.jpg) ](https://geninvo.com/breast-cancer-detection-using-machine-learning/) ## [Breast Cancer Detection Using Machine Learning](https://geninvo.com/breast-cancer-detection-using-machine-learning/) [ ![Doc QC tool as a one-stop solution for all Quality Control (QC) needs of a medical writer](https://geninvo.com/wp-content/uploads/2021/08/Case-Studies-8-DocQC-300x169.jpg) ](https://geninvo.com/doc-qc-tool-as-a-one-stop-solution-for-all-quality-control-qc-needs-of-a-medical-writer/) ## [Doc QC tool as a one-stop solution for all Quality Control (QC) needs of a medical writer](https://geninvo.com/doc-qc-tool-as-a-one-stop-solution-for-all-quality-control-qc-needs-of-a-medical-writer/) [ ![Provide ApoGI as a Metadata Driven Platform](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-7-300x169.jpg) ](https://geninvo.com/provide-apogitmas-a-metadatadriven-platform/) ## [Provide ApoGI as a Metadata Driven Platform](https://geninvo.com/provide-apogitmas-a-metadatadriven-platform/) [ ![Provide ApoGI as a MDR Visualization](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-6-300x169.jpg) ](https://geninvo.com/provide-apogitmas-a-mdrvisualization/) ## [Provide ApoGI as a MDR Visualization](https://geninvo.com/provide-apogitmas-a-mdrvisualization/) [ ![Provide ApoGI as a Metadata Driven Transformations](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-5-300x169.jpg) ](https://geninvo.com/provide-apogitm-asa-metadata-driventransformations/) ## [Provide ApoGI as a Metadata Driven Transformations](https://geninvo.com/provide-apogitm-asa-metadata-driventransformations/) [ ![How a Big Pharma Company Achieved Compliance with Health Canada Under Tight Deadlines](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-4-300x169.jpg) ](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-health-canada-under-tight-deadlines/) ## [How a Big Pharma Company Achieved Compliance with Health Canada Under Tight Deadlines](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-health-canada-under-tight-deadlines/) [ ![How a Pharmaceutical Firm Established Anonymization Process](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-3-300x169.jpg) ](https://geninvo.com/how-a-pharmaceutical-firm-established-anonymization-process/) ## [How a Pharmaceutical Firm Established Anonymization Process](https://geninvo.com/how-a-pharmaceutical-firm-established-anonymization-process/) [ ![Big Pharma Company Achieves Compliance with EMA 0070 Policy](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-2-300x169.jpg) ](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-ema-0070-policy-with-a-tight-deadline/) ## [Big Pharma Company Achieves Compliance with EMA 0070 Policy](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-ema-0070-policy-with-a-tight-deadline/) [ ![How a Global Medical Writing CRO Increased Functional Capability with Shadow™](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-1-300x169.jpg) ](https://geninvo.com/how-a-global-medical-writing-cro-increased-functional-capability-with-shadowtm/) ## [How a Global Medical Writing CRO Increased Functional Capability with Shadow™](https://geninvo.com/how-a-global-medical-writing-cro-increased-functional-capability-with-shadowtm/) --- ### [all-section-tabs-noslide](https://geninvo.com/?elementor_library=all-section-tabs-noslide) **Published:** April 8, 2021 **Author:** admin **Content:** ## Blogs [ ](https://geninvo.com/insights/blog/) ![](https://geninvo.com/wp-content/uploads/2025/10/Blog-12.jpg "Blog-12 - GenInvo - GenInvo") ##### Quantitative Risk Assessment: A Smarter Approach to Clinical Data Anonymization [ Read More ](https://geninvo.com/quantitative-risk-assessment-a-smarter-approach-to-clinical-data-anonymization/) ![](https://geninvo.com/wp-content/uploads/2025/09/Blog-11.jpg "Blog-11 - GenInvo - GenInvo") ##### Secure Scanning with Confidential Information Scanner: Safeguarding Your CCIs During Clinical Research [ Read More ](https://geninvo.com/secure-scanning-with-confidential-information-scanner-safeguarding-your-ccis-during-clinical-research/) ![Clinical Trials](https://geninvo.com/wp-content/uploads/2025/08/Blog-8.jpg "Blog-8 - GenInvo - GenInvo") ##### Python’s Future in Clinical Trials: Innovations and Collaborative Advancements [ Read More ](https://geninvo.com/pythons-future-in-clinical-trials-innovations-and-collaborative-advancements/) ## Case Studies [ ![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-10-Case-Study-WB-List_v3.jpg "Case-Studies-10-Case-Study-WB-List_v3 - GenInvo - GenInvo") ](https://geninvo.com/white-list-black-list-enhanced-ner-model/) - September 17, 2021 ##### [White List & Black List: Enhanced NER Model](https://geninvo.com/white-list-black-list-enhanced-ner-model/) [ Read More ](https://geninvo.com/white-list-black-list-enhanced-ner-model/) [ ![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity.jpg "Case-Studies-11-DocQc-Table-41---NLP-for-Text-Similarity - GenInvo - GenInvo") ](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) - September 17, 2021 ##### [NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) [ Read More ](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) [ ![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-12-Eprotocol-presentation.jpg "Case-Studies-12-Eprotocol-presentation - GenInvo - GenInvo") ](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) - September 17, 2021 ##### [DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) [ Read More ](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) [ ](https://geninvo.com/insights/case-studies/) ## News [ ![](https://geninvo.com/wp-content/uploads/2021/11/dsa-coe.jpg "dsa-coe - GenInvo - GenInvo") ](https://geninvo.com/geninvo-launches-centre-of-excellence-for-data-science-and-analytics/) - November 16, 2021 ##### [GENINVO Launches Centre of Excellence for Data Science and Analytics](https://geninvo.com/geninvo-launches-centre-of-excellence-for-data-science-and-analytics/) [ Read More ](https://geninvo.com/geninvo-launches-centre-of-excellence-for-data-science-and-analytics/) [ ![](https://geninvo.com/wp-content/uploads/2021/06/feat-ns.jpg "feat-ns - GenInvo - GenInvo") ](https://geninvo.com/new-website-launch-announcement-geninvo-launches-updated-website/) - June 15, 2021 ##### [NEW WEBSITE LAUNCH ANNOUNCEMENT](https://geninvo.com/new-website-launch-announcement-geninvo-launches-updated-website/) [ Read More ](https://geninvo.com/new-website-launch-announcement-geninvo-launches-updated-website/) [ ![](https://geninvo.com/wp-content/uploads/2021/03/feat-shadow.jpg "feat-shadow - GenInvo - GenInvo") ](https://geninvo.com/geninvo-launches-shadow-version-2/) - November 6, 2020 ##### [GENINVO Launches Shadow™ Version 2](https://geninvo.com/geninvo-launches-shadow-version-2/) [ Read More ](https://geninvo.com/geninvo-launches-shadow-version-2/) [ ](https://geninvo.com/insights/news/) ## Events [![Geninvo at Dpharm 2026 Banner: Sept 15–16, 2026 in Boston, Usa; Sheraton Boston Hotel Exhibition Booth #116.](https://geninvo.com/wp-content/uploads/2026/06/DPHARM-1-300x186.png "Meet Geninvo at DPHARM 2026 — Booth 116, Boston - GenInvo - GenInvo") ](https://geninvo.com/dpharm-2026/)### [ Meet GenInvo at DPHARM 2026, Booth 116, Boston ](https://geninvo.com/dpharm-2026/) [ Read More ](https://geninvo.com/dpharm-2026/) [![Geninvo Booth 10 at Emwa 61st Spring Conference 2026 Barcelona.](https://geninvo.com/wp-content/uploads/2026/04/539-X-334-1-300x186.png "539 X 334 1 - GenInvo - GenInvo") ](https://geninvo.com/emwa-2026-barcelona/)### [ Meet GENINVO at the EMWA 61st Spring Conference 2026 ](https://geninvo.com/emwa-2026-barcelona/) [ Read More ](https://geninvo.com/emwa-2026-barcelona/) [ ](https://geninvo.com/insights/events/) ## Videos [ ![](https://geninvo.com/wp-content/uploads/2022/11/2022-11-29T20_55_50-1024x575.png "2022-11-29T20_55_50 - GenInvo - GenInvo") ](https://geninvo.com/shadow-for-eu-ctr-compliance/) ##### [Shadow for EU-CTR Compliance](https://geninvo.com/shadow-for-eu-ctr-compliance/) [ Watch Video ](https://geninvo.com/shadow-for-eu-ctr-compliance/) [ ![](https://geninvo.com/wp-content/uploads/2021/04/docqc-img-overlay.png "docqc-img-overlay - GenInvo - GenInvo") ](https://geninvo.com/docqc-medical-writers-automation-tool-for-qc-checks/) ##### [DocQC - Medical Writers automation tool for QC checks](https://geninvo.com/docqc-medical-writers-automation-tool-for-qc-checks/) [ Watch Video ](https://geninvo.com/docqc-medical-writers-automation-tool-for-qc-checks/) [ ![](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-shadow-1-1024x717.jpg "Mockups Design - GenInvo - GenInvo") ](https://geninvo.com/shadow-risk-analysis-tool/) ##### [Shadow- Risk Analysis Tool](https://geninvo.com/shadow-risk-analysis-tool/) [ Watch Video ](https://geninvo.com/shadow-risk-analysis-tool/) [ ](https://geninvo.com/insights/videos/) --- ### [insights-template](https://geninvo.com/?elementor_library=news-template) **Published:** April 7, 2021 **Author:** admin **Content:** ## Blogs [ ![Quantitative Risk Assessment: A Smarter Approach to Clinical Data Anonymization ](https://geninvo.com/wp-content/uploads/2025/10/Blog-12-300x189.jpg) ](https://geninvo.com/quantitative-risk-assessment-a-smarter-approach-to-clinical-data-anonymization/) ## [Quantitative Risk Assessment: A Smarter Approach to Clinical Data Anonymization ](https://geninvo.com/quantitative-risk-assessment-a-smarter-approach-to-clinical-data-anonymization/) [ ![Secure Scanning with Confidential Information Scanner: Safeguarding Your CCIs During Clinical Research](https://geninvo.com/wp-content/uploads/2025/09/Blog-11-300x189.jpg) ](https://geninvo.com/secure-scanning-with-confidential-information-scanner-safeguarding-your-ccis-during-clinical-research/) ## [Secure Scanning with Confidential Information Scanner: Safeguarding Your CCIs During Clinical Research](https://geninvo.com/secure-scanning-with-confidential-information-scanner-safeguarding-your-ccis-during-clinical-research/) [ ![Python’s Future in Clinical Trials: Innovations and Collaborative Advancements](https://geninvo.com/wp-content/uploads/2025/08/Blog-8-300x189.jpg) ](https://geninvo.com/pythons-future-in-clinical-trials-innovations-and-collaborative-advancements/) ## [Python’s Future in Clinical Trials: Innovations and Collaborative Advancements](https://geninvo.com/pythons-future-in-clinical-trials-innovations-and-collaborative-advancements/) [ ![The Changing Role of the Clinical Programmer in an Open-Source World](https://geninvo.com/wp-content/uploads/2025/07/Blog-7-300x189.jpg) ](https://geninvo.com/the-changing-role-of-the-clinical-programmer-in-an-open-source-world/) ## [The Changing Role of the Clinical Programmer in an Open-Source World](https://geninvo.com/the-changing-role-of-the-clinical-programmer-in-an-open-source-world/) [ ![Beyond the Buzzwords: How GenInvo’s AI/ML Tools Are Transforming Life Sciences](https://geninvo.com/wp-content/uploads/2025/07/Blog-6-300x189.jpg) ](https://geninvo.com/ai-ml-tools-life-sciences-geninvo/) ## [Beyond the Buzzwords: How GenInvo’s AI/ML Tools Are Transforming Life Sciences](https://geninvo.com/ai-ml-tools-life-sciences-geninvo/) [ ![Empowering the Future of Life Sciences: A GenInvo Perspective from the Inside](https://geninvo.com/wp-content/uploads/2025/06/Blog-5-300x196.jpg) ](https://geninvo.com/empowering-the-future-of-life-sciences-a-geninvo-perspective-from-the-inside/) ## [Empowering the Future of Life Sciences: A GenInvo Perspective from the Inside](https://geninvo.com/empowering-the-future-of-life-sciences-a-geninvo-perspective-from-the-inside/) [ ![GenInvo’s CIS Tool: Safeguarding Confidential Company Information in Life Sciences.](https://geninvo.com/wp-content/uploads/2025/06/Blog-4-300x196.jpg) ](https://geninvo.com/geninvos-cis-tool-safeguarding-confidential-company-information-in-life-sciences/) ## [GenInvo’s CIS Tool: Safeguarding Confidential Company Information in Life Sciences.](https://geninvo.com/geninvos-cis-tool-safeguarding-confidential-company-information-in-life-sciences/) [ ![Why Clinical Data Transparency Matters: Benefits for Patients, Researchers, and Industry](https://geninvo.com/wp-content/uploads/2025/06/Blog-3-300x196.jpg) ](https://geninvo.com/why-clinical-data-transparency-matters-benefits-for-patients-researchers-and-industry/) ## [Why Clinical Data Transparency Matters: Benefits for Patients, Researchers, and Industry](https://geninvo.com/why-clinical-data-transparency-matters-benefits-for-patients-researchers-and-industry/) [ ![How Meaningful Synthetic Data Generation Tools Are Transforming AI Development ](https://geninvo.com/wp-content/uploads/2025/01/Blog-2-300x169.jpg) ](https://geninvo.com/how-meaningful-synthetic-data-generation-tools-are-transforming-ai-development/) ## [How Meaningful Synthetic Data Generation Tools Are Transforming AI Development ](https://geninvo.com/how-meaningful-synthetic-data-generation-tools-are-transforming-ai-development/) [ ![Empowering Clinical and Regulatory Writing: Harnessing AI as Your Assistant  ](https://geninvo.com/wp-content/uploads/2024/10/Untitled-1-1-300x189.webp) ](https://geninvo.com/empowering-clinical-and-regulatory-writing-harnessing-ai-as-your-assistant/) ## [Empowering Clinical and Regulatory Writing: Harnessing AI as Your Assistant ](https://geninvo.com/empowering-clinical-and-regulatory-writing-harnessing-ai-as-your-assistant/) [ ![The Impact of AI on Medical Writing: How Artificial Intelligence is Revolutionizing Medical Content Creation ](https://geninvo.com/wp-content/uploads/2024/09/mdw-1-300x169.jpg) ](https://geninvo.com/the-impact-of-ai-on-medical-writing-how-artificial-intelligence-is-revolutionizing-medical-content-creation/) ## [The Impact of AI on Medical Writing: How Artificial Intelligence is Revolutionizing Medical Content Creation ](https://geninvo.com/the-impact-of-ai-on-medical-writing-how-artificial-intelligence-is-revolutionizing-medical-content-creation/) [ ![CDISC Standards and Data Transformation in Clinical Trial.](https://geninvo.com/wp-content/uploads/2024/07/dtct-1-300x169.webp) ](https://geninvo.com/cdisc-standards-and-data-transformation-in-clinical-trial/) ## [CDISC Standards and Data Transformation in Clinical Trial.](https://geninvo.com/cdisc-standards-and-data-transformation-in-clinical-trial/) [ ![Transforming Document Creation in Life Sciences with DocWrightAI™ – GenInvo’s Advanced AI Assistant!](https://geninvo.com/wp-content/uploads/2024/06/DocWright-lifscience-300x169.jpg) ](https://geninvo.com/transforming-document-creation-in-life-sciences-with-docwrightai-geninvos-advanced-ai-assistant/) ## [Transforming Document Creation in Life Sciences with DocWrightAI™ – GenInvo’s Advanced AI Assistant!](https://geninvo.com/transforming-document-creation-in-life-sciences-with-docwrightai-geninvos-advanced-ai-assistant/) [ ![Embracing the Digital Era: The Transformative Power of Digitalization in Medical Writing](https://geninvo.com/wp-content/uploads/2024/03/1672114503523rf-1-300x169.jpg) ](https://geninvo.com/embracing-the-digital-era-the-transformative-power-of-digitalization-in-medical-writing/) ## [Embracing the Digital Era: The Transformative Power of Digitalization in Medical Writing](https://geninvo.com/embracing-the-digital-era-the-transformative-power-of-digitalization-in-medical-writing/) [ ![Data Masking and Data Anonymization: The need for healthcare companies](https://geninvo.com/wp-content/uploads/2024/03/data-m-300x169.jpg) ](https://geninvo.com/data-masking-and-data-anonymization-the-need-for-healthcare-companies/) ## [Data Masking and Data Anonymization: The need for healthcare companies](https://geninvo.com/data-masking-and-data-anonymization-the-need-for-healthcare-companies/) [ ![Artificial Intelligence in the Healthcare Domain: How AI Reviews Clinical Documents](https://geninvo.com/wp-content/uploads/2024/03/maxresdefault.jpgr_-300x169.jpg) ](https://geninvo.com/artificial-intelligence-in-the-healthcare-domain-how-ai-reviews-clinical-documents/) ## [Artificial Intelligence in the Healthcare Domain: How AI Reviews Clinical Documents](https://geninvo.com/artificial-intelligence-in-the-healthcare-domain-how-ai-reviews-clinical-documents/) [ ![Importance and examples of usage of Data Anonymization in Healthcare & Other sectors](https://geninvo.com/wp-content/uploads/2024/02/dah-sector-300x169.jpg) ](https://geninvo.com/importance-and-examples-of-usage-of-data-anonymization-in-healthcare-other-sectors/) ## [Importance and examples of usage of Data Anonymization in Healthcare & Other sectors](https://geninvo.com/importance-and-examples-of-usage-of-data-anonymization-in-healthcare-other-sectors/) [ ![Data Anonymization and HIPAA Compliance: Protecting Health Information Privacy](https://geninvo.com/wp-content/uploads/2024/02/Untitled-1df-300x169.jpg) ](https://geninvo.com/data-anonymization-and-hipaa-compliance-protecting-health-information-privacy/) ## [Data Anonymization and HIPAA Compliance: Protecting Health Information Privacy](https://geninvo.com/data-anonymization-and-hipaa-compliance-protecting-health-information-privacy/) [ ![Automation of Unstructured Clinical Data: A collaboration of automation and Medical Writers](https://geninvo.com/wp-content/uploads/2024/01/cdf-300x169.png) ](https://geninvo.com/automation-of-unstructured-clinical-data-a-collaboration-of-automation-and-medical-writers/) ## [Automation of Unstructured Clinical Data: A collaboration of automation and Medical Writers](https://geninvo.com/automation-of-unstructured-clinical-data-a-collaboration-of-automation-and-medical-writers/) [ ![Quality Control of the Methods and Procedures of Clinical Study](https://geninvo.com/wp-content/uploads/2024/01/quloi-300x169.jpg) ](https://geninvo.com/quality-control-of-the-methods-and-procedures-of-clinical-study/) ## [Quality Control of the Methods and Procedures of Clinical Study](https://geninvo.com/quality-control-of-the-methods-and-procedures-of-clinical-study/) ## Case Studies [ ![White List & Black List: Enhanced NER Model](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-10-Case-Study-WB-List_v3-300x169.jpg) ](https://geninvo.com/white-list-black-list-enhanced-ner-model/) ## [White List & Black List: Enhanced NER Model](https://geninvo.com/white-list-black-list-enhanced-ner-model/) [ ![NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity-300x169.jpg) ](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) ## [NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) [ ![DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-12-Eprotocol-presentation-300x169.jpg) ](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) ## [DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) [ ![Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-13-Shadow-Recommendation-Engine-300x169.jpg) ](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) ## [Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) [ ![Lung Cancer Detection](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-8-Lung-Cancer-Detection-use-cases-300x169.jpg) ](https://geninvo.com/lung-cancer-detection/) ## [Lung Cancer Detection](https://geninvo.com/lung-cancer-detection/) [ ![Breast Cancer Detection Using Machine Learning](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-9-Case-Study-Breast-Cancer-Detection_v3-use-cases-300x169.jpg) ](https://geninvo.com/breast-cancer-detection-using-machine-learning/) ## [Breast Cancer Detection Using Machine Learning](https://geninvo.com/breast-cancer-detection-using-machine-learning/) [ ![Doc QC tool as a one-stop solution for all Quality Control (QC) needs of a medical writer](https://geninvo.com/wp-content/uploads/2021/08/Case-Studies-8-DocQC-300x169.jpg) ](https://geninvo.com/doc-qc-tool-as-a-one-stop-solution-for-all-quality-control-qc-needs-of-a-medical-writer/) ## [Doc QC tool as a one-stop solution for all Quality Control (QC) needs of a medical writer](https://geninvo.com/doc-qc-tool-as-a-one-stop-solution-for-all-quality-control-qc-needs-of-a-medical-writer/) [ ![Provide ApoGI as a Metadata Driven Platform](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-7-300x169.jpg) ](https://geninvo.com/provide-apogitmas-a-metadatadriven-platform/) ## [Provide ApoGI as a Metadata Driven Platform](https://geninvo.com/provide-apogitmas-a-metadatadriven-platform/) [ ![Provide ApoGI as a MDR Visualization](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-6-300x169.jpg) ](https://geninvo.com/provide-apogitmas-a-mdrvisualization/) ## [Provide ApoGI as a MDR Visualization](https://geninvo.com/provide-apogitmas-a-mdrvisualization/) [ ![Provide ApoGI as a Metadata Driven Transformations](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-5-300x169.jpg) ](https://geninvo.com/provide-apogitm-asa-metadata-driventransformations/) ## [Provide ApoGI as a Metadata Driven Transformations](https://geninvo.com/provide-apogitm-asa-metadata-driventransformations/) [ ![How a Big Pharma Company Achieved Compliance with Health Canada Under Tight Deadlines](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-4-300x169.jpg) ](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-health-canada-under-tight-deadlines/) ## [How a Big Pharma Company Achieved Compliance with Health Canada Under Tight Deadlines](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-health-canada-under-tight-deadlines/) [ ![How a Pharmaceutical Firm Established Anonymization Process](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-3-300x169.jpg) ](https://geninvo.com/how-a-pharmaceutical-firm-established-anonymization-process/) ## [How a Pharmaceutical Firm Established Anonymization Process](https://geninvo.com/how-a-pharmaceutical-firm-established-anonymization-process/) [ ![Big Pharma Company Achieves Compliance with EMA 0070 Policy](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-2-300x169.jpg) ](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-ema-0070-policy-with-a-tight-deadline/) ## [Big Pharma Company Achieves Compliance with EMA 0070 Policy](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-ema-0070-policy-with-a-tight-deadline/) [ ![How a Global Medical Writing CRO Increased Functional Capability with Shadow™](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-1-300x169.jpg) ](https://geninvo.com/how-a-global-medical-writing-cro-increased-functional-capability-with-shadowtm/) ## [How a Global Medical Writing CRO Increased Functional Capability with Shadow™](https://geninvo.com/how-a-global-medical-writing-cro-increased-functional-capability-with-shadowtm/) ## Events [ ![Meet GenInvo at DPHARM 2026, Booth 116, Boston](https://geninvo.com/wp-content/uploads/2026/06/DPHARM-1-300x186.png) ](https://geninvo.com/dpharm-2026/) ## [Meet GenInvo at DPHARM 2026, Booth 116, Boston](https://geninvo.com/dpharm-2026/) [ ![Meet GENINVO at the EMWA 61st Spring Conference 2026](https://geninvo.com/wp-content/uploads/2026/04/539-X-334-1-300x186.png) ](https://geninvo.com/emwa-2026-barcelona/) ## [Meet GENINVO at the EMWA 61st Spring Conference 2026](https://geninvo.com/emwa-2026-barcelona/) [ ![GenInvo at PharmaSUG 2026 SDE Conference](https://geninvo.com/wp-content/uploads/2026/04/539-X-334-300x186.png) ](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) ## [GenInvo at PharmaSUG 2026 SDE Conference](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) [ ![GenInvo @ PHUSE US Connect 2026](https://geninvo.com/wp-content/uploads/2026/03/image-16-300x186.png) ](https://geninvo.com/geninvo-phuse-us-connect-2026/) ## [GenInvo @ PHUSE US Connect 2026](https://geninvo.com/geninvo-phuse-us-connect-2026/) [ ![Live Webinar: Accelerating Authoring and QC of Clinical Documents with AI-Powered Automation](https://geninvo.com/wp-content/uploads/2025/08/Blog-9-300x186.jpg) ](https://geninvo.com/live-webinar-accelerating-authoring-and-qc-of-clinical-documents-with-ai-powered-automation/) ## [Live Webinar: Accelerating Authoring and QC of Clinical Documents with AI-Powered Automation](https://geninvo.com/live-webinar-accelerating-authoring-and-qc-of-clinical-documents-with-ai-powered-automation/) [ ![GenInvo is Powering the Future of Medical Writing at AMWA 2025!](https://geninvo.com/wp-content/uploads/2025/08/GI-AMWA-conference-blog-2025-300x186.jpg) ](https://geninvo.com/geninvo-is-powering-the-future-of-medical-writing-at-amwa-2025/) ## [GenInvo is Powering the Future of Medical Writing at AMWA 2025!](https://geninvo.com/geninvo-is-powering-the-future-of-medical-writing-at-amwa-2025/) [ ![GENINVO™ Sponsors PHUSE Data Transparency Autumn Event 2025](https://geninvo.com/wp-content/uploads/2025/07/Blog-GI-Phusevirtualevent-Sept-2025-300x189.jpg) ](https://geninvo.com/geninvo-sponsors-phuse-data-transparency-autumn-event-2025/) ## [GENINVO™ Sponsors PHUSE Data Transparency Autumn Event 2025](https://geninvo.com/geninvo-sponsors-phuse-data-transparency-autumn-event-2025/) [ ![GENINVO™ at PHUSE US Connect 2025](https://geninvo.com/wp-content/uploads/2025/02/GI-US-PHUSE-connect-2025-300x186.jpg) ](https://geninvo.com/geninvo-at-phuse-us-connect-2025/) ## [GENINVO™ at PHUSE US Connect 2025](https://geninvo.com/geninvo-at-phuse-us-connect-2025/) [ ![Join GENINVO™ at the DIA Medical Affairs and Scientific Communications Forum](https://geninvo.com/wp-content/uploads/2025/02/GI-DIA-blogpost-mar2025-300x186.webp) ](https://geninvo.com/join-geninvo-at-the-dia-medical-affairs-and-scientific-communications-forum/) ## [Join GENINVO™ at the DIA Medical Affairs and Scientific Communications Forum](https://geninvo.com/join-geninvo-at-the-dia-medical-affairs-and-scientific-communications-forum/) [ ![Thank You for Attending the GENINVO’s AMWA Webinar](https://geninvo.com/wp-content/uploads/2024/11/blog-post-AMWA-24nov-300x169.webp) ](https://geninvo.com/thank-you-for-attending-the-geninvos-amwa-webinar/) ## [Thank You for Attending the GENINVO’s AMWA Webinar](https://geninvo.com/thank-you-for-attending-the-geninvos-amwa-webinar/) [ ![Join Our Free Webinar!](https://geninvo.com/wp-content/uploads/2024/10/GI-AMWA-blog-AI-writers-24-V2-300x169.webp) ](https://geninvo.com/join-our-free-webinar/) ## [Join Our Free Webinar!](https://geninvo.com/join-our-free-webinar/) [ ![Shake hands with GENINVO at DIA’s Global Clinical Trial Disclosure and Data Transparency Conference](https://geninvo.com/wp-content/uploads/2024/04/GI-and-sha-DIA-V1-3-300x169.jpg) ](https://geninvo.com/shake-hands-with-geninvo-at-dias-global-clinical-trial-disclosure-and-data-transparency-conference/) ## [Shake hands with GENINVO at DIA’s Global Clinical Trial Disclosure and Data Transparency Conference](https://geninvo.com/shake-hands-with-geninvo-at-dias-global-clinical-trial-disclosure-and-data-transparency-conference/) [ ![Meet GENINVO at DPHARM 2023 in Boston, MA!](https://geninvo.com/wp-content/uploads/2023/08/MicrosoftTeams-image-142-300x169.jpg) ](https://geninvo.com/meet-geninvo-at-dpharm-2023-in-boston-ma/) ## [Meet GENINVO at DPHARM 2023 in Boston, MA!](https://geninvo.com/meet-geninvo-at-dpharm-2023-in-boston-ma/) [ ![Shake hands with GENINVO at PHUSE CSS 2023! ](https://geninvo.com/wp-content/uploads/2023/08/MicrosoftTeams-image-151-300x169.jpg) ](https://geninvo.com/shake-hands-with-geninvo-at-phuse-css-2023/) ## [Shake hands with GENINVO at PHUSE CSS 2023! ](https://geninvo.com/shake-hands-with-geninvo-at-phuse-css-2023/) [ ![GENINVO is delighted to exhibit and present again at the PHUSE US Connect 2023! You can visit us at Booth #7.](https://geninvo.com/wp-content/uploads/2023/02/MicrosoftTeams-image-53-300x169.jpg) ](https://geninvo.com/phuse-us-connect-2023/) ## [GENINVO is delighted to exhibit and present again at the PHUSE US Connect 2023! You can visit us at Booth #7.](https://geninvo.com/phuse-us-connect-2023/) [ ![American Medical Writers Association (AMWA 2022)](https://geninvo.com/wp-content/uploads/2022/10/MicrosoftTeams-image-24-300x170.jpg) ](https://geninvo.com/american-medical-writers-association-amwa-2022/) ## [American Medical Writers Association (AMWA 2022)](https://geninvo.com/american-medical-writers-association-amwa-2022/) [ ![PHUSE EU Connect 2022](https://geninvo.com/wp-content/uploads/2022/10/MicrosoftTeams-image-23-300x170.jpg) ](https://geninvo.com/phuse-eu-connect-2022/) ## [PHUSE EU Connect 2022](https://geninvo.com/phuse-eu-connect-2022/) [ ![EU-CTR New regulations are here – Are you ready for the changes?](https://geninvo.com/wp-content/uploads/2022/09/MicrosoftTeams-image-8-300x172.jpg) ](https://geninvo.com/eu-ctr-new-regulations-are-here-are-you-ready-for-the-changes/) ## [EU-CTR New regulations are here – Are you ready for the changes?](https://geninvo.com/eu-ctr-new-regulations-are-here-are-you-ready-for-the-changes/) [ ![PHUSE’s Data Transparency Winter Event – virtual](https://geninvo.com/wp-content/uploads/2022/02/GI_phuse-8-10-feb-22-01-300x172.jpg) ](https://geninvo.com/phuses-data-transparency-winter-event-virtual/) ## [PHUSE’s Data Transparency Winter Event – virtual](https://geninvo.com/phuses-data-transparency-winter-event-virtual/) [ ![PHUSE US Connect 2022](https://geninvo.com/wp-content/uploads/2021/10/Phuse-event-US-May-300x169.png) ](https://geninvo.com/phuse-us-connect-2022/) ## [PHUSE US Connect 2022](https://geninvo.com/phuse-us-connect-2022/) ## News [ ![GENINVO Launches Centre of Excellence for Data Science and Analytics](https://geninvo.com/wp-content/uploads/2021/11/dsa-coe-300x170.jpg) ](https://geninvo.com/geninvo-launches-centre-of-excellence-for-data-science-and-analytics/) ## [GENINVO Launches Centre of Excellence for Data Science and Analytics](https://geninvo.com/geninvo-launches-centre-of-excellence-for-data-science-and-analytics/) [ ![NEW WEBSITE LAUNCH ANNOUNCEMENT](https://geninvo.com/wp-content/uploads/2021/06/feat-ns-300x170.jpg) ](https://geninvo.com/new-website-launch-announcement-geninvo-launches-updated-website/) ## [NEW WEBSITE LAUNCH ANNOUNCEMENT](https://geninvo.com/new-website-launch-announcement-geninvo-launches-updated-website/) [ ![GENINVO Launches Shadow™ Version 2](https://geninvo.com/wp-content/uploads/2021/03/feat-shadow-300x170.jpg) ](https://geninvo.com/geninvo-launches-shadow-version-2/) ## [GENINVO Launches Shadow™ Version 2](https://geninvo.com/geninvo-launches-shadow-version-2/) [ ![Youth Initiative – Introduction to Robotics Workshop](https://geninvo.com/wp-content/uploads/2021/10/event-feature-2020-300x170.jpg) ](https://geninvo.com/youth-initiative-introduction-to-robotics-workshop/) ## [Youth Initiative – Introduction to Robotics Workshop](https://geninvo.com/youth-initiative-introduction-to-robotics-workshop/) [ ![GENINVO Celebrates Anniversary](https://geninvo.com/wp-content/uploads/2021/05/feat-annivers-300x170.jpg) ](https://geninvo.com/geninvo-anniversary/) ## [GENINVO Celebrates Anniversary](https://geninvo.com/geninvo-anniversary/) [ ![GENINVO Announces Upcoming Version Launch of Shadow™](https://geninvo.com/wp-content/uploads/2021/03/feat-shadow-300x170.jpg) ](https://geninvo.com/geninvo-announces-upcoming-launch-of-shadow-version-2/) ## [GENINVO Announces Upcoming Version Launch of Shadow™](https://geninvo.com/geninvo-announces-upcoming-launch-of-shadow-version-2/) [ ![GENINVO provides technological solutions to the problems in Life Sciences and Pharmaceutical Industry.](https://geninvo.com/wp-content/uploads/2021/05/feat-lsp-300x170.jpg) ](https://geninvo.com/geninvo-provides-technological-solutions-to-the-problems-in-life-sciences-and-pharmaceutical-industry/) ## [GENINVO provides technological solutions to the problems in Life Sciences and Pharmaceutical Industry.](https://geninvo.com/geninvo-provides-technological-solutions-to-the-problems-in-life-sciences-and-pharmaceutical-industry/) [ ![See the Impact of Innovation](https://geninvo.com/wp-content/uploads/2021/05/feat-impact-300x170.jpg) ](https://geninvo.com/see-the-impact-of-innovation/) ## [See the Impact of Innovation](https://geninvo.com/see-the-impact-of-innovation/) [ ![Standing strong with Community](https://geninvo.com/wp-content/uploads/2021/03/feat-stand-str-300x170.jpg) ](https://geninvo.com/standing-strong-with-community/) ## [Standing strong with Community](https://geninvo.com/standing-strong-with-community/) [ ![COVID-19](https://geninvo.com/wp-content/uploads/2021/03/feat-covid-300x170.jpg) ](https://geninvo.com/covid-19/) ## [COVID-19](https://geninvo.com/covid-19/) ## Videos [ ![Shadow for EU-CTR Compliance](https://geninvo.com/wp-content/uploads/2022/11/2022-11-29T20_55_50-300x168.png) ](https://geninvo.com/shadow-for-eu-ctr-compliance/) ## [Shadow for EU-CTR Compliance](https://geninvo.com/shadow-for-eu-ctr-compliance/) [ ![DocQC – Medical Writers automation tool for QC checks](https://geninvo.com/wp-content/uploads/2021/04/docqc-img-overlay-300x171.png) ](https://geninvo.com/docqc-medical-writers-automation-tool-for-qc-checks/) ## [DocQC – Medical Writers automation tool for QC checks](https://geninvo.com/docqc-medical-writers-automation-tool-for-qc-checks/) [ ![Shadow- Risk Analysis Tool](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-shadow-1-e1617726618274-300x168.jpg) ](https://geninvo.com/shadow-risk-analysis-tool/) ## [Shadow- Risk Analysis Tool](https://geninvo.com/shadow-risk-analysis-tool/) [ ![Shadow- Data Anonymization Tool](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-shadow-2-e1617726656616-300x144.jpg) ](https://geninvo.com/shadow-data-anonymization-tool/) ## [Shadow- Data Anonymization Tool](https://geninvo.com/shadow-data-anonymization-tool/) [ ![DocQc – Medical Writer’s Best Friend](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-docqc-300x210.jpg) ](https://geninvo.com/docqc-medical-writers-best-friend/) ## [DocQc – Medical Writer’s Best Friend](https://geninvo.com/docqc-medical-writers-best-friend/) [ ![GENINVO Anniversary](https://geninvo.com/wp-content/uploads/2021/04/overlay_annv-300x168.jpg) ](https://geninvo.com/geninvo-anniversary-2/) ## [GENINVO Anniversary](https://geninvo.com/geninvo-anniversary-2/) [ ![Shadow – Health Canada, France’s MR001-MR004, EMA Policy 0070 (Phase 1 and 2), compliant](https://geninvo.com/wp-content/uploads/2021/04/overlay_sh-300x168.jpg) ](https://geninvo.com/shadow-health-canada-frances-mr001-mr004-ema-policy-0070-phase-1-and-2-compliant/) ## [Shadow – Health Canada, France’s MR001-MR004, EMA Policy 0070 (Phase 1 and 2), compliant](https://geninvo.com/shadow-health-canada-frances-mr001-mr004-ema-policy-0070-phase-1-and-2-compliant/) [ ![Shadow – Solution to Evolving Data Transparency Requirements](https://geninvo.com/wp-content/uploads/2021/04/healthcanadapolicy-over-300x170.jpg) ](https://geninvo.com/shadow-solution-to-evolving-data-transparency-requirements/) ## [Shadow – Solution to Evolving Data Transparency Requirements](https://geninvo.com/shadow-solution-to-evolving-data-transparency-requirements/) [ ![Machine Learning – Shadow](https://geninvo.com/wp-content/uploads/2021/04/overlay_ml-300x168.jpg) ](https://geninvo.com/machine-learning-shadow/) ## [Machine Learning – Shadow](https://geninvo.com/machine-learning-shadow/) [ ![GENINVO – Covid-19](https://geninvo.com/wp-content/uploads/2021/04/covid-over-300x170.jpg) ](https://geninvo.com/geninvo-covid-19/) ## [GENINVO – Covid-19](https://geninvo.com/geninvo-covid-19/) [ ![Shadow](https://geninvo.com/wp-content/uploads/2021/04/shadow-over-300x170.jpg) ](https://geninvo.com/shadow-video/) ## [Shadow](https://geninvo.com/shadow-video/) [ ![ApoGI](https://geninvo.com/wp-content/uploads/2021/04/apogi-over-300x170.jpg) ](https://geninvo.com/apogi-video/) ## [ApoGI](https://geninvo.com/apogi-video/) [ ![DocQC](https://geninvo.com/wp-content/uploads/2021/04/docqc-over-300x170.jpg) ](https://geninvo.com/docqc-video/) ## [DocQC](https://geninvo.com/docqc-video/) [ ![GENINVO](https://geninvo.com/wp-content/uploads/2021/04/self_animation-300x169.jpg) ](https://geninvo.com/geninvo-video/) ## [GENINVO](https://geninvo.com/geninvo-video/) --- ### [insights-template](https://geninvo.com/?elementor_library=insights-template) **Published:** April 7, 2021 **Author:** admin **Content:** ## Blogs [ ![Quantitative Risk Assessment: A Smarter Approach to Clinical Data Anonymization ](https://geninvo.com/wp-content/uploads/2025/10/Blog-12-300x189.jpg) ](https://geninvo.com/quantitative-risk-assessment-a-smarter-approach-to-clinical-data-anonymization/) ## [Quantitative Risk Assessment: A Smarter Approach to Clinical Data Anonymization ](https://geninvo.com/quantitative-risk-assessment-a-smarter-approach-to-clinical-data-anonymization/) [ ![Secure Scanning with Confidential Information Scanner: Safeguarding Your CCIs During Clinical Research](https://geninvo.com/wp-content/uploads/2025/09/Blog-11-300x189.jpg) ](https://geninvo.com/secure-scanning-with-confidential-information-scanner-safeguarding-your-ccis-during-clinical-research/) ## [Secure Scanning with Confidential Information Scanner: Safeguarding Your CCIs During Clinical Research](https://geninvo.com/secure-scanning-with-confidential-information-scanner-safeguarding-your-ccis-during-clinical-research/) [ ![Python’s Future in Clinical Trials: Innovations and Collaborative Advancements](https://geninvo.com/wp-content/uploads/2025/08/Blog-8-300x189.jpg) ](https://geninvo.com/pythons-future-in-clinical-trials-innovations-and-collaborative-advancements/) ## [Python’s Future in Clinical Trials: Innovations and Collaborative Advancements](https://geninvo.com/pythons-future-in-clinical-trials-innovations-and-collaborative-advancements/) [ ![The Changing Role of the Clinical Programmer in an Open-Source World](https://geninvo.com/wp-content/uploads/2025/07/Blog-7-300x189.jpg) ](https://geninvo.com/the-changing-role-of-the-clinical-programmer-in-an-open-source-world/) ## [The Changing Role of the Clinical Programmer in an Open-Source World](https://geninvo.com/the-changing-role-of-the-clinical-programmer-in-an-open-source-world/) [ ![Beyond the Buzzwords: How GenInvo’s AI/ML Tools Are Transforming Life Sciences](https://geninvo.com/wp-content/uploads/2025/07/Blog-6-300x189.jpg) ](https://geninvo.com/ai-ml-tools-life-sciences-geninvo/) ## [Beyond the Buzzwords: How GenInvo’s AI/ML Tools Are Transforming Life Sciences](https://geninvo.com/ai-ml-tools-life-sciences-geninvo/) [ ![Empowering the Future of Life Sciences: A GenInvo Perspective from the Inside](https://geninvo.com/wp-content/uploads/2025/06/Blog-5-300x196.jpg) ](https://geninvo.com/empowering-the-future-of-life-sciences-a-geninvo-perspective-from-the-inside/) ## [Empowering the Future of Life Sciences: A GenInvo Perspective from the Inside](https://geninvo.com/empowering-the-future-of-life-sciences-a-geninvo-perspective-from-the-inside/) [ ![GenInvo’s CIS Tool: Safeguarding Confidential Company Information in Life Sciences.](https://geninvo.com/wp-content/uploads/2025/06/Blog-4-300x196.jpg) ](https://geninvo.com/geninvos-cis-tool-safeguarding-confidential-company-information-in-life-sciences/) ## [GenInvo’s CIS Tool: Safeguarding Confidential Company Information in Life Sciences.](https://geninvo.com/geninvos-cis-tool-safeguarding-confidential-company-information-in-life-sciences/) [ ![Why Clinical Data Transparency Matters: Benefits for Patients, Researchers, and Industry](https://geninvo.com/wp-content/uploads/2025/06/Blog-3-300x196.jpg) ](https://geninvo.com/why-clinical-data-transparency-matters-benefits-for-patients-researchers-and-industry/) ## [Why Clinical Data Transparency Matters: Benefits for Patients, Researchers, and Industry](https://geninvo.com/why-clinical-data-transparency-matters-benefits-for-patients-researchers-and-industry/) [ ![How Meaningful Synthetic Data Generation Tools Are Transforming AI Development ](https://geninvo.com/wp-content/uploads/2025/01/Blog-2-300x169.jpg) ](https://geninvo.com/how-meaningful-synthetic-data-generation-tools-are-transforming-ai-development/) ## [How Meaningful Synthetic Data Generation Tools Are Transforming AI Development ](https://geninvo.com/how-meaningful-synthetic-data-generation-tools-are-transforming-ai-development/) [ ![Empowering Clinical and Regulatory Writing: Harnessing AI as Your Assistant  ](https://geninvo.com/wp-content/uploads/2024/10/Untitled-1-1-300x189.webp) ](https://geninvo.com/empowering-clinical-and-regulatory-writing-harnessing-ai-as-your-assistant/) ## [Empowering Clinical and Regulatory Writing: Harnessing AI as Your Assistant ](https://geninvo.com/empowering-clinical-and-regulatory-writing-harnessing-ai-as-your-assistant/) [ ![The Impact of AI on Medical Writing: How Artificial Intelligence is Revolutionizing Medical Content Creation ](https://geninvo.com/wp-content/uploads/2024/09/mdw-1-300x169.jpg) ](https://geninvo.com/the-impact-of-ai-on-medical-writing-how-artificial-intelligence-is-revolutionizing-medical-content-creation/) ## [The Impact of AI on Medical Writing: How Artificial Intelligence is Revolutionizing Medical Content Creation ](https://geninvo.com/the-impact-of-ai-on-medical-writing-how-artificial-intelligence-is-revolutionizing-medical-content-creation/) [ ![CDISC Standards and Data Transformation in Clinical Trial.](https://geninvo.com/wp-content/uploads/2024/07/dtct-1-300x169.webp) ](https://geninvo.com/cdisc-standards-and-data-transformation-in-clinical-trial/) ## [CDISC Standards and Data Transformation in Clinical Trial.](https://geninvo.com/cdisc-standards-and-data-transformation-in-clinical-trial/) [ ![Transforming Document Creation in Life Sciences with DocWrightAI™ – GenInvo’s Advanced AI Assistant!](https://geninvo.com/wp-content/uploads/2024/06/DocWright-lifscience-300x169.jpg) ](https://geninvo.com/transforming-document-creation-in-life-sciences-with-docwrightai-geninvos-advanced-ai-assistant/) ## [Transforming Document Creation in Life Sciences with DocWrightAI™ – GenInvo’s Advanced AI Assistant!](https://geninvo.com/transforming-document-creation-in-life-sciences-with-docwrightai-geninvos-advanced-ai-assistant/) [ ![Embracing the Digital Era: The Transformative Power of Digitalization in Medical Writing](https://geninvo.com/wp-content/uploads/2024/03/1672114503523rf-1-300x169.jpg) ](https://geninvo.com/embracing-the-digital-era-the-transformative-power-of-digitalization-in-medical-writing/) ## [Embracing the Digital Era: The Transformative Power of Digitalization in Medical Writing](https://geninvo.com/embracing-the-digital-era-the-transformative-power-of-digitalization-in-medical-writing/) [ ![Data Masking and Data Anonymization: The need for healthcare companies](https://geninvo.com/wp-content/uploads/2024/03/data-m-300x169.jpg) ](https://geninvo.com/data-masking-and-data-anonymization-the-need-for-healthcare-companies/) ## [Data Masking and Data Anonymization: The need for healthcare companies](https://geninvo.com/data-masking-and-data-anonymization-the-need-for-healthcare-companies/) [ ![Artificial Intelligence in the Healthcare Domain: How AI Reviews Clinical Documents](https://geninvo.com/wp-content/uploads/2024/03/maxresdefault.jpgr_-300x169.jpg) ](https://geninvo.com/artificial-intelligence-in-the-healthcare-domain-how-ai-reviews-clinical-documents/) ## [Artificial Intelligence in the Healthcare Domain: How AI Reviews Clinical Documents](https://geninvo.com/artificial-intelligence-in-the-healthcare-domain-how-ai-reviews-clinical-documents/) [ ![Importance and examples of usage of Data Anonymization in Healthcare & Other sectors](https://geninvo.com/wp-content/uploads/2024/02/dah-sector-300x169.jpg) ](https://geninvo.com/importance-and-examples-of-usage-of-data-anonymization-in-healthcare-other-sectors/) ## [Importance and examples of usage of Data Anonymization in Healthcare & Other sectors](https://geninvo.com/importance-and-examples-of-usage-of-data-anonymization-in-healthcare-other-sectors/) [ ![Data Anonymization and HIPAA Compliance: Protecting Health Information Privacy](https://geninvo.com/wp-content/uploads/2024/02/Untitled-1df-300x169.jpg) ](https://geninvo.com/data-anonymization-and-hipaa-compliance-protecting-health-information-privacy/) ## [Data Anonymization and HIPAA Compliance: Protecting Health Information Privacy](https://geninvo.com/data-anonymization-and-hipaa-compliance-protecting-health-information-privacy/) [ ![Automation of Unstructured Clinical Data: A collaboration of automation and Medical Writers](https://geninvo.com/wp-content/uploads/2024/01/cdf-300x169.png) ](https://geninvo.com/automation-of-unstructured-clinical-data-a-collaboration-of-automation-and-medical-writers/) ## [Automation of Unstructured Clinical Data: A collaboration of automation and Medical Writers](https://geninvo.com/automation-of-unstructured-clinical-data-a-collaboration-of-automation-and-medical-writers/) [ ![Quality Control of the Methods and Procedures of Clinical Study](https://geninvo.com/wp-content/uploads/2024/01/quloi-300x169.jpg) ](https://geninvo.com/quality-control-of-the-methods-and-procedures-of-clinical-study/) ## [Quality Control of the Methods and Procedures of Clinical Study](https://geninvo.com/quality-control-of-the-methods-and-procedures-of-clinical-study/) ## Case Studies [ ![White List & Black List: Enhanced NER Model](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-10-Case-Study-WB-List_v3-300x169.jpg) ](https://geninvo.com/white-list-black-list-enhanced-ner-model/) ## [White List & Black List: Enhanced NER Model](https://geninvo.com/white-list-black-list-enhanced-ner-model/) [ ![NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity-300x169.jpg) ](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) ## [NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) [ ![DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-12-Eprotocol-presentation-300x169.jpg) ](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) ## [DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) [ ![Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-13-Shadow-Recommendation-Engine-300x169.jpg) ](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) ## [Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) [ ![Lung Cancer Detection](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-8-Lung-Cancer-Detection-use-cases-300x169.jpg) ](https://geninvo.com/lung-cancer-detection/) ## [Lung Cancer Detection](https://geninvo.com/lung-cancer-detection/) [ ![Breast Cancer Detection Using Machine Learning](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-9-Case-Study-Breast-Cancer-Detection_v3-use-cases-300x169.jpg) ](https://geninvo.com/breast-cancer-detection-using-machine-learning/) ## [Breast Cancer Detection Using Machine Learning](https://geninvo.com/breast-cancer-detection-using-machine-learning/) [ ![Doc QC tool as a one-stop solution for all Quality Control (QC) needs of a medical writer](https://geninvo.com/wp-content/uploads/2021/08/Case-Studies-8-DocQC-300x169.jpg) ](https://geninvo.com/doc-qc-tool-as-a-one-stop-solution-for-all-quality-control-qc-needs-of-a-medical-writer/) ## [Doc QC tool as a one-stop solution for all Quality Control (QC) needs of a medical writer](https://geninvo.com/doc-qc-tool-as-a-one-stop-solution-for-all-quality-control-qc-needs-of-a-medical-writer/) [ ![Provide ApoGI as a Metadata Driven Platform](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-7-300x169.jpg) ](https://geninvo.com/provide-apogitmas-a-metadatadriven-platform/) ## [Provide ApoGI as a Metadata Driven Platform](https://geninvo.com/provide-apogitmas-a-metadatadriven-platform/) [ ![Provide ApoGI as a MDR Visualization](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-6-300x169.jpg) ](https://geninvo.com/provide-apogitmas-a-mdrvisualization/) ## [Provide ApoGI as a MDR Visualization](https://geninvo.com/provide-apogitmas-a-mdrvisualization/) [ ![Provide ApoGI as a Metadata Driven Transformations](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-5-300x169.jpg) ](https://geninvo.com/provide-apogitm-asa-metadata-driventransformations/) ## [Provide ApoGI as a Metadata Driven Transformations](https://geninvo.com/provide-apogitm-asa-metadata-driventransformations/) [ ![How a Big Pharma Company Achieved Compliance with Health Canada Under Tight Deadlines](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-4-300x169.jpg) ](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-health-canada-under-tight-deadlines/) ## [How a Big Pharma Company Achieved Compliance with Health Canada Under Tight Deadlines](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-health-canada-under-tight-deadlines/) [ ![How a Pharmaceutical Firm Established Anonymization Process](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-3-300x169.jpg) ](https://geninvo.com/how-a-pharmaceutical-firm-established-anonymization-process/) ## [How a Pharmaceutical Firm Established Anonymization Process](https://geninvo.com/how-a-pharmaceutical-firm-established-anonymization-process/) [ ![Big Pharma Company Achieves Compliance with EMA 0070 Policy](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-2-300x169.jpg) ](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-ema-0070-policy-with-a-tight-deadline/) ## [Big Pharma Company Achieves Compliance with EMA 0070 Policy](https://geninvo.com/how-a-big-pharma-company-achieved-compliance-with-ema-0070-policy-with-a-tight-deadline/) [ ![How a Global Medical Writing CRO Increased Functional Capability with Shadow™](https://geninvo.com/wp-content/uploads/2021/05/Case-Studies-1-300x169.jpg) ](https://geninvo.com/how-a-global-medical-writing-cro-increased-functional-capability-with-shadowtm/) ## [How a Global Medical Writing CRO Increased Functional Capability with Shadow™](https://geninvo.com/how-a-global-medical-writing-cro-increased-functional-capability-with-shadowtm/) ## News [ ![GENINVO Launches Centre of Excellence for Data Science and Analytics](https://geninvo.com/wp-content/uploads/2021/11/dsa-coe-300x170.jpg) ](https://geninvo.com/geninvo-launches-centre-of-excellence-for-data-science-and-analytics/) ## [GENINVO Launches Centre of Excellence for Data Science and Analytics](https://geninvo.com/geninvo-launches-centre-of-excellence-for-data-science-and-analytics/) [ ![NEW WEBSITE LAUNCH ANNOUNCEMENT](https://geninvo.com/wp-content/uploads/2021/06/feat-ns-300x170.jpg) ](https://geninvo.com/new-website-launch-announcement-geninvo-launches-updated-website/) ## [NEW WEBSITE LAUNCH ANNOUNCEMENT](https://geninvo.com/new-website-launch-announcement-geninvo-launches-updated-website/) [ ![GENINVO Launches Shadow™ Version 2](https://geninvo.com/wp-content/uploads/2021/03/feat-shadow-300x170.jpg) ](https://geninvo.com/geninvo-launches-shadow-version-2/) ## [GENINVO Launches Shadow™ Version 2](https://geninvo.com/geninvo-launches-shadow-version-2/) [ ![Youth Initiative – Introduction to Robotics Workshop](https://geninvo.com/wp-content/uploads/2021/10/event-feature-2020-300x170.jpg) ](https://geninvo.com/youth-initiative-introduction-to-robotics-workshop/) ## [Youth Initiative – Introduction to Robotics Workshop](https://geninvo.com/youth-initiative-introduction-to-robotics-workshop/) [ ![GENINVO Celebrates Anniversary](https://geninvo.com/wp-content/uploads/2021/05/feat-annivers-300x170.jpg) ](https://geninvo.com/geninvo-anniversary/) ## [GENINVO Celebrates Anniversary](https://geninvo.com/geninvo-anniversary/) [ ![GENINVO Announces Upcoming Version Launch of Shadow™](https://geninvo.com/wp-content/uploads/2021/03/feat-shadow-300x170.jpg) ](https://geninvo.com/geninvo-announces-upcoming-launch-of-shadow-version-2/) ## [GENINVO Announces Upcoming Version Launch of Shadow™](https://geninvo.com/geninvo-announces-upcoming-launch-of-shadow-version-2/) [ ![GENINVO provides technological solutions to the problems in Life Sciences and Pharmaceutical Industry.](https://geninvo.com/wp-content/uploads/2021/05/feat-lsp-300x170.jpg) ](https://geninvo.com/geninvo-provides-technological-solutions-to-the-problems-in-life-sciences-and-pharmaceutical-industry/) ## [GENINVO provides technological solutions to the problems in Life Sciences and Pharmaceutical Industry.](https://geninvo.com/geninvo-provides-technological-solutions-to-the-problems-in-life-sciences-and-pharmaceutical-industry/) [ ![See the Impact of Innovation](https://geninvo.com/wp-content/uploads/2021/05/feat-impact-300x170.jpg) ](https://geninvo.com/see-the-impact-of-innovation/) ## [See the Impact of Innovation](https://geninvo.com/see-the-impact-of-innovation/) [ ![Standing strong with Community](https://geninvo.com/wp-content/uploads/2021/03/feat-stand-str-300x170.jpg) ](https://geninvo.com/standing-strong-with-community/) ## [Standing strong with Community](https://geninvo.com/standing-strong-with-community/) [ ![COVID-19](https://geninvo.com/wp-content/uploads/2021/03/feat-covid-300x170.jpg) ](https://geninvo.com/covid-19/) ## [COVID-19](https://geninvo.com/covid-19/) ## Events [ ![Meet GenInvo at DPHARM 2026, Booth 116, Boston](https://geninvo.com/wp-content/uploads/2026/06/DPHARM-1-300x186.png) ](https://geninvo.com/dpharm-2026/) ## [Meet GenInvo at DPHARM 2026, Booth 116, Boston](https://geninvo.com/dpharm-2026/) [ ![Meet GENINVO at the EMWA 61st Spring Conference 2026](https://geninvo.com/wp-content/uploads/2026/04/539-X-334-1-300x186.png) ](https://geninvo.com/emwa-2026-barcelona/) ## [Meet GENINVO at the EMWA 61st Spring Conference 2026](https://geninvo.com/emwa-2026-barcelona/) [ ![GenInvo at PharmaSUG 2026 SDE Conference](https://geninvo.com/wp-content/uploads/2026/04/539-X-334-300x186.png) ](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) ## [GenInvo at PharmaSUG 2026 SDE Conference](https://geninvo.com/geninvo-at-pharmasug-2026-sde-conference/) [ ![GenInvo @ PHUSE US Connect 2026](https://geninvo.com/wp-content/uploads/2026/03/image-16-300x186.png) ](https://geninvo.com/geninvo-phuse-us-connect-2026/) ## [GenInvo @ PHUSE US Connect 2026](https://geninvo.com/geninvo-phuse-us-connect-2026/) [ ![Live Webinar: Accelerating Authoring and QC of Clinical Documents with AI-Powered Automation](https://geninvo.com/wp-content/uploads/2025/08/Blog-9-300x186.jpg) ](https://geninvo.com/live-webinar-accelerating-authoring-and-qc-of-clinical-documents-with-ai-powered-automation/) ## [Live Webinar: Accelerating Authoring and QC of Clinical Documents with AI-Powered Automation](https://geninvo.com/live-webinar-accelerating-authoring-and-qc-of-clinical-documents-with-ai-powered-automation/) [ ![GenInvo is Powering the Future of Medical Writing at AMWA 2025!](https://geninvo.com/wp-content/uploads/2025/08/GI-AMWA-conference-blog-2025-300x186.jpg) ](https://geninvo.com/geninvo-is-powering-the-future-of-medical-writing-at-amwa-2025/) ## [GenInvo is Powering the Future of Medical Writing at AMWA 2025!](https://geninvo.com/geninvo-is-powering-the-future-of-medical-writing-at-amwa-2025/) [ ![GENINVO™ Sponsors PHUSE Data Transparency Autumn Event 2025](https://geninvo.com/wp-content/uploads/2025/07/Blog-GI-Phusevirtualevent-Sept-2025-300x189.jpg) ](https://geninvo.com/geninvo-sponsors-phuse-data-transparency-autumn-event-2025/) ## [GENINVO™ Sponsors PHUSE Data Transparency Autumn Event 2025](https://geninvo.com/geninvo-sponsors-phuse-data-transparency-autumn-event-2025/) [ ![GENINVO™ at PHUSE US Connect 2025](https://geninvo.com/wp-content/uploads/2025/02/GI-US-PHUSE-connect-2025-300x186.jpg) ](https://geninvo.com/geninvo-at-phuse-us-connect-2025/) ## [GENINVO™ at PHUSE US Connect 2025](https://geninvo.com/geninvo-at-phuse-us-connect-2025/) [ ![Join GENINVO™ at the DIA Medical Affairs and Scientific Communications Forum](https://geninvo.com/wp-content/uploads/2025/02/GI-DIA-blogpost-mar2025-300x186.webp) ](https://geninvo.com/join-geninvo-at-the-dia-medical-affairs-and-scientific-communications-forum/) ## [Join GENINVO™ at the DIA Medical Affairs and Scientific Communications Forum](https://geninvo.com/join-geninvo-at-the-dia-medical-affairs-and-scientific-communications-forum/) [ ![Thank You for Attending the GENINVO’s AMWA Webinar](https://geninvo.com/wp-content/uploads/2024/11/blog-post-AMWA-24nov-300x169.webp) ](https://geninvo.com/thank-you-for-attending-the-geninvos-amwa-webinar/) ## [Thank You for Attending the GENINVO’s AMWA Webinar](https://geninvo.com/thank-you-for-attending-the-geninvos-amwa-webinar/) [ ![Join Our Free Webinar!](https://geninvo.com/wp-content/uploads/2024/10/GI-AMWA-blog-AI-writers-24-V2-300x169.webp) ](https://geninvo.com/join-our-free-webinar/) ## [Join Our Free Webinar!](https://geninvo.com/join-our-free-webinar/) [ ![Shake hands with GENINVO at DIA’s Global Clinical Trial Disclosure and Data Transparency Conference](https://geninvo.com/wp-content/uploads/2024/04/GI-and-sha-DIA-V1-3-300x169.jpg) ](https://geninvo.com/shake-hands-with-geninvo-at-dias-global-clinical-trial-disclosure-and-data-transparency-conference/) ## [Shake hands with GENINVO at DIA’s Global Clinical Trial Disclosure and Data Transparency Conference](https://geninvo.com/shake-hands-with-geninvo-at-dias-global-clinical-trial-disclosure-and-data-transparency-conference/) [ ![Meet GENINVO at DPHARM 2023 in Boston, MA!](https://geninvo.com/wp-content/uploads/2023/08/MicrosoftTeams-image-142-300x169.jpg) ](https://geninvo.com/meet-geninvo-at-dpharm-2023-in-boston-ma/) ## [Meet GENINVO at DPHARM 2023 in Boston, MA!](https://geninvo.com/meet-geninvo-at-dpharm-2023-in-boston-ma/) [ ![Shake hands with GENINVO at PHUSE CSS 2023! ](https://geninvo.com/wp-content/uploads/2023/08/MicrosoftTeams-image-151-300x169.jpg) ](https://geninvo.com/shake-hands-with-geninvo-at-phuse-css-2023/) ## [Shake hands with GENINVO at PHUSE CSS 2023! ](https://geninvo.com/shake-hands-with-geninvo-at-phuse-css-2023/) [ ![GENINVO is delighted to exhibit and present again at the PHUSE US Connect 2023! You can visit us at Booth #7.](https://geninvo.com/wp-content/uploads/2023/02/MicrosoftTeams-image-53-300x169.jpg) ](https://geninvo.com/phuse-us-connect-2023/) ## [GENINVO is delighted to exhibit and present again at the PHUSE US Connect 2023! You can visit us at Booth #7.](https://geninvo.com/phuse-us-connect-2023/) [ ![American Medical Writers Association (AMWA 2022)](https://geninvo.com/wp-content/uploads/2022/10/MicrosoftTeams-image-24-300x170.jpg) ](https://geninvo.com/american-medical-writers-association-amwa-2022/) ## [American Medical Writers Association (AMWA 2022)](https://geninvo.com/american-medical-writers-association-amwa-2022/) [ ![PHUSE EU Connect 2022](https://geninvo.com/wp-content/uploads/2022/10/MicrosoftTeams-image-23-300x170.jpg) ](https://geninvo.com/phuse-eu-connect-2022/) ## [PHUSE EU Connect 2022](https://geninvo.com/phuse-eu-connect-2022/) [ ![EU-CTR New regulations are here – Are you ready for the changes?](https://geninvo.com/wp-content/uploads/2022/09/MicrosoftTeams-image-8-300x172.jpg) ](https://geninvo.com/eu-ctr-new-regulations-are-here-are-you-ready-for-the-changes/) ## [EU-CTR New regulations are here – Are you ready for the changes?](https://geninvo.com/eu-ctr-new-regulations-are-here-are-you-ready-for-the-changes/) [ ![PHUSE’s Data Transparency Winter Event – virtual](https://geninvo.com/wp-content/uploads/2022/02/GI_phuse-8-10-feb-22-01-300x172.jpg) ](https://geninvo.com/phuses-data-transparency-winter-event-virtual/) ## [PHUSE’s Data Transparency Winter Event – virtual](https://geninvo.com/phuses-data-transparency-winter-event-virtual/) [ ![PHUSE US Connect 2022](https://geninvo.com/wp-content/uploads/2021/10/Phuse-event-US-May-300x169.png) ](https://geninvo.com/phuse-us-connect-2022/) ## [PHUSE US Connect 2022](https://geninvo.com/phuse-us-connect-2022/) ## Videos [ ![Shadow for EU-CTR Compliance](https://geninvo.com/wp-content/uploads/2022/11/2022-11-29T20_55_50-300x168.png) ](https://geninvo.com/shadow-for-eu-ctr-compliance/) ## [Shadow for EU-CTR Compliance](https://geninvo.com/shadow-for-eu-ctr-compliance/) [ ![DocQC – Medical Writers automation tool for QC checks](https://geninvo.com/wp-content/uploads/2021/04/docqc-img-overlay-300x171.png) ](https://geninvo.com/docqc-medical-writers-automation-tool-for-qc-checks/) ## [DocQC – Medical Writers automation tool for QC checks](https://geninvo.com/docqc-medical-writers-automation-tool-for-qc-checks/) [ ![Shadow- Risk Analysis Tool](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-shadow-1-e1617726618274-300x168.jpg) ](https://geninvo.com/shadow-risk-analysis-tool/) ## [Shadow- Risk Analysis Tool](https://geninvo.com/shadow-risk-analysis-tool/) [ ![Shadow- Data Anonymization Tool](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-shadow-2-e1617726656616-300x144.jpg) ](https://geninvo.com/shadow-data-anonymization-tool/) ## [Shadow- Data Anonymization Tool](https://geninvo.com/shadow-data-anonymization-tool/) [ ![DocQc – Medical Writer’s Best Friend](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-docqc-300x210.jpg) ](https://geninvo.com/docqc-medical-writers-best-friend/) ## [DocQc – Medical Writer’s Best Friend](https://geninvo.com/docqc-medical-writers-best-friend/) [ ![GENINVO Anniversary](https://geninvo.com/wp-content/uploads/2021/04/overlay_annv-300x168.jpg) ](https://geninvo.com/geninvo-anniversary-2/) ## [GENINVO Anniversary](https://geninvo.com/geninvo-anniversary-2/) [ ![Shadow – Health Canada, France’s MR001-MR004, EMA Policy 0070 (Phase 1 and 2), compliant](https://geninvo.com/wp-content/uploads/2021/04/overlay_sh-300x168.jpg) ](https://geninvo.com/shadow-health-canada-frances-mr001-mr004-ema-policy-0070-phase-1-and-2-compliant/) ## [Shadow – Health Canada, France’s MR001-MR004, EMA Policy 0070 (Phase 1 and 2), compliant](https://geninvo.com/shadow-health-canada-frances-mr001-mr004-ema-policy-0070-phase-1-and-2-compliant/) [ ![Shadow – Solution to Evolving Data Transparency Requirements](https://geninvo.com/wp-content/uploads/2021/04/healthcanadapolicy-over-300x170.jpg) ](https://geninvo.com/shadow-solution-to-evolving-data-transparency-requirements/) ## [Shadow – Solution to Evolving Data Transparency Requirements](https://geninvo.com/shadow-solution-to-evolving-data-transparency-requirements/) [ ![Machine Learning – Shadow](https://geninvo.com/wp-content/uploads/2021/04/overlay_ml-300x168.jpg) ](https://geninvo.com/machine-learning-shadow/) ## [Machine Learning – Shadow](https://geninvo.com/machine-learning-shadow/) [ ![GENINVO – Covid-19](https://geninvo.com/wp-content/uploads/2021/04/covid-over-300x170.jpg) ](https://geninvo.com/geninvo-covid-19/) ## [GENINVO – Covid-19](https://geninvo.com/geninvo-covid-19/) [ ![Shadow](https://geninvo.com/wp-content/uploads/2021/04/shadow-over-300x170.jpg) ](https://geninvo.com/shadow-video/) ## [Shadow](https://geninvo.com/shadow-video/) [ ![ApoGI](https://geninvo.com/wp-content/uploads/2021/04/apogi-over-300x170.jpg) ](https://geninvo.com/apogi-video/) ## [ApoGI](https://geninvo.com/apogi-video/) [ ![DocQC](https://geninvo.com/wp-content/uploads/2021/04/docqc-over-300x170.jpg) ](https://geninvo.com/docqc-video/) ## [DocQC](https://geninvo.com/docqc-video/) [ ![GENINVO](https://geninvo.com/wp-content/uploads/2021/04/self_animation-300x169.jpg) ](https://geninvo.com/geninvo-video/) ## [GENINVO](https://geninvo.com/geninvo-video/) ## Blogs [ ](https://geninvo.com/insights/blog/) ![](https://geninvo.com/wp-content/uploads/2025/10/Blog-12.jpg "Blog-12 - GenInvo - GenInvo") ##### Quantitative Risk Assessment: A Smarter Approach to Clinical Data Anonymization [ Read More ](https://geninvo.com/quantitative-risk-assessment-a-smarter-approach-to-clinical-data-anonymization/) ![](https://geninvo.com/wp-content/uploads/2025/09/Blog-11.jpg "Blog-11 - GenInvo - GenInvo") ##### Secure Scanning with Confidential Information Scanner: Safeguarding Your CCIs During Clinical Research [ Read More ](https://geninvo.com/secure-scanning-with-confidential-information-scanner-safeguarding-your-ccis-during-clinical-research/) ![Clinical Trials](https://geninvo.com/wp-content/uploads/2025/08/Blog-8.jpg "Blog-8 - GenInvo - GenInvo") ##### Python’s Future in Clinical Trials: Innovations and Collaborative Advancements [ Read More ](https://geninvo.com/pythons-future-in-clinical-trials-innovations-and-collaborative-advancements/) ## Case Studies [ ![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-10-Case-Study-WB-List_v3.jpg "Case-Studies-10-Case-Study-WB-List_v3 - GenInvo - GenInvo") ](https://geninvo.com/white-list-black-list-enhanced-ner-model/) - September 17, 2021 ##### [White List & Black List: Enhanced NER Model](https://geninvo.com/white-list-black-list-enhanced-ner-model/) [ Read More ](https://geninvo.com/white-list-black-list-enhanced-ner-model/) [ ![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity.jpg "Case-Studies-11-DocQc-Table-41---NLP-for-Text-Similarity - GenInvo - GenInvo") ](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) - September 17, 2021 ##### [NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) [ Read More ](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) [ ![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-12-Eprotocol-presentation.jpg "Case-Studies-12-Eprotocol-presentation - GenInvo - GenInvo") ](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) - September 17, 2021 ##### [DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) [ Read More ](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) [ ](https://geninvo.com/insights/case-studies/) ## News [ ![](https://geninvo.com/wp-content/uploads/2021/11/dsa-coe.jpg "dsa-coe - GenInvo - GenInvo") ](https://geninvo.com/geninvo-launches-centre-of-excellence-for-data-science-and-analytics/) - November 16, 2021 ##### [GENINVO Launches Centre of Excellence for Data Science and Analytics](https://geninvo.com/geninvo-launches-centre-of-excellence-for-data-science-and-analytics/) [ Read More ](https://geninvo.com/geninvo-launches-centre-of-excellence-for-data-science-and-analytics/) [ ![](https://geninvo.com/wp-content/uploads/2021/06/feat-ns.jpg "feat-ns - GenInvo - GenInvo") ](https://geninvo.com/new-website-launch-announcement-geninvo-launches-updated-website/) - June 15, 2021 ##### [NEW WEBSITE LAUNCH ANNOUNCEMENT](https://geninvo.com/new-website-launch-announcement-geninvo-launches-updated-website/) [ Read More ](https://geninvo.com/new-website-launch-announcement-geninvo-launches-updated-website/) [ ![](https://geninvo.com/wp-content/uploads/2021/03/feat-shadow.jpg "feat-shadow - GenInvo - GenInvo") ](https://geninvo.com/geninvo-launches-shadow-version-2/) - November 6, 2020 ##### [GENINVO Launches Shadow™ Version 2](https://geninvo.com/geninvo-launches-shadow-version-2/) [ Read More ](https://geninvo.com/geninvo-launches-shadow-version-2/) [ ](https://geninvo.com/insights/news/) ## Events [![Geninvo at Dpharm 2026 Banner: Sept 15–16, 2026 in Boston, Usa; Sheraton Boston Hotel Exhibition Booth #116.](https://geninvo.com/wp-content/uploads/2026/06/DPHARM-1-300x186.png "Meet Geninvo at DPHARM 2026 — Booth 116, Boston - GenInvo - GenInvo") ](https://geninvo.com/dpharm-2026/)### [ Meet GenInvo at DPHARM 2026, Booth 116, Boston ](https://geninvo.com/dpharm-2026/) [ Read More ](https://geninvo.com/dpharm-2026/) [![Geninvo Booth 10 at Emwa 61st Spring Conference 2026 Barcelona.](https://geninvo.com/wp-content/uploads/2026/04/539-X-334-1-300x186.png "539 X 334 1 - GenInvo - GenInvo") ](https://geninvo.com/emwa-2026-barcelona/)### [ Meet GENINVO at the EMWA 61st Spring Conference 2026 ](https://geninvo.com/emwa-2026-barcelona/) [ Read More ](https://geninvo.com/emwa-2026-barcelona/) [ ](https://geninvo.com/insights/events/) ## Videos [ ![](https://geninvo.com/wp-content/uploads/2022/11/2022-11-29T20_55_50-1024x575.png "2022-11-29T20_55_50 - GenInvo - GenInvo") ](https://geninvo.com/shadow-for-eu-ctr-compliance/) ##### [Shadow for EU-CTR Compliance](https://geninvo.com/shadow-for-eu-ctr-compliance/) [ Watch Video ](https://geninvo.com/shadow-for-eu-ctr-compliance/) [ ![](https://geninvo.com/wp-content/uploads/2021/04/docqc-img-overlay.png "docqc-img-overlay - GenInvo - GenInvo") ](https://geninvo.com/docqc-medical-writers-automation-tool-for-qc-checks/) ##### [DocQC - Medical Writers automation tool for QC checks](https://geninvo.com/docqc-medical-writers-automation-tool-for-qc-checks/) [ Watch Video ](https://geninvo.com/docqc-medical-writers-automation-tool-for-qc-checks/) [ ![](https://geninvo.com/wp-content/uploads/2021/04/overlay-ddl-shadow-1-1024x717.jpg "Mockups Design - GenInvo - GenInvo") ](https://geninvo.com/shadow-risk-analysis-tool/) ##### [Shadow- Risk Analysis Tool](https://geninvo.com/shadow-risk-analysis-tool/) [ Watch Video ](https://geninvo.com/shadow-risk-analysis-tool/) [ ](https://geninvo.com/insights/videos/) --- ### [case-studies-temp](https://geninvo.com/?elementor_library=case-studies-temp) **Published:** April 6, 2021 **Author:** admin **Content:** ## Case Studies [ Back ](https://geninvo.com/insights/) ![](https://geninvo.com/wp-content/uploads/2021/03/insights-top.jpg) - [All](https://geninvo.com/insights/) - [Blogs](https://geninvo.com/insights/blog/) - [Case Studies](https://geninvo.com/insights/case-studies/) - [Events](https://geninvo.com/insights/events/) - [News](https://geninvo.com/insights/news/) - [Videos](https://geninvo.com/insights/videos/) - [All](https://geninvo.com/insights/) - [Blogs](https://geninvo.com/insights/blog/) - [Case Studies](https://geninvo.com/insights/case-studies/) - [Events](https://geninvo.com/insights/events/) - [News](https://geninvo.com/insights/news/) - [Videos](https://geninvo.com/insights/videos/) [ ![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-10-Case-Study-WB-List_v3.jpg "Case-Studies-10-Case-Study-WB-List_v3 - GenInvo - GenInvo") ](https://geninvo.com/white-list-black-list-enhanced-ner-model/) ###### [White List & Black List: Enhanced NER Model](https://geninvo.com/white-list-black-list-enhanced-ner-model/) [ Read More ](https://geninvo.com/white-list-black-list-enhanced-ner-model/) [ ![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-11-DocQc-Table-41-NLP-for-Text-Similarity.jpg "Case-Studies-11-DocQc-Table-41---NLP-for-Text-Similarity - GenInvo - GenInvo") ](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) ###### [NLP TEXT SIMILARITY Quality Check for DocQc Table 41](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) [ Read More ](https://geninvo.com/nlp-text-similarity-quality-check-for-docqc-table-41/) [ ![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-12-Eprotocol-presentation.jpg "Case-Studies-12-Eprotocol-presentation - GenInvo - GenInvo") ](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) ###### [DS/ML capabilities in E Protocol module in APOGI](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) [ Read More ](https://geninvo.com/ds-ml-capabilities-in-e-protocol-module-in-apogi/) [ ![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-13-Shadow-Recommendation-Engine.jpg "Case-Studies-13-Shadow---Recommendation-Engine - GenInvo - GenInvo") ](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) ###### [Recommendation Engine: Algorithmically Predicting Anonymization](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) [ Read More ](https://geninvo.com/recommendation-engine-algorithmically-predicting-anonymization/) [ ![](https://geninvo.com/wp-content/uploads/2021/09/Case-Studies-8-Lung-Cancer-Detection-use-cases.jpg "Case-Studies-8-Lung-Cancer-Detection-use-cases - GenInvo - GenInvo") ](https://geninvo.com/lung-cancer-detection/) ###### [Lung Cancer Detection](https://geninvo.com/lung-cancer-detection/) [ Read More ](https://geninvo.com/lung-cancer-detection/) « PreviousPage1[Page2](https://geninvo.com/?elementor_library=case-studies-temp%2F2%2F&doing_wp_cron=1783869150.2234899997711181640625)[Page3](https://geninvo.com/?elementor_library=case-studies-temp%2F3%2F&doing_wp_cron=1783869150.2234899997711181640625)[Next »](https://geninvo.com/?elementor_library=case-studies-temp/2/) --- ### [Products-Services](https://geninvo.com/?elementor_library=products-services) **Published:** March 19, 2021 **Author:** admin **Content:** ## Our Product Portfolio All Geninvo products are high on scalability, security, and customization. Our industry leading life science products also come with Plug and play modules and off the shelf licensing for hassle free deployment with your existing infrastructure. ![](https://geninvo.com/wp-content/uploads/2021/03/product-img.jpg "product-img - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/03/metaworks_box_mckup_2021-1024x717.jpg "Mockups Design - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ## ApoGI™ #### Next-Gen End to End Platform, Automating your Clinical Study Deliverables ApoGI™ is an integrated, automation platform that leverages AI (Artificial Intelligence) and ML (Machine Learning) and puts focus on standards and metadata management to streamline processes and the generation of artifacts typically associated with the clinical study lifecycle. Find Out More ## DocQC™ #### Medical Writers automation tool for QC checks DocQC™ is a tool for automation of Quality Control (QC) checks that have historically required multiple, time-consuming cycles of manual review. Checks of various complexities are programmed leveraging cutting‒edge technologies. DocQC™enables your Medical Writers to maintain their focus on the science, analyses, and presentation of results. Find Out More ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/03/docqc_box_mckup-1024x717.jpg "Mockups Design - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/03/shadow_box_mckup-1024x717.jpg "Mockups Design - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ## Shadow™ #### Your Solution to Evolving Data Transparency Requirements Shadow™ is a leader in automating Data and Document De-Identification and Anonymization technology. Built from the ground up by the innovative team at GenInvo, a team comprised of both life sciences and software development professionals committed to producing innovative and long-standing solutions that allow you to focus on innovative science and results. [ ](https://geninvo.com/our-products/data-anonymization-tool/) [ Find Out More ](https://geninvo.com/our-products/data-anonymization-tool/) ## Automation of Data Conversion™ #### Automation of Data Conversion The SDTM (Study Data Tabulation Model) and ADaM (Analysis Data Model) are standards for human clinical trials (research) data tables and non-clinical data tables submitted by researchers to health authorities. The specification has been developed by the Federation of Clinical data Exchange Standards (CDISC). ApoGI is AI and meta-data driven solution that is designed for automation of end to end Drug Development process. [ ](https://geninvo.com/our-products/automation-of-data-conversion/) [ Find Out More ](https://geninvo.com/our-products/automation-of-data-conversion/) ![](https://geninvo.com/wp-content/uploads/2021/03/circle.png "circle - GenInvo - GenInvo") ![](https://geninvo.com/wp-content/uploads/2021/03/adc-pr-1024x717.jpg "Mockups Design - GenInvo - GenInvo") --- ## Categories ### [Uncategorized](https://geninvo.com/category/uncategorized/) --- ### [blogs](https://geninvo.com/category/blogs/) --- ### [news](https://geninvo.com/category/news/) --- ### [case studies](https://geninvo.com/category/case-studies/) --- ### [videos](https://geninvo.com/category/videos/) --- ### [events](https://geninvo.com/category/events/) --- ### [job](https://geninvo.com/category/job/) --- ### [Apogi](https://geninvo.com/category/blogs/apogi/) --- ### [QA/CSV](https://geninvo.com/category/blogs/qa-csv/) --- ### [IT](https://geninvo.com/category/blogs/it/) --- ### [2019](https://geninvo.com/category/events/2019/) --- ### [DocQC](https://geninvo.com/category/blogs/docqc/) --- ### [Shadow](https://geninvo.com/category/blogs/shadow/) --- ### [Datalution](https://geninvo.com/category/blogs/datalution/) --- ### [DocGen](https://geninvo.com/category/blogs/docgen/) --- ## Tags ### [Medical Writing](https://geninvo.com/tag/medical-writing/) --- ### [Innovation](https://geninvo.com/tag/innovation/) --- ### [Compliance](https://geninvo.com/tag/compliance/) --- ### [regulatory compliance](https://geninvo.com/tag/regulatory-compliance/) --- ### [apogi](https://geninvo.com/tag/apogi/) --- ### [shadow](https://geninvo.com/tag/shadow/) --- ### [docqc](https://geninvo.com/tag/docqc/) --- ### [ISO Certification](https://geninvo.com/tag/iso-certification/) --- ### [password protection](https://geninvo.com/tag/password-protection/) --- ### [ISMS](https://geninvo.com/tag/isms/) --- ### [Security Policy](https://geninvo.com/tag/security-policy/) --- ### [PHUSE EU Connect 2022](https://geninvo.com/tag/phuse-eu-connect-2022/) --- ### [AMWA's 2022](https://geninvo.com/tag/amwas-2022/) --- ### [data protection](https://geninvo.com/tag/data-protection/) --- ### [Synthetic data](https://geninvo.com/tag/synthetic-data/) --- ### [real data](https://geninvo.com/tag/real-data/) --- ### [Synthetic data solutions](https://geninvo.com/tag/synthetic-data-solutions/) --- ### [Synthetic data technology](https://geninvo.com/tag/synthetic-data-technology/) --- ### [Data Extraction and Analysis](https://geninvo.com/tag/data-extraction-and-analysis/) --- ### [Mining in Medical Writing](https://geninvo.com/tag/mining-in-medical-writing/) --- ### [Clinical Trial Automation](https://geninvo.com/tag/clinical-trial-automation/) --- ### [Machine Learning in Medical Writing](https://geninvo.com/tag/machine-learning-in-medical-writing/) --- ### [Medical Writing Automation Automated Medical Writing AI in Medical Writing Natural Language Processing (NLP)](https://geninvo.com/tag/medical-writing-automation-automated-medical-writing-ai-in-medical-writing-natural-language-processing-nlp/) --- ### [Policy 0070 relaunch](https://geninvo.com/tag/policy-0070-relaunch/) --- ### [Data Transparency](https://geninvo.com/tag/data-transparency/) --- ### [HC PRCI](https://geninvo.com/tag/hc-prci/) --- ### [EU CTR](https://geninvo.com/tag/eu-ctr/) --- ### [CTIS](https://geninvo.com/tag/ctis/) --- ### [Clinical Data Disclosure](https://geninvo.com/tag/clinical-data-disclosure/) --- ### [Clinical dataset anonymization](https://geninvo.com/tag/clinical-dataset-anonymization/) --- ### [Data De-identification](https://geninvo.com/tag/data-de-identification/) --- ### [Clinical Document anonymization](https://geninvo.com/tag/clinical-document-anonymization/) --- ### [Document Redaction](https://geninvo.com/tag/document-redaction/) --- ### [Clinical Data Privacy](https://geninvo.com/tag/clinical-data-privacy/) --- ### [risk of re-identification](https://geninvo.com/tag/risk-of-re-identification/) --- ### [GDPR](https://geninvo.com/tag/gdpr/) --- ### [Quantitative risk assessment](https://geninvo.com/tag/quantitative-risk-assessment/) --- ### [Qualitative risk assessment](https://geninvo.com/tag/qualitative-risk-assessment/) --- ### [HIPPA](https://geninvo.com/tag/hippa/) --- ### [HITRUST](https://geninvo.com/tag/hitrust/) --- ### [Redaction vs anonymization](https://geninvo.com/tag/redaction-vs-anonymization/) --- ### [Reference population](https://geninvo.com/tag/reference-population/) --- ### [anonymization of structured and unstructured data](https://geninvo.com/tag/anonymization-of-structured-and-unstructured-data/) --- ### [pseudonymization vs anonymization](https://geninvo.com/tag/pseudonymization-vs-anonymization/) --- ### [Clinical Data Anonymization services](https://geninvo.com/tag/clinical-data-anonymization-services/) --- ### [CTIS redaction services](https://geninvo.com/tag/ctis-redaction-services/) --- ### [Data Anonymization](https://geninvo.com/tag/data-anonymization/) --- ### [Privacy Protection](https://geninvo.com/tag/privacy-protection/) --- ### [Data Security](https://geninvo.com/tag/data-security/) --- ### [De-identification](https://geninvo.com/tag/de-identification/) --- ### [Pseudonymization](https://geninvo.com/tag/pseudonymization/) --- ### [Data Governance](https://geninvo.com/tag/data-governance/) --- ### [Confidentiality](https://geninvo.com/tag/confidentiality/) --- ### [Product Development](https://geninvo.com/tag/product-development/) --- ### [Regulatory Changes](https://geninvo.com/tag/regulatory-changes/) --- ### [Risk Management](https://geninvo.com/tag/risk-management/) --- ### [Agile Product Development](https://geninvo.com/tag/agile-product-development/) --- ### [Cross-Functional Collaboration](https://geninvo.com/tag/cross-functional-collaboration/) --- ### [Market Access](https://geninvo.com/tag/market-access/) --- ### [Regulatory Intelligence](https://geninvo.com/tag/regulatory-intelligence/) --- ### [Market Expansion](https://geninvo.com/tag/market-expansion/) --- ### [Technology Solutions](https://geninvo.com/tag/technology-solutions/) --- ### [Business Strategy](https://geninvo.com/tag/business-strategy/) --- ### [Training and Education](https://geninvo.com/tag/training-and-education/) --- ### [Regulatory Authorities](https://geninvo.com/tag/regulatory-authorities/) --- ### [Pharmaceutical Industry (if applicable)](https://geninvo.com/tag/pharmaceutical-industry-if-applicable/) --- ### [Product Design](https://geninvo.com/tag/product-design/) --- ### [AI-powered Compliance Tools](https://geninvo.com/tag/ai-powered-compliance-tools/) --- ### [Market Penetration](https://geninvo.com/tag/market-penetration/) --- ### [Market Dynamics](https://geninvo.com/tag/market-dynamics/) --- ### [GDPR Compliance](https://geninvo.com/tag/gdpr-compliance/) --- ### [Advanced Data Techniques](https://geninvo.com/tag/advanced-data-techniques/) --- ### [Data Privacy](https://geninvo.com/tag/data-privacy/) --- ### [Personal Data Protection](https://geninvo.com/tag/personal-data-protection/) --- ### [Privacy by Design](https://geninvo.com/tag/privacy-by-design/) --- ### [Differential Privacy](https://geninvo.com/tag/differential-privacy/) --- ### [Anonymization Strategies](https://geninvo.com/tag/anonymization-strategies/) --- ### [K-Anonymity](https://geninvo.com/tag/k-anonymity/) --- ### [Secure Multi-Party Computation](https://geninvo.com/tag/secure-multi-party-computation/) --- ### [Privacy Regulations](https://geninvo.com/tag/privacy-regulations/) --- ### [Ethical Data Management](https://geninvo.com/tag/ethical-data-management/) --- ### [Data Insights](https://geninvo.com/tag/data-insights/) --- ### [GDPR Guidelines](https://geninvo.com/tag/gdpr-guidelines/) --- ### [Data Stewardship](https://geninvo.com/tag/data-stewardship/) --- ### [Responsible Data Use](https://geninvo.com/tag/responsible-data-use/) --- ### [Healthcare Documentation](https://geninvo.com/tag/healthcare-documentation/) --- ### [Clinical Communication](https://geninvo.com/tag/clinical-communication/) --- ### [Medical Terminology](https://geninvo.com/tag/medical-terminology/) --- ### [Scientific Writing](https://geninvo.com/tag/scientific-writing/) --- ### [Medical Research](https://geninvo.com/tag/medical-research/) --- ### [Health Informatics](https://geninvo.com/tag/health-informatics/) --- ### [Writing Tools](https://geninvo.com/tag/writing-tools/) --- ### [Academic Medicine](https://geninvo.com/tag/academic-medicine/) --- ### [Literature Review](https://geninvo.com/tag/literature-review/) --- ### [Synthetic Dataset](https://geninvo.com/tag/synthetic-dataset/) --- ### [Data Generation](https://geninvo.com/tag/data-generation/) --- ### [Machine Learning](https://geninvo.com/tag/machine-learning/) --- ### [Data Augmentation](https://geninvo.com/tag/data-augmentation/) --- ### [Privacy Preservation](https://geninvo.com/tag/privacy-preservation/) --- ### [AI Development](https://geninvo.com/tag/ai-development/) --- ### [Model Training](https://geninvo.com/tag/model-training/) --- ### [Data Science](https://geninvo.com/tag/data-science/) --- ### [Anonymization Tools](https://geninvo.com/tag/anonymization-tools/) --- ### [Document Automation](https://geninvo.com/tag/document-automation/) --- ### [Content Generation](https://geninvo.com/tag/content-generation/) --- ### [Document Management](https://geninvo.com/tag/document-management/) --- ### [Text Generation](https://geninvo.com/tag/text-generation/) --- ### [Productivity Tools](https://geninvo.com/tag/productivity-tools/) --- ### [Workflow Automation](https://geninvo.com/tag/workflow-automation/) --- ### [Template-Based Documents](https://geninvo.com/tag/template-based-documents/) --- ### [Data Merge](https://geninvo.com/tag/data-merge/) --- ### [Document Assembly](https://geninvo.com/tag/document-assembly/) --- ### [Text Processing](https://geninvo.com/tag/text-processing/) --- ### [Document Formatting](https://geninvo.com/tag/document-formatting/) --- ### [Dynamic Document Creation](https://geninvo.com/tag/dynamic-document-creation/) --- ### [Document Collaboration](https://geninvo.com/tag/document-collaboration/) --- ### [Efficiency Tools](https://geninvo.com/tag/efficiency-tools/) --- ### [Data Automation](https://geninvo.com/tag/data-automation/) --- ### [Information Governance](https://geninvo.com/tag/information-governance/) --- ### [Data Catalog](https://geninvo.com/tag/data-catalog/) --- ### [Automated Data Discovery](https://geninvo.com/tag/automated-data-discovery/) --- ### [Metadata Integration](https://geninvo.com/tag/metadata-integration/) --- ### [Data Quality](https://geninvo.com/tag/data-quality/) --- ### [Metadata Management](https://geninvo.com/tag/metadata-management/) --- ### [Data Classification](https://geninvo.com/tag/data-classification/) ---